PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Fujiwara, K; Okamura-Ikeda, K; Motokawa, Y				Fujiwara, K; Okamura-Ikeda, K; Motokawa, Y			Cloning and expression of a cDNA encoding bovine lipoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOLOCARBOXYLASE SYNTHETASE; GLYCINE CLEAVAGE SYSTEM; ESCHERICHIA-COLI; H-PROTEIN; LIPOYLATION; SEQUENCE; COMPLEXES; MUTATIONS; ACID; GENE	Lipoyltransferase catalyzes the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of the lipoate-dependent enzymes, We have isolated lipoyl-transferase I (LipTI) and II (LipTII) from bovine liver (Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1994) J. Biol. Chem. 269, 16605-16609), N-terminal amino acid sequences of LipTI and LipTII were identical except that LipTI had an additional Asn residue on the N terminus. We cloned LipTII cDNA from a bovine liver cDNA library, The cDNA insert contained a 1119-base pair open reading frame encoding a precursor peptide of 373 amino acids including a mitochondrial targeting signal of 26 amino acids, The calculated molecular mass of the mature protein is 39,137 Da, The predicted amino acid sequence showed 35% identity with that of Escherichia coli lipoate-protein ligase A. Northern and Southern blot analyses showed a single band, and a single species of mRNA for lipoyltransferase was found by reverse transcription-polymerase chain reaction, Recombinant LipTII was expressed in E. coli and purified to apparent homogeneity. The K-m(app) values of the recombinant enzyme for lipoyl-AMP and apoH-protein were comparable with those of native LipTII, An antibody raised against recombinant enzyme cross-reacted with LipTI and LipTII in a similar manner. The results suggest that LipTI and LipTII are derived from the same translated product but processed differently.	Univ Tokushima, Inst Enzyme Res, Tokushima 770, Japan	Tokushima University	Motokawa, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Kuramotocho 3 Chome, Tokushima 770, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI Y, 1994, NAT GENET, V8, P122, DOI 10.1038/ng1094-122; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9	21	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31974	31978		10.1074/jbc.272.51.31974	http://dx.doi.org/10.1074/jbc.272.51.31974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405389	hybrid			2022-12-27	WOS:000071108000008
J	Wong, AKC; Pero, R; Ormonde, PA; Tavtigian, SV; Bartel, PL				Wong, AKC; Pero, R; Ormonde, PA; Tavtigian, SV; Bartel, PL			RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; OVARIAN-CANCER; DIFFERENTIATION; PROLIFERATION; RECOMBINATION	Recent work has shown that the murine BRCA2 tumor suppressor protein interacts with the murine RAD51 protein, This interaction suggests that BRCA2 participates in DNA repair. Residues 3196-3232 of the murine BRCA2 protein were shown to be involved in this interaction. Here, we report the detailed mapping of additional domains that are involved in interactions between the human homologs of these two proteins. Through yeast two-hybrid and biochemical assays, we demonstrate that the RAD51 protein interacts specifically with the eight evolutionarily conserved BRC motifs encoded in exon 11 of brca2 and with a similar motif found in a Caenorhabditis elegans hypothetical protein. Deletion analysis demonstrates that residues 98-339 of human RAD51 interact with the 59-residue minimal region that is conserved in all BRC motifs. These data suggest that the BRC repeats function to bind RAD51.	Myriad Genet Inc, Salt Lake City, UT 84108 USA	Myriad Genetics, Inc	Wong, AKC (corresponding author), Myriad Genet Inc, 390 Wakara Way, Salt Lake City, UT 84108 USA.		Wong, Alexander/GZM-2929-2022	Wong, Alexander/0000-0002-5295-2797				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; EASTON DF, 1993, AM J HUM GENET, V52, P678; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; OGAWA T, 1992, J MOL BIOL, V226, P651, DOI 10.1016/0022-2836(92)90622-Q; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Sambrook J., 2002, MOL CLONING LAB MANU; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Vaughn JP, 1996, CANCER RES, V56, P4590; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	31	424	436	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31941	31944		10.1074/jbc.272.51.31941	http://dx.doi.org/10.1074/jbc.272.51.31941			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405383	hybrid			2022-12-27	WOS:000071108000002
J	Yao, ZB; Diener, K; Wang, XS; Zukowski, M; Matsumoto, G; Zhou, GS; Mo, R; Sasaki, T; Nishina, H; Hui, CC; Tan, TH; Woodgett, JP; Penninger, JM				Yao, ZB; Diener, K; Wang, XS; Zukowski, M; Matsumoto, G; Zhou, GS; Mo, R; Sasaki, T; Nishina, H; Hui, CC; Tan, TH; Woodgett, JP; Penninger, JM			Activation of stress-activated protein kinases c-Jun N-terminal protein kinases (SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase (MKK7)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GENE; PHOSPHORYLATION; EXPRESSION; THREONINE; CYTOKINES; TYROSINE; CASCADES; INSULIN; CLONING	Mitogen-activated protein kinase (MAPK) kinases (MKKs) are dual-specificity protein kinases that phosphorylate and activate MAPK. We have isolated a cDNA encoding a novel protein kinase that has significant homology to MKKs. The novel kinase MKK7 has a nucleotide sequence that encodes an open reading frame of 347 amino acids with 11 kinase subdomains. MKK7 is ubiquitously expressed in all adult and embryonic organs but displays high expression in epithelial tissues at later stages of fetal development. When transiently expressed in 293 cells, MKK7 specifically activated stress-activated protein kinases (SAPKs)/c-Jun N-terminal protein kinases (JNKs) but not extracellular-regulated kinase or p38 kinase. A kinase-negative mutant of MKK7 inhibits interleukin-1 beta, lipopolysaccharide, and MEKK1-induced SAPK/JNH activation. Thus, MKK7 is a new member of the MAPK kinase family that functions upstream of SAPK/JNK in the SAPK/JNK signaling pathway.	Amgen Inc, Boulder, CO 80301 USA; Amgen Inst, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	Amgen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Baylor College of Medicine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Penninger, JM (corresponding author), Amgen Inc, 3200 Walnut St,AC-4B, Boulder, CO 80301 USA.		Penninger, Josef M/I-6860-2013; Woodgett, Jim/F-1087-2010; Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Penninger, Josef M/0000-0002-8194-3777; Woodgett, Jim/0000-0003-3731-5797; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Sasaki, Takehiko/0000-0003-1837-3748				BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIENER D, 1997, IN PRESS P NATL ACAD; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NISHINA N, 1997, J EXP MED, V186, P941; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	91	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32378	32383		10.1074/jbc.272.51.32378	http://dx.doi.org/10.1074/jbc.272.51.32378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405446	hybrid			2022-12-27	WOS:000071108000065
J	Oh, HJ; Chen, X; Subjeck, JR				Oh, HJ; Chen, X; Subjeck, JR			hsp110 protects heat-denatured proteins and confers cellular thermoresistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEINS; LARGE HSP70-LIKE; IDENTIFICATION; SUBFAMILY; THERMOTOLERANCE; EXPRESSION; CLONING; HDJ-1	The 110-kDa heat shock protein (hsp110) has long been recognized as one of the primary heat shock proteins in mammalian cells. It belongs to a recently described protein family that is a significantly diverged subgroup of the hsp70 family and has been found in organisms as diverse as yeast and mammals. We describe here the first analysis of the ability of hsp110 to protect cellular and molecular targets from heat damage. It was observed that the overexpression in vivo of hsp110 conferred substantial heat resistance to both Rat-1 and HeLa cells. In vitro heat denaturation and refolding assays demonstrate that hsp110 is highly efficient in selectively recognizing denatured proteins and maintaining them in a soluble, folding-competent state and is significantly more efficient in performing this function than is hsc70. hsp110-bound proteins can then be refolded by the addition of rabbit reticulocyte lysate or hsc70 and Hdj-1, whereas Hdj-1 does not itself function as a co-chaperone in folding with hsp110. hsp110 is one of the principal molecular chaperones of mammalian cells and represents a newly identified component of the primary protection/repair pathway for denatured proteins and thermotolerance expression in vivo.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute				Oh, Kelly/0000-0001-8203-5247	NIGMS NIH HHS [GM45994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Chen X, 1996, FEBS LETT, V380, P68, DOI 10.1016/0014-5793(96)00011-7; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Just ML, 1997, DEV BIOL, V184, P25, DOI 10.1006/dbio.1997.8504; Kaneko Y, 1997, J BIOL CHEM, V272, P2640, DOI 10.1074/jbc.272.5.2640; Kaneko Y, 1997, GENE, V189, P19, DOI 10.1016/S0378-1119(96)00807-4; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LANDRY J, 1982, CANCER RES, V42, P2457; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Mauk R, 1997, DEV BIOL, V184, P31, DOI 10.1006/dbio.1997.8512; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MOROZOV A, 1995, FEBS LETT, V371, P214, DOI 10.1016/0014-5793(95)00884-C; MUKAI H, 1993, GENE, V132, P57; NEMMESGERN E, 1993, FEBS LETT, V331, P25; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	30	158	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31636	31640		10.1074/jbc.272.50.31636	http://dx.doi.org/10.1074/jbc.272.50.31636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395504	hybrid			2022-12-27	WOS:A1997YL41900063
J	Orlando, S; Sironi, M; Bianchi, G; Drummond, AH; Boraschi, D; Yabes, D; Mantovani, A				Orlando, S; Sironi, M; Bianchi, G; Drummond, AH; Boraschi, D; Yabes, D; Mantovani, A			Role of metalloproteases in the release of the IL-1 type II decoy receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; FACTOR-ALPHA; RAPID RELEASE; TNF RECEPTOR; L-SELECTIN; INTERLEUKIN-1; INHIBITOR; CELLS; CLONING; EXPRESSION	The IL-1 type II receptor (decoy RII) is a nonsignaling molecule the only established function of which is to capture IL-1 and prevent it from interacting with signaling receptor. The decoy RII is released in a regulated way from the cell surface. Here, we reported that hydroxamic acid inhibitors of matrix metalloproteases inhibit different pathways of decoy RII release, including the following: (a) the slow (18 h) gene expression dependent release from monocytes and polymorphonuclear cells exposed to dexamethasone; (b) rapid release (minutes) from myelomonocytic cells exposed to tumor necrosis factor, chemoattractants, or phorbol myristate acetate; (c) phorbol myristate acetate-induced release from decoy RII-transfected fibroblasts and B cells. Inhibition of release was associated with increased surface expression of decoy RII. Inhibitors of other protease classes did not substantially affect release. However, serine protease inhibitors increased the molecular mass of the decoy RII released from polymorphonuclear cells from 45 to 60 kDa. Thus, irrespective of the pathway responsible for release and of the cellular context, matrix metalloproteases, rather than differential splicing, play a key role in production of soluble decoy RII.	MARIO NEGRI INST PHARMACOL RES, DEPT IMMUNOL & CELL BIOL, I-20157 MILAN, ITALY; BRITISH BIOTECH, OXFORD OX4 5LY, ENGLAND; RES CTR DOMPE SPA, I-67100 LAQUILA, ITALY; PHARMACIA & UPJOHN RES CTR, DEPT IMMUNOL, I-20014 NERVIANO, ITALY; UNIV BRESCIA, SECT GEN PATHOL, DEPT BIOTECHNOL, I-25100 BRESCIA, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Dompe; University of Brescia			Boraschi, Diana/AAA-7171-2020; sironi, marina/AAB-5757-2020; Mantovani, Alberto/HCI-7449-2022	Boraschi, Diana/0000-0002-3953-4056; sironi, marina/0000-0002-3342-1149; Mantovani, Alberto/0000-0001-5578-236X				AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COLOTTA F, 1995, J EXP MED, V181, P2181, DOI 10.1084/jem.181.6.2181; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Colotta F, 1996, J IMMUNOL, V156, P2534; COLOTTA F, 1984, J IMMUNOL, V132, P936; Couet J, 1996, J BIOL CHEM, V271, P4545; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI 10.1016/S0065-2776(08)60642-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIRI JG, 1994, J IMMUNOL, V153, P5802; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Liu CL, 1996, J BIOL CHEM, V271, P20965, DOI 10.1074/jbc.271.34.20965; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCKEAN DJ, 1993, J IMMUNOL, V151, P3500; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MUZIO M, 1995, J EXP MED, V182, P623, DOI 10.1084/jem.182.2.623; Orlando S, 1997, J IMMUNOL, V158, P3861; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PERI G, 1994, J IMMUNOL METHODS, V174, P249, DOI 10.1016/0022-1759(94)90029-9; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Pruitt JH, 1996, BLOOD, V87, P3282; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Sambo P, 1996, BLOOD, V87, P1682; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOZZANI S, 1991, J IMMUNOL, V147, P2215; STOPPACCIARO A, 1991, J IMMUNOL, V147, P1561; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Williams LM, 1996, J CLIN INVEST, V97, P2833, DOI 10.1172/JCI118739	48	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31764	31769		10.1074/jbc.272.50.31764	http://dx.doi.org/10.1074/jbc.272.50.31764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395521	hybrid			2022-12-27	WOS:A1997YL41900080
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The carboxyl terminus of the Saccharomyces cerevisiae succinate dehydrogenase membrane subunit, SDH4p, is necessary for ubiquinone reduction and enzyme stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDOREDUCTASE; COLI FUMARATE REDUCTASE; RESPIRATORY COMPLEX-II; ESCHERICHIA-COLI; FLAVOPROTEIN SUBUNIT; ELECTRON-TRANSFER; GENE; INFORMATION; INHIBITORS; QUINONES	The succinate dehydrogenase (SDH) of Saccharomyces cerevisiae is composed of four nonidentical subunits encoded by the nuclear genes SDH1, SDH2, SDH3, and SDH4. The hydrophilic subunits, SDH1p and SDH2p, comprise the catalytic domain involved in succinate oxidation. They are anchored to the inner mitochondrial membrane by two small, hydrophobic subunits, SDH3p and SDH4p, which are required for electron transfer and ubiquinone reduction. Comparison of the deduced primary sequence of the yeast SDH4p subunit to SDH4p subunits from other species reveals the presence of an unusual 25-30 amino acid carboxyl-terminal extension following the last predicted transmembrane domain. The extension is predicted to be on the cytoplasmic side of the inner mitochondrial membrane. To investigate the extension's function, three truncations were created and characterized. The results reveal that the carboxyl-terminal extension is necessary for respiration and growth on nonfermentable carbon sources, for ubiquinone reduction, and for enzyme stability. Combined with inhibitor studies using a ubiquinone analog, our results suggest that the extension and more specifically, residues 128-135 are involved in the formation of a ubiquinone binding site. Our findings support a two ubiquinone binding site model for the S. cerevisiae SDH.	UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Bruel C, 1995, J BIOENERG BIOMEMBR, V27, P527, DOI 10.1007/BF02110192; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; Burger G, 1996, P NATL ACAD SCI USA, V93, P2328, DOI 10.1073/pnas.93.6.2328; CAMMACK R, 1986, BIOCHEM SOC T, V14, P1207, DOI 10.1042/bst0141207; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; GIETZ RD, 1988, GENE AMST, V74, P427; GRIVENNIKOV AVG, 1982, BIOCHIM BIOPHYS ACTA, V682, P491; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KITA K, 1989, J BIOL CHEM, V264, P2672; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Robinson KM, 1996, J BIOL CHEM, V271, P4055; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WRAIGHT CA, 1982, FUNCTIONS QUINONES E, P181; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; ZHU QS, 1988, J BIOL CHEM, V263, P193	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31382	31388		10.1074/jbc.272.50.31382	http://dx.doi.org/10.1074/jbc.272.50.31382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395469	hybrid			2022-12-27	WOS:A1997YL41900028
J	Tsoporis, JN; Marks, A; Kahn, HJ; Butany, JW; Liu, PP; OHanlon, D; Parker, TG				Tsoporis, JN; Marks, A; Kahn, HJ; Butany, JW; Liu, PP; OHanlon, D; Parker, TG			S100 beta inhibits alpha(1)-adrenergic induction of the hypertrophic phenotype in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-ACTIN PROMOTER; HEAVY-CHAIN PROMOTER; AMINO-ACID-SEQUENCE; ENHANCER FACTOR-I; GENE-EXPRESSION; MYOCARDIAL-INFARCTION; MESSENGER-RNA; ALPHA-1-ADRENERGIC RECEPTOR; SKELETAL-MUSCLE	In an experimental rat model of myocardial infarction, surviving cardiac myocytes undergo hypertrophy in response to trophic effecters. This response involves gene reprogramming manifested by the re-expression of fetal genes, such as the previously reported isoform switch from adult alpha- to embryonic beta-myosin heavy chain. We now report the transient re-expression of a second fetal gene, skeletal alpha-actin in rat myocardium at 7 days post-infarction, and its subsequent down-regulation coincident with the delayed induction of S100 beta, a protein normally expressed in brain. In cultured neonatal rat cardiac myocytes, co-transfection with an S100 beta-expression vector inhibits a pathway associated with hypertrophy, namely, alpha(1)-adrenergic induction of beta-myosin heavy chain and skeletal alpha-actin promoters mediated by beta-protein kinase C. The induction of beta-myosin heavy chain by hypoxia was similarly blocked by forced expression of S100 beta. Our results suggest that S100 beta may be an intrinsic negative regulator of the hypertrophic response of surviving cardiac myocytes post-infarction. Such negative regulators may be important in limiting the adverse consequences of unchecked hypertrophy leading to ventricular remodeling and dysfunction.	UNIV TORONTO, TORONTO HOSP,DEPT MED,CARDIOVASC RES CTR, DIV CARDIOL, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, TORONTO HOSP, DEPT PATHOL, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, WOMENS COLL HOSP, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital								ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; ALLORE RJ, 1990, J BIOL CHEM, V265, P15537; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; CAPASSO JM, 1993, AM J PHYSIOL, V265, pH1953, DOI 10.1152/ajpheart.1993.265.6.H1953; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DONATO R, 1985, CELL CALCIUM, V6, P343, DOI 10.1016/0143-4160(85)90004-1; DUNN R, 1987, J BIOL CHEM, V262, P3562; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ECKEL J, 1991, J MOL CELL CARDIOL, V23, P617, DOI 10.1016/0022-2828(91)90053-O; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIDHJAIN M, 1995, BIOCHEM BIOPH RES CO, V216, P892, DOI 10.1006/bbrc.1995.2705; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAIMOTO H, 1988, EUR J BIOCHEM, V171, P409, DOI 10.1111/j.1432-1033.1988.tb13805.x; HANATANI A, 1995, J MOL CELL CARDIOL, V27, P1905, DOI 10.1016/0022-2828(95)90013-6; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; ITAGAKI T, 1989, JPN CIRC J, V53, P313, DOI 10.1253/jcj.53.313; Ito H, 1996, J MOL CELL CARDIOL, V28, P1271, DOI 10.1006/jmcc.1996.0117; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KAHN HJ, 1991, MODERN PATHOL, V4, P698; KANDA T, 1993, EXP CLIN ENDOCRINOL, V101, P173, DOI 10.1055/s-0029-1211226; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; NADALGINARD B, 1993, BASIC RES CARDIOL, V88, P65; ORENSTEIN TL, 1995, J CLIN INVEST, V96, P858, DOI 10.1172/JCI118132; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARKER TG, 1993, HERZ, V18, P245; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROKOSH DG, 1994, BIOCHEM BIOPH RES CO, V200, P1177, DOI 10.1006/bbrc.1994.1575; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHEU FS, 1994, MOL BRAIN RES, V21, P62, DOI 10.1016/0169-328X(94)90378-6; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIGURDSSON A, 1993, AM HEART J, V126, P1068, DOI 10.1016/0002-8703(93)90656-T; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; ZIMMER DB, 1987, AM J PHYSIOL, V252, pC285, DOI 10.1152/ajpcell.1987.252.3.C285	51	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31915	31921		10.1074/jbc.272.50.31915	http://dx.doi.org/10.1074/jbc.272.50.31915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395540	hybrid			2022-12-27	WOS:A1997YL41900099
J	Mummidi, S; Ahuja, SS; McDaniel, BL; Ahuja, SK				Mummidi, S; Ahuja, SS; McDaniel, BL; Ahuja, SK			The human CC chemokine receptor 5 (CCR5) gene - Multiple transcripts with 5 '-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR RECEPTOR; MESSENGER-RNA; HIV-1 INFECTION; FUNCTIONAL-CHARACTERIZATION; GENOMIC ORGANIZATION; MOLECULAR-CLONING; EXPRESSION; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA	Human CC chemokine receptor 5 (CCR5), mediates the activation of cells by the chemokines macrophage inflammatory protein-la; macrophage inflammatory protein-1 beta, and RANTES, and serves as a fusion cofactor for macrophage-tropic strains of human immunodeficiency virus type 1. To understand the molecular mechanisms that regulate human CCR5 gene expression, we initiated studies to determine its genomic and mRNA organization, Previous studies have identified a single CCR5 mRNA isoform whose open reading frame is intronless, We now report the following novel findings, 1) Complex alternative splicing and multiple transcription start sites give rise to several distinct CCR5 transcripts that differ in their 5'-untranslated regions (UTR), 2) The gene is organized into four exons and two introns, Exons 2 and 3 are not interrupted by an intron, Exon 4 and portions of exon 3 are shared by all isoforms, Exon 4 contains the open reading frame, 11 nucleotides of the 5'-UTR and the complete 3'-UTR. 3) The transcripts appear to be initiated from two distinct promoters: an upstream promoter (P-U), upstream of exon 1, and a downstream promoter (P-D), that includes the "intronic" region between exons 1 and 3, 4) P-U and P-D lacked the canonical TATA or CAAT motifs, and are AT-rich, 5) P-D demonstrated strong constitutive promoter activity, whereas P-U was a weak promoter in all three leukocyte cell environments tested (THP-1, Jurkat, and K562), 6) We provide evidence for polymorphisms in the noncoding sequences, including the regulatory regions and 5'-UTRs, The structure of CCR5 was strikingly reminiscent of the overall structure of other chemokine/chemoattractant receptors, underscoring an important evolutionarily conserved function for a prototypical gene structure. This is the first description of functional pro meters for any CC chemokine receptor gene, and we speculate that the complex pattern of splicing events and dual promoter usage may function as a versatile mechanism to create diversity and flexibility in the regulation of CCR5 expression.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78284 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Mummidi, Srinivas/C-1004-2008; Mummidi, Srinivas/H-3335-2017	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; AHUJA SK, 1994, J BIOL CHEM, V269, P26381; Ahuja SS, 1996, J IMMUNOL, V156, P4345; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ANGOTTI E, 1994, J BIOL CHEM, V269, P17371; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HUANG Y, 1996, NAT MED, V11, P1240; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; Iwamoto S, 1996, BLOOD, V87, P378; IWAMOTO S, 1995, BLOOD, V85, P622, DOI 10.1182/blood.V85.3.622.bloodjournal853622; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEEN MPJM, 1994, HUM IMMUNOL, V41, P112; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1993, GENE, V133, P285, DOI 10.1016/0378-1119(93)90653-K; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; Naganawa S, 1997, J CLIN INVEST, V99, P1958, DOI 10.1172/JCI119363; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SLOAN JH, 1992, J IMMUNOL, V148, P2591; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Song ZM, 1996, J IMMUNOL, V156, P424; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	54	145	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30662	30671		10.1074/jbc.272.49.30662	http://dx.doi.org/10.1074/jbc.272.49.30662			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388201	hybrid			2022-12-27	WOS:000071640800014
J	Nemoto, Y; Arribas, M; Haffner, C; DeCamilli, P				Nemoto, Y; Arribas, M; Haffner, C; DeCamilli, P			Synaptojanin 2, a novel synaptojanin isoform with a distinct targeting domain and expression pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; SYNAPTIC VESICLE ENDOCYTOSIS; NERVE-TERMINALS; BOVINE BRAIN; SYNAPSIN-I; MEMBRANE; PROTEIN; POLYPHOSPHATE-5-PHOSPHATASE; DYNAMIN; PHOSPHATASES	Synaptojanin (synaptojanin 1) is a recently identified inositol 5'-phosphatase, which is highly enriched in nerve terminals and is implicated in synaptic vesicle recycling. It is composed of three domains: an aminoterminal SacI homology region, a central inositol 5'-phosphatase homology region, and a carboxyl-terminal proline rich region. We have now identified and characterized a novel form of synaptojanin, synaptojanin 2, which has a broader tissue distribution. Synaptojanin 2 cDNA from rat brain library encodes a protein of 1,248 amino acids with a predicted M-r of 138,268. The two synaptojanin isoforms share 57.2 and 53.8% amino acid identity in their SacI and phosphatase domains, respectively. In marked contrast, their carboxyl-terminal proline-rich regions bear little homology. Expression of synaptojanin 2 in COS7 cells produced a 110-kDa protein with inositol 5'-phosphatase activity. Protein binding assays demonstrated that among the major src homology 3-proteins known to bind to the proline-rich region of synaptojanin 1, Grb2, amphiphysin, and members of SH3p4/8/13 protein family, only Grb2 bound to that of synaptojanin 2. Furthermore, subcellular fractionation studies in transfected Chinese hamster ovary cells revealed that synaptojanin 2 was predominantly associated with the particulate fraction while synaptojanin 1 was mainly localized in the soluble fraction. This observation suggests that the proline-rich regions of synaptojanins 1 and 2 are implicated in different protein protein interactions and direct the two isoforms to different subcellular compartments. Our results demonstrate the presence of a family of synaptojanin-type inositol 5'-phosphatases with different tissue and subcellular distributions, which may be involved in distinct membrane trafficking and signal transduction pathways in mammalian cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol,Boyer Ctr Mol Med, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	DeCamilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol,Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu	Haffner, Christof/AAG-6676-2020	Arribas, Monica/0000-0002-1405-9391	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA48128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1997, NATURE, V387, pS; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; Bauerfeind Rudolf, 1995, Molecular Biology of the Cell, V6, p405A; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; Haffner Christof, 1996, Molecular Biology of the Cell, V7, p78A; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; Harlow E., 1988, ANTIBODIES LAB MANUA; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROSS TS, 1991, J BIOL CHEM, V266, P20283; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN S, 1997, IN PRESS EUR J CELL, V73; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377	41	87	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30817	30821		10.1074/jbc.272.49.30817	http://dx.doi.org/10.1074/jbc.272.49.30817			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388224	hybrid			2022-12-27	WOS:000071640800037
J	Cuppen, E; Nagata, S; Wieringa, B; Hendriks, W				Cuppen, E; Nagata, S; Wieringa, B; Hendriks, W			No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; CELL-DEATH; MOLECULAR-CLONING; GUANYLATE KINASES; ANTI-FAS; DOMAIN; BINDING; FAMILY; PSD-95/SAP90; SIMILARITIES	Recently, one of the PDZ domains in the cytosolic protein-tyrosine phosphatase Fas-associated phosphatase-1 (FAP-1)/protein-tyrosine phosphatase-BAS (PTP-BAS) was shown to interact with the carboxyl-terminal tS-L-V peptide of the human Fas receptor (Sato, T., Irie, S., Kitada, S., and Reed, J. C. (1995) Science 268, 411-415), suggesting a role for protein (de)phosphorylation in Fas signaling, To investigate whether this interaction is conserved in mouse, we performed yeast two-hybrid interaction experiments and transfection studies in mouse T cell lines, For the corresponding PDZ motif in the mouse homologue of FAP-1/PTP-BAS, protein-tyrosine phosphatase-BAS-like (PTP-BL), only an interaction with human but not with mouse Fas could be detected, Presence of the tS-L-V motif proper, which is unique for human Fas, rather than the structural context of its carboxyl terminus, apparently explains the initially observed binding, To test for functional conservation of any indirect involvement of PTP-BL in Fas-mediated signaling, we generated T lymphoma cell lines stably expressing mouse or human Fas receptor with and without PTP-BL, No inhibitory effect of PTP-BL was observed upon triggering apoptosis using mouse or human Fas-activating antibodies. Together with the markedly different tissue expression patterns for PTP-BL and Fas receptor, our findings suggest that protein-tyrosine phosphatase PTP-BL does not play a key role in the Fas-mediated death pathway.	UNIV NIJMEGEN,INST CELLULAR SIGNALING,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Radboud University Nijmegen; Osaka University			Hendriks, Wiljan/Q-4325-2019; Cuppen, Edwin/H-2389-2016; Cuppen, Edwin/F-5696-2011; Hendriks, Wiljan J.A.J./A-5214-2013; Nagata, Shigekazu/AAG-3203-2019; Wieringa, Berend/A-5346-2011	Hendriks, Wiljan/0000-0001-9481-8281; Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Nagata, Shigekazu/0000-0001-9758-8426; Wieringa, Berend/0000-0001-9192-8020				Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDA D, 1995, FEBS LETT, V358, P233, DOI 10.1016/0014-5793(94)01432-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Janssen O, 1996, IMMUNOL LETT, V49, P63, DOI 10.1016/0165-2478(95)02482-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LEMMONMA, 1996, CELL, V85, P621; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Niethammer M, 1996, J NEUROSCI, V16, P2157; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Orlinick JR, 1996, J BIOL CHEM, V271, P8627, DOI 10.1074/jbc.271.15.8627; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1997, PROTEIN SCI, V6, P464; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Takayama H, 1996, J IMMUNOL, V157, P3943; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30215	30220		10.1074/jbc.272.48.30215	http://dx.doi.org/10.1074/jbc.272.48.30215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374505	Green Published, hybrid			2022-12-27	WOS:A1997YH61300037
J	Fukata, M; Kuroda, S; Fujii, K; Nakamura, T; Shoji, I; Matsuura, Y; Okawa, K; Iwamatsu, A; Kikuchi, A; Kaibuchi, K				Fukata, M; Kuroda, S; Fujii, K; Nakamura, T; Shoji, I; Matsuura, Y; Okawa, K; Iwamatsu, A; Kikuchi, A; Kaibuchi, K			Regulation of cross-linking of actin filament by IQGAP1, a target for Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; RHO-FAMILY GTPASES; BINDING PROTEIN; PUTATIVE TARGET; ALPHA-ACTININ; F-ACTIN; KINASE; IDENTIFICATION; CALMODULIN; EFFECTOR	We have previously shown that IQGAP1, a recently identified target for Cdc42 and Rad small GTPases, showed a distribution similar to that of cortical actin cytoskeleton at the membrane ruffling area induced by insulin and Rac1(val12) (Kuroda, S., Fukata, M,, Kobayashi, K., Nakafuku, M., Nomura, N., Iwamatsu, A., and Kaibuchi, K. (1996) J. Biol. Chem. 271, 28363-23367). Here we identified an IQGAP1-interacting molecule with molecular mass of 43 kDa (p43) from bovine brain cytosol, using glutathione S-transferase (GST)-IQGAP1 affinity column chromatography. The amino acid sequencing of the protein revealed that p43 was identical to beta- and gamma-actin. IQGAP1 was cosedimentated with filamentous actin (F-actin). The amino-terminal domain (amino acids 1-216) of IQGAP1 was responsible for the interaction with F-actin. Falling ball viscometry assay revealed that IQGAP1 cross-linked the F-actin. This IQGAP1 activity was further enhanced by guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) GST-Cdc42 but not by GDP-GST-Cdc42. The gel filtration analysis of IQGAP1 revealed that IQGAP1 appeared as oligomers and that GTP gamma S-GST-Cdc42 but not GDP GST-Cdc42 enhanced the oligomerization of IQGAP1. These results strongly suggest that IQGAP1, acting downstream of Cdc42, can cross-link the actin filament through its oligomerization.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,HIROSHIMA 734,JAPAN; PRECURSORY RES EMBRYON SCI & TECHNOL,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN; NATL INST INFECT DIS,DIV VIROL 2,TOKYO 162,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Hiroshima University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID); Kirin Brewery Company Limited			Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021; KURODA, SHINYA/G-4961-2014	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806; 				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; APSENSTROM P, 1996, CURR BIOL, V6, P70; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; Brill S, 1996, MOL CELL BIOL, V16, P4869; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SANTOS E, 1988, J BIOL CHEM, V263, P9853; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	160	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29579	29583		10.1074/jbc.272.47.29579	http://dx.doi.org/10.1074/jbc.272.47.29579			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368021	hybrid			2022-12-27	WOS:A1997YG64700031
J	Hoedemaeker, FJ; Signorelli, T; Johns, K; Kuntz, DA; Rose, DR				Hoedemaeker, FJ; Signorelli, T; Johns, K; Kuntz, DA; Rose, DR			A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219 - Design, expression, and crystal structure at 2.4 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CELL-LINES; ESCHERICHIA-COLI; PROTEIN; IMMUNOGLOBULIN; ANTIGEN; CRYSTALLIZATION; RECOGNITION; DOMAIN; MODEL	A construct encoding a single chain variable fragment of the anti-P-glycoprotein monoclonal antibody C219 was made by combining the coding sequences for the heavy and light chain variable domains with a sequence encoding the flexible linker (GGGGS)(3), an OmpA signal sequence, a c-myc identification tag, and a five-histidine purification tag, The construct was expressed in Escherichia coli and purified from the periplasmic fraction using a nickel chelate column and ion exchange chromatography, Three-step Western blot analysis showed that the construct retains binding affinity for P-glycoprotein, Crystals of 1.0 x 0.2 x 0.2 mm were grown in 100 mM citrate, pH 4.5, 21% polyethylene glycol 6000 in the presence of low concentrations of subtilisin, resulting in proteolytic removal of the linker and purification tags, The structure was solved to a resolution of 2.4 Angstrom with an R factor of 20.6, an R-free of 28.5, and good stereochemistry, This result could lead to a clinically useful product based on antibody C219 for the diagnosis of P-glycoprotein-mediated multidrug resistance, The molecule will also be useful in biophysical studies of functional do mains of P-glycoprotein, as well as studies of the intact molecule.	UNIV TORONTO, ONTARIO CANC INST, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								Alvarez RD, 1997, HUM GENE THER, V8, P229, DOI 10.1089/hum.1997.8.2-229; Alyahyaee SAS, 1996, BIOCONJUGATE CHEM, V7, P451, DOI 10.1021/bc960030k; ANAND NN, 1991, J BIOL CHEM, V266, P21874; Annereau JP, 1997, FEBS LETT, V407, P303, DOI 10.1016/S0014-5793(97)00363-3; BARRAND MA, 1992, BRIT J CANCER, V65, P239, DOI 10.1038/bjc.1992.48; BEAULIEU E, 1995, BBA-BIOMEMBRANES, V1233, P27, DOI 10.1016/0005-2736(94)00239-L; Beck WT, 1996, CANCER RES, V56, P3010; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETTER M, 1995, J BIOL CHEM, V270, P14951, DOI 10.1074/jbc.270.25.14951; BRUNGER AT, 1989, XPLOR VERSION 3 1; CHAN HSL, 1995, HEMATOL ONCOL CLIN N, V9, P889, DOI 10.1016/S0889-8588(18)30077-7; CHAN HSL, 1995, HEMATOL ONCOL CLIN N, V9, P275, DOI 10.1016/S0889-8588(18)30096-0; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FINSTAD CL, 1991, J HISTOCHEM CYTOCHEM, V39, P1603, DOI 10.1177/39.12.1682363; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOEDEMAEKER PJ, 1997, IN PRESS PROTEINS ST; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Kovari LC, 1995, STRUCTURE, V3, P1291, DOI 10.1016/S0969-2126(01)00266-0; KRISHAN A, 1991, CYTOMETRY, V12, P731, DOI 10.1002/cyto.990120807; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U; Lynch TJ, 1997, J CLIN ONCOL, V15, P723, DOI 10.1200/JCO.1997.15.2.723; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORRIS MD, 1995, GENE, V1565, P313; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; VASUDEVAN S, 1996, PROTEIN MOTIONS, P109; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; YOKOTA T, 1992, CANCER RES, V52, P3402; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	50	27	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29784	29789		10.1074/jbc.272.47.29784	http://dx.doi.org/10.1074/jbc.272.47.29784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368049	hybrid			2022-12-27	WOS:A1997YG64700059
J	Layton, JE; Iaria, J; Smith, DK; Treutlein, HR				Layton, JE; Iaria, J; Smith, DK; Treutlein, HR			Identification of a ligand-binding site on the granulocyte colony-stimulating factor receptor by molecular modeling and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; COMMON BETA-CHAIN; GROWTH-HORMONE RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; IL-5 RECEPTORS; GM-CSF; COMPLEX; RESIDUES; IMMUNOGLOBULIN	Granulocyte colony-stimulating factor (G-CSF) initiates its effects on cells of the neutrophil lineage by inducing formation of a homodimeric receptor complex. The structure of the G-CSF receptor has not yet been determined, therefore we used molecular modeling to identify regions of the receptor that were likely to be involved in ligand binding, The G-CSF receptor sequence was aligned with all the available sequences of the gp130 and growth hormone receptor families and a model of the cytokine receptor homologous domain was constructed, based on the growth hormone receptor structure. Alanine substitution mutagenesis was performed on loops and individual residues that mere predicted to bind ligand. Mutant receptors were expressed in factor-dependent Ba/F3 cells and assessed for proliferation response and ligand binding, Six residues were identified that significantly reduced receptor function, with Arg(288) in the F'-G' loop having the greatest effect. These residues formed a binding face on the receptor model resembling the growth hormone receptor site, which suggests that the model is reasonable. However, electrostatic analysis of the model provided further evidence that the mechanism of receptor dimerization is different from that of the growth hormone receptor.	ROYAL MELBOURNE HOSP,COOPERAT RES CTR CELLULAR GROWTH FACTORS,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital	Layton, JE (corresponding author), ROYAL MELBOURNE HOSP,MELBOURNE TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,POB 2008,PARKVILLE,VIC 3050,AUSTRALIA.		Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Smith, David/0000-0003-3608-0586				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NICOLA NA, 1987, J CELL PHYSL S5, V133, P9; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; SMITH DK, 1994, FEBS LETT, V350, P275, DOI 10.1016/0014-5793(94)00785-3; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGN HM, 1992, J BIOL CHEM, V267, P979; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498	59	30	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29735	29741		10.1074/jbc.272.47.29735	http://dx.doi.org/10.1074/jbc.272.47.29735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368043	hybrid			2022-12-27	WOS:A1997YG64700053
J	Nishino, T; Nishino, T				Nishino, T; Nishino, T			The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DROSOPHILA-MELANOGASTER; ALDEHYDE OXIDOREDUCTASE; O-2-DEPENDENT TYPES; MOLECULAR-CLONING; DEPENDENT TYPE; CDNA CLONING; ROSY LOCUS; PURIFICATION; ENZYME	When rat liver xanthine dehydrogenase was incubated with fluorodinitrobenzene (FDNB) at pH 8.5, the total enzyme activity decreased gradually to a Limited value of initial activity with modification of two lysine residues in a similar way to the modification of bovine milk xanthine oxidase with FDNB (Nishino, T., Tsushima, R., Hille, R. and Massey, V. (1982) J. Biol. Chem. 257, 7348-1353). After modification with FDNB, the two peptides containing dinitrophenyl-lysine were isolated from the molybdopterin domain after proteolytic digestion and were identified as Lys(754) and Lys(771) by sequencing the peptides. During the modification of these lysine residues, xanthine dehydrogenase was found to be converted to an oxidase form in the early stage of incubation. Incorporation of the H-3-dinitrophenyl group into enzyme cysteine residues was 0.96 mol per enzyme FAD for 68% conversion to the oxidase form. The modified enzyme was reconverted to the dehydrogenase form by incubation with dithiothreitol with concomitant release of H-3-dinitrophenyl compounds. After modification with H-3-FDNB followed by carboxymethylation under denaturating conditions, the enzyme was digested with proteases. Three H-3-dinitrophenyl-labeled peptides were isolated and sequenced. The modified residues were identified to be Cys(535), Cys(992) and Cys(1324). These residues are conserved among the all known mammalian enzymes, but Cys(992) and Cys(1324) are not conserved in the chicken enzyme. Cys(1324) Of the rat enzyme was found not to be involved in the conversion from the dehydrogenase to the oxidase by limited proteolysis experiments, but Cys(535) and Cys(992) which seemed to be modified alternatively with FDNB appear to be involved in the conversion.	YOKOHAMA CITY UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Yokohama City University	Nishino, T (corresponding author), NIPPON MED COLL, DEPT BIOCHEM & MOL BIOL, BUNKYO KU, 1-1-5 SENDAGI, TOKYO 113, JAPAN.							AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; Della Corte E, 1968, Biochem J, V108, P349; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUNT J, 1992, J BIOL CHEM, V267, P21479; ICHIDA K, 1993, GENE, V133, P279; IKEDA T, 1976, EXPT METHODS BIOCH 2, V1, P118; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; KAMINSKI ZW, 1982, BIOCHEM J, V207, P341, DOI 10.1042/bj2070341; KEITH TP, 1987, GENETICS, V116, P67; LEE CS, 1987, GENETICS, V116, P55; Li Calzi Marco, 1995, Journal of Biological Chemistry, V270, P31037; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1994, J BIOCHEM, V116, P1; NISHINO T, 1982, J BIOL CHEM, V257, P7348; RAKITZIS ET, 1985, BIOCHEM J, V231, P492; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; SHALTIEL S, 1967, BIOCHEM BIOPH RES CO, V29, P178, DOI 10.1016/0006-291X(67)90583-9; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WEBER K, 1969, J BIOL CHEM, V244, P4406; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690	38	65	66	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29859	29864		10.1074/jbc.272.47.29859	http://dx.doi.org/10.1074/jbc.272.47.29859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368059	hybrid			2022-12-27	WOS:A1997YG64700069
J	Bae, H; Anderson, K; Flood, LA; Skiba, NP; Hamm, HE; Graber, SG				Bae, H; Anderson, K; Flood, LA; Skiba, NP; Hamm, HE; Graber, SG			Molecular determinants of selectivity in 5-hydroxytryptamine(1B) receptor-G protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; HETEROTRIMERIC G-PROTEINS; TRANSDUCIN ALPHA-SUBUNIT; GAMMA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; CGMP PHOSPHODIESTERASE; GUANINE-NUCLEOTIDES; SYNTHETIC PEPTIDES; AGONIST BINDING	The recognition between G protein and cognate receptor plays a key role in specific cellular responses to environmental stimuli, Here we explore specificity in receptor-G protein coupling by taking advantage of the ability of the 5-hydroxytryptamine(1B) (5-HT1B) receptor to discriminate between G protein heterotrimers containing G alpha(i1) or G alpha(t). G(i1) can interact with the 5-HT1B receptor and stabilize a high affinity agonist binding state of this receptor, but G(t) cannot. A series of G alpha(t)/G alpha(i1) chimeric proteins have been generated in Escherichia coli, and their functional integrity has been reported previously (Skiba, N. P., Bae, H., and Hamm, H. E. (1996) J. Biol. Chem. 271, 413-424), We have tested the functional coupling abilities of the G alpha(t)/G alpha(i1) chimeras to 5-HT1B receptors using high affinity agonist binding and receptor-stimulated guanosine 5'-3-0-(thio)triphosphate (GTP gamma S) binding, In the presence of beta gamma subunits, amino acid residues 299-318 of G alpha(i1) increase agonist binding to the 5-HT1B receptor and receptor stimulation of GTP gamma S binding, Moreover, G alpha(i1) containing only G alpha(t) amino acid sequences from this region does not show any coupling ability to 5-HT1B receptors, Our studies suggest that the alpha 4 helix and alpha 4-beta 6 loop region of G alpha s are an important region for specific recognition between receptors and G(i) family members.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; W Virginia Univ, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; West Virginia University	Graber, SG (corresponding author), 3152 Hlth Sci N,POB 9223, Morgantown, WV 26506 USA.		Bae, Hyunsu/ABH-6248-2020; Hamm, Heidi E/G-2374-2014	Bae, Hyunsu/0000-0002-0299-3582	NEI NIH HHS [EY10291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Artemyev NO, 1997, BIOCHEMISTRY-US, V36, P4188, DOI 10.1021/bi963002y; ASANO T, 1985, J BIOL CHEM, V260, P2653; ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Figler RA, 1996, MOL PHARMACOL, V50, P1587; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; KERAVIS TM, 1991, EUR J PHARM-MOLEC PH, V207, P149, DOI 10.1016/0922-4106(91)90090-5; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; LEFKOWITZ RJ, 1976, J BIOL CHEM, V251, P4686; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MAZZONI MR, 1991, J BIOL CHEM, V266, P1072; MIGEON JC, 1995, J BIOL CHEM, V270, P16070, DOI 10.1074/jbc.270.27.16070; MIGEON JC, 1994, J BIOL CHEM, V269, P9767; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; POBINER BF, 1991, MOL PHARMACOL, V40, P156; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; ROSSI GC, 1995, NEUROSCI LETT, V198, P99, DOI 10.1016/0304-3940(95)11977-5; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	47	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32071	32077		10.1074/jbc.272.51.32071	http://dx.doi.org/10.1074/jbc.272.51.32071			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405403	hybrid, Green Published			2022-12-27	WOS:000071108000022
J	Communi, D; Govaerts, C; Parmentier, M; Boeynaems, JM				Communi, D; Govaerts, C; Parmentier, M; Boeynaems, JM			Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE NUCLEOTIDE RECEPTOR; FUNCTIONAL EXPRESSION; MEDIATED INHIBITION; TISSUE DISTRIBUTION; MOLECULAR-CLONING; NG108-15 CELLS; ATP RECEPTOR; CHO-K1 CELLS; CYCLIC-AMP; PURINOCEPTOR	Clones encoding a new human P2Y receptor, provisionally called P2Y(11), have been isolated from human placenta complementary DNA and genomic DNA libraries, The 1113-base pair open reading frame is interrupted by one intron, The P2Y(11) receptor is characterized by considerably larger second and third extracellular loops than the subtypes described so far. The deduced amino acid sequence exhibits 33% amino acid identity with the P2Y(1) receptor, its closest homolog. Northern blot analysis detected human P2Y(11) receptor messenger RNA in spleen and HL-60 cells. The level of P2Y(11) transcripts was strongly increased in these cells after granulocyte differentiation induced by retinoic acid or dimethyl sulfoxide. The new receptor was stably expressed in 1321N1 astrocytoma and CHO-K1 cells, where it couples to the stimulation of both the phosphoinositide and adenylyl cyclase pathways, a unique feature among the P2Y family. The rank order of agonists potency was: ATP > 8-methylthio-ATP >>> ADP, whereas UTP and UDP were inactive, indicating that it behaves as a selective purinoceptor.	Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Dept Med Chem, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, Campus Erasme,Bldg C,5th Floor,Route Lennik 808, B-1070 Brussels, Belgium.			Parmentier, Marc/0000-0001-8081-4685				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; BLAINEAU C, 1983, EMBO J, V11, P2007; Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; COMMUNI D, 1995, CIRC RES, V76, P191, DOI 10.1161/01.RES.76.2.191; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Communi D, 1996, EUR J PHARMACOL, V317, P383, DOI 10.1016/S0014-2999(96)00740-6; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; Godecke S, 1996, AM J PHYSIOL-CELL PH, V270, pC570, DOI 10.1152/ajpcell.1996.270.2.C570; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; Janssens R, 1997, BIOCHEM BIOPH RES CO, V236, P106, DOI 10.1006/bbrc.1997.6895; Jiang LL, 1997, BIOCHEM BIOPH RES CO, V232, P626, DOI 10.1006/bbrc.1997.6345; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MATSUOKA I, 1995, MOL PHARMACOL, V47, P855; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Song SL, 1996, BRAIN RES, V734, P243, DOI 10.1016/0006-8993(96)00645-2; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V152, P77; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	33	297	305	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31969	31973		10.1074/jbc.272.51.31969	http://dx.doi.org/10.1074/jbc.272.51.31969			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405388	hybrid			2022-12-27	WOS:000071108000007
J	Gibson, RM; Taylor, SS				Gibson, RM; Taylor, SS			Dissecting the cooperative reassociation of the regulatory and catalytic subunits of cAMP-dependent protein kinase - Role of Trp-196 in the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYCLIC-AMP; BINDING-SITES; ESCHERICHIA-COLI; SKELETAL-MUSCLE; HOLOENZYME FORMATION; KINETIC-ANALYSIS; EXPRESSION; INHIBITOR; MUTATIONS	The catalytic (C) subunit of cAMP-dependent protein kinase requires two distinct surfaces to form a stable complex with its physiological inhibitors, the regulatory (R) subunits and the heat-stable protein kinase inhibitors. In addition to a substrate-like segment that is common to both inhibitors, R requires a peripheral recognition site, PRS2. This surface is comprised of the essential phosphorylation site, Thr-197, His-87, Trp-196, and several surrounding basic residues. To probe the role of Trp-196 in the recognition of R, Trp-196 was replaced with Arg and Ala. Although both rC(W196A) and rC(W196R) were inhibited readily with cAMP-free R, they failed to form an inhibited holoenzyme complex with native R under conditions in which wild-type holoenzyme formed readily. Pairing rC(W196R) with mutant forms of R lacking domain B or having defects in cAMP binding sites A or B highlighted the importance of the conformation of R, and, in particular, the accessibility of site A. One of these mutants, rR(R333K), having a defect in cAMP binding site B formed a stable complex with rC(W196R) in the absence of cAMP. However, unlike wild-type holoenzyme, this complex was active.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	staylor@ucad.edu	Gibson, Robin/A-6841-2009		NCI NIH HHS [T32 CA0952223-08] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1988, BIOCHEMISTRY-US, V27, P1570, DOI 10.1021/bi00405a026; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; COX S, 1994, J BIOL CHEM, V269, P22614; DOSTMANN WRG, 1995, FEBS LETT, V375, P231, DOI 10.1016/0014-5793(95)01201-O; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEN DA, 1991, BIOCHEMISTRY-US, V30, P3035; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; Narayana N, 1997, STRUCTURE, V5, P921, DOI 10.1016/S0969-2126(97)00246-3; Narayana N, 1997, BIOCHEMISTRY-US, V36, P4438, DOI 10.1021/bi961947+; OGREID D, 1981, FEBS LETT, V129, P282, DOI 10.1016/0014-5793(81)80184-6; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; RIGHETTI PG, 1983, LABORATORY TECHNIQUE, P148; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YONEMOTO W, 1997, IN PRESS PROTEIN ENG; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	53	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31998	32005		10.1074/jbc.272.51.31998	http://dx.doi.org/10.1074/jbc.272.51.31998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405392	hybrid			2022-12-27	WOS:000071108000011
J	Ollendorf, V; Donoghue, DJ				Ollendorf, V; Donoghue, DJ			The serine/threonine phosphatase PP5 interacts with CDC16 and CDC27, two tetratricopeptide repeat-containing subunits of the anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MAMMALIAN-CELLS; PROTEIN-KINASE; HUMAN HOMOLOG; S-PHASE; MITOSIS; YEAST; PROTEOLYSIS; IDENTIFICATION; GENE	The evolutionarily conserved multisubunit complex known as the cyclosome or anaphase-promoting complex is involved in catalyzing the ubiquitination of diverse substrates in M phase, allowing their destruction by the 26 S proteasome and the completion of mitosis, Three of the eight subunits of the anaphase-promoting complex (CDC16, CDC23, and CDC27) have been shown to be phosphorylated in M phase, and their phosphorylation is required for the anaphase-promoting complex to be active as a ubiquitin ligase, Several subunits of the anaphase-promoting complex contain tetratricopeptide repeats, a protein motif involved in protein/protein interactions, PP5 is a serine/threonine phosphatase that also contains four copies of the tetratricopeptide repeats motif, Here we show by a combination of two-hybrid analysis and in vitro binding that PP5 interacts with CDC16 and CDC27, two subunits of the anaphase-promoting complex, Only the NH2-terminal domain of PP5, containing all four tetratricopeptide repeats, is required for this physical interaction, Deletion analysis suggests that the site of binding to PP5 is localized to the COOH-terminal block of tetratricopeptide repeats in CDC16 and CDC27, In addition, indirect immunofluorescence showed that PP5 localizes to the mitotic spindle apparatus, The direct interaction of PP5 with CDC16 and CDC27, as well as its overlapping spindle localization in mitosis, suggests that PP5 may be involved in the regulation of the activity of the anaphase-promoting complex.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 6114 Urey Hall,9500 Gilman Dr, La Jolla, CA 92093 USA.			Ollendorff, Vincent/0000-0001-9751-2202	NATIONAL CANCER INSTITUTE [R01CA034456] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BECKER W, 1994, J BIOL CHEM, V269, P22586; BLANC S, 1993, VIROLOGY, V192, P651, DOI 10.1006/viro.1993.1081; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JAMES SW, 1995, J CELL SCI, V108, P3485; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu XL, 1996, BIOCHEM BIOPH RES CO, V218, P514, DOI 10.1006/bbrc.1996.0092; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	43	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32011	32018		10.1074/jbc.272.51.32011	http://dx.doi.org/10.1074/jbc.272.51.32011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405394	Green Published, hybrid			2022-12-27	WOS:000071108000013
J	Gringhuis, SI; deLeij, LFMH; Wayman, GA; Tokumitsu, H; Vellenga, E				Gringhuis, SI; deLeij, LFMH; Wayman, GA; Tokumitsu, H; Vellenga, E			The Ca2+/calmodulin-dependent kinase type IV is involved in the CD5-mediated signaling pathway in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR IONIZED CALCIUM; ANTIGEN RECEPTOR COMPLEX; TRANSCRIPTION FACTOR; GENE-EXPRESSION; C-JUN; RESPONSE ELEMENT; ACTIVATED LYMPHOCYTES; CELL-PROLIFERATION; TYROSINE KINASES	The CD5 receptor on T lymphocytes is involved in T cell activation and T-B cell interactions. In the present study, we have characterized the signaling pathways induced by anti-CD5 stimulation in human T lymphocytes, In T lymphocytes, anti-CD5 co-stimulation enhances the phytohemagglutinin/anti-CD28-induced interleukin-2 (IL-2) mRNA accumulation 1.6-fold and IL-2 protein secretion 2.2-fold, whereby the up-regulation is mediated at both the transcriptional and post-transcriptional level. The CD5 signaling pathway up-regulates the IL-2 gene expression by increasing the DNA binding and transactivation activity of activator protein 1 but affects none of the other transcription factors like nuclear factor of activated T cells, nuclear factor kappa B, OCt, and CD28-responsive complex/nuclear factor of mitogen-activated T cells involved in the regulation of the IL-2 promoter activity. The CD5-induced increase of the activator protein 1 activity is mediated through the activation of calcium/calmodulin-dependent (CaM) kinase type IV, and is independent of the activation of mitogen-activated protein kinases Jun N-terminal kinase, extracellular signal-regulated kinase, and p38/Mpk2, and calcium/calmodul-independent kinase type IL The expression of a dominant negative mutant of CaM kinase IV in T Iymphocytes transfected with an IL-2 promoter-driven reporter construct completely abrogates the response to CD5 stimulation, indicating that CaM kinase IV is essential to the CD5 signaling pathway, In addition, it is demonstrated that calciuml/calmodulin-dependent kinase type IV is also involved in the stabilization of the IL-2 transcripts, which is observed after co-stimulation of phytohemagglutinin/anti-CD28 activated T lymphocytes with anti-CD5.	UNIV GRONINGEN, DIV HEMATOL, DEPT INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN, DIV CLIN IMMUNOL, DEPT INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	University of Groningen; University of Groningen; Oregon Health & Science University			; Tokumitsu, Hiroshi/M-3978-2015	Gringhuis, Sonja/0000-0003-0383-4978; Tokumitsu, Hiroshi/0000-0002-2193-6794				ALBEROLAILA J, 1992, J IMMUNOL, V148, P1287; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cerutti A, 1996, J IMMUNOL, V157, P1854; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Civil A, 1996, J BIOL CHEM, V271, P8321, DOI 10.1074/jbc.271.14.8321; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAMBROSIO D, 1993, EUR J IMMUNOL, V23, P2993, DOI 10.1002/eji.1830231140; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Ishida A, 1996, BBA-MOL CELL RES, V1311, P211, DOI 10.1016/0167-4889(95)00197-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J IMMUNOL, V148, P1240; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; JUNE CH, 1987, J IMMUNOL, V138, P2782; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEDERER JA, 1994, J IMMUNOL, V152, P77; LI GD, 1992, MOL PHARMACOL, V42, P489; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NOBES CD, 1995, J CELL SCI, V108, P225; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PARK JH, 1993, J BIOL CHEM, V268, P6299; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SIHRA TS, 1995, NEUROPHARMACOLOGY, V34, P731, DOI 10.1016/0028-3908(95)00051-7; SPERTINI F, 1991, J IMMUNOL, V146, P47; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THOMAS Y, 1984, J IMMUNOL, V133, P724; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VAN DE VELDE H, 1991, NATURE, V351, P662; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VELLENGA E, 1988, BLOOD, V71, P1529; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xia ZG, 1996, J NEUROSCI, V16, P5425; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	86	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31809	31820		10.1074/jbc.272.50.31809	http://dx.doi.org/10.1074/jbc.272.50.31809			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395527	hybrid			2022-12-27	WOS:A1997YL41900086
J	Huang, CF; Wong, GW; Ghildyal, N; Gurish, MF; Sali, A; Matsumoto, R; Qiu, WT; Stevens, RL				Huang, CF; Wong, GW; Ghildyal, N; Gurish, MF; Sali, A; Matsumoto, R; Qiu, WT; Stevens, RL			The tryptase, mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN; COMPLEMENTARY-DNA; ENDOTHELIAL-CELLS; PURIFICATION; CLONING; IDENTIFICATION; EXPRESSION; PEPTIDE; AIRWAY; GENE	Mouse mast cell protease (mMCP) 7 is a tryptase of unknown function expressed by a subpopulation of mast cells that reside in numerous connective tissue sites. Because enzymatically active mMCP-7 is selectively released into the plasma of V3 mastocytosis mice undergoing passive systemic anaphylaxis, we used this in vivo model system to identify a physiologic substrate of the tryptase. Plasma samples taken from V3 mastocytosis mice that had been sensitized with immunoglobulin (Ig) E and challenged with antigen were found to contain substantial amounts of four 34-55-kDa peptides, all of which were derived from fibrinogen. To confirm the substrate specificity of mMCP-7, a pseudozymogen form of the recombinant tryptase was generated that could be activated after its purification, The resulting 1 recombinant mMCP-7 exhibited potent anticoagulant activity in the presence of normal plasma and selectively cleaved the a-chain of fibrinogen to fragments of similar size as that seen in the plasma of the IgE/antigen-treated V3 mastocytosis mouse. Subsequent analysis of a tryptase-specific, phage display peptide library revealed that recombinant mMCP-7 preferentially cleaves an amino acid sequence that is nearly identical to that in the middle of the alpha-chain of rat fibrinogen. Because fibrinogen is a physiologic substrate of mMCP-7, this tryptase can regulate clot formation and fibrinogen/integrin-dependent cellular responses during mast cell-mediated inflammatory reactions.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RHEUMATOL ALLERGY & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; ROCKEFELLER UNIV,NEW YORK,NY 10021	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Rockefeller University				Wong, G. William/0000-0002-5286-6506	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI023483, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R01GM054762] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31599, AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAGANZA VJ, 1991, BIOCHEMISTRY-US, V30, P4997, DOI 10.1021/bi00234a023; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROWN B, 1988, HEMATOLOGY PRINCIPLE, P219; Cairns JA, 1996, J IMMUNOL, V156, P275; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P1333; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; CRABTREE GR, 1985, J MOL BIOL, V185, P1, DOI 10.1016/0022-2836(85)90179-2; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DIEM K, 1970, SCI TABLES, P579; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GRANT RA, 1981, J BIOL CHEM, V256, P539; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; Gruber BL, 1997, J IMMUNOL, V158, P2310; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HAWIGER J, 1995, SEMIN HEMATOL, V32, P99; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; LAM SCT, 1987, J BIOL CHEM, V262, P947; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LUTZELSCHWAB C, 1996, J EXP MED, V185, P13; MAIER M, 1983, J IMMUNOL, V130, P2352; MARGUERIE GA, 1984, EUR J BIOCHEM, V139, P5, DOI 10.1111/j.1432-1033.1984.tb07968.x; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEKORI YA, 1990, J IMMUNOL, V145, P3719; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; PERONA JJ, 1993, J MOL BIOL, V230, P919, DOI 10.1006/jmbi.1993.1210; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STACK MS, 1994, J BIOL CHEM, V269, P9416; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Svendsen L., 1972, THROMB RES, V1, P267, DOI 10.1016/0049-3848(72)90023-0; Thiagarajan P, 1996, BIOCHEMISTRY-US, V35, P4169, DOI 10.1021/bi952532b; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8	61	96	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31885	31893		10.1074/jbc.272.50.31885	http://dx.doi.org/10.1074/jbc.272.50.31885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395536	hybrid			2022-12-27	WOS:A1997YL41900095
J	Nagy, JM; Cass, AEG; Brown, KA				Nagy, JM; Cass, AEG; Brown, KA			Purification and characterization of recombinant catalase-peroxidase, which confers isoniazid sensitivity in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID SYNTHESIS; NEW-YORK-CITY; ESCHERICHIA-COLI; RESISTANT TUBERCULOSIS; FRONT-LINE; GENE; DRUG; EXPRESSION; KATG; ETHIONAMIDE	The Mycobacterium tuberculosis katG gene encodes a dual-function enzyme called catalase-peroxidase, which confers sensitivity in M. tuberculosis to isonicotinic acid hydrazide. We have constructed a system for the high level expression of a recombinant form of this enzyme by amplifying the katG gene from the pYZ56 construct (1) and subcloning into a vector suitable for expression in Escherichia coli, The resulting plasmid, pTBCP, produced the catalase-peroxidase in large quantities, corresponding to 30% of total cell protein. The enzyme has been purified to homogeneity and appears to be a dimer in the native form, Using either hydrogen peroxide or t-butyl hydroperoxide and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as substrates, k(cat) and K-m values have been obtained for both catalatic and peroxidatic activities, respectively. The availability of significant quantities of an active, folded, recombinant form of M. tuberculosis catalase-peroxidase should thus facilitate future studies of its role in drug activation and antibiotic resistance.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	Imperial College London								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Becker R, 1974, METHODS ENZYMATIC AN, V3, P286; BEERS RF, 1952, J BIOL CHEM, V195, P133; BEKIERKUNST A, 1967, ARCH BIOCHEM BIOPHYS, V122, P385, DOI 10.1016/0003-9861(67)90209-3; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DAVIS WB, 1977, ANTIMICROB AGENTS CH, V12, P213, DOI 10.1128/AAC.12.2.213; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; DIAZ GA, 1974, AM REV RESPIR DIS, V110, P312, DOI 10.1164/arrd.1974.110.3.312; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FUKUMORI Y, 1985, J BIOCHEM-TOKYO, V98, P1055, DOI 10.1093/oxfordjournals.jbchem.a135352; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HOCHMAN A, 1987, J BIOL CHEM, V262, P6871; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V69, P471; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; NADLER V, 1986, BIOCHIM BIOPHYS ACTA, V882, P234, DOI 10.1016/0304-4165(86)90160-1; NAKANE PK, 1966, J HISTOCHEM CYTOCHEM, V14, P929, DOI 10.1177/14.12.929; NIES D, 1982, J GEN APPL MICROBIOL, V28, P311, DOI 10.2323/jgam.28.311; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAINE BLT, 1988, J BACTERIOL, V170, P4415; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; SRIPRAKASH KS, 1970, J GEN MICROBIOL, V60, P125, DOI 10.1099/00221287-60-1-125; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1979, ANTIBIOTICS, P98; WAYNE LG, 1986, ANAL BIOCHEM, V157, P89, DOI 10.1016/0003-2697(86)90200-9; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WOODBURY W, 1971, ANAL BIOCHEM, V44, P301, DOI 10.1016/0003-2697(71)90375-7; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; Zhang Ying, 1993, Trends in Microbiology, V1, P109, DOI 10.1016/0966-842X(93)90117-A	53	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31265	31271		10.1074/jbc.272.50.31265	http://dx.doi.org/10.1074/jbc.272.50.31265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395452	hybrid			2022-12-27	WOS:A1997YL41900011
J	Tornaletti, S; Donahue, BA; Reines, D; Hanawalt, PC				Tornaletti, S; Donahue, BA; Reines, D; Hanawalt, PC			Nucleotide sequence context effect of a cyclobutane pyrimidine dimer upon RNA polymerase II transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; ELONGATION COMPLEX; EXCISION-REPAIR; ACTIVE GENE; DHFR GENE; STRAND; TRANSLOCATION; CLEAVAGE; REMOVAL; ADDUCTS	We have studied the role of sequence context upon RNA polymerase II arrest by a cyclobutane pyrimidine dimer using an in vitro transcription system consisting of templates containing a specifically located cyclobutane pyrimidine dimer (CPD) and purified RNA polymerase II (RNAP II) and initiation factors, We selected a model sequence containing a well characterized site for RNAP II arrest in vitro, the human histone H3.3 gene arrest site, The 13-base pair core of the arrest sequence contains two runs of T in the nontranscribed strand that impose a bend in the DNA. We hypothesized that arrest of RNAP II might be affected by the presence of a CPD, based upon the observation that a CPD located at the center of a dA(6).dT(6) tract eliminates bending (Wang, C.-I., and Taylor, J.-S. (1991) Proc. Natl. Acad Sci. U. S. A. 88, 9072-9076). We examined the normal H3.3 sequence and a mutant sequence containing a T --> G transversion, which reduces bending and efficiency of arrest, We show that a CPD in the transcribed strand at either of two locations in the arrest site is a potent block to transcription, However, a CPD in the nontranscribed strand only transiently pauses RNAP II. The CPD in concert with a mutation in the arrest site can reduce the extent of bending of the DNA and improve readthrough efficiency. These results demonstrate the potential importance of sequence context for the effect of CPDs within transcribed sequences.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Stanford University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [CA44349, R01 CA077712] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044349, R01CA077712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; KAHN M, 1974, BIOPOLYMERS, V13, P669, DOI 10.1002/bip.1974.360130403; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIM SH, 1988, BIOCHEM PHARMACOL, V37, P1791, DOI 10.1016/0006-2952(88)90448-0; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORDOUKHANIAN P, 1997, IN PRESS NUCL ACIDS; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tommasi S, 1996, BIOCHEMISTRY-US, V35, P15693, DOI 10.1021/bi962117z; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204	37	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31719	31724		10.1074/jbc.272.50.31719	http://dx.doi.org/10.1074/jbc.272.50.31719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395515	Green Accepted, hybrid			2022-12-27	WOS:A1997YL41900074
J	El-Shemerly, MYM; Besser, D; Nagasawa, M; Nagamine, Y				El-Shemerly, MYM; Besser, D; Nagasawa, M; Nagamine, Y			12-O-tetradecanoylphorbol-13-acetate activates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway upstream of SOS involving serine phosphorylation of Shc in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE-T ANTIGEN; PROTEIN-KINASE; GENE-EXPRESSION; RAS; TRANSDUCTION; TRANSFORMATION; DOMAINS; MANNER; RAF-1; DELTA	We investigated the activation of the Ras/ERK signaling pathway by 12-O-tetradecanoylphorbol-13-acetate (TPA) in NIH3T3 fibroblasts, Interestingly, the activation was suppressed not only by dominant negative Raf-1 but also by dominant negative Ras and SOS. Further analysis revealed that TPA treatment induced, dependently on protein kinase C, the mobility shift of p6(shc) in SDS-polyacrylamide gel electrophoresis, which could be prevented by treatment of the Shc immunoprecipitate with serine/threonine specific protein phosphatase 1 (PP1) or 2A (PPSA), Phosphoamino acid analysis of Shc showed that unlike growth factor-induced Shc phosphorylation, where Shc is mainly phosphorylated at tyrosine residues, TPA-induced phosphorylation was only at serine residues, Like growth factor-induced Shc phosphorylation, which leads to the association of Shc with Grb2, TPA also induced this association, but, correspondingly to the above results, the TPA-induced association was disrupted by in vitro treatment of the Shc immunoprecipitate with PP1, Taken together, these results suggest that the TPA signal was fed at or upstream of Shc to activate the Ras/ERK signaling pathway involving serine phosphorylation of Shc.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Nagamine, Y (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	nagamine@fmi.ch	Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624				ADCOCK MR, 1992, NATURE, V360, P689; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEREZ L, 1995, VIROLOGY, V208, P26, DOI 10.1006/viro.1995.1126; SALCINI AE, 1994, ONCOGENE, V9, P2827; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915	30	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30599	30602		10.1074/jbc.272.49.30599	http://dx.doi.org/10.1074/jbc.272.49.30599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388190	hybrid			2022-12-27	WOS:000071640800003
J	Emkey, R; Kahn, CR				Emkey, R; Kahn, CR			Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes I. Activation of protein kinase C stimulates tyrosine phosphorylation and activation of ErbB2 and ErbB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; HUMAN-BREAST-CANCER; INSULIN-RECEPTOR; ENDOGENOUS SUBSTRATE; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSFORMED CELLS; EPITHELIAL-CELLS; TUMOR-CELLS; ECTO-ATPASE	The tumor-promoting phorbol ester, phorbol 12 myristate 13-acetate (PMA), acutely stimulates the tyrosine phosphorylation of proteins of approximately 190, 120, and 70 kDa in the well differentiated Fao rat hepatoma cell line, This phosphorylation is dependent on protein kinase C (PKC) and is abolished by down-regulation of PKC or pretreatment with a PKC inhibitor, Purification of the 190-kDa tyrosine phosphorylated protein revealed that it consists of both ErbB2 and ErbB3, Following PMA-induced tyrosine phosphorylation, ErbB2 and ErbB3 were able to associate with the SH2 domains of several signaling proteins including the p85 alpha subunit of phosphatidylinositol S-kinase, Syp, and Grb2, The 120-kDa protein phosphorylated in response to PMA consists of at least two proteins: focal adhesion kinase that exhibits a minor increase in tyrosine phosphorylation following treatment with PMA, and a major 120-kDa tyrosine-phosphorylated species in PMA-stimulated Fao cells which as yet is unidentified, Similarly, the 70 kDa tyrosine phosphorylated protein also appears to represent more than one protein, including paxillin and a second protein of similar mobility which appears to be the major tyrosine phosphorylation in response to PMA, Both ErbB2 and paxillin also exhibit reduced migration on SDS-polyacrylamide gel electrophoresis following PMA treatment, suggesting that they are also phosphorylated on serine/threonine residues, The mobility shift of both of these proteins is abolished by treatment with inhibitors of PKC or mitogen-activated protein kinase/extracellular signal-related kinase kinase, These results suggest a novel mechanism of cross-talk between the serine/threonine kinase PKC and tyrosine phosphorylation pathways, The activation of ErbB2 and ErbB3 that is initiated by PMA may contribute to the tumor promoting activity of these compounds.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BELL RM, 1991, J BIOL CHEM, V266, P4661; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DICKER P, 1979, J SUPRAMOL STR CELL, V11, P79, DOI 10.1002/jss.400110109; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EARP HS, 1995, J BIOL CHEM, V270, P28440; Emkey R, 1997, J BIOL CHEM, V272, P31182, DOI 10.1074/jbc.272.49.31182; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRUNBERGER G, 1984, P NATL ACAD SCI-BIOL, V81, P2762, DOI 10.1073/pnas.81.9.2762; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOON SO, 1984, P NATL ACAD SCI-BIOL, V81, P2298, DOI 10.1073/pnas.81.8.2298; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NAJJAR SM, 1993, ADV EXP MED BIOL, V343; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OGAWA W, 1995, ENDOCRINOLOGY, V136, P476, DOI 10.1210/en.136.2.476; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; SEGATTO O, 1993, ONCOGENE, V8, P2105; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	77	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31172	31181		10.1074/jbc.272.49.31172	http://dx.doi.org/10.1074/jbc.272.49.31172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388271	hybrid			2022-12-27	WOS:000071640800084
J	Rodgers, AJW; Wilkens, S; Aggeler, R; Morris, MB; Howitt, SM; Capaldi, RA				Rodgers, AJW; Wilkens, S; Aggeler, R; Morris, MB; Howitt, SM; Capaldi, RA			The subunit delta subunit b domain of the Escherichia coli F(1)F(0)ATPase - The b subunits interact with F-1 as a dimer and through the delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ATP-SYNTHASE; H+-ATPASE; OXIDATIVE-PHOSPHORYLATION; EPSILON-SUBUNITS; CATALYTIC SITES; GAMMA-SUBUNITS; UNC OPERON; C-SUBUNIT; F1	The delta and b subunits are both involved in binding the F-1, to the F-0, part in the Escherichia coli ATP synthase (ECF1F0,). The interaction of the purified delta subunit and the isolated hydrophilic domain of the b subunit (b(sol),,,) has been studied here. Purified delta binds to b(sol),,, weakly in solution, as indicated by NMR studies and protease protection experiments. On F-1,, i.e. in the presence of ECF1-delta,, delta, and b(sol),,, interact strongly, and a complex of ECF1 . b(sol), b(sol),,, can be isolated by native gel electrophoresis. Both delta subunit and b(sol),,, are protected from trypsin cleavage in this complex. In contrast, the delta subunit is rapidly degraded by the protease when bound to ECF1, when b(sol),,, is absent. The interaction of b(sol),,, with ECF1, involves the C-terminal domain of delta as delta((1-134)), cannot replace intact delta in the binding experiments. As purified, b(sol),,, is a stable dimer with 80% alpha helix. A monomeric form of b(sol),,, can be obtained by introducing the mutation A128D (Howitt, S. M., Rodgers, A. J.,W., Jeffrey, P. D., and Cox, G., B. (1996) J. Biol. Chem. 271, 7038-7042). Monomeric b(sol),,, has less cu helix, i.e. only 58%, is much more sensitive to trypsin cleavage than dimer, and unfolds at much lower temperatures than the dimer in circular dichroism melting studies, indicating a less stable structure. The b(sol),,, dimer, but not monomer, binds to delta in ECF1,. To examine whether subunit b is a monomor or dimer in intact ECF1F0,, CuCl2, was used to induce cross-link formation in the mutants bS60C, bQ104C, bA128C, bG131C, and bS146C. With the exception of bS60C, CuCl2, treatment resulted in formation of b subunit dimers in all mutants. Cross-linking yield was independent of nucleotide conditions and did not affect ATPase activity. These results show the b subunit to be dimeric for a large portion of the C terminus, with residues 124-131 likely forming a pair of parallel alpha helices.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Sydney, Dept Pharm, Sydney, NSW 2006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	University of Oregon; University of Sydney; Australian National University; John Curtin School of Medical Research	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu	Howitt, Susan M/C-9308-2009; Morris, Michael/AAP-6590-2021; Rodgers, Andrew/H-3527-2013; Rodgers, Andrew/AAT-8756-2021	Howitt, Susan M/0000-0002-2192-2317; Rodgers, Andrew/0000-0002-8897-6221; Rodgers, Andrew/0000-0003-2063-4521; Morris, Michael/0000-0002-1286-4784	NHLBI NIH HHS [HL22450] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; DOWNIE JA, 1980, J BACTERIOL, V143, P8, DOI 10.1128/JB.143.1.8-17.1980; DUNN SD, 1992, J BIOL CHEM, V267, P7630; GIBSON F, 1978, J BACTERIOL, V134, P728, DOI 10.1128/JB.134.3.728-736.1978; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; HOWITT SM, 1992, P NATL ACAD SCI USA, V89, P9799, DOI 10.1073/pnas.89.20.9799; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	34	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31058	31064		10.1074/jbc.272.49.31058	http://dx.doi.org/10.1074/jbc.272.49.31058			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388256	hybrid			2022-12-27	WOS:000071640800069
J	Haller, M; Hoffmann, U; Schanding, T; Goody, RS; Vogel, PD				Haller, M; Hoffmann, U; Schanding, T; Goody, RS; Vogel, PD			Nucleotide hydrolysis-dependent conformational changes in p21(ras) as studied using ESR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-RESONANCE SPECTROSCOPY; H-RAS P21; BINDING-SITES; GTPASE REACTION; MECHANISM; F1-ATPASE; PROTEINS; SUPERFAMILY; ANALOG; ATP	We have employed ESR spectroscopy using guanine nucleotides that contain a spin label at the 2',3'-position of the ribose to investigate structural changes in the proto oncogene product p21(ras) that are dependent on nucleotide hydrolysis. The three nucleotide analogs used were 2',3'-(2,2,5,5-tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid ester (SL) GTP, SL-GDP, and the nonhydrolyzable analog SL-guanylylimidodiphosphate. SL-GTP was hydrolyzed by p21 with rates similar to those for GTP hydrolysis and appears to be an excellent substrate analog, The ESR spectra of SL-GTP and SL-GDP in complex with p21 differ significantly when acquired at 0 degrees C or 5 degrees C indicating different environments (conformations) of the protein-bound radicals depending on the phosphorylation state of the bound nucleotide, We calculated the rate constant for the conformational change as deduced from the changes in the corresponding ESR spectra upon incubation of the p21 SL-GTP complex at 25 degrees C and compared it to the rate constant of hydrolysis of SL-GTP at the same temperature. The rate constant deduced from the ESR method was similar to that determined by a high performance liquid chromatography technique, The data are in agreement with the idea that a conformational change during GTP hydrolysis by p21 occurs simultaneously with the actual hydrolysis step.	UNIV KAISERSLAUTERN,FACHBEREICH CHEM BIOCHEM,D-67663 KAISERSLAUTERN,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Kaiserslautern; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Vogel, Pia/0000-0002-8135-4649				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGARD S, 1994, J BIOL CHEM, V269, P17815; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOFFMANN U, 1995, THESIS U DORTMUND DO; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Losel RM, 1997, BIOCHEMISTRY-US, V36, P1188, DOI 10.1021/bi9614601; Losel RM, 1996, SPECTROCHIM ACTA A, V52, P73, DOI 10.1016/0584-8539(95)01549-3; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; MACARA IG, 1991, CELL SIGNAL, V3, P179, DOI 10.1016/0898-6568(91)90043-T; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NIXON AE, 1995, BIOCHEMISTRY-US, V34, P15592, DOI 10.1021/bi00047a026; PARK JH, 1989, BIOL MAGN RESON, V8, P547; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Satoh T, 1992, Semin Cancer Biol, V3, P169; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; TROMMER WE, 1987, PYRIDINE NUCLEOTID A, V2, P613; TROMMER WE, 1992, BIOACTIVE SPIN LABEL, P405; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0	29	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30103	30107		10.1074/jbc.272.48.30103	http://dx.doi.org/10.1074/jbc.272.48.30103			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374488	hybrid			2022-12-27	WOS:A1997YH61300020
J	Mackey, D; Sugden, B				Mackey, D; Sugden, B			Studies on the mechanism of DNA linking by Epstein-Barr virus nuclear antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; PLASMID MAINTENANCE; REPLICATION ORIGIN; LATENT INFECTION; EBNA-1; CELLS; SEQUENCE; DOMAIN; SITES; ORIP	Epstein-Barr virus nuclear antigen 1 (EBNA1) can both bind to and link DNA. Dimers of EBNA1 bind specific sites, two clusters of which, the FR and DS, comprise the necessary cis-acting elements of the Epstein-Barr viral origin of plasmid replication. EBNA1-dimers can link FR and DS, looping out the intervening DNA. EBNA1 can also intermolecularly link DNAs to which it binds. Residues of EBNA1 that can mediate linking have been mapped to at least three, non-overlapping domains. These domains, when fused to the dimerization and DNA-binding domain of GALA, can self-associate and thereby link DNAs bound site specifically by GAL4. Two disparate mechanisms could underlie self-association of linking domains: 1) linking domains could associate with other linking domains directly, or 2) linking domains could associate indirectly by binding to a common nucleic acid intermediate. We have found that EBNA1 can link DNA by each of these mechanisms, however, the linking domains associate directly with a greater apparent affinity than through a nonspecific nucleic acid intermediate.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NCI NIH HHS [CA22443, CA07175] Funding Source: Medline; NIGMS NIH HHS [T32-GM07215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; INOUE N, 1991, VIROLOGY, V182, P84, DOI 10.1016/0042-6822(91)90651-Q; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; KIRCHMAIER AL, 1995, J VIROL, V69, P1280, DOI 10.1128/JVI.69.2.1280-1283.1995; Laine A, 1995, J BIOL CHEM, V270, P30914, DOI 10.1074/jbc.270.52.30914; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; POLVINOBODNAR M, 1992, VIROLOGY, V187, P591, DOI 10.1016/0042-6822(92)90461-W; Puglielli MT, 1997, J VIROL, V71, P120, DOI 10.1128/JVI.71.1.120-128.1997; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Sambrook J., 2002, MOL CLONING LAB MANU; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; STERNAS L, 1990, J VIROL, V64, P2407; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; SUGDEN B, 1988, MOL BIOL MED, V5, P84; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; YATES JL, 1988, CANCER CELL, V6, P197	36	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29873	29879		10.1074/jbc.272.47.29873	http://dx.doi.org/10.1074/jbc.272.47.29873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368061	hybrid			2022-12-27	WOS:A1997YG64700071
J	Simon, KO; Nutt, EM; Abraham, DG; Rodan, GA; Duong, LT				Simon, KO; Nutt, EM; Abraham, DG; Rodan, GA; Duong, LT			The alpha(v)beta(3) integrin regulates alpha(5)beta(1)-mediated cell migration toward fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-MONOCYTES; HUMAN-ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIB-IIIA; SMOOTH-MUSCLE CELLS; VITRONECTIN RECEPTOR; CYTOPLASMIC DOMAIN; ALPHA-V; ALPHA-V-BETA-3 INTEGRIN; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION	This study examines the interactions of alpha(v) beta(3) and alpha(5) beta(1) in the regulation of cell migration, Human embryonic kidney (HEK) 293 cells that express alpha(5) beta(1) endogenously were transfected with alpha(v) beta(3) and beta(3) mutants, and their attachment and migration to fibronectin (Fn) and vitronectin (Vn) were measured, An alpha(v) beta(3) blocking antibody and the alpha(v) beta(3) ligand cyclic G-Pen-GRGDSPC-A inhibited alpha(5) beta(1)-mediated migration toward Fn, but not attachment to Fn. This function was alpha(v) beta(3)-specific since alpha(v) beta(5) transfection and alpha(v) beta(5) blocking antibody did not produce this effect, Mutations introduced into the beta(3) integrin subunit to dissect this phenomenon revealed the following, Disruption of the ligand binding domain by the Glanzmann thrombasthenia mutation beta(3)-D119Y constitutively abolished migration toward both Vn and Fn, and attachment to Vn but not to Fn. Insertion of the Glanzmann mutation beta(3)-S752P into the cytoplasmic domain or its truncation (beta(3)-Delta 717) abolished binding to Vn but not to Fn, Inhibition of migration toward Fn was inhibited in these cells by alpha(v) beta(3), blocking antibody. alpha(v) beta(3)-mediated inhibition was, however, abolished by truncation of the transmembrane domain (beta(3)-Delta 693). These findings demonstrate alpha(v) beta(3) regulation of alpha(5) beta(1)-mediated cell migration and suggest that the beta(3) transmembrane domain is essential for this function.	MERCK RES LABS, DEPT BONE BIOL & OSTEOPOROSIS, West Point, PA 19486 USA; MERCK RES LABS, DEPT PHARMACOL, West Point, PA 19486 USA	Merck & Company; Merck & Company								Abraham DG, 1997, MOL PHARMACOL, V52, P227, DOI 10.1124/mol.52.2.227; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONFORTI G, 1992, BLOOD, V80, P437; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DONATI MB, 1977, THROMB RES, V10, P173, DOI 10.1016/0049-3848(77)90092-5; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUJIMOTO T, 1995, BLOOD, V86, P2174, DOI 10.1182/blood.V86.6.2174.bloodjournal8662174; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hendey B, 1996, BLOOD, V87, P2038; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KIM JP, 1994, J BIOL CHEM, V269, P26926; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANTZ LM, 1995, BIOTECHNIQUES, V18, P56; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; REINHOLD MI, 1995, J CELL SCI, V108, P3419; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Simon K. O., 1994, INTEGRINS MOL BIOL R, P49; SMYTH SS, 1993, BLOOD, V81, P2827; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WRIGHT SD, 1984, J CELL BIOL, V99, P336, DOI 10.1083/jcb.99.1.336; WRIGHT SD, 1983, J EXP MED, V158, P1338, DOI 10.1084/jem.158.4.1338; WU CY, 1995, J CELL SCI, V108, P821; YLANNE J, 1995, J BIOL CHEM, V270, P9550	58	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29380	29389		10.1074/jbc.272.46.29380	http://dx.doi.org/10.1074/jbc.272.46.29380			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361020	hybrid			2022-12-27	WOS:A1997YF68400079
J	Aoki, H; Dekany, K; Adams, SL; Ganoza, MC				Aoki, H; Dekany, K; Adams, SL; Ganoza, MC			The gene encoding the elongation factor P protein is essential for viability and is required for protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; PEPTIDE-BOND SYNTHESIS; ESCHERICHIA-COLI; RIBOSOMAL-RNA; FACTOR-II; TRANSFERASE; TRANSLATION; IDENTIFICATION; SEQUENCE; CLONING	Elongation factor P (EFP) is a protein that stimulates the peptidyltransferase activity of fully assembled 70 S prokaryotic ribosomes and enhances the synthesis of certain dipeptides initiated by N-formylmethionine. This reaction appears conserved throughout species and is promoted in eukaryotic cells by a homologous protein, eIF5A. Here we ask whether the Escherichia coli gene encoding EFP is essential for cell viability, A kanamycin resistance (Kan(R)) gene was inserted near the N-terminal end of the efp gene and was cloned into a plasmid, pMAK705, that has a temperature-sensitive origin of replication. After transformation into a recA(+) E. coli strain, temperature-sensitive mutants were isolated, and their chromosomal DNA was sequenced. Mutants containing the efp-Kan(R) gene in the chromosome grew at 33 degrees C only in the presence of the wild-type copy of the efp gene in the pMAK705 plasmid and were unable to grow at 44 degrees C. Incorporation of various isotopes in vivo suggests that translation is impaired in the efp mutant at 44 degrees C. At 44 degrees C, mutant cells are severely defective in peptide-bond formation. We conclude that the efp gene is essential for cell viability and is required for protein synthesis.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	Ganoza, MC (corresponding author), Univ Toronto, Charles H Best Inst, Toronto, ON M5G 1L6, Canada.	m.ganoza@utoronto.ca		GANOZA MELGAREJO, MICHAEL RICHARD/0000-0003-0196-8104				AN G, 1980, CAN J BIOCHEM, V97, P23; Aoki H, 1997, BIOCHIMIE, V79, P7, DOI 10.1016/S0300-9084(97)87619-5; AOKI H, 1991, NUCLEIC ACIDS RES, V19, P6215, DOI 10.1093/nar/19.22.6215; BARTIG D, 1992, EUR J BIOCHEM, V204, P751, DOI 10.1111/j.1432-1033.1992.tb16690.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOSCH L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P293, DOI 10.1016/0167-4781(90)90184-4; CHUNG DG, 1990, RIBOSOMES PROTEIN SY, P69; COOPERMAN BS, 1990, RIBOSOME, P491; DABBS ER, 1983, MOL GEN GENET, V192, P301, DOI 10.1007/BF00392166; FELICETT.L, 1969, BIOCHEMISTRY-US, V8, P3428, DOI 10.1021/bi00836a044; GANOZA MC, 1993, EUR J BIOCHEM, V217, P839, DOI 10.1111/j.1432-1033.1993.tb18312.x; GANOZA MC, 1985, CELLULAR REGULATION, P123; GANOZA MC, 1985, EUR J BIOCHEM, V97, P23; GLICK BR, 1979, EUR J BIOCHEM, V97, P23, DOI 10.1111/j.1432-1033.1979.tb13081.x; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; KANG HA, 1994, J BIOL CHEM, V269, P3934; KAWAKAMI K, 1990, P NATL ACAD SCI USA, V87, P8432, DOI 10.1073/pnas.87.21.8432; KUWANO M, 1971, BIOCHEM BIOPH RES CO, V42, P441, DOI 10.1016/0006-291X(71)90390-1; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; MANIATIS T, 1982, MOL CLONING LABORATO, P153; NIERHAUS KH, 1979, RIBOSOMES STRUCTURE, P267; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; RACKEE ID, 1971, BIOCHEM BIOPH RES CO, V43, P169; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; RYDEN M, 1986, J BACTERIOL, V168, P1066, DOI 10.1128/jb.168.3.1066-1069.1986; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P1578; SPRINGER M, 1977, MOL GEN GENET, V151, P17, DOI 10.1007/BF00446908; SPRINGER M, 1977, P NATL ACAD SCI USA, V74, P3970, DOI 10.1073/pnas.74.9.3970; SYMONS RH, 1978, BIOORG CHEM, V4, P409; TOCCHINI.GP, 1968, P NATL ACAD SCI USA, V61, P146, DOI 10.1073/pnas.61.1.146; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x	41	68	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32254	32259		10.1074/jbc.272.51.32254	http://dx.doi.org/10.1074/jbc.272.51.32254			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405429	hybrid			2022-12-27	WOS:000071108000048
J	Chicheportiche, Y; Bourdon, PR; Xu, HD; Hsu, YM; Scott, H; Hession, C; Garcia, I; Browning, JL				Chicheportiche, Y; Bourdon, PR; Xu, HD; Hsu, YM; Scott, H; Hession, C; Garcia, I; Browning, JL			TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING RECEPTOR; MEDIATES APOPTOSIS; LYMPHOTOXIN-BETA; LYMPHOID ORGANS; MESSENGER-RNA; CELL-DEATH; T-CELLS; TNF; ANTIGEN; FAS	The members of the tumor necrosis factor (TNF) family play pivotal roles in the regulation of the immune system. Here we describe a new ligand in this family, designated TWEAK. The mouse and human versions of this protein are unusually conserved with 93% amino acid identity in the receptor binding domain. The protein was efficiently secreted from cells indicating that, like TNF, TWEAK may have the long range effects of a secreted cytokine. TWEAK transcripts were abundant and found in many tissues, suggesting that TWEAK and TRAIL belong to a new group of widely expressed ligands, Like many members of the TNF family, TWEAK was able to induce interleukin-8 synthesis in a number of cell lines. The human adenocarcinoma cell line, HT29, underwent apoptosis in the presence of both TWEAK and interferon-gamma. Thus, TWEAK resembles many other TNF ligands in the capacity to induce cell death; however, the fact that TWEAK-sensitive cells are relatively rare suggests that TWEAK. along with lymphotoxins alpha/beta and possibly CD30L trigger death via a weaker, nondeath domain-dependent mechanism.	Biogen Inc, Dept Cell Biol, Cambridge, MA 02142 USA; Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Biogen Inc, Dept Mol Genet, Cambridge, MA 02142 USA; Biogen Inc, Dept Prot Chem, Cambridge, MA 02142 USA	Biogen; University of Geneva; University of Geneva; Biogen; Biogen	Browning, JL (corresponding author), Biogen Inc, Dept Cell Biol, 12 Cambridge Ctr, Cambridge, MA 02142 USA.		Scott, Hamish/B-2122-2009	Scott, Hamish/0000-0002-5813-631X; Browning, Jeffrey/0000-0001-9168-5233				ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; AGEMATSU K, 1995, EUR J IMMUNOL, V25, P2825, DOI 10.1002/eji.1830251017; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHICHEPORTICHE Y, 1995, BIOCHEM BIOPH RES CO, V209, P1076, DOI 10.1006/bbrc.1995.1607; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DEBENEDETTE MA, 1995, J EXP MED, V181, P985, DOI 10.1084/jem.181.3.985; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GRELL M, 1994, J IMMUNOL, V153, P1963; GRUSS HJ, 1994, BLOOD, V83, P2045; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HANNUN YA, 1996, NATURE, V274, P1855; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Mackay F, 1997, J IMMUNOL, V159, P3299; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; SANTOS AA, 1993, ARCH SURG-CHICAGO, V128, P138; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRUBER E, 1996, J EXP MED, V183, P979; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	52	551	639	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32401	32410		10.1074/jbc.272.51.32401	http://dx.doi.org/10.1074/jbc.272.51.32401			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405449	hybrid			2022-12-27	WOS:000071108000068
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTED TRANSMEMBRANE DOMAIN; STIMULATED ATPASE ACTIVITY; FUNCTIONAL CONSEQUENCES; MUTATIONS; NUCLEOTIDE; CYSTEINE; MUTANTS; GENE; MDR1; SPECIFICITY	We identified a thiol-reactive compound, dibromobimane (dBBn), that was a potent stimulator (8.2-fold) of the ATPase activity of Cys-less P-glycoprotein, We then used this compound together with cysteine-scanning mutagenesis to identify residues in transmembrane segment (TM) 6 and TM12 that are important for function, TM6 and TM12 he close to each other in the tertiary structure and are postulated to be important for drug-protein interactions, The majority of P-glycoprotein mutants containing a single cysteine residue retained substantial amounts of drug-stimulated ATPase activity and were not inhibited by dBBn, The ATPase activities of mutants L339C, A342C, L975C, V982C, and A985C, however, were markedly inhibited (>60%) by dBBn, The drug substrates verapamil, vinblastine, and colchicine protected these mutants against inhibition by dBBn, suggesting that these residues are important for interaction of substrates with P-glycoprotein, We previously showed that residues Leu(339), Ala(342), Leu(975), Val(982), and Ala(985) lie along the point of contact between helices TM6 and TM12, when both are aligned in a left-handed coiled coil (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem, 272, 20986-20989), Taken together, these results suggest that the interface between TM6 and TM12 likely forms part of the potential drug-binding pocket in P-glycoprotein.	Univ Toronto, Dept Med, MRC, Membrane Biol Grp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Membrane Biol Grp, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; SCHEUTZ EG, 1996, P NATL ACAD SCI USA, V93, P4001; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	26	135	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31945	31948		10.1074/jbc.272.51.31945	http://dx.doi.org/10.1074/jbc.272.51.31945			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405384	hybrid			2022-12-27	WOS:000071108000003
J	Mallo, GV; Fiedler, F; Calvo, EL; Ortiz, EM; Vasseur, S; Keim, V; Morisset, J; Iovanna, JL				Mallo, GV; Fiedler, F; Calvo, EL; Ortiz, EM; Vasseur, S; Keim, V; Morisset, J; Iovanna, JL			Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INDUCED APOPTOSIS; EXOCRINE PANCREAS; PROTEIN; SEQUENCES; STRESS; CELLS; PROLIFERATION; THYMOCYTES; DEATH	To characterize at the molecular level the pancreatic emergency program set up by the pancreatic cells in response to pancreatitis, we have developed a strategy in which the phenotype of the pancreatitis affected pancreas is established by characterization of a large number of its transcripts. Herein, we describe the cloning, sequence, and expression of a new gene, named p8, which is strongly activated in pancreatic acinar cells during the acute phase of pancreatitis, in developing pancreas and during pancreatic regeneration. In acinar cells, p8 mRNA is expressed rapidly and specifically in response to cellular pancreatitis-induced injury; its induction occurred almost similarly in edematous and necrohemorrhagic pancreatitis, indicating that p8 mRNA is maximally activated even in response to a mild pancreatic injury. Furthermore, in vitro studies suggest that p8 mRNA is induced in pancreatic and non-pancreatic cells in response to some apoptotic stimuli. p8 acts as a promoter of cellular growth factor when its cDNA is transfected into COS-7 and AR4-2J cells. Although we failed to identify p8-related sequences, analysis of its primary and secondary structure suggests that p8 is a basic helix-turn-helix-containing gene with slight homology to several homeotic genes and sufficient signal to be targeted to the nucleus. We therefore propose p8 as a putative transcriptional factor which can regulate pancreatic growth.	INSERM, U315, F-13009 Marseille, France; Heidelberg Univ, Klinikum Mannheim, Inst Anasthesie, D-68167 Mannheim, Germany; Univ Sherbrooke, Fac Med, Dept Med, Gastroenterol Serv, Sherbrooke, PQ J1H 5N4, Canada; Univ Leipzig, Zentrum Innere Med, Med Klin 2, D-04103 Leipzig, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg; University of Sherbrooke; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Iovanna, JL (corresponding author), INSERM, U315, 46 Bd De La Gaye, F-13009 Marseille, France.	iovanna@marseille.inserm.fr	vasseur, sophie/O-9803-2017; Iovanna, Juan/M-9805-2017	vasseur, sophie/0000-0002-2339-8854; Iovanna, Juan/0000-0003-1822-2237				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRENNAN RG, 1989, TRENDS BIOCHEM SCI, V14, P286, DOI 10.1016/0968-0004(89)90066-2; Brown IR, 1995, NEUROPATH APPL NEURO, V21, P473, DOI 10.1111/j.1365-2990.1995.tb01088.x; Calvo E., 1993, Pancreas, V8, P751; Calvo E., 1993, Digestion, V54, P268; CALVO E, 1995, GASTROENTEROLOGY, V108, pA955; Calvo EL, 1997, J MOL ENDOCRINOL, V18, P233, DOI 10.1677/jme.0.0180233; Calvo EL, 1997, GASTROENTEROLOGY, V112, pA432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUSETTI NJ, 1995, BIOCHEM J, V307, P9, DOI 10.1042/bj3070009; Foglia Virgilio G., 1944, REV SOC ARGENTINA BIOL, V20, P21; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; GO VLW, 1993, PANCREAS BIOL PATHOB, P1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSILLI E, 1992, BIOCHEM BIOPH RES CO, V188, P1261, DOI 10.1016/0006-291X(92)91367-Y; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; HUTTUNEN R, 1975, SCAND J GASTROENTERO, V10, P177; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA JL, 1992, PANCREAS, V7, P712, DOI 10.1097/00006676-199211000-00013; IOVANNA JL, 1991, AM J PHYSIOL, V261, pG485, DOI 10.1152/ajpgi.1991.261.3.G485; IWANIJ V, 1982, J CELL BIOL, V95, P742, DOI 10.1083/jcb.95.3.742; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KEIM V, 1994, DIGESTION, V55, P65, DOI 10.1159/000201127; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; KOMMINOTH P, 1995, LAB INVEST, V72, P424; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANKISCH PG, 1974, SCAND J GASTROENTERO, V9, P725; McIntosh TK, 1995, NEUROPATH APPL NEURO, V21, P477; OATES PS, 1989, J ANAT, V167, P235; OHLSSON K, 1991, PANCREATIC DIS PROGR, P213; PARSA I, 1969, AM J PATHOL, V57, P457; PARSA I, 1969, AM J PATHOL, V57, P489; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SESSO A, 1973, ACTA PHYSIOL LAT AM, V23, P36; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; TROIANO L, 1995, BIOCHEM BIOPH RES CO, V214, P941, DOI 10.1006/bbrc.1995.2377; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON C, 1991, PANCREATIC DIS PROGR, P287; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMAGUCHI H, 1989, PANCREAS, V4, P565, DOI 10.1097/00006676-198910000-00007	56	197	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32360	32369		10.1074/jbc.272.51.32360	http://dx.doi.org/10.1074/jbc.272.51.32360			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405444	hybrid			2022-12-27	WOS:000071108000063
J	Nagel, G; Volk, C; Friedrich, T; Ulzheimer, JC; Bamberg, E; Koepsell, H				Nagel, G; Volk, C; Friedrich, T; Ulzheimer, JC; Bamberg, E; Koepsell, H			A reevaluation of substrate specificity of the rat cation transporter rOCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MECHANISMS; SYSTEM; DRUGS; LIVER	The substrate specificity of the previously cloned rat cation transporter rOCT1, which is expressed in kidney, liver, and small intestine, was reevaluated. rOCT1 is the first member of a new protein family comprising electrogenic and polyspecific cation transporters that transport hydrophilic cations like tetraethylammonium, choline, and monoamine neurotransmitters. Previous electrical measurements suggested that cations like quinine, quinidine, and cyanine 863, which have been classified as type 2 cations in the liver, are also transported by rOCT1, since they may induce inward currents in rOCT1 expressing Xenopus oocytes (Busch, A. E., Quester, S., Ulzheimer, J. C., Waldegger, S., Gorboulev, V., Arndt, P., Lang, F., and Koepsell, H. (1996) J. Biol. Chem. 271, 32599-32604). Tracer flux measurements with oocytes and with stably transfected human embryonic kidney cells showed that [H-3]quinine and [H-3]quinidine are not transported by rOCT1. The voltage dependence observed for the quinine-or quinidine-induced inward currents in rOCT1-expressing oocytes, and tracer efflux measurements indicate that the in ward currents by type 2 cations are generated by the inhibition of electrogenic efflux of transported type I cations. Therefore, rOCT1 cannot contribute to transport of type 2 cations in the liver and the hepatic transporter for type 2 cations remains to be identified.	Max Planck Inst Biophys, D-60596 Frankfurt, Germany; Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany; Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	Max Planck Society; Goethe University Frankfurt; University of Wurzburg	Nagel, G (corresponding author), Max Planck Inst Biophys, Kennedy Allee 70, D-60596 Frankfurt, Germany.		Friedrich, Thomas/AAA-3418-2022	Nagel, Georg/0000-0001-8174-8712				Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1996, FEBS LETT, V395, P153, DOI 10.1016/0014-5793(96)01030-7; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Groothuis GMM, 1996, J HEPATOL, V24, P3; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MOL WEM, 1988, J PHARMACOL EXP THER, V244, P268; Nagel G, 1995, FEBS LETT, V377, P263, DOI 10.1016/0014-5793(95)01356-3; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; ROCHRAMEL F, 1992, HDB PHYSL, P2189; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; STEEN H, 1991, J PHARMACOL EXP THER, V258, P537; STEEN H, 1992, BIOCHEM PHARMACOL, V44, P2323, DOI 10.1016/0006-2952(92)90676-A; Zhang L, 1997, J BIOL CHEM, V272, P16548, DOI 10.1074/jbc.272.26.16548; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	21	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31953	31956		10.1074/jbc.272.51.31953	http://dx.doi.org/10.1074/jbc.272.51.31953			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405386	hybrid			2022-12-27	WOS:000071108000005
J	Plant, PJ; Yeger, H; Staub, O; Howard, P; Rotin, D				Plant, PJ; Yeger, H; Staub, O; Howard, P; Rotin, D			The C2 domain of the ubiquitin protein ligase Nedd4 mediates Ca2+-dependent plasma membrane localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; GTPASE-ACTIVATING PROTEIN; LIPID-BINDING DOMAIN; KINASE-C; PHOSPHOLIPASE-C; SYNAPTOTAGMIN-I; LIDDLE SYNDROME; BETA-SUBUNIT; MISSENSE MUTATION; WW DOMAINS	Neuronal precursor cell-expressed developmentally down-regulated 4 (Nedd4) is a ubiquitin protein ligase (E3) containing a beet domain, 3 or 4 WW domains, and a putative C2 domain. We have recently demonstrated an association between the WW domains of Nedd4 and the proline-rich PY motifs (XPPXY) of the epithelial Na+ channel, as well as with PY motifs of several other proteins. The role of the putative C2 domain of Nedd4 has not been elucidated. Here we show that Nedd4, endogenously expressed in Madin-Darby canine kidney cells, was redistributed from the cytosolic to the particulate fraction in response to ionomycin plus Ca2+ treatment. A similar treatment of polarized Madin-Darby canine kidney cells led to an apical and lateral membrane localization of Nedd4, as determined by immunostaining and confocal microscopy. The C2 domain of Nedd4, expressed as a glutathione S-transferase (GST) fusion protein, was sufficient to bind cellular membranes in a Ca2+- dependent manner. Moreover, this GST-Nedd4-C2 domain was able to mediate Ca2+-dependent interactions with phosphatidylserine, phosphatidylinositol, and phosphatidylcholine liposomes in. vitro. An epitope-tagged Nedd4 lacking its C2 domain and stably expressed in Madin-Darby canine kidney cells failed to mediate the Ca2+-induced plasma membrane localization seen in wild-type (epitope-tagged) Nedd4. These results indicate that the putative C2 domain of Nedd4 acts as a bona fide C2 domain which binds phospholipids and membranes in a Ca2+-dependent fashion and is involved in localizing the protein primarily to the apical region of polarized epithelial cells in response to Ca2+.	Hosp Sick Children, Div Resp Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Rotin, D (corresponding author), Hosp Sick Children, Div Resp Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Howard, Perry/0000-0002-9837-9359				BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAMER CK, 1994, J BIOL CHEM, V269, P31115; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DELLES C, 1995, J PHYSIOL-LONDON, V486, P557, DOI 10.1113/jphysiol.1995.sp020834; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GAWLER DJ, 1995, BIOCHEM J, V307, P487, DOI 10.1042/bj3070487; GAWLER DJ, 1995, ONCOGENE, V10, P817; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LANG F, 1990, RENAL PHYSIOL BIOCH, V13, P82; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; PALMER LG, 1987, AM J PHYSIOL, V253, pF333, DOI 10.1152/ajprenal.1987.253.2.F333; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Ponting CP, 1996, PROTEIN SCI, V5, P162; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; ULRICH U, 1994, NEURON, V13, P1281; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	53	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32329	32336		10.1074/jbc.272.51.32329	http://dx.doi.org/10.1074/jbc.272.51.32329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405440	hybrid			2022-12-27	WOS:000071108000059
J	DeFea, K; Roth, RA				DeFea, K; Roth, RA			Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; IN-VIVO; RESIDUES; ALPHA; IRS-1; DESENSITIZATION; IDENTIFICATION; SPECIFICITY; PATHWAYS	Increased serine phosphorylation of insulin receptor substrate-1 (IRS-1) has been observed in several systems to correlate with a decreased ability of the insulin receptor to tyrosine-phosphorylate this endogenous substrate and to inhibit its subsequent association with phosphatidylinositol 3-kinase. In the present studies we have examined the potential role of the mitogen-activated protein (MAP) kinase in the increased serine phosphorylation of IRS-1 observed in human embryonic kidney cells treated with an activator of protein kinase C, phorbol 12-myristate 13-acetate. First, recombinantly produced kinase was shown to phosphorylate intact IRS-1 in a way that decreased the ability of isolated insulin receptor to phosphorylate the tyrosines recognized by the SH2 domains of the phosphatidylinositol 3-kinase. Second, an inhibitor of MAP kinase activation, PD98059, blocked the phorbol 12-myristate 13-acetate-induced inhibition of the insulin-stimulated increase in IRS-1 associated phosphatidylinositol 3-kinase. Third, activation of MAP kinase in intact cells via a regulatable upstream kinase, a RAF:estrogen receptor construct, could also inhibit the insulin-stimulated increase in IRS-1-associated phosphatidylinositol 3-kinase. Fourth, an in gel kinase assay showed that MAP kinase was the primary renaturable kinase in cell extracts capable of phosphorylating an IRS-1 fusion protein. Finally, IRS-1 was found to associate in coprecipitation studies with endogenous MAP kinase. These studies implicate MAP kinase as one of the kinases capable of phosphorylating and regulating IRS-1 tyrosine phosphorylation.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK 34926, DK09310] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, F32DK009310, R01DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DEFEA K, 1997, BIOCHEMISTRY-US, V36, P181; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Leitner JW, 1997, ENDOCRINOLOGY, V138, P2211, DOI 10.1210/en.138.5.2211; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD ER, 1992, J BIOL CHEM, V267, P14138; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	36	245	250	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31400	31406		10.1074/jbc.272.50.31400	http://dx.doi.org/10.1074/jbc.272.50.31400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395471	hybrid			2022-12-27	WOS:A1997YL41900030
J	Okamoto, M; Sudhof, TC				Okamoto, M; Sudhof, TC			Mints, Munc18-interacting proteins in synaptic vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTB DOMAIN; SYNTAXIN; PHOSPHOTYROSINE; INTERACTS; BINDING; FUSION; SYNAPTOBREVIN; SNAP-25; DOCKING; SYSTEM	Munc18-1 is a neuronal protein that interacts with syntaxin 1 and is required for synaptic vesicle exocytosis. We have now identified two Munc18-1-interacting proteins called Mint1 and Mint2 that may mediate the function of Munc18-1. Mint proteins are detectable only in brain and are composed of an N-terminal sequence that binds Munc18-1, a middle phosphotyrosine-binding domain, and two C-terminal PDZ domains thought to attach proteins to the plasma membrane. In brain, Mint proteins are part of a multimeric complex containing Munc18-1 and syntaxin that likely functions as an intermediate in synaptic vesicle docking/fusion. The phosphotyrosine-binding domain specifically binds to phosphatidylinositol phosphates known to be produced during vesicle exocytosis (Hay, J. C., Fisette, P. L., Jenkins, G. H., Fukami, K., Takonawa, T., Anderson, R. A., and Martin, T. F. J. (1995) Nature 374, 173-177). Our data suggest a model whereby local production of phosphatidylinositol phosphates may trigger the binding of vesicles to the active zone via the Minc.Munc18-1 complex in conjunction with syntaxin 1.	UNIV TEXAS,SW MED SCH,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; DUCLOS F, 1995, MAMM GENOME, V6, P57, DOI 10.1007/BF00350899; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Sambrook J., 2002, MOL CLONING LAB MANU; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	29	263	277	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31459	31464		10.1074/jbc.272.50.31459	http://dx.doi.org/10.1074/jbc.272.50.31459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395480	hybrid			2022-12-27	WOS:A1997YL41900039
J	Force, WR; Cheung, TC; Ware, CF				Force, WR; Cheung, TC; Ware, CF			Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; TRANSDUCING PROTEINS; ACTIVATION; FAMILY; ALPHA; CD40; BINDING; LMP1; ASSOCIATION	Ligation of the lymphotoxin-beta receptor (LT beta R) recruits tumor necrosis factor receptor-associated factor-3 (TRAF3) and initiates cell death in HT29 adenocarcinoma cells. The minimal receptor binding domain (TRAF-C) defined by two hybrid analyses is not sufficient for direct recruitment to the ligated receptor. A series of TRAF3 deletion mutants reveal that a subregion of the coiled coil motif is required for efficient recruitment to the LT beta R. Furthermore, the ability of TRAF3 to self-associate maps to an adjacent subregion, A TRAF3 deletion mutant that lacks the N-terminal zinc RING and zinc finger motifs, but retains the coiled coil and TRAF-C motifs, competitively displaces endogenous TRAF3 from the LT beta R. A second TRAF3 mutant that lacks the receptor binding domain, yet contains the TRAF3 self association domain, prevents TRAF3 homodimers from being recruited to the LT beta R. Both of these mutants have a dominant negative effect on cell death and demonstrate that the recruitment of TRAF3 oligomers is necessary to initiate signal transduction that activates the cell death pathway.	La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Ware, CF (corresponding author), La Jolla Inst Allergy & Immunol, Div Mol Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	CarlWare@liai.org			NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FORCE WR, 1995, J IMMUNOL, V155, P5280; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Hochman PS, 1996, J INFLAMM, V46, P220; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KRAJEWSKI JS, 1997, IN PRESS J IMMUNOL; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1997, GENOMICS, V42, P26, DOI 10.1006/geno.1997.4697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5	44	78	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30835	30840		10.1074/jbc.272.49.30835	http://dx.doi.org/10.1074/jbc.272.49.30835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388227	hybrid			2022-12-27	WOS:000071640800040
J	Johnson, JE; Edwards, AS; Newton, AC				Johnson, JE; Edwards, AS; Newton, AC			A putative phosphatidylserine binding motif is not involved in the lipid regulation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HIGH-AFFINITY; NULL ALLELE; CLONING; DECARBOXYLASE; GENE; EXPRESSION; DOMAIN; DIACYLGLYCEROL; ACTIVATION	Protein kinase C is specifically regulated by diacylglycerol and the amino phospholipid, phosphatidylserine. The molecular basis for the phosphatidylserine specificity was recently proposed to arise hom the presence of a putative phosphatidylserine binding motif, FXFXLKXXXKXR, localized in the C2 domain of protein kinase C (Igarashi, K., Kaneda, M., Yamaji, A. Saido, T. C., Kikkawa, Il,, One, U,, Inoue, a, and Umeda, M, (1995) J. Biol. Chem. 270, 29075-29078). To determine whether this moth mediates the interaction of protein kinase C with phosphatidylserine, the carboxyl terminal basic residues were mutated to Ala in protein kinase C beta II (K236A and R238A), and the phosphatidylserine regulation of the mutant enzyme was examined. Membrane binding and activity measurements revealed that the phosphatidylserine regulation for the mutant protein was indistinguishable from that of wild-type protein kinase C. Specifically, neither the apparent membrane affinity for phosphatidylserine-containing membranes in the presence or absence of diacylglycerol nor the phosphatidyl-serine-dependence for activation was affected by removal of the conserved basic residues at the carboxyl terminus of the consensus sequence. In addition, a synthetic peptide corresponding to the amino terminus of the consensus sequence (FTFNVK) had no effect on the concentration of phosphatidylserine resulting in half-maximal activation of protein kinase C. These results reveal that the carboxyl-terminal basic residues in the consensus moth FXFXLKXXXKXR are not responsible for the phosphatidylserine selectivity of protein kinase C and that, furthermore, the region of the C2 domain containing this moth is not involved in the membrane binding of protein kinase C.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	anewton@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; EDWARDS AS, 1998, IN PRESS BIOCHEMISTR; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JEAN T, 1986, J BIOL CHEM, V261, P6414; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUGE O, 1991, J BIOL CHEM, V266, P6370; LEE MH, 1989, J BIOL CHEM, V264, P14797; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1988, J BIOL CHEM, V263, P6927; OREILLY DR, 1994, BACULOVIRUS EXPRESSI, P128; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Sato T, 1997, J BIOL CHEM, V272, P2192; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416	31	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30787	30792		10.1074/jbc.272.49.30787	http://dx.doi.org/10.1074/jbc.272.49.30787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388219	hybrid			2022-12-27	WOS:000071640800032
J	Storm, D; Herz, J; Trinder, P; Loos, M				Storm, D; Herz, J; Trinder, P; Loos, M			C1 Inhibitor-C(1)over-bar-s complexes are internalized and degraded by the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; AMYLOID-BETA PEPTIDE; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; PLASMINOGEN-ACTIVATOR; SEC RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR; PROTEOLYTIC INACTIVATION; CULTURED-CELLS	Like other serpin-enzyme complexes (SECs), proteinase-complexed C1 inhibitor (C1-INH) is rapidly cleared from the circulation and thought to be a neutrophil chemoattractant, suggesting that complex formation causes structural rearrangements exposing a domain which is recognized by specific cell surface receptors. However, the cellular receptor(s) responsible for the catabolism and potential mediation of chemotaxis by C1-INH-protease complexes remained obscure, To determine whether the SEC receptor mediates the binding and potential chemotaxis of C1-INH . C (1) over bar s, we performed binding assays with HepG2 cells, neutrophils, and monocytes, and the results show that C1-INH . C (1) over bar s neither bind to these cells nor cause a chemotactic response of neutrophils and monocytes, Furthermore, C1-INH . C (1) over bar s, the COOH-terminal C1 inhibitor peptide, or the tetrameric C1-INH . C (1) over bar s . C (1) over bar r . C1-INH complex were found to be significantly less effective in competing with the SEC receptor ligand I-125-peptide 105Y for the binding to HepG2; cells than unlabeled 105Y, indicating that the SEC receptor does not sufficiently recognize C1-INH-proteaae complexes. The asialoglycoprotein receptor was also ruled out to be responsible for the removal of the heavily glycosylated C1-INH . C (1) over bar s complex, since asialoorosomucoid did not compete for the clearance of C1-INH .I-125-C (1) over bar s and asialoglycoprotein receptor knockout mice showed no alterations in the C1-INH .I-125-C (1) over bar s clearance rate. We found that C1-INH .I-125-C (1) over bar s complexes were efficiently degraded by normal murine fibroblasts expressing the low density lipoprotein receptor-related protein (LRP) and cellular degradation was significantly reduced by chloroquine and the receptor-associated protein, which is a potent inhibitor of the binding of all known ligands to LRP. Moreover, receptor-associated protein inhibited the in vivo clearance of C1-INH .I-125-C (1) over bar s .,and murine fibroblasts genetically deficient for LRP did not degrade C1-INH .I-125-C (1) over bar s. Our results demonstrate that C1-INH . C (1) over bar s complexes do not stimulate neutrophil or monocytic chemotaxis but are removed by LRP, further underscoring its role as a serpin-enzyme complex clearance receptor.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Johannes Gutenberg University of Mainz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Loos, M (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; ALSENZ J, 1987, J IMMUNOL METHODS, V96, P107, DOI 10.1016/0022-1759(87)90373-5; ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BRANDES ME, 1991, J IMMUNOL, V147, P1600; BRENNEIS H, 1993, EUR J CLIN INVEST, V23, P693, DOI 10.1111/j.1365-2362.1993.tb01288.x; COUTINHO M, 1994, J IMMUNOL, V153, P3648; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; FUCHS HE, 1984, J CELL BIOCHEM, V25, P231, DOI 10.1002/jcb.240250405; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; Malek R, 1996, CLIN EXP IMMUNOL, V105, P191, DOI 10.1046/j.1365-2249.1996.d01-714.x; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MINTA JO, 1981, J IMMUNOL, V126, P245; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NILSSON T, 1983, BIOCHEM J, V213, P617, DOI 10.1042/bj2130617; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PATSTON PA, 1993, BLOOD, V82, P3371; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1989, AM J MED, V87, pS10, DOI 10.1016/0002-9343(89)80524-8; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; REBOUL A, 1987, BIOCHEM J, V244, P117, DOI 10.1042/bj2440117; REID KBM, 1988, MOL IMMUNOL, P199; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; Storm D, 1996, J IMMUNOL METHODS, V199, P87, DOI 10.1016/S0022-1759(96)00172-X; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOSI M, 1993, COMPLEMENT HLTH DIS, P248; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; ZICCARDI RJ, 1979, J IMMUNOL, V123, P788	55	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31043	31050		10.1074/jbc.272.49.31043	http://dx.doi.org/10.1074/jbc.272.49.31043			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388254	hybrid			2022-12-27	WOS:000071640800067
J	Broer, S; Rahman, B; Pellegri, G; Pellerin, L; Martin, JL; Verleysdonk, S; Hamprecht, B; Magistretti, PJ				Broer, S; Rahman, B; Pellegri, G; Pellerin, L; Martin, JL; Verleysdonk, S; Hamprecht, B; Magistretti, PJ			Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes - Expression of two different monocarboxylate transporters in astroglial cells and neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; CDNA CLONING; RAT-BRAIN; INHIBITOR SPECIFICITY; CULTURED ASTROCYTES; MEMBRANE-PROTEINS; GLIOMA-CELLS; GLIAL-CELLS; ACID; GLUTAMATE	The transport of lactate is an essential part of the concept of metabolic coupling between neurons and glia. Lactate transport in primary cultures of astroglial cells was shown to be mediated by a single saturable transport system with a K-m value for lactate of 7.7 mM and a V-max value of 250 nmol(min x mg of protein). Transport was inhibited by a variety of monocarboxylates and by compounds known to inhibit monocarboxylate transport in other cell types, such as alpha-cyano-4-hydroxycinnamate and p-chloromercubenzenesulfonate. Using reverse transcriptase-polymerase chain reaction and Northern blotting, the presence of mRNA coding for the monocarboxylate transporter 1 (MCT1) was demonstrated in primary cultures of astroglial cells. Ln contrast, neuron-rich primary cultures were found to contain the mRNA coding for the monocarboxylate transporter 2 (MCT2), MCT1 was cloned and expressed in Xenopus laevis oocytes, Comparison of lactate transport in MCT1 expressing oocytes with lactate transport in glial cells revealed that MCT1 can account for all characteristics of lactate transport in glial cells. These data provide further molecular support for the existence of a lactate shuttle between astrocytes and neurons.	UNIV LAUSANNE,FAC MED,INST PHYSIOL,CH-1005 LAUSANNE,SWITZERLAND	University of Geneva; University of Lausanne	Broer, S (corresponding author), UNIV TUBINGEN,INST PHYSIOL CHEM,HOPPE SEYLER STR 4,D-72076 TUBINGEN,GERMANY.		Broer, Stefan/A-1286-2008; Pellerin, Luc/A-8912-2017	Broer, Stefan/0000-0002-8040-1634; Pellerin, Luc/0000-0002-1016-1970; Magistretti, Pierre Julius/0000-0002-6678-320X				Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; BROER S, 1994, BBA-BIOMEMBRANES, V1192, P95, DOI 10.1016/0005-2736(94)90147-3; BRUNE T, 1994, PFLUG ARCH EUR J PHY, V429, P64, DOI 10.1007/BF02584031; Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; DRINGEN R, 1995, DEV NEUROSCI-BASEL, V17, P63, DOI 10.1159/000111275; DRINGEN R, 1993, NEUROSCI LETT, V163, P5, DOI 10.1016/0304-3940(93)90215-7; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JACKSON VN, 1995, BBA-BIOMEMBRANES, V1238, P193, DOI 10.1016/0005-2736(95)00160-5; KIM CM, 1992, J BIOL CHEM, V267, P23113; KIMGARCIA C, 1994, CELL, V76, P865; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P1284, DOI 10.1021/bi00219a018; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; NEDERGAARD M, 1993, AM J PHYSIOL, V265, pR282, DOI 10.1152/ajpregu.1993.265.2.R282; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; SCHNEIDER U, 1993, NEUROSCIENCE, V53, P1153, DOI 10.1016/0306-4522(93)90497-4; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SORG O, 1991, BRAIN RES, V563, P227, DOI 10.1016/0006-8993(91)91538-C; STELLA N, 1995, J NEUROSCI, V15, P3307; TAKANAGA H, 1995, BIOCHEM BIOPH RES CO, V217, P370, DOI 10.1006/bbrc.1995.2786; TILDON JT, 1993, NEUROCHEM RES, V18, P177, DOI 10.1007/BF01474682; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; Volk C, 1997, NEUROSCI LETT, V223, P121, DOI 10.1016/S0304-3940(97)13420-6; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588; YUDKOFF M, 1986, BIOCHEM J, V234, P185, DOI 10.1042/bj2340185	41	268	277	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30096	30102		10.1074/jbc.272.48.30096	http://dx.doi.org/10.1074/jbc.272.48.30096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374487	hybrid			2022-12-27	WOS:A1997YH61300019
J	SanchezAlcazar, JA; RuizCabello, J; HernandezMunoz, I; Pobre, PS; delaTorre, P; SilesRivas, E; Garcia, I; Kaplan, O; MunozYague, MT; SolisHerruzo, JA				SanchezAlcazar, JA; RuizCabello, J; HernandezMunoz, I; Pobre, PS; delaTorre, P; SilesRivas, E; Garcia, I; Kaplan, O; MunozYague, MT; SolisHerruzo, JA			Tumor necrosis factor-alpha increases ATP content in metabolically inhibited L929 cells preceding cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXICITY; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANISMS; CONSUMING PROCESSES; OXIDATIVE STRESS; MAMMALIAN-CELLS; APOPTOSIS; CYTOTOXICITY; INVOLVEMENT; GENERATION	The effects of tumor necrosis factor-alpha (TNF) on ATP levels were studied in metabolically inhibited L929 cells. Treatment of these cells with TNF in the presence of actinomycin D or cycloheximide induces cyclic changes in the intracellular ATP content preceding cell death. After 3 h of incubation, the intracellular ATP content increased by 48 +/- 6% (p < 0.001), but at 4 h, it decreased to the control level. Two hours later, it increased again by 23 +/- 5% over the control level (p < 0.001). Coinciding with cell death, ATP content decreased progressively until almost complete depletion. These changes in ATP content were associated with parallel alterations in the respiratory coupling and with increased generation of reactive oxygen species. The mechanism by which TNF/ actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP synthesis and related to the cytotoxic effect of TNF, since blockade of mitochondrial electron transport prevented the increase in cellular ATP, the formation of reactive oxygen species, and the apoptotic cell death caused by TNF. We suggest that the TNF/actinomycin Dor TNF/cycloheximide-induced changes in intracellular ATP levels may be involved in the cytotoxic effect of TNF in metabolically inhibited L929 cells.	HOSP UNIV 12 OCTUBRE,CTR INVEST,MADRID 28041,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,DEPT QUIM FIS 2,INST PLURIDISCIPLINAR,E-28040 MADRID,SPAIN; TEL AVIV MED CTR & SCH MED,DEPT SURG A,IL-64239 TEL AVIV,ISRAEL	Hospital Universitario 12 de Octubre; Complutense University of Madrid; Tel Aviv University; Sackler Faculty of Medicine			Sanchéz-Alcázar, José A. A/L-4925-2014; Ruiz-Cabello, Jesus/A-9570-2012; García-Ruiz, Inmaculada/G-8204-2015	Sanchéz-Alcázar, José A. A/0000-0001-9705-1469; Ruiz-Cabello, Jesus/0000-0001-8681-5056; García-Ruiz, Inmaculada/0000-0003-4185-8524; Siles Rivas, Eva/0000-0003-4192-7008				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; BROWN GC, 1992, BIOCHEM J, V284, P1; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHOU CC, 1995, CANCER LETT, V96, P181, DOI 10.1016/0304-3835(95)03927-O; COLTTON T, 1979, ESTADICTICA MED, P103; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; EGUCHI Y, 1997, CANCER RES, V57, P835; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Grunfeld C, 1990, Adv Intern Med, V35, P45; Hampp R, 1985, METHOD ENZYMAT AN, VVII, P370; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KULL FC, 1981, CANCER RES, V41, P4885; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; MULLER M, 1986, EUR J BIOCHEM, V161, P701, DOI 10.1111/j.1432-1033.1986.tb10496.x; MURPHY MP, 1989, BIOCHIM BIOPHYS ACTA, V977, P123, DOI 10.1016/S0005-2728(89)80063-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OLLER AR, 1989, J CELL SCI, V94, P43; REID TR, 1989, J BIOL CHEM, V264, P4583; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RUFF MR, 1986, LYMPHOKINES, V6, P549; SANCHEZALCAZAR JA, 1995, J BIOL CHEM, V270, P23944, DOI 10.1074/jbc.270.41.23944; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	50	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30167	30177		10.1074/jbc.272.48.30167	http://dx.doi.org/10.1074/jbc.272.48.30167			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374498	hybrid, Green Published			2022-12-27	WOS:A1997YH61300030
J	Shapiro, RE; Specht, CD; Collins, BE; Woods, AS; Cotter, RJ; Schnaar, RL				Shapiro, RE; Specht, CD; Collins, BE; Woods, AS; Cotter, RJ; Schnaar, RL			Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM NEUROTOXIN; NUCLEOTIDE-SEQUENCE; AXONAL-TRANSPORT; B NEUROTOXIN; FRAGMENT-C; BINDING; GLYCOSPHINGOLIPIDS; RECEPTOR; ACIDS; CHROMATOGRAPHY	Tetanus toxin entry into vertebrate motorneurons may involve binding of neuronal surface gangliosides containing the ''1b'' substructure (a NeuAc alpha 2,8NeuAc group on an internal galactose residue), The domains of tetanus toxin involved in ganglioside binding are known to reside within the carboxyl-terminal half of the toxin's heavy chain (''C fragment''). We developed a navel photoaffinity reagent based upon the structure of the 1b ganglioside G(D1b) (I-125-azido-G(D1b)) to define the ganglioside-binding domains of tetanus toxin. Using this ligand, we observed radiolabeling of tetanus toxin C fragment which could be specifically inhibited by a ganglioside of the 1b series (G(T1b)) but not by a non-1b series ganglioside (G(M3)). When tetanus toxin C fragment was proteolyzed with clostripain, whether before or after reaction with I-125-azido-G(D1b), a radiolabelled band was observed by SDS-polyacrylamide gel electrophoresis autoradiography, which was selectively inhibited by G(T1b) Protein sequencing of proteolyzed tetanus toxin C fragment comigrating with that band revealed the carboxyl-terminal 34 amino acid residues of tetanus toxin. Matrix-assisted laser desorption/ionization mass spectrometry of a photoaffinity labeled synthetic polypeptide representing the 34-amino acid domain revealed modification at a single residue (His(1293)). We propose that this domain of tetanus toxin is sufficient for ganglioside binding.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Specht, Chelsea/0000-0001-7746-512X	NIGMS NIH HHS [R01 GM54882] Funding Source: Medline; NINDS NIH HHS [R01 NS37096, K08 NS01518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, K08NS001518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSENBECKH B, 1989, INFECT IMMUN, V57, P3498, DOI 10.1128/IAI.57.11.3498-3505.1989; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BIZZINI B, 1977, J NEUROCHEM, V28, P529, DOI 10.1111/j.1471-4159.1977.tb10423.x; BUTTNERENNEVER JA, 1981, NEUROSCI LETT, V26, P233, DOI 10.1016/0304-3940(81)90138-5; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; KAMATA Y, 1993, BIOCHIM BIOPHYS ACTA, V1156, P213, DOI 10.1016/0304-4165(93)90138-X; KIMURA K, 1990, BIOCHEM BIOPH RES CO, V171, P1304, DOI 10.1016/0006-291X(90)90828-B; KITAMURA M, 1980, BIOCHIM BIOPHYS ACTA, V628, P328, DOI 10.1016/0304-4165(80)90382-7; KOZAKI S, 1989, INFECT IMMUN, V57, P2634, DOI 10.1128/IAI.57.9.2634-2639.1989; KOZAKI S, 1987, INFECT IMMUN, V55, P3051, DOI 10.1128/IAI.55.12.3051-3056.1987; KOZAKI S, 1984, FEMS MICROBIOL LETT, V211, P219; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENGRUND CL, 1991, J NEUROCHEM, V57, P1024, DOI 10.1111/j.1471-4159.1991.tb08253.x; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; SCHWAB ME, 1976, BRAIN RES, V105, P213, DOI 10.1016/0006-8993(76)90422-4; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; VANHEYNINGEN S, 1980, PHARMACOL THERAPEUT, V11, P141, DOI 10.1016/0163-7258(80)90070-4; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7; WELLHONER HH, 1982, REV PHYSIOL BIOCH P, V93, P1, DOI 10.1007/BFb0032668; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992; WHELAN SM, 1992, EUR J BIOCHEM, V191, P657; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; [No title captured]	35	72	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30380	30386		10.1074/jbc.272.48.30380	http://dx.doi.org/10.1074/jbc.272.48.30380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374528	hybrid			2022-12-27	WOS:A1997YH61300060
J	Wade, DP; Puckey, LH; Knight, BL; Acquati, F; Mihalich, A; Taramelli, R				Wade, DP; Puckey, LH; Knight, BL; Acquati, F; Mihalich, A; Taramelli, R			Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATION; HORMONE RECEPTOR SUPERFAMILY; CORONARY HEART-DISEASE; APO(A) MESSENGER-RNA; TRANS-ACTING FACTOR; TRANSCRIPTION FACTOR; PEROXISOME PROLIFERATORS; HYPERSENSITIVE SITES; TRANSPOSABLE ELEMENT; SIZE HETEROGENEITY	Plasma concentrations of the atherogenic lipoprotein(a) (Lp(a)) are predominantly determined by inherited sequences within or closely linked to the apolipoprotein(a) gene locus, Much of the interindividual variability in Lp(a) levels is likely to originate at the level of apo(a) gene transcription, However, the liver-specific apo(a) basal promoter is extremely weak and does not exhibit common functional variations that affect plasma Lp(a) concentrations, In a search for additional apo(a) gene control elements, we have identified two fragments with enhancer activity within the 40-kilobase pair apo(a)-plasminogen intergenic region that coincide with DNase I-hypersensitive sites (DHII and DHIII) observed in liver chromatin of mice expressing a human apo(a) transgene. Neither enhancer exhibits tis sue specificity. DHIII activity was mapped to a BOG-base pair fragment containing nine DNase I-protected elements (footprints) that stimulates luciferase expression from the apo(a) promoter 10-15-fold in HepG2 cells, Binding of the ubiquitous transcription factor Spl plays a major role in the function of this enhancer, but no single site was indispensable for activity, DHIII com prises part of the regulatory region of an inactive long interspersed nucleotide element 1 retrotransposon, raising the possibility that retrotransposon insertion can influence the regulation of adjacent genes. DHII enhancer activity was localized to a 180-base pair fragment that stimulates transcription from the aps(a) promoter 4-8-fold in HepG2 cells. Mutations within an Spl site or either of two elements composed of direct repeats of the nuclear hormone receptor half-site AGGTCA in this sequence completely abolished enhancer function. Both nuclear hormone receptor elements were shown to bind peroxisome proliferator-activated receptors and other members of the nuclear receptor family, suggesting that this enhancer may mediate drug and hormone responsiveness.	HAMMERSMITH HOSP, MRC, LIPOPROT TEAM, CTR CLIN SCI, LONDON W12 0NN, ENGLAND; SAN RAFFAELE SCI INST, I-20132 MILAN, ITALY; UNIV CATANIA, DIPARTIMENTO BIOL ANIM, I-95124 CATANIA, ITALY	Imperial College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Catania				Mihalich, Alessandra/0000-0002-1835-8241				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOPP S, 1995, J LIPID RES, V36, P1721; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; Costa MW, 1996, BIOCHEMISTRY-US, V35, P8662, DOI 10.1021/bi952801y; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DUBIK D, 1992, ONCOGENE, V7, P1587; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HASSTEDT SJ, 1986, GENET EPIDEMIOL, V3, P53, DOI 10.1002/gepi.1370030106; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAGNA G, 1990, NUCLEIC ACIDS RES, V18, P5811, DOI 10.1093/nar/18.19.5811; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAGNAGHI P, 1994, BIOCHEM BIOPH RES CO, V205, P930, DOI 10.1006/bbrc.1994.2754; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; Neele DM, 1996, CIRCULATION, V94, P214; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; RAMHARACK R, 1995, J LIPID RES, V36, P1294; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; SUN XM, 1995, HUM MOL GENET, V4, P2125, DOI 10.1093/hmg/4.11.2125; Suzuki K, 1997, J CLIN INVEST, V99, P1361, DOI 10.1172/JCI119295; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WADE DP, 1994, J BIOL CHEM, V269, P19757; WADE DP, 1991, ATHEROSCLEROSIS, V91, P63, DOI 10.1016/0021-9150(91)90187-8; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1994, J BIOL CHEM, V269, P28716; Wild SH, 1997, ARTERIOSCL THROM VAS, V17, P239, DOI 10.1161/01.ATV.17.2.239; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58	80	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30387	30399		10.1074/jbc.272.48.30387	http://dx.doi.org/10.1074/jbc.272.48.30387			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374529	hybrid			2022-12-27	WOS:A1997YH61300061
J	Spiro, MJ; Bhoyroo, VD; Spiro, RG				Spiro, MJ; Bhoyroo, VD; Spiro, RG			Molecular cloning and expression of rat liver endo-alpha-mannosidase, an N-linked oligosaccharide processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; GLUCOSIDASE-II-DEFICIENT; NITRIC-OXIDE SYNTHASE; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; GOLGI; ENDOMANNOSIDASE; PROTEIN; PATHWAY; INHIBITORS	A clone containing the open reading frame of endo-alpha-D-mannosidase, an enzyme involved in early N-linked oligosaccharide processing, has been isolated from a rat Liver lambda gt11 cDNA library. This was accomplished by a strategy that involved purification of the endomannosidase from rat liver Golgi by Ligand affinity chromatography (Hiraizumi, S., Spohr, U., and Spiro, R. G, (1991) J, Biol, Chem. 269, 4697-4700) and preparative electrophoresis, followed by sequence determinations of tryptic peptides. Using degenerate primers based on these sequences, the polymerase chain reaction with rat liver cDNA as a template yielded a 470-base pair product suitable for library screening as web as Northern blot hybridization. EcoRI digestion of the purified lambda DNA released a 5.4-kilobase fragment that was amplified in Bluescript II SK(-) vector. Sequence analysis indicated that the deduced open reading frame of the endomannosidase extended from nucleotides 89 to 1441, encoding a protein of 451 amino acids and corresponding to a molecular mass of 52 kDa. Data base searches revealed no homology with any other known protein. When a vector coding for this protein fused to an NH2-terminal peptide containing a polyhistidine region was introduced into Escherichia coli, high levels of the enzyme were expressed upon induction with isopropyl-beta-D-thiogalactoside. Purification of the endomannosidase to electrophoretic homogeneity from E. coli lysates was accomplished by Ni2+-chelate and Glc alpha 1-->3Man-O-(CH2)(8)CONH-Affi-Gel Ligand chromatographies. Polyclonal antibodies raised against this protein reacted with Golgi endomannosidase. By both immunoblotting and silver staining, the purified E. coli-expressed enzyme was approximately 8 kDa smaller than anticipated from the open reading frame; timed induction studies indicated that this was due to scission of the enzyme's COOH-terminal end by host cell proteases. All rat tissues examined demonstrated mRNA levels (4,9-kilobase message) for the endomannosidase that correlated well with their enzyme activity.	JOSLIN DIABET CTR, ELLIOT P JOSLIN RES LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; Dairaku K, 1997, GLYCOBIOLOGY, V7, P579, DOI 10.1093/glycob/7.4.579; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HIRAIZUMI S, 1994, J BIOL CHEM, V269, P4697; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LIU JW, 1994, J BIOL CHEM, V269, P11691; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Sambrook J., 2002, MOL CLONING LAB MANU; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Weng S, 1996, GLYCOBIOLOGY, V6, P861, DOI 10.1093/glycob/6.8.861	31	27	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29356	29363		10.1074/jbc.272.46.29356	http://dx.doi.org/10.1074/jbc.272.46.29356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361017	hybrid			2022-12-27	WOS:A1997YF68400076
J	Melen, K; Julkunen, I				Melen, K; Julkunen, I			Nuclear cotransport mechanism of cytoplasmic human MxB protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORNE THOGOTO-VIRUS; INFLUENZA-VIRUS; CONFERS RESISTANCE; DHORI-VIRUS; MURINE MX1; GTPASE; GENE; MICE; EXPRESSION; REGION	Interferon-alpha/beta-inducible Mx proteins belong to the family of large GTPases and share high sequence homology with dynamins in their N-terminal GTP-binding domains, In addition, Nix proteins have a conserved C-terminal leucine zipper element that is involved in their oligomerization, Cytoplasmic human MxA protein mediates resistance to multiple RNA viruses, whereas no antiviral activity has been found for human MxB protein, We have previously shown that MxB protein exists as a nuclear 78-kDa and as a cytoplasmic 76-kDa form in interferon-alpha-induced human cells, Using various influenza hemagglutinin epitope-tagged MxB gene constructs in transient transfection experiments in COS-1 cells, we show that the cytoplasmic 76-kDa MxB protein forms hetero-oligomers with the nuclear 78-kDa MxB protein via the C-terminal leucine zipper element. This enables the cytoplasmic form of MxB protein to be translocated into the nucleus together with the nuclear form of MxB protein, This finding was confirmed in interferon-alpha-induced HEp-2 and T98G cells transfected with various MxB gene constructs, Cell fractionation studies also suggest that a considerable amount of the cytoplasmic MxB protein is also found in the nucleus, Using confocal laser microscopy, we also demonstrate that the cytoplasmic MxA and the nuclear MxB proteins do not colocalize/oligomerize with each other, and both of these proteins are retained in their specific cellular compartments.	Natl Publ Hlth Inst, Dept Virol, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Melen, K (corresponding author), Natl Publ Hlth Inst, Dept Virol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.							AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119; Cantell K, 1981, Methods Enzymol, V78, P29; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; HALLER O, 1995, J VIROL, V69, P2596, DOI 10.1128/JVI.69.4.2596-2601.1995; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; Kanerva M, 1996, VIROLOGY, V224, P55, DOI 10.1006/viro.1996.0506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; MELEN K, 1992, J BIOL CHEM, V267, P25898; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; MELEN K, 1994, VIROLOGY, V205, P269, DOI 10.1006/viro.1994.1643; MELEN K, 1994, J BIOL CHEM, V269, P2009; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; Ronni T, 1997, J IMMUNOL, V158, P2363; RONNI T, 1993, J IMMUNOL, V150, P1715; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; Sareneva T, 1996, EUR J BIOCHEM, V242, P191, DOI 10.1111/j.1432-1033.1996.0191r.x; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SURDEJ P, 1994, BIOTECHNIQUES, V17, P560; THIMME R, 1995, VIROLOGY, V211, P296, DOI 10.1006/viro.1995.1404; Trobridge GD, 1997, J VIROL, V71, P5304, DOI 10.1128/JVI.71.7.5304-5311.1997	31	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32353	32359		10.1074/jbc.272.51.32353	http://dx.doi.org/10.1074/jbc.272.51.32353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405443	hybrid			2022-12-27	WOS:000071108000062
J	Andjelkovic, M; Alessi, DR; Meier, R; Fernandez, A; Lamb, NJC; Frech, M; Cron, P; Cohen, P; Lucocq, JM; Hemmings, BA				Andjelkovic, M; Alessi, DR; Meier, R; Fernandez, A; Lamb, NJC; Frech, M; Cron, P; Cohen, P; Lucocq, JM; Hemmings, BA			Role of translocation in the activation and function of protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; C-AKT; SER/THR KINASE; EXPRESSION; ONCOGENE; CELLS; PHOSPHORYLATION; 3-KINASE; AMPLIFICATION	We have investigated the role of subcellular localization in the regulation of protein kinase B (PKB) activation. The myristoylation/palmitylation motif from the Lck tyrosine kinase was attached to the N terminus of protein kinase B to alter its subcellular location. Myristoylated/palmitylated (m/p)-PKB alpha was associated with the plasma membrane of transfected cells, whereas the wild-type kinase was mostly cytosolic. The activity of m/p-PKB alpha was 60-fold higher compared with the unstimulated wild-type enzyme, and could not be stimulated further by growth factors or phosphatase inhibitors. In vivo P-32 labeling and mutagenesis demonstrated that m/p-PKB alpha activity was due to phosphorylation on Thr(308) and Ser(473), that are normally induced on PKB following stimulation of the cells with insulin or insulin-like growth factor-1 (IGF-1). A dominant negative form of phosphoinositide 3-kinase (PI3-K) did not affect m/p-PKB alpha activity. The pleckstrin homology (PH) domain of m/p-PKB alpha was not required for its activation or phosphorylation on Thr(308) and Ser(473), suggesting that this domain may serve as a membrane-targeting module. Consistent with this view, PKB alpha was translocated to the plasma membrane within minutes after stimulation with IGF-1. This translocation required the PH domain and was sensitive to wortmannin. Our results indicate that PI3-K activity is required for translocation of PKB to the plasma membrane, where its activation occurs through phosphorylation of the same sites that are induced by insulin or IGF-1. Following activation the kinase detached from the membrane and translocated to the nucleus.	FRIEDRICH MIESCHER INST,CH-4056 BASEL,SWITZERLAND; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; CNRS,INSERM,CTR RECH BIOCHIM MACROMOL,DEPT CELL BIOL,F-34033 MONTPELLIER,FRANCE; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND	Friedrich Miescher Institute for Biomedical Research; University of Dundee; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Dundee				lucocq, john/0000-0002-5191-0093; Alessi, Dario/0000-0002-2140-9185				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALESSI DR, 1977, CURR BIOL, V7, P776; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1996, CURR OPIN CELL BIOL, V8, P253; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LUCOCQ J, 1994, J ANAT, V184, P1; LUCOCQ JM, 1993, FINE STRUCTURE IMMUN, P279; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Zlatkine P, 1997, J CELL SCI, V110, P673	53	869	896	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31515	31524		10.1074/jbc.272.50.31515	http://dx.doi.org/10.1074/jbc.272.50.31515			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395488	hybrid			2022-12-27	WOS:A1997YL41900047
J	Meyer, WKH; Reichenbach, P; Schindler, U; Soldaini, E; Nabholz, M				Meyer, WKH; Reichenbach, P; Schindler, U; Soldaini, E; Nabholz, M			Interaction of STAT5 dimers on two low affinity binding sites mediates interleukin 2 (IL-2) stimulation of IL-2 receptor alpha gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GAMMA-CHAIN; CYTOLYTIC ACTIVITY; TRANSGENIC MICE; BETA-CHAIN; EXPRESSION; ACTIVATION; ELEMENTS; CELLS; SEQUENCE	Stimulation of the interleukin 2 receptor alpha (IL-2R alpha) gene by IL-2 is important for the proliferation of antigen-activated T lymphocytes. IL-2 regulates IL-2R alpha transcription via a conserved 51-nucleotide IL-2 responsive enhancer. Mouse enhancer function depends on cooperative activity of three distinct sites. Two of these are weak binding sites for IL-2-activated STATE (signal transducer and activator of transcription) proteins, and mutational analysis indicates that binding of STAT5 to both sites is required for IL-2 responsiveness of the enhancer. The STATE dimers interact to form a STATE tetramer. The efficiency of tetramerization depends on the relative rotational orientation of the two STAT motifs on the DNA helix. STAT5 tetramerization on enhancer mutants correlates well with the IL-2 responsiveness of these mutants. This provides strong evidence that interactions between STAT dimers binding to a pair of weak binding sites play a biological role by controlling the activity of a well characterized, complex cytokine-responsive enhancer.	SWISS INST EXPT CANC RES,LYMPHOCYTE BIOL UNIT,CH-1066 EPALINGES,SWITZERLAND; TULARIK INC,S SAN FRANCISCO,CA 94080	Swiss Institute Experimental Cancer Research								ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BUCHER P, 1997, IMMUNOBIOLOGY, V197, P13; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; GEERING G, 1966, J EXP MED, V124, P753, DOI 10.1084/jem.124.4.753; GUYER NB, 1995, J IMMUNOL, V155, P3472; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LOWENTHAL JW, 1985, J IMMUNOL, V134, P931; Mikita T, 1996, MOL CELL BIOL, V16, P5811; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; PLAETINCK G, 1990, J IMMUNOL, V145, P3340; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SILVA A, 1983, IMMUNOL REV, V76, P105, DOI 10.1111/j.1600-065X.1983.tb01099.x; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Sperisen P, 1992, PCR Methods Appl, V1, P164; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WILSON A, 1994, EUR J IMMUNOL, V24, P1729, DOI 10.1002/eji.1830240802; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	53	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31821	31828		10.1074/jbc.272.50.31821	http://dx.doi.org/10.1074/jbc.272.50.31821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395528	hybrid			2022-12-27	WOS:A1997YL41900087
J	Peters, MF; OBrien, KF; SadouletPuccio, HM; Kunkel, LM; Adams, ME; Froehner, SC				Peters, MF; OBrien, KF; SadouletPuccio, HM; Kunkel, LM; Adams, ME; Froehner, SC			beta-dystrobrevin, a new member of the dystrophin family - Identification, cloning, and protein associations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO ELECTRIC ORGAN; SKELETAL-MUSCLE; GLYCOPROTEIN-COMPLEX; SUBCELLULAR-DISTRIBUTION; INSITU HYBRIDIZATION; AGRIN RECEPTOR; SYNTROPHIN; UTROPHIN; DYSTROGLYCAN; BINDING	Dystrophin, the protein disrupted in Duchenne muscular dystrophy, is one of several related proteins that are key components of the submembrane cytoskeleton. Three dystrophin-related proteins (utrophin, dystrophin-related protein-2 (DRP2), and dystrobrevin) have been described. Here, we identify a human gene on chromosome 2p22-23 that encodes a novel protein, beta-dystrobrevin, with significant homology to the other known dystrobrevin (now termed alpha-dystrobrevin), Sequence alignments including this second dystrobrevin strongly support the concept that two distinct subfamilies exist within the dystrophin family, one composed of dystrophin, utrophin, and DRP2 and the other composed of alpha- and beta-dystrobrevin, The possibility that members of each subfamily form distinct protein complexes was examined by immunopurifying dystrobrevins and dystrophin. A beta-dystrobrevin antibody recognized a protein of the predicted size (71 kDa) that copurified with the dystrophin short form, Dp71, Thus, like alpha-dystrobrevin, beta-dystrobrevin is likely to associate directly with dystrophin. alpha- and beta-dystrobrevins failed to copurify with each other, however, These results suggest that members of the dystrobrevin subfamily form heterotypic associations with dystrophin and raise the possibility that pairing of a particular dystrobrevin with dystrophin may be regulated, thereby providing a mechanism for assembly of distinct submembrane protein complexes.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, DIV GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Puccio, Hélène/G-1717-2013	Puccio, Hélène/0000-0003-4711-2248	NINDS NIH HHS [NS33145, NS14871, NS23740-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023740, R01NS014871, R01NS033145] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FITZGERALD KM, 1994, J CLIN INVEST, V93, P2425, DOI 10.1172/JCI117250; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Froehner SC, 1997, SOC GEN PHY, V52, P197; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1998, IN PRESS J NEUROSCI; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Roberts RG, 1996, NAT GENET, V13, P223, DOI 10.1038/ng0696-223; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Sadoulet-Puccio HM, 1997, NEUROGENETICS, V1, P37, DOI 10.1007/s100480050006; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; Sharp AA, 1996, J NEUROSCI, V16, P6775; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; VERMA RS, 1989, HUMAN CHROMOSOMES MA; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; Winder SJ, 1996, BIOCHEM SOC T, V24, P497, DOI 10.1042/bst0240497; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	59	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31561	31569		10.1074/jbc.272.50.31561	http://dx.doi.org/10.1074/jbc.272.50.31561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395493	hybrid			2022-12-27	WOS:A1997YL41900052
J	Antonny, B; Huber, I; Paris, S; Chabre, M; Cassel, D				Antonny, B; Huber, I; Paris, S; Chabre, M; Cassel, D			Activation of ADP-ribosylation factor 1 GTPase-activating protein by phosphatidylcholine-derived diacylglycerols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; PHOSPHOLIPASE-D; ALPHA-THROMBIN; ARF; FIBROBLASTS; HYDROLYSIS; EXCHANGE	Disassembly of the coatomer from Golgi vesicles requires that the small GTP-binding protein ADP-ribosylation factor 1 (ARF1) hydrolyzes its bound GTP by the action of a GTPase-activating protein. In vitro, the binding of the ARF1 GTPase-activating protein to lipid vesicles and its activity on membrane-bound ARF1(GTP) are increased by diacylglycerols with monounsaturated acyl chains, such as those arising in vivo as secondary products from the hydrolysis of phosphatidylcholine by ARF-activated phospholipase D. Thus, the phospholipase D pathway may provide a feedback mechanism that promotes GTP hydrolysis on ARF1 and the consequent uncoating of vesicles.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Technion Israel Institute of Technology	Antonny, B (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	antonny@unice.fr	Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; APPLEGATE KR, 1991, J LIPID RES, V32, P1645; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; HA KS, 1993, J BIOL CHEM, V268, P10534; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Randazzo PA, 1997, BIOCHEM J, V324, P413, DOI 10.1042/bj3240413; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Stricker R, 1997, FEBS LETT, V405, P229, DOI 10.1016/S0014-5793(97)00188-9; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	27	131	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30848	30851		10.1074/jbc.272.49.30848	http://dx.doi.org/10.1074/jbc.272.49.30848			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388229	hybrid			2022-12-27	WOS:000071640800042
J	Ramirez, S; Ali, SAS; Robin, P; Trouche, D; Harel-Bellan, A				Ramirez, S; Ali, SAS; Robin, P; Trouche, D; Harel-Bellan, A			The CREB-binding protein (CBP) cooperates with the serum response factor for transactivation of the c-fos serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; ETS TRANSCRIPTION FACTOR; COACTIVATOR CBP; CELL DIFFERENTIATION; INDUCED STIMULATION; FACTORS ELK-1; FACTOR P62TCF; IN-VIVO; ACTIVATION; DNA	The serum response element is one of the major promoter elements of the immediate early response to extracellular signals. The serum response element includes two main binding sites for proteins: the Ets box, which binds p62(TCF), and the CArG box, which binds p67(SRF). These two proteins are direct targets for signal transduction pathways; p62(TCF) is a nuclear end point of the Ras/mitogen-activated protein kinase pathway, and p67(SRF) is targeted by the Rho/Rac small G-proteins. The mechanism by which the signal is further transduced from the transcription factors to the basal transcriptional machinery is poorly understood. Recent data have suggested that the cAMP-responsive element-binding protein (CREB)-binding protein, a transcriptional adaptor involved in the transactivation through a wide variety of enhancer elements, participates in p62(TCF) activity., We here show that the CREB-binding protein also cooperates in the process of transactivation by p67(SRF). Cotransfections of expression vectors for the CREB-binding protein increased the expression, in response to serum, of reporters under the control of the c-fos serum response element, Interestingly, the C-terminal moiety of the CREB-binding protein was not necessary to observe this effect. The cooperation did not require the Ets box in the serum response element, and the CArG box was sufficient, indicating that the CREB-binding protein is able to cooperate with p67(SRF) in, the absence of an Ets protein, Co-immunoprecipitation experiments using cell extracts showed that p67(SRF) could be retained with antibodies directed against the CREB-binding protein, suggesting that the two proteins form a multimolecular complex in live cells, The physical interaction between p67(SRF) and the CREB-binding protein was further confirmed by two-hybrid assays in mammalian cells, Our results indicate that the CREB-binding protein cooperates with p67(SRF) and, thus, suggest that the serum response element is regulated by a multimolecular complex, which includes the CREB-binding protein, p67(SRF), and p62(TCF), With multiple interactions between the components of the complex.	Inst Federat Canc, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Harel-Bellan, A (corresponding author), Inst Federat Canc, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015; Ramirez-Clavijo, Sandra/G-5268-2016	Harel-Bellan, Annick/0000-0002-2339-153X; Ramirez-Clavijo, Sandra/0000-0003-0336-5614; Trouche, Didier/0000-0003-1398-6481				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Groisman R, 1996, J BIOL CHEM, V271, P5258; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU SH, 1993, J BIOL CHEM, V268, P21147; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	63	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31016	31021		10.1074/jbc.272.49.31016	http://dx.doi.org/10.1074/jbc.272.49.31016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388250	hybrid, Green Published			2022-12-27	WOS:000071640800063
J	Dickson, RC; Nagiec, EE; Skrzypek, M; Tillman, P; Wells, GB; Lester, RL				Dickson, RC; Nagiec, EE; Skrzypek, M; Tillman, P; Wells, GB; Lester, RL			Sphingolipids are potential heat stress signals in Saccharomyces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT STRE; TRANSCRIPTIONAL ACTIVATOR; TREHALOSE SYNTHESIS; CEREVISIAE; YEAST; PROTEIN; GENE; CERAMIDE; THERMOTOLERANCE; IDENTIFICATION	The ability of organisms to quickly respond to stresses requires the activation of many intracellular signal transduction pathways. The sphingolipid intermediate ceramide is thought to be particularly important for activating and coordinating signaling pathways during mammalian stress responses. Here we present the first evidence that ceramide and other sphingolipid intermediates are signaling molecules in the Saccharomyces cerevisiae heat stress response. Our data show a 2-3 fold transient increase in the concentration of C-18-dihydrosphingosine and C18-phytosphingosine, more than a 100-fold transient increase in C-20-dihydrosphingosine and C-20-phytosphingosine, and a more stable 2-fold increase in ceramide containing C-18-phytosphingosine and a 5-fold increase in ceramide containing C-20-phytosphingosine following heat stress. Treatment of cells with dihydrosphingosine activates transcription of the TPS2 gene encoding a subunit of trehalose synthase and causes trehalose, a known thermoprotectant, to accumulate. Dihydrosphingosine induces expression of a STRE-LacZ reporter gene, showing that the global stress response element, STRE, found in many yeast promoter sequences can be activated by sphingolipid signals. The TPS2 promoter contains four STREs that may mediate dihydrosphingosine responsiveness. Using genetic and other approaches it should be possible to identify sphingolipid signaling pathways in S. cerevisiae and quantify the importance of each during heat stress.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky	Dickson, RC (corresponding author), UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536, USA.				NIGMS NIH HHS [GM41302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; GHEGREGZABHER M, 1976, J CHROMATOGR, V127, P133; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANSEN SA, 1975, J CHROMATOGR, V107, P224, DOI 10.1016/S0021-9673(00)82770-3; HANSON BA, 1980, J LIPID RES, V21, P309; HOTTIGER T, 1994, EUR J BIOCHEM, V219, P187, DOI 10.1111/j.1432-1033.1994.tb19929.x; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LESTER RL, 1993, ADV LIPID RES, V26, P253; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MERRILL AHJ, 1996, LIPID 2 MESSENGERS, V8, P205; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SUR IP, 1994, YEAST, V10, P199, DOI 10.1002/yea.320100207; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	33	211	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30196	30200		10.1074/jbc.272.48.30196	http://dx.doi.org/10.1074/jbc.272.48.30196			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374502	hybrid			2022-12-27	WOS:A1997YH61300034
J	Hamawy, MM; Swieter, M; Mergenhagen, SE; Siraganian, RP				Hamawy, MM; Swieter, M; Mergenhagen, SE; Siraganian, RP			Reconstitution of high affinity IgE receptor-mediated secretion by transfecting protein tyrosine kinase pp125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; RBL-2H3 CELLS; MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; HISTAMINE-RELEASE; CALCIUM SIGNAL	To study the role of the focal adhesion tyrosine kinase (FAK) in receptor-mediated secretion, we transfected FAK cDNA into a variant (3B6) of the RBL-2H3 mast cell line. This 3B6 cell line expressed low levels of FAK and was defective in high affinity IgE receptor (Fc epsilon RI) but not Ca2+ ionophore-mediated secretion. Fc epsilon RI-mediated secretion was reconstituted after transfection of wild-type FAK. Histamine release was also enhanced by the stable expression of two mutants of FAK: a kinase-inactive form in which the ATP binding site Lys-454 was replaced by Arg or a mutant in which the autophosphorylation site Tyr-397 was replaced by Phe. Therefore, the catalytic activity and the autophosphorylation site of FAK are not essential for secretion. Fc epsilon RI aggregation increased. the tyrosine phosphorylation of both mutants of FAK to the same extent as wild-type FAK. Therefore, tyrosine kinases activated by Fc epsilon RI aggregation are phosphorylating FAK and some of these phosphorylation sites are other than Tyr-397. These results strongly suggest that FAK plays a role in Fc epsilon RI-induced secretion by functioning as an adapter or linker molecule.			Hamawy, MM (corresponding author), NIDR,IMMUNOL LAB,NIH,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; EISEMAN E, 1992, NATURE, V355, P78; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; HAMAWY MM, 1995, J BIOL CHEM, V270, P12305, DOI 10.1074/jbc.270.20.12305; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ILLC D, 1995, NATURE, V377, P539; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LIN PY, 1991, J IMMUNOL, V146, P1609; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER CE, 1994, J CELL SCI, V107, P1583; WHITE KN, 1988, J IMMUNOL, V141, P942; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; YU KT, 1991, J BIOL CHEM, V266, P22564; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	50	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30498	30503		10.1074/jbc.272.48.30498	http://dx.doi.org/10.1074/jbc.272.48.30498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374543	hybrid			2022-12-27	WOS:A1997YH61300075
J	Lindstedt, KA; Mahon, MG; Foisner, R; Hermann, M; Nimpf, J; Schneider, WJ				Lindstedt, KA; Mahon, MG; Foisner, R; Hermann, M; Nimpf, J; Schneider, WJ			Receptor-associated protein in an oviparous species is correlated with the expression of a receptor variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHICKEN OOCYTE RECEPTOR; HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND-BINDING; MULTIFUNCTIONAL RECEPTOR; SORTING RECEPTOR; FAMILY MEMBER; LAYING HEN; VITELLOGENIN	The biosynthesis of proteins containing cysteine-rich domains requires chaperones for their correct folding. For instance, the 39-kDa receptor-associated protein (RAP) aides in the cell-surface targeting of newly synthesized members of the mammalian low density lipoprotein receptor (LDLR) gene family, which contains tandemly arranged clusters of hexacysteine repeats. In the chicken, an LDLR relative with eight such repeats is expressed as two different splice variant forms in cell type-specific fashion (Bujo, H., Lindstedt, K. A., Hermann, M., Mola Dalmau, L., Nimpf, J., and Schneider, W. J. (1995) J. Biol. Chem. 270, 23546-23551). To learn more about evolutionary aspects of RAP, its role in escorting of these different receptor splice variants, and other potential functions, we have extended our studies on the avian LDLR family to RAP. cDNA cloning, determination of tissue expression at both the transcript and the protein level, stable expression in COS cells, and binding studies with chicken RAP revealed that mammalian RAPs have retained many features of the nonamniotic proteins. However, structural details, e.g. the well defined internal triplicate repeats in the chicken protein, have been somewhat diluted during evolution. Interestingly, chicken RAP was found to correlate positively with the expression levels in somatic cells of the larger splice variant of the eight-cysteine repeat receptor, but not with those of the smaller variant, expressed only in germ cells. This is compatible with the possibility that RAP may play a role in receptor biology that could be complementing its function in assisting folding. Chicken RAP in crude extracts of the stable expressor COS cells is able to bind to LDLR relatives in ligand blots without requirement for prior purification of the ligand. Thus, in conjunction with the avian model of massive lipid transport to germ cells, these cells provide a novel comparative system amenable to investigation of the biological functions of RAP.	UNIV & BIOCTR VIENNA, DEPT MOL GENET, A-1030 VIENNA, AUSTRIA; UNIV & BIOCTR VIENNA, DEPT BIOCHEM & CELL BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; University of Vienna			Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647; Nimpf, Johannes/0000-0002-9273-3492; Hermann, Marcela/0000-0003-2298-4269				BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU G, 1995, EMBO J, V14, P2389; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; ELKIN RG, 1995, J NUTR, V125, P1258; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; Hermann M, 1997, J LIPID RES, V38, P1308; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hiesberger T, 1996, J BIOL CHEM, V271, P28792, DOI 10.1074/jbc.271.46.28792; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Morwald S, 1997, ARTERIOSCL THROM VAS, V17, P996, DOI 10.1161/01.ATV.17.5.996; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P271, DOI 10.1016/0005-2760(90)90130-P; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	44	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30221	30227		10.1074/jbc.272.48.30221	http://dx.doi.org/10.1074/jbc.272.48.30221			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374506	hybrid			2022-12-27	WOS:A1997YH61300038
J	Scherzinger, E; Ziegelin, G; Barcena, M; Carazo, JM; Lurz, R; Lanka, E				Scherzinger, E; Ziegelin, G; Barcena, M; Carazo, JM; Lurz, R; Lanka, E			The RepA protein of plasmid RSF1010 is a replicative DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; OLIGOMERIC STRUCTURE; ELECTRON-MICROSCOPY; EXCISION-REPAIR; GENE-4 PROTEIN; T-ANTIGEN; BACTERIOPHAGE-T7; ORIGIN	The RepA protein of the mobilizable broad host range plasmid RSF1010 has a key function in its replication. RepA is one of the smallest known helicases. The protein forms a homohexamer of 29,896-Da subunits. A variety of methods were used to analyze the quaternary structure of RepA. Gel filtration and cross-linking experiments demonstrated the hexameric structure, which was confirmed by electron microscopy and image reconstruction. These results agree with recent data obtained from RepA crystals diffracting at 3.5-Angstrom resolution (Roleke, D., Hoier, H., Bartsch, C., Umbach, P., Scherzinger, E., Lurz, R., and Saenger, W. (1997) Acta Crystallogr. Sec. D 53, 213-216). The RepA helicase has 5' --> 3' polarity. As do most true replicative helicases, RepA prefers a tailed substrate with an unpaired 3'-tail mimicking a replication fork. Optimal unwinding activity was achieved at the remarkably low pH of 5.5. In the presence of Mg2+ (Mn2+) ions, the RepA activity is fueled by ATP, dATP, GTP, and dGTP and less efficiently by CTP and dCTP. UTP and dTTP are poor effectors. Nonhydrolyzable ATP analogues, ADP, and pyrophosphate inhibit the helicase activity, whereas inorganic phosphate does not. The presence of Escherichia coli single-stranded DNA-binding protein stimulates unwinding at physiological pH 2-3-fold, whereas the RSF1010 replicon-specific primase, RepB' protein, has no effect, either in the presence or in the absence of single-stranded DNA-binding protein.	MAX PLANCK INST MOL GENET, ABT LEHRACH, D-14195 BERLIN, GERMANY; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN	Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Barcena, Montserrat/B-5823-2012; Garcia, Jose Maria Carazo/E-9234-2016	Barcena, Montserrat/0000-0002-7719-4443; Garcia, Jose Maria Carazo/0000-0003-0788-8447				ARAI KI, 1951, PROG NUCL ACID RES M, V26, P9; Bollum F.J., 1974, ENZYMES, P145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DREISEIKELMANN B, 1987, NUCLEIC ACIDS RES, V15, P385, DOI 10.1093/nar/15.2.385; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GORMLEY EP, 1991, J BACTERIOL, V173, P6705, DOI 10.1128/jb.173.21.6705-6708.1991; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARING V, 1985, P NATL ACAD SCI USA, V82, P6090, DOI 10.1073/pnas.82.18.6090; HARING V, 1989, PROMISCUOUS PLASMIDS, P95; HONDA Y, 1992, NUCLEIC ACIDS RES, V20, P1733, DOI 10.1093/nar/20.7.1733; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1978, J BIOL CHEM, V253, P5847; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Richardson C. C., 1981, ENZYMES, P299; Roleke D, 1997, ACTA CRYSTALLOGR D, V53, P213, DOI 10.1107/S0907444996012565; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHEKMAN R, 1972, P NATL ACAD SCI USA, V69, P2691, DOI 10.1073/pnas.69.9.2691; SCHERZINGER E, 1991, NUCLEIC ACIDS RES, V19, P1203, DOI 10.1093/nar/19.6.1203; SCHERZINGER E, 1984, P NATL ACAD SCI-BIOL, V81, P654, DOI 10.1073/pnas.81.3.654; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TANAKA K, 1994, NUCLEIC ACIDS RES, V22, P767, DOI 10.1093/nar/22.5.767; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	63	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30228	30236		10.1074/jbc.272.48.30228	http://dx.doi.org/10.1074/jbc.272.48.30228			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374507	hybrid			2022-12-27	WOS:A1997YH61300039
J	Takahashi, Y; Nakayama, K; Itoh, S; FujiiKuriyama, Y; Kamataki, T				Takahashi, Y; Nakayama, K; Itoh, S; FujiiKuriyama, Y; Kamataki, T			Inhibition of the transcription of CYP1A1 gene by the upstream stimulatory factor 1 in rabbits - Competitive binding of USF1 with AhR center dot Arnt complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; ARYL-HYDROCARBON RECEPTOR; NEGATIVE REGULATORY ELEMENT; DIOXIN-RESPONSIVE ENHANCER; HEAT-SHOCK PROTEIN; RNA POLYMERASE-II; DNA RECOGNITION; ONTOGENETIC EXPRESSION; CRYSTAL-STRUCTURE; HEPATOMA-CELLS	A xenobiotic-responsive element (XRE)-binding factor(s) other than the AhR.Arnt complex was found to inhibit the transcription of CYP1A1 gene in the liver from adult rabbits, known to be nonresponsive to CYP1A1 inducers, The constitutive factor(s) in liver nuclear extracts bound to the core sequence of XRE. The binding was eliminated by the presence of an excess amount of the AhR.Arnt complex synthesized in vitro. To identify the constitutive factor(s), a sequence similar to rabbit XRE was sought. It was found that the sequence of rabbit XRE overlapped with that of the upstream stimulatory factor 1 (USF1)-binding site in the mouse metallothionein I promoter, In fact, a super shift assay using a specific antibody against human USF1 indicated that USF1 was capable of binding to rabbit XRE. Additionally, the AhR.Arnt-mediated activation of XRE-TK/Luc reporter gene in RK13 cells was blocked by the transfection with a USF1 expression vector with the amounts of the expression vector transfected. These results indicate that the XRE of the rabbit CYP1A1 gene is recognized by the basic helix-loop-helix proteins to regulate the expression of CYP1A1 in both an agonistic (AhR.Arnt) and an antagonistic (USF1) manner.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,DIV DRUG METAB,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University				Itoh, Susumu/0000-0002-7967-0730				ALVARES AP, 1982, LIFE SCI, V30, P747, DOI 10.1016/0024-3205(82)90608-7; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; ATLAS SA, 1977, J BIOL CHEM, V252, P4712; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bhat R, 1996, INT J BIOCHEM CELL B, V28, P217; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BOUCHER PD, 1995, CARCINOGENESIS, V16, P383, DOI 10.1093/carcin/16.2.383; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; Corton JC, 1996, TOXICOL LETT, V85, P67, DOI 10.1016/0378-4274(96)03636-3; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GONZALEZ FJ, 1993, PHARMACOGENETICS, V3, P51, DOI 10.1097/00008571-199302000-00006; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; KAGAWA N, 1987, J BIOCHEM-TOKYO, V101, P1471, DOI 10.1093/oxfordjournals.jbchem.a122017; KAHL GF, 1980, DEV PHARMACOL THERAP, V1, P137, DOI 10.1159/000455531; KITAMURA R, 1992, ARCH BIOCHEM BIOPHYS, V292, P136, DOI 10.1016/0003-9861(92)90061-Z; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MIMURA J, 1996, ABSTRACT JAPANESE BI, V68, P1302; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrock J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STERLING K, 1993, MOL PHARMACOL, V44, P560; STORM DK, 1992, ARCH BIOCHEM BIOPHYS, V294, P707; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	61	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30025	30031		10.1074/jbc.272.48.30025	http://dx.doi.org/10.1074/jbc.272.48.30025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374477	hybrid			2022-12-27	WOS:A1997YH61300009
J	Monden, T; Wondisford, FE; Hollenberg, AN				Monden, T; Wondisford, FE; Hollenberg, AN			Isolation and characterization of a novel ligand-dependent thyroid hormone receptor-coactivating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; RESPONSE ELEMENT; TRANSACTIVATION DOMAIN; ESTROGEN-RECEPTOR; CO-REPRESSOR; A/B DOMAIN; IDENTIFICATION	The thyroid hormone receptor (TR) regulates the expression of target genes upon binding to triiodothyro nine (T-3) response elements, In the presence of T-3, the TR recruits coactivating proteins that both modulate and integrate the ligand response, We report here the cloning of a novel protein using the TR ligand-binding domain as bait in the yeast two-hybrid system. Analysis of a putative full length clone demonstrates a cDNA sequence that encodes a protein of 920 amino acids with a size of 120 kDa (p120), Alignment with known sequences shows homology to a previously identified protein of unknown function, termed skeletal muscle abundant protein, Interaction studies demonstrate that p120 interacts with the TR AF-2 domain in the presence of ligand through a 111-amino acid region. Northern analysis demonstrates widespread expression in human tissues. Cotransfection assays in CV-1 cells demonstrate that p120 enhances TR-mediated transactivation on multiple T-3 response elements in the presence of T-3. In addition, CREB-binding protein synergizes with p120 to enhance this effect. When linked to the GAL4 DNA-bind ing domain, p120 is an activator of transcription alone. Thus, p120 satisfies a number of important criteria as a nuclear receptor coactivator.	BETH ISRAEL MED CTR, DEPT MED, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, K08DK002354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02354, DK-49126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CARR FE, 1994, J BIOL CHEM, V269, P4175; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; Nielsen MS, 1996, BBA-GENE STRUCT EXPR, V1306, P14, DOI 10.1016/0167-4781(95)00239-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TOMURA H, 1995, P NATL ACAD SCI USA, V92, P5600, DOI 10.1073/pnas.92.12.5600; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	46	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29834	29841		10.1074/jbc.272.47.29834	http://dx.doi.org/10.1074/jbc.272.47.29834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368056	hybrid			2022-12-27	WOS:A1997YG64700066
J	Sugimoto, T; Stewart, S; Guan, KL				Sugimoto, T; Stewart, S; Guan, KL			The calcium/calmodulin-dependent protein phosphatase calcineurin is the major Elk-1 phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; TRANSCRIPTIONAL ACTIVATION; CYCLOSPORINE-A; FACTOR P62TCF; KINASE; PHOSPHORYLATION; CELLS; SPECIFICITY; TRANSIENT; PROMOTER	The transcription factor Elk-1 is a component of ternary complex factor and regulates gene expression in response to a wide variety of extracellular stimuli. Phosphorylation of the C-terminal domain of Elk-1, especially at serine 383, is important for its transactivation activity. Recently mitogen-activated protein kinases, such as extracellular signal-regulated kinase, stress-activated protein kinase, and p38 mitogen-activated protein kinase have been demonstrated to be Elk-1 kinases. However, negative regulators of Elk-1, such as protein phosphatases, still remain to be identified. Here we report that COS cell. lysates were able to dephosphorylate an extracellular signal-regulated kinase-phosphorylated glutathione S-transferase-Elkc fusion protein, in eluding serine 383, The phosphatase activity was inhibited by cyclosporin A (a calcineurin inhibitor) but not by okadaic acid (a PPI and PP2A inhibitor). Purified calcineurin also could efficiently dephosphorylate glutathione S-transferase-Elkc in vitro. Pretreatment of COS cells with cyclosporin A significantly enhanced epidermal growth factor-induced serine 383 Elk-l phosphorylation whereas ionomycin inhibited the Elk-1 phosphorylation. These data provide both in vitro and in vivo evidence that calcineurin is the major Elk-l phosphatase and plays a critical role in Elk-l regulation. The identification of calcineurin as the major Elk-1 phosphatase may provide a mechanism for Elk-l regulation by Ca2+ signals as well as a possible biochemical basis for the neurotoxicity and nephrotoxicity of the immunosuppressant drug cyclosporin A.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIGMS NIH HHS [GM 51586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAISER AR, 1989, CURRENT PROTOCOLS MO; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Hardie D. G., 1993, PROTEIN PHOSPHORYLAT; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; SEGAR R, 1995, FASEB J, V9, P726; SU QX, 1995, RENAL PHYSIOL BIOCH, V18, P128; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	36	111	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29415	29418		10.1074/jbc.272.47.29415	http://dx.doi.org/10.1074/jbc.272.47.29415			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367995	hybrid			2022-12-27	WOS:A1997YG64700005
J	Thompson, LJ; Bollen, M; Fields, AP				Thompson, LJ; Bollen, M; Fields, AP			Identification of protein phosphatase 1 as a mitotic lamin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE-1; SACCHAROMYCES-CEREVISIAE; AFFINITY-CHROMATOGRAPHY; PHOSPHORYLATION SITES; OKADAIC ACID; TYPE-1; MITOSIS; ENCODES	At the onset of mitosis, the nuclear lamins are hyperphosphorylated leading to nuclear lamina disassembly, a process required for nuclear envelope breakdown and entry into mitosis, Multiple Iamin kinases have been identified, including protein kinase C, that mediate mitotic lamin phosphorylation and mitotic nuclear lamina disassembly. Conversely, lamin dephosphorylation is required for nuclear lamina reassembly at the completion of mitosis, However, the protein phosphatase(s) responsible for the removal of mitotic phosphates from the lamins is unknown, In this study, we use human lamin B phosphorylated at mitosis-specific sites as a substrate to identify and characterize a lamin phosphatase activity from mitotic human cells, Several lines of evidence demonstrate that the mitotic lamin phosphatase corresponds to type 1 protein phosphatase (PP1), First, mitotic lamin phosphatase activity is inhibited by high nanomolar concentrations of okadaic acid and the specific PPI peptide inhibitor, inhibitor-a, Second, mitotic Iamin phosphatase activity cofractionates with PP1 after ion exchange chromatography, Third, microcystin-agarose depletes mitotic extracts of both PP1 and Iamin phosphatase activity. Our results demonstrate that PP1 is the major mitotic lamin phosphatase responsible for removal of mitotic phosphates from lamin B, a process required for nuclear lamina reassembly.	UNIV TEXAS, MED BRANCH, SEALY CTR ONCOL & HEMATOL, GALVESTON, TX 77555 USA; KATHOLIEKE UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM	University of Texas System; University of Texas Medical Branch Galveston; KU Leuven								Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; JOHNSTON JA, 1994, CELL MOTIL CYTOSKEL, V29, P280, DOI 10.1002/cm.970290311; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; Moir RD, 1993, CURR OPIN CELL BIOL, V5, P408, DOI 10.1016/0955-0674(93)90004-A; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; Paulson JR, 1996, J CELL SCI, V109, P1437; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Tu JL, 1996, MOL CELL BIOL, V16, P4199	37	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29693	29697		10.1074/jbc.272.47.29693	http://dx.doi.org/10.1074/jbc.272.47.29693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368037	hybrid			2022-12-27	WOS:A1997YG64700047
J	Scherer, PE; Lewis, RY; Volonte, D; Engelman, JA; Galbiati, F; Couet, J; Kohtz, DS; vanDonselaar, E; Peters, P; Lisanti, MP				Scherer, PE; Lewis, RY; Volonte, D; Engelman, JA; Galbiati, F; Couet, J; Kohtz, DS; vanDonselaar, E; Peters, P; Lisanti, MP			Cell-type and tissue-specific expression of caveolin-2 - Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEMBRANE-PROTEIN; TRANSPORT VESICLES; TRANSFORMED-CELLS; PLASMA-MEMBRANE; COMPONENT; SEQUENCE; VIP21-CAVEOLIN; DIFFERENTIATION; IDENTIFICATION	Caveolae are microdomains of the plasma membrane that have been implicated in organizing and compartmentalizing signal transducing molecules, Caveolin, a 21-24-kDa integral membrane protein, is a principal structural component of caveolae membrane in vivo. Recently, we and other laboratories have identified a family of caveolin-related proteins; caveolin has been retermed caveolin-1. Here, we examine the cell type and tissue-specific expression of caveolin-2, For this purpose, we generated a novel mono-specific monoclonal antibody probe that recognizes only caveolin-2, but not caveolins-1 and -3, A survey of cell and tissue types demonstrates that the caveolin-2 protein is most abundantly expressed in endothelial cells, smooth muscle cells, skeletal myoblasts (L6, BC3H1, C2C12), fibroblasts, and 3T3-L1 cells differentiated to adipocytes. This pattern of caveolin-2 protein expression most closely resembles the cellular distribution of caveolin-1, In line with these observations, co-immunoprecipitation experiments with mono-specific antibodies directed against either caveolin-1 or caveolin-2 directly show that these molecules form a stable hetero-oligomeric complex, The in vivo relevance of this complex was further revealed by dual-labeling studies employing confocal laser scanning fluorescence microscopy. Our results indicate that caveolins 1 and 2 are strictly co localized within the plasma membrane and other internal cellular membranes, Ultrastructurally, this pattern of caveolin-2 localization corresponds to caveolae membranes as seen by immunoelectron microscopy, Despite this strict co-localization, it appears that regulation of caveolin-2 expression occurs independently of the expression of either caveolin-1 or caveolin-3 as observed using two different model cell systems, Although caveolin-1 expression is down-regulated in response to oncogenic transformation of NIH 3T3 cells, caveolin-2 protein levels remain unchanged, Also, caveolin-2 protein levels remain unchanged during the differentiation of C2C12 cells from myoblasts to myotubes, while caveolin-3 levels are dramatically induced by this process, These results suggest that expression levels of caveolins 1, 2, and 3 can be independently up-regulated or down-regulated in response to a variety of distinct cellular cues.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; LAVAL HOSP, RES CTR, Ste Foy, PQ, CANADA; CUNY MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA; UNIV UTRECHT, FAC MED, NL-3584 CX UTRECHT, NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Utrecht University			Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Couet, Jacques/0000-0001-5409-8689				BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Harlow E., 1988, ANTIBODIES LAB MANUA; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIMIONESCU N, 1983, HISTOLOGY CELL TISSU, P371; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	43	457	472	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29337	29346		10.1074/jbc.272.46.29337	http://dx.doi.org/10.1074/jbc.272.46.29337			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361015	hybrid			2022-12-27	WOS:A1997YF68400074
J	Zhang, XH; Xing, GX; Fraizer, GC; Saunders, GF				Zhang, XH; Xing, GX; Fraizer, GC; Saunders, GF			Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; FUNCTIONAL SYNERGY; MAMMALIAN-CELLS; WT1; EXPRESSION; DELETION; FAMILY; DNA; DIFFERENTIATION; LEUKEMIAS	The Wilms' tumor 1 gene (WT1) encodes a zinc-finger transcription factor which is expressed in a tissue-specific manner. Our studies indicate that in addition to the promoter, other regulatory elements are required for tissue-specific expression of this gene, A 258-base pair hematopoietic specific enhancer in intron 3 of the WT1 gene increased the transcriptional activity of the WT1 promoter by 8-10-fold in K562 and HL60 cells, Sequence analysis revealed both a GATA and a c-Myb motif in the enhancer fragment. Mutation of the GATA motif decreased the enhancer activity by 60% in K562 cells. Electrophoretic mobility shift assays showed that the GATA-1 protein in K562 nuclear extracts binds to this motif. Cotransfection of the enhancer containing reporter construct with a GATA-1 expression vector showed that GATA-1 transactivated this enhancer, increasing the CAT reporter activity 10-15-fold. Similar analysis of the c-Myb motif by cotransfection with the enhancer CAT reporter construct and a c-Myb expression vector showed that c-Myb transactivated the enhancer by B-fold. A DNase I-hypersensitive site has also been mapped in the 258-base pair enhancer region, These data suggest that GATA-1 and c-Myb are responsible for the activity of this enhancer in hematopoietic cells and may bind to the enhancer in vivo.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34936, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HUFF V, 1991, AM J HUM GENET, V48, P997; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MANIATIS T, 1982, MOL CLONING LABORATO, P309; MATSUNAGA E, 1981, HUM GENET, V57, P231; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIWA H, 1992, LEUKEMIA, V6, P405; OKA T, 1991, ONCOGENE, V6, P2077; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PEVNY L, 1995, DEVELOPMENT, V121, P163; PHELAN SA, 1994, CELL GROWH DIFFER, V5, P667; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKIYA M, 1994, BLOOD, V83, P1876; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	36	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29272	29280		10.1074/jbc.272.46.29272	http://dx.doi.org/10.1074/jbc.272.46.29272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361007	hybrid			2022-12-27	WOS:A1997YF68400066
J	Chiron, MF; Fryling, CM; FitzGerald, D				Chiron, MF; Fryling, CM; FitzGerald, D			Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; RECEPTOR-RELATED PROTEIN; DIPHTHERIA-TOXIN; CYTOPLASMIC DOMAIN; CELL-SURFACE; MOUSE FURIN; ACTIVATION; LOCALIZATION; EXPRESSION; SEQUENCE	Pseudomonas exotoxin (PE) requires proteolytic cleavage to generate a 37-kDa C-terminal fragment that translocates to the cytosol and ADP-ribosylates elongation factor 2. Cleavage within cells is mediated by furin, occurs between arginine 279 and glycine 280, and requires an arginine at both P1 and P4 residues. To study the proteolytic processing of PE-derived chimeric toxins, TGF alpha-PE38 (transforming growth factor fused to the domains II and III of PE) and a mutant form, TGF alpha-PE38gly279, were each produced in Escherichia coli, When assessed on various epidermal growth factor (EGF) receptor-positive cell lines, TGF alpha-PE38 was 100-500-fold more toxic than TGF alpha-PE38gly279. In contrast to PE, where cleavage by furin is only evident at pH 5.5, furin cleaved TGF alpha-PE38 over a broad pH range, while TGF alpha-PE38gly279 was resistant to cleavage, TGF alpha-PE38 was poorly toxic for furin-deficient LoVo cells, unless it was first pretreated in vitro with furin, Furin treatment produced a nicked protein that was 30-fold more toxic than its unnicked counterpart. Using the single chain immunotoxin HB21scFv-PE40 as a substrate, furin-mediated processing of an antibody-based immunotoxin was also evaluated, HB21scFv-PE40, which targets cells expressing the transferrin receptor, was cleaved in a similar fashion to that of TGF alpha-PE38 and nicked HB21scFv-PE40 exhibited increased toxicity for LoVo cells, In short-term experiments, the rate of reduction in protein synthesis by furin-nicked immunotoxins was increased compared with unnicked protein, indicating that cleavage by furin can be a rate-limiting step, We conclude that furin-mediated cleavage of PE-derived immunotoxins is important for their cytotoxic activity.	NCI,BIOTHERAPY SECT,MOL BIOL LAB,DBS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; Chiron MF, 1996, MOL MICROBIOL, V22, P769, DOI 10.1046/j.1365-2958.1996.d01-1721.x; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GARRED O, 1995, J BIOL CHEM, V270, P10817; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGIEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; Mansfield E, 1997, BIOCHEM SOC T, V25, P709, DOI 10.1042/bst0250709; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; OGATA M, 1990, J BIOL CHEM, V265, P20678; OGATA M, 1992, J BIOL CHEM, V267, P25396; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PASTAN IH, 1995, ANN NY ACAD SCI, V758, P345, DOI 10.1111/j.1749-6632.1995.tb24840.x; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673	34	38	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31707	31711		10.1074/jbc.272.50.31707	http://dx.doi.org/10.1074/jbc.272.50.31707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395513	hybrid			2022-12-27	WOS:A1997YL41900072
J	Johns, DC; Nuss, HB; Marban, E				Johns, DC; Nuss, HB; Marban, E			Suppression of neuronal and cardiac transient outward currents by viral gene transfer of dominant-negative Kv4.2 constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RAT HIPPOCAMPAL-NEURONS; ION-CHANNEL EXPRESSION; K+ CHANNEL; POTASSIUM CHANNELS; VENTRICULAR MYOCYTES; DIFFERENTIAL EXPRESSION; XENOPUS-OOCYTES; IN-VITRO; HEART	To probe the molecular identity of transient outward (A-type) potassium currents, we expressed a truncated version of Kv4.2 in heart cells and neurons. The rat Kv4.2 coding sequence was truncated at a position just past the first transmembrane segment and subcloned into an adenoviral shuttle vector downstream of a cytomegalovirus promoter (pE1Kv4.2ST). We hypothesized that this construct would act as a dominant-negative suppressor of currents encoded by the Kv4 family by analogy to Kv1 channels. Cotransfection of wild-type Kv4.2 with a beta-galactosidase expression vector in Chinese hamster ovary (CHO)-K1 cells produced robust transient outward currents (I-to) after two days (14.0 pA/pF at 50 mV, n = 5). Cotransfection with pE1Kv4.2ST markedly suppressed the Kv4.2 currents (0.8 pA/pF, n = 6, p < 0.02; cDNA ratio of 2:1 Kv4.2ST:wild type), but in parallel experiments, it did not alter the current density of coexpressed Kv1.4 or Kv1.5 channels, Kv4.2ST also effectively suppressed rat Kv4.3 current when coexpressed in CHO-K1 cells. We then engineered a recombinant adenovirus (AdKv4.2ST) designed to overexpress Kv4.2ST in infected cells. A-type currents in rat cerebellar granule cells were decreased two days after AdKv4.2ST infection as compared with those infected by a beta-galactosidase reporter virus (116.0 pA/pF versus 281.4 pA/pF in Ad beta-galactosidase cells, n = 8 each group, p < 0.001). Likewise, I-to in adult rat ventricular myocytes was suppressed by AdKv4.2ST but not by Ad beta-galactosidase (8.8 pA/pF versus 21.4 pA/pF in beta-galactosidase cells, n = 6 each group, p < 0.05). Expression of a GFP-Kv4.2ST fusion construct enabled imaging of subcellular protein localization by confocal microscopy. The protein was distributed throughout the surface membrane and intracellular membrane systems, We conclude that genes from the Kv4 family are the predominant contributors to the A-type currents in cerebellar granule cells and I-to in rat ventricle. Overexpression of dominant-negative constructs may be of general utility in dissecting the contributions of various ion channel genes to excitability.	JOHNS HOPKINS UNIV,SECT MOL & CELLULAR CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,GRAD PROGRAM CELLULAR & MOL MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Marban, Eduardo/GWC-8514-2022					BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Chen ML, 1996, NEURON, V17, P535, DOI 10.1016/S0896-6273(00)80185-3; CHUNG SW, 1995, P NATL ACAD SCI USA, V92, P5955, DOI 10.1073/pnas.92.13.5955; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; GORTER JA, 1995, J NEUROPHYSIOL, V74, P298, DOI 10.1152/jn.1995.74.1.298; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILALDANDAN R, 1991, J MOL CELL CARDIOL, V23, P705, DOI 10.1016/0022-2828(91)90980-Z; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JOHNS DC, 1995, J CLIN INVEST, V96, P1152, DOI 10.1172/JCI118103; Kaab S, 1996, CIRC RES, V78, P262, DOI 10.1161/01.RES.78.2.262; Kass RS, 1996, CARDIOVASC RES, V32, P443, DOI 10.1016/S0008-6363(96)00122-8; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEVI G, 1989, MANUAL NERVOUS SYSTE, P211; LI M, 1992, SCIENCE, V257, P125; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Panyi G, 1996, J GEN PHYSIOL, V107, P409, DOI 10.1085/jgp.107.3.409; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PO S, 1992, CIRC RES, V71, P732, DOI 10.1161/01.RES.71.3.732; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; Ribera AB, 1996, J NEUROSCI, V16, P1123; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHREUR K, 1997, CIRCULATION, V96, P422; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; TOMITA F, 1994, CIRC RES, V75, P296, DOI 10.1161/01.RES.75.2.296; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253; ZEGARRAMORAN O, 1994, EXP BRAIN RES, V98, P298; ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424	45	138	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31598	31603		10.1074/jbc.272.50.31598	http://dx.doi.org/10.1074/jbc.272.50.31598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395498	hybrid			2022-12-27	WOS:A1997YL41900057
J	Latinis, KM; Norian, LA; Eliason, SL; Koretzky, GA				Latinis, KM; Norian, LA; Eliason, SL; Koretzky, GA			Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; CD28 COSTIMULATION; INDUCED APOPTOSIS; ANTIGEN RECEPTOR; CYCLOSPORINE-A; DEATH; GENE; LYMPHOCYTES; FAMILY; REQUIREMENT	Antigen receptor engagement on T lymphocytes activates transcription factors important for stimulating cytokine gene expression, This is critical for clonal expansion of antigen-specific T cells and propagation of immune responses. Additionally, under some conditions antigen receptor stimulation initiates apoptosis of T lymphocytes through the induced expression of CD95 ligand and its receptor. Here we demonstrate that the transcription factor, NFAT, which is critical for the inducible expression of many cytokine genes, also plays a critical role in the regulation of T cell receptor-mediated CD95 ligand expression, Two sites within the CD95 ligand promoter, identified through DNase I footprinting, bind NFAT proteins from nuclear extracts of activated T cells. Although both sites appear important for optimal expression of CD95 ligand in activated T cells, mutational analysis suggests that the distal NFAT site plays a more significant role. Furthermore, these sites do not appear to be required for constitutive CD95 ligand expression in Sertoli cells.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,INTERDISCIPLINARY GRAD PROGRAM IMMUNOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021	Norian, Lyse/0000-0003-1016-313X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA66470] Funding Source: Medline; NIAID NIH HHS [T32-AI07485] Funding Source: Medline; NIGMS NIH HHS [5232-GM07337] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HO S, 1994, ADV EXP MED BIOL, V365, P167; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Latinis KM, 1997, J IMMUNOL, V158, P4602; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Musci MA, 1997, CLIN IMMUNOL IMMUNOP, V83, P205, DOI 10.1006/clin.1996.4315; Noel PJ, 1996, J IMMUNOL, V157, P636; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; PASTOR MI, 1995, CANCER SURV, V22, P75; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	46	193	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31427	31434		10.1074/jbc.272.50.31427	http://dx.doi.org/10.1074/jbc.272.50.31427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395475	hybrid			2022-12-27	WOS:A1997YL41900034
J	Pietroni, P; Young, MC; Latham, GJ; vonHippel, PH				Pietroni, P; Young, MC; Latham, GJ; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .1. Conformational changes within the gp44/62-gp45-ATP complex during clamp loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; SINGLE-STRANDED-DNA; PRIMER-TEMPLATE; REPLICATION COMPLEX; III HOLOENZYME; ATP HYDROLYSIS; CROSS-LINKING; PROCESSIVITY; JUNCTION; HELICASE	A multisubunit ring-shaped protein complex is used to tether the polymerase to the DNA at the primer-template junction in most DNA replication systems. This ''sliding clamp'' interacts with the polymerase, completely encircles the DNA duplex, and is assembled onto the DNA by a specific clamp loading complex in an ATP-driven process. Site-specific mutagenesis has been used to introduce single cysteine residues as reactive sites for adduct formation within each of the three subunits of the bacteriophage T4-coded sliding clamp complex (gp45). Two such mutants, gp45S19C and gp45K81C, are reacted with the cysteine-specific photoactivable crosslinker TFPAM-3 and used to track the changes in the relative positioning of the gp45 subunits with one another and with the other components of the clamp loading complex (gp44/62) in the various stages of the loading process. Cross linking interactions performed in the presence of nucleotide cofactors show that ATP binding and hydrolysis, interaction with primer-template DNA, and release of ADP all result in significant conformational changes within the clamp loading cycle, A structural model is presented to account for the observed rearrangements of intersubunit contacts within the complex during the loading process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Berdis AJ, 1997, BIOCHEMISTRY-US, V36, P2733, DOI 10.1021/bi962139l; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; HOCKENSMITH JW, 1993, J BIOL CHEM, V268, P15721; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KEANA JFW, 1990, J ORG CHEM, V55, P3640, DOI 10.1021/jo00298a048; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; Latham GJ, 1997, J BIOL CHEM, V272, P31685, DOI 10.1074/jbc.272.50.31685; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RUSH J, 1989, J BIOL CHEM, V264, P10943; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	32	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31666	31676		10.1074/jbc.272.50.31666	http://dx.doi.org/10.1074/jbc.272.50.31666			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395508	hybrid			2022-12-27	WOS:A1997YL41900067
J	Simon, M; Montezin, M; Guerrin, M; Durieux, JJ; Serre, G				Simon, M; Montezin, M; Guerrin, M; Durieux, JJ; Serre, G			Characterization and purification of human corneodesmosin, an epidermal basic glycoprotein associated with corneocyte-specific modified desmosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM; DESQUAMATION; DIFFERENTIATION; ANTIGENS; INVITRO; PROTEIN; IDENTIFICATION; PROTEOLYSIS; EXPRESSION; EPITHELIA	Using monoclonal antibodies, we identified a new protein in mammalian epidermis, which we called corneodesmosin. It is located in the extracellular part of the modified desmosomes in the cornified layer of the tissue, and its proteolysis (from 52-56 to 33 kDa) is thought to be a major prerequisite of desquamation. We have now further characterized human corneodesmosin. Proteolysis of purified cornified cell envelopes produced immunoreactive fragments, confirming the covalent linkage of the protein to these structures. Sequential extraction of epidermal proteins indicated that the 52-56-kDa precursor form of the protein exists in two distinct pools, one extracted with a nondenaturing hypotonic buffer, and the other with urea. Two-dimensional gel analysis and reactivity with phosphoserine-specific antibodies showed that it is a basic phosphoprotein. Deglycosylation experiments, reactivity with lectins, and chromatography on concanavalin A-Sepharose indicated that corneodesmosin is N-glycosylated. Partial sequences, 10 and 15 amino acids long, of the purified 52-56-kDa corneodesmosin showed identity with sequences predicted from a previously cloned gene, proved to be expressed in the epidermis and designated S. This indicates that corneodesmosin is probably encoded by the S gene, the function of which was unknown until now. A model of corneodesmosin maturation during cornification is proposed.	INSERM, CJF 96 02, DEPT PATHOL & CELL BIOL, TOULOUSE, FRANCE; UNIV TOULOUSE 3, PURPAN SCH MED, IFR30, INSERM, CNRS, UPS, CHU, F-31073 TOULOUSE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			Simon, Michel/B-7308-2011	Simon, Michel/0000-0003-3655-6329				ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; CHAPMAN SJ, 1991, ARCH DERMATOL RES, V283, P167, DOI 10.1007/BF00372057; EGELRUD T, 1988, ACTA DERM-VENEREOL, V68, P93; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HENSELER T, 1985, J AM ACAD DERMATOL, V13, P450, DOI 10.1016/S0190-9622(85)70188-0; HOLBROOK K, 1994, KERATINOCYTE HDB, P275; KAPPRELL HP, 1985, EUR J CELL BIOL, V36, P217; KING CS, 1979, BRIT J DERMATOL, V100, P165, DOI 10.1111/j.1365-2133.1979.tb05556.x; KING IA, 1989, J INVEST DERMATOL, V92, P22, DOI 10.1111/1523-1747.ep13070408; LUNDSTROM A, 1990, ARCH DERMATOL RES, V282, P234, DOI 10.1007/BF00371642; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; MENTON DN, 1971, J ULTRA MOL STRUCT R, V35, P247, DOI 10.1016/S0022-5320(71)80155-7; MILS V, 1992, J HISTOCHEM CYTOCHEM, V40, P1329, DOI 10.1177/40.9.1506670; Montezin M, 1997, EXP CELL RES, V231, P132, DOI 10.1006/excr.1996.3452; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SANDILANDS A, 1995, EUR J CELL BIOL, V67, P238; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Simon M, 1996, BIOCHEM J, V317, P173, DOI 10.1042/bj3170173; SKERROW CJ, 1989, J CELL SCI, V92, P667; SUZUKI Y, 1993, ARCH DERMATOL RES, V285, P372, DOI 10.1007/BF00371839; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; Vicanova J, 1996, CELL TISSUE RES, V286, P115, DOI 10.1007/s004410050680; WALSH A, 1991, ARCH DERMATOL RES, V283, P174, DOI 10.1007/BF00372058; ZHOU YQ, 1993, P NATL ACAD SCI USA, V90, P9470, DOI 10.1073/pnas.90.20.9470	29	71	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31770	31776		10.1074/jbc.272.50.31770	http://dx.doi.org/10.1074/jbc.272.50.31770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395522	hybrid			2022-12-27	WOS:A1997YL41900081
J	Vu, TKH; Liu, RW; Haaksma, CJ; Tomasek, JJ; Howard, EW				Vu, TKH; Liu, RW; Haaksma, CJ; Tomasek, JJ; Howard, EW			Identification and cloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; DORSAL-VENTRAL PATTERN; SPERM-EGG FUSION; DROSOPHILA EMBRYO; DISINTEGRIN DOMAIN; ASTACIN FAMILY; C-PROTEINASE; GENE ENCODES; FACTOR-VII; EXPRESSION	Previous studies have suggested the existence of a membrane-associated serine protease expressed by mammalian preimplantation embryos, In this study, we have identified hepsin, a type II transmembrane serine protease, in early mouse blastocysts. Mouse hepsin was highly homologous to the previously identified human and rat cDNAs. Two isoforms, differing in their cytoplasmic domains, were detected. The tissue distribution of mouse hepsin was similar to that seen in humans, with prominent expression in liver and kidney. In mouse embryos, hepsin expression was observed in the two-cell stage, reached a maximal level at the early blastocyst stage, and decreased subsequent to blastocyst hatching. Expression of a soluble form of hepsin revealed its ability to autoactivate in a concentration-dependent manner. Catalytically inactive soluble hepsin was unable to autoactivate. These results suggest that hepsin may be the first serine protease expressed during mammalian development, making its ability to autoactivate critical to its function.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT ANAT SCI,OKLAHOMA CITY,OK 73190; COLUMBIA PRESBYTERIAN MED CTR,CTR ASSISTED REPROD TECHNOL,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; Columbia University	Vu, TKH (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,BIOMED SCI BLDG,RM 434,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73190, USA.							APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELAROUSSI MA, 1994, BBA-GENE STRUCT EXPR, V1217, P1, DOI 10.1016/0167-4781(94)90116-3; EVANS JP, 1995, J CELL SCI, V108, P3267; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Hishida R, 1996, EMBO J, V15, P4111, DOI 10.1002/j.1460-2075.1996.tb00786.x; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; Katagiri C, 1997, INT J DEV BIOL, V41, P19; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; McLaren A., 1982, REPROD MAMMALS; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; PERONA RM, 1986, DEV BIOL, V114, P42, DOI 10.1016/0012-1606(86)90382-9; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SAWADA H, 1990, J EXP ZOOL, V253, P83; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; STEARNS DJ, 1988, J BIOL CHEM, V263, P829; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Tanimoto H, 1997, CANCER RES, V57, P2884; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; TSUJI A, 1991, J BIOL CHEM, V266, P16948; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAN L, 1995, DEVELOPMENT, V121, P1591; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3; Zhukov A, 1997, BBA-PROTEIN STRUCT M, V1337, P85, DOI 10.1016/S0167-4838(96)00152-5	39	63	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31315	31320		10.1074/jbc.272.50.31315	http://dx.doi.org/10.1074/jbc.272.50.31315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395459	hybrid			2022-12-27	WOS:A1997YL41900018
J	Emkey, R; Kahn, CR				Emkey, R; Kahn, CR			Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes II Comparison of phorbol ester and sphingomyelinase-induced phosphorylation of ErbB2 and ErbB3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR FAMILY; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; CELL-DIFFERENTIATION; ACTIVATING PROTEIN; FACTOR-ALPHA; CERAMIDE; PATHWAY	In the accompanying paper (Emkey, R., and Kahn, C, R. (1997) J. Biol, Chem. 272, 31172-31181), we demonstrated that phorbol 12-myristate 13-acetate (PMA) treatment of Fao cells induces tyrosine phosphorylation of several proteins including ErbB2 and ErbB3, In the present study we show that sphingomyelinase also results in the enhanced tyrosine phosphorylation of ErbB2 and ErbB3 in these cells. In contrast to activation by PMA, the sphingomyelinase-induced phosphorylation of these proteins is independent of protein kinase C. However, both agents stimulate tyrosine phosphorylation of the kinase Pyk2 suggesting that it may be involved in the PMA and sphingomyelinase activation of these ErbB proto-oncogenes. Insulin plays a negative regulatory role in the ligand and non-ligand-induced phosphorylation of the ErbB proto-oncogenes via two mechanisms. Prolonged insulin treatment resulted in decreased expression of both ErbB2 and ErbB3. Insulin also appears to negatively regulate the protein tyrosine kinase responsible for phosphorylating ErbB2 in PMA-stimulated cells. The former effect of insulin was relieved by treatment with inhibitors of phosphatidylinositol 3-kinase. The similarities in PMA and sphingomyelinase-induced effects and the negative regulatory role of insulin suggest a mechanism by which multiple ligands can synergize with or protect against the tumorigenic effects of phorbol esters.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Res, Joslin Pl, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BELL RM, 1991, J BIOL CHEM, V266, P4661; Carver RS, 1996, J BIOL CHEM, V271, P13491, DOI 10.1074/jbc.271.23.13491; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KIM MY, 1991, J BIOL CHEM, V266, P484; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OGAWA W, 1995, ENDOCRINOLOGY, V136, P476, DOI 10.1210/en.136.2.476; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PELES E, 1992, J BIOL CHEM, V267, P12266; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI T, 1995, BIOCHEM J, V311, P829, DOI 10.1042/bj3110829; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; SEGATTO O, 1993, ONCOGENE, V8, P2105; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	52	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31182	31189		10.1074/jbc.272.49.31182	http://dx.doi.org/10.1074/jbc.272.49.31182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388272	hybrid			2022-12-27	WOS:000071640800085
J	Sewack, GF; Hansen, U				Sewack, GF; Hansen, U			Nucleosome positioning and transcription-associated chromatin alterations on the human estrogen-responsive pS2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; MAMMARY EPITHELIAL-CELLS; TUMOR VIRUS PROMOTER; DNA-BINDING DOMAINS; BREAST-CANCER CELLS; FACTOR ACCESS; IN-VIVO; VITELLOGENIN-B1 PROMOTER; REGULATED TRANSCRIPTION; TRANSLATIONAL POSITION	The positioning of nucleosomes on a promoter is a significant determinant in its responsiveness to inducing signals. We have mapped the chromatin structure of the human, estrogen-responsive pS2 promoter at nucleotide level resolution within the context of its normal genomic location in human mammary epithelial cells, In vivo digestion by nucleases followed by ligation-mediated polymerase chain reaction analysis revealed two rotationally phased and translationally positioned nucleosomes within the promoter between nucleotide positions -450 and +7, The estrogen response elements at -400 and TATAA box at -35 are each located at the edge of a nucleosome. The two precisely positioned nucleosomes exist in both transformed and nontransformed human mammary epithelial cells, regardless of estrogen receptor status or transcriptional activity of the gene, However, two structural alterations correlate with the transcriptional potential of the promoter, In MCF-7 cells, in which the pS2 promoter is inducible, the chromatin exhibits an increased sensitivity to DNase I in a region of DNA adjacent to the TATAA box and an additional micrococcal nuclease-hypersensitive site in the linker DNA between the two positioned nucleosomes. We were also able to demonstrate that nucleotides -1100 to +10 of the pS2 promoter are sufficient to determine the positioning of these two nucleosomes, Our results establish the structural features of the chromatin covering the pS2 promoter as well as transcriptionally associated alterations, suggesting how the nucleosomal template influences transcriptional regulation by estrogen receptor.	Dana Farber Canc Inst, Dept Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hansen, U (corresponding author), Dana Farber Canc Inst, Dept Mol Genet, Boston, MA 02115 USA.	ulla_hansen@dfci.harvard.edu		Hansen, Ulla/0000-0001-9803-4185				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALMER A, 1986, EMBO J, V5, P2696; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORTHESY B, 1990, MOL CELL BIOL, V10, P3926, DOI 10.1128/MCB.10.8.3926; COSTANZO G, 1995, J BIOL CHEM, V270, P11091, DOI 10.1074/jbc.270.19.11091; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CREMISI C, 1979, MICROBIOL REV, V43, P297; CULLEN KE, 1993, SCIENCE, V261, P203, DOI 10.1126/science.8327891; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEPAMPHILIS ML, 1982, ORG REPLICATION VIRA, P37; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; Englander EW, 1996, J BIOL CHEM, V271, P5819, DOI 10.1074/jbc.271.10.5819; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ KB, 1978, CANCER RES, V38, P2434; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI Q, 1995, MOL CELL BIOL, V15, P4375; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGHEE JD, 1983, CELL, V32, P1205, DOI 10.1016/0092-8674(83)90303-3; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PHAM TA, 1991, J BIOL CHEM, V266, P18179; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verdone L, 1996, MOL CELL BIOL, V16, P1978; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WASSERMAN PM, 1989, METHOD ENZYMOL, V170, P3; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhu ZW, 1996, CELL, V87, P459, DOI 10.1016/S0092-8674(00)81366-5	77	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31118	31129		10.1074/jbc.272.49.31118	http://dx.doi.org/10.1074/jbc.272.49.31118			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388265	hybrid			2022-12-27	WOS:000071640800078
J	Shneider, BL; Thevananther, S; Moyer, MS; Walters, HC; Rinaldo, P; Devarajan, P; Sun, AQ; Dawson, PA; Ananthanarayanan, M				Shneider, BL; Thevananther, S; Moyer, MS; Walters, HC; Rinaldo, P; Devarajan, P; Sun, AQ; Dawson, PA; Ananthanarayanan, M			Cloning and characterization of a novel peptidase from rat and human ileum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID TRANSPORTER; MEMBRANE ANTIGEN; DIPEPTIDYLPEPTIDASE-IV; SEQUENCE-ANALYSIS; SMALL-INTESTINE; GENE; HYDROLASE; CDNA; PURIFICATION; EXPRESSION	A novel 100-kDa ileal brush border membrane protein (I100) has been purified by anionic glycocholate affinity chromatography, Polyclonal antibodies raised against this protein were utilized to clone and characterize I100 in rats, A partial length human I100 cDNA was identified by hybridization screening, In the rat, the I100 protein is a 746-amino acid glycosylated (calculated core molecular mass of 80 kDa) type II integral membrane protein found on the apical surface of ileal villus enterocytes, Its a,6-kilobase mRNA is expressed in distal small intestine in rats and in humans, The I100 cDNA is homologous to but distinct from human prostate-specific membrane antigen and rat brain N-acetylaspartylglutamate peptidase, It is expressed on both the basolateral and apical surfaces of stably transfected Madin Darby canine kidney cells, Analysis of these stably transfected Madin Darby canine kidney cells and I100 immunoprecipitates of rat ileal brush border membrane vesicles reveals that it has dipeptidyl peptidase TV activity. Future invesitgations will need to determine the exact substrate specificity of this novel peptidase.	Yale Univ, Sch Med, Dept Pediat, Div Pediat Gastroenterol Hepatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, Div Pediat Nephrol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med Gastroenterol, Winston Salem, NC 27157 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Yale University; Yale University; Yale University; Wake Forest University; Wake Forest Baptist Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Shneider, BL (corresponding author), Mt Sinai Med Ctr, Div Pediat Gastroenterol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002076, P30DK034989, R01DK043509, R29DK047987] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43509, DK-02076, DK-34989, R29 DK047987] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAI JPF, 1995, J PHARM PHARMACOL, V47, P698, DOI 10.1111/j.2042-7158.1995.tb05863.x; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BLACKMON DL, 1992, ANAL BIOCHEM, V200, P352, DOI 10.1016/0003-2697(92)90478-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DARMOUL D, 1994, BIOCHEM BIOPH RES CO, V203, P1224, DOI 10.1006/bbrc.1994.2313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; HARDISON WGM, 1991, HEPATOLOGY, V13, P68, DOI 10.1002/hep.1840130111; ISRAELI RS, 1993, CANCER RES, V53, P227; Jacotot E, 1996, EUR J BIOCHEM, V239, P248, DOI 10.1111/j.1432-1033.1996.0248u.x; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACK L, 1961, AM J PHYSIOL, V200, P313, DOI 10.1152/ajplegacy.1961.200.2.313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; MARCUS SN, 1991, GASTROENTEROLOGY, V100, P212; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MENTLEIN R, 1993, REGUL PEPTIDES, V49, P133, DOI 10.1016/0167-0115(93)90435-B; Mentzel S, 1996, J HISTOCHEM CYTOCHEM, V44, P445, DOI 10.1177/44.5.8627002; OGATA S, 1989, J BIOL CHEM, V264, P3596; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Pederson RA, 1996, METABOLISM, V45, P1335, DOI 10.1016/S0026-0495(96)90112-2; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RINKERSCHAEFFER CW, 1995, GENOMICS, V30, P105, DOI 10.1006/geno.1995.0019; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS KP, 1990, MOL CELL ENDOCRINOL, V14, P531; SCHIFF ER, 1972, J CLIN INVEST, V51, P1351, DOI 10.1172/JCI106931; SHNEIDER B, 1991, GASTROENTEROLOGY, V100, P796; SHNEIDER BL, 1993, PEDIATR RES, V33, P221, DOI 10.1203/00006450-199303000-00002; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; SUN AQ, 1995, HEPATOLOGY, V22, P318; SUZUKI Y, 1993, AM J PHYSIOL, V264, pG1153, DOI 10.1152/ajpgi.1993.264.6.G1153; SWANSON ML, 1988, BIOCHEM J, V255, P229; TIRUPPATHI C, 1993, AM J PHYSIOL, V265, pG81, DOI 10.1152/ajpgi.1993.265.1.G81; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4351; VONDIPPE P, 1986, BIOCHIM BIOPHYS ACTA, V862, P352, DOI 10.1016/0005-2736(86)90238-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340; XU SY, 1986, GENE ANAL TECH, V3, P90	53	28	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31006	31015		10.1074/jbc.272.49.31006	http://dx.doi.org/10.1074/jbc.272.49.31006			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388249	hybrid			2022-12-27	WOS:000071640800062
J	Guesdon, F; Knight, CG; Rawlinson, LM; Saklatvala, J				Guesdon, F; Knight, CG; Rawlinson, LM; Saklatvala, J			Dual specificity of the interleukin 1- and tumor necrosis factor-activated beta casein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; PROTEIN-KINASE; C-JUN; INFLAMMATORY CYTOKINES; PHOSPHORYLATION; SUBSTRATE; PATHWAY; DOMAIN; IDENTIFICATION; TYROSINE	Tumor necrosis factor (TNF) and interleukin 1 (IL1) activate a protein kinase, TIP kinase, which phosphorylates beta casein in vitro. We have now identified its main phosphorylation site on beta casein, Ser(124) (K-m approximate to 28 mu M), and a minor phosphorylation site, Ser(142) (K-m approximate to 0.7 mM). The sequence motif that determined the phosphorylation of Ser(124) by the kinase was studied with synthetic peptides bearing deletions or substitutions of the neighboring residues. This allowed synthesis of improved substrates (K-m approximate to 6 mu M) and showed that efficient phosphorylation of Ser(124) was favored by the presence of large hydrophobic residues at positions +1, +9, +11, and +13 (counted relative to the position of the phosphoacceptor amino acid) and of a cysteine at position -2. Peptides in which Ser(124) was replaced by tyrosine were also phosphorylated by TIP kinase, showing it to have dual specificity. It is unable to phosphorylate the MAP kinases in vitro and is therefore not directly involved in their activation. Its biochemical characteristics indicate that TIP kinase is a novel dual specificity kinase, perhaps related to the mixed lineage kinases. It copurified with a phosphoprotein of about 95 kDa, which could correspond either to the autophosphorylated kinase or to an associated substrate.	HAMMERSMITH HOSP,KENNEDY INST RHEUMATOL,LONDON W6 8LH,ENGLAND; STRANGEWAYS RES LAB,DEPT CELL ADHES & SIGNALING,CAMBRIDGE CB1 4RN,ENGLAND; ROYAL HALLAMSHIRE HOSP,DIV MOL & GENET MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	Imperial College London; University of Oxford; University of Sheffield	Guesdon, F (corresponding author), ROYAL HALLAMSHIRE HOSP,DIV MOL & GENET MED,M FLOOR,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							Baker SJ, 1996, ONCOGENE, V12, P1; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BIRD TA, 1994, J BIOL CHEM, V269, P31836; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CARLES C, 1988, FEBS LETT, V229, P265, DOI 10.1016/0014-5793(88)81138-4; CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DINARELLO CA, 1991, BLOOD, V77, P1627; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GUESDON F, 1993, J BIOL CHEM, V268, P4236; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hirai S, 1996, ONCOGENE, V12, P641; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; LEATHERBARROW RJ, 1990, ANAL BIOCHEM, V184, P274, DOI 10.1016/0003-2697(90)90680-8; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30017	30024		10.1074/jbc.272.48.30017	http://dx.doi.org/10.1074/jbc.272.48.30017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374476	hybrid			2022-12-27	WOS:A1997YH61300008
J	Liu, LH; Paul, RJ; Sutliff, RL; Miller, ML; Lorenz, JN; Pun, RYK; Duffy, JJ; Doetschman, T; Kimura, Y; MacLennan, DH; Hoying, JB; Shull, GE				Liu, LH; Paul, RJ; Sutliff, RL; Miller, ML; Lorenz, JN; Pun, RYK; Duffy, JJ; Doetschman, T; Kimura, Y; MacLennan, DH; Hoying, JB; Shull, GE			Defective endothelium-dependent relaxation of vascular smooth muscle and endothelial cell Ca2+ signaling in mice lacking sarco(endo)plasmic reticulum Ca2+-ATPase isoform 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; RELAXING FACTOR; FUNCTIONAL CONSEQUENCES; SKELETAL-MUSCLE; CA-2+ PUMP; CA-2+-ATPASE GENE; CALCIUM PUMPS; CDNA CLONING	Sarco(endo)plasmic reticulum Ca2+ ATPase isoform 3 (SERCA3) is one of two Ca2+ pumps serving intracellular Ca2+ signaling pools in non-muscle tissues; however, unlike the ubiquitous SERCA2b, it exhibits a restricted cell-type distribution. Gene targeting was used to generate a mouse with a null mutation in the SERCA3 gene, Homozygous mutant mice were viable, fertile, and did not exhibit an overt disease phenotype. Because SERCA3 is expressed in arterial endothelial cells, aortic ring preparations were analyzed to determine whether it is involved in the regulation of vascular tone, Contraction-isometric force relations in response to phenylephrine or KCl, as well as relaxation produced by exposure to a nitric oxide donor, were similar in wild-type and null mutant aortas, Acetylcholine-induced endothelium-dependent relaxation of aortas after precontraction with phenylephrine was significantly reduced in homozygous mutants (61.3 +/- 5.6% in wild type, 35.4 +/- 7.3% in mutants). Ca2+ imaging of cultured aortic endothelial cells demonstrated that the acetylcholine-induced intracellular Ca2+ signal is sharply diminished in SERCA3-deficient cells and also indicated that replenishment of the acetylcholine-responsive Ca2+ stores is severely impaired. These results indicate that SERCA3 plays a critical role in endothelial cell Ca2+ signaling events involved in nitric oxide-mediated relaxation of vascular smooth muscle.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOL & CELLULAR PHYSIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Toronto					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, P01HL041496, R01HL023240] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23240, TG HL07382, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANGER M, 1993, FEBS LETT, V334, P45, DOI 10.1016/0014-5793(93)81677-R; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; BUSSE R, 1993, EUR HEART J, V14, P2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DANTHULURI NR, 1988, AM J PHYSIOL, V255, pH1549, DOI 10.1152/ajpheart.1988.255.6.H1549; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JARRELL B, 1984, J VASC SURG, V1, P757, DOI 10.1067/mva.1984.avs0010757; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lalli J, 1997, CIRC RES, V80, P506, DOI 10.1161/01.RES.80.4.506; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHILLING WP, 1992, AM J PHYSIOL, V262, pH1617, DOI 10.1152/ajpheart.1992.262.6.H1617; SESSA WC, 1992, J BIOL CHEM, V267, P15274; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; WANG XD, 1995, CIRC RES, V77, P37, DOI 10.1161/01.RES.77.1.37; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Wuytack F, 1995, BIOSCIENCE REP, V15, P299, DOI 10.1007/BF01788362; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	48	84	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30538	30545		10.1074/jbc.272.48.30538	http://dx.doi.org/10.1074/jbc.272.48.30538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374548	hybrid			2022-12-27	WOS:A1997YH61300080
J	Nonaka, T; Dohmae, N; Hashimoto, T; Takio, K				Nonaka, T; Dohmae, N; Hashimoto, T; Takio, K			Amino acid sequences of metalloendopeptidases specific for acyl-lysine bonds from Grifola frondosa and Pleurotus ostreatus fruiting bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED FUCOSE; GROWTH-FACTOR DOMAIN; PROTEIN; CLONING; PURIFICATION; COLLAGENASES; ALIGNMENT; ASTACINS; PEPTIDE; YEAST	The complete amino acid sequences of two lysine-specific zinc metalloendopeptidases (EC 3.4.24), Grifola frondosa metalloendopeptidase (GFMEP) and Pleurotus ostreatus metalloendopeptidase (POMEP), from the fruiting bodies of these two edible mushrooms have been established based on the sequence information of the peptides generated from the reduced and alkylated GFMEP and POMEP by proteolytic digestions using GFMEP, trypsin, and other proteinases as well as by several chemical cleavages. From the sequences, it was found that GFMEP and POMEP were polypeptides composed of 167 and 168 amino acid residues, from which their molecular weights were calculated to be 18,040.5 and 17,921.3 in accord with the observed (M+H)(+) values of 18,028 and 17,927, respectively, as determined by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Two disulfide bonds in GFMEP were found to link Cys(5) to Cys(75) and Cys(77) to Cys(97). An unusual post-translational modification of GFMEP was corroborated to be a partial attachment of a single mannose to Thr(42). Comparison of the sequences revealed that overall identity between the enzymes was 61.3%. Although a highly homologous sequence was not found in sequence data bases except for a consensus zinc-binding sequence, HEXXH, both metalloendopeptidases somewhat resembled a family of metalloproteinases categorized as deuterolysin. These proteases together with GFMEP and POMEP do not have conserved third and/or fourth liganding amino acid residues seen in metzincin or thermolysin superfamily proteins and belong to a novel zinc metalloendopeptidase superfamily.	RIKEN, INST PHYS & CHEM RES, DIV BIOMOL CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN; SAITAMA UNIV, FAC SCI, DEPT BIOCHEM, URAWA, SAITAMA 338, JAPAN	RIKEN; Saitama University			Dohmae, Naoshi/C-2040-2011; Nonaka, Takashi/L-8572-2017	Dohmae, Naoshi/0000-0002-5242-9410; Nonaka, Takashi/0000-0002-0830-9403				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cole R.D., 1967, METHOD ENZYMOL, V11, P315; DOHMAE N, 1995, BIOSCI BIOTECH BIOCH, V59, P2074, DOI 10.1271/bbb.59.2074; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; DOONAN S, 1975, EUR J BIOCHEM, V56, P421, DOI 10.1111/j.1432-1033.1975.tb02248.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS WG, 1978, BIOCHIM BIOPHYS ACTA, V522, P551, DOI 10.1016/0005-2744(78)90087-6; MATSUMOTO K, 1994, BBA-GENE STRUCT EXPR, V1218, P469, DOI 10.1016/0167-4781(94)90209-7; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; NONAKA T, 1995, J BIOCHEM-TOKYO, V118, P1014, DOI 10.1093/jb/118.5.1014; OMENN GS, 1970, J BIOL CHEM, V245, P1895; RAMESH MV, 1995, GENE, V165, P121, DOI 10.1016/0378-1119(95)00434-8; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; SPIRO RG, 1980, J BIOL CHEM, V255, P5347; STAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185; Stark G R, 1977, Methods Enzymol, V47, P129; STOCKER W, 1995, PROTEIN SCI, V4, P823; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; TATSUMI H, 1991, MOL GEN GENET, V228, P97, DOI 10.1007/BF00282453; TERASHITA T, 1985, AGR BIOL CHEM TOKYO, V49, P2293, DOI 10.1080/00021369.1985.10867077; TERASHITA T, 1985, T MYCOL SOC JPN, V26, P397; YUN SJ, 1991, J BIOL CHEM, V266, P693	35	50	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30032	30039		10.1074/jbc.272.48.30032	http://dx.doi.org/10.1074/jbc.272.48.30032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374478	hybrid			2022-12-27	WOS:A1997YH61300010
J	Upston, JM; Neuzil, J; Witting, PK; Alleva, R; Stocker, R				Upston, JM; Neuzil, J; Witting, PK; Alleva, R; Stocker, R			Oxidation of free fatty acids in low density lipoprotein by 15-lipoxygenase stimulates nonenzymic, alpha-tocopherol-mediated peroxidation of cholesteryl esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPID-PROTEIN ADDUCTS; MAMMALIAN LIPOXYGENASES; SCREENING-TEST; MESSENGER-RNA; VITAMIN-E; HYDROPEROXIDES; OXYGENATION; LDL	15-Lipoxygenase has been implicated in the in vivo oxidation of low density lipoprotein (LDL) a process thought to be important in the origin and/or progression of human atherogenesis, We have suggested previously that oxidation of LDL's cholesteryl esters (CE) and phospholipids by soybean (SLO) or human recombinant 15-lipoxygenase (rhLO) can be ascribed largely to alpha-tocopherol (alpha-TOH)-mediated peroxidation (TMP). In this study we demonstrate that addition to LDL of unesterified linoleate (18:2), other free fatty acid (FFA) substrates, or phospholipase A(2) (PLA(2)) significantly enhanced the accumulation of CE hydro(pero)xides (CEO(O)H) induced by rhLO, whereas the corresponding CE and nonsubstrate FFA were without effect. The enhanced CE-O(O)H accumulation showed a dependence on the concentration of free 18:2 in LDL, In contrast, addition of 18:2 had little effect on LDL oxidation induced by aqueous peroxyl radicals or Cu2+ ions, Analyses of the regio- and stereoisomers of oxidized 18:2 in SLO-treated native LDL demonstrated that the small amounts of 18:2 associated with the lipoprotein were oxidized enzymically and within minutes, whereas cholesteryl linoleate (Ch18:2) was oxidized nonenzymically and continuously over hours, alpha-Tocopheroxyl radical (alpha-TO.) formed in LDL exposed to SLO was enhanced by addition of 18:2 or PLA(2). With rhLO and 18:2-supplemented LDL, oxidation of 18:2 was entirely enzymic, whereas that of Ch18:2 was largely, though not completely, nonenzymic, The small extent of enzymic Ch18:2 oxidation increased with increasing enzyme to LDL ratios. Ascorbate and the reduced form of coenzyme Q, ubiquinol-10, which are both capable of reducing alpha-TO. and thereby preventing TMP, inhibited nonenzymic Ch18:2 oxidation induced by rhLO. Trolox and ascorbyl palmitate, which also inhibit TMP, ameliorated both enzymic and nonenzymic oxidation of LDL's lipids, whereas probucol, a radical scavenger not capable of preventing TRIP, was ineffective, These results demonstrate that rhLO-induced oxidation of CE is largely nonenzymic and increases with LDL's content of FFA substrates, We propose that conditions which increase LDL's FFA content, such as the presence of lipases, increase 15-LO-induced LDL lipid peroxidation and that this process requires only an initial, transient enzymic activity.	HEART RES INST,BIOCHEM UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA; UNIV ANCONA,SCH MED,INST BIOCHEM,I-60131 ANCONA,ITALY	University of Sydney; Heart Research Institute; Marche Polytechnic University			Stocker, Roland/AAV-4489-2021; Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019; Neuzil, Jiri/H-7204-2014	Witting, Paul/0000-0003-2237-7004; Neuzil, Jiri/0000-0002-2478-2460				BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; DAVIES MJ, 1987, BIOCHEM J, V245, P167, DOI 10.1042/bj2450167; ESKOLA J, 1983, BIOCHIM BIOPHYS ACTA, V751, P305, DOI 10.1016/0005-2760(83)90288-6; EZAKI M, 1995, J LIPID RES, V36, P1996; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ITABE H, 1994, J BIOL CHEM, V269, P15274; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; Kenar JA, 1996, CHEM RES TOXICOL, V9, P737, DOI 10.1021/tx9600098; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; Lass A, 1996, BIOCHEM J, V314, P577, DOI 10.1042/bj3140577; LUND E, 1992, J BIOL CHEM, V267, P12462; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; RAPAPORT SM, 1979, EUR J BIOCHEM, V96, P545; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; Upston JM, 1996, J LIPID RES, V37, P2650; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1997, BIOCHEMISTRY-US, V36, P1251, DOI 10.1021/bi962493j; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	43	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30067	30074		10.1074/jbc.272.48.30067	http://dx.doi.org/10.1074/jbc.272.48.30067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374483	hybrid			2022-12-27	WOS:A1997YH61300015
J	Zheng, WJ; Xu, HE; Johnston, SA				Zheng, WJ; Xu, HE; Johnston, SA			The cysteine-peptidase bleomycin hydrolase is a member of the galactose regulon in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY GENE GAL80; SACCHAROMYCES-CEREVISIAE; EXPRESSION; CLONING; PROTEIN; VECTORS; FAMILY; DNA; TRANSCRIPTION; SEQUENCE	Bleomycin hydrolase is a cysteine peptidase discovered through its ability to detoxify the anti-cancer glycopeptide, bleomycin, Although found in all tissues in mammals and in both eukaryotes and prokaryotes, the normal cellular function of this peptidase is not known. We had previously reported the purification of bleomycin hydrolase hom yeast based on its unexpected ability to bind DNA. Recently we collaborated in solving the crystal structure of this protein, revealing a hexameric ring organization. We now report that the molecular characterization of the gene encoding yeast bleomycin hydrolase is also surprising. The transcription of the gene is regulated by galactose. Furthermore, this regulation is conveyed by a binding site for the Gal4 regulatory protein in its promoter, prompting the designation of this gene as GAL6. Gal6p also appears to have a negative effect on the GAL system as a deletion of the gene leads to a 2-5-fold higher expression of the GAL1, GAL2, GAL7, and MEL1 genes. The GAL6 deletion does slat affect the expression of another inducible gene, HSP26. Neither the peptidase nor the nucleic acid binding activity of Gal6p as assayed is apparently required to convey this regulation, implying yet another function for this new member of the GAL regulon.	UNIV TEXAS,SW MED CTR,DEPT MED,GRAD PROGRAM BIOCHEM & MOL BIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,GRAD PROGRAM BIOCHEM & MOL BIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Xu, H. Eric/ABD-7487-2021	Xu, H. Eric/0000-0002-6829-8144	NATIONAL CANCER INSTITUTE [R01CA067982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040700] Funding Source: NIH RePORTER; NCI NIH HHS [CA67982] Funding Source: Medline; NIGMS NIH HHS [GM40700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BHAT PJ, 1990, GENETICS, V125, P281; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; CIGAN AM, 1987, GENE, V59, P1; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI M, 1987, MOL GEN GENET, V207, P273, DOI 10.1007/BF00331589; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; Lazo J S, 1993, Cancer Chemother Biol Response Modif, V14, P37; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Melcher K., 1997, YEAST SUGAR METABOLI, P235; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NOGI Y, 1986, J BACTERIOL, V165, P101, DOI 10.1128/jb.165.1.101-106.1986; NOGI Y, 1984, NUCLEIC ACIDS RES, V12, P9287, DOI 10.1093/nar/12.24.9287; Pei ZD, 1996, BIOCHEMISTRY-US, V35, P10751, DOI 10.1021/bi9605447; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHIMADA H, 1985, GENE, V39, P1; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TORCHIA TE, 1986, GENETICS, V113, P229; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; XU HE, 1994, J BIOL CHEM, V269, P21177	33	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30350	30355		10.1074/jbc.272.48.30350	http://dx.doi.org/10.1074/jbc.272.48.30350			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374524	hybrid			2022-12-27	WOS:A1997YH61300056
J	Garces, C; RuizHidalgo, MJ; deMora, JF; Park, C; Miele, L; Goldstein, J; Bonvini, E; Porras, A; Laborda, J				Garces, C; RuizHidalgo, MJ; deMora, JF; Park, C; Miele, L; Goldstein, J; Bonvini, E; Porras, A; Laborda, J			Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-DIFFERENTIATION; BINDING-PROTEIN-ALPHA; PEROXISOME PROLIFERATOR; ADIPOCYTE DIFFERENTIATION; DROSOPHILA-MELANOGASTER; RECEPTOR-GAMMA; 3T3-L1 CELLS; NEUROGENESIS; GENE; WINGLESS	Notch, a transmembrane receptor member of the homeotic epidermal growth factor-like family of proteins, participates in cell-to-cell signaling to control cell fate during development, Activated Notch-1 constructs lacking the extracellular region prevent differentiation of several mammalian cells in vitro, This effect, however, bypasses the normal mechanisms of cell-to-cell interactions in which Notch-1 participates, We investigated the role of Notch-1. in the hormone-induced adipocyte differentiation of 3T3-L1 fibroblasts, a paradigmatic model of adipogenesis that requires cell-to-cell contact, Unlike other differentiation models, Notch-1 expression and function were necessary conditions for adipogenesis, Impaired Notch-1 expression by antisense Notch-1 constructs prevented adipocyte differentiation. Strategies aimed at blocking putative Notch/ligand interactions also blocked adipogenesis, implicating Notch as a critical molecule in cell-to-cell signaling necessary for differentiation, Inhibition of Notch-1 expression or function decreased the expression of peroxisomal proliferator-activated receptors delta and gamma, transcription factors that control adipocyte differentiation and that are up-regulated at cell confluence, These results implicate Notch in the commitment of 3T3-L1 cells to undergo adipogenesis by controlling the expression of the principal regulators of this process.	CTR BIOL EVALUAT & RES, DIV MONOCLONAL ANTIBODIES, IMMUNOBIOL LAB, ROCKVILLE, MD 20852 USA; NCI, CELLULAR & MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Porras, Almudena/N-2121-2015; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021; Laborda, Jorge/L-5726-2014; Ruiz-Hidalgo, Maria J/L-1956-2014	Porras, Almudena/0000-0002-6495-3308; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095; Laborda, Jorge/0000-0002-9210-838X; Ruiz-Hidalgo, Maria J/0000-0003-2508-8398; Miele, Lucio/0000-0002-5853-7287; Garces, Carmen/0000-0002-1099-2061				AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Blair SS, 1996, SCIENCE, V271, P1822, DOI 10.1126/science.271.5257.1822; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Heitzler P, 1996, DEVELOPMENT, V122, P161; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lardelli M, 1995, INT J DEV BIOL, V39, P769; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; PAN MG, 1995, ONCOGENE, V11, P2005; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PORRAS A, 1992, J BIOL CHEM, V267, P21124; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SAFONOVA I, 1994, BIOCHEM BIOPH RES CO, V204, P498, DOI 10.1006/bbrc.1994.2487; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464	59	133	134	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29729	29734		10.1074/jbc.272.47.29729	http://dx.doi.org/10.1074/jbc.272.47.29729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368042	hybrid			2022-12-27	WOS:A1997YG64700052
J	Sabourin, LA; Tamai, K; Narang, MA; Korneluk, RG				Sabourin, LA; Tamai, K; Narang, MA; Korneluk, RG			Overexpression of 3'-untranslated region of the myotonic dystrophy kinase cDNA inhibits myoblast differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PROTEIN-KINASE; TRIPLET REPEAT; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; CTG REPEAT; EXPRESSION; GENE; EXPANSION; CELLS	The genetic defect underlying myotonic dystrophy (DM) has been identified as an unstable CTG trinucleotide repeat amplification in the 3'-untranslated region (3'-UTR) of the DM kinase gene (DMK). Individuals with the most severe congenital form display a marked delay in muscle terminal differentiation. To gain insight into the role of DMK during myogenesis, we have examined the effect of DMK overexpression on the terminal differentiation of the murine myoblast cell line C2C12, We demonstrate that a 4-10-fold constitutive overexpression of DMK mRNA in myoblasts caused a marked inhibition of terminal differentiation. Surprisingly, this activity was mapped to a 239-nucleotide region of the 3'-UTR of the DMK transcript. When the DMK 3'-UTR was placed downstream of a reporter gene, the same inhibition of myogenesis was observed, Following the induction of differentiation of myoblast clones overexpressing the DMK 3'-UTR, the levels of myogenin mRNA were reduced by approximately Li-fold, whereas the steady state levels of mef-2c transcripts were not affected. These data suggest that overexpression of the DMK 3'-UTR may interfere with the expression of muscle leading to a delay in terminal specific mRNAs differentiation.	UNIV OTTAWA,DEPT IMMUNOL & MICROBIOL,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DEPT PEDIAT,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DEPT GENET,OTTAWA,ON K1H 8L1,CANADA	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; Belasco J.G., 2012, CONTROL MESSENGER RN; BLACK RA, 1985, P NATL ACAD SCI USA, V82, P124, DOI 10.1073/pnas.82.1.124; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bush EW, 1996, J BIOL CHEM, V271, P548, DOI 10.1074/jbc.271.1.548; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Dunne PW, 1996, CELL MOTIL CYTOSKEL, V33, P52; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FARKASBARGETON E, 1988, J NEUROL SCI, V83, P145, DOI 10.1016/0022-510X(88)90064-0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER T, 1991, METHODS ENZYMOL, V200; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J., 2002, MOL CLONING LAB MANU; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P466, DOI 10.1001/archneur.1976.00500070008002; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; Soussi-Yanicostas N, 1991, Neuromuscul Disord, V1, P103, DOI 10.1016/0960-8966(91)90057-Y; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a	54	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29626	29635		10.1074/jbc.272.47.29626	http://dx.doi.org/10.1074/jbc.272.47.29626			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368029	hybrid			2022-12-27	WOS:A1997YG64700039
J	Nanbru, C; Lafon, I; Audigier, S; Gensac, MC; Vagner, S; Huez, G; Prats, AC				Nanbru, C; Lafon, I; Audigier, S; Gensac, MC; Vagner, S; Huez, G; Prats, AC			Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST GROWTH-FACTOR-2; ENCEPHALOMYOCARDITIS VIRUS-RNA; TRACT-BINDING PROTEIN; MESSENGER-RNA; INITIATED FORMS; EXPRESSION; GROWTH; CELLS; LYMPHOMAS; SEQUENCES	The human proto-oncogene c-myc encodes two proteins, c-Myc1 and c-Myc2, from two initiation codons, CUG and AUG, respectively. It is also transcribed from four alternative promoters (P0, P1, P2, and P3), giving rise to different RNA 5'-leader sequences, the long sizes of which suggest that they must be inefficiently translated by the classical ribosome scanning mechanism. Here we have examined the influence of three c-myc mRNA 5'-leaders on the translation of chimeric myc-CAT mRNAs. We observed that in the reticulocyte rabbit lysate, these 5'-leaders lead to cap-independent translation initiation. To determine whether this kind of initiation resulted from the presence of an internal ribosome entry site (IRES), COS-7 cells were transfected with bicistronic vectors containing the different c-myc 5'-leaders in the intercistronic region. An IRES was identified, requiring elements located within the P2 leader, between nucleotides -363 and -94 upstream from the CUG start codon. This is the first demonstration of the existence of IRES-dependent translation for a proto-oncogene. This IRES could be a translation enhancer, allowing activation of c-myc expression under the control of trans-acting factors and in response to specific cell stimuli.	CHU Rangueil, Inst Louis Bugnard, INSERM, U397, F-31403 Toulouse 04, France; Free Univ Brussels, Dept Biol Mol, Chim Biol Lab, B-1640 Rhode St Genese, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Prats, AC (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U397, Ave Jean Poulhes, F-31403 Toulouse 04, France.		Vagner, Stephan/G-3664-2013; Prats, Anne-Catherine/E-5051-2016	Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164				ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; EICK D, 1990, ONCOGENE, V5, P1397; Fraser SD, 1996, ONCOGENE, V12, P1223; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; West MJ, 1995, ONCOGENE, V11, P2515; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	202	217	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32061	32066		10.1074/jbc.272.51.32061	http://dx.doi.org/10.1074/jbc.272.51.32061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405401	hybrid			2022-12-27	WOS:000071108000020
J	Takahashi, H; Ishikawa, G; Ueki, K; Azumi, K; Yokosawa, H				Takahashi, H; Ishikawa, G; Ueki, K; Azumi, K; Yokosawa, H			Cloning and tyrosine phosphorylation of a novel invertebrate immunocyte protein containing immunoreceptor tyrosine-based activation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; HEMOCYTE AGGREGATION; SIGNAL-TRANSDUCTION; ENDOCYTOSIS; RECEPTORS; CELLS	Immunoreceptor tyrosine-based activation motif (ITAM) plays an important role in signal transduction through mammalian T-cell and B-cell antigen receptors and Fe receptors. The ITAM has been found only in vertebrate immunocytes. Ascidians are intriguing invertebrates from the viewpoint of the evolution of immune systems because they are considered to be ancestors of the vertebrates. We have previously shown that the monoclonal antibody A74 inhibits cellular defense reactions of the ascidian. In the present studies, we found that the A74 antigen protein has two ITAMs and several motifs that are proposed to function in signal transduction, The A74 protein is tyrosine-phosphorylated and associated with other proteins in the initial stages of cellular defense reactions. The ITAMs of the A74 protein are tyrosine-phosphorylated by a c-Src kinase in vitro. The A74 protein provides a key to the understanding of the origin of vertebrate immune systems.	Hokkaido Univ, Fac Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 060, Japan	Hokkaido University	Yokosawa, H (corresponding author), Hokkaido Univ, Fac Pharmaceut Sci, Dept Biochem, Kita 12, Sapporo, Hokkaido 060, Japan.		Takahashi, Helio/J-1725-2012	Ishikawa, Go/0000-0002-4324-5185; Takahashi, Hiroki/0000-0002-7658-0246				Azumi Kaoru, 1996, P43; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottaviani E, 1997, IMMUNOL TODAY, V18, P169, DOI 10.1016/S0167-5699(97)84663-4; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Sambrook J., 2002, MOL CLONING LAB MANU; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TAKAHASHI H, 1994, BIOL BULL, V186, P247, DOI 10.2307/1542270; TAKAHASHI H, 1995, EUR J BIOCHEM, V233, P778, DOI 10.1111/j.1432-1033.1995.778_3.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	18	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32006	32010		10.1074/jbc.272.51.32006	http://dx.doi.org/10.1074/jbc.272.51.32006			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405393	hybrid			2022-12-27	WOS:000071108000012
J	Wolner, BS; Gralla, JD				Wolner, BS; Gralla, JD			Promoter activation via a cyclic AMP response element in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BINDING PROTEIN CREB; TRANSCRIPTION FACTORS IIE; PREINITIATION COMPLEX; IN-VITRO; FACTOR ATF; INITIATION; CAMP; CLEARANCE; INTERACTS	Transcription activation via activating transcription factor cyclic AMP response element binding (ATF/CREB) sites in vitro was explored using transcription and permanganate assay for open complex formation. These sites were used to drive transcription from an adenovirus major late core sequence. Under conditions where activation is strong, 20-50-fold, ATF/CREB is required for preinitiation complexes to reach the open complex stage. Complete opening requires activator, ATP, and initiating nucleotides. In exploration of postinitiation steps, no stimulation of promoter clearance was observed but a modest stimulation of the rate of continuous transcription occurred. High amounts of DNA template, commonly used in in vitro studies, allows some templates to open without activator, but leaves the nucleotide requirements intact. This leads to a drastic lowering of the dependence on ATF/CREB. Taken together, the data indicate that ATF/CREB activates this system primarily by stimulating the formation of functional preinitiation complexes.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NIGMS NIH HHS [GM07185, GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Blau J, 1996, MOL CELL BIOL, V16, P2044; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1994, J BIOL CHEM, V269, P5505; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kobayashi M, 1997, NUCLEIC ACIDS RES, V25, P877, DOI 10.1093/nar/25.4.877; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Wang JT, 1996, J BIOL CHEM, V271, P32707, DOI 10.1074/jbc.271.51.32707; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1994, J BIOL CHEM, V269, P28732; YAN M, IN PRESS EMBO J; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809; Yean D, 1996, NUCLEIC ACIDS RES, V24, P2723, DOI 10.1093/nar/24.14.2723; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	42	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32301	32307		10.1074/jbc.272.51.32301	http://dx.doi.org/10.1074/jbc.272.51.32301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405436	hybrid			2022-12-27	WOS:000071108000055
J	Das, S; Maiti, T; Das, K; Maitra, U				Das, S; Maiti, T; Das, K; Maitra, U			Specific interaction of eukaryotic translation initiation factor 5 (eIF5) with the beta-subunit of eIF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IMMUNOCHEMICAL CHARACTERIZATION; RABBIT RETICULOCYTES; PROTEIN-SYNTHESIS; KINASE-II; EXPRESSION; COMPLEX; BINDING; RELEASE; CLONING	Eukaryotic translation initiation factor 5 (eIF5) interacts with the 40 S initiation complex (40 S.mRNA. eIF3.Met-tRNA(f).eIF2.GTP) and mediates hydrolysis of the bound GTP, To characterize the molecular interactions involved in eIF5 function, we have used P-32-labeled recombinant rat eIF5 as a probe in filter overlay assay to identify eIF5 interacting proteins in crude initiation factor preparations. We observed that eIF5 specifically interacted with the beta subunit of initiation factor eIF2. No other initiation factors including the gamma subunit of eIF2 tested positive in this assay, Furthermore, both yeast and mammalian eIF5 bind to the beta subunit of either mammalian or yeast eIF2. Binding analysis with human eIF2 beta deletion mutants expressed in Escherichia coli identified a 22-amino acid domain, between amino acids 68 and 89, as the primary eIF5-binding region of eIF2 beta. These results along with our earlier observations that (a) eIF5 neither binds nor hydrolyzes free GTP or GTP bound as Met-tRNA(f).eIF2.GTP ternary complex, and (b) eIF5 forms a specific complex with eIF2 suggests that the specific interaction between eIF5 and the beta subunit of eIF2 may be critical for the hydrolysis of GTP during translation initiation.			Das, S (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; DAS K, 1995, THESIS A EINSTEIN CO; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; FASANO O, 1982, J BIOL CHEM, V257, P3145; GASPAR NJ, 1994, J BIOL CHEM, V269, P32415; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; KOZAK M, 1983, MICROBIOL REV, V47, P1; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick WC., 1996, TRANSLATION CONTROL, P31; Metz AM, 1997, ARCH BIOCHEM BIOPHYS, V342, P187, DOI 10.1006/abbi.1997.0119; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; Sambrook J., 2002, MOL CLONING LAB MANU; Si KS, 1996, J BIOL CHEM, V271, P16934, DOI 10.1074/jbc.271.28.16934; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204	29	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31712	31718		10.1074/jbc.272.50.31712	http://dx.doi.org/10.1074/jbc.272.50.31712			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395514	hybrid			2022-12-27	WOS:A1997YL41900073
J	Katagiri, Y; Hirata, Y; Milbrandt, J; Guroff, G				Katagiri, Y; Hirata, Y; Milbrandt, J; Guroff, G			Differential regulation of the transcriptional activity of the orphan nuclear receptor NGFI-B by membrane depolarization and nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; INDUCIBLE MEMBER; GENE; PHOSPHORYLATION; SUPERFAMILY; ACTIVATION; EXPRESSION; KINASE; NUR77; PROTEIN	The immediate-early gene NGFI-B (also called nur77) encodes an orphan nuclear receptor that activates transcription through a unique response element (NBRE), NGFI-B is rapidly induced and modified via phosphorylation by a variety of stimuli that induce cells to differentiate or to proliferate, We have shown that the in vitro phosphorylation of Ser(350) located within the ''A-box,'' a motif necessary for DNA binding by NGFI-B, results in a decrease in the binding of NGFI-B to its response element (Hirata, Y., Kiuchi, K., Chen, H.-C., Milbrandt, J., and Guroff, G, (1993) J, Biol. Chem. 268, 24808-24812). We show here that nerve growth factor (NGF)-induced changes in the in vivo phosphorylation of Ser(350) accompany transcriptional deactivation of NGFI-B in PC12 cells, that membrane depolarization and NGF treatment cause differential phosphorylation of NGFI-B, and that the transcriptional activation caused by exogenous expression of NGFI-B or membrane depolarization can be inhibited by NGF treatment, In addition, the mutation of Ser(350) to Ala abolished the inhibitory effect of NGF on the transcriptional activation of NGFI-B in PC12 cells, These data could provide new insights into the regulation of transcriptional activity required for some neurons to switch from activity-dependent survival to neurotrophin-dependent survival during development.	NICHHD,NIH,GROWTH FACTORS SECT,BETHESDA,MD 20892; RIKEN,BIOMIMET CONTROL RES CTR,MORIYAMA KU,NAGOYA,AICHI 463,JAPAN; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); RIKEN; Washington University (WUSTL)			Hirata, Yoko/AAG-6798-2020; Hirata, Yoko/L-3142-2019	Hirata, Yoko/0000-0002-7081-4937; Milbrandt, Jeffrey/0000-0002-5477-7689				BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; KUES WA, 1995, J CELL BIOL, V130, P949, DOI 10.1083/jcb.130.4.949; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	25	74	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31278	31284		10.1074/jbc.272.50.31278	http://dx.doi.org/10.1074/jbc.272.50.31278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395454	hybrid			2022-12-27	WOS:A1997YL41900013
J	Oliveros, M; Yanez, RJ; Salas, ML; Salas, J; Vinuela, E; Blanco, L				Oliveros, M; Yanez, RJ; Salas, ML; Salas, J; Vinuela, E; Blanco, L			Characterization of an African swine fever virus 20-kDa DNA polymerase involved in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; YEAST CHROMOSOME-III; CRYSTAL-STRUCTURE; REVERSE-TRANSCRIPTASE; CATALYTIC DOMAIN; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; EXPRESSION SYSTEM; PRIMER BINDING; LARGE FRAGMENT	African swine fever virus (ASFV) encodes a novel DNA polymerase, constituted of only 174 amino acids, belonging to the polymerase (pol) X family of DNA polymerases. Biochemical analyses of the purified enzyme indicate that ASFV pol X is a monomeric DNA-directed DNA polymerase, highly distributive, lacking a proofreading 3'-5'-exonuclease, and with a poor discrimination against dideoxynucleotides. A multiple alignment of family X DNA polymerases, together with the extrapolation to the crystal structure of mammalian DNA polymerase beta (pol beta), showed the conservation in ASFV pol X of the most critical residues involved in DNA binding, nucleotide binding, and catalysis of the polymerization reaction. Therefore, the 20-kDa ASFV pol X most likely represents the minimal functional version of an evolutionarily conserved pol beta-type DNA polymerase core, constituted by only the "palm" and "thumb" subdomains. It is worth noting that such an "unfingered" DNA polymerase is able to handle templated DNA polymerization with a considerable high fidelity at the base discrimination level. Base excision repair is considered to be a cellular defense mechanism repairing modified bases in DNA. Interestingly, the fact that ASFV pol X is able to conduct filling of a single nucleotide gap points to a putative role in base excision repair during the ASFV life cycle.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Blanco, L (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Canto Blanco, E-28049 Madrid, Spain.		Blanco, Luis/I-1848-2015	Yanez-Munoz, Rafael J/0000-0001-7113-1938				Afonso CL, 1996, J VIROL, V70, P4858, DOI 10.1128/JVI.70.7.4858-4863.1996; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLASCO R, 1990, VIROLOGY, V178, P301, DOI 10.1016/0042-6822(90)90409-K; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; Brown NC, 1995, METHOD ENZYMOL, V262, P202; Brun A, 1996, VIROLOGY, V225, P227, DOI 10.1006/viro.1996.0592; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chacon MR, 1995, VIROLOGY, V214, P670, DOI 10.1006/viro.1995.0083; Costa J. V., 1990, Molecular Biology of Iridoviruses., P247; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ELDEIRY WS, 1988, BIOCHEMISTRY-US, V27, P546, DOI 10.1021/bi00402a007; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KARAWYA E, 1983, ANAL BIOCHEM, V135, P318, DOI 10.1016/0003-2697(83)90689-9; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MARTINS A, 1994, NUCLEIC ACIDS RES, V22, P208, DOI 10.1093/nar/22.2.208; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; MORENO MA, 1978, J GEN VIROL, V93, P253; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Revilla Y, 1997, VIROLOGY, V228, P400, DOI 10.1006/viro.1996.8395; RODRIGUEZ JM, 1993, GENE, V136, P103, DOI 10.1016/0378-1119(93)90453-A; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWEASY JB, 1995, MOL GEN GENET, V248, P217, DOI 10.1007/BF02190803; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; Vinuela E., 1987, African swine fever, P31; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; Wilkinson P. J., 1989, Virus infections of porcines., P17; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YANEZ RJ, 1993, VIROLOGY, V193, P531, DOI 10.1006/viro.1993.1161; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	79	84	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30899	30910		10.1074/jbc.272.49.30899	http://dx.doi.org/10.1074/jbc.272.49.30899			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388236	hybrid, Green Published			2022-12-27	WOS:000071640800049
J	Phung, TL; Roncone, A; Jensen, KLD; Sparks, CE; Sparks, JD				Phung, TL; Roncone, A; Jensen, KLD; Sparks, CE; Sparks, JD			Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I PHOSPHATIDYLINOSITOL KINASE; PROTEIN DISULFIDE ISOMERASE; LOW-DENSITY LIPOPROTEINS; ZUCKER-FATTY RAT; 3T3-L1 ADIPOCYTES; GOLGI-APPARATUS; GROWTH-FACTOR; PRIMARY CULTURES; MESSENGER-RNA; BREFELDIN-A	Insulin inhibits apolipoprotein B (apoB) secretion by primary rat hepatocytes through activation of phosphoinositide 3-kinase (PI 3-K). Current studies demonstrate that the PI 3-K inhibitor wortmannin inhibits both basal and insulin-stimulated PI 3-K activities, Wortmannin and LY 294002, two structurally distinct PI 3-K inhibitors, prevent insulin-dependent inhibition of apoE secretion in a dose-dependent manner, To link PI 3-K activation to insulin action on apoB, we investigated whether insulin induced localization of activated PI 3-K to the endoplasmic reticulum (ER), where apoB biogenesis is initiated, Insulin action results in a significant redistribution of PI 3-K to a low density microsome (LDM) fraction containing apoB protein and apoB mRNA, Insulin stimulates a significant increase in PI 3-K activity associated with insulin receptor substrate-1 as well as an increase in insulin receptor substrate-1/PI 3-K mass in LDM. Subfractionation of LDM on sucrose density gradients shows that insulin significantly increases the amount of PI 3-K present in an ER fraction containing apoB. Insulin stimulates PI 3-K activity in smooth and rough microsomes isolated from rat hepatocytes, the latter of which contain rough ER as demonstrated by electron microscopy, Studies indicate that 1) PI 3-K activity is necessary for insulin-dependent inhibition of apoB secretion by rat hepatocytes; 2) insulin action leads to the activation and localization of PI 3-K in an ER fraction containing apoB; and 3) insulin stimulates PI 3-K activity in the rough ER.	Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA	University of Rochester	Sparks, JD (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Box 626,601 Elmwood Ave, Rochester, NY 14642 USA.		Adiels, Martin/C-9278-2011	Sparks, Janet/0000-0002-0072-766X	NHLBI NIH HHS [HL 29837] Funding Source: Medline; NIDDK NIH HHS [DK 50376S1, DK 50376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BJORNSSON OG, 1992, BIOCHEM J, V281, P381; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRAY GA, 1977, FED PROC, V36, P148; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; CHEN XL, 1993, J BIOL CHEM, V268, P21007; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURRINGTON PN, 1982, J CLIN INVEST, V70, P63, DOI 10.1172/JCI110604; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P2442; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy E, 1996, FEBS LETT, V393, P253, DOI 10.1016/0014-5793(96)00896-4; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; PATSCH W, 1986, J BIOL CHEM, V261, P9603; PATSCH W, 1983, J CLIN INVEST, V71, P1161, DOI 10.1172/JCI110865; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SALHANICK AI, 1991, METABOLISM, V40, P275, DOI 10.1016/0026-0495(91)90109-A; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; Sparks JD, 1996, METHOD ENZYMOL, V263, P104; SPARKS JD, 1994, METABOLISM, V43, P681, DOI 10.1016/0026-0495(94)90115-5; SPARKS JD, 1986, ATHEROSCLEROSIS, V61, P205, DOI 10.1016/0021-9150(86)90139-5; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1994, BIOCHEM BIOPH RES CO, V205, P417, DOI 10.1006/bbrc.1994.2681; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WAY BA, 1993, J BIOL CHEM, V268, P26409; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WITZTUM JL, 1979, DIABETES, V28, P509, DOI 10.2337/diab.28.5.509; WONG L, 1987, EUR J BIOCHEM, V164, P357, DOI 10.1111/j.1432-1033.1987.tb11066.x; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	69	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30693	30702		10.1074/jbc.272.49.30693	http://dx.doi.org/10.1074/jbc.272.49.30693			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388205	hybrid			2022-12-27	WOS:000071640800018
J	Li, F; Srinivasan, A; Wang, Y; Armstrong, RC; Tomaselli, KJ; Fritz, LC				Li, F; Srinivasan, A; Wang, Y; Armstrong, RC; Tomaselli, KJ; Fritz, LC			Cell-specific induction of apoptosis by microinjection of cytochrome c - Bcl-x(L) has activity independent of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; DEATH; ENCODES; PRODUCT; MEDIATOR; PROTEIN; ENZYME; FAMILY; CPP32; BCL-2	Bcl-x(L), an antiapoptotic member of the Bcl-2 family, inhibits programmed cell death in a broad variety of cell types, Recent reports have demonstrated that cytochrome c is released from mitochondria during apoptosis and have suggested that this release may be a critical step in the activation of proapoptotic caspases and subsequent cell death, Furthermore, it has been demonstrated that Bcl-2 can prevent the release of cytochrome c from mitochondria in cells triggered to undergo apoptosis, This has led to the hypothesis that the antiapoptotic effects of Bcl-2 family members are due specifically to their ability to prevent cytochrome c release thus preventing subsequent cytochrome c-dependent caspase activation, In the present report, we use microinjection techniques to investigate the relationship between cytochrome c release, induction of apoptosis, and Bcl-x(L) activity in intact cells, We demonstrate that microinjection of cytochrome c into the cytosol of human kidney 293 cells results in a dose-dependent induction of apoptosis, In contrast, MCF7 breast carcinoma cells (stably transfected to express the Fas antigen CD95, and denoted MCF7F) that lack detectable levels of caspase 3 (CPP32), are totally resistant to microinjection of cytochrome c, However, transfection of MCF7F cells with an expression plasmid coding for pro-caspase 3, but not other pro-caspases, restores cytochrome c sensitivity, Although MCF7F cells are insensitive to cytochrome c microinjection, they rapidly undergo apoptosis in a caspase dependent manner in response to either tumor necrosis factor or anti-Fas plus cycloheximide, and these deaths are strongly inhibited by Bcl-x(L) expression, Furthermore, microinjection of cytochrome c does not overcome these antiapoptotic effects of Bcl-x(L). Our results support the concept that the release of cytochrome c into the cytoplasm can promote the apoptotic process in cells expressing pro-caspase 3 but that cytochrome c release is not sufficient to induce death in all cells, Importantly, the ability of Bcl-x(L) to inhibit cell death in the cytochrome c-insensitive MCF7F cells cannot be due solely to inhibition of cytochrome c release from mitochondria.	IDUN PHARMACEUT INC,LA JOLLA,CA 92037									Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BORDEN D, 1976, HDB BIOCHEMISTRY MOL, V3, P268; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; DEROBERTIS EDP, 1975, CELL BIOL, P200; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU W, 1996, J EMBO, V15, P4130	37	330	335	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30299	30305		10.1074/jbc.272.48.30299	http://dx.doi.org/10.1074/jbc.272.48.30299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374516	hybrid			2022-12-27	WOS:A1997YH61300048
J	Meier, R; Alessi, DR; Cron, P; Andjelkovic, M; Hemmings, BA				Meier, R; Alessi, DR; Cron, P; Andjelkovic, M; Hemmings, BA			Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; SER/THR KINASE; C-AKT; ONCOGENE; AMPLIFICATION; INHIBITION; CARCINOMAS; EXPRESSION	Protein kinase B (PKB) is a member of the second messenger-dependent family of serine/threonine kinases that has been implicated in signaling pathways downstream of growth factor receptor tyrosine kinases and phosphatidylinositol 3-kinase. Here we report the characterization of the human beta-isoform of PKB (PKB beta). PKB beta is ubiquitously expressed in a number of human tissues, with mRNA and protein levels elevated in heart, liver, skeletal muscle, and kidney. After transfection into HEK-293 or COS-1 cells, PKB beta is activated 2- to 12-fold by mitogens and survival factors. Activation was due to phosphorylation on Thr-309 and Ser-474, which correspond to Thr-308 and Ser-473 implicated in the regulation of PKB alpha, Both phosphorylation and activation were prevented by the phosphatidylinositol 3-kinase inhibitor wortmannin, Moreover, membrane-targeted PKB beta was constitutively activated when overexpressed in HEK-293 cells, Although the specific activity of PKB beta was lower than that of PKB alpha toward Crosstide as a substrate (23 nmol/min/mg compared with 170 nmol/ min/mg for PKB alpha), both enzymes showed similar substrate specificities, Using confocal microscopy, we show that activation of PKB beta results in its nuclear translocation within 20 to 30 min after stimulation, These observations provide evidence that PKB beta undergoes nuclear translocation upon mitogenic activation and support a role for PKB in signaling from receptor tyrosine kinases to the nucleus through phosphatidylinositol 3-kinase.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	Friedrich Miescher Institute for Biomedical Research; University of Dundee				Alessi, Dario/0000-0002-2140-9185				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDJELKOVIC M, 1997, IN PRESS J BIOL CHEM; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HASLAM RJ, 1993, NATURE, V363, P310; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648	38	314	339	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30491	30497		10.1074/jbc.272.48.30491	http://dx.doi.org/10.1074/jbc.272.48.30491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374542	hybrid			2022-12-27	WOS:A1997YH61300074
J	Zheng, J; Chen, RH; CorblanGarcia, S; Cahill, SM; BarSagi, D; Cowburn, D				Zheng, J; Chen, RH; CorblanGarcia, S; Cahill, SM; BarSagi, D; Cowburn, D			The solution structure of the pleckstrin homology domain of human SOS1. A possible structural role for the sequential association of diffusion and pleckstrin homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; EXCHANGE FACTOR SON; INOSITOL PHOSPHATES; BINDING-SITE; PH DOMAIN; DYNAMIN; RAS; IDENTIFICATION; DBL; SEVENLESS	A large subset of pleckstrin homology (PH) domains are immediately to the C terminus of diffuse B cell lymphoma (Dbl) homology (DbH) domains. Dbl domains are generally considered to be GTPase-exchange factors; many are proto oncogenes. PH domains appear to function as membrane-recruitment factors, or have specific protein-protein interactions, Since dual domain (DbH/PH) constructs are known to have significant properties in other pathways, it is possible that a defined interdomain relationship is required for DbH/PH function. We determined the solution structure of the human SOS1 PH domain for a construct partially extended into the preceding DbH domain, There are specific structural contacts between the PH and the vestigial DbH domain. This appears to involve structural elements common to this subfamily of PH domains, and to DbH domains. The human SOS1 PH domain binds to inositol 1,4,5-triphosphate with a similar to 60 mu M affinity. Using chemical shift titration, the binding site is identified to be essentially identical to that observed crystallographically for the inositol 1,4,5-triphosphate complex with the PH domain of phospholipase C delta. This site may serve as an interdomain regulator of DbH or other domains' functions. While the overall fold of the human SOS1 PH domain is similar to other PH domains, the size and position of the intrastrand loops and the presence of an N-terminal cu-helix of the vestigial DbH domain suggest that the subfamily of PH domains associated with DbH domains may be a well defined structural group in which the PR domain is a membrane recruiter and modulator.	ROCKEFELLER UNIV,LAB PHYS BIOCHEM,NEW YORK,NY 10021; SUNY STONY BROOK,DEPT MOL GENET & MICROBIOL,STONY BROOK,NY 11794	Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Corbalan-Garcia, Senena/C-6477-2009; Cowburn, David/A-8448-2008	Corbalan-Garcia, Senena/0000-0003-1840-5578; Zheng, Jie/0000-0001-6524-6800; Bar-Sagi, Dafna/0000-0003-2597-8948; Cowburn, David/0000-0001-6770-7172	NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Dalvit C, 1996, J MAGN RESON SER B, V112, P282, DOI 10.1006/jmrb.1996.0143; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	32	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30340	30344		10.1074/jbc.272.48.30340	http://dx.doi.org/10.1074/jbc.272.48.30340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374522	hybrid			2022-12-27	WOS:A1997YH61300054
J	Kudo, N; Khochbin, S; Nishi, K; Kitano, K; Yanagida, M; Yoshida, M; Horinouchi, S				Kudo, N; Khochbin, S; Nishi, K; Kitano, K; Yanagida, M; Yoshida, M; Horinouchi, S			Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FUNGAL ANTIBIOTICS; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; LEPTOMYCIN-B; CHROMOSOME CONDENSATION; DOSAGE COMPENSATION; GENE; TRANSCRIPTION; RESISTANCE; MUTATIONS	Crm1 of Schizosaccharomyces pombe, a nuclear protein essential for proliferation and chromosome region maintenance, is a possible target of leptomycin B, an antifungal and antitumor antibiotic with cell cycle-arresting activity, cDNA encoding a human homolog of Crm1 was cloned, Human CRM1 (hCRM1) consisted of 1071 amino acids, of which the sequence showed 52% homology with S. pombe Crm1. hCRM1 weakly complemented the cold sensitive mutation of S. pombe crm1-809, as did S. pombe crm1(+), Overproduction of hCRM1 under the control of a series of nmt1 promoters suppressed cell proliferation in wild-type S. pombe in an expression level-dependent manner, A similar inhibitory effect was also observed for crm1(+). Cells overproducing either hCRM1 or S. pombe Crm1 were distinctly larger than uninduced cells and contained compacted and fragmented nuclei, Furthermore, calcofluor stain ing demonstrated that most of these cells formed two septa per cell and accumulated a large amount of chitin or its related polysaccharides around the septa, Closely similar phenotypes between hCRM1- and S. pombe Crm1-induced cells indicate that the cloned cDNA encodes a functional homolog of S. pombe crm1(+). Northern blot analyses with RNAs isolated from synchronized mammalian cells showed that the expression of mammalian CRM1 was initiated in late G(1) and reached a peak at G(2)/M, although its protein level unchanged during the cell cycle, Transient expression of hCRM1 fused to the green fluorescent protein (GFP) in NIH3T3 cells showed that hCRM1 was localized preferentially in the nuclear envelope and was also detectable in the nucleoplasm and the cytoplasm, A crm1 mutation of S. pombe caused nuclear import of a GFP fusion protein containing a nuclear export signal but no change in the distribution of a GFP fusion protein containing a nuclear localization signal, All of these data suggest that CRM1 is a novel cell-cycle regulated gene that is essential for the nuclear export signal-dependent nuclear export of proteins.	UNIV TOKYO, GRAD SCH AGR & LIFE SCI, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN; FAC MED, INST ALBERT BONNIOT, INSERM, U309, LA TRONCHE, FRANCE; TAKEDA CHEM IND LTD, PHARMACEUT DISCOVERY RES DIV, TSUKUBA, IBARAKI 30042, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 60601, JAPAN	University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Takeda Chemical Industries; Kyoto University			Yoshida, Minoru/C-8049-2014; Khochbin, Saadi/M-8090-2013; Kudo, Nobuaki/AAU-7196-2021	Yoshida, Minoru/0000-0002-4376-5674; Khochbin, Saadi/0000-0002-0455-0857; Kudo, Nobuaki/0000-0001-8134-1242				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Alfa C, 1993, EXPT FISSION YEAST L; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GANNON JV, 1991, NATURE, V349, P802; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gutz H., 1974, HDB GENETICS, V1, P395; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hensey C, 1995, Prog Cell Cycle Res, V1, P149; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KHOCHBIN S, 1989, CYTOMETRY, V10, P484, DOI 10.1002/cyto.990100418; KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Maniatis T., 1982, MOL CLONING; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHIMANUKI M, 1995, J CELL SCI, V108, P569; TANAKA K, 1993, MOL CELL BIOL, V13, P80, DOI 10.1128/MCB.13.1.80; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; USUI T, 1995, GENE, V161, P93, DOI 10.1016/0378-1119(95)00229-Y; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	39	184	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29742	29751		10.1074/jbc.272.47.29742	http://dx.doi.org/10.1074/jbc.272.47.29742			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368044	hybrid			2022-12-27	WOS:A1997YG64700054
J	Ochem, AE; Skopac, D; Costa, M; Rabilloud, T; Vuillard, L; Simoncsits, A; Giacca, M; Falaschi, A				Ochem, AE; Skopac, D; Costa, M; Rabilloud, T; Vuillard, L; Simoncsits, A; Giacca, M; Falaschi, A			Functional properties of the separate subunits of human DNA helicase II Ku autoantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; V(D)J RECOMBINATION; BINDING PROPERTIES; P70; ANTIGEN; PURIFICATION; REQUIREMENT; MECHANISM; ENZYME; CELLS	The Ku antigen consists of two subunits of 70 and 83 kDa and is endowed with both duplex DNA end-binding capacity and helicase activity (human DNA helicase II). HeLa Ku can be isolated from in vitro cultured human cells uniquely as a heterodimer, and the subunits can be separated by electrophoresis only under denaturing conditions. To dissect the molecular functions of the two subunits of the heterodimer, we have cloned and expressed their cDNAs separately in Escherichia coli. The two activities of Ku (DNA binding and unwinding) were reconstituted by mixing and refolding both subunits in equimolar amounts (Tuteja, N., Tuteja, R, Ochem, A, Taneja, P., Huang, N-W., Simoncsits, A, Susic, S., Rahman, K., Marusic, L., Chen, J., Zang, J., Wang, S., Pongor, S., and Falaschi, k (1994) EMBO J. 13, 4991-5001). Renaturation of the separate subunits can be achieved in the presence of a synthetic solubilizing and stabilizing agent, dimethyl ethylammonium propane sulfonate (NDSB 195). The helicase activity of the Ku protein resides uniquely in the 70-kDa subunit, whereas the DNA end-binding activity can be reconstituted only through renaturation of the two subunits in the heterodimeric form and is practically absent in the separate subunits. The 83-kDa subunit, when refolded in the absence of the 70-kDa subunit, forms homodimers unable to unwind DNA and bind duplex ends. The three separate species (heterodimer, 70-kDa subunit, and 83-kDa subunit homodimer) all have ssDNA-dependent ATPase activity.	INT CTR GENET ENGN & BIOTECHNOL, MOL BIOL UNIT, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, PROT STRUCT & FUNCT GRP, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, MOL MED UNIT, I-34012 TRIESTE, ITALY; CTR ETUD NUCL GRENOBLE, DEPT BIOL MOL & STRUCT, F-38042 GRENOBLE 09, FRANCE; INST MAX VON LAUE PAUL LANGEVIN, F-38042 GRENOBLE 09, FRANCE; CNR, IST GENET BIOCHIM & EVOLUZIONIST, I-27100 PAVIA, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB); CEA; Institut Laue-Langevin (ILL); Consiglio Nazionale delle Ricerche (CNR)			Giacca, Mauro/J-9287-2016	Giacca, Mauro/0000-0003-2927-7225				CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CSORDASTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3257; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HIGASHIURA M, 1992, EXP CELL RES, V201, P444, DOI 10.1016/0014-4827(92)90293-H; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TRIBIOLI C, 1987, NUCLEIC ACIDS RES, V15, P10211, DOI 10.1093/nar/15.24.10211; TUTEJA N, 1995, NUCLEIC ACIDS RES, V23, P2457, DOI 10.1093/nar/23.13.2457; TUTEJA N, 1992, NUCLEIC ACIDS RES, V20, P5329, DOI 10.1093/nar/20.20.5329; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; VUILLARD L, 1995, BIOCHEM J, V305, P339; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	30	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29919	29926		10.1074/jbc.272.47.29919	http://dx.doi.org/10.1074/jbc.272.47.29919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368068	hybrid			2022-12-27	WOS:A1997YG64700078
J	Okumura, N; Gorkun, OV; Lord, ST				Okumura, N; Gorkun, OV; Lord, ST			Severely impaired polymerization of recombinant fibrinogen gamma-364 Asp->His, the substitution discovered in a heterozygous individual	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FIBRINOGEN; FIBRINOPEPTIDE-B; CLOT FORMATION; THROMBIN; RELEASE; CALCIUM; CHAIN; SITE; AGGREGATION	During blood coagulation, soluble fibrinogen is converted to fibrin monomers that polymerize to form an insoluble clot, Polymerization has been described as a two-step process: the formation of double-stranded protofibrils and the subsequent lateral aggregation of protofibrils into fibers, Previous studies have shown that gamma chain residues Tyr-363 and Asp-364 have a significant role in polymerization, most likely in protofibril formation, To better define the role of these residues, me synthesized three fibrinogens with single substitutions at these two positions: Tyr-363 --> Ala, Asp-364 --> Ala, and Asp-364 --> His, We found that the release of fibrinopeptides A and B was the same for these variants and normal recombinant fibrinogen, showing that all variants had normal fibrin formation, In contrast, we found that polymerization was significantly delayed for both Ala variants and was almost nonexistent for the His variant, Clottability for the Ala variants was only slightly reduced, and fibrin gels were formed. Surprisingly, clottability of the His variant was substantially reduced, and fibrin gels were not formed, Our data suggest that both protofibril formation and lateral aggregation were altered by these substitutions, indicating that the C-terminal domain of the gamma chain has a role in both polymerization steps.	UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048, R23HL031048] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31048] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BIRKEN S, 1975, THROMB RES, V7, P599, DOI 10.1016/0049-3848(75)90106-1; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; CIERNIEWSKI CS, 1992, BIOCHEMISTRY-US, V31, P4248, DOI 10.1021/bi00132a014; COTE H, 1997, THROMB HAEMOSTASIS S, V78, P757; Ebert RF., 1994, INDEX VARIANT HUMAN; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; LEWIS SD, 1985, J BIOL CHEM, V260, P192; LITVINOVICH SV, 1995, EUR J BIOCHEM, V229, P605, DOI 10.1111/j.1432-1033.1995.tb20504.x; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; NG AS, 1993, METHOD ENZYMOL, V222, P341; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; OKADA M, 1983, THROMB RES, V29, P269, DOI 10.1016/0049-3848(83)90039-7; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; RUF W, 1988, BIOCHIM BIOPHYS ACTA, V965, P169, DOI 10.1016/0304-4165(88)90053-0; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; TAKEBE M, 1995, THROMB HAEMOSTASIS, V73, P662; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; YOSHIDA N, 1991, BLOOD, V77, P1958	32	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29596	29601		10.1074/jbc.272.47.29596	http://dx.doi.org/10.1074/jbc.272.47.29596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368024	hybrid			2022-12-27	WOS:A1997YG64700034
J	Hao, LN; Tiganis, T; Tonks, NK; Charbonneau, H				Hao, LN; Tiganis, T; Tonks, NK; Charbonneau, H			The noncatalytic C-terminal segment of the T cell protein tyrosine phosphatase regulates activity via an intramolecular mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; ACTIVATION; SEQUENCE; PHOSPHOTYROSINE; TRANSCRIPTION; PURIFICATION; SPECIFICITY; MUTAGENESIS; QUANTITIES	Human T cell protein tyrosine phosphatase (TCPTP) is a nontransmembrane enzyme, the first of the protein tyrosine phosphatase family to be cloned, Alternative mRNA splicing results in variation in the sequence at the extreme C terminus of TCPTP and generates a 45-kDa form (TC45) that is targeted to the nucleus and a 48-kDa variant (TC48) associated with membranes of the endoplasmic reticulum, In this report, we assessed the role of the C-terminal, noncatalytic segment of TCPTP in regulating activity, concentrating primarily on the TC45 variant, We have demonstrated that limited tryptic proteolysis of TC45 releases first a 42-kDa fragment, then a 33-kDa catalytic domain, Using reduced carboxyamidomethylated and maleylated lysozyme as substrate (RCML), the catalytic domain displays 20-100-fold more activity than the full-length enzyme, Analysis of the time course of limited trypsinolysis revealed that proteolytic activation occurred following cleavage of a protease-sensitive region (residues 353-387) located at the C terminus of TC45, The activity of truncation mutants illustrated that removal of 20 C-terminal residues was sufficient to activate the enzyme fully, The 33-kDa catalytic domain, but not the full-length enzyme, was inhibited in a concentration-dependent manner by addition of the noncatalytic C-terminal segment of TC45, A monoclonal antibody to TCPTP, CF4, which recognizes an epitope located between residues 350 and 363, was capable of fully activating TC45. These data indicate that the noncatalytic segment of TC45 contains an autoregulatory site that modulates activity via a reversible intramolecular interaction with the catalytic domain, These studies suggest that the C-terminal noncatalytic segment of TC45, and possibly TC48, may not only direct the enzyme to different subcellular locations but may also modulate activity in response to the binding of regulatory proteins and/or posttranslational modification.	PURDUE UNIV,DEPT BIOCHEM 1153,W LAFAYETTE,IN 47907; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Cold Spring Harbor Laboratory			Tiganis, Tony/AAV-3495-2020	Tiganis, Tony/0000-0002-8065-9942	NCI NIH HHS [CA53840, CA59935] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840, R29CA059935, R01CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; Kemp B E, 1996, Adv Pharmacol, V36, P221, DOI 10.1016/S1054-3589(08)60584-0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Reddy RS, 1995, DNA CELL BIOL, V14, P1007, DOI 10.1089/dna.1995.14.1007; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHAO ZZ, 1992, ANAL BIOCHEM, V202, P361, DOI 10.1016/0003-2697(92)90119-R	32	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29322	29329		10.1074/jbc.272.46.29322	http://dx.doi.org/10.1074/jbc.272.46.29322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361013	hybrid			2022-12-27	WOS:A1997YF68400072
J	Faure, V; Courtois, Y; Goureau, O				Faure, V; Courtois, Y; Goureau, O			Inhibition of inducible nitric oxide synthase expression by interferons alpha and beta in bovine retinal pigmented epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE PERITONEAL-MACROPHAGES; FIBROBLAST GROWTH-FACTORS; FACTOR-KAPPA-B; NO SYNTHASE; REGULATORY FACTOR-1; MOLECULAR-CLONING; MOUSE MACROPHAGES; GLIAL-CELLS; IN-VITRO; INDUCTION	Bovine retinal pigmented epithelial (RPE) cells express an inducible nitric oxide synthase (NOS-2) after activation with interferon (IFN)-gamma and lipopolysaccharide (LPS). Experiments were performed to investigate the effects of IFN-alpha and IFN-beta on NOS-2 activity. These types of interferons did not aid LPS in the production of nitrite, but markedly inhibited in a concentration-dependent manner the nitrite release due to LPS/IFN-gamma. Analysis by Western and Northern blots showed that RPE cells co-stimulated with IFN-alpha or IFN-beta with LPS/IFN-gamma accumulated lower levels of NOS-2 protein and mRNA than in the presence of LPS/IFN-gamma alone. The presence of IFN-alpha or IFN-beta did not accelerate mRNA degradation, implying that these interferons did not affect NOS-2 mRNA stability, but more probably NOS-2 gene expression. Furthermore, IFN-gamma binding studies demonstrated that the inhibitory effect of IFN-alpha and IFN-beta is not caused by a blocking of IFN-gamma receptors. Analysis of NF-kappa B activation by electrophoretic mobility shift assay demonstrated that LPS/IFN-gamma-induced NF-kappa B binding was not changed by the presence of IFN-alpha. However, similar experiments revealed that the activation of interferon regulatory factor-1 (IRF-1) by LPS/IFN-gamma was decreased by IFN-alpha. This phenomenon could be due to the decline of IRF-1 mRNA and the up-regulation of IRF-2 mRNA, an IRF-1 repressor, by IFN-1. These results suggest that the inhibitory effect of IFN-alpha and -beta on NOS-2 induction could be partially explained by their effect on the induction of the IRFs, which were involved in NOS-2 gene transcription.	INSERM, Ass Claude Bernard, U450, F-75016 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Goureau, O (corresponding author), INSERM, Ass Claude Bernard, U450, F-75016 Paris, France.		GOUREAU, Olivier/F-2752-2017; GOUREAU, Olivier/ABH-9547-2020	GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU, Olivier/0000-0001-7730-9143				BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGUCHI M, 1995, J INTERF CYTOK RES, V15, P977, DOI 10.1089/jir.1995.15.977; DEGUCHI M, 1995, IMMUNOL LETT, V45, P157, DOI 10.1016/0165-2478(94)00246-N; DIGHIERO P, 1994, NEUROSCI LETT, V166, P31, DOI 10.1016/0304-3940(94)90833-8; DING AH, 1988, J IMMUNOL, V141, P2407; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GOUREAU O, 1995, J IMMUNOL, V154, P6518; GOUREAU O, 1992, BIOCHEM BIOPH RES CO, V186, P854, DOI 10.1016/0006-291X(92)90824-5; GOUREAU O, 1994, BIOCHEM BIOPH RES CO, V198, P120, DOI 10.1006/bbrc.1994.1017; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GOUREAU O, 1995, EUR J BIOCHEM, V230, P1046, DOI 10.1111/j.1432-1033.1995.tb20654.x; GOUREAU O, 1994, J NEUROCHEM, V63, P310; GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1145; KASAI K, 1995, ENDOCRINOLOGY, V136, P4261, DOI 10.1210/en.136.10.4261; KISHI H, 1994, CURR EYE RES, V13, P661, DOI 10.3109/02713689408999902; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KREIL TR, 1995, VIROLOGY, V212, P174, DOI 10.1006/viro.1995.1465; LePage C, 1996, IMMUNOLOGY, V89, P274, DOI 10.1046/j.1365-2567.1996.d01-728.x; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MASCARELLI F, 1993, GROWTH FACTORS, V8, P211, DOI 10.3109/08977199309011024; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; POLITIS AD, 1994, J IMMUNOL, V152, P2270; SIREN V, 1993, OPHTHALMIC RES, V26, P1; SPARROW JR, 1994, EXP EYE RES, V59, P129, DOI 10.1006/exer.1994.1091; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; Vodovotz Yoram, 1994, Progress in Growth Factor Research, V5, P341, DOI 10.1016/0955-2235(94)00004-5; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG XO, 1994, INFECT IMMUN, V62, P33, DOI 10.1128/IAI.62.1.33-40.1994; ZHOU AQ, 1995, J INTERF CYTOK RES, V15, P897, DOI 10.1089/jir.1995.15.897	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32169	32175		10.1074/jbc.272.51.32169	http://dx.doi.org/10.1074/jbc.272.51.32169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405417	hybrid			2022-12-27	WOS:000071108000036
J	Xiao, ZC; Bartsch, U; Margolis, RK; Rougon, G; Montag, D; Schachner, M				Xiao, ZC; Bartsch, U; Margolis, RK; Rougon, G; Montag, D; Schachner, M			Isolation of a tenascin-R binding protein from mouse brain membranes - A phosphacan-related chondroitin sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; EXTRACELLULAR-MATRIX GLYCOPROTEINS; NEURITE OUTGROWTH; N-CAM; TYROSINE-PHOSPHATASE; CALCIUM-BINDING; ADULT-MOUSE; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; MARFAN-SYNDROME	We have isolated a chondroitin sulfate proteoglycan from mouse brain by affinity chromatography with a fragment of the extracellular matrix glycoprotein tenascin-a (TN-R) that comprises the amino-terminal cysteine-rich stretch and the 4.5 epidermal growth factor-like repeats. The isolated chondroitin sulfate proteoglycan has a molecular mass of 500-600 kDa and carries the HNK-1 carbohydrate epitope. Treatment with chondroitinase ABC reveals a major band of approximately 400 kDa and two minor bands at 200 and 150 kDa. Immunoblot analysis relates the molecule to phosphacan but not to the chondroitin sulfate proteoglycans neurocan and versican. Binding of the phosphacan-related molecule to the epidermal growth factor-like repeats of TN-R is Ca2+-dependent. Co-localization of the molecule with TN-R in the retina and optic nerve by immunocytochemistry suggests a functional relationship between the two molecules in vivo. Inhibition of neurite outgrowth from hippocampal neurons by the phosphacan-related molecule in vitro is neutralized by TN-R when coated as a uniform substrate. Furthermore, the phosphacan-related molecule neutralizes growth cone repulsion induced by TN-R coated as a sharp substrate boundary with or without prior treatment with chondroitinase ABC. These observations indicate that TN-R can interact with a phosphacan-related molecule and thereby modulate its inhibitory influence on neuritogenesis.	Swiss Fed Inst Technol, Dept Neurobiol, CH-8093 Zurich, Switzerland; Univ Hamburg, Zentrum Mol Biol, D-20246 Hamburg, Germany; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA; Fac Sci Luminy, CNRS 9943, Lab Genet & Physiol Dev, F-13288 Marseille 9, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Hamburg; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Schachner, M (corresponding author), Swiss Fed Inst Technol, Dept Neurobiol, CH-8093 Zurich, Switzerland.		Montag, Dirk/D-3925-2014; xiao, zhicheng/G-5887-2010; xiao, zhicheng/A-1529-2011; ROUGON, Genevieve/G-2578-2013	Montag, Dirk/0000-0002-4964-1330; ROUGON, Genevieve/0000-0003-1316-8200				ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; Bartsch U, 1996, PROG NEUROBIOL, V49, P145; BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; BOVOLENTA P, 1993, EUR J NEUROSCI, V5, P454, DOI 10.1111/j.1460-9568.1993.tb00512.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P792, DOI 10.1111/j.1460-9568.1995.tb00682.x; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Dorries U, 1996, J NEUROSCI RES, V43, P420; DOU CL, 1994, J NEUROSCI, V14, P7616; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; ERNST H, 1995, J CELL SCI, V108, P3807; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; FISCHER G, 1986, J NEUROSCI, V6, P605; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LOCHTER A, 1993, J NEUROSCI, V13, P3986; LOCHTER A, 1994, EUR J NEUROSCI, V6, P597, DOI 10.1111/j.1460-9568.1994.tb00304.x; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; ROUSSELET A, 1988, DEV BIOL, V129, P495, DOI 10.1016/0012-1606(88)90395-8; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SCHULZ M, 1990, J NEUROCHEM, V55, P832, DOI 10.1111/j.1471-4159.1990.tb04567.x; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	68	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32092	32101		10.1074/jbc.272.51.32092	http://dx.doi.org/10.1074/jbc.272.51.32092			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405406	hybrid			2022-12-27	WOS:000071108000025
J	Dudek, AZ; Pennell, CA; Decker, TD; Young, TA; Key, NS; Slungaard, A				Dudek, AZ; Pennell, CA; Decker, TD; Young, TA; Key, NS; Slungaard, A			Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C - A potential mechanism for enhancing generation of activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; HUMAN SOLUBLE THROMBOMODULIN; FACTOR-IV; RABBIT THROMBOMODULIN; GRANULE PROTEINS; RAT MODEL; ANTICOAGULANT ACTIVITIES; HEPARIN ANTICOAGULATION; VENOUS THROMBOSIS; COFACTOR ACTIVITY	Platelet factor 4 (PF4) is an abundant platelet alpha-granule heparin-binding protein. We have previously shown that PF4 accelerates up to 25-fold the proteolytic conversion of protein C to activated protein C by the thrombin thrombomodulin complex by increasing its affinity for protein C 30-fold. This stimulatory effect requires presence of the gamma-carboxyglutamic acid (Gla) domain in protein C and is enhanced by the presence of a chondroitin sulfate glycosaminoglycan (GAG) domain on thrombomodulin. We hypothesized that cationic PF4 binds to both protein C and thrombomodulin through these anionic domains. Qualitative SDS-polyacrylamide gel electrophoresis analysis of avidin extracts of solutions containing biotinylated PF4 and candidate ligands shows that PF4 binds to GAG+ but not GAG- forms of thrombomodulin and native but not Gla-domainless protein C. Quantitative analysis using the surface plasmon resonance-based BIAcore(TM) biosensor system confirms the extremely high affinity of PF4 for heparin (K-D = 4 nM) and shows that PF4 binds to GAG+ thrombomodulin with a K-D of 31 nM and to protein C with a K-D of 0.37 mu M. In contrast, PF4 had no measurable interaction with GAG- thrombomodulin or Gla-domainless protein C. Western blot analysis of normal human plasma extracted with biotinylated PF4 demonstrates PF4 binding to protein C in a physiologic context. Thus, PF4 binds with relative specificity and high affinity to the GAG-domain of thrombomodulin and the Gla domain of protein C, These interactions may enhance the affinity of the thrombin thrombomodulin complex for protein C and thereby promote the generation of activated protein C.	UNIV MINNESOTA,DEPT INTERNAL MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; BERLEX BIOSCI,RICHMOND,CA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Dudek, Arkadiusz Zbigniew/HGD-1339-2022	Dudek, Arkadiusz Zbigniew/0000-0002-9114-8945; Pennell, Christopher/0000-0002-2901-6554	NATIONAL CANCER INSTITUTE [R29CA059510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055219] Funding Source: NIH RePORTER; NCI NIH HHS [CA59510] Funding Source: Medline; NHLBI NIH HHS [R29-HL55219] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI Y, 1994, THROMB HAEMOSTASIS, V71, P452; BERNABEI A, 1995, J THORAC CARDIOV SUR, V109, P765, DOI 10.1016/S0022-5223(95)70359-4; BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CAPITANIO AM, 1985, BIOCHIM BIOPHYS ACTA, V839, P161, DOI 10.1016/0304-4165(85)90033-9; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; COOK JJ, 1992, CIRCULATION, V85, P1102, DOI 10.1161/01.CIR.85.3.1102; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Dehmer GJ, 1996, CIRCULATION, V94, P347; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DITTMAN WA, 1990, BLOOD, V75, P329; DUMENCO LL, 1988, J LAB CLIN MED, V112, P394; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HOLT JC, 1985, SEMIN HEMATOL, V22, P151; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KUROSAWA S, 1985, THROMB RES, V37, P353, DOI 10.1016/0049-3848(85)90064-7; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LEVINE SP, 1976, J BIOL CHEM, V251, P324; LIN JH, 1994, J BIOL CHEM, V269, P25021; MANN KG, 1990, BLOOD, V76, P1; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; MILETICH JP, 1983, BLOOD, V62, P1127; ONO M, 1994, THROMB HAEMOSTASIS, V72, P421; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; PREISSNER KT, 1987, BIOCHEMISTRY-US, V26, P2521, DOI 10.1021/bi00383a018; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; RUCINSKI B, 1986, BIOCHEM J, V234, P485; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCULLY MF, 1980, THROMB RES, V20, P461, DOI 10.1016/0049-3848(80)90284-4; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SLUNGAARD A, 1994, J BIOL CHEM, V269, P25549; SLUNGAARD A, 1993, J CLIN INVEST, V91, P1721, DOI 10.1172/JCI116382; SLUNGAARD A, 1997, THROMB HAEMOSTASIS S, V77, P416; SOLIS MM, 1994, THROMB RES, V73, P385, DOI 10.1016/0049-3848(94)90040-X; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; TAI PC, 1987, LANCET, V1, P643; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	55	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31785	31792		10.1074/jbc.272.50.31785	http://dx.doi.org/10.1074/jbc.272.50.31785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395524	hybrid			2022-12-27	WOS:A1997YL41900083
J	Bren, N; Sine, SM				Bren, N; Sine, SM			Identification of residues in the adult nicotinic acetylcholine receptor that confer selectivity for curariform antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERFACES; MOLECULAR DISSECTION; LIGAND-BINDING; GAMMA-SUBUNIT; ALPHA-GAMMA; DETERMINANTS; SITES	We identify residues in the epsilon and delta subunits of the adult nicotinic acetylcholine receptor that give the alpha epsilon and alpha delta binding sites different affinities for the curariform antagonist dimethyl d-tubocurarine (DMT). By constructing epsilon-delta subunit chimeras, coexpressing them with complementary subunits, and measuring DMT binding, we identify two pairs of residues, Ile(epsilon 58)/His(delta 60) and Asp(epsilon 59)/Ala(delta 61), responsible for DMT site selectivity in the adult receptor. The two determinants contribute approximately equally to the binding site and interact in contributing to the site. Exchange of these residues from one subunit to the other exchanges the affinities of the resulting binding sites. These determinants in the adult receptor are far from those that confer site selectivity in the fetal receptor; determinants in the fetal receptor are Ile(gamma 116)/Val(delta 118), Tyr(gamma 117)/Thr(delta 119), and Ser(gamma 161)/Lys(delta 163). Thus, alternative residues confer DMT selectivity in fetal and adult acetylcholine receptors.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1991, J BIOL CHEM, V266, P14692; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; FU DX, 1994, J BIOL CHEM, V269, P26152; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; Harvey SC, 1996, J NEUROSCI, V16, P3798; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	20	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30793	30798		10.1074/jbc.272.49.30793	http://dx.doi.org/10.1074/jbc.272.49.30793			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388220	hybrid			2022-12-27	WOS:000071640800033
J	Kim, H; Baumann, H				Kim, H; Baumann, H			Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; CYTOPLASMIC DOMAIN; TRANSCRIPTIONAL INDUCTION; DIFFERENTIAL ACTIVATION; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 RECEPTOR; CYTOKINE RECEPTORS; MOLECULAR-CLONING; GROWTH-FACTOR; EXPRESSION	Interleukin-6 (IL-6) induces the expression of acute phase plasma protein genes in hepatic cells through the action of gp130, the signal-transducing subunit of the IL-6 receptor, To identify whether the transmembrane domain of gp130 is required for signaling function, cytoplasmic forms of gp130 were constructed that consisted of the tetramerizing N-terminal domain of Bcr linked to the transmembrane and cytoplasmic domains of gp130 (Bcr/gp130) or just to the cytoplasmic domain of gp130 (Bcr/gp130 Delta TM), The expression and function of both constructs were determined in transiently transfected COS-1 and HepG2 cells, Bcr/gp130 is capable of interacting with JAK1, JAK2, and TYK2; is constitutively active; and induces gene expression through IL-6-responsive elements, In contrast, Bcr/gp130 Delta TM, while expressed at a higher level than Bcr/gp130 and still able to interact with JAK1, is ineffective in recruiting the endogenous signal transduction pathways for inducing gene expression, However, Bcr/gp130 Delta TM initiates par tial signaling in the presence of overexpressed JAK1 and TYK2, but not JAK2. The data suggest that the transmembrane domain of gp130 is necessary for signal transduction and determines the interaction with members of the Janus kinase family.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.			Kim, Hongkyun/0000-0002-4879-7122	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; Baumann H, 1996, J IMMUNOL, V157, P284; BRECHNER T, 1991, MOL BIOL MED, V8, P267; DAWLEY GQ, 1990, SCIENCE, V247, P824; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	33	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30741	30747		10.1074/jbc.272.49.30741	http://dx.doi.org/10.1074/jbc.272.49.30741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388212	hybrid			2022-12-27	WOS:000071640800025
J	Saito, T; Hatada, M; Iwanaga, S; Kawabata, S				Saito, T; Hatada, M; Iwanaga, S; Kawabata, S			A newly identified horseshoe crab lectin with binding specificity to O-antigen of bacterial lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKROACH PERIPLANETA-AMERICANA; C-REACTIVE PROTEIN; TACHYPLEUS-TRIDENTATUS; PURIFICATION; HEMOCYTES; HEMOLYMPH; RECOGNITION; PENTRAXINS; IMMUNITY; CLONING	We identified a novel horseshoe crab hemocyte-derived lectin, which we named tachylectin-4. It has more potent hemagglutinating activity against human A-type erythrocytes than a previously identified hemocyte lectin with an affinity to N-acetylglucosamine, tachylectin-2, The purified tachylectin-4 is an oligomeric glycoprotein of 470 kDa, composed of subunits of 30 and 31.5 kDa. Ca2+ at 10 mM enhanced the hemagglutinating activity 4-fold, and the activity was inhibited by EDTA and o-phenanthroline. L-Fucose and N-acetylneuraminic acid at 100 mM completely inhibited the activity of tachylectin-4. The activity was also inhibited more strongly by bacterial S-type lipopolysaccharides (LPS) but not by R-type LPS lacking O-antigen. The most effective S-type LPS was from Escherichia coli O111:B4, and the minimum concentration required for inhibiting agglutination against human A-type erythrocytes (0.1 mu g/ml) was 160-fold lower than those of S-type LPS from Salmonella minnesota, Therefore, colitose (3-deoxy-L-fucose), a unique sugar present in the O-antigen of E. coli O111:B4 with structural similarity to L-fucose, is the most probable candidate for a specific ligand of tachylectin-4. A cDNA coding for tachylectin-4 was isolated from a hemocyte cDNA library, The open reading frame of the 1344-base pair cDNA coded for the mature protein with 232 amino acids. There is no significant sequence similarity to any other known LPS-binding lectins, whereas tachylectin-4 is homologous to the NH2-terminal domain with unknown functions of Xenopus laevis pentraxin 1.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81282, Japan	Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81282, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Saito, Tetsu/0000-0002-9045-6743				ARMSTRONG PB, 1991, IMMUNOLOGY INSECTS O, P4; ARMSTRONG PB, 1979, BIOMEDICAL APPLICATI, P73; Dodds Alister W., 1996, P303; DRICKAMER K, 1993, ANN REV CELL BIOL, V9, P236; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FAYE I, 1990, RES IMMUNOL, V141, P927, DOI 10.1016/0923-2494(90)90195-5; FINSTAD CL, 1972, J IMMUNOL, V108, P1704; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1994, ANN NY ACAD SCI, V712, P102, DOI 10.1111/j.1749-6632.1994.tb33566.x; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kawabata Shun-ichiro, 1996, P255; Kawasaki K, 1996, INSECT BIOCHEM MOLEC, V26, P355, DOI 10.1016/0965-1748(95)00101-8; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KUBO T, 1990, INSECT BIOCHEM, V20, P585, DOI 10.1016/0020-1790(90)90070-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEERY LT, 1993, P ROY SOC B-BIOL SCI, V253, P263, DOI 10.1098/rspb.1993.0112; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; VASTA GR, 1990, UCLA SYM BI, V121, P183	32	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30703	30708		10.1074/jbc.272.49.30703	http://dx.doi.org/10.1074/jbc.272.49.30703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388206	hybrid			2022-12-27	WOS:000071640800019
J	Chaturvedi, MM; Kumar, A; Darnay, BG; Chainy, GBN; Agarwal, S; Aggarwal, BB				Chaturvedi, MM; Kumar, A; Darnay, BG; Chainy, GBN; Agarwal, S; Aggarwal, BB			Sanguinarine (pseudochelerythrine) is a potent inhibitor of NP-kappa B activation, I kappa B alpha phosphorylation, and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BENZOPHENANTHRIDINE ALKALOIDS; ADENOSINE-TRIPHOSPHATASE; BASE COMPOSITION; PROTEINS; BINDING; DNA; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; CHELERYTHRINE	The nuclear factor NF-kappa B is a pleiotropic transcription factor whose activation results in inflammation, viral replication, and growth modulation. Due to its role in pathogenesis, NF-kappa KB is considered a key target for drug development. In the present report we show that sanguinarine (a benzophenanthridine alkaloid), a known anti-inflammatory agent, is a potent inhibitor of NF-kappa B activation. Treatment of human myeloid ML-1a cells with tumor necrosis factor rapidly activated NF-kappa B this activation was completely suppressed by sanguinarine in a dose- and time-dependent manner. Sanguinarine did not inhibit the binding of NF-kappa B protein to the DNA but rather inhibited the pathway leading to NF-kappa B activation. The reversal of inhibitory effects of sanguinarine by reducing agents suggests a critical sulfhydryl group is involved in NF-kappa B activation. Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and degradation of I kappa B alpha, an inhibitory subunit of NF-kappa B, and inhibited translocation of p65 subunit to the nucleus. As sanguinarine also inhibited NF-kappa B activation induced by interleukin-1, phorbol ester, and okadaic acid but not that activated by hydrogen peroxide or ceramide, the pathway leading to NF-kappa B activation is likely different for different inducers, Overall, our results demonstrate that sanguinarine is a potent suppressor of NF-kappa B activation and it acts at a step prior to I kappa B alpha phosphorylation.	UNIV TEXAS,MD ANDERSON CANC CTR,CYTOKINE RES SECT,DEPT MOL ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,SCH DENT MED,DEPT MICROBIOL BIOCHEM,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Aggarwal, Bharat B/G-3388-2013; Chainy, Gagan B.N./G-7020-2012	Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848; Chainy, Gagan/0000-0002-6418-0480				AGARWAL S, 1991, ORAL MICROBIOL IMMUN, V6, P51, DOI 10.1111/j.1399-302X.1991.tb00451.x; AKERA T, 1977, SCIENCE, V198, P569, DOI 10.1126/science.144320; ARNASON JT, 1992, PHOTOCHEM PHOTOBIOL, V55, P35, DOI 10.1111/j.1751-1097.1992.tb04206.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FADEEVA MD, 1988, TSITOLOGIYA, V30, P685; FADEEVA MD, 1987, TSITOLOGIYA+, V29, P576; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FIRATLI E, 1994, J CLIN PERIODONTOL, V21, P680, DOI 10.1111/j.1600-051X.1994.tb00786.x; GODOWSKI K C, 1989, Journal of Clinical Dentistry, V1, P96; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar Arvind, 1992, Biomedical and Environmental Sciences, V5, P251; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; Lombardini JB, 1996, BIOCHEM PHARMACOL, V51, P151, DOI 10.1016/0006-2952(95)02166-3; LUHOVA L, 1995, J ENZYM INHIB, V9, P295, DOI 10.3109/14756369509036558; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; MAITI M, 1987, J BIOMOL STRUCT DYN, V5, P159, DOI 10.1080/07391102.1987.10506383; MITSCHER LA, 1978, LLOYDIA, V41, P145; NANDI R, 1985, BIOCHEM PHARMACOL, V34, P321, DOI 10.1016/0006-2952(85)90038-3; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; PARSONS LG, 1987, J CLIN PERIODONTOL, V14, P381, DOI 10.1111/j.1600-051X.1987.tb01540.x; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SARAN A, 1995, INDIAN J BIOCHEM BIO, V32, P74; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; SHAMMA M, 1986, NAT PROD REP, V3, P345, DOI 10.1039/np9860300345; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SOUTHARD GL, 1984, J AM DENT ASSOC, V108, P338, DOI 10.14219/jada.archive.1984.0022; STRAUB KD, 1975, BIOCHEM BIOPH RES CO, V62, P913, DOI 10.1016/0006-291X(75)90410-6; ULRICHOVA J, 1983, PLANTA MED, V48, P174, DOI 10.1055/s-2007-969916; Vavreckova Ctirada, 1994, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V138, P7; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047	45	251	265	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30129	30134		10.1074/jbc.272.48.30129	http://dx.doi.org/10.1074/jbc.272.48.30129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374492	hybrid			2022-12-27	WOS:A1997YH61300024
J	Habecker, BA; Symes, AJ; Stahl, N; Francis, NJ; Economides, A; Fink, JS; Yancopoulos, G; Landis, SC				Habecker, BA; Symes, AJ; Stahl, N; Francis, NJ; Economides, A; Fink, JS; Yancopoulos, G; Landis, SC			A sweat gland-derived differentiation activity acts through known cytokine signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CULTURED SYMPATHETIC NEURONS; NEUROTRANSMITTER PLASTICITY INVIVO; NEUROPEPTIDE MESSENGER-RNAS; TRIPARTITE CNTF RECEPTOR; NEUROBLASTOMA CELL-LINE; ONCOSTATIN-M; CHOLINERGIC DIFFERENTIATION; NEUROPOIETIC CYTOKINES	The sympathetic innervation of sweat glands undergoes a target-induced noradrenergic to cholinergic/peptidergic switch during development. Similar changes are induced in cultured sympathetic neurons by sweat gland cells or by one of the following cytokines: leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), or cardiotrophin-1 (CT-1), None of these is the sweat gland-derived differentiation activity. LIF, CNTF, and CT-1 act through the known receptors LIF receptor beta (LIFR beta) and gp130 and well defined signaling pathways including receptor phosphorylation and STAT3 activation. Therefore, to determine whether the gland-derived differentiation activity was a member of the LIF/CNTF cytokine family, we tested whether it acted via these same receptors and signal cascades. Blockade of LIFR beta inhibited the sweat gland differentiation activity in neuron/gland co-cultures, and extracts of gland containing footpads stimulated tyrosine phosphorylation of LIFR beta and gp130, An inhibitor (CGX) of molecules that bind the CNTFR alpha, which is required for CNTF signaling, did not affect the gland derived differentiation activity. Soluble footpad extracts induced the same changes In NBFL neuroblastoma cells as LIF and CNTF, including increased vasoactive intestinal peptide mRNA, STAT3 dimerization, and DNA binding, and stimulation of transcription from the vasoactive intestinal peptide cytokine-responsive element. Thus, the sweat gland-derived differentiation activity uses the same signaling pathway as the neuropoietic cytokines, and is likely to be a family member.	CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,MOL NEUROBIOL LAB,BOSTON,MA 02114; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,BETHESDA,MD 20814	Case Western Reserve University; Harvard University; Massachusetts General Hospital; Regeneron; Uniformed Services University of the Health Sciences - USA	Habecker, BA (corresponding author), NINCDS,NEURAL DEV SECT,NIH,BLDG 36-5A05,36 CONVENT DR,BETHESDA,MD 20892, USA.		Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Economides, Aris/0000-0002-6508-8942; Habecker, Beth/0000-0002-4658-8730	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027514, R01NS023678] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27514, NS023678] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRUCE AG, 1992, J IMMUNOL, V149, P1271; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DERIGS HG, 1993, LEUKEMIA, V7, P630; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FANN M, 1993, J NEUROCHEM, V61, P1359; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; Francis NJ, 1997, DEV BIOL, V182, P76, DOI 10.1006/dbio.1996.8464; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; FUKADA K, 1992, NEUROREPORT, V3, P157, DOI 10.1097/00001756-199202000-00009; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Greenfield EM, 1996, J BIOL CHEM, V271, P10984, DOI 10.1074/jbc.271.18.10984; GRUNEBERG H, 1971, J EMBRYOL EXP MORPH, V25, P1; GUIDRY G, 1995, J NEUROSCI, V15, P7565; HABECKER BA, 1995, DEV BIOL, V167, P307, DOI 10.1006/dbio.1995.1025; HABECKER BA, 1994, SCIENCE, V264, P1602, DOI 10.1126/science.8202714; Habecker BA, 1995, NEUROREPORT, V7, P41, DOI 10.1097/00001756-199512000-00009; Habecker BA, 1996, J NEUROSCI, V16, P229; Hawrot E, 1979, Methods Enzymol, V58, P574; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP Y, 1992, CELL, V69, P1121; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LEBLANC G, 1986, J NEUROSCI, V6, P260; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NAWA H, 1991, J NEUROCHEM, V56, P2147, DOI 10.1111/j.1471-4159.1991.tb03479.x; OH YJ, 1994, NEUROREPORT, V5, P937, DOI 10.1097/00001756-199404000-00021; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1993, NEURON, V11, P1175, DOI 10.1016/0896-6273(93)90229-K; RAO MS, 1992, DEVELOPMENT, V116, P731; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROHRER H, 1992, DEVELOPMENT, V114, P689; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHOTZINGER R, 1994, J NEUROBIOL, V25, P620, DOI 10.1002/neu.480250605; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; TSUKADA T, 1985, DNA-J MOLEC CELL BIO, V4, P293, DOI 10.1089/dna.1985.4.293; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YIN TG, 1993, J IMMUNOL, V151, P2555; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	89	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30421	30428		10.1074/jbc.272.48.30421	http://dx.doi.org/10.1074/jbc.272.48.30421			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374533	hybrid			2022-12-27	WOS:A1997YH61300065
J	Matthews, KS				Matthews, KS			Minireview series on enzyme superfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material											Matthews, KS (corresponding author), RICE UNIV,DEPT BIOCHEM & CELL BIOL,POB 1892,HOUSTON,TX 77005, USA.								0	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29985	29985		10.1074/jbc.272.48.29985	http://dx.doi.org/10.1074/jbc.272.48.29985			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374469	hybrid			2022-12-27	WOS:A1997YH61300001
J	Dong, LQ; Ma, Q; Whitlock, JP				Dong, LQ; Ma, Q; Whitlock, JP			Down-regulation of major histocompatibility complex Q1(b) gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENE; MESSENGER-RNA; AROMATIC-HYDROCARBONS; DIFFERENTIAL DISPLAY; CHROMATIN STRUCTURE; AH-RECEPTOR; MOUSE; CELLS; MECHANISM; TRANSCRIPTION	We analyzed mouse hepatoma cells using differential display to discover new genes that respond to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We identified a class I major histocompatibility complex (MHC) gene, which we designated as MHC Q1(b), whose expression decreases in the presence of TCDD. TCDD-induced down-regulation of MHC Q1(b) requires both the aromatic hydrocarbon receptor and the aromatic hydrocarbon receptor nuclear translocator, transcription factors that up-regulate other genes in response to TCDD. Down-regulation of MHC Q1(b) by TCDD appears to involve both transcriptional and posttranscriptional regulatory events; the post-transcriptional destabilization of MHC Q1(b) mRNA is probably a secondary response to TCDD. Our findings reveal new mechanistic aspects of gene regulation by TCDD, In addition, our observations suggest a mechanism that might account for some of TCDD's immunotoxic effects.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA 53887] Funding Source: Medline; NIEHS NIH HHS [NRSA ES 05679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CHEN YT, 1985, J EXP MED, V162, P1134, DOI 10.1084/jem.162.4.1134; CHEROUTRE H, 1991, J IMMUNOL, V146, P3263; CONNEY AH, 1982, CANCER RES, V42, P4875; DEVILIN JJ, 1985, EMBO J, V4, P369; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; DURAN LW, 1989, J IMMUNOL, V142, P288; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; KALIYAPERUMAL A, 1995, J IMMUNOL, V155, P2379; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Lee DC, 1996, TOXICOL APPL PHARM, V137, P90, DOI 10.1006/taap.1996.0060; LI H, 1994, J BIOL CHEM, V269, P28098; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; MELLOR AL, 1984, CELL, V36, P139, DOI 10.1016/0092-8674(84)90082-5; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; Murphy C, 1996, J BIOL CHEM, V271, P30992, DOI 10.1074/jbc.271.48.30992; OBATA Y, 1988, P NATL ACAD SCI USA, V85, P3541, DOI 10.1073/pnas.85.10.3541; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REYESENGEL A, 1993, J REPROD IMMUNOL, V23, P73, DOI 10.1016/0165-0378(93)90028-G; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; THIGPEN JE, 1975, INFECT IMMUN, V12, P1319, DOI 10.1128/IAI.12.6.1319-1324.1975; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WATTS S, 1989, EMBO J, V8, P1749, DOI 10.1002/j.1460-2075.1989.tb03568.x; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157	40	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29614	29619		10.1074/jbc.272.47.29614	http://dx.doi.org/10.1074/jbc.272.47.29614			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368027	hybrid			2022-12-27	WOS:A1997YG64700037
J	Ikonen, T; Palvimo, JJ; Janne, OA				Ikonen, T; Palvimo, JJ; Janne, OA			Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; HUMAN ESTROGEN-RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; ACTIVATION FUNCTION AF-2; BULBAR MUSCULAR-ATROPHY; NONRECEPTOR FACTORS; HORMONE RECEPTORS; RESPONSE ELEMENT; TRANS-ACTIVATION; PROMOTER-CONTEXT	Identical N-terminal deletions in the wild-type rat androgen receptor (rAR) and a constitutively active rAR (AR Delta 641-902) devoid of the ligand-binding domain (LED) resulted in dissimilar consequences in transcriptional activation: deletion of residues 149-295 abolished wild-type AR activity, but did not influence that of AR Delta 641-902. The activity of the N-terminal transactivation domain is thus controlled by the hormone-occupied LED, suggesting that the N- and C-terminal regions of rAR communicate. Consistent with this idea, a strong androgen-dependent interaction between the N-terminal region and LED was demonstrated in a mammalian two-hybrid system using GAL4 and VP16 fusion proteins. This interaction can be direct or indirect. Several nuclear receptor coactivators (CEP, F-SRC-1, SRC-1, and RIP140) that interact with other steroid receptors were tested as potential mediators of the Nand C-terminal interaction of rAR using the mammalian two-hybrid system. CBP or F-SRC-1 not only enhanced AR-mediated transactivation, but also facilitated the androgen-dependent interaction between the N- and C-terminal domains, implying that part of the coactivator-dependent transcriptional activation occurs via this mechanism. In contrast, SRC-1, a coactivator for the progesterone receptor, inhibited both AR-mediated transactivation and interaction between the Pd and C termini. Recruitment of coregulators may involve AR domains other than the LED, as F-SRC-1 and CBP enhanced, but SRC-1 repressed, the transcriptional activity of AR Delta 641-902. Collectively, interplay between the N-terminal region and LED of rAR results in the formation of a transactivation complex that includes coregulators and that is mandatory for optimal activation of androgen-induced promoters.	UNIV HELSINKI, INST BIOMED, DEPT PHYSIOL, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, FIN-00014 HELSINKI, FINLAND	University of Helsinki; University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Palvimo JJ, 1996, BIOCHEM J, V316, P993, DOI 10.1042/bj3160993; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILSON CM, 1994, P NATL ACAD SCI USA, V91, P1234, DOI 10.1073/pnas.91.4.1234; XIE YB, 1992, J BIOL CHEM, V267, P4939; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yen PM, 1997, MOL ENDOCRINOL, V11, P162, DOI 10.1210/me.11.2.162; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	67	309	312	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29821	29828		10.1074/jbc.272.47.29821	http://dx.doi.org/10.1074/jbc.272.47.29821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368054	hybrid			2022-12-27	WOS:A1997YG64700064
J	Sahlman, L; Wong, W; Powlowski, J				Sahlman, L; Wong, W; Powlowski, J			A mercuric ion uptake role for the integral inner membrane protein, MerC, involved in bacterial mercuric ion resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOBACILLUS-FERROOXIDANS MERC; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; TRANSPOSON TN501; BINDING-PROTEIN; INORGANIC MERCURY; STRUCTURAL GENES; OPERON; EXPRESSION; SEQUENCE	Bacterial detoxification of mercuric ion depends on the presence of one or more integral membrane proteins (MerT and/or MerC) whose postulated function is in transport of Hg2+ from a periplasmic Hg2+-binding protein (MerP) to cytoplasmic mercuric reductase, In this study, MerC from the Tn21-encoded mer operon was overexpressed and studied in vesicles and in purified form to clarify the role played by this protein in mercuric ion resistance. MerC-containing vesicles were found to take up mercuric ion independently of MerP. Since uptake correlated with the level of MerC expression was unaffected by osmotic pressure, and was only partially decreased in the presence of 0.05% Triton X-100, the observed uptake appears to represent mainly binding to MerC. Binding was inhibited by thiol-specific reagents, consistent with an essential role for cysteine residues, The essential thiol groups were inaccessible to hydrophilic thiol reagents, whereas hydrophobic reagents completely abolished Hg2+ binding, These observations are consistent with the predicted topology of the protein, wherein all 4 cysteine residues are either in the cytoplasm or the bilayer, A role for MerC in Hg2+ transport is thus also likely, Based on these results, a modified model for bacterial Hg2+ transport is proposed.	CONCORDIA UNIV, DEPT CHEM & BIOCHEM, MONTREAL, PQ H3G 1M8, CANADA	Concordia University - Canada	Sahlman, L (corresponding author), UMEA UNIV, DEPT BIOCHEM, S-90187 UMEA, SWEDEN.							AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BARRINEAU P, 1984, Journal of Molecular and Applied Genetics, V2, P601; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; BROWN NL, 1985, TRENDS BIOCHEM SCI, V10, P400, DOI 10.1016/0968-0004(85)90069-6; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FOSTER TJ, 1979, J BACTERIOL, V140, P167, DOI 10.1128/JB.140.1.167-181.1979; FOX BS, 1983, BIOCHEMISTRY-US, V22, P4082, DOI 10.1021/bi00286a014; Girault L, 1996, EUR BIOPHYS J BIOPHY, V24, P413, DOI 10.1007/BF00576713; GUTKNECHT J, 1981, J MEMBRANE BIOL, V61, P61, DOI 10.1007/BF01870753; HAMLETT NV, 1992, J BACTERIOL, V174, P6377, DOI 10.1128/JB.174.20.6377-6385.1992; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hobman JL, 1996, MOL GEN GENET, V250, P129, DOI 10.1007/s004380050059; Inoue C, 1996, BIOSCI BIOTECH BIOCH, V60, P1289, DOI 10.1271/bbb.60.1289; INOUE C, 1990, GENE, V96, P115, DOI 10.1016/0378-1119(90)90349-V; JACKSON WJ, 1982, J BACTERIOL, V149, P479, DOI 10.1128/JB.149.2.479-487.1982; JACKSON WJ, 1982, J BACTERIOL, V151, P962, DOI 10.1128/JB.151.2.962-970.1982; Jones PC, 1996, MOL MEMBR BIOL, V13, P53, DOI 10.3109/09687689609160575; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KIM YJ, 1994, CELL, V78, P845; KUSANO T, 1990, J BACTERIOL, V172, P2688, DOI 10.1128/jb.172.5.2688-2692.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND PA, 1986, J GEN MICROBIOL, V132, P465; LUND PA, 1987, GENE, V52, P207, DOI 10.1016/0378-1119(87)90047-3; MISRA TK, 1985, GENE, V34, P253, DOI 10.1016/0378-1119(85)90134-9; MISRA TK, 1984, P NATL ACAD SCI-BIOL, V81, P5975, DOI 10.1073/pnas.81.19.5975; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; MUKHOPADHYAY D, 1991, J BIOL CHEM, V266, P18538; NAIR SK, 1991, J BIOL CHEM, V266, P17320; NAKAHARA H, 1979, J BACTERIOL, V140, P161, DOI 10.1128/JB.140.1.161-166.1979; NIBHRIAN N, 1986, GENE, V42, P323; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAHLMAN L, 1992, EUR J BIOCHEM, V205, P375, DOI 10.1111/j.1432-1033.1992.tb16790.x; SAHLMAN L, 1993, BIOCHEM BIOPH RES CO, V196, P583, DOI 10.1006/bbrc.1993.2289; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELIFONOVA OV, 1994, APPL ENVIRON MICROB, V60, P3503, DOI 10.1128/AEM.60.10.3503-3507.1994; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	48	37	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29518	29526		10.1074/jbc.272.47.29518	http://dx.doi.org/10.1074/jbc.272.47.29518			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368013	hybrid			2022-12-27	WOS:A1997YG64700023
J	StClair, EG; Anderson, SJ; Oltvai, ZN				StClair, EG; Anderson, SJ; Oltvai, ZN			Bcl-2 counters apoptosis by Bax heterodimerization-dependent and -independent mechanisms in the T cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS MULTIPLE FORMS; CAENORHABDITIS-ELEGANS; NEGATIVE SELECTION; TRANSGENIC MICE; DEFICIENT MICE; IN-VIVO; DEATH; PROTEIN; EXPRESSION; RECEPTOR	The effect of the cell death inhibitor Bcl-2 in relation to its capacity to dimerize with apoptosis promoter Bax or its homologs at their physiological expression levels was explored in the T-cell lineage. Transgenic mice expressing a BH1 mutant Bcl-2 (Bcl-2 mI-3), which fails to heterodimerize with proapoptotic members of the Bcl-2 family, such as Bax, were generated. Bcl-2 mI-3 protected immature CD4(+)8(+) thymocytes from spontaneous, glucocorticoid and anti-CD3-induced apoptosis and altered T cell maturation, resulting in increased percentages of CD3(hi) and CD4(-)8(+) thymocytes. In contrast, apoptosis of peripheral T-cells was unaffected by transgene expression. This correlated with their high Bax expression level and insensitivity to the caspase inhibitor, zVAD-fmk, a functional hallmark of Bax-like activity. Thus, within the T-cell lineage Bcl-2 can inhibit apo ptosis independent of its association with Bax or its homologs; yet, above a threshold level of their physiologic proapoptotic activity, the capacity of Bcl-2 to heterodimerize with Bax or its homologs appears essential for it to counter cell death.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University					NATIONAL CANCER INSTITUTE [R29CA072535, K08CA071890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71890-01, CA72535-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Blomgren H, 1970, Cell Immunol, V1, P545, DOI 10.1016/0008-8749(70)90041-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; COHEN JJ, 1984, J IMMUNOL, V132, P38; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GERDES K, 1990, New Biologist, V2, P946; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li T, 1996, CELL GROWTH DIFFER, V7, P107; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TucekSzabo CL, 1996, J IMMUNOL, V156, P192; VASILAKOS JP, 1995, J IMMUNOL, V155, P3433; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	65	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29347	29355						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361016				2022-12-27	WOS:A1997YF68400075
J	Caterina, NCM; Windsor, LJ; Yermovsky, AE; Bodden, MK; Taylor, KB; Birkedal-Hansen, H; Engler, JA				Caterina, NCM; Windsor, LJ; Yermovsky, AE; Bodden, MK; Taylor, KB; Birkedal-Hansen, H; Engler, JA			Replacement of conserved cysteines in human tissue inhibitor of metalloproteinases-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; HUMAN-FIBROBLASTS; PLASMID DNA; COLLAGENASE INHIBITORS; DIRECTED MUTAGENESIS; TERMINAL DOMAIN; EXPRESSION; TIMP; GELATINASE; GROWTH	Tissue inhibitor of metalloproteinases-l (TIMP-1) is resistant to extremes of temperature and pH, This is thought to be due in part to the presence of six sulfhydryl bridges presumed to maintain the structural integrity of the molecule, As part of a study looking at structure-function relationships, a number of the conserved cysteine residues in TIMP-1 were targeted for replacement: with serine, Single and double replacements of these conserved cysteines, as well as replacements around these cysteines, were expressed using a vaccinia virus system and analyzed for functional and structural competence, Analysis by circular dichroism indicated that these mutants maintained secondary structures similar to those of mild-type TIMP-1. Trypsin susceptibility experiments indicated that the tertiary structure of the mutants had not been drastically changed, Analysis of functional competence demonstrated that there were significant changes in some of these mutants, Assays using collagen fibrils or gelatin as substrates indicated that the double mutant C1S/C70S, but not C3S/C99S, had lost inhibitory activity against human fibroblast-type collagenase (FIB-CL) and at high concentrations only had slight activity against M-r 72,000 gelatinase (M-r 72,000 gelatinase). Kinetic analysis of TIMP-1 inhibition of FIB-CL cleavage of a peptide substrate indicated that mutants C1S/C70S, C3S/C99S, and CEEC --> CQQC retained their ability to inhibit FIB-CL in a manner similar to wild-type TIMP-1, while mutants C1S and C70S showed little inhibitory activity, The mutants C99S and C137S could also inhibit FIB-CL cleavage of the peptide substrate, The results indicated that the degree of inhibition by the TIMP-1 mutants varied somewhat depending on the choice of substrates, interestingly replacing both cysteines from a disulfide bond in the wild-type molecule resulted in a more competent inhibitor than either of the single site "parent" mutations, Taken together, these experiments indicate that TIMP-1 can be rendered inactive by the loss of a single cysteine.	Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Oral Biol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Restorat Dent, Birmingham, AL 35294 USA; Univ Alabama, Oral Biol Res Ctr, Birmingham, AL 35294 USA; NIDR, NIH, Bethesda, MD 20892 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Engler, JA (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, Sch Med, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, P50DE008228] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10631, DE08228, DE00283] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Akaike H., 1976, MATH SCI, V14, P5; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1997, IN PRESS P C INH MET; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CARMICHAEL DF, 1989, AGENTS ACTIONS, V27, P378, DOI 10.1007/BF01972827; CAWSTON TE, 1984, ARTHRITIS RHEUM, V27, P285, DOI 10.1002/art.1780270306; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; COLIGE AC, 1992, BIOCHEM J, V285, P215, DOI 10.1042/bj2850215; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HEMBRY RM, 1993, AM J PATHOL, V143, P628; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIEVRE Y, 1990, MATRIX, V10, P292, DOI 10.1016/S0934-8832(11)80184-8; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1450; *MICR SCI SOFTW, 1993, SCI HDB, P207; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; SU TZ, 1988, GENE, V69, P81, DOI 10.1016/0378-1119(88)90380-0; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	46	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32141	32149		10.1074/jbc.272.51.32141	http://dx.doi.org/10.1074/jbc.272.51.32141			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405413	hybrid			2022-12-27	WOS:000071108000032
J	Matsuzawa, A; Hattori, K; Aoki, J; Arai, H; Inoue, K				Matsuzawa, A; Hattori, K; Aoki, J; Arai, H; Inoue, K			Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; HUMAN-PLASMA; MONOCLONAL-ANTIBODIES; PHOSPHOLIPASE A(2); ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; NUCLEAR-ENVELOPE; PURIFICATION; PROTEIN; PHOSPHATIDYLCHOLINE	Platelet-activating factor-acetylhydrolase (PAF-AH), which removes the acetyl group at the sn-2 position of PAF, is distributed widely in tissues and plasma. Tissue cytosol contains at least two types of PAF-AH, isoforms Ib and II. Isoform Ib is a tertiary G-protein complex-like heterotrimeric enzyme that is involved in brain development such as formation of the brain cortex. Isoform II (PAF-AH(II)), however, is a 40-kDa monomer and has an amino acid sequence that exhibits a 41% identity with that of plasma PAF-AH. Although PAF-AH(II) preferentialy hydrolyzes oxidized phospholipids as well as PAF in vitro, the function of this enzyme has not, as yet, been elucidated. Here, we report that PAF-AH(II) functions as an anti-oxidant phospholipase. PAF-AH(II) was found to be an N-myristoylated enzyme that has never been reported among lipases and phospholipases. In MDBK cells treated with oxidants, PAF-AH(II) translocated from cytosol to membranes within 20 min, whereas in cells treated with anti-oxidants, it translocated, conversely, from membranes to cytosol. Overexpression of PAF-AH(II) in Chinese hamster ovary-K1 cells suppressed oxidative stress-induced cell death, which occurs by apoptosis. These findings suggest that intracellular PAF-AH(II) translocates between cytosol and membranes in response to a redox state of the cell and protects the cell against oxidative stress most probably by hydrolyzing oxidized phospholipids.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Matsuzawa, Atsushi/GLU-1387-2022	Aoki, Junken/0000-0001-9435-1896; Matsuzawa, Atsushi/0000-0001-8303-3905				BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BLANK ML, 1981, J BIOL CHEM, V256, P175; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DISTELHORST CW, 1996, ONCOGENE, V12, P21; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HHANAHAN DJ, 1996, ANN REV BIOCH, V55, P483; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADIN SH, 1958, P SOC EXP BIOL MED, V98, P574, DOI 10.3181/00379727-98-24111; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shimizu S, 1996, ONCOGENE, V13, P21; SPITZ M, 1986, METHOD ENZYMOL, V121, P33; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAMATANI T, 1990, INT IMMUNOL, V2, P165, DOI 10.1093/intimm/2.2.165; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VENABLE ME, 1993, J LIPID RES, V34, P691; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATOSON AD, 1995, J CLIN INVEST, V95, P774; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	44	105	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32315	32320		10.1074/jbc.272.51.32315	http://dx.doi.org/10.1074/jbc.272.51.32315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405438	hybrid			2022-12-27	WOS:000071108000057
J	Kitagawa, H; Tsutsumi, K; Tone, Y; Sugahara, K				Kitagawa, H; Tsutsumi, K; Tone, Y; Sugahara, K			Developmental regulation of the sulfation profile of chondroitin sulfate chains in the chicken embryo brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6B4 PROTEOGLYCAN/PHOSPHACAN; 6-SULFOTRANSFERASE; EXPRESSION; CARTILAGE; PURIFICATION; AGE; ABC	Developmentally regulated and cell type-specific expression of distinct sulfated glycosaminoglycan structures on cell surface proteoglycans is increasingly recognized as providing information relevant to cell-cell interactions and differentiation in developing organisms. In this report, developmental regulation of both the sulfation profile of chondroitin sulfate chains and activities of chondroitin 4-sulfotransferase (C4ST) and chondroitin 6-sulfotransferase (C6ST) were evaluated in embryonic chicken brain. The results revealed that the sulfation profile and the sulfotransferase activities changed markedly with development, and these alterations were precisely coordinated. Specifically, the proportions of both chondroitin 6-sulfate to 4-sulfate and C6ST to C4ST activities progressively decreased with development. In addition, the total amounts of both chondroitin sulfate chains and the sulfotransferase activities were highest during early embryonic stages and decreased sharply as the development reached completion. The developmental expression of the C6ST gene was also found to parallel the developmental down-regulation of both the C6ST activity and the chondroitin 6-sulfate structure. These findings suggest that the developmentally regulated expression of the sulfotransferases is a predominant factor for stage-specific regulation of chondroitin sulfate structures.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN	Kobe Pharmaceutical University			Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				ADANY R, 1990, J BIOL CHEM, V265, P11389; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INEROT S, 1983, COLLAGEN REL RES, V3, P245; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P221; KINOSHITA A, 1997, 19 JAP CARB S AUG 5, P106; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1996, J BIOL CHEM, V271, P6583, DOI 10.1074/jbc.271.12.6583; KITAGAWA H, 1997, BIOCHEMISTRY-US, V26, P3998; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MATHEWS MB, 1966, J CLIN INVEST, V45, P1103, DOI 10.1172/JCI105416; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; POOLE AR, 1986, BIOCHEM J, V236, P1; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBINSON HC, 1969, J BIOL CHEM, V244, P348; RODEN L, 1980, BIOCH GLYCOPROTEINS, pJ9U; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SILBERT JE, 1991, TRENDS GLYCOSCI GLYC, V3, P343; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745	33	158	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31377	31381		10.1074/jbc.272.50.31377	http://dx.doi.org/10.1074/jbc.272.50.31377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395468	hybrid			2022-12-27	WOS:A1997YL41900027
J	Jin, DY; Chae, HZ; Rhee, SG; Jeang, KT				Jin, DY; Chae, HZ; Rhee, SG; Jeang, KT			Regulatory role for a novel human thioredoxin peroxidase in NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; THIOL-SPECIFIC ANTIOXIDANT; ALKYL HYDROPEROXIDE REDUCTASE; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; REDOX REGULATION; BINDING-PROTEIN; CLONING; CELLS; GENE	Reduction-oxidation (redox) plays a critical role in NF-kappa B activation. Diverse stimuli appear to utilize reactive oxygen species (e.g. hydrogen peroxide) as common effecters for activating NF-kappa B. Antioxidants govern intracellular redox status, and many such molecules can reduce H2O2.,, However, functionally, it does appear that different antioxidants are variously selective for redox regulation of certain transcription factors such as NF-kappa B, For NF-kappa B, thioredoxin has been described to be a more potent antioxidant than either glutathione or N-acetylcysteine. Thioredoxin peroxidase is the immediate enzyme that links reduction of H2O2, to thioredoxin. Several putative human thioredoxin peroxidases have been identified using recursive sequence searches/ alignments with yeast or prokaryotic enzymes. None has been characterized in detail for intracellular function(s), Here, we describe a new human thioredoxin peroxidase, antioxidant enzyme AOE372, identified by virtue of its protein-protein interaction with the product of a proliferation association gene, pag, which is also a thiol specific antioxidant, In human cells, AOE372 defines a redox pathway that specifically regulates NF-kappa B activity via a modulation of I kappa B-alpha phosphorylation in the cytoplasm, We show that AOE372 activity is regulated through either home-or heterodimerization with other thiol peroxidases, implicating subunit assortment as a mechanism for regulating antioxidant specificities, AOE372 function suggests thioredoxin peroxidase as an immediate regulator of H2O2-mediated activation of NF-kappa B.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008					ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FIELDS S, 1989, NATURE, V340, P246; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P457; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ISHII T, 1993, J BIOL CHEM, V268, P18633; IWAHARA S, 1995, BIOCHEMISTRY-US, V34, P13398, DOI 10.1021/bi00041a017; JIN DY, 1997, NUCLEIC ACIDS RES, V25, P378; JIN L, 1990, MOL BIOL EVOL, V7, P82; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KIM KW, 1988, J BIOL CHEM, V263, P4704; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Scandalios J.G., 1997, OXIDATIVE STRESS MOL; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; WU BY, 1995, P NATL ACAD SCI USA, V92, P1480, DOI 10.1073/pnas.92.5.1480; YAMAMOTO T, 1989, GENE, V80, P337	54	368	385	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30952	30961		10.1074/jbc.272.49.30952	http://dx.doi.org/10.1074/jbc.272.49.30952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388242	hybrid			2022-12-27	WOS:000071640800055
J	Miranda-Vizuete, A; Damdimopoulos, AE; Gustafsson, JA; Spyrou, G				Miranda-Vizuete, A; Damdimopoulos, AE; Gustafsson, JA; Spyrou, G			Cloning, expression, and characterization of a novel Escherichia coli thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; HYDROGEN DONOR; SALMONELLA-TYPHIMURIUM; PROTEIN; IDENTIFICATION; INSULIN; GROWTH; DNA; GLUTAREDOXIN-1; RESOLUTION	Thioredoxin (Trx) is a small ubiquitous protein that displays different functions mainly via redox mediated processes, We here report the cloning of a gene (trxC) coding for a novel thioredoxin in Escherichia coli as well as the expression and characterization of its product. The gene encodes a protein of 139 amino acids (Trx2) with a calculated molecular mass of 15.5 kDa, Trx2 contains two distinct domains: an N-terminal domain of 32 amino acids including two CXXC motifs and a C-terminal domain, with the conserved active site, Trp-Cys-Gly-Pro-Cys, showing high homology to the prokaryotic thioredoxins, Trx2 together with thioredoxin reductase and NADPH is an efficient electron donor for the essential enzyme ribonucleotide reductase and is also able to reduce the interchain disulfide bridges of insulin. The apparent K-m value of Trx2 for thioredoxin reductase is similar to that of the previously characterized E. coli thioredoxin (Trx1). The enzymatic activity of Trx2 as a protein-disulfide reductase is increased by preincubation with dithiothreitol, suggesting that oxidation of cysteine residues other than the ones in the active site might regulate its activity. A truncated form of the protein, lacking the N-terminal domain, is insensitive to the presence of dithiothreitol, further confirming the involvement of the additional cysteine residues in modulating Trx2 activity. In addition, the presence of the N-terminal domain appears to confer heat sensitivity to Trx2, unlike Trx1. Finally, Trx2 is present normally in growing E. coli cells as shown by Western blot analysis.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Spyrou, G (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden.	Giannis.Spyrou@mbb.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Besse I, 1997, BOT BULL ACAD SINICA, V38, P1; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; EJIRI SI, 1979, J BACTERIOL, V139, P161, DOI 10.1128/JB.139.1.161-164.1979; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Fontecave M., 1992, ADV ENZYMOL RELAT AR, V65, P147; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1978, J BIOL CHEM, V253, P430; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lim CJ, 1996, BBA-GENE STRUCT EXPR, V1307, P13, DOI 10.1016/0167-4781(96)00038-3; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SONG CS, 1985, J IMMUNOL, V135, P3354; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thelander L, 1978, Methods Enzymol, V51, P227; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698	49	121	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30841	30847		10.1074/jbc.272.49.30841	http://dx.doi.org/10.1074/jbc.272.49.30841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388228	hybrid			2022-12-27	WOS:000071640800041
J	Narayan, S; Jaiswal, AS				Narayan, S; Jaiswal, AS			Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N '-nitro-N-nitrosoguanidine requires p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; COLORECTAL TUMORIGENESIS; BETA-CATENIN; IN-VITRO; CANCER; PRODUCT; ASSOCIATION; MUTATIONS; PROMOTES; PROTEIN	Development of colon cancer is a multistep process frequently involving mutations in both the APC and p53 tumor suppressor genes. In this study we treated the HCT-116 colon cancer cell line with alkylating agents including N-methyl-N'-nitro-N-nitrosoguanidine (MNNG),which is known to cause colon cancer in animals, and examined the expression of both APC and p53 genes. Exposure of cells with MNNG caused an 8-12-fold increase in the level of APC mRNA and protein. APC induction was shown to result from increased nuclear transcription of the APC gene and correlated with a concomitant increase in the p53 protein level after MNNG treatment. A necessary role for p53 in APC gene regulation is supported by the failure of MNNG to induce APC expression in cell lines either expressing very low levels of p53 (HeLa cells) or no p53 (K562 erythroleukemia cells). The overexpression of wild-type p53 gene into HCT-116 cells mimicked the effect of MNNG-induced expression of APC mRNA. A direct causal role for p53 in APC gene regulation was further evaluated by transfecting the wild-type p53 gene into K562 cells and observing a B-fold increase in the APC gene expression. These results support a model featuring a direct link between p53 and APC in response to alkylation-induced DNA damage and suggest a novel role for p53 in a stress-response pathway involving APC.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Narayan, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 9-104 Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	snarayan@mspo7.med.utmb.edu						BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Cheng KC, 1997, CURR TOP MICROBIOL, V221, P5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIOVANNUCCI E, 1994, ANN MED, V26, P443, DOI 10.3109/07853899409148367; GRODEN J, 1995, CANCER RES, V55, P1531; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARGEST R, 1995, GUT, V37, P826, DOI 10.1136/gut.37.6.826; HARPER JW, 1993, CELL, V75, P805; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMITH KJ, 1994, CANCER RES, V54, P3672; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TASO J, 1994, AM J PATHOL, V145, P531; WALDMAN T, 1995, CANCER RES, V55, P5187; ZUSMAN I, 1995, BIOL REV, V70, P107, DOI 10.1111/j.1469-185X.1995.tb01441.x	34	59	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30619	30622		10.1074/jbc.272.49.30619	http://dx.doi.org/10.1074/jbc.272.49.30619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388195	hybrid			2022-12-27	WOS:000071640800008
J	Schweppe, RE; Frazer-Abel, AA; Gutierrez-Hartmann, A; Bradford, AP				Schweppe, RE; Frazer-Abel, AA; Gutierrez-Hartmann, A; Bradford, AP			Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells - Identification of fgf response elements in the prolactin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS DEVELOPMENT; PROTEIN-KINASE; MAP KINASE; MESODERM INDUCTION; NEUROENDOCRINE CELLS; TRANSCRIPTION FACTOR; TRANSFORMING GENE; OSTEOCALCIN GENE; RAF-1 KINASE; RAS	Fibroblast growth factors (FGFs) have been implicated in pituitary lactotroph tumorigenesis; however, little is known about the molecular mechanisms of FGF signal transduction. We used a transient transfection approach, in GH4 cells, to identify components of the FGF signaling pathway leading to activation of the rat prolactin (rPRL) promoter. Using dominant-negative constructs of p21(Ras), Raf-1 kinase, and mitogen activated protein (MAP) kinase, we show that FGF activation of the rPRL promoter is independent of Pas and Raf-1 but requires MAP kinase. Furthermore, MAP kinase but not Raf-1 kinase catalytic activity is stimulated by FGFs. The rPRL promoter FGF response maps to two Ets binding sites, centered at -212 (FRE1) and -96 (FRE2), and co transfection of dominant-negative Ets inhibits FGF activation, FRE1 co-localizes with a composite, Ets/GHF-1, has response element. However, overexpression of Ets-1 and GHF-1, which potentiate the Ras response, inhibits FGF stimulation of the rPRL promoter, implying that Ras and FGF signaling pathways target distinct factors to elicit their effects. These data suggest that Ets factors serve to sort and integrate MAP kinase-dependent growth factor signals, allowing highly specific transcriptional responses to be mediated via the interaction of distinct Ets proteins and cofactors at common response elements.	Univ Colorado, Hlth Sci Ctr, Dept Med, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bradford, AP (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Program Mol Biol, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011	Schweppe, Rebecca/0000-0001-7502-0151	NIDDK NIH HHS [DK37667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbass SAA, 1997, J CLIN ENDOCR METAB, V82, P1160, DOI 10.1210/jc.82.4.1160; ATKIN SL, 1993, J CLIN ENDOCR METAB, V77, P831, DOI 10.1210/jcem.77.3.8370706; BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; Diamond SE, 1996, J BIOL CHEM, V271, P28925, DOI 10.1074/jbc.271.46.28925; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONSKY R, 1991, MOL ENDOCRINOL, V5, P1687, DOI 10.1210/mend-5-11-1687; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; Hurley MM, 1996, J BONE MINER RES, V11, P1256; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LOGAN A, 1991, CELL SIGNAL, V3, P215, DOI 10.1016/0898-6568(91)90047-X; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PICKETT CA, 1994, P NATL ACAD SCI USA, V91, P8612, DOI 10.1073/pnas.91.18.8612; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Reiss N, 1997, ENDOCRINOLOGY, V138, P1673, DOI 10.1210/en.138.4.1673; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZIMERING MB, 1993, J CLIN ENDOCR METAB, V76, P1182, DOI 10.1210/jc.76.5.1182	66	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30852	30859		10.1074/jbc.272.49.30852	http://dx.doi.org/10.1074/jbc.272.49.30852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388230	hybrid			2022-12-27	WOS:000071640800043
J	Ahmad, S; Alsayed, YM; Druker, BJ; Platanias, LC				Ahmad, S; Alsayed, YM; Druker, BJ; Platanias, LC			The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ALPHA-BETA RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; SUPPRESSOR ACTIVITY; KINASE; CELLS; GENE; ACTIVATION	Interferon (IFN) alpha induces rapid and transient tyrosine phosphorylation of the Src homology 2/Src homology 3 (SH2/SH3)-containing CrkL adaptor protein in a time-and dose-dependent manner. Such phosphorylation is most likely regulated by the Type I interferon receptor (IFNR)-associated Tyk-2 kinase, as suggested by the detection of Type I IFN-dependent tyrosine kinase activity in anti-CrkL immunoprecipitates and the IFN alpha-dependent association of CrkL with Tyk-2 in intact cells. Two other Type I IFNs, IFN beta and IFN omega, also induce tyrosine phosphorylation of CrkL, suggesting that the protein is involved in the signaling pathways of several different Type I IFNs. In the IFN alpha-sensitive U-266 and Daudi cell lines, CrkL interacts via its N terminus SH3 domain with the guanine exchange factor C3G that regulates activation of Rap-1, a small G-protein that exhibits tumor suppressor activity, Thus, tyrosine phosphorylation of CrkL links the functional Type I IFNR complex to the C3G-Rap-1 signaling cascade that mediates growth inhibitory responses.	UNIV ILLINOIS, HEMATOL ONCOL SECT, MBRB, CHICAGO, IL 60607 USA; W SIDE VET ADM MED CTR, CHICAGO, IL 60607 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Oregon Health & Science University				Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA73381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Boussiotis VA, 1996, BLOOD, V88, P1847; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLS GL, 1994, BLOOD, V84, P2912; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ODA T, 1994, J BIOL CHEM, V269, P22925; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; Pestka S, 1997, Semin Oncol, V24, pS9; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SOH JM, 1994, J BIOL CHEM, V269, P18102; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	49	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29991	29994		10.1074/jbc.272.48.29991	http://dx.doi.org/10.1074/jbc.272.48.29991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374471	hybrid			2022-12-27	WOS:A1997YH61300003
J	DiGennaro, P; Sello, G; Bianchi, D; DAmico, P				DiGennaro, P; Sello, G; Bianchi, D; DAmico, P			Specificity of substrate recognition by Pseudomonas fluorescens N3 dioxygenase - The role of the oxidation potential and molecular geometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDRODIOL DEHYDROGENASE; SUBSTITUTED NAPHTHALENES; BIOCONVERSION	Pseudomonas fluorescens N3 is able to grow on naphthalene as the sole carbon and energy source, The mutant TTC1, blocked at the dihydrodiol dehydrogenase level, which can transform the hydrocarbon into the corresponding dihydrodiol, has been used to produce bioconversion products, To rationalize the different grades of conversion obtained with different substrates, a study was performed using non-naphthalene derivatives, including benzenes, conjugated benzenes, and polycyclic aromatic hydrocarbons, The corresponding diols obtained by bioconversion have been isolated and characterized, ia theoretical model that considers both energy and geometry factors has been proposed to rationalize the experimental data, Good agreement has been found between the calculated values and the experimental results.	UNIV MILAN,DIPARTIMENTO CHIM ORGAN & IND,I-20133 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGANISMI,I-20133 MILAN,ITALY; IST GUIDO DONEGANI SPA,I-28100 NOVARA,ITALY	University of Milan; University of Milan			Sello, Guido/O-5833-2016	Sello, Guido/0000-0003-2538-9107				BESTETTI G, 1994, APPL MICROBIOL BIOT, V40, P791, DOI 10.1007/BF00173976; Bestetti G, 1995, APPL MICROBIOL BIOT, V44, P306, DOI 10.1007/BF00169921; Bosetti A, 1996, J CHEM TECHNOL BIOT, V66, P375, DOI 10.1002/(SICI)1097-4660(199608)66:4<375::AID-JCTB509>3.0.CO;2-A; *CHEM DES LTD, 1995, CHEMX VERS JUL95; CIDARIA D, 1994, APPL MICROBIOL BIOT, V41, P689, DOI 10.1007/BF00167286; Dagley S., 1986, BACTERIA, V10, P527; DIGENNARO P, 1995, THESIS U STUDI MILAN; ENSLEY BD, 1982, J BACTERIOL, V149, P948, DOI 10.1128/JB.149.3.948-954.1982; GEARY PJ, 1980, METHOD ENZYMOL, V188, P52; GIBSON DT, 1982, OXYGENASES OXYGEN ME, P51; Harayama S., 1989, Genetics of bacterial diversity., P151; KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001; Maniatis T., 1982, MOL CLONING; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Nugiel DA, 1996, J MED CHEM, V39, P2156, DOI 10.1021/jm960083n; PROVENCHER L, 1994, J ORG CHEM, V59, P2729, DOI 10.1021/jo00089a015; Silverman BD, 1996, J MED CHEM, V39, P2129, DOI 10.1021/jm950589q; SNYDER JP, 1993, 3D QSAR DRUG DESIGN, P336; STEWART JJP, 1990, 527 MOPAC IND U QUAN; Swaminathan P, 1996, J MED CHEM, V39, P2141, DOI 10.1021/jm950579p; TAKIZAWA N, 1994, J BACTERIOL, V176, P2444, DOI 10.1128/JB.176.8.2444-2449.1994	21	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30254	30260		10.1074/jbc.272.48.30254	http://dx.doi.org/10.1074/jbc.272.48.30254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374510	hybrid			2022-12-27	WOS:A1997YH61300042
J	Leppa, S; Pirkkala, L; Chow, SC; Eriksson, JE; Sistonen, L				Leppa, S; Pirkkala, L; Chow, SC; Eriksson, JE; Sistonen, L			Thioredoxin is transcriptionally induced upon activation of heat shock factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; T-CELL LEUKEMIA; HSP70 GENE-TRANSCRIPTION; AUTOCRINE GROWTH-FACTOR; ARBITRARILY PRIMED PCR; NF-KAPPA-B; OXIDATIVE STRESS; FACTOR-II; EXPRESSION; PROTEIN	Heat shock gene expression is differentially regulated in cells exposed to stress stimuli and in cells undergoing processes of differentiation and development. Regulation of the classical heat shock response is mediated by heat shock factor 1 (HSF1), whereas heat shock factor 2 (HSF2) is activated in certain differentiating cells, for example during hemin-mediated differentiation of human K562 erythroleukemia cells, Hence, the signalling pathways leading to induction of heat shock gene expression upon different stimuli are likely to be distinct. We have used RNA arbitrarily primed polymerase chain reaction to identify genes that are differentially regulated upon activation of HSF1 and HSF2. In this study, me report that thioredoxin (TRX) expression is induced in K562 cells in response to hemin in an HSF2-dependent manner. Increased TRX expression was primarily detected on the transcriptional level, subsequently leading to elevated TRX mRNA and protein levels. Hemin treatment caused no reduction in cellular glutathione concentrations, indicating that the increased TRX expression was not due to oxidative stress. Studies using cell lines where overexpression of the HSF2-beta isoform represses HSF2 activation implied that active HSF2 is required for transcriptional induction of TRX. Unlike HSF2, activation of HSF1 did not induce TRX expression. Taken together, our results suggest that HSF1 and HSF2 may regulate distinct target genes, and activation of HSF2 could be involved in the regulation of TRX expression during hemin-mediated differentiation of K562 cells.	UNIV TURKU, ABO AKAD UNIV, TURKU CTR BIOTECHNOL, FIN-20521 TURKU, FINLAND; ABO AKAD UNIV, DEPT BIOL, FIN-20521 TURKU, FINLAND; UNIV LEICESTER, CTR MECHANISM HUMAN TOXIC, LEICESTER LE1 9HN, LEICS, ENGLAND	Abo Akademi University; University of Turku; Abo Akademi University; University of Leicester				Leppa, Sirpa/0000-0002-8265-511X; Sistonen, Lea/0000-0003-1341-2867				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; Berggren M, 1996, ANTICANCER RES, V16, P3459; CHAPUT M, 1983, BIOCHIMIE, V65, P501, DOI 10.1016/S0300-9084(83)80132-1; Feige U., 1996, STRESS INDUCIBLE CEL; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FRISCHER H, 1993, J CLIN INVEST, V92, P2761, DOI 10.1172/JCI116894; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1994, BBA-GENE STRUCT EXPR, V1218, P292, DOI 10.1016/0167-4781(94)90180-5; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGHTOWER L, 1991, HEAT SHOCK DEV; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; POWIS G, 1996, ANTICANCER DRUGS S3, V7, P121; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; THOR H, 1982, J BIOL CHEM, V257, P2419; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; YODOI J, 1991, ADV CANCER RES, V57, P381	53	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30400	30404		10.1074/jbc.272.48.30400	http://dx.doi.org/10.1074/jbc.272.48.30400			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374530	hybrid			2022-12-27	WOS:A1997YH61300062
J	Kasahara, K; Watanabe, Y; Yamamoto, T; Sanai, Y				Kasahara, K; Watanabe, Y; Yamamoto, T; Sanai, Y			Association of Src family tyrosine kinase Lyn with ganglioside G(D3) in rat brain - Possible regulation of Lyn by glycosphingolipid in caveolae-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CENTRAL-NERVOUS-SYSTEM; GPI-ANCHORED PROTEINS; ALPHA-2,8-SIALYLTRANSFERASE GD3 SYNTHASE; DETERGENT-RESISTANT COMPLEXES; ENRICHED MEMBRANE SUBDOMAINS; MONOCLONAL-ANTIBODY AA4; DEVELOPMENTAL-CHANGES; IMMUNOHISTOCHEMICAL LOCALIZATION; NEUROBLASTOMA-CELLS	Association of gangliosides with specific proteins in the central nervous system was examined by co-immunoprecipitation with anti-ganglioside antibody, Protein kinase activity was detected in precipitates with monoclonal antibody to ganglioside G(D3) (R24) from membranal fraction of rat brain, Using in vitro kinase assay, several phosphorylated proteins of 40, 53, 56, and 80 kDa were isolated by gel electrophoresis. Of these proteins, the proteins of 53 and 56 kDa (p55/56) were identified as two isoforms of Src family tyrosine kinase Lyn, based on co-migration during gel electrophoresis, comparative peptide mapping, and sequential immunoprecipitation with anti-lyn antibody, The identification was confirmed using a cDNA expression system in Chinese hamster ovary (CHO) cells, which express solely ganglioside G(M3), the enzymatic substrate of G(D3) synthase, In cotransfection with G(D3) synthase and Lyn expression plasmids, R24 immunoprecipitated Lyn and anti-lyn antibody immunoprecipitated G(D3). R24 treatment of rat primary cerebellar cultures induced Lyn activation and rapid tyrosine phosphorylation of several substrates including mitogen-activated protein kinases, Furthermore, sucrose density gradient analysis showed that Lyn of cerebellum and CHO transfectants were detected in a low density light-scattering band, i,e, the caveolae membrane fraction, R24 immunoprecipitated caveolin from Triton X-100 extract of CHO transfectants, These observations suggest that G(D3) may regulate Lyn in a caveolae-like domain on brain cell membranes.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	Kasahara, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM CELL RES,INST MED SCI,BUNKYO KU,3-18-22 HONKOMAGONE,TOKYO 113,JAPAN.			Kasahara, Kohji/0000-0001-7010-8365				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHATTERJEE D, 1992, BRAIN RES, V583, P31, DOI 10.1016/S0006-8993(10)80007-1; Chen S, 1996, NEUROSCIENCE, V71, P89, DOI 10.1016/0306-4522(95)00386-X; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Draberova L, 1996, IMMUNOLOGY, V87, P141; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FUKUDA M, 1995, ONCOGENE, V11, P239; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRAUS F, 1984, BRAIN RES, V324, P190, DOI 10.1016/0006-8993(84)90642-5; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HIDARI KIPJ, 1994, EUR J BIOCHEM, V221, P603, DOI 10.1111/j.1432-1033.1994.tb18772.x; HIDARI KIPJ, 1994, FEBS LETT, V353, P25, DOI 10.1016/0014-5793(94)01005-6; KASAHARA K, 1994, ANAL BIOCHEM, V218, P224, DOI 10.1006/abio.1994.1164; Kawashima I, 1996, BRAIN RES, V732, P75, DOI 10.1016/0006-8993(96)00493-3; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOTANI M, 1995, BRAIN RES, V700, P40, DOI 10.1016/0006-8993(95)00923-E; KOTANI M, 1994, GLYCOBIOLOGY, V4, P855, DOI 10.1093/glycob/4.6.855; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MANESS PF, 1992, DEV NEUROSCI-BASEL, V14, P257, DOI 10.1159/000111670; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MORI A, 1991, BIOCHEMISTRY-US, V30, P9341, DOI 10.1021/bi00102a029; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Nara K, 1996, EUR J BIOCHEM, V238, P647, DOI 10.1111/j.1432-1033.1996.0647w.x; NORIHISA Y, 1994, J IMMUNOL, V152, P485; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; OLIVE S, 1995, J NEUROCHEM, V65, P2307; OLIVER C, 1992, J CELL BIOL, V116, P635, DOI 10.1083/jcb.116.3.635; Ortaldo JR, 1996, J LEUKOCYTE BIOL, V60, P533, DOI 10.1002/jlb.60.4.533; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PURPURA DP, 1978, NATURE, V276, P520, DOI 10.1038/276520a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANAI Y, 1990, J BIOCHEM-TOKYO, V107, P740, DOI 10.1093/oxfordjournals.jbchem.a123118; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; THANGNIPON W, 1992, NEUROCHEM RES, V17, P45, DOI 10.1007/BF00966864; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Watanabe Y, 1996, J BIOCHEM-TOKYO, V120, P1020; WELTE K, 1987, J IMMUNOL, V139, P1763; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; YAMAKAWA T, 1978, TRENDS BIOCHEM SCI, V3, P128, DOI 10.1016/S0968-0004(78)80031-0; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x; YUZAKI M, 1992, J NEUROSCI, V12, P4253	79	168	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29947	29953		10.1074/jbc.272.47.29947	http://dx.doi.org/10.1074/jbc.272.47.29947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368072	hybrid			2022-12-27	WOS:A1997YG64700082
J	Schwaller, B; Durussel, I; Jermann, D; Herrmann, B; Cox, JA				Schwaller, B; Durussel, I; Jermann, D; Herrmann, B; Cox, JA			Comparison of the Ca2+-binding properties of human recombinant calretinin-22k and calretinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CONFORMATIONAL-CHANGES; HAIR-CELLS; RAT-BRAIN; EXPRESSION; BACTERIA; NEURONS; CHICK; GENE; RNA	Calretinin-22k (CR-22k) is a splice product of calretinin (CR) found specifically in cancer cells, and possesses four EF-hands and a differently processed C-terminal end, The Ca2+-binding properties of recombinant human calretinin CR-22k were investigated by flow dialysis and spectroscopic methods and compared with those of CR, CR possesses four Ca2+-binding sites with positive cooperativity (n(H) = 1.3) and a [Ca2+](0.5) of 1.5 mu M, plus one low affinity site with an intrinsic dissociation constant (K'(D)) of 0.5 mM. CR-22k contains three Ca2+-binding sites with n(H) of 1.3 and [Ca2+](0.5) of 1.2 mu M, plus a low affinity site with K'(D) of 1 mM. All the sites seem to be of the Ca2+-specific type. Limited proteolysis and thiol reactivity suggest that that the C terminus of full-length CR, but not of CR-22k, is in close proximity of site I leading to mutual shielding. Circular dichroism (CD) spectra predict that the content of alpha-helix in CR and CR-22k is similar and that Ca2+ binding leads to very small changes in the CD spectra of both proteins. The optical properties are very similar for CR-22k and CR, even though CR-22k possesses one additional Trp at the C-terminal end, and revealed that the Trp residues are organized into a hydrophobic core in the metal-free proteins and become even better shielded from the aqueous environment upon binding of Ca2+, The fluorescence of the hydrophobic probe 2-p-toluidinylnaphtalene-6-sulfonate is markedly enhanced by the two proteins already in the absence of Ca2+ and is further increased by binding of Ca2+, The trypsinolysis patterns of CR and CR-22k are markedly dependent on the presence or absence of Ca2+, Together, our data suggest the presence of an allosteric conformational unit encompassing sites I-III for CR-22k and I-IV for CR, with a very similar conformation and conformational changes for both proteins. In the allosteric unit of CR, site IV is fully active, whereas in CR-22k this site has a 80-fold decreased affinity, due to the decreased amphiphilic properties of the C-terminal helix of this site. Some very specific Ca2+-dependent conformational changes suggest that both CR and CR-22k belong to the ''sensor''-type family of Ca2+-binding proteins.	UNIV GENEVA,DEPT BIOCHEM 30,CH-1211 GENEVA 4,SWITZERLAND; UNIV FRIBOURG,INST HISTOL & GEN EMBRYOL,PEROLLES,CH-1705 FRIBOURG,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,PHARMA RES,NERVOUS SYST DIS,CH-4002 BASEL,SWITZERLAND	University of Geneva; University of Fribourg; Roche Holding				Schwaller, Beat/0000-0002-8277-7555				ANDRESSEN C, 1993, CELL TISSUE RES, V271, P181, DOI 10.1007/BF00318606; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEUNG WT, 1993, EUR J BIOCHEM, V215, P401, DOI 10.1111/j.1432-1033.1993.tb18047.x; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; COX JA, 1994, J BIOL CHEM, V269, P32807; Gander JC, 1996, CELL CALCIUM, V20, P63, DOI 10.1016/S0143-4160(96)90051-2; GOTZOS V, 1992, EXP CELL RES, V202, P292, DOI 10.1016/0014-4827(92)90078-M; HUBBARD MJ, 1995, FEBS LETT, V374, P333, DOI 10.1016/0014-5793(95)01135-2; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JACOBOWITZ DM, 1991, J COMP NEUROL, V304, P198, DOI 10.1002/cne.903040205; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KUZNICKI J, 1995, BIOCHEM J, V308, P607; KUZNICKI J, 1995, BIOCHEMISTRY-US, V34, P15389, DOI 10.1021/bi00047a001; KUZNICKI J, 1994, BIOCHEM MOL BIOL INT, V33, P713; Lenzi David, 1994, Current Opinion in Neurobiology, V4, P496, DOI 10.1016/0959-4388(94)90049-3; LUKAS W, 1994, NEUROSCIENCE, V61, P307, DOI 10.1016/0306-4522(94)90233-X; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; PARMENTIER M, 1991, EUR J BIOCHEM, V196, P79, DOI 10.1111/j.1432-1033.1991.tb15788.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBERTS WM, 1993, NATURE, V363, P74, DOI 10.1038/363074a0; ROGERS JH, 1987, J CELL BIOL, V105, P1343, DOI 10.1083/jcb.105.3.1343; ROGERS JH, 1991, NOVEL CALCIUM BINDIN, P251; SCHWALLER B, 1995, EUR J BIOCHEM, V230, P424; Schwaller B, 1997, CELL DEATH DIFFER, V4, P325, DOI 10.1038/sj.cdd.4400240; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; Stevens J, 1997, PROTEIN EXPRES PURIF, V9, P171, DOI 10.1006/prep.1996.0677; STRAUSS KI, 1993, MOL BRAIN RES, V20, P229, DOI 10.1016/0169-328X(93)90045-Q; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TANAKA T, 1980, J BIOL CHEM, V255, P1078; WINSKY L, 1995, J NEUROCHEM, V65, P381	34	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29663	29671		10.1074/jbc.272.47.29663	http://dx.doi.org/10.1074/jbc.272.47.29663			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368033	hybrid			2022-12-27	WOS:A1997YG64700043
J	Thomas, SL; Chmelar, RS; Lu, CW; Halvorsen, SW; Nathanson, NM				Thomas, SL; Chmelar, RS; Lu, CW; Halvorsen, SW; Nathanson, NM			Tissue-specific regulation of G-protein-coupled inwardly rectifying K+ channel expression by muscarinic receptor activation in Ovo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC CHICK HEART; GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; POTASSIUM CHANNELS; CHOLINERGIC RECEPTORS; OPIOID RECEPTORS; XENOPUS OOCYTES; ATRIAL CELLS; RAT-BRAIN; AGONIST	We investigated the effects of muscarinic acetylcholine receptor stimulation on the expression levels of the G-protein-coupled inwardly rectifying K+ channel (GIRK) subunits using solution hybridization and immunoblot analyses, We report here that treatment of chick embryos in ovo with muscarinic agonist causes decreases in mRNA levels encoding GIRK1 and GIRK4 in atria but does not alter GIRK1 expression in ventricles, In addition, GIRKI protein levels also demonstrate a decrease in atria upon muscarinic acetylcholine receptor stimulation, Numerous receptors couple to the activation of the GIRK family of inwardly rectifying K+ channels; thus, these decreases represent a novel mechanism for regulating physiological responses to chronic agonist exposure.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; Gadbut AP, 1996, J BIOL CHEM, V271, P6398, DOI 10.1074/jbc.271.11.6398; GADBUT AP, 1995, LIFE SCI, V56, P1022, DOI 10.1016/0024-3205(95)93756-5; GALPER JB, 1982, J BIOL CHEM, V257, P344; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5030; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HENRY DJ, 1995, NEUROSCI LETT, V186, P91, DOI 10.1016/0304-3940(95)11289-9; HUNTER DD, 1984, P NATL ACAD SCI-BIOL, V81, P3582, DOI 10.1073/pnas.81.11.3582; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LINDEN J, 1987, FASEB J, V1, P119, DOI 10.1096/fasebj.1.2.2440752; Lu C. W., 1995, Society for Neuroscience Abstracts, V21, P1325; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; MARTIN JM, 1987, J PHARMACOL EXP THER, V240, P683; MCKNIGHT GS, 1988, METHOD ENZYMOL, V159, P299; PAPPANO AJ, 1974, J PHARMACOL EXP THER, V191, P468; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; Spauschus A, 1996, J NEUROSCI, V16, P930; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40	31	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29958	29962		10.1074/jbc.272.47.29958	http://dx.doi.org/10.1074/jbc.272.47.29958			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368074	hybrid			2022-12-27	WOS:A1997YG64700084
J	Colognato, H; MacCarrick, M; ORear, JJ; Yurchenco, PD				Colognato, H; MacCarrick, M; ORear, JJ; Yurchenco, PD			The laminin alpha 2-chain short arm mediates cell adhesion through both the alpha 1 beta 1 and alpha 2 beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; HEPARIN-BINDING; BASEMENT-MEMBRANES; NEURITE OUTGROWTH; DIFFERENTIAL EXPRESSION; SCHWANN-CELLS; CHAIN GENE; MEROSIN; ISOFORMS; RECEPTOR	Laminin-2, a heterotrimer composed of alpha 2, beta 1, and gamma 1 subunits, is the primary laminin isoform found in muscle and peripheral nerve and is essential for the development and stability of basement membranes in these tissues, Expression of a domain VI-truncated laminin alpha 2-chain results in muscle degeneration and peripheral nerve dysmyelination in the dy(2J) dystrophic mouse, We have expressed amino-terminal domains VI through IVb of the laminin alpha 2-chain, as well as its laminin-1 alpha 1-chain counterpart, to identify candidate cell-interactive functions of this critical region, Using integrin-specific antibodies, recognition sites for the alpha 1 beta 1 and alpha 2 beta 1 integrins were identified in the short arms of both laminin alpha 1- and alpha 2-chain isoforms, Comparisons with a beta-alpha chimeric short arm protein possessing beta 1-chain domain VI further localized these activities to alpha-chain domain VI, In addition, we found that the laminin alpha 2-chain short arm supported neurite outgrowth independent of other laminin-2 subunits, A heparin/heparan sulfate binding activity was also localized to this region of the laminin alpha 2 subunit, These data provide the first evidence that domain VI of the laminin aa-chain mediates interactions with cell surface receptors and suggest that these integrin and heparin binding sites, alone or in concert, may play an important role in muscle and peripheral nerve function.	ROBERT W JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854					Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425, R01-DK48045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048045, R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allamand V, 1997, HUM MOL GENET, V6, P747, DOI 10.1093/hmg/6.5.747; ANDREW SM, 1992, BRIT J DERMATOL, V127, P359, DOI 10.1111/j.1365-2133.1992.tb00454.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN JC, 1994, J CELL SCI, V107, P329; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DUBAND JL, 1987, DEVELOPMENT, V101, P461; DUBAND JL, 1992, DEVELOPMENT, V116, P585; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GEE SH, 1993, J BIOL CHEM, V268, P14972; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HSIAO LL, 1991, J CLIN INVEST, V87, P811, DOI 10.1172/JCI115084; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MECHTERSHEIMER G, 1994, LAB INVEST, V70, P740; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Nissinen M, 1996, AM J HUM GENET, V58, P1177; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PERKINS CS, 1981, DEV BRAIN RES, V1, P213, DOI 10.1016/0165-3806(81)90109-7; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; SCHULER F, 1995, J CELL SCI, V108, P3795; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yao CC, 1996, J CELL SCI, V109, P3139; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	62	87	90	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29330	29336		10.1074/jbc.272.46.29330	http://dx.doi.org/10.1074/jbc.272.46.29330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361014	hybrid			2022-12-27	WOS:A1997YF68400073
J	Capon, C; Wieruszeski, JM; Lemoine, J; Byrd, JC; Leffler, H; Kim, YS				Capon, C; Wieruszeski, JM; Lemoine, J; Byrd, JC; Leffler, H; Kim, YS			Sulfated Lewis X determinants as a major structural motif in glycans from LS174T-HM7 human colon carcinoma mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; MAGNETIC-RESONANCE SPECTROSCOPY; RESOLUTION H-1-NMR SPECTROSCOPY; MOLECULAR-DYNAMICS SIMULATIONS; GAS-LIQUID-CHROMATOGRAPHY; OLIGOSACCHARIDE STRUCTURES; LINKED OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURES; MONOCLONAL-ANTIBODIES; RESPIRATORY MUCINS	This article describes oligosaccharide structures of mucin isolated from nude mouse xenograft tumors produced by LS174T-HM7 cells, a subline of the human colon carcinoma LS174T with higher metastatic tendency and higher mucin production. A striking feature of the oligosaccharides of the LS174T-HM7 xenograft tumor mucin was a predominance of sulfated Lewis X determinants: HSO3-Gal beta 1-4(Fuc alpha 1-3)GlcNAc. In addition to one previously known saccharide with one sulfated Lewis X determinant, the HM7 xenograft tumor mucin contained multiple novel structures containing one, two, or three sulfated Lewis X determinants. This determinant, known to act as a selectin ligand, has been found previously in minor saccharide components of human milk as well as mucins, but never before as a predominant structure in one mucin source.	Univ Calif San Francisco, Vet Affairs Med Ctr, GI Res Lab 151M2, San Francisco, CA 94121 USA; Univ Sci & Technol Lille, CNRS, Chim Biol Lab, Unite Mixte 111, F-59655 Villeneuve Dascq, France; Inst Pasteur, CNRS, Lab Chim Biomol, URA 1309, F-59019 Lille, France; Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kim, YS (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, GI Res Lab 151M2, San Francisco, CA 94121 USA.		Leffler, Hakon/A-2416-2019; lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; Leffler, Hakon/0000-0003-4482-8945	NCI NIH HHS [CA 29321] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMINOFF D, 1980, ANAL BIOCHEM, V101, P44, DOI 10.1016/0003-2697(80)90038-X; BAENZIGER JU, 1981, ANAL BIOCHEM, V112, P357, DOI 10.1016/0003-2697(81)90305-5; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; Bresalier RS, 1996, CANCER RES, V56, P4354; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; BYRD JC, 1988, CANCER RES, V48, P6678; CAPON C, 1992, J BIOL CHEM, V267, P19248; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; GARRIGUES J, 1994, J CELL BIOL, V125, P129, DOI 10.1083/jcb.125.1.129; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Gum JR, 1995, BIOCHEM SOC T, V23, P795, DOI 10.1042/bst0230795; HAKOMORI S, 1985, CANCER RES, V45, P2405; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Irimura Tatsuro, 1994, Cancer Bulletin (Houston), V46, P336; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAMERLING JP, 1992, BIOL MAGN RESON, V10, P1; KEMPERMAN H, 1994, J CELL BIOL, V127, P2071, DOI 10.1083/jcb.127.6.2071; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; KIM YS, 1992, J CELL BIOCHEM, P91; KOCHETKOV NK, 1976, EUR J BIOCHEM, V67, P129, DOI 10.1111/j.1432-1033.1976.tb10641.x; KOGELBERG H, 1994, GLYCOBIOLOGY, V4, P49, DOI 10.1093/glycob/4.1.49; Kogelberg H, 1996, BIOCHEMISTRY-US, V35, P1954, DOI 10.1021/bi9521598; KUAN SF, 1987, CANCER RES, V47, P5715; KUROSAKA A, 1983, J BIOL CHEM, V258, P1594; Kurutz JW, 1997, GLYCOBIOLOGY, V7, P337, DOI 10.1093/glycob/7.3.337; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; MANNORI G, 1995, CANCER RES, V55, P4425; MAORET JJ, 1989, BIOCHEM J, V258, P793, DOI 10.1042/bj2580793; MCCOOL DJ, 1995, BIOCHEM J, V312, P125, DOI 10.1042/bj3120125; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PODOLSKY DK, 1985, J BIOL CHEM, V260, P5510; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1263, DOI 10.1172/JCI112429; PODOLSKY DK, 1985, J BIOL CHEM, V260, P8262; QI YM, 1995, J SURG ONCOL, V59, P3, DOI 10.1002/jso.2930590103; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; SPENCER B, 1960, BIOCHEM J, V75, P435, DOI 10.1042/bj0750435; Stranahan PL, 1996, GLYCOCONJUGATE J, V13, P741, DOI 10.1007/BF00702338; STRECKER G, 1992, BIOCHIMIE, V74, P39, DOI 10.1016/0300-9084(92)90182-E; VANHALBEEK H, 1984, BIOCHEM SOC T, V12, P601, DOI 10.1042/bst0120601; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P7; VANHALBEEK H, 1994, GLYCOBIOLOGY, V4, P203, DOI 10.1093/glycob/4.2.203; VANHALBEEK H, 1980, BIOCHIM BIOPHYS ACTA, V623, P295, DOI 10.1016/0005-2795(80)90257-3; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; Veerman ECI, 1997, GLYCOBIOLOGY, V7, P37, DOI 10.1093/glycob/7.1.37; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VLIEGENTHART JFG, 1981, PURE APPL CHEM, V53, P45, DOI 10.1351/pac198153010045; YAMORI T, 1989, CANCER RES, V49, P887; Yoon WH, 1996, BIOCHEM BIOPH RES CO, V222, P694, DOI 10.1006/bbrc.1996.0806; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085; Zhang K, 1997, TUMOR BIOL, V18, P175, DOI 10.1159/000218028	62	68	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31957	31968		10.1074/jbc.272.51.31957	http://dx.doi.org/10.1074/jbc.272.51.31957			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405387	hybrid			2022-12-27	WOS:000071108000006
J	Staudinger, J; Lu, JR; Olson, EN				Staudinger, J; Lu, JR; Olson, EN			Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; NITRIC-OXIDE SYNTHASE; BINDING-PROTEIN; INTRACELLULAR RECEPTOR; GUANYLATE KINASES; 2-HYBRID SYSTEM; PSD-95; FAMILY; CELL; IDENTIFICATION	PICK1 is a protein kinase C (PKC) alpha-binding protein initially identified using the yeast two-hybrid system. Here we report that PICK1 contains a PDZ domain that interacts specifically with a previously unidentified PDZ-binding domain (QSAV) at the extreme COOH terminus of PKC alpha and that mutation of a putative carboxylate-binding loop within the PICK1 PDZ domain abolishes this interaction. The PDZ binding domain in PKC alpha is absent from other PKC isoforms that do not interact with PICK1, We also demonstrate that PICK1 can homooligomerize through sequences that are distinct from the carboxylate-binding loop, suggesting that self-association and PKC alpha binding are not mutually exclusive. A Caenorhabditis elegans PICK1-like protein is also able to bind to PKC alpha, suggesting a conservation of function through evolution. Association of PKC alpha with PICK1 provides a potential mechanism for the selective targeting of PKC alpha to unique subcellular sites.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Hamon Ctr Basic Canc Res, Dallas, TX 75235 USA; Glaxo Wellcome Inc, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Hamon Ctr Basic Canc Res, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040				Angenstein F, 1997, BRAIN RES, V745, P46, DOI 10.1016/S0006-8993(96)01129-8; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cowburn D, 1996, STRUCTURE, V4, P1005, DOI 10.1016/S0969-2126(96)00106-2; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FUJISAWA N, 1992, FEBS LETT, V309, P409, DOI 10.1016/0014-5793(92)80818-2; HALL AV, 1994, J BIOL CHEM, V269, P33082; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kornau HC, 1997, NAT BIOTECHNOL, V15, P319, DOI 10.1038/nbt0497-319; KVANTA A, 1991, FEBS LETT, V283, P321, DOI 10.1016/0014-5793(91)80618-D; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MUELLER BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; ROCHE KW, NEURON, V1179, P96; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SHARMA S, 1989, ONCOGENE RES, V5, P91; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539	45	198	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32019	32024		10.1074/jbc.272.51.32019	http://dx.doi.org/10.1074/jbc.272.51.32019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405395	hybrid			2022-12-27	WOS:000071108000014
J	Wang, SK; He, CG; Hashemi, T; Bayne, M				Wang, SK; He, CG; Hashemi, T; Bayne, M			Cloning and expressional characterization of a novel galanin receptor - Identification of different pharmacophores within galanin for the three galanin receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEXUAL-BEHAVIOR; MALE-RATS; ALIGNMENT; BINDING; INHIBITION; ANTAGONIST	Galanin, a 29-30 amino acid neuropeptide, is found in the central and peripheral nervous systems and displays several important physiological activities, The actions are believed to be mediated through distinct G protein-coupled receptors. To date, two galanin receptor subtypes have been cloned. In this report, we describe the cloning and expression of a cDNA encoding a novel galanin receptor (GalR3). The receptor has 370 amino acids and shares 36 and 54% homology with the rat GalR1 and GalR2 receptors, I-125-Porcine galanin binds the rat GalR3 receptor expressed in COS-7 cells with high affinity (K-d = 0.6 nM) and could be displaced by galanin and galanin fragments and galanin-chimeric peptides, The pharmacological profile of this novel receptor is distinct from those of GalR1 and GalR2, revealing different pharmacophores within galanin for the three galanin receptor subtypes, Northern blot analysis showed expression in heart, spleen, and testis, Unlike GalR1 and GalR2, no expression of GalR3 was detectable in the brain, suggesting that GalR3 may mediate some of the peripheral functions of galanin.	Schering Plough Corp, Schering Plough Res Inst, Dept CNS CV Biol Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Schering-Plough Research Institute	Wang, SK (corresponding author), Schering Plough Corp, Schering Plough Res Inst, Dept CNS CV Biol Res, Kenilworth, NJ 07033 USA.	suke.wang@spcorp.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEDECS K, 1995, NEUROPEPTIDES, V29, P137, DOI 10.1016/0143-4179(95)90015-2; BENELLI A, 1994, EUR J PHARMACOL, V260, P279, DOI 10.1016/0014-2999(94)90352-2; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BURGEVIN MC, 1995, J MOL NEUROSCI, V6, P33, DOI 10.1007/BF02736757; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRAWLEY JN, 1990, J NEUROSCI, V10, P3695; CRAWLEY JN, 1995, REGUL PEPTIDES, V59, P1, DOI 10.1016/0167-0115(95)00083-N; DUNNING BE, 1986, AM J PHYSIOL, V251, pE127, DOI 10.1152/ajpendo.1986.251.1.E127; EKBLAD E, 1985, BRIT J PHARMACOL, V86, P241, DOI 10.1111/j.1476-5381.1985.tb09455.x; FISONE G, 1989, P NATL ACAD SCI USA, V86, P9589; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; JUREUS A, 1997, 7 ANN SUMM NEOR C KE; Kakuyama H, 1997, BIOMED RES-TOKYO, V18, P49, DOI 10.2220/biomedres.18.49; PARKER EM, 1995, MOL BRAIN RES, V34, P17; POGGIOLI R, 1992, EUR J PHARMACOL, V213, P87, DOI 10.1016/0014-2999(92)90236-W; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROSSOWSKI WJ, 1990, PEPTIDES, V11, P333, DOI 10.1016/0196-9781(90)90089-N; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; ULMAN LG, 1994, REGUL PEPTIDES, V51, P17, DOI 10.1016/0167-0115(94)90130-9; ULMAN LG, 1992, NEUROSCI LETT, V136, P105, DOI 10.1016/0304-3940(92)90659-U; VERGE VMK, 1993, NEUROSCI LETT, V149, P193, DOI 10.1016/0304-3940(93)90769-H; Wang S, 1997, MOL PHARMACOL, V52, P337, DOI 10.1124/mol.52.3.337; Wang SK, 1997, FEBS LETT, V411, P225, DOI 10.1016/S0014-5793(97)00695-9; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231	28	191	203	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31949	31952		10.1074/jbc.272.51.31949	http://dx.doi.org/10.1074/jbc.272.51.31949			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405385	hybrid			2022-12-27	WOS:000071108000004
J	ChiRosso, G; Gotwals, PJ; Yang, JL; Ling, L; Jiang, K; Chao, B; Baker, DP; Burkly, LC; Fawell, SE; Koteliansky, VE				ChiRosso, G; Gotwals, PJ; Yang, JL; Ling, L; Jiang, K; Chao, B; Baker, DP; Burkly, LC; Fawell, SE; Koteliansky, VE			Fibronectin type III repeats mediate RGD-independent adhesion and signaling through activated beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; MONOCLONAL-ANTIBODY; DEPENDENT EPITOPE; DIVALENT-CATIONS; LIGAND; BINDING; MATRIX; EXPRESSION; SUBUNIT; DOMAIN	Many cell-surface and extracellular matrix proteins contain multiple modular domains known as fibronectin type III (FNIII) repeats. Cells adhere to the extracellular matrix proteins fibronectin and tenascin in part by the interaction of certain integrins with the Arg-Gly-Asp (RGD) sequence, displayed on specific FNIII repeats, We have found that, after experimental activation of beta 1 integrins, a number of cell types adhere and spread on FNIII repeats lacking RGD, derived from extracellular matrix proteins and cytokine receptors, Interaction between individual FNIII domains and beta 1 integrins mediates focal adhesion kinase phosphorylation and subsequent stress fiber and focal contact formation, These data suggest that many FNIII-containing proteins may bind and signal through activated beta 1 integrins, dramatically expanding the potential for integrin-dependent intercellular and cell-matrix communication.	BIOGEN INC,CAMBRIDGE,MA 02142	Biogen								AOTA S, 1994, J BIOL CHEM, V269, P24756; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Koyama N, 1996, AM J PATHOL, V148, P749; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MENDRICK DL, 1995, LAB INVEST, V72, P367; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SMITH JW, 1994, J BIOL CHEM, V269, P960; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; Wong LD, 1996, CELL ADHES COMMUN, V4, P201, DOI 10.3109/15419069609014223; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	39	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31447	31452		10.1074/jbc.272.50.31447	http://dx.doi.org/10.1074/jbc.272.50.31447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395478	hybrid			2022-12-27	WOS:A1997YL41900037
J	Ghosh, JK; Shaool, D; Guillaud, P; Ciceron, L; Mazier, D; Kustanovich, I; Shai, Y; Mor, A				Ghosh, JK; Shaool, D; Guillaud, P; Ciceron, L; Mazier, D; Kustanovich, I; Shai, Y; Mor, A			Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparium and the underlying molecular basis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING PEPTIDE ALAMETHICIN; RED-BLOOD-CELLS; PHOSPHOLIPID-MEMBRANES; ANTIMICROBIAL ACTIVITY; INFECTED ERYTHROCYTES; MALARIA PARASITES; CHANNEL FORMATION; LIPID BILAYERS; FROG-SKIN; PARDAXIN	The antimicrobial activity of various naturally occurring microbicidal peptides was reported to result from their interaction with microbial membrane. In this study, we investigated the cytotoxicity of the hemolytic peptide dermaseptin S4 (DS4) and the nonhemolytic peptide dermaseptin S3 (DS3) toward human erythrocytes infected by the malaria parasite Plasmodium falciparum. Both DS4 and DS3 inhibited the parasite's ability to incorporate [H-3]hypoxanthine. However, while DS4 was toxic toward both the parasite and the host erythrocyte, DS3 was toxic only toward the intraerythrocytic parasite. To gain insight into the mechanism of this selective cytotoxicity, we labeled the peptides with fluorescent probes and investigated their organization in solution and in membranes. In Plasmodium-infected cells, rhodamine-labeled peptides interacted directly with the intracellular parasite, in contrast to noninfected cells, where the peptides remained bound to the erythrocyte plasma membrane. Binding experiments to phospholipid membranes revealed that DS3 and DS4 had similar binding characteristics. Membrane permeation studies indicated that the peptides were equally potent in permeating phosphatidylserine/phosphatidylcholine vesicles, whereas DS4 was more permeative with phosphatidylcholine vesicles. In aqueous solutions, DS4 was found to be in a higher aggregation state. Nevertheless, both DS3 and DS4 spontaneously dissociated to monomers upon interaction with vesicles, albeit with different kinetics. In light of these results, we propose a mechanism by which dermaseptins permeate cells and affect intraerythrocytic parasites.	HEBREW UNIV JERUSALEM, WOLFSON CTR APPL STRUCT BIOL, IL-91904 GIVAT RAM, JERUSALEM, ISRAEL; WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; INST JACQUES MONOD, SERV IMAGERIE, F-75251 PARIS 05, FRANCE; UNIV PARIS 06, INSERM, U313, F-75634 PARIS 13, FRANCE	Hebrew University of Jerusalem; Weizmann Institute of Science; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECHINGER B, 1992, BIOPHYS J, V62, P12, DOI 10.1016/S0006-3495(92)81763-0; BECHINGER B, 1993, PROTEIN SCI, V2, P2077, DOI 10.1002/pro.5560021208; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; HIBBS RA, 1996, EUR J CELL BIOL, V72, P182; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MATSUZAKI K, 1991, BIOCHIM BIOPHYS ACTA, V1063, P162, DOI 10.1016/0005-2736(91)90366-G; MIROVSKY P, 1990, T ROY SOC TROP MED H, V84, P511, DOI 10.1016/0035-9203(90)90018-A; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; OPDENKAMP JAF, 1985, TRENDS BIOCHEM SCI, V10, P320; Oren Z, 1996, EUR J BIOCHEM, V237, P303, DOI 10.1111/j.1432-1033.1996.0303n.x; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P624, DOI 10.1016/0005-2736(67)90094-6; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SHAI Y, 1994, TOXICOLOGY, V87, P109, DOI 10.1016/0300-483X(94)90157-0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; TARASCHI TF, 1994, PARASITOL TODAY, V10, P399, DOI 10.1016/0169-4758(94)90232-1; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Wuthrich K, 1986, NMR PROTEINS NUCL AC	49	133	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31609	31616		10.1074/jbc.272.50.31609	http://dx.doi.org/10.1074/jbc.272.50.31609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395500	hybrid			2022-12-27	WOS:A1997YL41900059
J	Mehlen, P; Mehlen, A; Godet, J; Arrigo, AP				Mehlen, P; Mehlen, A; Godet, J; Arrigo, AP			hsp27 as a switch between differentiation and apoptosis in murine embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; PROMYELOCYTIC LEUKEMIA-CELLS; GROWTH ARREST; OXIDATIVE STRESS; HL-60 CELLS; CELLULAR THERMORESISTANCE; CARCINOMA-CELLS; RETINOIC ACID; EXPRESSION; PHOSPHORYLATION	Small stress proteins are developmentally regulated and Linked to cell growth and differentiation. The early phase of murine embryonic stem (ES) cell differentiation, characterized by a gradual growth arrest, is accompanied with hsp27 transient accumulation. This differentiation process also correlated with changes in hsp27 phosphorylation and oligomerization. The role of hsp27 was investigated in ES clones stably transfected with murine or human hsp27 genes, placed in sense or antisense orientation. Several clones were obtained that either underexpressed endogenous murine hsp27 or overexpressed murine or human hsp27. Maintained undifferentiated, these clones showed similar growth rates. We report here that hsp27 constitutive overexpression enhanced the differentiation-mediated decreased rate of ES cell proliferation but did not alter morphological changes. In contrast, hsp27 underexpression, which attenuated cell growth arrest, induced differentiation abortion because of an overall cell death by apoptosis. Recently, we showed that hsp27 interfered with cell death probably because of its ability to modulate intracellular glutathione. hsp27 accumulation during ES cell differentiation was also correlated with an increase in glutathione, which was attenuated by hsp27 down-expression. Hence, hsp27 transient expression seems essential for preventing differentiating ES cells from undergoing apoptosis, a switch that may be redox regulated.	UNIV LYON 1,CNRS,UMR 5534,LAB STRESS CELLULAIRE,CTR GENET MOL & CELLULAIRE,F-69622 VILLEURBANNE,FRANCE; UNIV LYON 1,CNRS,UMR 5534,LAB GENET THALASSEMIES,CTR GENET MOL & CELLULAIRE,F-69622 VILLEURBANNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; ARRIGO AP, 1991, HEAT SHOCK DEV, P106; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; ARRIGO AP, 1995, HEAT SHOCK DEV, V21, P488; ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BENNDORF R, 1988, BIOCHEM INT, V17, P225; BERNET A, 1995, BLOOD, V86, P1202; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Huot J, 1996, CANCER RES, V56, P273; HUOT J, 1991, CANCER RES, V51, P245; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Kohno T, 1996, J IMMUNOL, V156, P4722; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LIANG SM, 1991, J IMMUNOL, V146, P1909; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MEHLEN P, 1994, EUR J BIOCHEM, V221, P321; MINOWADA G, 1995, J BIOL CHEM, V270, P7047, DOI 10.1074/jbc.270.13.7047; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MUSCHEL RJ, 1995, CANCER RES, V55, P995; PARK JR, 1994, BLOOD, V84, P440; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Savatier P, 1996, ONCOGENE, V12, P309; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; SPECTOR NL, 1995, J BIOL CHEM, V270, P1003, DOI 10.1074/jbc.270.3.1003; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; STAHL J, 1992, DIFFERENTIATION, V51, P33, DOI 10.1111/j.1432-0436.1992.tb00677.x; SUSUKI K, 1992, RADIAT RES, V129, P157; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WANG R, 1992, DEVELOPMENT, V114, P303; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; YANG H, 1993, NUCLEIC ACIDS RES, V21, P3337, DOI 10.1093/nar/21.14.3337	65	195	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31657	31665		10.1074/jbc.272.50.31657	http://dx.doi.org/10.1074/jbc.272.50.31657			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395507	hybrid			2022-12-27	WOS:A1997YL41900066
J	Shaper, NL; Meurer, JA; Joziasse, DH; Chou, TDD; Smith, EJ; Schnaar, RL; Shaper, JH				Shaper, NL; Meurer, JA; Joziasse, DH; Chou, TDD; Smith, EJ; Schnaar, RL; Shaper, JH			The chicken genome contains two functional nonallelic beta 1,4-galactosyltransferase genes - Chromosomal assignment to syntenic regions tracks fate of the two gene lineages in the human genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE BETA-1,4-GALACTOSYLTRANSFERASE; HUMAN GALACTOSYLTRANSFERASE; CELL-MIGRATION; PROTEIN; BINDING; IDENTIFICATION; ENZYME; GOLGI; SITE; EXPRESSION	Two distinct but related groups of cDNA clones, CK beta 4GT-I and CK beta 4GT-II, have been isolated by screening a chicken hepatoma cDNA library with a bovine beta 1,4-galactosyltransferase (beta 4GT) cDNA clone, CK beta 4GT-I is predicted to encode a type II transmembrane glycoprotein of 41 kDa with one consensus site for N-linked glycosylation, CK beta 4GT-II is predicted to encode a type II transmembrane glycoprotein of 43 kDa with five potential N-linked glycosylation sites, At the amino acid level, the coding regions of CK beta 4GT-I and CK beta 4GT-II are 52% identical to each other and 62 and 49% identical, respectively, to bovine beta 4GT, Despite this divergence in amino acid sequence, high levels of expression of each cDNA in Trichoplusia ni insect cells demonstrate that both CK beta 4GT-I and CK beta 4GT-II encode an alpha-lactalbumin-responsive, UDP-galactose:N-acetylglucosamine beta 4-galactosyltransferase. An analysis of CK beta 4GT-I and CK beta 4GT-II, genomic clones established that the intron positions within the coding region are conserved when compared with each other, and these positions are identical to the mouse and human beta 4GT genes. Thus CK beta 4GT-I and CK beta 4GT-II are the result of the duplication of an ancestral gene and subsequent divergence, CK beta 4GT-I maps to chicken chromosome Z in a region of conserved synteny with the centromeric region of mouse chromosome 4 and human chromosome 9p, where beta 4-galactosyltransferase (EC 2.4.1.38) had previously been mapped, Consequently, during the evolution of mammals, it is the CK beta 4GT-I gene lineage that has been recruited for the biosynthesis of lactose, CK beta 4GT-II maps to a region of chicken chromosome 8 that exhibits conserved synteny with human chromosome Ip, An inspection of the current human gene map of expressed sequence tags reveals that there is a gene noted to be highly similar to beta 4GT located in this syntenic region on human chromosome Ip, Because both the CK beta 4GT-I and CK beta 4GT-II gene lineages are detectable in mammals, duplication of the ancestral beta 4-galactosyltransferase gene occurred over 250 million years ago in an ancestral species common to both mammals and birds.	JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, CELL STRUCT & FUNCT LAB, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOL SCI, BALTIMORE, MD 21287 USA; VRIJE UNIV AMSTERDAM, DEPT MED CHEM, NL-1081 BT AMSTERDAM, NETHERLANDS; USDA ARS, E LANSING, MI 48823 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Vrije Universiteit Amsterdam; United States Department of Agriculture (USDA)			Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014010] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NICHD NIH HHS [HD14010] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1974, BIKEN J, V17, P105; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; APPEDDU PA, 1994, P NATL ACAD SCI USA, V91, P2095, DOI 10.1073/pnas.91.6.2095; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BEYER TA, 1982, GLYCOCONJUGATES, P25; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HATHAWAY HJ, 1992, J CELL BIOL, V117, P369, DOI 10.1083/jcb.117.2.369; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; Nanda I, 1996, GENE, V170, P159, DOI 10.1016/0378-1119(95)00828-4; POWELL JT, 1974, BIOCHEM J, V142, P203, DOI 10.1042/bj1420203; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; RUSSO RN, 1990, THESIS J HOPKINS U; Saitoh Y, 1993, CHROMOSOME RES, V1, P239, DOI 10.1007/BF00710129; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHAPER JH, 1995, GLYCOCONJUGATE J, V12, P477; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHAPER NL, 1990, CYTOGENET CELL GENET, V54, P172, DOI 10.1159/000132987; Smith EJ, 1996, POULTRY SCI, V75, P642, DOI 10.3382/ps.0750642; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; WATZELE G, 1990, NUCLEIC ACIDS RES, V18, P7174, DOI 10.1093/nar/18.23.7174; YADAV S, 1990, J BIOL CHEM, V265, P14163; YADAV SP, 1991, J BIOL CHEM, V266, P698	43	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31389	31399		10.1074/jbc.272.50.31389	http://dx.doi.org/10.1074/jbc.272.50.31389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395470	Green Submitted, hybrid			2022-12-27	WOS:A1997YL41900029
J	Taura, T; Schlenstedt, G; Silver, PA				Taura, T; Schlenstedt, G; Silver, PA			Yrb2p is a nuclear protein that interacts with Prp20p, a yeast Rcc1 homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RNA1 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; BINDING-PROTEINS; IMPORT SUBSTRATE; PORE COMPLEXES; RAN/TC4 GTPASE; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE	A conserved family of Ran binding proteins (RBPs) has been defined by their ability to bind to the Ran GTPase and the presence of a common region of approximately 100 amino acids (the Ran binding domain). The yeast Saccharomyces cerevisiae genome predicts only three proteins with canonical Ran binding domains. Mutation of one of these, YRB1, results in defects in transport of macromolecules across the nuclear envelope (Schlenstedt, G., Wong, D. H., Roepp, D. M., and Silver, P. A. (1995) EMBO J. 14, 5367-5378). The second one, encoded by YRB2, is a 327-amino acid protein with a Ran binding domain at its C terminus and an internal cluster of FXFG and FG repeats conserved in nucleoporins. Yrb2p is located inside the nucleus, and this localization relies on the N terminus. Results of both genetic and biochemical analyses show interactions of Yrb2p with the Ran nucleotide exchanger Prp20p/Rcc1. Yrb2p binding to Gsp1p (yeast Ran) as well as to a novel 150-kDa GTP-binding protein is also detected. The Ran binding domain of Yrb2p is essential for function and for its association with Prp20p and the GTP-binding proteins. Taken together, we suggest that Yrb2p may play a role in the Ran GTPase cycle distinct from nuclear transport.	CHILDRENS HOSP, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Avis JM, 1996, J CELL SCI, V109, P2423; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DEMETER J, 1995, P NATL ACAD SCI USA, V92, P1436, DOI 10.1073/pnas.92.5.1436; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; HUTCHISON HT, 1969, J BACTERIOL, V99, P807, DOI 10.1128/JB.99.3.807-814.1969; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A, 1993, J CELL SCI, V106, P287; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakashima N, 1996, J CELL SCI, V109, P2311; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Pante N, 1995, J CELL SCI, P1; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	74	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31877	31884		10.1074/jbc.272.50.31877	http://dx.doi.org/10.1074/jbc.272.50.31877			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395535	hybrid			2022-12-27	WOS:A1997YL41900094
J	Babbitt, PC; Gerlt, JA				Babbitt, PC; Gerlt, JA			Understanding enzyme superfamilies - Chemistry as the fundamental determinant in the evolution of new catalytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MANDELATE RACEMASE; ESCHERICHIA-COLI; ACTIVE-SITE; DEHALOGENASE; 4-CHLOROBENZOATE; IDENTIFICATION; RESIDUES; ACIDS		Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Illinois, Sch Chem Sci, Dept Biochem, Urbana, IL 61801 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Urbana-Champaign	Babbitt, PC (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052594, R01GM040570] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01081] Funding Source: Medline; NIGMS NIH HHS [GM-52594, GM-40570] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BABBITT PC, 1995, SCIENCE, V267, P1159, DOI 10.1126/science.7855594; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Bernat BA, 1997, BIOCHEMISTRY-US, V36, P3050, DOI 10.1021/bi963172a; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HAWES JW, 1996, J BIOL CHEM, V271, P14248; HOROWITZ NH, 1945, P NATL ACAD SCI USA, V31, P153, DOI 10.1073/pnas.31.6.153; IZARD T, 1994, STRUCTURE, V2, P361, DOI 10.1016/S0969-2126(00)00038-1; MIRWALDT C, 1995, J MOL BIOL, V246, P227, DOI 10.1006/jmbi.1994.0078; MURPHY PJ, 1993, J BACTERIOL, V175, P5193, DOI 10.1128/JB.175.16.5193-5204.1993; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; Palmer DRJ, 1996, J AM CHEM SOC, V118, P10323, DOI 10.1021/ja962126v; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; RAO JP, 1995, MICROBIOL-UK, V141, P1683, DOI 10.1099/13500872-141-7-1683; Shan SO, 1996, P NATL ACAD SCI USA, V93, P14474, DOI 10.1073/pnas.93.25.14474; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P4325, DOI 10.1021/bi00013a022; Yang GA, 1996, BIOCHEMISTRY-US, V35, P10879, DOI 10.1021/bi9609533	27	231	233	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30591	30594		10.1074/jbc.272.49.30591	http://dx.doi.org/10.1074/jbc.272.49.30591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388188	hybrid			2022-12-27	WOS:000071640800001
J	Chaudhuri, J; Chakrabarti, A; Maitra, U				Chaudhuri, J; Chakrabarti, A; Maitra, U			Biochemical characterization of mammalian translation initiation factor 3 (eIF3) - Molecular cloning reveals that p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; RABBIT RETICULOCYTES; IMMUNOCHEMICAL CHARACTERIZATION; BINDING-PROTEIN; HELA-CELLS; WHEAT-GERM; CALF LIVER; FACTOR-III; PURIFICATION; COMPLEX	Eukaryotic translation initiation factor 3 (eIF3), which plays an essential role in initiation of protein synthesis, was purified from rabbit reticulocyte lysates using an assay that specifically measures its ability to stimulate the binding of Met-tRNA(f), (as a Met-tRNA.eIF2. GTP ternary complex) to 40 S ribosomal subunits, Purified eIF3 consisted of six major polypeptides of molecular masses 110, 67, 42, 40, 36, and 35 kDa but lacked the 170-kDa polypeptide reported to be a constituent of other eIF3 preparations, Characterization of purified eIF3 lacking the 170-kDa polypeptide showed that the eIF3-mediated 40 S initiation complex formed in the presence of AUG codon efficiently joined 60 S ribosomal subunits in an eIF5-dependent reaction to form a functional 80 S initiation complex, eIF3, which was originally bound to the 40 S initiation complex, was released from the 40 S subunit during the subunit joining reaction, Additionally, chicken antibodies raised against rabbit reticulocyte eIF3 were used to immunochemically characterize eIF3 subunits and to isolate a 3.1-kilobase pair human cDNA that encodes the p110 subunit of mammalian eIF3, The derived amino acid sequence (calculated M-r, 95,214) shows that the p110 subunit is the mammalian homologue of Saccharomyces cerevisiae protein Prt1p, a subunit of yeast eIF3.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Chaudhuri, J (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA1330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CARROLL SB, 1983, J BIOL CHEM, V258, P24; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; CHECKLEY JW, 1981, J BIOL CHEM, V256, P1582; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; FEINBERG B, 1982, J BIOL CHEM, V257, P846; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1983, MICROBIOL REV, V47, P1; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick WC., 1996, TRANSLATION CONTROL, P31; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SEAL SN, 1983, J BIOL CHEM, V258, P866; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; SPREMULLI LL, 1979, J BIOL CHEM, V254, P143; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; VALENZUELA DM, 1982, J BIOL CHEM, V257, P7712; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	51	40	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30975	30983		10.1074/jbc.272.49.30975	http://dx.doi.org/10.1074/jbc.272.49.30975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388245	hybrid			2022-12-27	WOS:000071640800058
J	Johnson, BD; Dombroski, AJ				Johnson, BD; Dombroski, AJ			The role of the pro sequence of Bacillus subtilis sigma(K) in controlling activity in transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; OPEN COMPLEX; AMINO-ACIDS; PROMOTER; BINDING; REGION; MECHANISM; DNA	The sigma (sigma) subunit of prokaryotic RNA polymerase is required for specific recognition of promoter DNA sequences and transcription initiation. Regulation of gene expression can therefore be achieved by modulating the activity of the sigma subunit, In Bacillus subtilis the mother cell-specific sporulation sigma factor, sigma(K), is synthesized as a precursor protein, pro-sigma(K), with 20-amino acid pro sequence. This pro sequence renders sigma(K) inactive for directing transcription of sigma(K)-dependent genes in vivo until the pro sequence is proteolytically removed. To understand the role of the pro sequence in controlling sigma(K) activity, we have constructed NH2,-terminal truncations of pro-sigma(K) and characterized their behavior in vitro at the gerE promoter, In this report me show that the pro sequence inactivates sigma(K) by interfering with the ability of sigma(K) to associate with the core subunits of polymerase and also influences the interactions between holoenzyme and promoter DNA. Additionally, removal of as few as 6 amino acids (pro-sigma(K) Delta 6) is sufficient to activate pro-sigma(K) for DNA binding and transcription initiation, Surprisingly, pro-sigma K Delta 6 binds to DNA with higher affinity and stimulates transcription 30-fold more efficiently than sigma(K), under certain conditions.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dombroski, AJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.	dombros@utmmg.med.uth.tmc.edu						AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; Carlson HC, 1996, J BACTERIOL, V178, P546, DOI 10.1128/jb.178.2.546-549.1996; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; LU SJ, 1994, J BACTERIOL, V176, P3936, DOI 10.1128/JB.176.13.3936-3943.1994; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; Mita BC, 1995, J BIOL CHEM, V270, P30428, DOI 10.1074/jbc.270.51.30428; MORAN CP, 1988, BACILLUS SUBTILIS OT, P653; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OKE V, 1993, J BACTERIOL, V175, P7341, DOI 10.1128/JB.175.22.7341-7347.1993; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SHORENSTEIN RG, 1973, J BIOL CHEM, V248, P6170; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992	38	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31029	31035		10.1074/jbc.272.49.31029	http://dx.doi.org/10.1074/jbc.272.49.31029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388252	hybrid			2022-12-27	WOS:000071640800065
J	Li, W; Wang, JC				Li, W; Wang, JC			Footprinting of yeast DNA topoisomerase II lysyl side chains involved in substrate binding and interdomainal interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; GYRASE-B-PROTEIN; ELECTRON-MICROSCOPY; 2-GATE MECHANISM; RNA-POLYMERASE; TRANSPORT; PURIFICATION; COMPLEXES	Footprinting of yeast DNA topoisomerase II and its NH2- and COOH-terminal truncation derivatives was carried out to map the locations of lysyl side chains that are involved in enzyme-DNA interaction, in the binding of ATP, or in interaction between domains of the same enzyme molecule, Several conclusions were drawn based on these measurements and the crystal structures of a 92-kDa fragment of the yeast enzyme and a 43-kDa fragment of Escherichia coli gyrase B-subunit, First, the footprinting results support the model previously in ferred from the 92-kDa fragment crystal structure that the main site of DNA binding is comprised of a pair of semicircular grooves, Second, the binding of a nonhydrolyzable ATP analog to the yeast enzyme appears to affect citraconylation at a minimum of six lysines in the ATPase domain of each polypeptide, Two of these lysines are probably involved in contacting the nucleotide directly, and one probably becomes buried when the two ATPase domains of a dimeric enzyme come into contact upon ATP binding; for the others, changes in lysine reactivity appear to reflect allosteric changes following ATP binding, Third, from a comparison of the footprint of the intact enzyme and those of the truncated polypeptides comprised of either the NH2- or the COOH-terminal half of the intact polypeptide, it appears that there are few contacts between the NH2- and COOH-terminal half of yeast DNA topoisomerase II.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Li, W (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BERGER JM, 1995, THESIS HARVARD U; Caron P R, 1994, Adv Pharmacol, V29B, P271; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; GOTO T, 1982, J BIOL CHEM, V257, P5866; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; Greiner DP, 1996, BIOCHEM BIOPH RES CO, V225, P1006, DOI 10.1006/bbrc.1996.1285; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCKENSMITH JW, 1991, METHOD ENZYMOL, V208, P211; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; Lundblad R.L., 1994, TECHNIQUES PROTEIN M; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	28	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31190	31195		10.1074/jbc.272.49.31190	http://dx.doi.org/10.1074/jbc.272.49.31190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388273	hybrid			2022-12-27	WOS:000071640800086
J	Yao, M; Kow, YW				Yao, M; Kow, YW			Further characterization of Escherichia coli endonuclease V - Mechanism of recognition for deoxyinosine, deoxyuridine, and base mismatches in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; 3'-ENDONUCLEASE; CLEAVAGE; GLYCOSYLASE; REPAIR; ENZYME	Endonuclease V from Escherichia coli has a wide substrate spectrum. In addition to deoxyinosine-containing DNA, the enzyme cleaves DNA containing urea residues, AP sites, base mismatches, insertion/deletion mismatches, flaps, and pseudo-Y structures. The gene coding for the enzyme was identified to be orf 225 or nfi (endonuclease five). Using enzyme purified from an overproducing strain, the deoxyinosine-and mismatch-specific activities of endonuclease V was found to have different divalent metal requirements. The affinity of the enzyme is greater than 20-fold higher for DNA containing deoxyinosine than deoxynebularine or base mismatches. Under optimal cleavage conditions, endonuclease V forms two stable complexes with DNA containing deoxyinosine, but not with DNA containing base mismatches or deoxynebularine, suggesting that the 6-keto group of hypoxanthine in DNA is critical for stable interactions with the protein. The enzyme recognizes deoxyuridine in DNA but exhibits a much lower affinity to DNA containing deoxyuridine compared with DNA containing deoxyinosine. Interestingly, deoxyuridine-specific endonuclease activity of endonuclease V has a divalent metal requirement similar to the mismatch activity, A model for the mechanism of substrate recognition is proposed to explain these different activities.	Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, Atlanta, GA 30335 USA	Emory University	Kow, YW (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, 145 Edgewood Ave SE, Atlanta, GA 30335 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; DEMPLE B, 1982, J BIOL CHEM, V257, P2848; GATES FT, 1977, J BIOL CHEM, V252, P1647; Guo GM, 1997, J BACTERIOL, V179, P310, DOI 10.1128/jb.179.2.310-316.1997; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; YAO M, 1995, J BIOL CHEM, V270, P28609, DOI 10.1074/jbc.270.48.28609; Yao M, 1996, J BIOL CHEM, V271, P30672, DOI 10.1074/jbc.271.48.30672; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	12	56	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30774	30779		10.1074/jbc.272.49.30774	http://dx.doi.org/10.1074/jbc.272.49.30774			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388217	hybrid			2022-12-27	WOS:000071640800030
J	Gommerman, JL; Rottapel, R; Berger, SA				Gommerman, JL; Rottapel, R; Berger, SA			Phosphatidylinositol 3-kinase and Ca2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; CLATHRIN LIGHT-CHAINS; FACTOR-BETA-RECEPTOR; MAST-CELLS; TYROSINE KINASE; BINDING-SITE; INDEPENDENT MECHANISMS; SIGNAL TRANSDUCTION; COATED VESICLES	We have evaluated the role of phosphatidylinositol 3-kinase (PI3-kinase) and Ca2+ influx in ligand-stimulated internalization of the c-Kit receptor. The wild type (wt) c-Kit receptor and YF719, a mutant receptor in which the SH2-mediated binding site for the p85 subunit of PI3-kinase is disrupted, were expressed in DA-1 cells. YF719 internalized with similar kinetics as wt c-Kit although the receptor remained localized close to the plasma membrane. However, in the absence of extracellular Ca2+, or in the presence of the competitive Ca2+ influx blocker Ni2+, the YF719 mutant failed to internalize, Failure to internalize in the absence of Ca2+ was also observed for the wt c-Kit receptor in cells that were pretreated with the PI3-kinase inhibitor, wortmannin. Following stimulation with ligand, clathrin heavy chains were found to co-immunoprecipitate with c-Kit, However, under conditions in which PI3-kinase activity is inhibited and Ca2+ influx is blocked, clathrin failed to co-immunoprecipitate with c-Kit, Our results demonstrate that both Ca2+ influx and PI3-kinase activity influence c-Kit endocytosis, and inhibition of these two signals disrupts the earliest stages of ligand-mediated internalization.	WELLESLEY HOSP,RES INST,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M4Y 1J3,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto				Gommerman, Jennifer/0000-0003-4576-6168; Rottapel, Robert/0000-0002-6024-5558				APODACA G, 1994, J BIOL CHEM, V269, P19005; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; CATT KJ, 1991, J BIOENERG BIOMEMBR, V23, P7; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU QL, 1995, J CLIN INVEST, V95, P2530, DOI 10.1172/JCI117954; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOOIBROEK MJ, 1987, J BIOL CHEM, V262, P25; MORI S, 1994, J BIOL CHEM, V269, P4917; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NATHKE I, 1990, J BIOL CHEM, V265, P18621; PLEY UM, 1995, J BIOL CHEM, V270, P2395, DOI 10.1074/jbc.270.5.2395; POWIS G, 1994, CANCER RES, V54, P2419; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SMYTHE E, 1994, J CELL BIOL, V124, P301, DOI 10.1083/jcb.124.3.301; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	49	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30519	30525		10.1074/jbc.272.48.30519	http://dx.doi.org/10.1074/jbc.272.48.30519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374546	hybrid			2022-12-27	WOS:A1997YH61300078
J	Hoivik, D; Willett, K; Wilson, C; Safe, S				Hoivik, D; Willett, K; Wilson, C; Safe, S			Estrogen does not inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; CYTOCHROME P450IA1; GENE-EXPRESSION; MESSENGER-RNA; TRANSIENT EXPRESSION; ISOLATED HEPATOCYTES; DOWN-REGULATION; RECEPTOR; INDUCTION; CYP1A1	The estrogen receptor and aryl hydrocarbon receptor (AhR) are coexpressed in several Ah and estrogen-responsive human breast cancer cell lines. However, a recent study reported that 17 beta-estradiol (E2) inhibited Ah responsiveness in mouse Hepa 1c1c7 hepatoma cells (Kharat, I., and Saatcioglu, F. (1996) J. Biol. Chem. 271, 10533-10537), and therefore, estrogen receptor-AhR cross-talk was reinvestigated in MCF-7 and mouse Hepa 1c1c7 cells, Treatment of 1MCF-7 or Hepa 1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) resulted in induction of CYP1A1-dependent activity and mRNA levels, Treatment of both cell lines with E2 had no effect on basal or TCDD-inducible CYP1A1-dependent activity or mRNA levels, In MCF-7 and Hepa 1c1c7 cells transiently transfected with an Ah-responsive plasmid containing the 5'-regulatory region of the human CYP1A1 gene fused to the chloramphenicol acetyltransferase reporter gene 10 nM TCDD significantly induced chloramphenicol acetyltransferase activity; in cells cotreated with TCDD plus E2 the induced response was not affected by the hormone, Nuclear extracts from cells treated with dimethyl sulfoxide, E2, TCDD, and TCDD plus E2 were incubated with the [P-32]dioxin-responsive element and analyzed by gel electrophoretic mobility shift assays, A retarded band associated with formation of a [P-32]dioxin-responsive element-AhR complex was observed in nuclear extracts from cells treated with TCDD or TCDD plus E2 (cotreated), Collectively these studies suggest that E2 does not modulate AhR-mediated CYP1A1 gene expression in MCF-7 or Hepa 1c1c7 cells.	TEXAS A&M UNIV,DEPT PHYSIOL & PHARMACOL,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station					NIEHS NIH HHS [ESO3843, ESO5734] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005734, R01ES003843] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARKER CW, 1992, J BIOL CHEM, V267, P8050; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BEIGEL L, 1990, J STEROID BIOCH MOL, V37, P725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUAN R, 1995, TOXICOLOGIST, V15, P1253; FUKUDA Y, 1994, BIOCHEM PHARMACOL, V47, P1187, DOI 10.1016/0006-2952(94)90391-3; GIERTHY JF, 1993, CANCER RES, V53, P3149; HARPER N, 1994, MOL CELL ENDOCRINOL, V104, P47, DOI 10.1016/0303-7207(94)90050-7; HARRIS M, 1990, TOXICOL APPL PHARM, V105, P243, DOI 10.1016/0041-008X(90)90186-X; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOHNE M, 1990, FEBS LETT, V273, P219, DOI 10.1016/0014-5793(90)81089-7; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KAWAJIRI K, 1991, JPN J CANCER RES, V82, P1325, DOI 10.1111/j.1349-7006.1991.tb01800.x; KELLERMANN G, 1973, NEW ENGL J MED, V289, P934, DOI 10.1056/NEJM197311012891802; KENNEDY SW, 1994, ANAL BIOCHEM, V222, P217, DOI 10.1006/abio.1994.1476; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; PORTER W, 1995, TOXICOLOGIST, V15, P1261; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; SCHOLLER A, 1994, MOL PHARMACOL, V45, P944; SIVARAMAN L, 1994, CANCER RES, V54, P3692; SUNDSTROM S, 1989, BIOCHEM PHARMACOL, V38, P2215, DOI 10.1016/0006-2952(89)90079-8; TEIFELD RM, 1989, DNA-J MOLEC CELL BIO, V8, P329, DOI 10.1089/dna.1.1989.8.329; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; THOMSEN JS, 1995, TOXICOLOGIST, V15, P1270; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; VOGEL C, 1994, ARCH TOXICOL, V68, P303, DOI 10.1007/s002040050073; Wang WL, 1996, BRIT J CANCER, V73, P316, DOI 10.1038/bjc.1996.55; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; ZACHAREWSKI T, 1989, ARCH BIOCHEM BIOPHYS, V272, P344, DOI 10.1016/0003-9861(89)90228-2; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707	35	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30270	30274		10.1074/jbc.272.48.30270	http://dx.doi.org/10.1074/jbc.272.48.30270			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374512	hybrid			2022-12-27	WOS:A1997YH61300044
J	LeMaster, DM; Springer, PA; Unkefer, CJ				LeMaster, DM; Springer, PA; Unkefer, CJ			The role of the buried aspartate of Escherichia coli thioredoxin in the activation of the mixed disulfide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE CYSTEINE; BOND FORMATION; CRYSTAL-STRUCTURE; ISOMERASE; RESIDUES; CATALYSIS; DSBA; RESOLUTION; REACTIVITY; IONIZATION	The structurally homologous protein disulfide isomerases and thioredoxins exhibit a 10(5) variation of redox equilibria. It is demonstrated that the kinetic distinction among these protein family members lies primarily in the rate of breakdown of the mixed disulfide intermediate, The conserved buried acid group serves as a proton transfer catalyst for the buried active site cysteine in the formation and breakdown of the mixed disulfide, The reduction rats of Escherichia coli thioredoxin by dithiothreitol is directly proportional to the fraction of Asp-26 in the protonated farm over the pH range of 6-9. The kinetic role of Asp-26 is further probed via differential solvent kinetic isotope effect measurements versus a D26N variant, The differential solvent isotope effect of 0.6 is consistent with a direct proton donation to the thiolate leaving group (Cys-35) via an enforced general acid catalysis by trapping mechanism, Such a donation necessitates a structural rearrangement as these two buried side chains are separated by 6 Angstrom in both the oxidized and reduced forms of the protein.			LeMaster, DM (corresponding author), LOS ALAMOS NATL LAB,CHEM SCI & TECHNOL GRP 4,POB 1663,LOS ALAMOS,NM 87545, USA.							CREIGHTON TE, 1975, J MOL BIOL, V96, P767, DOI 10.1016/0022-2836(75)90151-5; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DYSON HJ, 1991, BIOCHEMISTRY-US, V30, P4262, DOI 10.1021/bi00231a023; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GILBERT HF, 1977, J AM CHEM SOC, V99, P7931, DOI 10.1021/ja00466a029; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LEMASTER DM, 1988, BIOCHEMISTRY-US, V27, P142, DOI 10.1021/bi00401a022; LeMaster DM, 1996, J AM CHEM SOC, V118, P9255, DOI 10.1021/ja960877r; LeMaster DM, 1996, BIOCHEMISTRY-US, V35, P14876, DOI 10.1021/bi961607o; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MILLS R, 1976, CHEM SOC REV, V5, P215, DOI 10.1039/cs9760500215; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEPPELE SE, 1972, CHEM REV, V72, P511, DOI 10.1021/cr60279a004; SCHOWEN KB, 1982, METHDOS ENZYMOL, V87, P275; Schowen R. L., 1972, PROGR PHYS ORG CHEM, V9, P275; SINGH R, 1990, J AM CHEM SOC, V112, P6304, DOI 10.1021/ja00173a018; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Takahashi N, 1996, BIOCHEMISTRY-US, V35, P8342, DOI 10.1021/bi960465v; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	33	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29998	30001		10.1074/jbc.272.48.29998	http://dx.doi.org/10.1074/jbc.272.48.29998			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374473	hybrid			2022-12-27	WOS:A1997YH61300005
J	Ulitzur, N; Rancano, C; Pfeffer, SR				Ulitzur, N; Rancano, C; Pfeffer, SR			Biochemical characterization of mapmodulin, a protein that binds microtubule-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE 2A; IN-VIVO; LOCALIZATION; PURIFICATION; VESICLES; PHAPI	Mapmodulin is a 31-kDa protein that stimulates the microtubule- and dynein-dependent localization of Golgi complexes in semi-intact Chinese hamster ovary cells, We have shown previously that it binds the microtubule binding domains of the microtubule associated proteins, MAP2, MAP4, and tau, We also showed that mapmodulin is identical to a protein named PHAPI (Vaesen, M., Barnikol-Watanabe, S., Gotz, H., Awni, L.A., Cole, T., Zimmermann, B., Kratzin, H.D. and Hilschmann, N. (1994) Biol. Chem. Hoppe-Seyler 375, 113-126). We report here that mapmodulin is a phosphoprotein that is predominantly cytosolic but is also found peripherally associated with endoplasmic reticulum and Golgi membranes in mammalian cells, The protein occurs as a trimer in cytosol, and phosphorylation is required for its microtubule-associated protein-binding activity, Heat treatment of nonphosphorylated mapmodulin can render it competent for binding to microtubule-associated proteins, suggesting that phosphorylation induces a conformational change in mapmodulin. Finally, despite identity in polypeptide sequence with a protein reported to act as an inhibitor of protein phosphatase 2A, native mapmodulin was not able to inhibit protein phosphatase 2A in Chinese hamster ovary cell cytosol.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; FINK TM, 1995, GENOMICS, V29, P309, DOI 10.1006/geno.1995.1257; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; PIERRE P, 1994, J CELL SCI, V107, P1909; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x	14	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30577	30582		10.1074/jbc.272.48.30577	http://dx.doi.org/10.1074/jbc.272.48.30577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374554	hybrid			2022-12-27	WOS:A1997YH61300086
J	Bell, LC; Guengerich, FP				Bell, LC; Guengerich, FP			Oxidation kinetics of ethanol by human cytochrome P450 2E1 - Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b(5) on steady-state kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; FLAVIN-CONTAINING MONOOXYGENASES; N-NITROSODIMETHYLAMINE; METHANE MONOOXYGENASE; INDUCIBLE CYTOCHROME-P-450; ALIPHATIC HYDROXYLATION; CATALYTIC PROPERTIES; MULTIPLE PRODUCTS; ELECTRON-TRANSFER; DEUTERIUM	A number of cytochrome P450 (P450) 2E1 substrates are known to show kinetic deuterium isotope effects of similar to 5 on K-m (K-D = K-D(m)/K-H(m)), but not on k(cat), in rat liver microsomes (e.g. N-nitrosodimethylamine, ethanol, and CH2Cl2). We observed K-D(m) values of 3-5 for recombinant human P450 2E1-catalyzed ethanol oxidation. Replacing NADPH and O-2 with the oxygen surrogate cumene hydroperoxide yielded similar results. Ferric P450 2E1 reduction was fast (k > 1000 min(-1)) even in the absence of substrate. These results indicate that the basis for the increase in K-m is in the latter portion of the catalytic cycle, The intrinsic isotope effect ((D)k) for ethanol oxidation was determined (competitively) to be 3.8, indicating that C-H bond cleavage is isotopically sensitive. Presteady-state studies showed a burst of product formation (k = 410 min(-1)), with the burst amplitude corresponding to the P450 concentration, Deuteration of ethanol resulted in an isotope effect of 3.2 on the rate of the burst. We conclude that product release is rate-limiting in the oxidation of ethanol to acetaldehyde by P450 2E1. The steady-state kinetics can be described by a paradigm in which the k(cat) approximates the rate of product release, and K-m is an expression in which the denominator is dominated by the rate of C-H bond breaking.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [T32 ES0728, P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; ANDERSEN ME, 1994, TOXICOL APPL PHARM, V128, P158, DOI 10.1006/taap.1994.1193; BEATY NB, 1981, J BIOL CHEM, V256, P4611; BRADY JF, 1988, MOL PHARMACOL, V33, P148; BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; BROWN HC, 1967, J AM CHEM SOC, V89, P1522, DOI 10.1021/ja00982a043; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; DAGANI D, 1976, J NATL CANCER I, V57, P955, DOI 10.1093/jnci/57.4.955; EKSTROM G, 1987, BIOCHEMISTRY-US, V26, P7348, DOI 10.1021/bi00397a023; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GILLETTE JR, 1994, BIOCHEMISTRY-US, V33, P2927, DOI 10.1021/bi00176a024; GROVES JT, 1976, J AM CHEM SOC, V98, P859, DOI 10.1021/ja00419a049; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Guengerich FP, 1996, J BIOL CHEM, V271, P27321, DOI 10.1074/jbc.271.44.27321; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1995, BIOCHIMIE, V77, P573, DOI 10.1016/0300-9084(96)88173-9; GUENGERICH FP, 1985, CRC CR REV TOXICOL, V14, P259, DOI 10.3109/10408448509037460; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8176; Guengerich FP, 1989, PRINCIPLES METHODS T, P777; HARADA N, 1984, J BIOL CHEM, V259, P3005; JOHNSON WW, 1997, IN PRESS BIOCHEMISTR; JONES JP, 1986, J AM CHEM SOC, V108, P7074, DOI 10.1021/ja00282a037; KEEFER LK, 1973, J NATL CANCER I, V51, P299, DOI 10.1093/jnci/51.1.299; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P485; KORZEKWA KR, 1989, BIOCHEMISTRY-US, V28, P9012, DOI 10.1021/bi00449a009; KOSHY KT, 1975, J CHROMATOGR SCI, V13, P97, DOI 10.1093/chromsci/13.2.97; Kostrubsky VE, 1997, ANN CLIN LAB SCI, V27, P57; KUBY SA, 1991, STUDY ENZYMES, V1, P272; Kunitoh S, 1996, ALCOHOL CLIN EXP RES, V20, pA22, DOI 10.1111/j.1530-0277.1996.tb01721.x; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEVIN W, 1986, ARCH BIOCHEM BIOPHYS, V248, P158, DOI 10.1016/0003-9861(86)90412-1; LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353; MICO BA, 1985, CANCER RES, V45, P6280; MIWA GT, 1984, J BIOL CHEM, V259, P3000; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; NELSON SD, 1987, MAMMALIAN CYTOCHROME, V2, P19; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NORTHROP DB, 1977, P 4 ANN H STEENBOCK, P122; PALMER G, 1992, J BIOL CHEM, V267, P665; PATTEN CJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P504, DOI 10.1006/abbi.1995.1194; PATTEN CJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P629, DOI 10.1016/0003-9861(86)90373-5; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T; RATAJ MJ, 1991, J BIOL CHEM, V266, P18684; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHRINER RL, 1965, SYSTEMATIC IDENTIFIC, P253; SNYDER R, 1993, TOXICOL APPL PHARM, V122, P172, DOI 10.1006/taap.1993.1185; Sund H., 1963, ENZYMES, V7, P25; SWAIN CG, 1958, J AM CHEM SOC, V80, P5885, DOI 10.1021/ja01554a077; SWANN PF, 1983, CARCINOGENESIS, V4, P821, DOI 10.1093/carcin/4.7.821; TERELIUS Y, 1991, BIOCHEM BIOPH RES CO, V179, P689, DOI 10.1016/0006-291X(91)91427-E; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; WADE D, 1987, CANCER RES, V47, P3373; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; Yamazaki H, 1996, BIOCHEM PHARMACOL, V52, P301, DOI 10.1016/0006-2952(96)00208-0; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; YANG CS, 1991, CHEM RES TOXICOL, V4, P408, DOI 10.1021/tx00022a002; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	68	97	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29643	29651		10.1074/jbc.272.47.29643	http://dx.doi.org/10.1074/jbc.272.47.29643			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368031	hybrid			2022-12-27	WOS:A1997YG64700041
J	Haak, D; Gable, K; Beeler, T; Dunn, T				Haak, D; Gable, K; Beeler, T; Dunn, T			Hydroxylation of Saccharomyces cerevisiae ceramides requires Sur2p and Scs7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SPHINGOLIPIDS; ENDOPLASMIC-RETICULUM; YEAST; GENE; BIOSYNTHESIS; PROTEINS; DESATURASE; MUTANT; RVS161; IDENTIFICATION	The Saccharomyces cerevisiae SCS7 and SUR2 genes are members of a gene family that encodes enzymes that desaturate or hydroxylate lipids, Sur2p is required for the hydroxylation of C-4 of the sphingoid moiety of ceramide, and Scs7p is required for the hydroxylation of the very long chain fatty acid, Neither SCS7 nor SUR2 are essential for growth, and lack of the Scs7p- or Sur2p-dependent hydroxylation does not prevent the synthesis of mannosyldiinositolphosphorylceramide, the mature sphingolipid found in yeast, Deletion of either gene suppresses the Ca2+-sensitive phenotype of csg2 Delta mutants, which arises from overaccumulation of inositolphosphorylceramide due to a defect in sphingolipid mannosylation. Characterization of scs7 and sur2 mutants is expected to provide insight into the function of ceramide hydroxylation.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BERTELLO LE, 1995, BIOCHEM J, V310, P255, DOI 10.1042/bj3100255; Cliften P, 1996, MICROBIOL-SGM, V142, P477, DOI 10.1099/13500872-142-3-477; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DUNN TM, 1997, IN PRESS YEAST; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HUNG CY, 1995, BIOCHEM J, V307, P107, DOI 10.1042/bj3070107; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KARLSSON KA, 1971, J LIPID RES, V12, P466; KARLSSON KA, 1968, BIOCHIM BIOPHYS ACTA, V152, P798, DOI 10.1016/0005-2760(68)90130-6; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LESTER RL, 1993, ADV LIPID RES, V26, P253; LI L, 1966, J BIOL CHEM, V271, P16927; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MORRIS LJ, 1963, J CHROMATOGR, V12, P321, DOI 10.1016/S0021-9673(01)83692-X; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1986, METHODS YEAST GENETI; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WELLS GB, 1983, J BIOL CHEM, V258, P200; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; ZHAO C, 1994, J BIOL CHEM, V269, P21480	33	210	223	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29704	29710		10.1074/jbc.272.47.29704	http://dx.doi.org/10.1074/jbc.272.47.29704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368039	hybrid, Green Submitted			2022-12-27	WOS:A1997YG64700049
J	Zezula, J; Sexl, V; Hutter, C; Karel, A; Schutz, W; Freissmuth, M				Zezula, J; Sexl, V; Hutter, C; Karel, A; Schutz, W; Freissmuth, M			The cyclin-dependent kinase inhibitor p21(cip1) mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; PROTEIN; EXPRESSION; P21; ACTIVATION; PATHWAY; PROLIFERATION; ANGIOGENESIS; P27(KIP1); INDUCTION	Long-term application of the phorbol ester phorbol 12,18-dibutyrate (PDBu) inhibits the proliferation of human venous endothelial cells, The cyclin-dependent kinase inhibitor p21(cip1) is a potential candidate mediating the PDBu-induced delayed entry of the cells into S-phase (by similar to 10 h when compared with cells stimulated with basic fibroblast growth factor (bFGF)), Levels of p21(cip1) (protein and mRNA) rapidly rise (within similar to 2 h) in endothelial cells treated with the active isomer beta-PDBu, but not with alpha-PDBu; this effect is blocked by the mitogen-activated protein kinase kinase-l (Mek1) inhibitor PD098059 and by the protein kinase C (PRC) antagonists GF109203X and rottlerin (selective for PKC-delta), but not Go 6976 (selective for Ca2+-dependent PRC isoforms), Rapamycin blocks the PDBu-induced accumulation of p21(cip1) (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation, If endothelial cells are recruited into the cell cycle by bFGF, p21(cip1) mRNA and protein levels rise initially (within 2 h) and decline subsequently such that p21(cip1) drops to a minimum prior to the initiation of DNA synthesis (i.e. after similar to 12 h). In bFGF-stimulated cells, changes in p21(cip1) mRNA and protein are strictly linked, In contrast, the levels of p21(cip1) mRNA decline substantially (>10 h) before the protein decreases in PDBu-stimulated cells, Thus, PKC (presumably PKC-delta) regulates the amounts of p21(cip1) in endothelial cells at the level of mRNA accumulation and translation, leading to a rapid and robust induction; following persistent PKC activation, p21(cip1) remains elevated despite reduced mRNA levels, indicating an enhanced stability of the protein, The bFGF-mediated increase in p21(cip1) is blocked by the Mek1 inhibitor, but not by GF109203X; hence, in endothelial cells, induction of p21(cip1) by PKC- and growth factor-dependent signaling is achieved by distinct pathways that converge and require activation of the mitogen-activated protein kinase cascade, The beta-PDBu-induced delayed S-phase entry and drop in p21(cip1) are reversed if GF109203X is added 4 h after beta-PDBu to prevent persistent PKC activation, These observations indicate a cause and effect relation between sustained p21(cip1) elevations and the delay in S-phase entry induced by beta-PDBu.	UNIV VIENNA,INST PHARMACOL,A-1090 VIENNA,AUSTRIA	University of Vienna			Sexl, Veronika/B-8657-2016	Sexl, Veronika/0000-0001-9363-0412; Freissmuth, Michael/0000-0001-9398-1765				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEFLORA S, 1991, MUTAT RES, V250, P87, DOI 10.1016/0027-5107(91)90165-K; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Frey MR, 1997, J BIOL CHEM, V272, P9424; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HALEVY O, 1995, SCIENCE, V267, P963; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JEOUNG DI, 1995, BIOCHEM BIOPH RES CO, V214, P361, DOI 10.1006/bbrc.1995.2296; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI Y, 1994, ONCOGENE, V9, P2261; LIU M, 1996, GENE DEV, V10, P42; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mancusi G, 1996, BIOCHEM J, V315, P281, DOI 10.1042/bj3150281; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOODIE SA, 1991, BRIT J PHARMACOL, V102, P101, DOI 10.1111/j.1476-5381.1991.tb12139.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHOU W, 1993, J BIOL CHEM, V268, P23041; ZHOU W, 1994, BIOCHEM BIOPH RES CO, V199, P191, DOI 10.1006/bbrc.1994.1213	46	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29967	29974		10.1074/jbc.272.47.29967	http://dx.doi.org/10.1074/jbc.272.47.29967			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368076	hybrid			2022-12-27	WOS:A1997YG64700086
J	Forman, MS; Cook, DG; Leight, S; Doms, RW; Lee, VMY				Forman, MS; Cook, DG; Leight, S; Doms, RW; Lee, VMY			Differential effects of the Swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SENILE PLAQUES; HIPPOCAMPAL-NEURONS; CLEAVAGE; MUTATION; PEPTIDE; RELEASE; APP; EXPRESSION; SYSTEM	Expression of the Swedish Delta NL mutation in the beta-amyloid precursor protein (APP Delta NL) dramatically increases A beta generation in nonneuronal cell. lines, although it is unclear whether intracellular levels of beta-amyloid (A beta) are also elevated after APP Delta NL expression. Furthermore, the effects of expressing APP Delta NL in neurons on the production and secretion of A beta-(1-40) and A beta-(1-42) are unknown. To address these issues, we examined the generation of both intracellular and secreted A beta-(1-40) and A beta-(1-42) in human neuronal NT2N cells, in primary rat astrocytes, and in Chinese hamster ovary cells engineered to express wild-type APP or APP Delta NL using a recombinant Semliki Forest virus expression system. Expression of APP Delta NL led to a marked increase in APP beta and the C-terminal fragment containing the entire A beta sequence (C99) in all cells tested. However, a dramatic elevation of intracellular and secreted A beta-(1-40) and A beta-(1-42) was seen only in astrocytes and Chinese hamster ovary cells. The Delta NL mutation did not cause a significant increase in intracellular or secreted A beta-(1-40) or A beta-(1-42) in NT2N cells. Since NT2N cells expressing APP Delta NL accumulate much higher levels of C99 than cells expressing wild-type APP, we conclude that the rate-limiting step in A beta production could be the further processing of C99 by gamma-secretase in these cells. These results show that the Swedish Delta NL mutation causes nonneuronal cells to process APP via pathways more in common with the metabolism of wild-type APP in neurons.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3400 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.				NIA NIH HHS [P01 AG11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011542] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS PW, 1984, LAB INVEST, V50, P147; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; CRAS P, 1990, AM J PATHOL, V137, P241; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Iizuka T, 1996, BIOCHEM BIOPH RES CO, V218, P238, DOI 10.1006/bbrc.1996.0042; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PROCTER AW, 1994, ACTA NEUROPATHOL, V88, P545; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1986, NEUROBIOL AGING, V7, P425, DOI 10.1016/0197-4580(86)90055-2; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Simons M, 1996, J NEUROSCI, V16, P899; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; TROJANOWSKI JQ, 1995, NEUROBIOL AGING, V16, P335, DOI 10.1016/0197-4580(94)00176-2; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113	51	51	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32247	32253		10.1074/jbc.272.51.32247	http://dx.doi.org/10.1074/jbc.272.51.32247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405428	hybrid			2022-12-27	WOS:000071108000047
J	Fukuta, M; Inazawa, J; Torii, T; Tsuzuki, K; Shimada, E; Habuchi, O				Fukuta, M; Inazawa, J; Torii, T; Tsuzuki, K; Shimada, E; Habuchi, O			Molecular cloning and characterization of human keratan sulfate Gal-6-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACULAR CORNEAL-DYSTROPHY; CHONDROITIN 6-SULFOTRANSFERASE; ALZHEIMERS-DISEASE; PROTEOGLYCAN; EXPRESSION; PROTEIN; SV2; GLYCOSAMINOGLYCANS; SULFOTRANSFERASE; BIOSYNTHESIS	We have previously cloned chondroitin 6-sulfotransferase (C6ST) cDNA from chick embryo chondrocytes. C6ST catalyzes sulfation of chondroitin, keratan sulfate, and sialyl N-acetyllactosamine oligosaccharides. In this study, we report the cloning and characterization of a novel sulfotransferase that catalyzes sulfation of keratan sulfate, This new sulfotransferase cDNA clone was obtained from a human fetal brain library by cross-hybridization with chick C6ST cDNA. The cDNA clone obtained contains a single open reading frame that predicts a type II transmembrane protein composed of 411 amino acid residues, When the cDNA was introduced into a eukaryotic expression vector and transfected in COS-7 cells, keratan sulfate sulfotransferase activity was overexpressed, but C6ST activity was not increased over that of the control. Structural analysis of S-35-labeled glycosaminoglycan, which was formed from keratan sulfate by the reaction with S-35-labeled 3'-phosphoadenosine 5'-phosphosulfate and the recombinant sulfotransferase, showed that keratan sulfate was sulfated at position 6 of Gal residues, On the basis of the acceptor substrate specificity, we propose keratan sulfate Gal-6-sulfotransferase (KSGal6ST) for the name of the newly cloned sulfotransferase. KSGal6ST was assigned to chromosome 11p11.1-11.2 by fluorescence in situ hybridization. Among various human adult tissues, a 2.8-kilobase message of KSGal6ST was expressed mainly in the brain. When poly(A)(+) RNAs from the chick embryo cornea and brain were probed with the human KSGal6ST cDNA in Northern hybridization, a clear band with about 2.8 kilobases was detected. These observations suggest that KSGal6ST may participate in the biosynthesis of keratan sulfate in the brain and cornea.	Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 448, Japan; Univ Tokyo, Inst Med Sci, Lab Genome Med, Minato Ku, Tokyo 108, Japan	Aichi University Education; University of Tokyo	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Life Sci, Kariya, Aichi 448, Japan.							ARUFFO A, 1991, CURRENT PROTOCOL M S, V17; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chiba A, 1997, J BIOL CHEM, V272, P2156; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 1997, GLYCOBIOLOGY, V7, P405, DOI 10.1093/glycob/7.3.405; HART GW, 1976, J BIOL CHEM, V251, P6513; HASHIMOTO N, 1990, 15 INT CARB S YOK JA, P271; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lindahl B, 1996, J BIOL CHEM, V271, P16991, DOI 10.1074/jbc.271.29.16991; MIDURA RJ, 1990, J BIOL CHEM, V265, P15947; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NAKAZAWA K, 1995, J BIOCHEM-TOKYO, V117, P707, DOI 10.1093/oxfordjournals.jbchem.a124767; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; QUANTOCK AJ, 1994, GLYCOSYLATION DIS, V1, P143; RAUCH U, 1991, J BIOL CHEM, V266, P1785; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; WIGHT TN, 1993, CELL BIOL EXTRACELLU, P45; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	118	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32321	32328		10.1074/jbc.272.51.32321	http://dx.doi.org/10.1074/jbc.272.51.32321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405439	hybrid			2022-12-27	WOS:000071108000058
J	Kudlicki, W; Coffman, A; Kramer, G; Hardesty, B				Kudlicki, W; Coffman, A; Kramer, G; Hardesty, B			Renaturation of rhodanese by translational elongation factor (EF) Tu - Protein refolding by EF-Tu flexing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; ESCHERICHIA-COLI; FACTOR EF-1-ALPHA; KIRROMYCIN; RIBOSOMES; GTP; RNA	The translation elongation factor (EF) Tu has chaperone-like capacity to promote renaturation of denatured rhodanese. This renaturation activity is greatly increased under conditions in which the factor can oscillate between the open and closed conformations that are induced by GDP and GTP, respectively, Oscillation occurs during GTP hydrolysis and subsequent replacement of GDP by EF-Ts which is then displaced by GTP, Renaturation of rhodanese and GTP hydrolysis by EF-Tu are greatly enhanced by the guanine nucleotide exchange factor EF-Ts, However, renaturation is reduced under conditions that stabilize EF-Tu in either the open or closed conformation, Both GDP and the nonhydrolyzable analog of GTP, GMP-PCP, inhibit renaturation. Kirromycin and pulvomycin, antibiotics that specifically bind to EF-Tu and inhibit its activity in peptide elongation, also strongly inhibit EF-Tu-mediated renaturation of denatured rhodanese to levels near those observed for spontaneous, unassisted refolding, Kirromycin locks EF-Tu in the open conformation in the presence of either GTP or GDP, whereas pulvomycin locks the factor in the closed conformation, The results lead to the conclusion that flexing of EF-Tu, especially as occurs between its open and closed conformations, is a major factor in its chaperone-like refolding activity.	Univ Texas, Inst Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hardesty, B (corresponding author), Univ Texas, Inst Mol Biol, Austin, TX 78712 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; AN G, 1981, NUCLEIC ACIDS RES, V9, P4163, DOI 10.1093/nar/9.16.4163; BOCCHINI V, 1980, EUR J BIOCHEM, V113, P53; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; Gonen H, 1996, ADV EXP MED BIOL, V389, P209; HOROWITZ P, 1997, STRUCTURE FUNCTION M, P275; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JARABAK R, 1993, J BIOCHEM TOXICOL, V8, P41, DOI 10.1002/jbt.2570080107; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kraal B, 1995, BIOCHEM CELL BIOL, V73, P1167, DOI 10.1139/o95-126; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P29, DOI 10.1016/0003-2697(80)90272-9; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1994, J PROTEIN CHEM, V13, P15, DOI 10.1007/BF01891988; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; NEIDHARDT F, 1996, ESCHERICHIA COLI SAL, P1562; PARMEGGIANI A, 1985, ANNU REV MICROBIOL, V39, P557, DOI 10.1146/annurev.mi.39.100185.003013; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1988, BIOCHIM BIOPHYS ACTA, V955, P19, DOI 10.1016/0167-4838(88)90175-6; WOLF H, 1978, P NATL ACAD SCI USA, V75, P5324, DOI 10.1073/pnas.75.11.5324; ZARDENETA G, 1992, EUR J BIOCHEM, V210, P831, DOI 10.1111/j.1432-1033.1992.tb17486.x	25	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32206	32210		10.1074/jbc.272.51.32206	http://dx.doi.org/10.1074/jbc.272.51.32206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405422	hybrid			2022-12-27	WOS:000071108000041
J	Blackshear, PJ; Stumpo, DJ; Carballo, E; Lawrence, JC				Blackshear, PJ; Stumpo, DJ; Carballo, E; Lawrence, JC			Disruption of the gene encoding the mitogen-regulated translational modulator PHAS-I in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; 3T3-L1 ADIPOCYTES; INITIATION FACTOR-4E; CELL-GROWTH; INSULIN; PHOSPHORYLATION; KINASE; EIF-4E	PHAS-I is the prototype of a group of eIF4E-binding proteins that can regulate mRNA translation in response to hormones and growth factors. To investigate the importance of PHAS-I in the physiology of the intact animal, we disrupted the PHAS-I gene in mice. Tissues and cells derived from the knockout mice contained no detectable PHAS-I protein. A related protein, PHAS-II, and eIF4E were readily detectable in tissues from these animals, but neither appeared to be changed in a compensatory manner. Mice lacking PHAS-I appeared normal at birth, However, male knockout mice weighed approximately 10% less than controls at all ages, whereas female weights were similar to those of controls. Both males and females were fertile. Tissues from adult animals appeared to be normal by routine histological staining techniques, as were routine blood cell counts and chemistries. Fibroblasts derived from PHAS-I-deficient mouse embryos exhibited normal rates of growth and overall protein synthesis, responded normally to serum stimulation of ornithine decarboxylase activity and cell growth, and rapamycin inhibition of cell growth. Under these experimental conditions, PHAS-I is apparently not required for the normal development and reproductive behavior of female mice, but is required for normal body weight in male mice; the mechanisms responsible for this phenotype remain to be determined.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DIV METAB ENDOCRINOL & NUTR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SECT DIABET & METAB, DURHAM, NC 27710 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA 22908 USA	Duke University; Duke University; Duke University; Duke University; University of Virginia; University of Virginia			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [DK 50628, DK 28302] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DENTON RM, 1981, DIABETOLOGIA, V21, P347; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Lawrence John C. Jr.., 1997, V37, P239; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rousseau D, 1996, ONCOGENE, V13, P2415; SHATKIN AJ, 1987, BIOESSAYS, V7, P275, DOI 10.1002/bies.950070611; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARNER LM, 1994, ARTHRITIS RHEUM, V37, P289, DOI 10.1002/art.1780370219	32	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31510	31514		10.1074/jbc.272.50.31510	http://dx.doi.org/10.1074/jbc.272.50.31510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395487	hybrid			2022-12-27	WOS:A1997YL41900046
J	DeMar, JC; Anderson, RE				DeMar, JC; Anderson, RE			Identification and quantitation of the fatty acids composing the CoA ester pool of bovine retina, heart, and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-N-MYRISTOYLTRANSFERASE; ACYL-COENZYME-A; HUMAN MYRISTOYL-COA; PERFORMANCE LIQUID-CHROMATOGRAPHY; NH2-TERMINAL BLOCKING GROUP; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; ACYLATION; TISSUE; BRAIN	Several proteins found in retinal photoreceptor cells (guanylate cyclase activating protein, protein kinase A, recoverin, and transducin) are N-terminally modified with the fatty acids 12:0, 14:0, 14:1n-9, and 14:2n-6, whereas similar proteins in other tissues contain only 14:0. It has been hypothesized that the acyl-CoA pool of the retina contains amounts of 12:0, 14:1n-9, and 14:2n-6 elevated over 14:0, in comparison to other tissues, and this accounts for the specificity of N-terminal fatty acylation. To test this hypothesis, we performed fatty acid analysis on total acyl-CoAs purified from bovine retina (light-adapted), heart, and liver. We also examined the N- and S-linked fatty acid composition of the total protein pools from these tissues. Acyl-CoAs were prepared from heart, liver, and retina and separated by high performance Liquid chromatography (HPLC), Identities of peaks were based on HPLC of standard 12:0, 14:0, 14: 1n-9, and 14:2n-6 CoAs. Total protein was subjected to base hydrolysis followed by acidic methanolysis to release S- and N-linked fatty acids, respectively, and fatty acid phenacyl esters were prepared for HPLC analysis. Retina had levels of 12:0 (2.7 +/- 2.1%), 14:1n-9 (2.9 +/- 2.2%), and 14:2n-6 (1.6 +/- 0.7%) CoAs below that of 14:0 CoA (7.0 +/- 1.8%). Likewise, heart levels of 14:2n-6 CoA (3.7 +/- 0.1%) were near and 12:0 (2.6 +/- 0.6%) and 14:1n-9 (0.7 +/- 0.3%) CoAs were below that of 14:0 CoA (3.8 +/- 1.0%). Liver had levels of 12:0 (16.1 +/- 5.7%) and 14:2n-6 (8.1 +/- 1.2%) CoAs above and 14:1n-9 CoA (1.2 +/- 0.6%) below that of 14:0 CoA (5.9 +/- 0.8%). Fatty acid analysis of total protein showed that all tissues contained S-linked 16:0, 18:0, and 18:1n-9. Retina proteins contained N-linked 14:0, 14:1n-9, and 14:2n-6, whereas heart and liver had only 14:0. Our findings do not support the hypothesis that the CoA ester pool of the retina is enriched with 12:0, 14:1n-9, and 14:2n-6 over 14:0, in comparison to other tissues. This suggests that alternative models must be considered for the regulation of N-terminal fatty acylation of proteins in photoreceptor cells.	DEAN A MCGEE EYE INST, OKLAHOMA CITY, OK 73104 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; UNIV OKLAHOMA, HLTH SCI CTR, OKLAHOMA CTR NEUROSCI, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT OPHTHALMOL & BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MOL BIOL, OKLAHOMA CITY, OK 73104 USA	Baylor College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NEI NIH HHS [EY04149, EY07001, EY00871] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004149, R01EY000871] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGER M, 1984, J BIOL CHEM, V259, P7245; Bhatnagar RS, 1997, BIOCHEMISTRY-US, V36, P6700, DOI 10.1021/bi970311v; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1981, ANAL BIOCHEM, V118, P30, DOI 10.1016/0003-2697(81)90152-4; DeMar JC, 1996, J BIOL CHEM, V271, P5007; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Faergeman NJ, 1997, BIOCHEM J, V323, P1; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JI, 1990, CLIN RES, V38, P517; HAJRA AK, 1986, METHOD ENZYMOL, V122, P50; HALLAK H, 1994, J BIOL CHEM, V269, P4713; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KING MJ, 1994, MOL CELL BIOCHEM, V141, P79, DOI 10.1007/BF00926170; KING MJ, 1995, BIOCHEM BIOPH RES CO, V212, P580, DOI 10.1006/bbrc.1995.2009; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1995, BIOCHEM SOC T, V23, P549, DOI 10.1042/bst0230549; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; MOLAPARASTSALESS F, 1988, LIPIDS, V23, P490, DOI 10.1007/BF02535525; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OZOLS J, 1984, J BIOL CHEM, V259, P3349; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; POWELL GL, 1985, FED PROC, V44, P81; RAJALA RVS, 1995, BIOCHEM BIOPH RES CO, V208, P617, DOI 10.1006/bbrc.1995.1383; RAJU RVS, 1995, MOL CELL BIOCHEM, V149, P191, DOI 10.1007/BF01076577; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; REDDY TS, 1984, CURR EYE RES, V3, P1225, DOI 10.3109/02713688409000826; REDDY TS, 1985, EXP EYE RES, V41, P87, DOI 10.1016/0014-4835(85)90097-1; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROSENDAL J, 1992, ANAL BIOCHEM, V207, P63, DOI 10.1016/0003-2697(92)90500-7; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1992, BIOCHEMISTRY-US, V89, P10507; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; TARDI PG, 1992, LIPIDS, V27, P65, DOI 10.1007/BF02537062; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2	51	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31362	31368		10.1074/jbc.272.50.31362	http://dx.doi.org/10.1074/jbc.272.50.31362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395466	hybrid			2022-12-27	WOS:A1997YL41900025
J	Durbin, DM; Jonas, A				Durbin, DM; Jonas, A			The effect of apolipoprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; ACTIVATION; BINDING; HDL; ATHEROSCLEROSIS; KINETICS; CHOLATE	In this study we examined the effects of apoA-II on the structure and function of apoA-I in homogeneous reconstituted HDL (rHDL), First, we measured the binding of apoA-II to apoA-I-rHDL, containing dipalmitoylphosphatidylcholine or palmitoyloleoylphosphatidylcholine, and the degree of apoA-I displacement at various ratios of apolipoproteins. Using fluorescence methods, we determined that apoA-II binding is rapid, irreversible, and associated with apoA-I displacement only when the molar ratio of apoA-II/apoA-I is greater than 1:2, Next, we used the stable apoA-II/apoA-I-rHDL complex at the apoA-II/apoA-I ratio of 1:2 to examine its physical properties, apoA-I structure, and reactivity with lecithin: cholesterol acyltransferase (LCAT), Using chemical cross-linking in conjunction with fluorescence and electrophoretic methods, we demonstrated that the conformation of apoA-I must be flexible to allow apoA-II binding to the apoA-I-rHDL particles and showed that the hybrid particles have an unchanged Stokes diameter, Fluorescence and circular dichroism measurements revealed little or no change in the secondary structure or in the N-terminal domain of apoA-I, but showed a marked destabilization of apoA-I to denaturation by guanidine hydrochloride, Limited tryptic digestion indicated that the central region of apoA-I becomes accessible to proteolysis in the hybrid particles, Together, these results suggest that amphipathic alpha-helices of apoA-II replace four central helices of one apoA-I molecule (residues similar to 99-187) in the complex and in the process destabilize apoA-I, Thus, apoA-II binding at physiologic ratios may not completely displace apoA-I from HDL, but may provide a reservoir of easily exchangeable apoA-I, Finally, we showed that the reaction of the hybrid HDL with LCAT was inhibited 2-5-fold, relative to apoA-I-rHDL, due to a corresponding increase in the apparent K-m value. This suggests that LCAT binding to the hybrid particles is sterically hindered by the excess protein (portions of apoA-I and apoA-II not bound to lipid), Therefore, apoA-II can modulate the reaction of HDL with LCAT by decreasing LCAT binding to hybrid particles and making the enzyme available for reaction with other substrates.	UNIV ILLINOIS, COLL MED, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL 16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANCHE PJ, 1988, BIOCHIM BIOPHYS ACTA, V958, P143, DOI 10.1016/0005-2760(88)90171-3; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CHEN TC, 1979, BIOCHEMISTRY-US, V18, P1617, DOI 10.1021/bi00575a037; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; EDELSTEIN C, 1982, J BIOL CHEM, V257, P7189; FIELDING CJ, 1995, J LIPID RES, V36, P211; FORTE TM, 1995, J LIPID RES, V36, P148; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JONAS A, 1985, J BIOL CHEM, V260, P2757; JONAS A, 1987, J BIOL CHEM, V262, P3969; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Jonas A., 1992, STRUCTURE FUNCTION A, P217; Leren TP, 1997, J LIPID RES, V38, P121; LEROY A, 1993, J BIOL CHEM, V268, P4798; LEROY A, 1994, BIOCHIM BIOPHYS ACTA, V1213, P285; MAO SJT, 1977, BIOCHEMISTRY-US, V16, P4150, DOI 10.1021/bi00638a003; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1981, BIOCHEMISTRY-US, V20, P1569, DOI 10.1021/bi00509a025; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Mowri HO, 1996, ARTERIOSCL THROM VAS, V16, P755, DOI 10.1161/01.ATV.16.6.755; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; POWNALL HJ, 1992, STRUCTURE FUNCTION A, P1; Pussinen PJ, 1997, J LIPID RES, V38, P12; RAY E, 1980, BIOCHIM BIOPHYS ACTA, V617, P318, DOI 10.1016/0005-2760(80)90174-5; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; VANTORNOUT P, 1981, BIOCHIM BIOPHYS ACTA, V663, P630, DOI 10.1016/0005-2760(81)90073-4; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WEBER G, 1953, DISCUSS FARADAY SOC, P33; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	41	57	65	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31333	31339		10.1074/jbc.272.50.31333	http://dx.doi.org/10.1074/jbc.272.50.31333			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395462	hybrid			2022-12-27	WOS:A1997YL41900021
J	Laufs, U; LaFata, V; Liao, JK				Laufs, U; LaFata, V; Liao, JK			Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; PULMONARY-HYPERTENSION; CHOLESTEROL REDUCTION; MEVALONATE PATHWAY; MESSENGER-RNA; EXPRESSION; DECREASES; BENEFITS; THERAPY; RATS	Hypoxia induces vasoconstriction, in part, by down-regulating endothelial cell nitric oxide synthase (ecNOS) expression, Previous studies indicate that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors improve endothelium-dependent relaxation by increasing ecNOS activity, To determine whether HMG CoA reductase inhibitors can prevent hypoxia-mediated down-regulation of ecNOS function and expression, human endothelial cells were exposed to hypoxia (3% O-2) in the presence of HMG CoA reductase inhibitors simvastatin and lovastatin for various durations (0-48 h). Hypoxia decreased ecNOS protein and mRNA levels in a time-dependent manner, resulting in a 4- and 9-fold reduction after 48 h, respectively, In a concentration-dependent manner, simvastatin, and to a lesser extent, lovastatin, prevented the down-regulation of ecNOS expression by hypoxia, Simvastatin-induced changes in ecNOS expression correlated with changes in endothelial NO production and were reversed by treatment with L-mevalonate, Actinomycin D studies revealed that under hypoxic conditions, simvastatin increased ecNOS mRNA half-life from 13 to 38 h. Nuclear run-on studies showed that simvastatin had no effect on repression of ecNOS gene transcription by hypoxia. These results indicate that HMG CoA reductase inhibitors regulate ecNOS function and expression through changes in ecNOS mRNA stability and suggest that treatment with HMG CoA reductase inhibitors may have beneficial effects in patients with hypoxia-mediated pulmonary hypertension.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Andrews TC, 1997, CIRCULATION, V95, P324; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; GERSON RJ, 1989, AM J MED, V87, pS28, DOI 10.1016/S0002-9343(89)80596-0; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; LeCras TD, 1996, AM J PHYSIOL-LUNG C, V270, pL164, DOI 10.1152/ajplung.1996.270.1.L164; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LUI J, 1996, BIOCHEMISTRY-US, V35, P13277; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; RASBAND W, 1993, NIH IMAGE PROGRAM VE; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Shaul PW, 1997, AM J PHYSIOL-LUNG C, V272, pL1005, DOI 10.1152/ajplung.1997.272.5.L1005; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Takimoto M, 1996, ENDOCRINOLOGY, V137, P4542, DOI 10.1210/en.137.11.4542; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; vanVliet AK, 1996, BIOCHEM PHARMACOL, V52, P1387, DOI 10.1016/S0006-2952(96)00467-4; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	34	335	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31725	31729		10.1074/jbc.272.50.31725	http://dx.doi.org/10.1074/jbc.272.50.31725			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395516	hybrid			2022-12-27	WOS:A1997YL41900075
J	Palmieri, G; Giardina, P; Bianco, C; Scaloni, A; Capasso, A; Sannia, G				Palmieri, G; Giardina, P; Bianco, C; Scaloni, A; Capasso, A; Sannia, G			A novel white laccase from Pleurotus ostreatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN BIODEGRADATION; STRUCTURAL-ANALYSIS; GENE; OXIDASE; APPLICABILITY; DEGRADATION; CLEAVAGE; ENZYMES; CLONING; SYSTEM	Two laccase isoenzymes (POXA1 and POXA2) produced by Pleurotus ostreatus were purified and fully characterized, POXA1 and POXA2 are monomeric glycoproteins with 3 and 9% carbohydrate content, molecular masses of about 61 and 67 kDa by sodium dodecyl sulfate polyacrylamide gel electrophoresis, of about 54 and 59 kDa by gel filtration in native conditions, and of 61 kDa by matrix-assisted laser desorption ionization mass spectrometry (only for POXA1) and pI values of 6.7 and 4.0, respectively, The N terminus and three tryptic peptides of POXA1 have been sequenced, revealing clear homology with laccases from other microorganisms, whereas POXA2 showed a blocked N terminus, The stability of POXA2 as a function of temperature was particularly low, whereas POXA1 showed remarkable high stability with respect to both pH and temperature. Both enzymes oxidize syringaldazine and ABTS (2, 2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) together with a variety of different substituted phenols and aromatic amines with the concomitant reduction of oxygen, but POXA1 is unable to oxidize guaiacol, Both enzymes were strongly inhibited by sodium azide and thioglycolic acid but not by EDTA. UV/visible absorption spectra, atomic adsorption, and polarographic data indicated the presence of 4 copper atoms/mol of POXA2 but only one copper, two zinc, and one iron atoms were found/mol of POXA1. The neutral pI and the anomalous metal content of POXA1 laccase render this enzyme unique in its structural characteristics. The lack of typical absorbance at 600 nm allows its classification as a ''white'' laccase.	UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; IABBAM CONSIGLIO NAZL RIC,I-80147 NAPLES,ITALY; IBPE,I-80125 NAPLES,ITALY	University of Naples Federico II			Bianco, Carmelina/HHC-1591-2022; Palmieri, Gianna/S-4872-2017; Giardina, Paola/F-4130-2011; Palmieri, Gianna/AAW-6176-2020	Bianco, Carmelina/0000-0002-8489-3779; Giardina, Paola/0000-0002-5446-8130; Palmieri, Gianna/0000-0002-9007-4075; Scaloni, Andrea/0000-0001-9362-8515; SANNIA, Giovanni/0000-0002-7986-6223				BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; COHEN HJ, 1973, ANAL BIOCHEM, V53, P208, DOI 10.1016/0003-2697(73)90423-5; COLL PM, 1993, APPL ENVIRON MICROB, V59, P4129, DOI 10.1128/AEM.59.12.4129-4135.1993; Eggert C, 1996, APPL ENVIRON MICROB, V62, P1151, DOI 10.1128/AEM.62.4.1151-1158.1996; FLING M, 1963, J BIOL CHEM, V238, P2045; FUKUSHIMA Y, 1995, APPL ENVIRON MICROB, V61, P872, DOI 10.1128/AEM.61.3.872-876.1995; GIARDINA P, 1995, APPL ENVIRON MICROB, V61, P2408, DOI 10.1128/AEM.61.6.2408-2413.1995; Giardina P, 1996, EUR J BIOCHEM, V235, P508, DOI 10.1111/j.1432-1033.1996.00508.x; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; JONSSON L, 1995, BBA-PROTEIN STRUCT M, V1251, P210, DOI 10.1016/0167-4838(95)00104-3; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KOJIMA Y, 1990, J BIOL CHEM, V265, P15224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARZULLO L, 1995, J BIOL CHEM, V270, P3823, DOI 10.1074/jbc.270.8.3823; PALMIERI G, 1993, APPL MICROBIOL BIOT, V39, P632, DOI 10.1007/BF00205066; PERRY CR, 1993, J GEN MICROBIOL, V139, P1209, DOI 10.1099/00221287-139-6-1209; REINHAMMAR B, 1981, METAL IONS BIOL COPP, V3, P109; SALAS C, 1995, BIOTECHNOL APPL BIOC, V21, P323; SALOHEIMO M, 1991, J GEN MICROBIOL, V137, P1537, DOI 10.1099/00221287-137-7-1537; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; WOJTASWASILEWSKA M, 1983, ACTA BIOCHIM POL, V30, P291; YAROPOLOV AI, 1994, APPL BIOCHEM BIOTECH, V49, P257, DOI 10.1007/BF02783061	24	260	280	1	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31301	31307		10.1074/jbc.272.50.31301	http://dx.doi.org/10.1074/jbc.272.50.31301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395457	hybrid			2022-12-27	WOS:A1997YL41900016
J	Watson, DJ; Lander, AD; Selkoe, DJ				Watson, DJ; Lander, AD; Selkoe, DJ			Heparin-binding properties of the amyloidogenic peptides A beta and amylin - Dependence on aggregation state and inhibition by Congo red	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; ALZHEIMERS-DISEASE; SULFATE PROTEOGLYCAN; FIBRIL FORMATION; SENILE PLAQUES; CIRCULAR-DICHROISM; BASEMENT-MEMBRANE; PRECURSOR PROTEIN; DIABETES-MELLITUS; APOLIPOPROTEIN-E	Aggregation and deposition of the 40-42-residue amyloid beta-protein (A beta) are early and necessary neuropathological events in Alzheimer's disease. An understanding of the molecular interactions that trigger these events is important for therapeutic strategies aimed at blocking A beta plaque formation at the earliest stages. Heparan sulfate proteoglycans may play a fundamental role since they are invariably associated with A beta and other amyloid deposits at all stages. However, the nature of the A beta-heparan sulfate proteoglycan binding has been difficult to elucidate because of the strong tendency of A beta to self-aggregate. Affinity co-electrophoresis can measure the binding of proteoglycans or glycosaminoglycans to proteins without altering the physical state of the protein during the assay. We used affinity co-electrophoresis to study the interaction between A beta and the glycosaminoglycan heparin and found that the aggregation state of A beta governs its heparin-binding properties: heparin binds to fibrillar but not nonfibrillar A beta. The amyloid binding dye, Congo red, inhibited the interaction in a specific and dose-dependent manner. The ''Dutch'' mutant A beta(E22Q) peptide formed fibrils more readily than wild type A beta and it also attained a heparin-binding state more readily, but, once formed, mutant and wild type fibrils bound heparin with similar affinities. The heparin-binding ability of aggregated A beta(E22Q) was reversible with incubation in a solvent that promotes alpha-helical conformation, further suggesting that conformation of the peptide is important. Studies with another human amyloidogenic protein, amylin, suggested that its heparin-binding properties were also dependent on aggregation state. These results demonstrate the dependence of the A beta-heparin interaction on the conformation and aggregation state of A beta rather than primary sequence alone, and suggest methods of interfering with this association.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92697	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California Irvine; University of California System; University of California Irvine	Watson, DJ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,INST MED,CTR NEUROL DIS,77 AVE LOUIS PASTEUR 740,BOSTON,MA 02115, USA.		Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525	NIA NIH HHS [AG 06173, AG 12749] Funding Source: Medline; NINDS NIH HHS [NS 26862] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006173, R37AG006173, RF1AG006173, R01AG012749] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V627, P199, DOI 10.1016/0006-8993(93)90321-D; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; CORIA F, 1988, LAB INVEST, V58, P454; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; FABIAN H, 1993, BIOCHEM BIOPH RES CO, V191, P232, DOI 10.1006/bbrc.1993.1207; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HERNDON ME, 1997, IN PRESS LAB GUIDE G; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LIM WA, 1991, METHOD ENZYMOL, V208, P196; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LUYENDIJK W, 1988, J NEUROL SCI, V85, P267, DOI 10.1016/0022-510X(88)90186-4; MANN DMA, 1989, NEUROPATH APPL NEURO, V15, P317, DOI 10.1111/j.1365-2990.1989.tb01232.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MERZ PA, 1983, ACTA NEUROPATHOL, V60, P113, DOI 10.1007/BF00685355; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NARANG HK, 1980, J NEUROPATH EXP NEUR, V39, P621, DOI 10.1097/00005072-198011000-00001; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROBER A, 1986, P NATL ACAD SCI USA, V83, P2662; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SNOW AD, 1994, AM J PATHOL, V144, P337; SNOW AD, 1995, ARCH BIOCHEM BIOPHYS, V320, P84, DOI 10.1006/abbi.1995.1345; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SNOW AD, 1988, AM J PATHOL, V133, P456; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249; Yan G. M., 1996, Neurobiology of Aging, V17, pS109, DOI 10.1016/S0197-4580(96)80439-8; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951	52	123	127	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31617	31624		10.1074/jbc.272.50.31617	http://dx.doi.org/10.1074/jbc.272.50.31617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395501	hybrid			2022-12-27	WOS:A1997YL41900060
J	Chang, XB; Hou, YX; Riordan, JR				Chang, XB; Hou, YX; Riordan, JR			ATPase activity of purified multidrug resistance-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; HUMAN P-GLYCOPROTEIN; CARCINOMA CELL-LINE; HAMSTER OVARY CELLS; HUMAN TUMOR-CELLS; LUNG-CANCER; LEUKOTRIENE C-4; MEMBRANE-VESICLES; DRUG-EFFLUX; MRP	Human multidrug resistance protein (MRP) was expressed at high levels in stably transfected baby hamster kidney (BHK-21) cells. These cells exhibited a pattern of cross-resistance to several different drugs typical of an MRP-mediated phenotype despite the addition of 10 histidine residues at the C terminus to facilitate purification, Consistent with this functional evidence of the presence of MRP at the surface of these transfectants, strong signals were detected by immunoblotting and immunofluorescence using a specific monoclonal antibody to MRP. There was intense uniform staining of the cell surface as well as weaker staining of intracellular membranes. MRP containing membranes were solubilized in 1% N-dodecyl-beta-D-maltoside in the presence of 0.4% sheep brain phospholipids. Two sequential affinity purification steps on Ni-NTA agarose and wheat germ agglutinin agarose provided substantial enrichment, and contaminating bands were not de detected. ATPase activity of the purified protein was assayed in the presence of the phospholipids, which had been maintained throughout all purification steps. ATP was hydrolyzed in proportion to the amount of purified protein assayed, and typical Michaelis-Menten behavior was exhibited, yielding estimations of K-m, of similar to 3.0 mM and V-max,,, of 0.46 mu mol mg(-1) min(-1). This activity was moderately stimulated by the drugs that others have shown to be transported by MRP-containing membrane vesicles. This stimulation was enhanced by reduced glutathione as is its drug transport, and oxidized glutathione, itself a substrate for transport, caused a strong stimulation. These data describe the first purification of MRP and provide the first direct evidence that the molecule possesses drug-stimulated ATPase activity.	Mayo Clin Arizona, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin Arizona, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.							ALMQUIST KC, 1995, CANCER RES, V55, P102; AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; BREUNINGER LM, 1995, CANCER RES, V55, P5342; CHANG XB, 1993, J BIOL CHEM, V268, P11304; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1990, CANCER CHEMOTH PHARM, V26, P250, DOI 10.1007/BF02897225; EIJDEMS EWHM, 1995, BRIT J CANCER, V72, P298, DOI 10.1038/bjc.1995.328; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GIBSON SL, 1995, PHOTOCHEM PHOTOBIOL, V61, P390, DOI 10.1111/j.1751-1097.1995.tb08628.x; GRANT CE, 1994, CANCER RES, V54, P357; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; Jedlitschky G, 1996, CANCER RES, V56, P988; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MA LD, 1995, BIOCHEMISTRY-US, V34, P3338, DOI 10.1021/bi00010a024; MCGRATH T, 1987, BIOCHEM BIOPH RES CO, V145, P1171, DOI 10.1016/0006-291X(87)91560-9; MILROY R, 1992, ANTICANCER RES, V12, P193; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Muller M, 1996, SEMIN LIVER DIS, V16, P211, DOI 10.1055/s-2007-1007233; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Paul S, 1996, P NATL ACAD SCI USA, V93, P6929, DOI 10.1073/pnas.93.14.6929; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHLAIFER D, 1990, BRIT J CANCER, V62, P177, DOI 10.1038/bjc.1990.256; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Stride BD, 1996, MOL PHARMACOL, V49, P962; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	45	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30962	30968		10.1074/jbc.272.49.30962	http://dx.doi.org/10.1074/jbc.272.49.30962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388243	hybrid			2022-12-27	WOS:000071640800056
J	Dufourny, B; Alblas, J; van Teeffelen, HAAM; van Schaik, FMA; van der Burg, B; Steenbergh, PH; Sussenbach, JS				Dufourny, B; Alblas, J; van Teeffelen, HAAM; van Schaik, FMA; van der Burg, B; Steenbergh, PH; Sussenbach, JS			Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; S6 KINASE; KERATINOCYTE DIFFERENTIATION; P21(WAF1/CIP1) EXPRESSION; CARCINOMA-CELLS; INTACT-CELLS; INHIBITION; RECEPTOR; PATHWAYS; STIMULATION	Addition of insulin-like growth factor I (IGF-I) to quiescent breast tumor-derived MCF-7 cells causes stimulation of cyclin D1 synthesis, hyperphosphorylation of the retinoblastoma protein pRb, DNA synthesis, and cell division. All of these effects are independent of the mitogen-activated protein kinase (MAPK) pathway since none of them is blocked by PD098059, the specific inhibitor of the MAPK activating kinase MEK1, This observation is consistent with the finding that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a strong inducer of MAPK activity in MCF-7 cells, effectively inhibits proliferation, The anti-proliferative effect of TPA in these cells may be accounted for, at least in part, by the MAPK-dependent stimulation of the synthesis of p21(WAF1/CIP1), inhibitor of cyclin/cyclin-dependent kinase complexes. In contrast, all of the observed stimulatory effects of IGF-I on cell cycle progression, cyclin D1 synthesis, and pRb hyperphosphorylation were blocked by the specific phosphatidylinositol 3-kinase inhibitor LY294002, suggesting that phosphatidylinositol 3-kinase activity but not MAPK activity is required for transduction of the mitogenic IGF-I signal in MCF-7 cells.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Utrecht Grad Sch Dev Biol, Utrecht, Netherlands	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University	Dufourny, B (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80043, NL-3508 TA Utrecht, Netherlands.			Alblas, Jacqueline/0000-0002-2996-9697				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBLAS J, 1997, IN PRESS ONCOGENE; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COPPOCK DL, 1995, EXP CELL RES, V221, P92, DOI 10.1006/excr.1995.1356; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HUFF KK, 1986, CANCER RES, V46, P4613; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JONES KT, 1994, J CELL PHYSIOL, V159, P324, DOI 10.1002/jcp.1041590215; KAREY KP, 1988, CANCER RES, V48, P4083; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENNEDY MJ, 1992, CANCER RES, V52, P1278; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu Y, 1996, CANCER RES, V56, P31; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MENAPACE L, 1987, BIOCHEM BIOPH RES CO, V148, P1295, DOI 10.1016/S0006-291X(87)80274-7; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OSAWA Y, 1995, BIOCHEM BIOPH RES CO, V216, P429, DOI 10.1006/bbrc.1995.2641; Parrizas M, 1997, J BIOL CHEM, V272, P154; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Takahashi Y, 1997, ENDOCRINOLOGY, V138, P741, DOI 10.1210/en.138.2.741; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VALETTE A, 1987, CANCER RES, V47, P1615; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WINKELSTEIN A, 1986, EXP HEMATOL, V14, P1023; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	59	231	245	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31163	31171		10.1074/jbc.272.49.31163	http://dx.doi.org/10.1074/jbc.272.49.31163			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388270	hybrid			2022-12-27	WOS:000071640800083
J	Suda, SA; Dolmer, K; Gettins, PGW				Suda, SA; Dolmer, K; Gettins, PGW			Critical role of asparagine 1065 of human alpha(2)-macroglobulin in formation and reactivity of the thiol ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT COMPONENT-C4; THIOESTER BOND FORMATION; HUMAN ALPHA-2-MACROGLOBULIN; ALPHA-MACROGLOBULIN; INTERNAL THIOESTER; BINDING-PROPERTIES; MOLECULAR-CLONING; MESSENGER-RNA; CDNA; SEQUENCE	It has been shown that the relative reaction preference of the C4 thiol ester toward oxygen and nitrogen nucleophiles upon activation by proteinase depends on whether residue 1106 is aspartate or histidine (Dodds, A. W,, Ren, X. D., Willis, A. C., and Law, S, K, A. (1996) Nature 379, 177-179), To determine if the equivalent residue in the related thiol ester-containing protein human alpha(2)-macroglobulin (alpha(2)M), asparagine 1065, plays a similar role, we have expressed and characterized four alpha(2)M variants in which this asparagine has been replaced by aspartate, alanine, histidine, or lysine, The change from asparagine resulted in an altered ability to form the thiol ester. This ranged from failure to form the thiol ester (Asn --> Asp) to a maximum extent of formation of about 50% (Asn --> Ala), For the three variants that were able to form the thiol ester, the rates of thiol ester cleavage by a given amine were found to be different from one another and slower in nearly all cases than plasma alpha(2)M, but with the same relative reactivity of methylamine > ethylamine > ammonia, The rate of conformational change that follows cleavage of thiol esters in a functional half-molecule was also found to differ between the variants and to be slower than plasma alpha(2)M. TNS emission spectra indicated that the conformations of the transformed variants differed measurably from transformed plasma alpha(2)M. These findings suggest that residue 1065 plays a critical role in human alpha(2)M, for formation of the thiol ester, for its subsequent reaction with nucleophiles, and for the conformational change induced by this reaction, By analogy with C4, where this residue influences the nucleophile preference through direct interaction with the thiol ester, residue 1065 in alpha(2)M is expected to be located in or very close to the thiol ester region in alpha(2)M.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, MC 536,1819-1853 W Polk St, Chicago, IL 60612 USA.	pgettins@uic.edu	Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54414] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BELT KT, 1984, CELL, V36, P907; BJORK I, 1985, BIOCHEMISTRY-US, V24, P2653; BOEL E, 1990, BIOCHEMISTRY-US, V29, P4081, DOI 10.1021/bi00469a009; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dawson R. M. C., 1986, DATA BIOCH RES, P424; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; Gron H, 1996, BIOCHEM J, V318, P539, DOI 10.1042/bj3180539; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; ISAAC L, 1992, J BIOL CHEM, V267, P10062; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; Iwaki D, 1996, EUR J BIOCHEM, V242, P822, DOI 10.1111/j.1432-1033.1996.0822r.x; Iwasaki H, 1996, J BIOCHEM-TOKYO, V120, P1167, DOI 10.1093/oxfordjournals.jbchem.a021537; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1984, BIOCHEMISTRY-US, V23, P2802, DOI 10.1021/bi00307a041; LAW SKA, 1984, EMBO J, V3, P1819, DOI 10.1002/j.1460-2075.1984.tb02052.x; LAW SKA, 1984, BIOCHEMISTRY-US, V23, P3267, DOI 10.1021/bi00309a022; NIELSEN KL, 1994, ANN NY ACAD SCI, V737, P746; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; PANGBURN MK, 1992, FEBS LETT, V308, P280, DOI 10.1016/0014-5793(92)81293-U; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; SEPP A, 1993, PROTEIN SCI, V2, P706, DOI 10.1002/pro.5560020502; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; STRICKLAND DK, 1991, BIOCHEMISTRY-US, V30, P2797, DOI 10.1021/bi00225a009; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; WARMEGARD B, 1992, BIOCHEMISTRY-US, V31, P2346; WASSLER M, 1995, J BIOL CHEM, V270, P24598, DOI 10.1074/jbc.270.41.24598	38	9	9	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31107	31112		10.1074/jbc.272.49.31107	http://dx.doi.org/10.1074/jbc.272.49.31107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388263	hybrid			2022-12-27	WOS:000071640800076
J	Uchida, T; Ishimori, K; Morishima, I				Uchida, T; Ishimori, K; Morishima, I			The effects of heme pocket hydrophobicity on the ligand binding dynamics in myoglobin as studied with leucine 29 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; ACID SIDE-CHAINS; CARBON-MONOXIDE; DISTAL HISTIDINE; MOLECULAR-DYNAMICS; OPTICAL-SPECTRA; PROTEIN; ORIENTATION	To examine the effects of heme pocket hydrophobicity on the ligand binding in myoglobin, some artificial mutants of human myoglobin have been prepared, in which less hydrophobic amino acid residue (Ala, Gly, Ser) is located at the Leu(29) (10th residue of the B helix) position, CO rebinding rates for the mutants were markedly decelerated, while the H-1, and N-15 NMR spectra of the mutants show that the structural changes around the heme iron for these mutants are rather small. The kinetic and structural properties of the mutants indicate that the ligand binding rate depends on the hydrophobicity inside the heme cavity for these mutants in addition to the volume of the side chain at the 29-position, On the basis of the IR stretching frequency of liganded CO, invasion of water molecules into the heme pocket in the mutants is suggested, which would be induced by the decrease in the hydrophobicity due to the amino acid substitution. A slight red shift of the position of the Soret peak for the serine mutant L29S also supports the reduced hydrophobicity inside the heme cavity, We can concluded that, together with the kinetic properties of the mutants, the hydrophobicity of the heme pocket is one of the key factors in regulating the ligand binding to the heme iron.	KYOTO UNIV,GRAD SCH ENGN,DEPT MOL ENGN,KYOTO 60601,JAPAN	Kyoto University			Ishimori, Koichiro/S-1247-2016; Uchida, Takeshi/A-6455-2017; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Uchida, Takeshi/0000-0001-9270-8329; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1992, J BIOL CHEM, V267, P12614; ADACHI S, 1989, J BIOL CHEM, V264, P18896; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P193; AVILES G, 1992, J CHEM SOC CHEM COMM, P31, DOI 10.1039/c39920000031; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Eaton W A, 1981, Methods Enzymol, V76, P175; EATON WA, 1978, J AM CHEM SOC, V100, P4991, DOI 10.1021/ja00484a013; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GOFF H, 1977, J AM CHEM SOC, V99, P6599, DOI 10.1021/ja00462a022; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; IIZUKA T, 1974, BIOCHIM BIOPHYS ACTA, V371, P126, DOI 10.1016/0005-2795(74)90161-5; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LINDSTORM TR, 1972, BIOCHEMISTRY-US, V9, P1677; MCCOY S, 1970, BIOCHEMISTRY-US, V9, P2387, DOI 10.1021/bi00814a001; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MORISHIMA I, 1977, J CHEM SOC CHEM COMM, P616, DOI 10.1039/c39770000616; MORISHIMA I, 1977, BIOCHEM BIOPH RES CO, V78, P739, DOI 10.1016/0006-291X(77)90241-8; MORISHIMA I, 1978, J AM CHEM SOC, V100, P3568, DOI 10.1021/ja00479a046; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAMAPRASAD S, 1984, J AM CHEM SOC, V106, P5330, DOI 10.1021/ja00330a049; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHULMAN BA, 1994, PROTEIN SCI, V3, P2226, DOI 10.1002/pro.5560031208; SLICHTER CP, 1980, PHYS REV B, V22, P4097, DOI 10.1103/PhysRevB.22.4097; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; YAMAMOTO Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P287, DOI 10.1016/0167-4838(93)90164-M; YAMAMOTO Y, 1990, FEBS LETT, V264, P113; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518	60	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30108	30114		10.1074/jbc.272.48.30108	http://dx.doi.org/10.1074/jbc.272.48.30108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374489	hybrid			2022-12-27	WOS:A1997YH61300021
J	Gilbert, HF				Gilbert, HF			Protein disulfide isomerase and assisted protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NASCENT POLYPEPTIDE-CHAINS; GONADOTROPIN BETA-SUBUNIT; REDUCED RIBONUCLEASE-A; ENDOPLASMIC-RETICULUM; BOND FORMATION; ACTIVE-SITE; HETEROTYPIC AGGREGATION; MOLECULAR CHAPERONES; IN-VITRO; CATALYSIS				Gilbert, HF (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CAI H, 1994, J BIOL CHEM, V269, P24550; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; DEFELIPPIS MR, 1993, BIOCHEMISTRY-US, V32, P1555, DOI 10.1021/bi00057a021; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Feng WJ, 1996, J BIOL CHEM, V271, P18543, DOI 10.1074/jbc.271.31.18543; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1995, COLD SPRING HARB SYM, V60, P405, DOI 10.1101/SQB.1995.060.01.045; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUTH JR, 1993, J BIOL CHEM, V268, P16472; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAENICKE R, 1995, PHILOS T ROY SOC B, V348, P97, DOI 10.1098/rstb.1995.0050; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; KERN G, 1995, J BIOL CHEM, V270, P740, DOI 10.1074/jbc.270.2.740; KIM PS, 1993, J BIOL CHEM, V268, P4873; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KONISHI Y, 1982, BIOCHEMISTRY-US, V21, P4734, DOI 10.1021/bi00262a033; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P25889; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; RUOPPOLO M, 1995, BIOCHEMISTRY-US, V34, P9380, DOI 10.1021/bi00029a014; Ruoppolo M, 1996, BIOCHEMISTRY-US, V35, P13636, DOI 10.1021/bi960755b; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1997, J BIOL CHEM, V272, P8845; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WALKER KW, 1995, BIOCHEMISTRY-US, V34, P13642, DOI 10.1021/bi00041a045; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	73	236	243	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29399	29402		10.1074/jbc.272.47.29399	http://dx.doi.org/10.1074/jbc.272.47.29399			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367991	hybrid			2022-12-27	WOS:A1997YG64700001
J	Kennedy, MW; Garside, LH; Goodrick, LE; McDermott, L; Brass, A; Price, NC; Kelly, SM; Cooper, A; Bradley, JE				Kennedy, MW; Garside, LH; Goodrick, LE; McDermott, L; Brass, A; Price, NC; Kelly, SM; Cooper, A; Bradley, JE			The Ov20 protein of the parasitic nematode Onchocerca volvulus - A structurally novel class of small helix-rich retinol-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; FATTY-ACID; SECONDARY STRUCTURE; 3-DIMENSIONAL STRUCTURE; NEURAL NETWORKS; RAT-LIVER; ANTIGEN; POLYPROTEIN; ACCURACY; SITES	Ov20 is a major antigen of the parasitic nematode Onchocerca volvulus, the causative agent of river blindness in humans, and the protein is secreted into the tissue occupied by the parasite, DNA encoding Ov20 was isolated, and the protein was expressed in Escherichia coli, Fluorescence-based ligand binding assays show that the protein contains a high affinity binding site for retinol, fluorescent fatty acids (11-((5-dimethylamino-naphthalene-1-sulfonyl)amino)undecanoic acid, dansyl-DL-alpha-aminocaprylic acid, and parinaric acid) and, by competition, oleic and arachidonic acids, but not cholesterol, The fluorescence emission of dansylated fatty acids is significantly blue-shifted upon binding in comparison to similarly sized beta-sheet-rich mammalian retinol-and fatty acid-binding proteins, Secondary structure prediction algorithms indicate that a alpha-helix predominates in Ov20, possibly in a coiled coil motif, with no evidence of beta structures, and this was confirmed by circular dichroism, The protein is highly stable in solution, requiring temperatures in excess of 90 degrees C or high denaturant concentrations for unfolding, Ov20 there fore represents a novel class of small retinol-binding protein, which appears to be confined to nematodes, The retinol binding activity of Ov20 could possibly contribute to the eye defects associated with onchocerciasis and, because there is no counterpart in mammals? rep resents a strategic target for chemotherapy.	UNIV GLASGOW,DEPT CHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV SALFORD,DEPT BIOL SCI,SALFORD M5 4WT,LANCS,ENGLAND; UNIV MANCHESTER,DEPT BIOCHEM & MOL BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV STIRLING,DEPT BIOL & MOL SCI,STIRLING FK9 4LA,SCOTLAND	University of Glasgow; University of Salford; University of Manchester; University of Stirling	Kennedy, MW (corresponding author), UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV INFECT & IMMUN,JOSEPH BLACK BLDG,GLASGOW G12 8QQ,LANARK,SCOTLAND.		Cooper, Alan/F-7813-2011; Kelly, Sharon/K-4611-2013	Cooper, Alan/0000-0001-6709-7343; Brass, Andrew/0000-0002-0389-7058; Kelly, Sharon/0000-0002-3516-1387; Bradley, Janette/0000-0003-3973-7977; McDermott, Lindsay C./0000-0003-4723-6056	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRADLEY JE, 1995, J INFECT DIS, V172, P831, DOI 10.1093/infdis/172.3.831; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; CARMAN JA, 1992, J EXP MED, V175, P111, DOI 10.1084/jem.175.1.111; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Cooper A, 1994, Methods Mol Biol, V22, P109; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FRAPIN D, 1993, J PROTEIN CHEM, V12, P443, DOI 10.1007/BF01025044; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GERRARD JM, 1985, PROSTAGLANDINS LEUKO; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; KENNEDY MW, 1995, J BIOL CHEM, V270, P19277, DOI 10.1074/jbc.270.33.19277; KENNEDY MW, 1995, MOL BIOCHEM PARASIT, V71, P41, DOI 10.1016/0166-6851(95)00028-Y; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LAL PG, 1996, PARASITOLOGY, V112, P211; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; Mei BS, 1997, J BIOL CHEM, V272, P9933, DOI 10.1074/jbc.272.15.9933; MOSER D, 1991, J BIOL CHEM, V266, P8447; MURPHY RC, 1990, METHODS ENZYMOL, V187; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nozaki Y, 1972, Methods Enzymol, V26, P43; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RODGER FC, 1962, B WORLD HEALTH ORGAN, V27, P429; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANI BP, 1985, BIOCHEM J, V232, P577, DOI 10.1042/bj2320577; SANI BP, 1988, BIOCHEM J, V249, P929, DOI 10.1042/bj2490929; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Szilak L, 1997, NAT STRUCT BIOL, V4, P112, DOI 10.1038/nsb0297-112; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TREE TIM, 1995, MOL BIOCHEM PARASIT, V69, P185, DOI 10.1016/0166-6851(94)00204-Z; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419	49	91	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29442	29448		10.1074/jbc.272.47.29442	http://dx.doi.org/10.1074/jbc.272.47.29442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368002	hybrid			2022-12-27	WOS:A1997YG64700012
J	Paresce, DM; Chung, HY; Maxfield, FR				Paresce, DM; Chung, HY; Maxfield, FR			Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACYL-COENZYME-A; MOUSE PERITONEAL-MACROPHAGES; PRECURSOR PROTEIN; SCAVENGER RECEPTOR; SENILE PLAQUES; CHOLESTEROL ESTERIFICATION; ATHEROGENIC LIPOPROTEINS; CULTURED FIBROBLASTS; NEUROLOGICAL DISEASE	Microglia are immune system cells associated with senile plaques containing beta-amyloid (A beta) in Alzheimer's disease, Although microglia are an integral part of senile plaques, their role in the development of Alzheimer's disease is not known, Because microglia are phagocytic cells, it has been suggested that microglia may function as plaque-attacking scavenger cells, Microglia bind and internalize microaggregates of A beta that resemble those present in dense Alzheimer's disease plaques. In this study, we compared the degradation by microglia of A beta microaggregates with the degradation of two other proteins, acetylated low density lipoprotein and alpha(2)-macroglobulin. We found that the majority of the in internalized A beta in microaggregates was undegraded 72 h after uptake, whereas 70-80% of internalized acetylated low density lipoprotein or alpha(2)-macroglobulin was degraded and released from cells in trichloroacetic acid-soluble form after 4 h, In the continued presence of fluorescent A beta microaggregates for 4 days, microglia took up huge amounts of A beta and became engorged with undigested material, These data suggest that microglia can slowly degrade limited amounts of A beta plaque material, but the degradation mechanisms can be overwhelmed by larger amounts of A beta.	CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Cornell University; Columbia University			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NINDS NIH HHS [NS34761] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034761] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Christie RH, 1996, AM J PATHOL, V148, P399; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Elkabes S, 1996, J NEUROSCI, V16, P2508; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Greenberg BD, 1996, NEUROBIOL AGING, V17, P153, DOI 10.1016/0197-4580(96)00001-2; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Marx J, 1996, SCIENCE, V274, P1838, DOI 10.1126/science.274.5294.1838; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAXFIELD FR, 1981, BIOCHEMISTRY-US, V20, P5353, DOI 10.1021/bi00521a041; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MITCHINSON MJ, 1987, LANCET, V2, P146; MUNRO JM, 1988, LAB INVEST, V58, P249; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Oh YK, 1996, J CELL BIOL, V132, P585, DOI 10.1083/jcb.132.4.585; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PERLMUTTER LS, 1983, NEUROSCI LETT, V52, P223; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1994, J BIOL CHEM, V269, P22547; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WILLINGHAM MC, 1980, J HISTOCHEM CYTOCHEM, V28, P818, DOI 10.1177/28.8.6160180; WISNIEWSKI HM, 1990, AM J MED GENET, P287, DOI 10.1002/ajmg.1320370757; XU XX, 1991, J BIOL CHEM, V266, P17040; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIU WQ, 1996, J BIOL CHEM, V271, P8443	78	217	226	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29390	29397		10.1074/jbc.272.46.29390	http://dx.doi.org/10.1074/jbc.272.46.29390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361021	hybrid			2022-12-27	WOS:A1997YF68400080
J	Khandekar, SS; Bettencourt, BM; Wyss, DF; Naylor, JW; Brauer, PP; Huestis, K; Dwyer, DS; Profy, AT; Osburne, MS; Banerji, J; Jones, B				Khandekar, SS; Bettencourt, BM; Wyss, DF; Naylor, JW; Brauer, PP; Huestis, K; Dwyer, DS; Profy, AT; Osburne, MS; Banerji, J; Jones, B			Conformational integrity and ligand binding properties of a single chain T-cell receptor expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	XVIIth International Conference on Magnetic Resonance in Biological Systems	AUG 18-23, 1996	KEYSTONE, COLORADO				SURFACE-PLASMON RESONANCE; CLASS-II MHC; PROTEIN SECONDARY STRUCTURE; NONOBESE DIABETIC MICE; V-ALPHA DOMAIN; ANTIGEN RECEPTOR; BETA-CHAIN; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; POSITIVE SELECTION	We recently showed that a soluble, heterodimeric murine D10 T-cell receptor (TCR) (V alpha 2C alpha, V beta 8.2C beta) expressed in insect cells binds both V beta 8.2-specific bacterial superantigen staphylococcal enterotoxin C2 (SECB) and a soluble, heterodimeric major histocompatibility complex class II I-A(k).conalbumin peptide complex with a low micromolar affinity, To define further the structural requirements for the TCR/ligand interactions, we have produced in Escherichia coli a soluble, functional D10 single chain (sc) TCR molecule in which the V alpha and V beta domains are connected by a flexible peptide linker, Purified and refolded D10 scTCR bound to SEC2 and murine major histocompatibility complex class II I-A(k).conalbumin peptide complex with thermodynamic and kinetic binding constants similar to those measured for the baculovirus-derived heterodimeric D10 TCR suggesting that neither the TCR constant domains nor potential N- or O-linked carbohydrate moieties are necessary for ligand recognition and for expression and proper folding of the D10 scTCR. Purified D10 scTCR remained soluble at concentrations up to 1 mM. Circular dichroism and NMR spectroscopy indicated that D10 scTCR is stabilized predominantly by beta-sheet secondary structure, consistent with its native-like conformation. Because of its limited size, high solubility, and structural integrity, purified D10 scTCR appears to be suitable for structural studies by multidimensional NMR spectroscopy.	Procept Inc, Cambridge, MA 02139 USA		Khandekar, SS (corresponding author), SmithKline Beecham Pharmaceut, UE 0435,709 Swedeland Rd, King Of Prussia, PA 19406 USA.							Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; AVERY AC, 1994, J IMMUNOL, V153, P4853; BALASUBRAMANIAN S, 1995, INT IMMUNOL, V7, P1839, DOI 10.1093/intimm/7.11.1839; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BREGEGERE F, 1994, PROTEIN ENG, V7, P271; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Fremont DH, 1996, CURR OPIN IMMUNOL, V8, P93, DOI 10.1016/S0952-7915(96)80111-7; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; GUAN C, 1988, GENE, V67, P21; Harlow E., 1988, ANTIBODIES LAB MANUA; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000, DOI 10.1073/pnas.86.20.8000; HILYARD KL, 1994, P NATL ACAD SCI USA, V91, P9057, DOI 10.1073/pnas.91.19.9057; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KANAGAWA O, 1989, J EXP MED, V170, P1513, DOI 10.1084/jem.170.5.1513; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Khandekar SS, 1997, MOL IMMUNOL, V34, P493, DOI 10.1016/S0161-5890(97)00044-8; KHANDEKAR SS, 1993, PROTEIN EXPRES PURIF, V4, P580, DOI 10.1006/prep.1993.1076; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1994, METHOD ENZYMOL, V239, P596; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; MALMQVIST M, 1993, CURR OPIN IMMUNOL, V5, P282, DOI 10.1016/0952-7915(93)90019-O; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McKeever U, 1996, J EXP MED, V184, P1755, DOI 10.1084/jem.184.5.1755; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PAREKH RB, 1994, BIOLOGICALS, V22, P113, DOI 10.1006/biol.1994.1017; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; Plaksin D, 1996, J EXP MED, V184, P1251, DOI 10.1084/jem.184.4.1251; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; Sattler M, 1996, STRUCTURE, V4, P1245, DOI 10.1016/S0969-2126(96)00133-5; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SOOHOO WF, 1992, P NATL ACAD SCI USA, V89, P4759; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; Wuthrich K, 1986, NMR PROTEINS NUCL AC	60	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32190	32197		10.1074/jbc.272.51.32190	http://dx.doi.org/10.1074/jbc.272.51.32190			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405420	hybrid			2022-12-27	WOS:000071108000039
J	Orlinick, JR; Elkon, KB; Chao, MV				Orlinick, JR; Elkon, KB; Chao, MV			Separate domains of the human Fas ligand dictate self-association and receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-MEDIATED CYTOTOXICITY; FACTOR-INDUCED APOPTOSIS; MUTATIONAL ANALYSIS; TNF RECEPTOR; FACTOR-ALPHA; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; T-LYMPHOCYTES	The Fas receptor rapidly induces apoptosis when activated by ligand binding or by cross-linking with anti-Fas antibody, The Fas ligand (Fast), a member of the tumor necrosis factor family of ligands, is a IO-kilodalton type II transmembrane protein which is cleaved to produce soluble ligand. Although the Fas-FasL interaction plays a critical role in peripheral T cell homeostasis and cytotoxic T lymphocyte-mediated target cell killing, the requirements for human Fast receptor binding and oligomerization have not been defined. Here we report two distinct domains of the ligand which are responsible for self-association and binding to the Fas receptor. A COOH-terminal sequence of the Fast was found to be required for binding and biological activity, as verified by deletion mutagenesis, use of the NOK-1 blocking antibody and the humanized gld Fast mutation, N-Linked glycosylation of the Fast was not required for biological activity. However, the Fast expression level was dependent upon the three N-linked glycosylation sites. Moreover, the ability of the Fast to self-associate was not dependent upon transmembrane or cytoplasmic sequences, but was localized to a 47-amino acid region in its extracellular domain, These results indicate that the FasL-Fas receptor complex depends upon independent motifs located within the extracellular domain of the Fast.	Cornell Univ Med Coll, Dept Anat & Cell Biol, New York, NY 10021 USA; Hosp Special Surg, New York, NY 10021 USA	Cornell University	Orlinick, JR (corresponding author), Cornell Univ Med Coll, Dept Anat & Cell Biol, New York, NY 10021 USA.			Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIAMS NIH HHS [P50AR-425888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BROWNINGJ, 1989, J IMMUNOL, V147, P1230; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1993, J BIOL CHEM, V268, P10932; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PEITSCH MC, 1995, MOL IMMUNOL, V32, P761, DOI 10.1016/0161-5890(95)00016-8; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	52	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32221	32229		10.1074/jbc.272.51.32221	http://dx.doi.org/10.1074/jbc.272.51.32221			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405425	hybrid			2022-12-27	WOS:000071108000044
J	Papadopoulos, V; Amri, H; Li, H; Boujrad, N; Vidic, B; Garnier, M				Papadopoulos, V; Amri, H; Li, H; Boujrad, N; Vidic, B; Garnier, M			Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAZEPAM-BINDING INHIBITOR; ACUTE REGULATORY PROTEIN; STEROID-HORMONE BIOSYNTHESIS; MITOCHONDRIAL PROTEINS; ADRENAL-CORTEX; CONSTITUTIVE STEROIDOGENESIS; HOMOLOGOUS RECOMBINATION; CHOLESTEROL; STIMULATION; INDUCTION	To evaluate the role of the mitochondrial peripheral-type benzodiazepine receptor (PER) in steroidogenesis, we developed a molecular approach based on the disruption of the PER gene, by homologous recombination, in the constitutive steroid producing R2C rat Leydig tumor cell line, Inactivation of one allele of the PER gene resulted in the suppression of PER mRNA and ligand binding expression, Immunoblot and electron microscopic immunogold labeling analyses confirmed the absence of the 18-kDa PER protein in the selected clone, Although mitochondria from the PER-negative cells contained high levels of the constitutively expressed 30-kDa steroidogenic activity regulator protein, these cells produced minimal amounts of steroids compared with normal cells (5%). Moreover, mitochondria from PER-negative cells failed to produce pregnenolone when supplied with exogenous cholesterol, Addition of the hydrosoluble cholesterol derivative, 22R-hydroxycholesterol, increased steroid production by the PBR-negative R2C cells, indicating that the cholesterol transport mechanism was impaired. Stable transfection of the PER-negative R2C Leydig cells with a vector containing the PER cDNA resulted in the recovery of the steroidogenic function of the cells. These data demonstrate that PER is an indispensable element of the steroidogenic machinery, where it mediates the delivery of the substrate cholesterol to the inner mitochondrial side chain cleavage cytochrome P-450.	Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Papadopoulos, V (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, 3900 Reservoir Rd, Washington, DC 20007 USA.	papadopv@gunet.georgetown.edu	BOUJRAD, Noureddine/L-1367-2015; Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	NICHD NIH HHS [HD-01031] Funding Source: Medline; NIEHS NIH HHS [ES-07747] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007747] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; *AM TYP CULT COLL, 1992, ATCC CELL LIN HYBR; Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; AMSTERDAM A, 1991, ENDOCRINOLOGY, V129, P503, DOI 10.1210/endo-129-1-503; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BARNEA ER, 1989, MOL CELL ENDOCRINOL, V64, P155, DOI 10.1016/0303-7207(89)90141-X; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BOUJRAD N, 1994, ENDOCRINOLOGY, V135, P1576, DOI 10.1210/en.135.4.1576; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CASALOTTI SO, 1992, GENE, V121, P377, DOI 10.1016/0378-1119(92)90147-H; CAVALLARO S, 1992, P NATL ACAD SCI USA, V89, P10598, DOI 10.1073/pnas.89.22.10598; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FREEMAN DA, 1987, ENDOCRINOLOGY, V120, P124, DOI 10.1210/endo-120-1-124; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Hall P.F., 1988, P975; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JOYNER AL, 1992, GENE TARGETING; KIMURA T, 1986, J STEROID BIOCHEM, V25, P711, DOI 10.1016/0022-4731(86)90299-2; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVER HA, 1981, J ENDOCRINOL, V91, P123, DOI 10.1677/joe.0.0910123; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PAPADOPOULOS V, 1994, MOL CELL ENDOCRINOL, V104, pR5, DOI 10.1016/0303-7207(94)90061-2; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; PAPADOPOULOS V, 1996, LEYDIG CELL, P598; PON LA, 1986, J BIOL CHEM, V261, P6594; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; RITTA MN, 1989, NEUROENDOCRINOLOGY, V49, P262, DOI 10.1159/000125126; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SHIN SI, 1968, ENDOCRINOLOGY, V82, P614, DOI 10.1210/endo-82-3-614; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; YANAGIBASHI K, 1989, J BIOCHEM, V106, P1026, DOI 10.1093/oxfordjournals.jbchem.a122958; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	52	193	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32129	32135		10.1074/jbc.272.51.32129	http://dx.doi.org/10.1074/jbc.272.51.32129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405411	hybrid			2022-12-27	WOS:000071108000030
J	Ji, ZS; Dichek, HL; Miranda, RD; Mahley, RW				Ji, ZS; Dichek, HL; Miranda, RD; Mahley, RW			Heparan sulfate proteoglycans participate in hepatic lipase- and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; REVERSE CHOLESTEROL TRANSPORT; SITE-DIRECTED MUTAGENESIS; ESTER TRANSFER PROTEIN; CELL-SURFACE; A-I; ALPHA-2-MACROGLOBULIN RECEPTOR; REMNANT LIPOPROTEINS; SELECTIVE UPTAKE; TRANSGENIC MICE	High density lipoprotein (HDL) particles and HDL cholesteryl esters are taken up by both receptor-mediated and non-receptor-mediated pathways. Here we show that cell surface heparan sulfate proteoglycans (HSPG) participate in hepatic lipase (HL)- and apolipoprotein (apo) E-mediated binding and uptake of mouse and human HDL by cultured hepatocytes. The HL secreted by HL-transfected McA-RH7777 cells enhanced both HDL binding at 4 degrees C (similar to 2-4-fold) and HDL uptake at 37 degrees C (similar to 2-5-fold). The enhanced binding and uptake of HDL were partially inhibited by the 39-kDa protein, an inhibitor of low density lipoprotein receptor-related protein (LRP), but were almost totally blocked by heparinase, which removes the sulfated glycosaminoglycan chains from HSPG. Therefore, HL may mediate the uptake of HDL by two pathways: an HSPG-dependent LRP pathway and an HSPG-dependent but LRP-independent pathway. The HL-mediated binding and uptake of HDL were only minimally reduced when catalytically inactive HL or LRP binding-defective HL was substituted for mild-type HL, indicating that much of the HDL uptake required neither HL binding to the LRP nor lipolytic processing. To study the role of HL in facilitating the selective uptake of cholesteryl esters, we used HDL into which radiolabeled cholesteryl ether had been incorporated. HL increased the selective uptake of HDL cholesteryl ether; this enhanced uptake was reduced by more than 80% by heparinase but was unaffected by the 39-kDa protein. Like HL, apoE enhanced the binding and uptake of HDL (similar to 2-fold) but had little effect on the selective uptake of HDL cholesteryl ether. In the presence of HL, apoE did not further increase the uptake of HDL, and at a high concentration apoE impaired or decreased the HL-mediated uptake of HDL. Therefore, HL and apoE may utilize similar (but not identical) binding sites to mediate HDL uptake. Although the relative importance of cell surface HSPG in the overall metabolism of HDL in vivo remains to be determined, cultured hepatocytes clearly displayed an HSPG-dependent pathway that mediates the binding and uptake of HDL. This study also demonstrates the importance of HL in enhancing the binding and uptake of remnant and low density lipoproteins via an HSPG-dependent pathway.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; AZHAR S, 1989, J LIPID RES, V30, P1799; BAMBERGER M, 1983, J LIPID RES, V24, P869; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BENGTSSON G, 1980, FEBS LETT, V119, P290, DOI 10.1016/0014-5793(80)80274-2; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECROM RPG, 1992, ARTERIOSCLER THROMB, V12, P325, DOI 10.1161/01.ATV.12.3.325; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; DICHEK HL, 1993, J LIPID RES, V34, P1393; DONG LM, 1994, J BIOL CHEM, V269, P22358; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ENERBACK S, 1987, GENE, V58, P1, DOI 10.1016/0378-1119(87)90023-0; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROOT PHE, 1981, FEBS LETT, V129, P269, DOI 10.1016/0014-5793(81)80181-0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1980, TRENDS BIOCHEM SCI, V5, P265, DOI 10.1016/0968-0004(80)90033-X; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; JONES AL, 1984, J LIPID RES, V25, P1151; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KOO C, 1985, J BIOL CHEM, V260, P1934; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; Krapp A, 1996, J LIPID RES, V37, P926; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKINNON AM, 1987, J LIPID RES, V28, P847; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARQUESVIDAL P, 1994, J LIPID RES, V35, P373; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; OMALLEY JP, 1981, J LIPID RES, V22, P1214; OSWALD B, 1986, BIOCHEM BIOPH RES CO, V141, P158, DOI 10.1016/S0006-291X(86)80348-5; PITAS RE, 1980, J BIOL CHEM, V255, P5454; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; RIFICI VA, 1984, J BIOL CHEM, V259, P3814; RINNINGER F, 1990, BIOCHIM BIOPHYS ACTA, V1043, P318, DOI 10.1016/0005-2760(90)90033-T; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SEO T, 1995, CIRCULATION, V92, P3; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SPARKS DL, 1987, CLIN CHEM, V33, P390; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TALL AR, 1993, J LIPID RES, V34, P1255; VERHOEVEN AJM, 1994, BBA-LIPID LIPID MET, V1211, P121, DOI 10.1016/0005-2760(94)90146-5; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	93	130	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31285	31292		10.1074/jbc.272.50.31285	http://dx.doi.org/10.1074/jbc.272.50.31285			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395455	hybrid			2022-12-27	WOS:A1997YL41900014
J	Lupo, A; Costanzo, P; Medugno, L; Romeo, I; Salvatore, F; Izzo, P				Lupo, A; Costanzo, P; Medugno, L; Romeo, I; Salvatore, F; Izzo, P			Negative regulation of the mouse aldolase a gene - A cell cycle-dependent DNA binding activity functions as a silencer of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; A GENE; MESSENGER-RNA; CONTROL ELEMENTS; PROMOTER; RAT; REPRESSION; IDENTIFICATION; SEQUENCES; MECHANISM	The expression of aldolase A L-type mRNA is increased in growth-arrested mouse NIH3T3 cells and remarkably down-regulated in actively proliferating cells. Treatment of proliferating cells with cycloheximide abolished the down-regulation of L-type mRNA expression, thus indicating that a protein factor acts as repressor in proliferating cells. Transient transfection experiments in NIH3T3 cells showed that a negative regulatory cis-element (NRE) is involved in the modulation of the transcriptional activity of the distal L promoter. The repressor, which is a protein of similar to 97 kDa, binds the murine aldolase A NRE, revealing a much more intense DNA-protein complex in proliferating NIH3T3 cells than in serum-deprived cells. Mutations in the negative regulatory cis-element showed that the GA-rich motif is required for protein binding and silencer function. We conclude that the expression of L-type mRNA is modulated by the interaction between a cell cycle-dependent DNA-binding protein and the murine aldolase A NRE.	UNIV NAPLES FEDERICO II, FAC MED & CHIRURG, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CTR INGN GENET BIOTECNOL AVANZATE, I-80131 NAPLES, ITALY	University of Naples Federico II; University of Naples Federico II			Salvatore, Francesco/A-1966-2011	Salvatore, Francesco/0000-0002-2346-3564; Izzo, Paola/0000-0003-1549-0615; COSTANZO, Paola/0000-0002-0267-379X				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; COSTANZO P, 1993, BIOCHEM BIOPH RES CO, V195, P935, DOI 10.1006/bbrc.1993.2134; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hermfisse U, 1996, BIOCHEM BIOPH RES CO, V225, P997, DOI 10.1006/bbrc.1996.1284; IZZO P, 1989, FEBS LETT, V257, P75, DOI 10.1016/0014-5793(89)81790-9; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; IZZO P, 1987, EUR J BIOCHEM, V164, P9, DOI 10.1111/j.1432-1033.1987.tb10984.x; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; LUPO A, 1994, EXP CELL RES, V213, P359, DOI 10.1006/excr.1994.1210; LUPO A, 1995, BIOCHEM BIOPH RES CO, V216, P69, DOI 10.1006/bbrc.1995.2593; MAIRE P, 1987, J MOL BIOL, V197, P425, DOI 10.1016/0022-2836(87)90556-0; MUKAI T, 1991, EUR J BIOCHEM, V195, P781, DOI 10.1111/j.1432-1033.1991.tb15766.x; MUKAI T, 1986, J BIOL CHEM, V261, P3347; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Salvatore F, 1986, Horiz Biochem Biophys, V8, P611; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; STAUFFER JK, 1992, NUCLEIC ACIDS RES, V20, P327, DOI 10.1093/nar/20.2.327; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	33	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31641	31647		10.1074/jbc.272.50.31641	http://dx.doi.org/10.1074/jbc.272.50.31641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395505	hybrid			2022-12-27	WOS:A1997YL41900064
J	Persson, AL; Eriksson, M; Katterle, B; Potsch, S; Sahlin, M; Sjoberg, BM				Persson, AL; Eriksson, M; Katterle, B; Potsch, S; Sahlin, M; Sjoberg, BM			A new mechanism-based radical intermediate in a mutant R1 protein affecting the catalytically essential Glu(441) in Escherichia coli ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DIPHOSPHATE REDUCTASE; 2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; THIOREDOXIN REDUCTASE; PHENOTYPIC SELECTION; SUBUNIT INTERACTION; ELECTRON-TRANSFER; BOND-CLEAVAGE; IRON CENTER; INACTIVATION	The invariant active site residue Glu(441) in protein R1 of ribonucleotide reductase from Escherichia coli has been engineered to alanine, aspartic acid, and glutamic acid. Each mutant protein was structurally and enzymatically characterized, Glu(441) contributes to substrate binding, and a carboxylate side chain at position 441 is essential for catalysis. The most intriguing results are the suicidal mechanism-based reaction intermediates observed when R1 E441Q is incubated with protein R2 and natural substrates (CDP and GDP), In a consecutive reaction sequence, we observe at least three clearly discernible steps: (i) a rapid decay (k(1) greater than or equal to 1.2 s(-1)) of the catalytically essential tyrosyl radical of protein R2 concomitant with formation of an early transient radical intermediate species, (ii) a slower decay (k(2) = 0.03 s(-1)) of the early intermediate concomitant with formation of another intermediate with a triplet EPR signal, and (iii) decay (k(3) = 0.004 s(-1)) of the latter concomitant with formation of a characteristic substrate degradation product. The characteristics of the triplet EPR signal are compatible with a substrate radical intermediate (most likely localized at the S'-position of the ribose moiety of the substrate nucleotide) postulated to occur in the wild type reaction mechanism as well.	UNIV STOCKHOLM, DEPT MOL BIOL, S-10691 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT BIOPHYS, S-10691 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOL BIOL, S-75149 UPPSALA, SWEDEN	Stockholm University; Stockholm University; Swedish University of Agricultural Sciences				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ATOR MA, 1986, J BIOL CHEM, V261, P3595; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behravan G, 1995, BBA-GENE STRUCT EXPR, V1264, P323, DOI 10.1016/0167-4781(95)00168-9; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Coves J, 1996, BIOCHEMISTRY-US, V35, P8595, DOI 10.1021/bi960355o; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1977, J BIOL CHEM, V252, P6132; ERIKSSON S, 1975, EUR J BIOCHEM, V56, P289, DOI 10.1111/j.1432-1033.1975.tb02232.x; Fersht A., 1985, ENZYME STRUCTURE MEC; HARRIS G, 1984, BIOCHEMISTRY-US, V23, P5214, DOI 10.1021/bi00317a020; HELLWEGE KH, 1979, LANDOLTBORNSTEIN, V17; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LARSSON A, 1988, J BIOL CHEM, V263, P17780; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Lenz R, 1997, J AM CHEM SOC, V119, P2784, DOI 10.1021/ja962974q; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LUNN CA, 1984, J BIOL CHEM, V259, P469; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MORTON JR, 1964, CHEM REV, V64, P453, DOI 10.1021/cr60230a005; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SALOWE SP, 1987, BIOCHEMISTRY-US, V26, P3408, DOI 10.1021/bi00386a024; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; STUBBE JA, 1980, J BIOL CHEM, V255, P8027; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Uhlin U, 1996, J MOL BIOL, V262, P358, DOI 10.1006/jmbi.1996.0519; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; vanderDonk WA, 1996, BIOCHEMISTRY-US, V35, P8381, DOI 10.1021/bi960190j	59	74	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31533	31541		10.1074/jbc.272.50.31533	http://dx.doi.org/10.1074/jbc.272.50.31533			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395490	hybrid			2022-12-27	WOS:A1997YL41900049
J	Cawthern, KM; Narayan, M; Chaudhuri, D; Permyakov, EA; Berliner, LJ				Cawthern, KM; Narayan, M; Chaudhuri, D; Permyakov, EA; Berliner, LJ			Interactions of alpha-lactalbumin with fatty acids and spin label analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; BETA-LACTOGLOBULIN; CALCIUM-BINDING; FLUORESCENCE; VESICLES; BOVINE; CONFORMATION; STATES	Bovine alpha-lactalbumin (alpha-LA) has been shown by intrinsic protein fluorescence and electron spin resonance methods to interact with the spin-labeled fatty acid analog, 5-doxylstearic acid, as well as stearic acid. An intrinsic fluorescence titration of various alpha-LA forms with 5-doxylstearic acid causes first an increase and then a decrease in emission intensity with concomitant shifts in tryptophan emission wavelength. In some cases, up to three steps in the fluorescence titration curves were visible, which were fit to apparent binding steps from 10(-6) to 10(-4) M. The binding parameters of 5-doxylstearic acid for apo- and Ca2+-alpha-LA were an order of magnitude different from one another; the stronger one, apo-alpha-lactalbumin, exhibited a K-d of 35 mu M. Electron spin resonance titrations of 5-doxylstearic acid-loaded apo-alpha-LA with stearate (micelles) seem to suggest separate binding loci if alpha-LA indeed binds stearate at these concentrations. The titration of alpha-LA by stearic acid results in a fluorescence emission red shift and an apparent stepped increase in fluorescence intensity. Lipid-protein association occurred at concentrations at which stearic acid micelles and aggregates begin to form in the absence of protein. Nonetheless, the relatively strong association between stearic acid and apo-alpha-LA was also confirmed by means of the fluorescent indicator acrylodated fatty acid binding protein, in which addition of alpha-LA to the stearate-loaded indicator protein reverses the decrease in fluorescence of the acrylodan chromophore conjugated to the protein.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Berliner, LJ (corresponding author), Ohio State Univ, Dept Chem, 120 W 18Th Ave, Columbus, OH 43210 USA.	Berliner.2@osu.edu	Permyakov, Eugene A./M-8707-2014	Permyakov, Eugene A./0000-0002-9099-1148				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1991, J MOL BIOL, V221, P571; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BERLINER LJ, 1987, BIOCHEMISTRY-US, V26, P3006, DOI 10.1021/bi00385a008; Cawthern KM, 1996, PROTEIN SCI, V5, P1394, DOI 10.1002/pro.5560050718; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; Grishchenko VM, 1996, BIOCHEM MOL BIOL INT, V38, P453; HANSSENS I, 1980, BIOCHIM BIOPHYS ACTA, V602, P539, DOI 10.1016/0005-2736(80)90333-8; HANSSENS I, 1985, BIOCHIM BIOPHYS ACTA, V817, P154, DOI 10.1016/0005-2736(85)90078-1; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; HIRAI Y, 1992, J PROTEIN CHEM, V11, P51, DOI 10.1007/BF01025092; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; KRONMAN MJ, 1964, BIOCHEMISTRY-US, V3, P1152, DOI 10.1021/bi00896a025; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LINDAHL L, 1984, ANAL BIOCHEM, V140, P394, DOI 10.1016/0003-2697(84)90184-2; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; MURAKAMI K, 1982, BIOCHEMISTRY-US, V21, P5488, DOI 10.1021/bi00265a017; MURAKAMI K, 1983, BIOCHEMISTRY-US, V22, P3370, DOI 10.1021/bi00283a010; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P3852, DOI 10.1021/bi00336a006; NARAYAN M, 1997, BIOCHEMISTRY-US, V36, P190; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERMYAKOV EA, 1988, GEN PHYSIOL BIOPHYS, V7, P95; PERMYAKOV EA, 1991, BIOPHYS CHEM, V39, P111, DOI 10.1016/0301-4622(91)85012-F; PERMYAKOV EA, 1991, J PROTEIN CHEM, V10, P577, DOI 10.1007/BF01025709; PERMYAKOV EA, 1985, BIOPHYS CHEM, V21, P21, DOI 10.1016/0301-4622(85)85003-1; PERMYAKOV EA, 1981, BIOCHEM BIOPH RES CO, V100, P191, DOI 10.1016/S0006-291X(81)80081-2; PUYOL P, 1991, AGR BIOL CHEM TOKYO, V55, P2515, DOI 10.1080/00021369.1991.10871001; REHFELD SJ, 1978, J LIPID RES, V19, P841; REICH JG, 1972, EUR J BIOCHEM, V26, P368, DOI 10.1111/j.1432-1033.1972.tb01776.x; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; SPECTOR AA, 1970, LIPIDS, V5, P403, DOI 10.1007/BF02532106; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002	33	52	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30812	30816		10.1074/jbc.272.49.30812	http://dx.doi.org/10.1074/jbc.272.49.30812			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388223	hybrid			2022-12-27	WOS:000071640800036
J	Currie, RA				Currie, RA			Functional interaction between the DNA binding subunit trimerization domain of NF-Y and the high mobility group protein HMG-I(Y)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II GENE-TRANSCRIPTION; IFN-BETA GENE; CCAAT-BINDING; VIRUS INDUCTION; DRA PROMOTER; FACTOR CBF; HMG I(Y); EXPRESSION; COMPLEX; ELEMENTS	The mammalian transcription factor, NF-Y(CBF), contains three known subunit components, NF-YA (CBF-B), NF-YB(CBF-A), and NF-YC(CBF-C), which are all required to reconstitute specific CCAAT box DNA binding activity. In this study, the high mobility group chromosomal protein, HMG-I(Y), has been shown to activate NF-Y in transient transfections in vivo using the natural murine alpha 2(I) collagen promoter and a multimerized version of the proximal NF-Y(CBF) CCAAT box element. In vitro analysis of the alpha 2(I) collagen promoter region inclusive of the NF-Y(CBF) binding site (-106 to -65 base pairs) failed to identify any high affinity HMG-I(Y) DNA-binding sites. However, the heterotrimeric NF-Y complex, as well as the NF-YA subunit alone, was shown to stably interact in vitro with both HMG-I(Y) and phosphorylated HMG-I, as modified by casein kinase II, using far Western and protein-protein interaction solution assays in the absence of CCAAT box DNA. Furthermore, the interaction between HMG-I(Y) and NF-Y was mapped to the highly conserved DNA binding-subunit interaction domain (DBD) of the NF-YA subunit and to a single AT-hook motif in HMG-I(Y). Recombinant HMG-I was also found to stabilize the CCAAT box DNA binding activity of recombinant NF-Y, as well as the native NF-Y complex, in vitro. Together, these results suggest a functional HMG-I(Y) protein binding site has been identified in the NF-Y complex and mapped to the conserved DBD and AT-hook regions of NF-YA and HMG-I(Y), respectively. This protein-protein interaction site may function to modulate NF-Y activity through stabilization of NF-Y binding to its CCAAT box DNA-binding site.	Picower Inst Med Res, Lab Gene Regulat, Manhasset, NY 11030 USA	Northwell Health	Currie, RA (corresponding author), Picower Inst Med Res, Lab Gene Regulat, 350 Community Dr, Manhasset, NY 11030 USA.	racurrie@picower.edu	Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037686] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37686] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; CURRIE RA, 1992, ARCH BIOCHEM BIOPHYS, V298, P630, DOI 10.1016/0003-9861(92)90459-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; INOSTROZA JA, 1992, CELL, V70, P477; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEGER H, 1995, MOL CELL BIOL, V15, P3738; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT A, 1986, MOL CELL BIOL, V6, P347, DOI 10.1128/MCB.6.2.347; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1993, NUCLEIC ACIDS RES, V21, P6010, DOI 10.1093/nar/21.25.6010; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	45	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30880	30888		10.1074/jbc.272.49.30880	http://dx.doi.org/10.1074/jbc.272.49.30880			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388234	hybrid			2022-12-27	WOS:000071640800047
J	Lievremont, JP; Rizzuto, R; Hendershot, L; Meldolesi, J				Lievremont, JP; Rizzuto, R; Hendershot, L; Meldolesi, J			BiP, a major chaperone protein of the endoplasmic reticulum lumen, plays a direct and important role in the storage of the rapidly exchanging pool of Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; GLUCOSE-REGULATED PROTEIN; HAMSTER OVARY CELLS; DISULFIDE-ISOMERASE; CALRETICULIN INCREASES; MOLECULAR CHAPERONES; PC12 CELLS; CALCIUM; RAT; OVEREXPRESSION	The activity of BiP, the major chaperone of the endoplasmic reticulum (ER) lumen, is known to be Ca2+-regulated; however, the participation of this protein in the ER storage of the cation has not yet been investigated. Here such a role is demonstrated in human epithelial (HeLa) cells transiently transfected with the hamster BiP cDNA and incubated in Ca2+-free medium, as revealed by two different techniques. In the first, co-transfected aequorin was employed as a probe for assaying either the cytosolic of the mitochondrial free Ca2+ concentration. By this approach higher Ca2+ release responses were revealed in BiP-transfected cells by experiments in which extensive store depletion was induced either by repetitive stimulation with inositol 1,4,5-trisphosphate-generating agonists or by treatment with the Ca2+ ionophore, A23187. In the second technique the cells were loaded at the equilibrium with Ca-45, and the release of the tracer observed upon treatment with thapsigargin, a blocker of the ER Ca2+ ATPases, was larger in BiP-transfected than in control cells. The latter results were obtained also when BiP was overexpressed not via transfection but as a response to ER stress by tunicamycin, These results are sustained by increases of the ER Ca2+ storage capacity rather than by artifacts or indirect readjustments induced in the cells by the overexpression of the chaperone since (a) the exogenous and endogenous BiP were both confined to the ER, (b) the expression levels of other proteins active in the ER Ca2+ storage mere not changed, and (c) effects similar to those of wild type BiP were obtained with a deletion mutant devoid of chaperone activity. The specificity of the results was confirmed by parallel Ca-45 experiments carried out in HeLa cells transfected with two other Ca2+-binding proteins, calreticulin and CaBP2(ERp72), only the first of which induced increases of Ca2+ capacity. We conclude that BiP has a dual function, in addition to its chaperone role it is a bona fide ER lumenal Ca2+ storage protein contributing, under resting cell conditions, to around 25% of the store, with a stoichiometry of 1-2 moles of calcium/mole of BiP.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Mitochondrial Physiol, I-35121 Padua, Italy; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; Univ Milan, CNR, Ctr Mol & Cellular Pharmacol, Dept Pharmacol, I-20132 Milan, Italy; Univ Milan, CNR, Ctr Mol & Cellular Pharmacol, C Ceccarelli Ctr Neurobiol, I-20132 Milan, Italy; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; St Jude Children's Research Hospital; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University	Meldolesi, J (corresponding author), Hosp San Raffaele, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.	meldolj@dibit.hsr.it	Rizzuto, Rosario/B-6312-2008; Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [652, 850] Funding Source: Medline	Telethon(Fondazione Telethon)		BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Brewer J. W., 1997, MOL CHAPERONE PROTEI, P415; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; LUCERO HA, 1994, J BIOL CHEM, V269, P23112; MACER DRJ, 1988, J CELL SCI, V91, P61; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PERRIN D, 1991, FEBS LETT, V294, P47, DOI 10.1016/0014-5793(91)81340-E; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAICHMAN M, 1995, J CELL BIOL, V128, P341, DOI 10.1083/jcb.128.3.341; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; RUPP K, 1994, J BIOL CHEM, V269, P2501; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VAN PN, 1989, J BIOL CHEM, V264, P17494; VAN PN, 1993, EUR J BIOCHEM, V213, P789, DOI 10.1111/j.1432-1033.1993.tb17821.x; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WADA I, 1994, J BIOL CHEM, V269, P7464; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797	45	214	221	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30873	30879		10.1074/jbc.272.49.30873	http://dx.doi.org/10.1074/jbc.272.49.30873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388233	hybrid			2022-12-27	WOS:000071640800046
J	Pechatnikova, E; Taylor, EW				Pechatnikova, E; Taylor, EW			Kinetic mechanism of monomeric non-claret disjunctional protein (Ncd) ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; CRYSTAL-STRUCTURE; KINESIN ATPASE; MICROTUBULE; MYOSIN	The non-claret disjunctional protein (Ncd) is a kinesin-related microtubule motor that moves toward the negative end of microtubules. The kinetic mechanism of the monomer motor domain, residues 335-700, satisfied a simple scheme for the binding of 2'-3'-O-(N-methylanthraniloyl) (MANT) ATP, the hydrolysis step, and the binding and release of MANT ADP, [GRAPHICS] where T, D, and P-i refer to nucleotide triphosphate, nucleotide diphosphate, and inorganic phosphate, respectively, and MtN is the complex of an Ncd motor domain with a microtubule site, Rate constants k(1) and k(-4) are the rates of a first order step, an isomerization induced by nucleotide binding, The apparent second order rate constants for the binding steps are 1.5 x 10(6) M-1 s(-1) for MANT ATP and 3.5 x 10(6) M-1 s(-1) for MANT ADP (conditions, 50 mM NaCl, pH 6.9, 21 degrees C), The rate constant of the hydrolysis step (k(2)) was obtained from quench flow measurements of the phosphate burst phase corrected for the contribution of the rate of product release to the transient rate constant, The rate of phosphate dissociation was not measured; the value was assigned to account for a steady state rate of 3 s(-1). The MtN complex is dissociated by ATP at a rate of 10 s(-1) based on light scattering measurements, Dissociation constants of Ncd-nucleotide complexes from microtubules increased in the order adenosine 5'-O-(thiotriphosphate) (ATP gamma S) < ADP-AlF4 < ATP < ADP < ADP-vanadate, Comparison of the properties of Ncd with a monomeric kinesin K332 (Ma and Taylor (1997) J. Biol. Chem, 272, 717-723) showed a close similarity, except that the rate constants for the hydrolysis and ADP re lease steps and the steady state rate are approximately 15-20 times smaller for Ncd, There are two differences that may affect the reaction pathway, The rate of dissociation of MtN by ATP is comparable to the rate of the hydrolysis step, and N . T may dissociate in the cycle, whereas for kinesin, dissociation occurs after hydrolysis, The rate of dissociation of MtN by ADP is larger than the rate of ADP release from MtN . D, whereas for the microtubule-kinesin complex, the rate of dissociation by ADP is smaller than the rate of ADP release, The monomeric Mt . Ncd complex is not processive.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Taylor, EW (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.				NIGMS NIH HHS [GM 51858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; MACDONALD HB, 1990, CELL, V63, P1159; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	16	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30735	30740		10.1074/jbc.272.49.30735	http://dx.doi.org/10.1074/jbc.272.49.30735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388211	hybrid			2022-12-27	WOS:000071640800024
J	Aoki, N; Ito, K; Ito, M				Aoki, N; Ito, K; Ito, M			Isolation and characterization of mouse high-glycine/tyrosine proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIR FOLLICLE DIFFERENTIATION; KERATIN-ASSOCIATED PROTEIN; GENE-EXPRESSION; SEQUENCE; RICH; GLYCINE; GROWTH; SKIN	During hair follicle differentiation, several families of keratin proteins are synthesized sequentially. In the present study, cDNA clones encoding six members of mouse high-glycine/tyrosine protein were isolated by screening a cDNA library prepared from the mouse skin of an anagen phase with a differential hybridization technique, On the basis of their nucleotide and deduced amino acid sequences, they were found to encode two members of high-glycine/tyrosine protein type I and four of type II, Interestingly, one of the four type II proteins had been encoded by two distinct cDNAs. Among the cDNA clones isolated were included the ones encoding a new member of type I and II protein, respectively, which possessed an entire open reading frame. Novel type II protein, termed type II.4, with a molecular mass of 15,130 Da was revealed to have significant direct repeats and a cysteine residue at the carboxyl terminus, which indicates that this protein has characteristics intermediate between high-glycine/tyrosine proteins and cysteine-rich proteins, In addition, the new member of type I protein has some features common with type II protein. We propose to term this protein type I alpha until it is further characterized Northern blot analysis demonstrated that gene expression of mouse high-glycine/tyrosine proteins followed the hair cycle growth fundamentally and reached its peak at day 9 in the first hair cycle, while two peaks of their expression were observed at day 33 and day 39 in the second cycle, Their transcripts were expressed in the cortical cells of hair follicles but not in the cells of the outer root sheath, inner root sheath, or medulla. Moreover, their gene expression commenced at different levels in cortical cells, The novel findings that each gene is activated transcriptionally with a distinct expression pattern spatially and temporally suggest that there is a remarkable difference in the distribution of these proteins in hair.			Aoki, N (corresponding author), NIIGATA UNIV, SCH MED, DEPT DERMATOL, ASAHIMACHI DORI, NIIGATA 951, JAPAN.							DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; Emonet N, 1997, J DERMATOL SCI, V14, P1, DOI 10.1016/S0923-1811(96)00541-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRENKEL MJ, 1975, J CHROMATOGR, V111, P397, DOI 10.1016/S0021-9673(00)99289-6; FRENKEL MJ, 1973, EUR J BIOCHEM, V34, P112, DOI 10.1111/j.1432-1033.1973.tb02736.x; GILLESPIE JM, 1974, COMP BIOCHEM PHYSIOL, V47, P339, DOI 10.1016/0305-0491(74)90063-7; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; GILLESPIE JM, 1983, BIOCH PHYSL SKIN, V2, P475; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; MARSHALL RC, 1976, AUST J BIOL SCI, V29, P1; MARSHALL RC, 1980, P 6 INT WOOL TEXT RE, V2, P147; MCNAB AR, 1989, J INVEST DERMATOL, V92, P263, DOI 10.1111/1523-1747.ep12276832; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Rogers G. E., 1989, BIOL WOOL HAIR, P69; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WOOD L, 1990, J BIOL CHEM, V265, P21375	25	25	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30512	30518		10.1074/jbc.272.48.30512	http://dx.doi.org/10.1074/jbc.272.48.30512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374545	hybrid			2022-12-27	WOS:A1997YH61300077
J	Chinery, R; Brockman, JA; Dransfield, DT; Coffey, RJ				Chinery, R; Brockman, JA; Dransfield, DT; Coffey, RJ			Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta - A critical role for protein kinase A-mediated phosphorylation of Ser(299)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; LEUCINE ZIPPER; SIGNAL TRANSDUCTION; C/EBP FAMILY; EXPRESSION; NF-IL6; CANCER; MEMBER; CELLS; ACID	Alterations in intracellular oxidative status activate several signal transduction pathways resulting in distinct patterns of gene expression. Treatment of colorectal cancer cells with antioxidants can lead to apoptosis by induction of p21 through a mechanism involving CCAAT/enhancer-binding protein beta (C/EBP beta). Herein, we demonstrate that the antioxidant pyrrolidinedithio-carbamate activates cAMP-dependent protein kinase (PKA) in a colorectal cancer cell line DKO-1. Activation of PKA phosphorylates Ser(299) within C/EBP beta, which is essential for protein translocation to the nucleus. Pharmacological inhibition of PKA and mutation of Ser(299) to alanine blocks C/EBP beta nuclear translocation and induction of p21. Our results indicate that a cAMP-dependent phosphorylation of C/EBP beta at Ser(299) is critical for nuclear translocation of this protein and its subsequent transactivation of genes in response to antioxidant treatment.	VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232; MED COLL GEORGIA,INST MOL MED & GENET,AUGUSTA,GA 30912	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University System of Georgia; Augusta University	Chinery, R (corresponding author), VANDERBILT UNIV,MED CTR,DEPT MED,CC2201 MED CTR N,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER; NCI NIH HHS [CA46413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COFFEY RJ, 1987, CANCER RES, V47, P4590; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANIELSON P, 1988, DNA CELL BIOL, V12, P261; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; GREENWALD P, 1995, CANCER EPIDEM BIOMAR, V4, P691; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONEY CW, 1992, J BIOL CHEM, V267, P19296; MASUDA H, 1993, JPN CIRC J, V57, P1007, DOI 10.1253/jcj.57.1007; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORSON BC, 1983, CANCER SURV, V2, P451; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	29	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30356	30361		10.1074/jbc.272.48.30356	http://dx.doi.org/10.1074/jbc.272.48.30356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374525	hybrid			2022-12-27	WOS:A1997YH61300057
J	Sorensen, T; Vilsen, B; Andersen, JP				Sorensen, T; Vilsen, B; Andersen, JP			Mutation Lys(758)->Ile of the sarcoplasmic reticulum Ca2+-ATPase enhances dephosphorylation of E2P and inhibits the E-2 to E1Ca2 transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; PERTURBED REACTION CYCLES; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; KINETIC CHARACTERIZATION; ATP HYDROLYSIS; CA2+ TRANSPORT; ALPHA-SUBUNIT; CA-2+-ATPASE; MECHANISM	The highly conserved lysine residue Lys(758) in the fifth stalk segment of the sarcoplasmic reticulum Ca2+-ATPase was substituted with either isoleucine or arginine by site-directed mutagenesis. The substitution with arginine was without significant effects on Ca2+-ATPase function, whereas multiple changes of functional characteristics were observed with the Lys(758) --> Ile mutant. These included insensitivity of ATPase activity to the calcium ionophore A23187, an alkaline shift of the pH dependence of ATPase activity, reduced maximum molecular turnover rate and steady-state phosphorylation level, reduced apparent affinities for Ca2+ and inorganic phosphate, as well as increased sensitivity to inhibition by vanadate. Analysis of the partial reaction steps of the enzyme cycle traced these changes to two steps. The rate of dephosphorylation of the ADP-insensitive phosphoenzyme intermediate (E2P) was increased, irrespective of variations of pH, K+, Ca2+, and dimethyl sulfoxide concentration. In addition, the rate of conversion of the dephosphoenzyme with low Ca2+ affinity (E-2) to the Ca2+-bound form activated for phosphorylation (E1Ca2) was reduced in the mutant, and the ATP-induced rate enhancement of this step required higher ATP concentrations in the mutant compared with the wild type.	AARHUS UNIV,DEPT PHYSIOL,DK-8000 AARHUS C,DENMARK	Aarhus University			Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499; Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BISHOP JE, 1988, J BIOL CHEM, V263, P1886; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; FORGE V, 1993, J BIOL CHEM, V268, P10953; HARA H, 1986, J BIOL CHEM, V261, P6584; HENAO F, 1991, EUR J BIOCHEM, V202, P559, DOI 10.1111/j.1432-1033.1991.tb16408.x; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V705, P38, DOI 10.1016/0167-4838(82)90333-8; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LUND S, 1988, J BIOL CHEM, V263, P1654; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6947; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TAKISAWA H, 1978, J BIOCHEM-TOKYO, V83, P1275, DOI 10.1093/oxfordjournals.jbchem.a132034; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	54	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30244	30253		10.1074/jbc.272.48.30244	http://dx.doi.org/10.1074/jbc.272.48.30244			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374509	hybrid			2022-12-27	WOS:A1997YH61300041
J	Liu, C; Shen, K; Liu, ZY; Noguchi, CT				Liu, C; Shen, K; Liu, ZY; Noguchi, CT			Regulated human erythropoietin receptor expression in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; ERYTHROID-CELLS; NERVOUS-SYSTEM; TRANSCRIPTION; DIFFERENTIATION; PROLIFERATION; HEMATOPOIESIS	Erythropoietin (Epo) is known for its role in erythropoiesis and acts by binding to its receptor (EpoR) on the surface of erythroid progenitors, EpoR activity follows the site of hematopoiesis from the embryonic yolk sac to the fetal liver and then the adult spleen and bone marrow, Expression of EpoR has also been observed in selected cells of non-hematopoietic origin, such as the embryonic mouse brain during mid-gestation, at levels comparable to adult bone marrow, EpoR transcripts in brain decrease during development falling by birth to less than 1-3% of the level in hematopoietic tissue, We have now recapitulated this pattern of expression using a human EpoR transgene consisting of an 80-kb human EpoR genomic fragment. The highest level of expression was observed in the embryonic yolk sac and fetal liver, analogous to the endogenous gene, in addition to ex- pression in adult spleen and bone marrow, Although activity of this transgene in brain is initially lower than the endogenous gene, it does exhibit the down-regulation observed for the endogenous gene in adult brain, The expression pattern of hybrid transgenes of an hEpoR promoter fused to beta-galactosidase in 9.5-day embryos suggested that the hEpoR promoter region between -1778 and -150 bp 5' of the transcription start site is necessary to direct EpoR expression in the neural tube, EpoR expression in the neural tube may be the origin of the EpoR transcripts detected in brain during development, These data demonstrate that both the mouse and human EpoR genes contain regulatory elements to direct significant levels of expression in a developmentally controlled manner in brain and suggest that in addition to its function during erythropoiesis, EpoR may play a role in the development of selected non-hematopoietic tissue.	NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Noguchi, CT (corresponding author), NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA.	cnoguchi@helix.nih.gov						ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CARLINI RG, 1995, J CARDIOVASC PHARM, V26, P889, DOI 10.1097/00005344-199512000-00006; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; FLAMME I, 1992, DEVELOPMENT, V116, P435; Haller H, 1996, KIDNEY INT, V50, P481, DOI 10.1038/ki.1996.339; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Li Y, 1996, PEDIATR RES, V40, P376, DOI 10.1203/00006450-199609000-00002; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu C, 1996, P ASSOC AM PHYSICIAN, V108, P449; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; MAOUCHE L, 1991, BLOOD, V78, P2557; MAOUCHE L, 1994, NUCLEIC ACIDS RES, V22, P338, DOI 10.1093/nar/22.3.338; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; NITTA K, 1995, EUR J PHARM-ENVIRON, V293, P491, DOI 10.1016/S0014-2999(95)80109-X; NOGUCHI CT, 1991, BLOOD, V78, P2548; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; TABIRA T, 1995, INT J DEV NEUROSCI, V13, P241, DOI 10.1016/0736-5748(94)00020-4; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; YASUDA Y, 1993, DEV GROWTH DIFFER, V35, P711; YOUSSOUFIAN H, 1993, MOL CELL BIOL, V13, P98, DOI 10.1128/MCB.13.1.98; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; YOUSSOUFIAN H, 1994, BLOOD, V83, P1428; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	42	123	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32395	32400		10.1074/jbc.272.51.32395	http://dx.doi.org/10.1074/jbc.272.51.32395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405448	hybrid			2022-12-27	WOS:000071108000067
J	Huang, XF; Shelness, GS				Huang, XF; Shelness, GS			Identification of cysteine pairs within the amino-terminal 5% of apolipoprotein B essential for hepatic lipoprotein assembly and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; HETEROLOGOUS EXPRESSION; ENDOPLASMIC-RETICULUM; CELLS; HYPOBETALIPOPROTEINEMIA; LOCALIZATION; DENSITY; BINDING; MUTANT; LIPASE	There is growing evidence that the amino-terminal globular domain of apolipoprotein B (apoB) is essential for lipoprotein particle formation in the hepatic endoplasmic reticulum, To identify the structural requirements for its function in lipoprotein assembly, cysteine (Cys) pairs required to form the seven disulfide bonds within the amino-terminal 21% of apoB were replaced in groups or individually by serine. Substitution of Cys pairs required for formation of disulfide bonds 1-3 or 4-7 (numbered from amino to carboxyl terminus) completely blocked the secretion of apoB28 in transfected HepG2 cells. To identify the specific disulfide bonds required for secretion, Cys pairs were mutated individually, Substitution of Cys pairs required for disulfide bonds 1, 3, 5, 6, or 7 had little or no impact on apoB28 secretion or buoyant density. In contrast, individual substitution of Cys pair 2 (amino acid residues 51 and 70) or 4 (218 and 234) severely inhibited apoB28 secretion and its capacity to undergo intracellular assembly with lipid. The same assembly and secretion defects were observed when these mutations were expressed as part of apoB50. These studies provide direct evidence that the ability of the internal lipophilic regions of apoB to engage in the recruitment and sequestration of lipid during translation is critically dependent upon a structural configuration contained within or affected by the amino terminal 5% of the protein.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL49373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; COLLINS DR, 1988, NUCLEIC ACIDS RES, V16, P8361, DOI 10.1093/nar/16.17.8361; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HUANG LS, 1989, J BIOL CHEM, V264, P11394; Ingram MF, 1997, J BIOL CHEM, V272, P10279; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LINTON MF, 1993, J LIPID RES, V34, P521; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PATEL SB, 1995, J LIPID RES, V36, P2090; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; TANIYAMA Y, 1992, J BIOL CHEM, V267, P4619; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YUK MH, 1995, J BIOL CHEM, V270, P20169, DOI 10.1074/jbc.270.34.20169	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31872	31876		10.1074/jbc.272.50.31872	http://dx.doi.org/10.1074/jbc.272.50.31872			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395534	hybrid			2022-12-27	WOS:A1997YL41900093
J	Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH				Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .2. The gp44/62 clamp loader interacts with a single defined face of the sliding clamp ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; HEXAMERIC HELICASES; III HOLOENZYME; HYDROLYSIS; MECHANISM	The phage T4 gp45 sliding clamp is a ring-shaped replication accessory protein that is mounted onto DNA in an ATP-dependent manner by the gp44/62 clamp loader, In the preceding paper (Pietroni, P., Young, M. C., Latham, G. J., and von Hippel, P. H. (1997) J. Biol. Chem. 272, 31666-31676), two gp45 mutants were exploited to probe interactions of the sliding clamp ring with the gp44/62 loading machinery at various steps during the clamp loading process. In this report, these studies are extended to examine the polarity of the binding interaction between gp45 and gp44/62. Three different gp45 mutants containing a single cysteine in three topographically distinct positions were used, Several different reporter groups, including extrinsic fluorophores, a photo-cross-linker, and a biotin linker for use in a novel ''streptavidin interference assay,'' were covalently attached to these cysteine residues, Since gp45 is a trimeric protein, these three different mutations allowed us to probe up to nine distinct local environments along the surface of the sliding clamp in the presence and absence of other replication proteins. The results show that the gp44/62-ATP clamp loader complex binds exclusively to the C-terminal (S19C) face of the gp45 ring.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker T. A., 1992, DNA REPLICATION; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; HAUGLAND RP, 1992, MOL PROBES HDB FLUOR; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; LATHAM GJ, 1997, J BIOL CHEM, V272, P31666; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; PIETRONI P, 1997, J BIOL CHEM, V272, P31685; RUSH J, 1989, J BIOL CHEM, V264, P10943; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	23	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31677	31684		10.1074/jbc.272.50.31677	http://dx.doi.org/10.1074/jbc.272.50.31677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395509	hybrid			2022-12-27	WOS:A1997YL41900068
J	Wiemelt, AP; Engleka, MJ; Skorupa, AF; McMorris, FA				Wiemelt, AP; Engleka, MJ; Skorupa, AF; McMorris, FA			Immunochemical visualization and quantitation of cyclic AMP in single cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CENTRAL NERVOUS-SYSTEM; OLIGODENDROCYTE DIFFERENTIATION; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; CAMP; INDUCTION; RADIOIMMUNOASSAY; ANTIBODIES; IMMUNOCYTOCHEMISTRY	Adenosine 3':5'-cyclic monophosphate (cAMP) is a key second messenger in signaling pathways governing many cellular processes. To define the subcellular localization and relative abundance of cAMP, we developed a novel immunochemical approach based on acrolein fixation to visualize cAMP within cells. We describe here the fixation and immobilization of cAMP within cells and the production of specific, high titer polyclonal antibodies that recognize cAMP. Relative levels of cAMP immunofluorescence were quantitated in glial cells (oligodendrocytes, astrocytes, Schwann cells, and glioma cells) that were either untreated or treated with activators of endogenous adenylyl cyclase to raise cAMP levels, In treated cells, cAMP immunofluorescence is strongly localized in the perinuclear cytoplasm.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DAVID MAHONEY INST NEUROL SCI, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania					NINDS NIH HHS [NS32394, NS26119, NS32122] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032122, R01NS026119, R01NS032394] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOLSOVER S, 1995, BIOCHEM SOC T, V23, P627, DOI 10.1042/bst0230627; CAILLA HL, 1973, ANAL BIOCHEM, V56, P394, DOI 10.1016/0003-2697(73)90205-4; CUMMING R, 1980, J HISTOCHEM CYTOCHEM, V28, P54, DOI 10.1177/28.1.6243322; DEVENTE J, 1993, HISTOCHEMISTRY, V99, P457, DOI 10.1007/BF00274098; DEVENTE J, 1987, NEUROSCIENCE, V22, P361, DOI 10.1016/0306-4522(87)90226-0; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DILIBERTO PA, 1994, METHOD CELL BIOL, V40, P243; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; Horton J K, 1995, Methods Mol Biol, V41, P91; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JESSEN KR, 1991, ANN NY ACAD SCI, V633, P78; KAPOOR CL, 1982, HDB EXPT PHARM, P333; KING JC, 1983, J HISTOCHEM CYTOCHEM, V31, P62, DOI 10.1177/31.1.6187805; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LAD PJ, 1981, BIOCHEM BIOPH RES CO, V103, P629, DOI 10.1016/0006-291X(81)90497-6; LESTER DS, 1988, AM J PHYSIOL, V254, pC802, DOI 10.1152/ajpcell.1988.254.6.C802; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCMORRIS FA, 1983, BIOCHIM BIOPHYS ACTA, V762, P560, DOI 10.1016/0167-4889(83)90060-5; MCMORRIS FA, 1983, J NEUROCHEM, V41, P506, DOI 10.1111/j.1471-4159.1983.tb04768.x; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MIRSKY R, 1990, SEMINARS NEUROSCIENC, V2, P423; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; RAIBLE DW, 1990, J NEUROSCI RES, V27, P43, DOI 10.1002/jnr.490270107; RAIBLE DW, 1989, DEV BIOL, V133, P437, DOI 10.1016/0012-1606(89)90047-X; RAIBLE DW, 1993, J NEUROSCI RES, V34, P287, DOI 10.1002/jnr.490340305; RALL TW, 1982, J CYCLIC NUCL PROT, V8, P243; RATNER N, 1984, J CELL BIOL, V98, P1150, DOI 10.1083/jcb.98.3.1150; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEIN JC, 1987, J BIOL CHEM, V262, P3002; Steiner A L, 1976, Adv Cyclic Nucleotide Res, V7, P115; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TSIEN RY, 1992, AM J PHYSIOL, V263, pC723, DOI 10.1152/ajpcell.1992.263.4.C723; Villegas S, 1996, ANAL BIOCHEM, V235, P102, DOI 10.1006/abio.1996.0097; Zhang QH, 1996, DEV BIOL, V176, P51, DOI 10.1006/dbio.1996.9995; Zufall F, 1993, EXS, V66, P135	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31489	31495		10.1074/jbc.272.50.31489	http://dx.doi.org/10.1074/jbc.272.50.31489			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395484	hybrid			2022-12-27	WOS:A1997YL41900043
J	Takemura, T; Kondo, S; Homma, T; Sakai, M; Harris, RC				Takemura, T; Kondo, S; Homma, T; Sakai, M; Harris, RC			The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE TUBULAR-NECROSIS; FACTOR RECEPTOR; RAT-KIDNEY; EXTRACELLULAR-MATRIX; PHORBOL ESTER; FACTOR-ALPHA; APOPTOSIS; EGF; PROTEIN; REGENERATION	To understand whether expression of membrane-anchored heparin binding epidermal growth factor (proHB-EGF) is involved in renal epithelial cell survival, rat membrane-bound HB-EGF precursor was stably transfected into a renal epithelial cell line, NRK 52E cells (NRKproHB-EGF). When exposed to 10% fetal calf serum (FCS), there were no differences in growth rates among wild-type (WT), vector-transfected (NRKvector), and NRKproHB-EGF., However, when cells were grown in the presence of 1% FCS, the growth rate of NRKproHB-EGF was 65% faster, When confluent cell monolayers were exposed to H-2,O-2, or etoposide, WT or NRKvector exhibited significant apoptotic bodies and DNA laddering; in contrast, NRKproHB-EGF were resistant to both stimuli, as indicated by increased cell viability and marked decrease of apoptotic bodies and DNA laddering, When plated at high density onto plastic dishes without FCS, WT and NRKvector formed few attachments, did not proliferate, and underwent apoptosis, By day 3, no cells survived, Addition of exogenous recombinant HB-EGF (10(-8) nr) to WT or NRKvector increased cell survival by <10% and incubation with conditioned media of NRKproHB-EGF EGF had no effect, In contrast, NRKproHB-EGF attached and formed epithelial colonies, although they did not proliferate, After 3 days, cell viability was 84% of the initial cell number plated, and no evidence of apoptosis was present, When plated in 10% FCS, NRKproHB-EGF attachment to plastic substratum at 1, 2, and 3 h was 250% greater than that of WT or NRKvector. Addition of exogenous recombinant human HB-EGF to WT or NRKvector increased attachment by <50%., When grown on poly(2-hydroxyethyl methacrylate) or in the presence of the integrin receptor-blocking peptide GRG-DTP, neither WT nor NRKvector attached to the substratum or formed cell-cell attachments, Compared with WT or, NRKvector, NRKproHB-EGF exhibited 300% greater cell viability on either poly(a-hydroxyethyl methacrylate)coated dishes or in the presence of GRGDTP and formed cell clusters, When plated at low density (1 x 10(3) cells/1.5-cm dish) or at high density in the presence of an anti-HB-EGF blocking antibody, NRKproHB-EGF failed to form epithelial colonies, Addition of formalin fixed NRKproHB-EGF promoted EGF receptor tyrosine phosphorylation in quiescent A431 cells and stimulated DNA synthesis and prevented H-2,O-2,-induced apoptosis in renal epithelial cells, These results indicate that membrane bound HB-EGF promotes renal epithelial cell survival, possibly by promoting cell-matrix and cell-cell interactions, The failure of either conditioned media or exogenous HB-EGF to reproduce these findings suggests that juxtacrine or tightly coupled paracrine interactions underlie this cytoprotection.	Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Harris, RC (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, S-3223 Med Ctr N, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK51265, DK39261] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, R01DK051265] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALLEN J, 1992, RENAL FAILURE, V14, P453, DOI 10.3109/08860229209047652; BEHRENS MT, 1989, AM J PHYSIOL, V257, pF1059, DOI 10.1152/ajprenal.1989.257.6.F1059; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COIMBRA TM, 1990, AM J PHYSIOL, V259, pF438, DOI 10.1152/ajprenal.1990.259.3.F438; COLES HSR, 1993, DEVELOPMENT, V118, P777; CREELY JJ, 1988, CONNECT TISSUE RES, V18, P107, DOI 10.3109/03008208809008063; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GOBE GC, 1990, LAB INVEST, V63, P770; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOMMA T, 1995, J CLIN INVEST, V96, P1018, DOI 10.1172/JCI118087; HUMES HD, 1989, J CLIN INVEST, V84, P1757, DOI 10.1172/JCI114359; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENNEDY WA, 1994, J UROLOGY, V152, P658, DOI 10.1016/S0022-5347(17)32675-7; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCARTHY SA, GENES DEV, V9, P1953; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MILLER SB, 1992, P NATL ACAD SCI USA, V89, P11876, DOI 10.1073/pnas.89.24.11876; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; NORMAN J, 1990, CLIN SCI, V78, P445, DOI 10.1042/cs0780445; NOUWEN EJ, 1994, LAB INVEST, V70, P479; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RACUSEN LC, 1994, J LAB CLIN MED, V123, P357; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REISS R, 1990, KIDNEY INT, V37, P492; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; Sakai M, 1997, J CLIN INVEST, V99, P2128, DOI 10.1172/JCI119386; SCHUMER M, 1992, AM J PATHOL, V140, P831; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; WALKER C, 1991, CANCER RES, V51, P2973; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	43	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31036	31042		10.1074/jbc.272.49.31036	http://dx.doi.org/10.1074/jbc.272.49.31036			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388253	hybrid			2022-12-27	WOS:000071640800066
J	Krook, A; Whitehead, JP; Dobson, SP; Griffiths, MR; Ouwens, M; Baker, C; Hayward, AC; Sen, SK; Maassen, JA; Siddle, K; Tavare, JM; ORahilly, S				Krook, A; Whitehead, JP; Dobson, SP; Griffiths, MR; Ouwens, M; Baker, C; Hayward, AC; Sen, SK; Maassen, JA; Siddle, K; Tavare, JM; ORahilly, S			Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphoinositide 3-kinase activation alone is not sufficient for the mediation of insulin's metabolic and mitogenic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-UPTAKE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; P21(RAS)-GTP FORMATION; SIGNAL-TRANSDUCTION; GLUT4 TRANSLOCATION; SUBSTRATE-1; RESISTANCE; GENE	We have recently reported (1) that two naturally occurring mutants of the insulin receptor tyrosine kinase domain, Arg-1174 --> Gln and Pro-1178 --> Leu (Gln-1174 and Leu1178, respectively), both found in patients with inherited severe insulin resistance, markedly impaired receptor tyrosine autophosphorylation, with both mutant receptors; being unable to mediate the stimulation of glycogen synthesis or mitogenesis by insulin when expressed hh Chinese hamster ovary cells, However, these mutations did not fully prevent IRS-1 phosphorylation in response to insulin in these cells, suggesting that IRS-1 alone may not be sufficient to mediate insulin's metabolic and mitogenic effects, In the present study, we have demonstrated that these mutations also impair the ability of the insulin receptor to activate the transcription factor Elk-1 and promote GLUT4 translocation to the plasma membrane, Although at law concentrations of insulin, the mutant receptors were impaired in their ability to stimulate the tyrosine phosphorylation of IRS-1, at higher insulin concentrations we confirmed that the cells expressing the mutant receptors showed significantly increased tyrosine phosphorylation of IRS-1 compared with parental nontransfected cells, In addition, at comparable insulin concentrations, the association of the p85 alpha subunit of phosphoinositide 3-kinase (PI3-kinase) with IRS-1 and the enzymatic activity of IRS-1-associated PI3-kinase were significantly enhanced in cells expressing the mutant receptors, in contrast, no significant stimulation of the tyrosine phosphorylation of Shc, GTP loading of Ras, or mitogen-activated protein kinase phosphorylation was seen in cell lines expressing these mutant receptors. Thus, no activation of any measurable mitogenic or metabolic response was detectable, despite significant insulin-induced phosphorylation of IRS-1 and its association with PI3-kinase in cells stably expressing the mutant insulin receptors, These findings suggest that PI3-kinase activation alone may be insufficient to mediate a wide range of the metabolic and mitogenic effects of insulin, Additionally, the data provide support for the notion that insulin activation of Ras is more closely linked with Shc, and not IRS-1, phosphorylation.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; UNIV BRISTOL,DEPT BIOCHEM,BRISTOL,AVON,ENGLAND; LEIDEN UNIV,SYLVIUS LABS,DEPT MED BIOCHEM,NL-2300 RA LEIDEN,NETHERLANDS	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol; Leiden University; Leiden University - Excl LUMC			Ouwens, Margriet/H-2442-2013; Whitehead, Jonathan/F-5022-2014; Krook, Anna/K-1192-2015; O'Rahilly, Stephen/ABF-6509-2020	Ouwens, Margriet/0000-0001-6709-2702; Krook, Anna/0000-0002-0891-0258; O'Rahilly, Stephen/0000-0003-2199-4449; Whitehead, Jonathan/0000-0003-3978-3148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Dobson SP, 1996, FEBS LETT, V393, P179, DOI 10.1016/0014-5793(96)00879-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen BF, 1996, BIOCHEM J, V315, P271; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG B, 1991, J BIOL CHEM, V266, P990	34	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30208	30214		10.1074/jbc.272.48.30208	http://dx.doi.org/10.1074/jbc.272.48.30208			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374504	hybrid			2022-12-27	WOS:A1997YH61300036
J	Nunomura, W; Takakuwa, Y; Tokimitsu, R; Krauss, SW; Kawashima, M; Mohandas, N				Nunomura, W; Takakuwa, Y; Tokimitsu, R; Krauss, SW; Kawashima, M; Mohandas, N			Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin - Implications for modulation of CD44-ankyrin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SKELETAL PROTEIN-4.1; ERYTHROCYTE ANION-EXCHANGER; SPECTRIN-ACTIN BINDING; PLASMA-MEMBRANE; ANKYRIN-BINDING; TRANSMEMBRANE GLYCOPROTEIN; OPTICAL BIOSENSOR; RESONANT MIRROR; GLYCOPHORIN-C; CELLS	Erythrocyte membrane skeletal protein 4.1 isoforms have been identified in a variety of non-erythroid cells. However, interactions between protein 4.1 and its binding partners in non-erythroid cell membranes are poorly understood. In the erythrocyte membrane, protein 4.1 binds to the cytoplasmic domain of band 3 and, through this interaction, modulates ankyrin binding to band 3. The sequences LRRRY or IRRRY in band 3 mediate the interaction between band 3 and protein 4.1. The cytoplasmic domain of CD44, a transmembrane glycoprotein found in erythroid as well. as non-erythroid cells, has internal sequences SRRRC and QKKKL. We wanted to determine if protein 4.1 binds to CD44 in a fashion analogous to its binding to band 3 and through this interaction modulates ankyrin binding to CD44, We report here that protein 4.1 binds to the cytoplasmic domain of CD44 with a dissociation constant on the order of 10(-7) M and that Ca2+ and calmodulin reduce the affinity of this interaction Furthermore, although independent binding of both protein 4.1 and ankyrin to CD44 could be documented, binding of protein 4.1 prevented subsequent ankyrin binding These studies have enabled us to identify a potentially important functional role for protein 4.1 in modulating ankyrin binding to CD44.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720; TOKYO WOMENS MED COLL,DEPT BIOCHEM,SHINJUKU KU,TOKYO 162,JAPAN; TOKYO WOMENS MED COLL,DEPT DERMATOL,SHINJUKU KU,TOKYO 162,JAPAN	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tokyo Women's Medical University; Tokyo Women's Medical University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579] Funding Source: Medline; NIDDK NIH HHS [DK26263, DK32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DISCHER D, 1993, J BIOL CHEM, V268, P7186; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P887; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MORROW JS, 1998, IN PRESS HDB PHYSL; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shimizu T, 1996, HISTOL HISTOPATHOL, V11, P495; Shimizu T, 1996, BIOL CELL, V86, P19, DOI 10.1016/0248-4900(96)89520-7; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; TAMMI R, 1994, ARCH DERMATOL RES, V286, P21, DOI 10.1007/BF00375839; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010	54	108	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30322	30328		10.1074/jbc.272.48.30322	http://dx.doi.org/10.1074/jbc.272.48.30322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374519	hybrid			2022-12-27	WOS:A1997YH61300051
J	Perona, JJ; Craik, CS				Perona, JJ; Craik, CS			Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN CYTOMEGALOVIRUS PROTEASE; ALPHA-LYTIC PROTEASE; CONVERTING TRYPSIN; CRYSTAL-STRUCTURE; PLASMINOGEN-ACTIVATOR; CATALYTIC DOMAIN; BINDING POCKET; DEHYDROGENASE; RESOLUTION; MUTATIONS		UNIV CALIF SANTA BARBARA, INTERDEPT PROGRAM BIOCHEM & MOL BIOL, SANTA BARBARA, CA 93106 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Santa Barbara; University of California System; University of California San Francisco	Perona, JJ (corresponding author), UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA.							Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BONE R, 1987, BIOCHEMISTRY-US, V26, P7609, DOI 10.1021/bi00398a012; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; COREY DR, 1992, J AM CHEM SOC, V114, P4905, DOI 10.1021/ja00038a067; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MACE JE, 1995, J MOL BIOL, V251, P116, DOI 10.1006/jmbi.1995.0420; MACE JE, 1995, J MOL BIOL, V254, P720, DOI 10.1006/jmbi.1995.0650; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MATTHEWS BW, 1977, PROTEINS, V3, P404; NARAYANA SVL, 1994, J MOL BIOL, V235, P695, DOI 10.1006/jmbi.1994.1021; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; PERONA JJ, 1993, J MOL BIOL, V230, P934, DOI 10.1006/jmbi.1993.1211; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, BIOCHEMISTRY-US, V36, P5381, DOI 10.1021/bi9617522; Qiu XY, 1996, NATURE, V383, P275, DOI 10.1038/383275a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shieh HS, 1996, NATURE, V383, P279, DOI 10.1038/383279a0; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; TSU CA, 1994, J BIOL CHEM, V269, P19565; Tsu CA, 1997, BIOCHEMISTRY-US, V36, P5393, DOI 10.1021/bi961753u; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WILLETT WS, 1995, BIOCHEMISTRY-US, V34, P2172, DOI 10.1021/bi00007a010	36	288	299	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29987	29990		10.1074/jbc.272.48.29987	http://dx.doi.org/10.1074/jbc.272.48.29987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374470	hybrid			2022-12-27	WOS:A1997YH61300002
J	Bisaillon, M; Lemay, G				Bisaillon, M; Lemay, G			Characterization of the reovirus lambda 1 protein RNA 5'-triphosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CAPPING ENZYME; 5'-TERMINAL STRUCTURE; GUANYLYLTRANSFERASE; CONTAINS; SEQUENCE; CORE; SEGMENT; CELLS; ACIDS	Characterization of the phosphohydrolytic activities of recombinant reovirus lambda 1 protein demonstrates that, in addition to the previously reported nucleoside triphosphate phosphohydrolase and helicase activities, the protein also possesses RNA 5'-triphosphatase activity, This activity was absolutely dependent on the presence of a divalent cation, Mg2+ or Mn2+, and specifically removes the 5'-gamma-phosphate at the end of triphosphate-terminated RNAs, Kinetic competition analysis showed that nucleoside triphosphate phosphohydrolase and RNA 5'-triphosphatase reactions are carried out at a common active site, These results strongly support the idea that, in addition to its role as an RNA helicase during transcription of the viral genome, lambda 1 also participates during formation of the cap structure at the 5' end of newly synthesized reovirus mRNAs, The lambda 1 protein represents only the third RNA triphosphatase whose primary structure is known and the first described in a double stranded RNA virus.	UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				BANERJEE AK, 1971, NATURE-NEW BIOL, V230, P169, DOI 10.1038/newbio230169a0; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; BORSA J, 1970, J VIROL, V6, P295, DOI 10.1128/JVI.6.3.295-302.1970; CASHDOLLAR LW, 1994, RES VIROLOGY, V145, P277, DOI 10.1016/S0923-2516(07)80032-X; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; FAUST M, 1975, NUCLEIC ACIDS RES, V197, P1329; FURUICHI Y, 1977, NUCLEIC ACIDS RES, V4, P3341, DOI 10.1093/nar/4.10.3341; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; ITOH N, 1984, J BIOL CHEM, V259, P3923; KAPULER AM, 1970, NATURE, V225, P1209, DOI 10.1038/2251209a0; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; LEMAY G, 1994, J GEN VIROL, V75, P3261, DOI 10.1099/0022-1317-75-11-3261; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Nibert Max L., 1996, P691; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; XU PT, 1993, VIROLOGY, V197, P726, DOI 10.1006/viro.1993.1648; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996	30	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29954	29957		10.1074/jbc.272.47.29954	http://dx.doi.org/10.1074/jbc.272.47.29954			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368073	hybrid			2022-12-27	WOS:A1997YG64700083
J	Cryns, VL; Byun, Y; Rana, A; Mellor, H; Lustig, KD; Ghanem, L; Parker, PJ; Kirschner, MW; Yuan, JY				Cryns, VL; Byun, Y; Rana, A; Mellor, H; Lustig, KD; Ghanem, L; Parker, PJ; Kirschner, MW; Yuan, JY			Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis - Identification by a novel, small pool expression cloning strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; ACTIVATION; CLEAVAGE; CELLS; ICE; PKN	The caspase family of proteases plays a critical role in the execution of apoptosis, However, efforts to decipher the molecular mechanisms by which caspases induce cell death have been greatly hindered by the lack of systematic and broadly applicable strategies to identify their substrates. Here we describe a novel expression cloning strategy to rapidly isolate cDNAs encoding caspase substrates that are cleaved during apoptosis, Small cDNA pools (approximately 100 clones each) are transcribed/translated in vitro in the presence of [S-35]methionine; these labeled protein pools are then incubated with cytosolic extracts from control and apoptotic cells, cDNA pools encoding proteins that are specifically cleaved by the apoptotic extract and whose cleavage is prevented by the caspase inhibitor acetyl-Tyr-Val-Ala-Asp chloromethylketone are subdivided and retested until a single cDNA is isolated, Using this approach, we isolated a partial cDNA encoding protein kinase C-related kinase 2 (PRK2), a serine-threonine kinase, and demonstrate that full-length human PRK2 is proteolyzed by caspase-3 at Asp(117) and Asp(700) in vitro, In addition, PRK2 is cleaved rapidly during Fas-and staurosporine-induced apoptosis in vitro by caspase-3 or a closely related caspase, Both of the major apoptotic cleavage sites of PRK2 in vivo lie within its regulatory domain, suggesting that its activity may be deregulated by proteolysis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,CHARLESTOWN,MA 02129; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Cancer Research UK			Ghanem, Louis/R-3733-2016; Parker, Peter j/D-5192-2013	Ghanem, Louis/0000-0002-7723-5241; parker, peter/0000-0002-6218-2933; Mellor, Harry/0000-0003-3894-0623	NCI NIH HHS [K08-CA01752-04] Funding Source: Medline; NIA NIH HHS [AG12859-01] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859, R01AG012859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Lustig KD, 1996, DEVELOPMENT, V122, P4001; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Yu WP, 1997, J BIOL CHEM, V272, P10030	26	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29449	29453		10.1074/jbc.272.47.29449	http://dx.doi.org/10.1074/jbc.272.47.29449			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368003	hybrid			2022-12-27	WOS:A1997YG64700013
J	Dickson, RC; Nagiec, EE; Wells, GB; Nagiec, MM; Lester, RL				Dickson, RC; Nagiec, EE; Wells, GB; Nagiec, MM; Lester, RL			Synthesis of mannose-(inositol-P)(2)-ceramide, the major sphingolipid in Saccharomyces cerevisiae, requires the IPT1 (YDR072c) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITOL-CONTAINING SPHINGOLIPIDS; YEAST HISTOPLASMA-CAPSULATUM; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPID BIOSYNTHESIS; STRAINS; RESISTANCE; MEMBRANE; CLONING; ENCODES; LCB1	Knowledge of the Saccharomyces cerevisiae genes and proteins necessary for sphingolipid biosynthesis is far from complete, Such information should expedite studies of pathway regulation and sphingolipid functions, Using the Aur1 protein sequence, recently identified as necessary for synthesis of the sphingolipid inositol-P-ceramide (IPC), we show that a homolog (open reading frame YDR072c), termed Ipt1 (inositolphosphotransferase 1) is necessary for synthesis of mannose-(inositol-P)(2)-ceramide (M(IP)(2)C), the most abundant and complex sphingolipid in S. cerevisiae, This conclusion is based upon analysis of an ipt1-deletion strain, which fails to accumulate M(IP)(2)C and instead accumulates increased amounts of the precursor mannose inositol-P-ceramide. The mutant also fails to incorporate radioactive precursors into M(IP)(2)C, and membranes prepared from it do not incorporate [H-3-inositol]phosphatidylinositol into M(IP)(2)C, indicating a lack of M(IP)(2)C synthase activity (putatively phosphatidylinositol:mannose-inositol-P-ceramide phosphoinositol transferase), M(IP)(2)C synthase activity is inhibited in the micromolar range by aureobasidin A, but drug sensitivity is over 1000-fold lower than reported for IPC synthase activity. An ipt1-deletion mutant has no severe phenotypic effects but is slightly more resistant to growth inhibition by calcium ions, Identification of the IPT1 gene should be helpful in determining the function of the M(IP)(2)C sphingolipid and in determining the catalytic mechanism of TPC and M(IP)(2)C synthases.	UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	University of Kentucky	Dickson, RC (corresponding author), UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR K, 1984, BIOCHEMISTRY-US, V23, P5589, DOI 10.1021/bi00318a032; BARR K, 1984, BIOCHEMISTRY-US, V23, P5581, DOI 10.1021/bi00318a031; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HANSON BA, 1980, J LIPID RES, V21, P309; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HEIDLER SA, 1995, ANTIMICROB AGENTS CH, V39, P2765, DOI 10.1128/AAC.39.12.2765; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KERRIDGE D, 1986, ADV MICROB PHYSIOL, V27, P1, DOI 10.1016/S0065-2911(08)60303-3; Leber A, 1997, FEBS LETT, V411, P211, DOI 10.1016/S0014-5793(97)00692-3; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIPSKI VP, 1969, METHOD ENZYMOL, V14, P545; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VINCENT VL, 1995, MICROBIOL-UK, V141, P1829, DOI 10.1099/13500872-141-8-1829; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; ZHAO C, 1994, J BIOL CHEM, V269, P21480	36	142	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29620	29625		10.1074/jbc.272.47.29620	http://dx.doi.org/10.1074/jbc.272.47.29620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368028	hybrid			2022-12-27	WOS:A1997YG64700038
J	Kotake, K; Ozaki, N; Mizuta, M; Sekiya, S; Inagaki, N; Seino, S				Kotake, K; Ozaki, N; Mizuta, M; Sekiya, S; Inagaki, N; Seino, S			Noc2, a putative zinc finger protein involved in exocytosis in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; SYNAPTIC VESICLES; CHROMAFFIN CELLS; ALPHA-ACTININ; RABPHILIN-3A; SECRETION; RAB3A; DOC2; SYNAPTOTAGMINS	We have cloned a cDNA encoding a novel protein of 302 amino acids (designated Noc2, no C2 domain) that has 40.7% amino acid identity with and 77.9% similarity to the N-terminal region of rabphilin-3A, a target molecule of Rab3A However, unlike rabphilin-3A, Noc2 lacks two C2 domains that are thought to interact with Ca2+ and phospholipids. Noc2 is expressed predominantly in endocrine tissues and hormone-secreting cell lines and at very low levels in brain. Immunoblot analysis of subcellular fractions of the insulin-secreting cell line MING and immunocytochemistry reveal that Noc2 is a 38-kDa protein present in the cytoplasm. Overexpression of Noc2 in PC12 cells cotransfected with growth hormone enhances high K+-induced growth hormone secretion. Screening a mouse embryonic cDNA Library with the yeast two-hybrid system shows that Noc2 interacts with the LIM domain-containing protein zyxin, a component of the cytoskeleton, and this interaction is further confirmed by the coimmunoprecipitation experiment. Accordingly, Noc2 is probably involved in regulated exocytosis in endocrine cells by interacting with the cytoskeleton.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL MED,CHUO KU,CHIBA 260,JAPAN; MIYAZAKI MED COLL,DEPT INTERNAL MED 3,KIYOTAKE,MIYAZAKI 88916,JAPAN; CHIBA UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHUO KU,CHIBA 260,JAPAN	Chiba University; University of Miyazaki; Chiba University				Inagaki, Nobuya/0000-0001-8261-2593				Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; Calakos N, 1996, PHYSIOL REV, V76, P1; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; HOLTZ RE, 1994, J BIOL CHEM, V269, P10229; INAGAKI N, 1994, J BIOCHEM-TOKYO, V116, P239, DOI 10.1093/oxfordjournals.jbchem.a124512; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MIZUTA M, 1997, IN PRESS DIABETES; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WENDLAND B, 1994, MOL ENDOCRINOL, V8, P1070, DOI 10.1210/me.8.8.1070; WICK PF, 1993, J BIOL CHEM, V268, P10983	27	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29407	29410		10.1074/jbc.272.47.29407	http://dx.doi.org/10.1074/jbc.272.47.29407			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367993	hybrid			2022-12-27	WOS:A1997YG64700003
J	Nakano, T; Ishimoto, Y; Kishino, J; Umeda, A; Inoue, K; Nagata, K; Ohashi, K; Mizuno, K; Arita, H				Nakano, T; Ishimoto, Y; Kishino, J; Umeda, A; Inoue, K; Nagata, K; Ohashi, K; Mizuno, K; Arita, H			Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; K-DEPENDENT PROTEINS; GAS6; AXL; EXPRESSION; LIGAND; BRAIN; SKY; PROTOONCOGENE; EXPOSURE	Gas6, a product of a growth arrest-specific gene 6, potentiates proliferation of vascular smooth muscle cells and prevents cell death of vascular smooth muscle cells. It has been also demonstrated that Gas6 is a ligand of receptor tyrosine kinases Axl, Sky, and Mer. Gas6 contains gamma-carboxyglutamic acid residues, which are found in some blood coagulation factors and mediate the interaction of the coagulation factors with negatively charged phospholipid. In this study, we clarified that Gas6 specifically bound to phosphatidylserine and the binding was dependent on Ca2+ and gamma-carboxyglutamic acid residues. Furthermore, we found that U937 cells, which express Gas6 receptor on their surfaces, adhered to phosphatidylserine-coated enzyme-linked immunosorbent assay (ELISA) plate only in the presence of Gas6 and Ca2+. U937 cells also bound to ELISA plate coated with phosphatidylinositol, but the binding was independent of Gas6 and Ca2+. On the other hand, U937 cells did not adhere to phosphatidylcholine-or phosphatidylethanolamine-coated ELISA plate even in the presence of Gas6 and Ca2+. These findings suggest that Gas6 may play a role in recognition of cells exposing phosphatidylserine on their surfaces by phagocytic cells, which is supposed to be one of the mechanisms for clearing dying tells.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Kyushu University	Nakano, T (corresponding author), SHIONOGI & CO LTD,DISCOVERY RES LAB 2,FUKUSHIMA KU,5-12-4 SAGISU,OSAKA 553,JAPAN.		Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; FADOK VA, 1992, J IMMUNOL, V148, P2207; FUJIMOTO J, 1994, ONCOGENE, V9, P693; FUKUSAWA M, 1996, EXP CELL RES, V222, P246; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; LAI C, 1994, ONCOGENE, V9, P2567; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; Nakano T, 1996, FEBS LETT, V387, P75, DOI 10.1016/0014-5793(96)00394-8; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; RESCIGNO J, 1991, ONCOGENE, V6, P1909; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	29	196	199	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29411	29414		10.1074/jbc.272.47.29411	http://dx.doi.org/10.1074/jbc.272.47.29411			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367994	hybrid			2022-12-27	WOS:A1997YG64700004
J	Niccoli, P; Fayadat, L; Panneels, V; Lanet, J; Franc, JL				Niccoli, P; Fayadat, L; Panneels, V; Lanet, J; Franc, JL			Human thyroperoxidase in its alternatively spliced form (TPO2) is enzymatically inactive and exhibits changes in intracellular processing and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; CONGENITAL GOITER; SECRETORY PATHWAY; GENE; IDENTIFICATION; DISEASE; CELLS; IODINATION; MYELOPEROXIDASE; HYPOTHYROIDISM	Thyroid peroxidase (TPO1) is a membrane-bound heme-containing glycoprotein that catalyzes the synthesis of thyroid hormones. We generated stable cell lines expressing TPO1 and the alternatively spliced isoform TPO2. Pulse-chase studies showed that TPO2 half-life was dramatically decreased as compared with TPO1, The sensitivity of TPO2 to endo-beta-N-acetylglucosaminidase H indicated that the protein is processed through the endoplasmic reticulum and bears high mannose-type structures. Cell surface biotinylation experiments showed that the two isoforms also differ in their intracellular trafficking, TPO2 was totally retained in the cell, whereas 15% of TPO1 reached the cell surface. The inability of TPO2 to come out of the intracellular compartments was related to structural changes in the molecule. Evidence of these changes was obtained through the lack of recognition of TPO2 by half of the 13 TPO monoclonal antibodies tested in immunoprecipitation experiments. Our data suggest that because of an improper folding, TPO2 is trapped in the endoplasmic reticulum and rapidly degraded. The failure of incorporation of [C-14]aminolevulinic acid in the cultured cells showed that TPO2 did not bind to heme, whereas TPO1 did, This result was confirmed through a guaiacol assay showing that TPO2 is enzymatically inactive.	FAC MED MARSEILLE,INSERM,U38,F-13385 MARSEILLE 05,FRANCE; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,B-1070 BRUSSELS,BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				ABRAMOWICZ MJ, 1992, J CLIN INVEST, V90, P1200, DOI 10.1172/JCI115981; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BANGA JP, FEBS LETT, V266, P133; BIKKER H, 1995, HUM MUTAT, V6, P9, DOI 10.1002/humu.1380060104; Bikker H, 1996, J CLIN ENDOCR METAB, V81, P2076, DOI 10.1210/jc.81.6.2076; Bikker H, 1997, J CLIN ENDOCR METAB, V82, P649, DOI 10.1210/jc.82.2.649; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; Dermer SJ, 1996, ENDOCRINOLOGY, V137, P5502, DOI 10.1210/en.137.12.5502; EKHOLM R, 1984, ENDOCRINOLOGY, V115, P1558, DOI 10.1210/endo-115-4-1558; ELISEI R, 1990, J CLIN ENDOCR METAB, V72, P700; ELKOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; FINKE R, 1996, J ENDOCRINOL INVEST, V19, P20; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; FOTI D, 1990, ENDOCRINOLOGY, V126, P2983, DOI 10.1210/endo-126-6-2983; GIRAUD A, 1992, J ENDOCRINOL, V132, P317, DOI 10.1677/joe.0.1320317; GRUFFAT D, 1991, J ENDOCRINOL, V128, P51, DOI 10.1677/joe.0.1280051; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KULIAWAT R, 1995, J BIOL CHEM, V270, P2478, DOI 10.1074/jbc.270.6.2478; KULIAWAT R, 1994, J BIOL CHEM, V269, P4922; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; MEHTA A, 1997, CELL BIOL, V94, P1822; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Ohtaki S, 1996, ENDOCR J, V43, P1, DOI 10.1507/endocrj.43.1; Rapoport B., 1994, ENDOCRINE REVS, V3, P96; RICHARDSON DR, 1996, BLOOD, V87, P3447; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; Sambrook J., 2002, MOL CLONING LAB MANU; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; TAUROG A, 1990, ARCH BIOCHEM BIOPHYS, V278, P333, DOI 10.1016/0003-9861(90)90268-4; Taurog A., 1991, WERNER INGBARS THYRO, P51; TONACCHERA M, 1995, EUR J ENDOCRINOL, V132, P53, DOI 10.1530/eje.0.1320053; Zimmer KP, 1997, HISTOCHEM CELL BIOL, V107, P115, DOI 10.1007/s004180050095; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	42	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29487	29492		10.1074/jbc.272.47.29487	http://dx.doi.org/10.1074/jbc.272.47.29487			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368009	hybrid			2022-12-27	WOS:A1997YG64700019
J	Tsujimura, M; Dohmae, N; Odaka, M; Chijimatsu, M; Takio, K; Yohda, M; Hoshino, M; Nagashima, S; Endo, I				Tsujimura, M; Dohmae, N; Odaka, M; Chijimatsu, M; Takio, K; Yohda, M; Hoshino, M; Nagashima, S; Endo, I			Structure of the photoreactive iron center of the nitrile hydratase from Rhodococcus sp. N-771 - Evidence of a novel post-translational modification in the cysteine ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFENIC ACID; TRANSCRIPTIONAL REGULATOR; BREVIBACTERIUM SP; ESCHERICHIA-COLI; ALPHA-SUBUNIT; SULFUR CENTER; PROTEIN; OXIDATION; OXIDE; PURIFICATION	Nitrile hydratase (NHase) from Rhodococcus sp, N-771 is a photoreactive enzyme that is inactivated by nitrosylation of the non-heme iron center and activated by photodissociation of nitric oxide (NO), To obtain structural information on the iron center, we isolated peptide complexes containing the iron center by proteolysis. When the tryptic digest of the alpha subunit isolated from the inactive form was analyzed by reversed-phase high performance liquid chromatography, the absorbance characteristic of the nitrosylated iron center was observed in the peptide fragment, Asn(105)-Val-Ile-Val-Cys-Ser-Leu-Cys-Ser-Cys-Thr-Ala-Trp-Pro-Ile-Pro-Pro-Thr-Trp-Tyr-Lys(128). The peptide contained 0.79 mol of iron/mol of molecule as well as endogenous NO. Subsequently, by digesting the peptide with thermolysin, carboxypeptidase Y, and leucine aminopeptidase hi, we found that the minimum peptide segment required for the nitrosylated iron center is the 11 amino acid residues from alpha lle(107) to alpha Trp(117), Furthermore, by using mass spectrometry, protein sequence, and amino acid composition analyses, we have shown that the 112th Cys residue of the cu subunit is post-translationally oxidized to a cysteine-sulfinic acid (Cys-SO2H) in the NHase, These results indicate that the NHase from Rhodococcus sp, N-771 has a novel non-heme iron enzyme containing a cysteine-sulfinic acid in the iron center, Possible ligand residues of the iron center are discussed.	SAITAMA UNIV,GRAD SCH SCI & ENGN,URAWA,SAITAMA 338,JAPAN; RIKEN,INST PHYS & CHEM RES,DIV BIOMOL CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; RIKEN,INST PHYS & CHEM RES,BIOCHEM SYST LAB,WAKO,SAITAMA 35101,JAPAN; RIKEN,CHEM DYNAM LAB,WAKO,SAITAMA 35101,JAPAN	Saitama University; RIKEN; RIKEN; RIKEN			Odaka, Masafumi/C-2378-2013; Yohda, Masafumi/A-5149-2013; Dohmae, Naoshi/C-2040-2011	Yohda, Masafumi/0000-0001-8307-9671; Dohmae, Naoshi/0000-0002-5242-9410				ABATE C, 1990, SCIENCE, V249; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BEISSEL T, 1993, INORG CHEM, V32, P124, DOI 10.1021/ic00054a002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan BA, 1996, BIOCHEMISTRY-US, V35, P10068, DOI 10.1021/bi960163t; Brennan BA, 1996, J AM CHEM SOC, V118, P9194, DOI 10.1021/ja961920d; BRIAND D, 1994, MICROBIOS, V78, P205; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; Doan PE, 1996, J AM CHEM SOC, V118, P7014, DOI 10.1021/ja960611k; HAYASHI T, 1993, ANAL BIOCHEM, V209, P163, DOI 10.1006/abio.1993.1097; Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2; IKEHATA O, 1989, EUR J BIOCHEM, V181, P563, DOI 10.1111/j.1432-1033.1989.tb14761.x; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOMAROV A, 1993, BIOCHEM BIOPH RES CO, V195, P1191, DOI 10.1006/bbrc.1993.2170; Kowalak JA, 1996, PROTEIN SCI, V5, P1625, DOI 10.1002/pro.5560050816; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; NAGAMUNE T, 1990, PHOTOCHEM PHOTOBIOL, V51, P87, DOI 10.1111/j.1751-1097.1990.tb01687.x; NAGAMUNE T, 1990, BIOCHEM BIOPH RES CO, V168, P437, DOI 10.1016/0006-291X(90)92340-6; NAGAMUNE T, 1991, J MOL BIOL, V220, P221, DOI 10.1016/0022-2836(91)90006-R; NAKAJIMA Y, 1987, CHEM LETT, V9, P1767; NELSON MJ, 1991, J AM CHEM SOC, V113, P7072, DOI 10.1021/ja00018a074; NOGUCHI T, 1995, FEBS LETT, V358, P9, DOI 10.1016/0014-5793(94)01374-A; Noguchi T, 1996, BIOCHEMISTRY-US, V35, P16777, DOI 10.1021/bi961562r; Odaka M, 1996, BIOCHEM BIOPH RES CO, V221, P146, DOI 10.1006/bbrc.1996.0560; Odaka M, 1997, J AM CHEM SOC, V119, P3785, DOI 10.1021/ja962179c; RADI R, 1991, J BIOL CHEM, V266, P4244; SAKURAI H, 1988, INORG CHEM, V27, P3877; Scarrow RC, 1996, BIOCHEMISTRY-US, V35, P10078, DOI 10.1021/bi960164l; SHONER SC, 1995, INORG CHEM, V34, P4517, DOI 10.1021/ic00122a001; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Tsujimura M, 1996, J BIOCHEM-TOKYO, V119, P407; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	39	88	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29454	29459		10.1074/jbc.272.47.29454	http://dx.doi.org/10.1074/jbc.272.47.29454			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368004	hybrid			2022-12-27	WOS:A1997YG64700014
J	Dreher, I; Jakobs, TC; Kohrle, J				Dreher, I; Jakobs, TC; Kohrle, J			Cloning and characterization of the human selenoprotein P promoter - Response of selenoprotein P expression to cytokines in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; RAT PLASMA; GLUTATHIONE-PEROXIDASE; TRANSCRIPTION FACTOR; SELENIUM DEFICIENCY; LIPID-PEROXIDATION; GROWTH-FACTORS; SERUM; PURIFICATION; GENES	We isolated an 18-kilobase (kb) genomic selenoprotein P clone from a human placenta library and cloned, sequenced, and characterized the 5'-flanking region of the human selenoprotein P gene. Sequence analysis revealed an intron between base pairs (bp) -13 and -14 upstream of the ATG codon and another one between bp 534 and 535 of the coding region. The major transcription start site of selenoprotein P in human HepG2 hepatocarcinoma cells was mapped to bp -70 by 5'-rapid amplification of cDNA ends and by primer extension, 1.8 kb of the 5'-flanking sequence were fused to a luciferase reporter gene, They exhibited functional promoter activity in HepG2 hepatocarcinoma and Caco2 colon carcinoma cells in transient transfection experiments, Treatment of transfected HepG2 cells with the cytokines interleukin 1 beta, tumor necrosis factor alpha, and interferon gamma repressed promoter activity, Nuclear extracts of interferon gamma-treated cells bound to a signal transducer and activator of transcription response element of the promoter in gel retardation experiments, By transfection of promoter-deletion constructs, a TATA box and a putative SP1 site were identified to be necessary for selenoprotein P transcription, These data indicate that the human selenoprotein P gene contains a strong promoter that is cytokine responsive, Furthermore, selenoprotein P, secreted by the liver, might react as a negative acute phase protein.	UNIV WURZBURG,MED POLIKLIN,KLIN FORSCHERGRP,D-97070 WURZBURG,GERMANY	University of Wurzburg			Köhrle, Josef/AAH-6438-2020	Köhrle, Josef/0000-0002-9187-9078; Jakobs, Tatjana/0000-0002-8104-9206				ADAMS MD, 1995, NATURE, V377, P3; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1995, HEPATOLOGY, V21, P561; Dreher I, 1997, J TRACE ELEM MED BIO, V11, P83, DOI 10.1016/S0946-672X(97)80031-4; EBERLE B, 1993, J TRACE ELEM ELECT H, V7, P217; EDWARDS JBD, 1991, NUCLEIC ACIDS RES, V11, P1475; EMI M, 1988, GENE, V62, P229, DOI 10.1016/0378-1119(88)90561-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRANDISON L, 1994, MOL CELL ENDOCRINOL, V106, P9; GROSS M, 1995, BIOCHEM J, V306, P851, DOI 10.1042/bj3060851; HERRMAN JL, 1977, BIOCHIM BIOPHYS ACTA, V500, P61, DOI 10.1016/0304-4165(77)90046-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Jakobs TC, 1997, EUR J BIOCHEM, V247, P288, DOI 10.1111/j.1432-1033.1997.00288.x; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; LUPO A, 1995, BIOCHEM BIOPH RES CO, V216, P69, DOI 10.1006/bbrc.1995.2593; Martin GW, 1996, RNA, V2, P171; MOTCHNIK PA, 1989, BIOCHIM BIOPHYS ACTA, V993, P27, DOI 10.1016/0304-4165(89)90138-4; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V709, P160, DOI 10.1016/0167-4838(82)90456-3; PERSSONMOSCHOS M, 1995, ANALYST, V120, P833, DOI 10.1039/an9952000833; READ R, 1990, J BIOL CHEM, V265, P17899; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steinert P, 1997, BIOFACTORS, V6, P311, DOI 10.1002/biof.5520060302; Sunde R. A., 1994, Selenium in biology and human health., P45; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON DS, 1993, J INORG BIOCHEM, V51, P707, DOI 10.1016/0162-0134(93)85003-Q; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YANG JG, 1987, J BIOL CHEM, V262, P13372; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; Yasui Y, 1996, GENE, V175, P269, DOI 10.1016/0378-1119(96)00127-8; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449	39	93	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29364	29371		10.1074/jbc.272.46.29364	http://dx.doi.org/10.1074/jbc.272.46.29364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361018	hybrid			2022-12-27	WOS:A1997YF68400077
J	Allen, JR; Ensign, SA				Allen, JR; Ensign, SA			Purification to homogeneity and reconstitution of the individual components of the epoxide carboxylase multiprotein enzyme complex from Xanthobacter strain Py2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DEGRADATION; METABOLISM; EPOXYALKANES; OXIDE	Epoxide metabolism in the aerobic bacterium Xanthobacter strain Py2 proceeds by an NADPH-and NAD(+)-dependent carboxylation reaction that forms beta-keto acids as products, Epoxide carboxylase, the enzyme catalyzing this reaction, was resolved from the soluble fraction of cell-free extracts into four protein components that are obligately required for functional reconstitution of epoxide carboxylase activity, One of these components, component II, has previously been purified and characterized as an NADPH:disulfide oxidoreductase, In the present study, the three additional epoxide carboxylase components have been purified to homogeneity and characterized, These component proteins are as follows: component I, a homohexameric protein consisting of 41.7-kDa subunits; component III, a dimeric protein consisting of 26.0- and 26.2-kDa polypeptides; and component TV, a dimeric protein consisting of a single 25.4-kDa polypeptide, Component I contained 5 mol of tightly bound zinc per mol of protein, Component I was specifically inactivated by methylepoxypropane, a time-dependent irreversible inactivator of epoxide carboxylase activity, suggesting that this component plays an integral role in epoxide binding and activation, No metals or organic cofactors were detected for components III and IV, The molecular weights, N-terminal sequences, and amino acid compositions of the purified epoxide carboxylase components were determined and found to correlate with open reading frames within and adjacent to a cloned fragment of DNA that complements Xanthobacter Py2 mutants defective in epoxide degradation, Using the purified epoxide carboxylase system, epoxide carboxylation was found to be stoichiometrically coupled to the transhydrogenation of pyridine nucleotide cofactors according to the following equation: epoxypropane + CO2 + NADPH + NAD(+) --> acetoacetate + H+ + NADP(+) + NADH.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Ensign, SA (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.				NIGMS NIH HHS [GM51805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051805, R01GM051805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 1997, J BACTERIOL, V179, P3110, DOI 10.1128/jb.179.10.3110-3115.1997; Allen JR, 1996, J BACTERIOL, V178, P1469, DOI 10.1128/jb.178.5.1469-1472.1996; Chion CKNCK, 1996, BIOCHEM J, V319, P499, DOI 10.1042/bj3190499; CHROMY V, 1974, CLIN CHEM, V20, P1362; Ensign SA, 1996, APPL ENVIRON MICROB, V62, P61, DOI 10.1128/AEM.62.1.61-66.1996; HARTMANS S, 1989, FEMS MICROBIOL LETT, V63, P235, DOI 10.1016/0168-6445(89)90034-X; HARTMANS S, 1989, APPL ENVIRON MICROB, V55, P2850, DOI 10.1128/AEM.55.11.2850-2855.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Sluis MK, 1996, J BACTERIOL, V178, P4020, DOI 10.1128/jb.178.14.4020-4026.1996; Small FJ, 1997, J BIOL CHEM, V272, P24913, DOI 10.1074/jbc.272.40.24913; SMALL FJ, 1995, J BACTERIOL, V177, P6170, DOI 10.1128/jb.177.21.6170-6175.1995; Swaving J, 1996, J BACTERIOL, V178, P6644, DOI 10.1128/jb.178.22.6644-6646.1996; SWAVING J, 1995, MICROBIOL-UK, V141, P477, DOI 10.1099/13500872-141-2-477; THOMAS H, 1990, PRINCIPLES MECHANISM, V2, P280; WADE DR, 1978, MUTAT RES, V58, P217, DOI 10.1016/0165-1218(78)90012-5; WEIJERS CAGM, 1995, APPL MICROBIOL BIOT, V42, P775, DOI 10.1007/BF00171961	17	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32121	32128		10.1074/jbc.272.51.32121	http://dx.doi.org/10.1074/jbc.272.51.32121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405410	hybrid			2022-12-27	WOS:000071108000029
J	Ye, LH; Hayakawa, K; Kishi, H; Imamura, M; Nakamura, A; Okagaki, T; Takagi, T; Iwata, A; Tanaka, T; Kohama, K				Ye, LH; Hayakawa, K; Kishi, H; Imamura, M; Nakamura, A; Okagaki, T; Takagi, T; Iwata, A; Tanaka, T; Kohama, K			The structure and function of the actin-binding domain of myosin light chain kinase of smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT INTERACTION; CHICKEN GIZZARD MYOSIN; PROTEIN; CALDESMON; LOCALIZATION; PURIFICATION; STIMULATION; CALMODULIN; FILAMENTS; ANTIBODY	In addition to its kinase activity, the myosin light chain kinase (MLCK) of smooth muscle has an actin binding activity through which it can regulate the actin-myosin interaction of smooth muscle (Kohama, K., Okagaki, T., Hayakawa, K., Lin, Y., Ishikawa, R., Shimmen, T., and Inoue, A (1992) Biochem. Biophys. Res. Commun. 184, 1204-1211). In this study, we have analyzed the actin binding activity of MLCK and related it to its amino acid sequence by producing native and recombinant fragments of MLCK. Parent MLCK exhibited both calcium ion (Ca2+) and calmodulin (Ca2+/CaM)-sensitive and Ca2+/CaM-insensitive binding to actin filaments. The native fragment, which consists of the Met(1)-Lys(114) sequence (Kanoh, S., Ito, M., Niwa, E., Kawano, Y., and Hartshorne, D. J. (1993) Biochemistry 32, 8902-8907), and the recombinant NN fragment, which contains this 1-114 sequence, showed only Ca2+/CaM-sensitive binding. An inhibitory effect of the NN fragment on the actin-myosin interaction was observed by assaying in vitro motility and by measuring the actin-activated ATPase activity of myosin. The recombinant NN/41 fragment, which is constructed without the Met(1)-Pro(41) sequence of the NN fragment, lost both the actin binding activity and the inhibitory effect. We confirmed the importance of the 1-41 sequence by using a few synthetic peptides to compete against the NN fragment in binding to actin filaments. The experiments using recombinant fragments and synthetic peptides also revealed that the site for CaM-binding is the Pro(26)-Pro(41) sequence. The site for the Ca2+/CaM-insensitive binding, which is shown to be localized between the Ca2+/CaM-sensitive site and the central kinase domain of MLCK, exerted no regulatory effects on the actin-myosin interaction.	Gunma Univ, Sch Med, Dept Pharmacol, Gunma 371, Japan; Tohoku Univ, Fac Sci, Inst Biol, Sendai, Miyagi 980, Japan; Japanese Red Cross Saitama Blood Ctr, Div Res, Yono, Saitama 338, Japan	Gunma University; Tohoku University	Kohama, K (corresponding author), Gunma Univ, Sch Med, Dept Pharmacol, Gunma 371, Japan.		Kishi, Hiroko/AAR-9148-2021	Kishi, Hiroko/0000-0003-2896-7355				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DABROWSKA R, 1982, BIOCHEM BIOPH RES CO, V107, P1524, DOI 10.1016/S0006-291X(82)80172-1; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HARTSHORNE DJ, 1977, BIOCH SMOOTH MUSCLE, P513; HAYAKAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P786, DOI 10.1006/bbrc.1994.1298; ISHIKAWA R, 1991, J BIOL CHEM, V266, P21784; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOHAMA K, 1992, BIOCHEM BIOPH RES CO, V184, P1204, DOI 10.1016/S0006-291X(05)80010-5; KUWAYAMA H, 1988, J BIOCHEM-TOKYO, V104, P862, DOI 10.1093/oxfordjournals.jbchem.a122565; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN Y, 1994, CELL MOTIL CYTOSKEL, V29, P250, DOI 10.1002/cm.970290308; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMURA F, 1982, J MOL BIOL, V157, P163, DOI 10.1016/0022-2836(82)90520-4; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIMURA N, 1986, J BIOL CHEM, V261, P680; NAKAMURA S, 1984, J BIOCHEM-TOKYO, V96, P575, DOI 10.1093/oxfordjournals.jbchem.a134870; OKAGAKI T, 1991, J BIOCHEM, V109, P858, DOI 10.1093/oxfordjournals.jbchem.a123471; Okagaki Tsuyoshi, 1995, P17; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; SATO M, 1995, J BIOCHEM, V118, P1; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SOBUE K, 1991, J BIOL CHEM, V266, P12115; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YAMAZAKI K, 1987, J BIOCHEM-TOKYO, V101, P1; YE LH, 1994, J BIOCHEM, V116, P1377, DOI 10.1093/oxfordjournals.jbchem.a124690; YE LH, 1995, REGULATION CONTRACTI, P159	37	39	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32182	32189		10.1074/jbc.272.51.32182	http://dx.doi.org/10.1074/jbc.272.51.32182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405419	hybrid			2022-12-27	WOS:000071108000038
J	Gueguen, Y; Voorhorst, WGB; vanderOost, J; deVos, WM				Gueguen, Y; Voorhorst, WGB; vanderOost, J; deVos, WM			Molecular and biochemical characterization of an endo-beta-1,3-glucanase of the hyperthermophilic archaeon Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-CIRCULANS WL-12; ACID-SEQUENCE SIMILARITIES; ESCHERICHIA-COLI; BETA-GLUCANASE; 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE; NUCLEOTIDE-SEQUENCE; GLYCOSYL HYDROLASES; ACTIVE-SITE; ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE	We report here the first molecular characterization of an endo-beta-1,3-glucanase from an archaeon. Pyrococcus furiosus is a hyperthermophilic archaeon that is capable of saccharolytic growth. The isolated lamA gene encodes an extracellular enzyme that shares homology with both endo-beta-1,3- and endo-beta-1,3-1,4-glucanases of the glycosyl hydrolase family 16. After deletion of the N-terminal leader sequence, a lamA fragment encoding an active endo-beta-1,3-glucanase was overexpressed in Escherichia coli using the T7-expression system. The purified P. furiosus endoglucanase has highest hydrolytic activity on the beta-1,3 glucose polymer laminarin and has some hydrolytic activity on the beta-1,3-1,4 glucose polymers lichenan and barley beta-glucan. The enzyme is the most thermostable endo-beta-1,3- glucanase described up to now; it has optimal activity at 100-105 degrees C. In the predicted active site of glycosyl hydrolases of family 16 that show predominantly endo-beta-1,3-glucanase activity, an additional methionine residue is present. Deletion of this methionine did not change the substrate specificity of the endoglucanase, but it did cause a severe reduction in its catalytic activity, suggesting a structural role of this residue in constituting the active site. High performance liquid chromatography analysis showed in vitro hydrolysis of laminarin by the endo-beta-1,3 glucanase proceeds more efficiently in combination with an exo-beta-glycosidase from P. furiosus (CelB). This most probably reflects the physiological role of these enzymes: cooperation during growth of P. furiosus on beta-glucans.	AGR UNIV WAGENINGEN, DEPT MICROBIOL, BACTERIAL GENET GRP, NL-6703 CT WAGENINGEN, NETHERLANDS	Wageningen University & Research			Gueguen, Yannick/O-3248-2014; van+der+Oost, John/Y-2548-2019	Gueguen, Yannick/0000-0002-8749-9582; 				BACON JSD, 1970, BIOCHEM J, V120, P67, DOI 10.1042/bj1200067; BATCHMAN ES, 1996, P NATL ACAD SCI USA, V93, P6808; Bauer MW, 1996, J BIOL CHEM, V271, P23749, DOI 10.1074/jbc.271.39.23749; BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENO A, 1990, J BACTERIOL, V172, P2160, DOI 10.1128/jb.172.4.2160-2167.1990; CHEN L, 1993, J BIOL CHEM, V268, P13318; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; DELACRUZ J, 1995, J BACTERIOL, V177, P6937, DOI 10.1128/jb.177.23.6937-6945.1995; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; ERFLE JD, 1988, BIOCHEM J, V255, P833, DOI 10.1042/bj2550833; Ferrer P, 1996, J BACTERIOL, V178, P4751, DOI 10.1128/jb.178.15.4751-4757.1996; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FISKE MJ, 1990, J GEN MICROBIOL, V136, P2377, DOI 10.1099/00221287-136-12-2377; FLINT HJ, 1989, APPL ENVIRON MICROB, V55, P1230, DOI 10.1128/AEM.55.5.1230-1233.1989; FLINT HJ, 1993, J BACTERIOL, V175, P2943, DOI 10.1128/JB.175.10.2943-2951.1993; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GIBSON TJ, 1994, THESIS CAMBRIDGE U C; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; GRENIER J, 1993, PLANT PHYSIOL, V103, P1277, DOI 10.1104/pp.103.4.1277; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HO NS, 1990, DNA PROTEIN ENG TECH, V2, P50; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IRVIN JE, 1988, APPL ENVIRON MICROB, V54, P2672, DOI 10.1128/AEM.54.11.2672-2676.1988; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KEITEL T, 1994, EUR J BIOCHEM, V222, P203, DOI 10.1111/j.1432-1033.1994.tb18858.x; Kengen SWM, 1996, FEMS MICROBIOL REV, V18, P119; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; KONIG H, 1983, H-S Z PHYSIOL CHEM, V364, P627, DOI 10.1515/bchm2.1983.364.1.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOUW ME, 1993, APPL MICROBIOL BIOT, V38, P507, DOI 10.1007/BF00242946; MA KS, 1994, FEMS MICROBIOL LETT, V122, P245, DOI 10.1016/0378-1097(94)00330-0; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; SAKELLARIS H, 1993, FEMS MICROBIOL LETT, V109, P269, DOI 10.1016/0378-1097(93)90031-V; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SCHIMMING S, 1991, BIOCHEM BIOPH RES CO, V177, P447, DOI 10.1016/0006-291X(91)92004-4; SCHWARTZ WH, 1988, BIOTECHNOL LETT, V101, P225; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SPILLIAERT R, 1994, EUR J BIOCHEM, V224, P923, DOI 10.1111/j.1432-1033.1994.00923.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMER JB, 1949, DINITROSALISYLIC MET; Sunna A, 1997, EXTREMOPHILES, V1, P2, DOI 10.1007/s007920050009; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; VOORHORST WGB, 1995, J BACTERIOL, V177, P7105, DOI 10.1128/JB.177.24.7105-7111.1995; WATANABE T, 1992, J BACTERIOL, V174, P186, DOI 10.1128/jb.174.1.186-190.1992; WELFLE K, 1995, EUR J BIOCHEM, V229, P726, DOI 10.1111/j.1432-1033.1995.tb20520.x; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; ZVERLOV VV, 1991, BIOCHEM BIOPH RES CO, V181, P507, DOI 10.1016/0006-291X(91)91217-Z	65	108	112	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31258	31264		10.1074/jbc.272.50.31258	http://dx.doi.org/10.1074/jbc.272.50.31258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395451	hybrid			2022-12-27	WOS:A1997YL41900010
J	Hanemaaijer, R; Sorsa, T; Konttinen, YT; Ding, YL; Sutinen, M; Visser, H; vanHinsbergh, VWM; Helaakoski, T; Kainulainen, T; Ronka, H; Tschesche, H; Salo, T				Hanemaaijer, R; Sorsa, T; Konttinen, YT; Ding, YL; Sutinen, M; Visser, H; vanHinsbergh, VWM; Helaakoski, T; Kainulainen, T; Ronka, H; Tschesche, H; Salo, T			Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells - Regulation by tumor necrosis factor-alpha and doxycycline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; DEGRADING METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; CLEAVAGE SITES; TETRACYCLINES; MMP-8; ACTIVATION; CARTILAGE; ARTHRITIS; GINGIVAL	Neutrophil collagenase (matrix metalloproteinase-8 or MMP-8) is regarded as being synthesized exclusively by polymorphonuclear neutrophils (PMN). However, in vivo MMP-8 expression was observed in mononuclear fibroblast-like cells in the rheumatoid synovial membrane. In addition, we detected MMP-8 mRNA expression in cultured rheumatoid synovial fibroblasts and human endothelial cells. Up-regulation of MMP-8 was observed after treatment of the cells with either tumor necrosis factor-alpha (10 ng/ml) or phorbol 12-myristate 13-acetate (10 nM). Western analysis showed a similar regulation at the protein level. The size of secreted MMP-8 was 50 kDa, which is about 30 kDa smaller than MMP-8 from PMN. Conditioned media from rheumatoid synovial fibroblasts contained both type I and II collagen degrading activity. However, degradation of type II collagen, but not that of type I collagen, was completely inhibited by 50 mu M doxycycline, suggesting specific MMP-8 activity. In addition, doxycycline down-regulated MMP-8 induction, at both the mRNA and protein levels. Thus MMP-8 exerts markedly wider expression in human cells than had been thought previously, implying that PMN are not the only source of cartilage degrading activity at arthritic sites. The inhibition of both MMP-8 activity and synthesis by doxycycline provides an incentive for further studies on the clinical effects of doxycycline in the treatment of rheumatoid arthritis.	UNIV OULU,DEPT ORAL SURG,FIN-90220 OULU,FINLAND; TNO,PG,GAUBIUS LAB,NL-2301 CE LEIDEN,NETHERLANDS; UNIV HELSINKI,DEPT PERIODONTOL & MED CHEM,FIN-00014 HELSINKI,FINLAND; UNIV HELSINKI,DEPT ANAT,FIN-00014 HELSINKI,FINLAND; UNIV OULU,DEPT MED BIOCHEM,FIN-90220 OULU,FINLAND; OULU UNIV HOSP,OULU,FINLAND; MEDIX BIOCHEM OY AB,KAUNIAINEN,FINLAND; UNIV BIELEFELD,FAC CHEM,DEPT BIOCHEM,D-33501 BIELEFELD,GERMANY	University of Oulu; Netherlands Organization Applied Science Research; University of Helsinki; University of Helsinki; University of Oulu; University of Oulu; University of Bielefeld			, tuula/ABG-2051-2021	Salo, Tuula/0000-0001-6039-0088				BALLAGIPORDANY A, 1991, ANAL BIOCHEM, V196, P89, DOI 10.1016/0003-2697(91)90122-A; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V29, P351; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chubinskaya S, 1996, LAB INVEST, V74, P232; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; COLE AA, 1995, ACTA ORTHOP SCAND, V26, P98; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Golub L M, 1992, Curr Opin Dent, V2, P80; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HIBBS MS, 1984, COLLAGEN REL RES, V4, P467; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KONTTINEN YT, 1991, MATRIX, V11, P395, DOI 10.1016/S0934-8832(11)80194-0; Kylmaniemi M, 1996, J DENT RES, V75, P919, DOI 10.1177/00220345960750030901; LAUHIO A, 1995, LANCET, V346, P645, DOI 10.1016/S0140-6736(95)91484-6; LAUHIO A, 1994, CLIN EXP IMMUNOL, V98, P21; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsuki H, 1996, CLIN CHIM ACTA, V244, P129, DOI 10.1016/0009-8981(95)06197-5; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; OIKARINEN K S, 1987, Endodontics and Dental Traumatology, V3, P95; POWER C, 1994, AM J RESP CRIT CARE, V150, P818, DOI 10.1164/ajrccm.150.3.8087357; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SELTZER JL, 1981, J BIOL CHEM, V256, P4662; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SUOMALAINEN K, 1992, ANTIMICROB AGENTS CH, V36, P227, DOI 10.1128/AAC.36.1.227; TONETTI MS, 1993, J PERIODONTAL RES, V28, P511, DOI 10.1111/j.1600-0765.1993.tb02114.x; TSCHESCHE H, 1991, BIOMED BIOCHIM ACTA, V50, P755; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	42	407	418	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31504	31509		10.1074/jbc.272.50.31504	http://dx.doi.org/10.1074/jbc.272.50.31504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395486	hybrid, Green Published			2022-12-27	WOS:A1997YL41900045
J	Lu, DS; Yuan, X; Zheng, XL; Sadler, JE				Lu, DS; Yuan, X; Zheng, XL; Sadler, JE			Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROKINASE; PURIFICATION; EXPRESSION; INHIBITORS; PROTEINS	Enteropeptidase, also known as enterokinase, initiates the activation of pancreatic hydrolases by cleaving and activating trypsinogen, Enteropeptidase is synthesized as a single-chain protein, whereas purified enteropeptidase contains a approximate to 47-kDa serine protease domain (light chain) and a disulfide-linked approximate to 120-kDa heavy chain, The heavy chain contains an amino-terminal membrane-spanning segment and several repeated structural motifs of unknown function, To study the role of heavy chain motifs in substrate recognition, secreted variants of recombinant bovine proenteropeptidase were constructed by replacing the transmembrane domain with a signal peptide, Secreted variants containing both the heavy chain (minus the transmembrane domain) and the catalytic light chain (pro-HL-BEK (where BEK is bovine enteropeptidase)) or only the catalytic domain (pro-L-BEK) were expressed in baby hamster kidney cells and purified, Single-chain pro-HL-BEK and pro-L-BEK were zymogens with extremely low catalytic activity, and both were activated readily by trypsin cleavage, Trypsinogen was activated efficiently by purified enteropeptidase from bovine intestine (K-m = 5.6 mu M and k(cat) = 4.0 s(-1)) and by HL-BEK (K-m = 5.6 mu M and k(cat) = 2.2 s(-1)), but not by L-BEK (K-m = 133 mu M and k(cat) = 0.1 s(-1)); HL-BEK cleaved trypsinogen at pH 5.6 with 520-fold greater catalytic efficiency than did L-BEK. Qualitatively similar results were obtained at pH 8.4. In contrast to this striking difference in trypsinogen recognition, the small synthetic substrate Gly-Asp-Asp-Asp-Asp-Lys-beta-naphthylamide was cleaved with similar kinetic parameters by both HL-BEK (K-m = 0.27 mM and k(cat) = 0.07 s(-1)) and L-BEK (K-m = 0.60 mM and k(cat) = 0.06 s(-1)). The presence of the heavy chain also influenced the rate of reaction with protease inhibitors, Bovine pancreatic trypsin inhibitor preferred HL-BEK (initial K-i = 99 nM and final Ki* = 1.8 nM) over L-BEK (K-i = 698 nM and K-i* = 6.2 nM). Soybean trypsin inhibitor exhibited a reciprocal pattern, inhibiting L-BEK (K-i* = 1.6 nM), but not HL-BEK. These kinetic data indicate that the enteropeptidase heavy chain has little influence on the recognition of small peptides, but strongly influences macromolecular substrate recognition and inhibitor specificity.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Sadler, Evan/D-8556-2011; Zheng, X. Long/ABD-7362-2021	Zheng, X. Long/0000-0003-1680-5295; Sadler, J. Evan/0000-0001-5705-469X	NIDDK NIH HHS [DK50053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LE, 1977, BIOCHEMISTRY-US, V16, P3354, DOI 10.1021/bi00634a011; BARATTI J, 1976, BIOCHIM BIOPHYS ACTA, V42, P488; BARNS RJ, 1974, BIOCHIM BIOPHYS ACTA, V350, P495, DOI 10.1016/0005-2744(74)90527-0; BRICTEUX.S, 1972, COMP BIOCHEM PHYSIOL, V42, P23, DOI 10.1016/0305-0491(72)90055-7; CHASE T, 1970, METHOD ENZYMOL, V19, P20; FONSECA P, 1983, J BIOL CHEM, V258, P3069; GRANT DAW, 1979, BIOCHIM BIOPHYS ACTA, V567, P207, DOI 10.1016/0005-2744(79)90187-6; GREEN GM, 1983, CLIN CHIM ACTA, V134, P363, DOI 10.1016/0009-8981(83)90375-3; HADORN B, 1969, LANCET, V1, P812; HAWORTH JC, 1971, J PEDIATR-US, V78, P481, DOI 10.1016/S0022-3476(71)80231-7; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Kunitz M, 1939, J GEN PHYSIOL, V22, P429, DOI 10.1085/jgp.22.4.429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LIEPNIEKS JJ, 1979, J BIOL CHEM, V254, P1677; LIGHT A, 1984, J BIOL CHEM, V259, P3195; LIVINGSTON DC, 1981, BIOCHEMISTRY-US, V20, P4298, DOI 10.1021/bi00518a010; LU D, 1997, IN PRESS HDB PROTEOL; MAROUX S, 1971, J BIOL CHEM, V246, P5031; MATSUSHIMA M, 1994, J BIOL CHEM, V269, P19976; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PAVLOV IP, 1902, WORK DIGESTIVE GLAND, P148; WU QY, 1994, J BIOL CHEM, V269, P3725	26	82	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31293	31300		10.1074/jbc.272.50.31293	http://dx.doi.org/10.1074/jbc.272.50.31293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395456	hybrid			2022-12-27	WOS:A1997YL41900015
J	Shao, RG; Cao, CX; Pommier, Y				Shao, RG; Cao, CX; Pommier, Y			Activation of PKC alpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DNA FRAGMENTATION; HL-60 CELLS; THYMOCYTE APOPTOSIS; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; ICE-LIKE; IN-VIVO; INDUCTION; UCN-01	We previously demonstrated that the anticancer agent and protein kinase C (PKC) inhibitor 7-hydroxy-staurosporine (UCN-01) induces apoptosis independently of p53 and protein synthesis in HL60 cells, We now report the associated changes of PKC isoforms, PKC alpha, beta I, beta II, delta, and zeta activities were measured after immunoprecipitation of cytosols from UCN-01-treated HL60 cells. UCN-01 had no effect on PKC zeta and inhibited kinase activity of PKC beta I, beta II, and delta. PKC alpha activity was initially inhibited at 1 h, and subsequently increased as cells underwent apoptosis 3 h after the beginning of UCN-01 treatment, Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKC alpha activity during apoptosis in HL60 cells. However, CPT did not affect PKC beta I, beta II and zeta, and activated PKC delta, PKC alpha activation was not due to increased protein levels or proteolytic cleavage but was associated with PKC alpha autophosphorylation in vitro and increased phosphorylation in vivo, We also found that not only PKC delta but also PKC beta I was proteolytically activated in HL60 cells during apoptosis. The PKC alpha activation and hyperphosphorylation were abrogated by N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoro-methylketone (z-VAD-fmk) under conditions that abrogated apoptosis, z-VAD-fmk also prevented PKC delta and beta I proteolytic activation, Together these findings suggest that caspases regulate PKC activity during apoptosis in HL60 cells, At least two modes of activation were observed: hyperphosphorylation for PKC alpha and proteolytic activation for PKC delta and beta I.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1991, CANCER RES, V51, P4888; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; JARVIS WD, 1994, CANCER RES, V54, P1707; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERCEP M, 1989, J IMMUNOL, V142, P4085; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OJEDA F, 1990, CELL IMMUNOL, V125, P535, DOI 10.1016/0008-8749(90)90106-2; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shao RG, 1996, EXP CELL RES, V227, P190, DOI 10.1006/excr.1996.0266; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHIMIZU T, 1995, CANCER RES, V55, P228; Shimizu T, 1996, EXP CELL RES, V226, P292, DOI 10.1006/excr.1996.0230; SOLARY E, 1993, BLOOD, V81, P1359; SUZUKI K, 1991, CELL IMMUNOL, V134, P235, DOI 10.1016/0008-8749(91)90346-D; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	36	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31321	31325		10.1074/jbc.272.50.31321	http://dx.doi.org/10.1074/jbc.272.50.31321			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395460	hybrid			2022-12-27	WOS:A1997YL41900019
J	Tvrdik, P; Asadi, A; Kozak, LP; Nedergaard, J; Cannon, B; Jacobsson, A				Tvrdik, P; Asadi, A; Kozak, LP; Nedergaard, J; Cannon, B; Jacobsson, A			Cig30, a mouse member of a novel membrane protein gene family, is involved in the recruitment of brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; SACCHAROMYCES-CEREVISIAE; UNCOUPLING PROTEIN; GLUCOSE-TRANSPORT; MESSENGER-RNA; COLD-EXPOSURE; SN-GLYCEROL-3-PHOSPHATE DEHYDROGENASE; NOREPINEPHRINE INFUSION; LIPOPROTEIN-LIPASE; MOLECULAR-CLONING	We have identified a previously uncharacterized gene that is implicated in the thermogenic function of brown adipose tissue of mice. This gene, termed Cig30, is the first mammalian member of a novel gene family comprising several nematode and yeast genes, such as SUR4 and FEN1, mutation of which is associated with highly pleiotropic phenotypes. It codes for a 30-kDa plasma membrane glycoprotein with five putative transmembrane domains. The Cig30 mRNA was readily detected only in brown fat and liver. When animals were exposed to a 3-day cold stress, the Cig30 expression was selectively elevated in brown fat more than 200-fold, Similar increases were brought about in two other conditions of brown fat recruitment, namely during perinatal development and after cafeteria diet, The magnitude of Cig30 mRNA induction in the cold could be mimicked by chronic norepinephrine treatment in vivo. However, in primary cultures of brown adipocytes, a synergistic action of norepinephrine and dexamethasone was required for full expression of the gene, indicating that both catecholamines and glucocorticoids are required for the induction of Cig30. We propose that the CIG30 protein is involved in a pathway connected with brown fat hyperplasia.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory	Tvrdik, P (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS F3,WENNER GREN INST,S-10691 STOCKHOLM,SWEDEN.		Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Tvrdik, Petr/AAK-4398-2021; Cannon, Barbara/B-3089-2016	Nedergaard, Jan/0000-0003-2070-1587; Cannon, Barbara/0000-0001-6594-2363; Tvrdik, Petr/0000-0002-8750-9672				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNARD T, 1980, BIOGENIC AMINES DEV; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; CARNEHEIM C, 1984, AM J PHYSIOL, V246, pE327, DOI 10.1152/ajpendo.1984.246.4.E327; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURRENS P, 1995, CURR GENET, V27, P213, DOI 10.1007/BF00326151; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GARCIAARRANZ M, 1994, J BIOL CHEM, V269, P18076; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIU XL, 1994, AM J PHYSIOL, V266, pR914, DOI 10.1152/ajpregu.1994.266.3.R914; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; MARETTE A, 1991, BIOCHEM J, V277, P119, DOI 10.1042/bj2770119; MITCHELL JRD, 1992, AM J PHYSIOL, V263, pE500, DOI 10.1152/ajpendo.1992.263.3.E500; MOHELL N, 1984, MOL PHARMACOL, V25, P64; MORY G, 1988, BIOSCIENCE REP, V8, P465, DOI 10.1007/BF01121645; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23; Nedergaard J., 1986, BROWN ADIPOSE TISSUE; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; RATNER PL, 1981, J BIOL CHEM, V256, P3576; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SENAULT C, 1988, COMP BIOCHEM PHYS A, V91, P141, DOI 10.1016/0300-9629(88)91606-4; SHIMIZU Y, 1993, AM J PHYSIOL, V264, pE890, DOI 10.1152/ajpendo.1993.264.6.E890; SHIMIZU Y, 1991, J BIOCHEM, V110, P688, DOI 10.1093/oxfordjournals.jbchem.a123642; SHIMIZU Y, 1994, J BIOCHEM-TOKYO, V115, P1069, DOI 10.1093/oxfordjournals.jbchem.a124459; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH RE, 1963, SCIENCE, V140, P199, DOI 10.1126/science.140.3563.199; STRUNECKA A, 1981, PHYSIOL BOHEMOSLOV, V30, P307; VALLERAND AL, 1990, AM J PHYSIOL, V259, pR1043, DOI 10.1152/ajpregu.1990.259.5.R1043; VITIELLO F, 1978, J CHROMATOGR, V166, P637, DOI 10.1016/S0021-9673(00)95654-1	47	92	102	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31738	31746		10.1074/jbc.272.50.31738	http://dx.doi.org/10.1074/jbc.272.50.31738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395518	hybrid			2022-12-27	WOS:A1997YL41900077
J	Aslund, F; Berndt, KD; Holmgren, A				Aslund, F; Berndt, KD; Holmgren, A			Redox potentials of glutaredoxins and other thiol-disulfide oxidoreductases of the thioredoxin superfamily determined by direct protein-protein redox equilibria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; SITE CYSTEINE RESIDUES; ACTIVE-SITE; BOND FORMATION; FUNCTIONAL-CHARACTERIZATION; RIBONUCLEOTIDE REDUCTASE; MIXED DISULFIDE; HYDROGEN DONOR; ISOMERASE DSBA; GLUTATHIONE	Glutaredoxins belong to the thioredoxin superfamily of structurally similar thiol-disulfide oxidoreductases catalyzing thiol-disulfide exchange reactions via reversible oxidation of two active-site cysteine residues separated by two amino acids (CX1X2C). Standard state redox potential (E-o') values for glutaredoxins are presently unknown, and use of glutathione/glutathione disulfide (GSH/GSSG) redox buffers for determining E-o' resulted in variable levels of GSH mixed disulfides. To overcome this complication, we have used reverse-phase high performance liquid chromatography to separate and quantify the oxidized and reduced forms present in the thiol-disulfide exchange reaction at equilibrium after mixing one oxidized and one reduced protein. This allowed for direct and quantitative pairwise comparisons of the reducing capacities of the proteins and mutant forms. Equilibrium constants from pair-wise reaction with thioredoxin or its P34H mutant, which have accurately determined E-o' values from their redox equilibrium with NADPH catalyzed by thioredoxin reductase, allowed for transformation into standard state values. Using this new procedure, the standard state redox potentials for the Escherichia coli glutaredoxins 1 and 3, which contain identical active site sequences CPYC, mere found to be E-o' = -233 and -198 mV, respectively. These values were confirmed independently by using the thermodynamic linkage between the stability of the disulfide bond and the stability of the protein to denaturation, Comparison of calculated E-o' values from a number of proteins ranging from -270 mV for E, coli Trx to -124 mV for DsbA obtained using this method with those determined using glutathione redox buffers provides independent confirmation of the standard state redox potential of glutathione as -240 mV. Determining redox potentials through direct protein-protein equilibria is of general interest as it overcomes errors in determining redox potentials calculated from large equilibrium constants with the strongly reducing NADPH or by accumulating mixed disulfides with GSH.	Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet	Berndt, KD (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	kurt.berndt@mbb.ki.se	Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CHAN HS, 1990, J CHEM PHYS, V92, P3118, DOI 10.1063/1.458605; CLARK WM, 1960, OXIDATIONREDUCTION P, P471; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; Hennecke J, 1997, J BIOL CHEM, V272, P189; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; JOELSON T, 1990, J BIOL CHEM, V265, P3183; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KELLEY JJ, 1977, BIOCHEMISTRY-US, V36, P5029; KELLEY RF, 1987, BIOCHEMISTRY-US, V26, P1406, DOI 10.1021/bi00379a029; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LIN TY, 1991, P NATL ACAD SCI USA, V88, P10573, DOI 10.1073/pnas.88.23.10573; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nozaki Y, 1972, Methods Enzymol, V26, P43; PACE CN, 1988, J BIOL CHEM, V263, P11820; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; SANDBERG VA, 1991, BIOCHEMISTRY-US, V30, P5475, DOI 10.1021/bi00236a021; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCOTT EM, 1963, J BIOL CHEM, V238, P3928; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	42	319	329	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30780	30786		10.1074/jbc.272.49.30780	http://dx.doi.org/10.1074/jbc.272.49.30780			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388218	hybrid			2022-12-27	WOS:000071640800031
J	Berchtold, S; Moriggl, R; Gouilleux, F; Silvennoinen, O; Beisenherz, C; Pfitzner, E; Wissler, M; Stocklin, E; Groner, B				Berchtold, S; Moriggl, R; Gouilleux, F; Silvennoinen, O; Beisenherz, C; Pfitzner, E; Wissler, M; Stocklin, E; Groner, B			Cytokine receptor-independent, constitutively active variants of STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; MAMMARY TISSUE; NUCLEAR FACTOR	STAT (signal transducers and activators of transcription) proteins are dual function proteins, which participate in cytokine-mediated signal transduction events at the cell. surface and transcriptional regulation in the nucleus, We have exploited insights into the activation mechanism of STAT factors to derive constitutively active variants, Chimeric genes encoding fusion proteins of STATE and the kinase domain of JAK2 have been derived, The functional properties of the fusion proteins have been investigated in transiently transfected COS cells or in HeLa cells stably transfected with STAT5-JAK2 gene constructs regulated by a tetracycline-sensitive promoter, The STAT5-JAK2 proteins exhibit tyrosine kinase activity and are phosphorylated on tyrosine, The molecules are activated through an intramolecular or a cross-phosphorylation reaction and exhibit constitutive, STAT5-specific DNA binding activity, The transactivation potentials of three constitutively activated STAT5-JAK2 variants comprising different transactivation domains (TADs) derived from STATE, STAT6, and VP16 were compared. The chimeric molecule containing the STAT5 TAD had no or only a very low, the molecule with the STAT6 TAD a medium, and the molecule with the VP16 TAD a very high transactivation potential, Transcription from STATE-responsive gene promoter regions of the beta-casein, oncostatin RI, and the cytokine-inducible Src homology 2 domain-containing protein genes was observed, These chimeric STAT molecules allow the study of the function of STATE independent of cytokine receptors and the activation of other signal transduction pathways.	TUMOR BIOL CTR,INST EXPT CANC RES,D-79106 FREIBURG,GERMANY; HOP COCHIN,INST COCHIN GENET MOL,INSERM,U363,F-75014 PARIS,FRANCE; UNIV TAMPERE,INST MED TECHNOL,FIN-33101 TAMPERE,FINLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Tampere University			Moriggl, Richard/H-8118-2019; Pfitzner, Edith/AAU-7927-2021	Moriggl, Richard/0000-0003-0918-9463; Pfitzner, Edith/0000-0002-3484-9649; Gouilleux, Fabrice/0000-0001-6047-1718				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MINAMI Y, 1994, J IMMUNOL, V152, P5680; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stoecklin Elisabeth, 1996, Nature (London), V383, P726; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30237	30243		10.1074/jbc.272.48.30237	http://dx.doi.org/10.1074/jbc.272.48.30237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374508	Green Published, hybrid			2022-12-27	WOS:A1997YH61300040
J	Chang, HC; Bush, DR				Chang, HC; Bush, DR			Topology of NAT2, a prototypical example of a new family of amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; LYSINE-SPECIFIC PERMEASE; SUGAR-BEET LEAVES; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; BAKERS-YEAST; H+-ATPASE	Amino acids are the predominant form of nitrogen available to the heterotrophic tissues of plants. These essential organic nutrients are transported across the plasma membrane of plant cells by proton-amino acid symporters, Our lab has cloned an amino acid transporter from Arabidopsis, NAT2/AAP1, that represents the first example of a new class of membrane transporters. We are investigating the structure and function of this porter because it is a member of a large gene family in plants and because its wide expression pattern suggests it plays a central role in resource allocation. In the results reported here, we investigated the topology of NAT2 by engineering a c-myc epitope on either the N or C terminus of the protein, We then used in vitro translation, partial digestion with proteinase K, and immunoprecipitation to identify a group of oriented peptide fragments, We modeled the topology of NAT2 based on the lengths of the peptide fragments that allowed us to estimate the location of protease accessible cleavage sites. We independently identified the location of the N and C termini using immunofluorescence microscopy of NAT2 expressed in COS-1 cells, We also investigated the glycosylation status of several sites of potential N-linked glycosylation. Based on the combined data, me propose a novel 11 transmembrane domain model with the N terminus in the cytoplasm and C terminus facing outside the cell. This model of protein topology anchors our complementary investigations of porter structure and function using site-directed and random mutagenesis.	UNIV ILLINOIS, USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PLANT BIOL, URBANA, IL 61801 USA	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Bush, Daniel R/AAG-8444-2019	Bush, Daniel/0000-0002-9160-5077				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BRISKIN DP, 1990, BIOCHIM BIOPHYS ACTA, V1019, P95, DOI 10.1016/0005-2728(90)90129-R; Bush DR, 1996, J EXP BOT, V47, P1205, DOI 10.1093/jxb/47.Special_Issue.1205; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; BUSH DR, 1991, RECENT ADV PHLOEM TR, P148; BUSH DR, 1998, IN PRESS PLANT AMINO; Chen LS, 1997, PLANT PHYSIOL, V115, P1127, DOI 10.1104/pp.115.3.1127; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; Dauterive R, 1996, J BIOL CHEM, V271, P11414, DOI 10.1074/jbc.271.19.11414; ELLIS J, 1995, MICROBIOL-UK, V141, P1927, DOI 10.1099/13500872-141-8-1927; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Frommer WB, 1995, P NATL ACAD SCI USA, V92, P12036, DOI 10.1073/pnas.92.26.12036; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HONORE N, 1990, NUCLEIC ACIDS RES, V18, P653, DOI 10.1093/nar/18.3.653; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1992, ARCH BIOCHEM BIOPHYS, V294, P519, DOI 10.1016/0003-9861(92)90719-D; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LIVELY MO, 1983, J BIOL CHEM, V258, P9488; MADDY AH, 1976, J THEOR BIOL, V62, P315, DOI 10.1016/0022-5193(76)90123-5; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Muchhal US, 1996, P NATL ACAD SCI USA, V93, P10519, DOI 10.1073/pnas.93.19.10519; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PATE JS, 1983, PLANT PHYSL TREATISE, V8, P335; PI J, 1991, J BACTERIOL, V173, P3622, DOI 10.1128/JB.173.12.3622-3629.1991; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; Smith FW, 1997, PLANT J, V11, P83, DOI 10.1046/j.1365-313X.1997.11010083.x; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; STEFFES C, 1992, J BACTERIOL, V174, P3242, DOI 10.1128/jb.174.10.3242-3249.1992; SYCHROVA H, 1993, YEAST, V9, P771, DOI 10.1002/yea.320090711; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; Tanner W, 1996, ANNU REV PLANT PHYS, V47, P595, DOI 10.1146/annurev.arplant.47.1.595; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P540, DOI 10.1007/BF02341029	55	44	48	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30552	30557		10.1074/jbc.272.48.30552	http://dx.doi.org/10.1074/jbc.272.48.30552			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374550	hybrid			2022-12-27	WOS:A1997YH61300082
J	Durante, W; Liao, L; Peyton, KJ; Schafer, AI				Durante, W; Liao, L; Peyton, KJ; Schafer, AI			Lysophosphatidylcholine regulates cationic amino acid transport and metabolism in vascular smooth muscle cells - Role in polyamine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; ORNITHINE DECARBOXYLASE ACTIVITY; NECROSIS-FACTOR-ALPHA; HYDROXY-L-ARGININE; GENE-EXPRESSION; GROWTH-FACTOR; ENDOTHELIAL-CELLS; CULTURED HUMAN; MOUSE KIDNEY	Lysophosphatidylcholine (lyso-PC) is a major component of atherogenic lipids that stimulate vascular smooth muscle cell (SMC) proliferation. Because cationic amino acids are metabolized to growth-stimulatory polyamines, we examined whether lyso-PC regulates this transcellular transport and metabolism of cationic amino acids by vascular SMC. Treatment of SMC with lyso-PC initially (0-2 h) decreased cationic amino acid uptake, whereas longer exposures (6-24 h) progressively increased transport. Kinetic studies indicated that lyso-PC-induced inhibition was associated with a decrease in affinity for cationic amino acids, but the stimulation was mediated by an increase in transport capacity. Lyso-PC strongly induced the expression of cationic amino acid transporter-2 mRNA while modestly elevating the level of cationic amino acid transporter-1 mRNA. In addition, lyso-PC stimulated intracellular cationic amino acid metabolism by inducing ornithine decarboxylase activity and mRNA expression and also by inducing arginase activity in vascular SMC. In contrast, lyso-PC inhibited the catabolism of L-arginine to nitric oxide by blocking inducible nitric oxide synthase expression. Lyso-PC increased markedly the capacity of SMC to generate putrescine, a polyamine, from extracellular L-ornithine and L-arginine. The lyso-PC-mediated increase in the production of putrescine was reversed by N-G-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor. The formation of putrescine from L-arginine was also prevented by arginase inhibitor NC-hydroxy-L-arginine, These results demonstrate that lyso-PC stimulates polyamine synthesis in vascular SMC by inducing the expression of the genes that regulate both the transport and metabolism of cationic amino acids. The actions of lyso-PC in stimulating cationic amino acid uptake and directing their metabolism to growth-stimulatory polyamines while simultaneously inhibiting the synthesis of antiproliferative NO, may contribute to lyso-PC-induced SMC proliferation and atherosclerotic lesion formation.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), VET ADM MED CTR,BLDG 109,RM 128,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36045] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BERGER FG, 1984, J BIOL CHEM, V259, P7941; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; Durante W, 1996, CIRC RES, V78, P1075, DOI 10.1161/01.RES.78.6.1075; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1993, AM J PHYSIOL, V264, pH617, DOI 10.1152/ajpheart.1993.264.2.H617; Durante W, 1996, P ASSOC AM PHYSICIAN, V108, P356; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; ENDEAN ED, 1991, J SURG RES, V50, P634, DOI 10.1016/0022-4804(91)90054-P; GARG UC, 1990, J CLIN INVEST, V83, P1018; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; GILMOUR SK, 1985, J BIOL CHEM, V260, P6439; GONZALEZ GG, 1991, CANCER RES, V51, P2932; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LOCHER R, 1992, BIOCHEM BIOPH RES CO, V183, P156, DOI 10.1016/0006-291X(92)91622-W; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSL, V56, P626; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MAJESKY MW, 1987, CIRC RES, V61, P296, DOI 10.1161/01.RES.61.2.296; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MELLION BT, 1981, BLOOD, V57, P946; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIDA K, 1990, ATHEROSCLEROSIS, V83, P119, DOI 10.1016/0021-9150(90)90157-E; PEGG AE, 1988, CANCER RES, V48, P759; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P3906; RUSSELL AS, 1980, J IMMUNOL METHODS, V32, P375, DOI 10.1016/0022-1759(80)90029-0; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SAKAI M, 1994, J BIOL CHEM, V269, P31430; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stiko A, 1996, ARTERIOSCL THROM VAS, V16, P194, DOI 10.1161/01.ATV.16.2.194; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; Ulrich K. H., 1981, PHARMACOL REV, V33, P17; VADAS P, 1986, LAB INVEST, V55, P391; WEN L, 1989, J BIOL CHEM, V264, P9016; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU GY, 1995, AM J PHYSIOL-HEART C, V269, pH1312, DOI 10.1152/ajpheart.1995.269.4.H1312; WU VS, 1984, BIOCHIM BIOPHYS ACTA, V804, P89, DOI 10.1016/0167-4889(84)90102-2; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	57	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30154	30159		10.1074/jbc.272.48.30154	http://dx.doi.org/10.1074/jbc.272.48.30154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374496	hybrid			2022-12-27	WOS:A1997YH61300028
J	Hughes, FM; Bortner, CD; Purdy, GD; Cidlowski, JA				Hughes, FM; Bortner, CD; Purdy, GD; Cidlowski, JA			Intracellular K+ suppresses the activation of apoptosis in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACID CLEAVAGE ACTIVITY; PROTEIN-SYNTHESIS; CAENORHABDITIS-ELEGANS; PROLYL OLIGOPEPTIDASE; THYMOCYTE APOPTOSIS; DNA-DEGRADATION; MICE DEFICIENT; ICE FAMILY; PROTEASES	Little is known about the mechanisms of suppression of apoptosis. We have addressed the novel possibility that the level of intracellular K+ regulates the apoptotic process by controlling the activity of death enzymes. We show that K+, at normal intracellular levels, inhibits both apoptotic DNA fragmentation and caspase-3(CPP32)-like protease activation, suggesting that intracellular K+ loss must occur early during apoptosis. Direct measurement of K+ by inductively coupled plasma/ mass spectrometry and flow cytometry indicates a major decrease in intracellular K+ concentration in the apoptotic cell. Flow cytometric analysis revealed that caspase and nuclease activity were restricted to the subpopulation of cells with reduced K+, Disruption of the natural K+ electrochemical gradient suppressed the activity of both caspase and nuclease independent of the mode of activation of the apoptotic inducing agent, demonstrating that a decrease in intracellular K+ concentration is a necessary, early event in programmed cell death.	NIEHS, LAB SIGNAL TRANSDUCT, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Cidlowski, John A/G-2548-2019; Hughes, Francis M/G-8036-2017	Cidlowski, John A/0000-0003-1420-0516; Hughes, Francis/0000-0003-3776-3653				Adamska I, 1996, EUR J BIOCHEM, V236, P591, DOI 10.1111/j.1432-1033.1996.00591.x; Alberts B., 1983, MOL BIOL CELL, P286; ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, PROGRAMMED CELL DEATH, P63; BORTNER CD, 1997, IN PRESS J BIOL CHEM; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONLESLIE LAM, 1994, ENDOCRINE, V2, P47; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; COTTER TG, 1990, ANTICANCER RES, V10, P1153; Creighton TE, 1983, PROTEINS STRUCTURES; DIPAOLO ML, 1995, ARCH BIOCHEM BIOPHYS, V323, P329, DOI 10.1006/abbi.1995.9957; Dixon M., 1979, ENZYMES, Vthird; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GRINSTEIN S, 1982, J GEN PHYSIOL, V80, P801, DOI 10.1085/jgp.80.6.801; Hasegawa J, 1996, CANCER RES, V56, P1713; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hughes FM, 1997, CELL DEATH DIFFER, V4, P200; HUGHES FM, 1998, IN PRESS J STEROID B; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONAS D, 1994, INFECT IMMUN, V62, P1304, DOI 10.1128/IAI.62.4.1304-1312.1994; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KREGENOW FM, 1981, ANNU REV PHYSIOL, V43, P493, DOI 10.1146/annurev.ph.43.030181.002425; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510, DOI 10.1152/physrev.1977.57.3.510; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, BIOCHEM SOC T, V18, P634, DOI 10.1042/bst0180634; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MINTA A, 1989, J BIOL CHEM, V264, P19449; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NALL BT, 1991, CONFORMATIONS FORCES; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; POLGAR L, 1995, BIOCHEM J, V312, P267, DOI 10.1042/bj3120267; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P10769, DOI 10.1021/bi00159a018; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SCHWARTZMAN RA, 1993, ENDOCRINOLOGY, V133, P591, DOI 10.1210/en.133.2.591; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SKALKA M, 1976, FEBS LETT, V72, P271, DOI 10.1016/0014-5793(76)80984-2; STRICKLAND JA, 1991, BIOCHEMISTRY-US, V30, P9749, DOI 10.1021/bi00104a026; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VUKELIC B, 1995, APPL MICROBIOL BIOT, V43, P1056, DOI 10.1007/BF00166925; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; WONDRAK EM, 1991, FEBS LETT, V280, P344, DOI 10.1016/0014-5793(91)80327-Y; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	70	412	431	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30567	30576		10.1074/jbc.272.48.30567	http://dx.doi.org/10.1074/jbc.272.48.30567			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374553	hybrid			2022-12-27	WOS:A1997YH61300085
J	McCallum, CD; Su, BX; Neuenschwander, PF; Morrissey, JH; Johnson, AE				McCallum, CD; Su, BX; Neuenschwander, PF; Morrissey, JH; Johnson, AE			Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain - A fluorescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR VIIA; FACTOR-X; CONFORMATIONAL SENSITIVITY; PHOSPHOLIPID SURFACE; EXTRACELLULAR DOMAIN; ORIENTATION FACTOR; HYDROPHOBIC STACK; CRYSTAL-STRUCTURE; BINDING; ASSOCIATION	Coagulation factor VIIa (fVIIa), a soluble serine protease, exhibits full proteolytic activity only when bound to its cofactor, tissue factor (TF). Both proteins interact with membranes; TF is an integral membrane protein, while fVIIa binds reversibly to phospholipid surfaces via its Gla domain. In this study, we examine the extent to which the location of the fVIIa active site in the fVIIa . TF complex is determined by the fVIIa Gla domain. A fluorescein dye was covalently attached to the active site of fVIIa lacking the Gla domain (Gla domainless fVIIa, GD-fVIIa) via a tripeptide tether to yield fluorescein- D-Phe-Pro-Arg-GD-fVIIa (Fl-FPR-GD-fVIIa). The location of the active site of GD-fVIIa relative to the membrane surface was determined using fluorescence resonance energy transfer between the fluorescein dye in the active site of GD-fVIIa and octadecylrhodamine (OR) at the surface of phospholipid vesicles. As expected, no energy transfer was observed between Fl-FPR-GD-fVIIa and OR in vesicles composed of phosphatidylcholine/phosphatidylserine (PC/PS, 4:1) because the Gla domain is required for the binding of fVIIa to phospholipid. However, when Fl-FPR-GD-fVIIa was titrated with PC or PC/PS vesicles into which purified TF had been reconstituted, energy transfer was observed. Based on the dependence of fluorescence resonance energy transfer on OR density, the average distance of closest approach between fluorescein in the active site of Fl-FPR-GD-fVIIa . TF and OR at the vesicle surface was determined to be 78 Angstrom (kappa(2) = 2/3). Since this value is nearly the same as that obtained with intact Fl-FPR-fVIIa bound to TF, the presence or absence of the fVIIa Gla domain has only a small effect on the location of the active site in the fVIIa . TF complex. The extracellular domain of tissue factor therefore must be fairly rigid and fixed relative to the surface to position and maintain the fVIIa active site far above the membrane even in the absence of the fVIIa Gla domain.	TEXAS A&M UNIV,HLTH SCI CTR,COLL MED,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Johnson, Arthur E/G-3457-2012; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 47014, R01 HL 32934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; FURIE B, 1988, CELL, V53, P508; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HOCHBERG Y, 1987, MULTIPLE COMP PROCED, P80; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; Persson E, 1996, HAEMOSTASIS, V26, P31; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	33	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30160	30166		10.1074/jbc.272.48.30160	http://dx.doi.org/10.1074/jbc.272.48.30160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374497	hybrid			2022-12-27	WOS:A1997YH61300029
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Identification of an amino acid residue that lies between the exofacial vestibule and exofacial substrate-binding site of the Glut1 sugar permeation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CHANNEL-LINING RESIDUES; ESCHERICHIA-COLI; XENOPUS-OOCYTES; TRANSLOCATION PATHWAY; SCANNING MUTAGENESIS; LACTOSE PERMEASE; LIGAND-BINDING; ALPHA-SUBUNIT; MEMBRANE	A valine-to-isoleucine mutation at amino acid residue 197 of Glut2 or the equivalent residue 165 of Glut1 has been shown to impair glucose transport activity. This mutation was originally discovered in the Glut2 gene of a patient with type 2 diabetes. We investigated the mechanism of the effect of this mutation on transport activity via the analysis of Glut1 mutants expressed in Xenopus oocytes combined with cysteine substitution mutagenesis and the use of cysteine-reactive chemical probes, Aliphatic side chain substitutions at position 165 that were bulkier than the native valine residue inhibited glucose transport activity, whereas substitutions of less bulky side chains had little effect on transport, suggesting a role for steric hindrance. A cysteine residue was introduced at position 165 of a functional, cysteine-less Glut1 construct, and this mutant was then tested for inhibition of transport activity by a membrane-impermeant sulfhydryl-specific reagent (p-chloromercuribenzenesulfonate). p-Chloromercuribenzenesulfonate inhibited activity of the Cys(165) mutant when it was added to the external buffer but not when it was injected directly into oocytes, indicating that this residue is accessible from the external solvent but not from the cytoplasm. Competition experiments indicated that Cys(165) lies near the exofacial substrate-binding site or directly in the sugar permeation pathway, These data provide evidence that the side chain of Val(165), which resides in the middle of transmembrane helix 5, juts into the aqueous permeation pathway of Glut1, probably between the exofacial substrate-binding site and the outer vestibule of the pathway.			Mueckler, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DAVIES A, 1990, BIOCHEM J, V266, P799; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P780; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KELLER K, 1989, J BIOL CHEM, V264, P18884; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER M, 1989, RED BLOOD CELL MEMBR, P31; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; TANIZAWA Y, 1994, DIABETOLOGIA, V37, P420, DOI 10.1007/BF00408481; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F; WIDDAS WF, 1988, BIOCHIM BIOPHYS ACTA, V947, P385, DOI 10.1016/0304-4157(88)90001-9; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30141	30146		10.1074/jbc.272.48.30141	http://dx.doi.org/10.1074/jbc.272.48.30141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374494	hybrid			2022-12-27	WOS:A1997YH61300026
J	Standaert, ML; Galloway, L; Karnam, P; Bandyopadhyay, G; Moscat, J; Farese, RV				Standaert, ML; Galloway, L; Karnam, P; Bandyopadhyay, G; Moscat, J; Farese, RV			Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes - Potential role in glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC3H-1 MYOCYTES; ADIPOSE-CELLS; ACTIVATION; TRANSLOCATION; INHIBITORS; INCREASES; 3,4,5-TRISPHOSPHATE; DIACYLGLYCEROL; METABOLISM; MUSCLE	Insulin provoked rapid increases in enzyme activity of immunoprecipitable protein kinase C-zeta (PKC-zeta) in rat adipocytes. Concomitantly, insulin provoked increases in P-32 labeling of PKC-zeta both in intact adipocytes and during in vitro assay of immunoprecipitated PKC-zeta; the latter probably reflected autophosphorylation, as it was inhibited by the PKC-zeta pseudosubstrate. Insulin-induced activation of immunoprecipitable PKC-zeta was inhibited by LY294002 and wortmannin; this suggested dependence upon phosphatidylinositol (PI) 3-kinase. Accordingly, activation of PI 3-kinase by a pYXXM-containing peptide in vitro resulted in a wortmannin-inhibitable increase in immunoprecipitable PKC-zeta enzyme activity, Also, PI-3,4-(PO4)(2), PI-3,4,5-(PO4)(3), and PI-4,5-(PO4)(2) directly stimulated enzyme activity and autophosphoralytion in control PKC-zeta immunoprecipitates to levels observed in insulin-treated PKC-zeta immunoprecipitates. In studies of glucose transport, inhibition of immunoprecipitated PKC-zeta enzyme activity in vitro by both the PKC-zeta pseudosubstrate and RO 31-8220 correlated well with inhibition of insulin stimulated glucose transport in intact adipocytes. Also, in adipocytes transiently expressing hemagglutinin antigen-tagged GLUT4, co-transfection of wild-type or constitutive PKC-zeta stimulated hemagglutinin antigen-GLUT4 translocation, whereas dominant-negative PKC-zeta partially inhibited it. Our findings suggest that insulin activates PKC-zeta through PI 3-kinase, and PKC-zeta may act as a downstream effector of PI 3-kinase and contribute to the activation of GLUT4 translocation.	JA HALEY VET HOSP,RES SERV VAR 151,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM MOL BIOL,TAMPA,FL 33612; UNIV AUTONOMA MADRID,CTR BIO MOL SERVERO OCHOA,MADRID 280049,SPAIN	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Autonomous University of Madrid			Moscat, Jorge/A-7011-2009; Farese, Robert/B-3605-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD TP, 1993, BIOCHEM J, V295, P155, DOI 10.1042/bj2950155; AVIGNON A, 1995, BIOCHEM J, V308, P181, DOI 10.1042/bj3080181; BANDYOPADHYAY B, 1997, J BIOL CHEM, V272, P2551; BANDYOPADHYAY G, 1997, IN PRESS ENDOCRINOLO; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FARESE RV, 1982, J BIOL CHEM, V257, P4042; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; FARESE RV, 1984, J BIOL CHEM, V259, P7094; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P296; KELLY KL, 1993, J BIOL CHEM, V268, P4391; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PENNINGTON SR, 1985, J BIOL CHEM, V260, P1039; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	23	402	409	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30075	30082		10.1074/jbc.272.48.30075	http://dx.doi.org/10.1074/jbc.272.48.30075			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374484	hybrid			2022-12-27	WOS:A1997YH61300016
J	Yamada, M; Ohnishi, H; Sano, S; Nakatani, A; Ikeuchi, T; Hatanaka, H				Yamada, M; Ohnishi, H; Sano, S; Nakatani, A; Ikeuchi, T; Hatanaka, H			Insulin receptor substrate (IRS)-1 and IRS-2 are tyrosine-phosphorylated and associated with phosphatidylinositol 3-kinase in response to brain-derived neurotrophic factor in cultured cerebral cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; SH2 DOMAINS; CHOLINERGIC NEURONS; SIGNAL-TRANSDUCTION; CATALYTIC DOMAINS; INTERFERON-GAMMA; BASAL FOREBRAIN; POSTNATAL RATS; BETA-RECEPTOR	Brain-derived neurotrophic factor (BDNF), a member of the neurotrophins, promotes differentiation and survival of various types of neurons in the central nervous system. BDNF binds to and activates the tyrosine kinase receptor, TrkB, initiating intracellular signaling and exerting its effects. Phosphatidylinositol 3-kinase (PI3-K), which has been implicated in promotion of neuronal survival by neurotrophic factors, is a component in the signaling pathway of BDNF. We examined how BDNF activates PI3-K in cultured cerebral cortical neurons. We found that insulin receptor substrate (IRS)-1 and -2 are involved in the BDNF signaling pathway that activates PI3-K, IRS-I and -2 were tyrosine-phosphorylated and bound to PI3-K in response to BDNF, This BDNF-stimulated signaling via IRS-I and -2 was inhibited by K-252a, an inhibitor of Trk tyrosine kinase, In addition, signaling via IRS-1 and -2 was markedly sustained as well as the BDNF-induced tyrosine phosphorylation of TrkB. On the other hand, we observed no association of PI3-K with TrkB in response to BDNF, These results indicate that the activation of TrkB by BDNF induces the activation of PI3-K via IRS-1 and -2 rather than by a direct interaction of TrkB with PI3-K in cultured cortical neurons.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN		Yamada, M (corresponding author), OSAKA UNIV, INST PROT RES, DIV PROT BIOSYNTH, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.		Sancheti, Harsh/H-3538-2012					Abiru Y, 1996, DEV BRAIN RES, V91, P260, DOI 10.1016/0165-3806(95)00190-5; Akaneya Y, 1996, J NEUROPHYSIOL, V76, P4198, DOI 10.1152/jn.1996.76.6.4198; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; COCHET C, 1991, J BIOL CHEM, V266, P637; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENOKIDO Y, 1992, BRAIN RES, V599, P261, DOI 10.1016/0006-8993(92)90400-4; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Nonomura T, 1996, DEV BRAIN RES, V97, P42, DOI 10.1016/S0165-3806(96)00130-7; NONOMURA T, 1995, BRAIN RES, V683, P129, DOI 10.1016/0006-8993(95)00357-V; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shimoke K, 1997, DEV BRAIN RES, V101, P197, DOI 10.1016/S0165-3806(97)00065-5; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEININGER TL, 1993, BRAIN RES, V612, P330, DOI 10.1016/0006-8993(93)91681-H; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takei N, 1996, MOL BRAIN RES, V37, P283; Takei N, 1997, J NEUROCHEM, V68, P370; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; XU B, 1995, J BIOL CHEM, V270, P29825; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YAMADA M, 1994, BRAIN RES, V661, P137, DOI 10.1016/0006-8993(94)91190-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	64	122	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30334	30339		10.1074/jbc.272.48.30334	http://dx.doi.org/10.1074/jbc.272.48.30334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374521	hybrid			2022-12-27	WOS:A1997YH61300053
J	Juhl, H; Downing, SG; Wellstein, A; Czubayko, F				Juhl, H; Downing, SG; Wellstein, A; Czubayko, F			HER-2/neu is rate-limiting for ovarian cancer growth - Conditional depletion of HER-2/neu by ribozyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; FACTOR PLEIOTROPHIN; GENE-EXPRESSION; BREAST-CANCER; NEU ONCOGENE; TUMOR-GROWTH; ERBB-2; CELLS; ANTIBODIES; RECEPTORS	Amplification and overexpression of the HER-2/neu proto-oncogene frequently coincide with an aggressive clinical course of certain human adenocarcinomas. To assess whether HER-2/neu plays a rate-limiting role in ovarian cancer, we used human SK-OV-3 ovarian cancer cells as a model, We applied a conditional mRNA depletion strategy of HER-2/neu with anti-HER-2/neu-targeted hammerhead ribozymes expressed under the con control of a tetracycline-regulated promoter system, In these ovarian cancer cells, we reduced HER-2/neu mRNA, protein expression, and tumor growth in nude mice by transfection with HER-a!neu-targeted ribozymes and generated cell lines expressing different levels of HER2/neu. Expression of the most effective ribozyme (Rz3) quenched HER-2/neu mRNA levels by >90%. Concomitantly, fluorescence-activated cell sorting analysis revealed that expression of the HER-2/neu encoded surface glycoprotein was almost completely abrogated, In nude mice, tumor growth was dramatically inhibited in the HER-2/neu-depleted Rz3-expressing SK-OV-3 cells, Furthermore, already established tumors started to regress when Rz3 expression was activated midstream by withdrawal of the tetracycline treatment, This study supports the thesis that HER-S/neu can be rate-limiting for the malignant phenotype of ovarian cancer in a gene dose dependent manner.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; CHRISTIAN ALBRECHTS UNIV KIEL KLINIKUM,DEPT SURG,D-24105 KIEL,GERMANY	Georgetown University; University of Kiel; Schleswig Holstein University Hospital				Wellstein, Anton/0000-0002-0570-4950				BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FENG M, 1995, CANCER RES, V55, P2024; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; Jarvis TC, 1996, RNA, V2, P419; JONES J, 1994, GYNECOL ONCOL, V55, P421, DOI 10.1006/gyno.1994.1316; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1994, REGULATORY MECH BREA, P161; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338	22	54	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29482	29486		10.1074/jbc.272.47.29482	http://dx.doi.org/10.1074/jbc.272.47.29482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368008	hybrid			2022-12-27	WOS:A1997YG64700018
J	Mellgren, RL				Mellgren, RL			Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DEGRADATION; TRANSCRIPTION; PROTEOLYSIS; LACTACYSTIN; GROWTH; CYCLE	Cell-permeant peptidyl aldehydes and diazomethylketones are frequently utilized as inhibitors of regulatory intracellular proteases, In the present study the specificities of several peptidyl inhibitors for purified human mu-calpain and 20 S proteasome were investigated, Acetyl-LLnL aldehyde, acetyl-LLM aldehyde, carbobenzyloxy-LLnV aldehyde (ZLLnVal), and carbobenzyloxy-LLY-diazomethyl ketone produced half-maximum inhibition of the caseinolytic activity of mu-calpain at concentrations of 1-5 x 10(-7) nr. In contrast, only ZLLnVal was a reasonably potent inhibitor of the caseinolytic activity of 20 S proteasome, producing 50% inhibition at 10(-5) M, The other inhibitors were at least 10-fold less potent, producing substantial inhibition only at near saturating concentrations in the assay buffer, Further studies with ZLLnVal demonstrated that its inhibition of the proteasome was independent of casein concentration over a 25-fold range, Proteolysis of calpastatin or lysozyme by the proteasome was half-maximally inhibited by 4 and 22 mu M ZLLnVal, respectively, Thus, while other studies have shown that ZLLnVal is a potent inhibitor of the hydrophobic peptidase activity of the proteasome, it appears to be a much weaker inhibitor of its proteinase activity, The ability of the cell permeant peptidyl inhibitors to inhibit growth of the yeast Saccharomyces cerevisiae was studied because this organism expresses proteasome but not calpains, Concentrations of ZLLnVal as high as 200 mu M had no detectable effect on growth rates of overnight cultures, However, yeast cell lysates prepared from these cultures contained 2 mu M ZLLnVal, an amount which should have been sufficient to fully inhibit hydrophobic peptidase activity of yeast proteasome. Degradation of ubiquitinylated proteins in yeast extracts by endogenous proteasome was likewise sensitive only to high concentrations of ZLLnVal, The higher sensitivity of the proteinase activity of calpains to inhibition by the cell permeant inhibitors suggests that calpain-like activities may be targets of these inhibitors in animal cells.			Mellgren, RL (corresponding author), MED COLL OHIO,DEPT THERAPEUT & PHARMACOL,TOLEDO,OH 43614, USA.				NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bush KT, 1997, J BIOL CHEM, V272, P9086; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HADARI T, 1992, J BIOL CHEM, V267, P719; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	35	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29899	29903		10.1074/jbc.272.47.29899	http://dx.doi.org/10.1074/jbc.272.47.29899			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368065	hybrid			2022-12-27	WOS:A1997YG64700075
J	Morris, JC; MensaWilmot, K				Morris, JC; MensaWilmot, K			Role of 2,6-dideoxy-2,6-diaminoglucose in activation of a eukaryotic phospholipase C by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; TRYPANOSOMA-BRUCEI; A-SITE; RESISTANCE; MECHANISMS	Recent emergence of microbial resistance to aminoglycoside antibiotics, and the documented cytotoxicity associated with their use, calls for sustained efforts at understanding the effects of the compounds on eukaryotic cells, Using a glycosyl phosphatidylinositol (GPI)phospholipase C (GPI-PLC) from the protozoan parasite Trypanosoma brucei, we demonstrate that a eukaryotic PLC can be activated 6-fold by aminoglycosides. Neomycin B protected GPI-PLC from a reduction in activity at pH 6.5, and increased the turnover number (k(cat)) of the enzyme, In structure-activity studies with the neomycin group, 2-deoxy-streptamine was mildly stimulatory; the concentration required to activate GPI-PLC a-fold (SC200) was 310 mu M. Neamine was 150-fold more active (SC200 = 2 mu M) than a deoxy-streptamine, indicating that a 2,6-dideoxy-2,6-diaminoglucose substituent at the 4-position of 2-deoxystreptamine plays an important role in activation of GPI-PLC. Ribostamycin and neomycin B also had SC200's of 2 mu M, implying that the ribose group in ribostamycin is not involved in activation of GPI-PLC, These conclusions were affirmed in studies with Bacillus thuringiensis phosphatidylinositol-specific phospholipase C, A 2,6-dideoxy-2,6-diaminoglucose substitution at the 4-OH of a deoxystreptamine activates the enzyme 17-fold, while a second 2,6-dideoxy-2,6-diaminoglucose moiety on the ribose ring of ribostamycin provides an additional 3.5-fold stimulation. Possible implications of these observations for the effects of aminoglycosides on eukaryote cells are discussed.	UNIV GEORGIA,DEPT CELLULAR BIOL,ATHENS,GA 30602	University System of Georgia; University of Georgia				Morris, James/0000-0003-2515-5714	NIAID NIH HHS [1-T32-AIO-78322, AI33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCHANAN JH, 1987, EUR J CELL BIOL, V43, P141; Butikofer P, 1996, J BIOL CHEM, V271, P15533, DOI 10.1074/jbc.271.26.15533; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GOMEZLUS R, 1995, J CHEMOTHERAPY, V7, P97, DOI 10.1179/joc.1995.7.2.97; Kettner M, 1995, INFECTION, V23, P380, DOI 10.1007/BF01713571; Landini P, 1996, BIOCHEMISTRY-US, V35, P15288, DOI 10.1021/bi9610818; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MILLER GH, 1995, J CHEMOTHERAPY, V7, P31; MINGEOTLECLERCQ MP, 1995, J TOXICOL ENV HEALTH, V44, P263, DOI 10.1080/15287399509531960; Miyaguchi H, 1996, NUCLEIC ACIDS RES, V24, P3700, DOI 10.1093/nar/24.19.3700; Morris JC, 1996, J BIOL CHEM, V271, P15468, DOI 10.1074/jbc.271.26.15468; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; SAGAWA N, 1983, BIOCHIM BIOPHYS ACTA, V752, P153, DOI 10.1016/0005-2760(83)90243-6; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; VANBAMBEKE F, 1995, EUR J PHARM-MOLEC PH, V289, P321, DOI 10.1016/0922-4106(95)90110-8; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; Wang Y, 1997, BIOCHEMISTRY-US, V36, P768, DOI 10.1021/bi962095g	18	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29554	29559		10.1074/jbc.272.47.29554	http://dx.doi.org/10.1074/jbc.272.47.29554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368017	hybrid			2022-12-27	WOS:A1997YG64700027
J	Thevissen, K; Osborn, RW; Acland, DP; Broekaert, WF				Thevissen, K; Osborn, RW; Acland, DP; Broekaert, WF			Specific, high affinity binding sites for an antifungal plant defensin on Neurospora crassa hyphae and microsomal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; TOMATO CELLS; L SEEDS; INHIBITION; PROTEINS; THIONINS; CHANNELS; RADISH; GROWTH	Hs-AFP1 an antifungal plant defensin from seed of the plant Heuchera sanguinea, was radioactively labeled using t-butoxycarbonyl-[S-35]L-methionine N-hydroxysuccinimidyl ester, resulting in a S-35-labeled peptide with unaltered antifungal activity. [S-35]Hs-AFP1 was used to assess binding on living hyphae of the fungus Neurospora crassa. Binding of [S-35]Hs-AFP1 was found to be competitive, reversible, and saturable with an apparent K-d of 29 nM and a B-max of 1.4 pmol/mg protein. [S-35]Hs-AFP1 also bound specifically and reversibly to microsomal membranes derived hom N. crassa hyphae with a K-d of 27 nM and a B-max of 102 pmol/mg protein. The similarity in K-d value between binding sites on hyphae and microsomes indicates that Hs-AFP1 binding sites reside on the plasma membrane. Binding of [S-35]Hs-AFP1 to both hyphae and microsomal membranes could be competed to some extent by four different structurally related plant defensins but not by various structurally unrelated antimicrobial peptides. In addition, an inactive single amino acid substitution variant of the antifungal plant defensin Rs-AFP2 from Raphanus sativus seed was also unable to displace [S-35]Hs-AFP1 from its binding sites, whereas Rs-AFP2 itself was able to compete with [S-35]Hs-AFP1.	Katholieke Univ Leuven, FA Janssens Lab Genet, B-3001 Heverlee, Belgium; Zeneca Agrochem, Jealotts Hill Res Stn, Bracknell RG42 6ET, Berks, England	KU Leuven	Broekaert, WF (corresponding author), Katholieke Univ Leuven, FA Janssens Lab Genet, K Mercierlaan 92, B-3001 Heverlee, Belgium.	willem.broekaert@agr.kuleuven.ac.be	Thevissen, Karin/B-7003-2015	Thevissen, Karin/0000-0003-0275-9072				BASSE CW, 1993, J BIOL CHEM, V268, P14724; BAUREITHEL K, 1994, J BIOL CHEM, V269, P17931; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; Cai G, 1997, TRENDS PLANT SCI, V2, P86, DOI 10.1016/S1360-1385(96)10057-1; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DeSamblanx GW, 1997, J BIOL CHEM, V272, P1171, DOI 10.1074/jbc.272.2.1171; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LAKEY JH, 1994, TOXICOLOGY, V87, P85, DOI 10.1016/0300-483X(94)90156-2; LEHRER RI, 1988, BLOOD, V72, P507; MORENO M, 1994, EUR J BIOCHEM, V223, P135, DOI 10.1111/j.1432-1033.1994.tb18974.x; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; Schmitt MJ, 1995, ARCH MICROBIOL, V164, P435; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tailor RH, 1997, J BIOL CHEM, V272, P24480, DOI 10.1074/jbc.272.39.24480; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1993, PLANT PHYSIOL, V103, P1311, DOI 10.1104/pp.103.4.1311; Thevissen K, 1996, J BIOL CHEM, V271, P15018, DOI 10.1074/jbc.271.25.15018	25	89	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32176	32181		10.1074/jbc.272.51.32176	http://dx.doi.org/10.1074/jbc.272.51.32176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405418	hybrid			2022-12-27	WOS:000071108000037
J	Faiman, GA; Horovitz, A				Faiman, GA; Horovitz, A			Thermodynamic analysis of the interaction between the 0.5 beta Fv fragment and the RP135 peptide antigen derived from the V3 loop of HIV-1 gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY; HEAT-CAPACITY; CRYSTAL-STRUCTURE; BINDING; SITE; PROTEINS; DETERMINANT; RECOGNITION; ASSOCIATION	The Fv fragment of the 0.5 beta monoclonal antibody has recently been constructed, expressed, and purified. It binds with nanomolar affinity to the immunogenic RP135 peptide that is derived from the principal neutralizing determinant of HIV-1 in the third hypervariable region of gp120. Here, we analyzed the temperature-dependence of binding of the 0.5 beta Fv fragment to the RP135 peptide and a series of mutants thereof. Our results show that there is almost complete enthalpy-entropy compensation in the effects of mutations in the peptide on binding to the Fv, indicating that the mutations do not change the binding mechanism. There is good correlation, for residues within the antigenic epitope, between mutational effects on Delta C-p and calculated values of Delta Delta C-p, based on the extent of burial of polar and non-polar surface areas of amino acids. The value of Delta C-p for the binding of the 0.5 beta Fv fragment to the wild-type RP135 peptide is found to be -5.0 (+/- 0.9) heal K-1 mol(-1) in the presence of 0.1% Tween-20 but only -0.1 (+/- 0.9) kcal K-1 mol(-1) in its absence. This result has important implications for the successful application of the structural parameterization approach to predicting changes in heat capacity that accompany binding reactions carried out in the presence of detergent or protein-stabilizing agents.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; DECRISTOFARO R, 1994, J MOL BIOL, V239, P569, DOI 10.1006/jmbi.1994.1396; Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829; Frisch C, 1997, J MOL BIOL, V267, P696, DOI 10.1006/jmbi.1997.0892; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; Hurle Mark R., 1994, Current Opinion in Biotechnology, V5, P428, DOI 10.1016/0958-1669(94)90053-1; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leffler J. E., 1963, RATES EQUILIBRIA ORG, P315; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NILSSON B, 1995, CURR OPIN STRUC BIOL, V5, P450, DOI 10.1016/0959-440X(95)80028-X; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; REES AR, 1994, TRENDS BIOTECHNOL, V12, P199, DOI 10.1016/0167-7799(94)90083-3; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015; ZVI A, 1995, EUR J BIOCHEM, V229, P178, DOI 10.1111/j.1432-1033.1995.tb20453.x; Zvi A, 1997, BIOCHEMISTRY-US, V36, P8619, DOI 10.1021/bi970520f	34	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31407	31411		10.1074/jbc.272.50.31407	http://dx.doi.org/10.1074/jbc.272.50.31407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395472	hybrid			2022-12-27	WOS:A1997YL41900031
J	Kim, TD; Eddlestone, GT; Mahmoud, SF; Kuchtey, J; Fewtrell, C				Kim, TD; Eddlestone, GT; Mahmoud, SF; Kuchtey, J; Fewtrell, C			Correlating Ca2+ responses and secretion in individual RBL-2H3 mucosal mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CALCIUM OSCILLATIONS; INTRACELLULAR CA-2+; HISTAMINE-RELEASE; QUANTAL SECRETION; VESICLE FUSION; TUMOR PROMOTER; EXOCYTOSIS; CATECHOLAMINES; STORES	The role of Ca2+ in stimulus-response coupling in nonexcitable cells is still not well understood. The Ca2+ responses of individual cells are extremely diverse, often displaying marked oscillations, and almost nothing is known about the specific features of these Ca2+ signals that are important for the functional response of a cell. Using the RBL-2H3 mucosal mast cell as a model, we have studied the temporal relationship between changes in intracellular Ca2+ and serotonin secretion at the single-cell level using simultaneous indo-1 photometry and constant potential amperometry. Secretion in response to antigen never occurs until intracellular Ca2+ is elevated, nor is it seen during the first few oscillations in Ca2+, Exocytotic events tend to be clustered around the peaks of oscillations, but excellent secretion is also seen in cells with sustained elevations in Ca2+. Ca2+ release from stores in the absence of influx fails to elicit secretion, If refilling and continued release of Ca2+ from stores is prevented with thapsigargin, Ca2+ influx can still trigger secretion, suggesting that store-associated microdomains of Ca2+ are not required for exocytosis. Our findings demonstrate the importance of an amplitude-encoded Ca2+ signal and Ca2+ influx for stimulus-secretion coupling in these nonexcitable cells.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA	Cornell University								Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1997, NATURE, V759, P760; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FEWTRELL C, 1989, CIBA F SYMP, V147, P114; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PENNER R, 1988, J EXP BIOL, V139, P329; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SALATHE M, 1995, J CELL SCI, V108, P431; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; SJODIN L, 1991, J PHYSIOL-LONDON, V444, P763; TATHAM PER, 1991, PFLUG ARCH EUR J PHY, V419, P409, DOI 10.1007/BF00371124; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WEINTRAUB WH, 1994, J CELL PHYSIOL, V160, P389, DOI 10.1002/jcp.1041600220; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	41	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31225	31229		10.1074/jbc.272.50.31225	http://dx.doi.org/10.1074/jbc.272.50.31225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395446	hybrid			2022-12-27	WOS:A1997YL41900005
J	Lawson, JE; Park, SH; Mattison, AR; Yan, JG; Reed, LJ				Lawson, JE; Park, SH; Mattison, AR; Yan, JG; Reed, LJ			Cloning, expression, and properties of the regulatory subunit of bovine pyruvate dehydrogenase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B PHOSPHATASE; CALCIUM-IONS; PURIFICATION; STIMULATION; SPERMINE; BINDING; KIDNEY; HEART	cDNA encoding the regulatory subunit of bovine mitochondrial pyruvate dehydrogenase phosphatase (PDPr) has been cloned. Overlapping cDNA fragments were generated by the polymerase chain reaction from bovine genomic DNA and from cDNA synthesized from bovine poly(A)(+) RNA and total RNA. The complete cDNA (2885 base pairs) contains an open reading frame of 2634 nucleotides encoding a putative presequence of 31 amino acid residues and a mature protein of 847 residues with a calculated M-r of 95,656. This value is in agreement with the molecular mass of native PDPr (95,800 +/- 200 Da) determined by matrix-assisted laser desorption-ionization mass spectrometry. The mature form of PDPr was expressed in Escherichia coli as a maltose-binding protein fusion, and the recombinant protein was purified to near homogeneity. It exhibited properties characteristic of the native PDPr, including recognition by antibodies against native bovine PDPr, ability to decrease the sensitivity of the catalytic subunit to Mg2+, and reversal of this inhibitory effect by the polyamine spermine. A BLAST search of protein data bases revealed that PDPr is distantly related to the mitochondrial flavoprotein dimethylglycine dehydrogenase, which functions in choline degradation.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; UNIV TEXAS,INST BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NIGMS NIH HHS [GM06590] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM006590] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; DAMUNI Z, 1984, BIOCHEM BIOPH RES CO, V24, P95; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; NIU XD, 1988, BIOTECHNIQUES, V85, P75426; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; PRATT ML, 1982, EUR J BIOCHEM, V125, P349, DOI 10.1111/j.1432-1033.1982.tb06690.x; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; SCHLOSS JV, 1988, NATURE, V331, P360, DOI 10.1038/331360a0; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; WITTWER AJ, 1980, P NATL ACAD SCI-BIOL, V77, P4484, DOI 10.1073/pnas.77.8.4484; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	20	32	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31625	31629		10.1074/jbc.272.50.31625	http://dx.doi.org/10.1074/jbc.272.50.31625			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395502	hybrid			2022-12-27	WOS:A1997YL41900061
J	Rellahan, BL; Graham, LJ; Stoica, B; DeBell, KE; Bonvini, E				Rellahan, BL; Graham, LJ; Stoica, B; DeBell, KE; Bonvini, E			Cbl-mediated regulation of T cell receptor-induced AP1 activation - Implications for activation via the Ras signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; PRODUCT C-CBL; ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT; SH3 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEINS; PHOSPHOLIPASE-C; EXCHANGE FACTOR	The functional role of Cbl in regulating T cell receptor (TCR)-mediated signal transduction pathways is unknown. This study uses Cbl overexpression in conjunction with a Ras-sensitive AP1 reporter construct to examine its role in regulating TCR mediated activation of the Ras pathway, Cbl overexpression in Jurkat T cells inhibited AP1 activity after TCR ligation, However, AP1 induction by 4 beta-phorbol 12-myristate 13-acetate, which up-regulates Ras activity in a protein kinase C-dependent, TCR/tyrosine kinase-independent manner was not affected by Cbl overexpression. Cbl overexpression also did not affect AP1 induction by an activated Ras protein or a membrane bound form of the guanine nucleotide exchange factor Sos. In addition, activation of the mitogen-activated protein kinase Erk2 was decreased by Cbl overexpression. Therefore, Cbl regulates events that are required for full TCR-mediated Ras activation, and data are presented to support a model whereby Cbl regulates events required for Ras activation via its association with Grb2.	US FDA, Immunobiol Lab, Div Monoclonal Antibodies, Off Therapeut Res & Review,Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Rellahan, BL (corresponding author), US FDA, Ctr Biol Evaluat & Res, HFM 564,Bldg 29B,Rm 5E16,1401 Rockville Pike, Rockville, MD 20852 USA.	rellahan@a1.cber.fda.gov	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434				BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Lee JM, 1996, ONCOGENE, V12, P253; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SASTRY L, 1995, ONCOGENE, V11, P1107; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	63	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30806	30811		10.1074/jbc.272.49.30806	http://dx.doi.org/10.1074/jbc.272.49.30806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388222	hybrid			2022-12-27	WOS:000071640800035
J	Yamanaka, Y; Wilson, EM; Rosenfeld, RG; Oh, Y				Yamanaka, Y; Wilson, EM; Rosenfeld, RG; Oh, Y			Inhibition of insulin receptor activation by insulin-like growth factor binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; DEPENDENT DIABETES-MELLITUS; SERUM PROTEASE ACTIVITY; FACTOR IGF BINDING; FACTOR-II; EPITHELIAL-CELLS; KINASE-ACTIVITY; RETINOIC ACID; PREGNANCY; COMPLEX	The insulin-like growth factors (IGFs) are transported by a family of high-affinity binding proteins (IGFBPs) that protect IGFs from degradation, limit their binding to IGF receptors, and modulate IGF actions. The six classical IGFBPs have been believed to have no affinity for insulin. We now demonstrate that IGFBP-7/mac25, a newly identified member of the IGFBP superfamily that binds IGFs specifically with low affinity is a high-affinity insulin binding protein. IGFBP-7 blocks insulin binding to the insulin receptor and thereby inhibiting the earliest steps in insulin action, such as autophosphorylation of the insulin receptor beta subunit and phosphorylation of IRS-1, indicating that IGFBP-7 is a functional insulin-binding protein. The affinity of other IGFBPs for insulin can be enhanced by modifications that disrupt disulfide bonds or remove the conserved COOH terminus. Like IGFBP-7, an NH2-terminal fragment of IGFBP-3 (IGFBP-3((1-87))), also binds insulin with high affinity and blocks insulin action. IGFBPs with enhanced affinity for insulin might contribute to the insulin resistance of pregnancy, type II diabetes mellitus, and other pathological conditions.	Oregon Hlth Sci Univ, Sch Med, Dept Pediat, Portland, OR 97201 USA	Oregon Health & Science University	Oh, Y (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Pediat, 3181 SW Sam Jackson Pk Rd,NRC5, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BANG P, 1994, J CLIN ENDOCR METAB, V78, P1119, DOI 10.1210/jc.78.5.1119; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P1312, DOI 10.1210/jc.80.4.1312; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; CARO JF, 1986, J CLIN INVEST, V78, P249, DOI 10.1172/JCI112558; CASELLA SJ, 1986, J BIOL CHEM, V261, P9268; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FIELDER PJ, 1990, ENDOCRINOLOGY, V127, P2270, DOI 10.1210/endo-127-5-2270; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; Gucev ZS, 1996, CANCER RES, V56, P1545; HARING H, 1989, DIABETES METAB REV, V5, P431; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KIM HS, 1997, IN PRESS P NATL ACAD; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; LASSARRE C, 1994, ENDOCRINOLOGY, V134, P1254, DOI 10.1210/en.134.3.1254; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LIU F, 1992, J CLIN ENDOCR METAB, V75, P1261, DOI 10.1210/jc.75.5.1261; MARSHALL RN, 1974, J CLIN ENDOCR METAB, V39, P283, DOI 10.1210/jcem-39-2-283; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rosenfeld R G, 1990, Recent Prog Horm Res, V46, P99; RUTISHAUSER J, 1993, FEBS LETT, V334, P23, DOI 10.1016/0014-5793(93)81672-M; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	42	164	178	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30729	30734		10.1074/jbc.272.49.30729	http://dx.doi.org/10.1074/jbc.272.49.30729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388210	hybrid			2022-12-27	WOS:000071640800023
J	Barden, JA; Cuthbertson, RM; Wu, JZ; Moseley, JM; Kemp, BE				Barden, JA; Cuthbertson, RM; Wu, JZ; Moseley, JM; Kemp, BE			Solution structure of parathyroid hormone related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 (PTHrP[Ala(15)]-(1-34))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAINS; STABILIZED NMR STRUCTURE; HUMORAL HYPERCALCEMIA; H-1-NMR SPECTROSCOPY; MAGNETIC-RESONANCE; RENAL RECEPTOR; PTH RECEPTOR; MALIGNANCY; FRAGMENT; IDENTIFICATION	The structure of human parathyroid hormone (PTH) related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 was studied by two-dimensional proton nuclear magnetic resonance spectroscopy, This mutant retains quite high levels of adenylate cyclase activity based on slightly reduced PTH receptor binding capacity, Three segments of helix were revealed extending from His(5) to Lys(11), Lys(13) to Arg(19), and from Phe(22) to Thr(33)/Ala(34), with a decided kink between the first two helices around Gly(12). N- and C-terminal helices were stabilized by charged and hydrophobic side chain interactions between His(5) and Glu(30), Asp(17) and both His(9) and His(25), and between Leu(8) and Ala(29,) resulting in a globular molecule occupying a single conformation, While the structure of the entire mid-molecule region differed greatly from the structure of the native peptide, the structure of both N- and C-terminal regions remains essentially unaltered, The residues responsible for initiating signal transduction in the mutant are located in the vicinity of the residues responsible for receptor binding, The C-terminal amphipathic helix forming the receptor binding site exhibits reduced binding as a result of the closely applied N-terminal signal transduction-activating region, Although not contributing directly to receptor binding, the N-terminal region can sterically affect hormone binding through modifications to certain N-terminal side chains.	UNIV SYDNEY,DEPT ANAT & HISTOL,SYDNEY,NSW 2006,AUSTRALIA; ST VINCENTS INST MED RES,MELBOURNE,VIC 3065,AUSTRALIA	University of Sydney; St. Vincent's Institute of Medical Research	Barden, JA (corresponding author), UNIV SYDNEY,BIOMED RES INST,SYDNEY,NSW 2006,AUSTRALIA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082				ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1994, BBA-PROTEIN STRUCT M, V1208, P256, DOI 10.1016/0167-4838(94)90111-2; Barden JA, 1996, BIOCHEM BIOPH RES CO, V220, P431, DOI 10.1006/bbrc.1996.0390; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BARDEN JA, 1995, B MAGN RESON, V17, P166; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1994, X PLOR VERSION 3 1 U; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; COHEN FE, 1991, J BIOL CHEM, V266, P1997; DRAPER MW, 1982, J BIOL CHEM, V257, P3714; Dunbar ME, 1996, AM J MED SCI, V312, P287, DOI 10.1097/00000441-199612000-00007; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; HUNT NH, 1980, CLIN SCI, V58, P463, DOI 10.1042/cs0580463; Jasonoff A., 1994, BIOCHEMISTRY-US, V33, P2129; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; LEE SC, 1989, BIOPOLYMERS, V28, P1115, DOI 10.1002/bip.360280606; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MCKEE RL, 1988, ENDOCRINOLOGY, V122, P3008, DOI 10.1210/endo-122-6-3008; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; REDFIELD AG, 1975, J MAGN RESON, V19, P250, DOI 10.1016/0022-2364(75)90073-6; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; SAUDEK V, 1990, BIOCHEMISTRY-US, V29, P4509, DOI 10.1021/bi00471a002; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; SCHNEIDER HG, 1991, BIOCHEM J, V280, P451, DOI 10.1042/bj2800451; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SMITH LM, 1987, ARCH BIOCHEM BIOPHYS, V253, P81, DOI 10.1016/0003-9861(87)90639-4; SOMJEN D, 1990, BIOCHEM J, V272, P781; STEWART JM, 1966, SOLID PHASE PEPTIDE, P44; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	48	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29572	29578		10.1074/jbc.272.47.29572	http://dx.doi.org/10.1074/jbc.272.47.29572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368020	hybrid			2022-12-27	WOS:A1997YG64700030
J	Inamoto, S; Segil, N; Pan, ZQ; Kimura, M; Roeder, RG				Inamoto, S; Segil, N; Pan, ZQ; Kimura, M; Roeder, RG			The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK activity on the POU domains of octamer transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; RING FINGER PROTEIN; FACTOR TFIIH; CELL-CYCLE; IMMUNOGLOBULIN PROMOTERS; SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; BINDING PROTEIN; DNA-REPAIR; COMPLEX	Octamer binding transcription factors (Oct factors) play important roles in activation of transcription of various genes but, in some cases, require cofactors that interact with the DNA binding (POU) domain, In the present study, a yeast two-hybrid screen with the Oct-1 POU domain as a bait identified MAT1 as a POU domain-binding protein, MAT1 is known to be required for the assembly of cyclin dependent kinase (CDK)-activating kinase (CAK), which is functionally associated with the general transcription factor IIH (TFIIH), Further analyses showed that MAT1 interacts with POU domains of Oct-1, Oct-2, and Oct-3 in vitro in a DNA-independent manner, MAT1-containing TFIIH was also shown to interact with POU domains of Oct-1 and Oct-2, MAT1 is shown to enhance the ability of a recombinant CDK7-cyclin H complex (bipartite CAK) to phosphorylate isolated POU domains, intact Oct-1, and the C-terminal domain of RNA polymerase II, but not the originally defined substrate, CDK2. Phosphopeptide mapping indicates that the site (Ser(385)) Of a mitosis-specific phosphorylation that inhibits Oct-1 binding to DNA is not phosphorylated by CAR, However, one CAK-phosphorylated phosphopeptide comigrates with a Cdc2-phosphorylated phosphopeptide previously shown to be mitosis-specific, suggesting that, in vitro, CAK is able to phosphorylate at least one site that is also phosphorylated in vivo, These results suggest (i) that interactions between POU domains and MAT1 can target CAK to Oct factors and result in their phosphorylation, (ii) that MAT1 not only functions as a CAK assembly factor but also acts to alter the spectrum of CAK substrates, and (iii) that a POU-MAT1 interaction may play a role in the recruitment of TFIIH to the preinitiation complex or in subsequent initiation and elongation reactions.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOL LAB,NEW YORK,NY 10021; MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai				Kimura, Makoto/0000-0003-0868-5334	NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI2732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; HARPER JW, 1993, CELL, V75, P805; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; YEE A, 1995, CANCER RES, V55, P6058; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	62	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29852	29858		10.1074/jbc.272.47.29852	http://dx.doi.org/10.1074/jbc.272.47.29852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368058	hybrid			2022-12-27	WOS:A1997YG64700068
J	Kundu, M; Guermah, M; Roeder, RG; Amini, S; Khalili, K				Kundu, M; Guermah, M; Roeder, RG; Amini, S; Khalili, K			Interaction between cell cycle regulator, E2F-1, and NF-kappa B mediates repression of HIV-1 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TATA-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; T-CELLS; MOLECULAR MECHANISMS; HUMAN-LYMPHOCYTES; HTLV-III/LAV; IN-VITRO; INFECTION; TYPE-1	The NF-kappa E/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression, Some of these extracellular stimuli arrest cells in the G(1) phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1, Earlier studies indicated that E2F-1, a transcription factor that stimulates expression of S phase-specific genes, is able to repress transcription directed by the human immunodeficiency virus (HIV-1) type-1 promoter in a variety of cells, including those of glial and lymphocytic origin, Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappa B enhancer region and to interact with the NF-kappa B subunit, p50, Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappa B elements, Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins, Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences, In vitro transcription assay demonstrates that E2F-1 represses NF-kappa B mediated transcription in a cell-free system, Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappa B binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo. The results of this study suggest that NF-kappa B activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.	ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL & NEUROONCOL,PHILADELPHIA,PA 19102; ALLEGHENY UNIV HLTH SCI,DEPT NEUROL,PHILADELPHIA,PA 19102; ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Drexel University; Drexel University; Rockefeller University								AHUJA SS, 1993, J IMMUNOL, V150, P3109; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FOLKS T, 1986, J IMMUNOL, V136, P4049; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KITAJIMA I, 1993, SCIENCE, V259, P1523, DOI 10.1126/science.8456277; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNDU M, 1995, J VIROL, V69, P6940, DOI 10.1128/JVI.69.11.6940-6946.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SCHUITEMAKER H, 1994, RES IMMUNOL, V145, P588, DOI 10.1016/S0923-2494(05)80038-0; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STENSTRAND K, 1987, PHOTODERMATOLOGY, V4, P36; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VINCENZI E, 1994, CHEM-BIOL INTERACT, V91, P101; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang LQ, 1997, J VIROL, V71, P1651, DOI 10.1128/JVI.71.2.1651-1656.1997	64	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29468	29474		10.1074/jbc.272.47.29468	http://dx.doi.org/10.1074/jbc.272.47.29468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368006	hybrid			2022-12-27	WOS:A1997YG64700016
J	Lallemand, C; BayatSarmadi, M; Blanchard, B; Tovey, MG				Lallemand, C; BayatSarmadi, M; Blanchard, B; Tovey, MG			Identification of a novel transcriptional regulatory element common to the p53 and interferon regulatory factor 1 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH INHIBITION; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE PKR; FACTOR-I IRF-1; DNA-DAMAGE; CYCLE CHECKPOINT; MESSENGER-RNA; KAPPA-B; EXPRESSION; BINDING	The promoter regions of both the interferon regulatory factor (IRF1) and p53 antioncogenes contain a previously unidentified sequence denoted IRF1 p53 common sequence (IPCS), which markedly increases the transcriptional activity of a reporter gene placed under the control of an heterologous promoter in transfected U937 cells, In contrast, transfection of U937 cells with reporter vectors containing p55 and IRF1 promoters with mutated IPCS sites resulted in a 4-fold reduction in the constitutive expression of those two genes. The transcriptional activity of IPCS is strictly correlated with the binding of a novel nuclear factor, IPCS-binding factor (IPCS-BF). IPCS-BF, which is composed of a single polypeptide of 26 kDa, is present constitutively in nuclear extracts of both U937 cells and peripheral blood mononuclear cells from healthy donors, The finding that the pattern of binding of IPCS-BF to the IPCS is unlike that of any known transcription factor and that the IPCS sequence does not exhibit any significant homology with any known binding site present in the data base, strongly suggest that IPCS-BF is a novel transcription factor which, by virtue of this ability to regulate the expression of the p53 and IRF1 genes, could play a central role in the control of cell proliferation and/or apoptosis.			Lallemand, C (corresponding author), IFC 1,CNRS,UPR 9045,LAB VIRAL ONCOL,7 RUE GUY MOQUET,F-94801 VILLEJUIF,FRANCE.			lallemand, christophe/0000-0001-5965-2482; Tovey, Michael/0000-0002-3058-0494				AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Beretta L, 1996, ONCOGENE, V12, P1593; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DITMER D, 1993, NAT GENET, V5, P42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUPT Y, 1995, GENE DEV, V9, P170; Hawker KL, 1996, ONCOGENE, V13, P283; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWASAKI T, 1994, CANCER LETT, V82, P113, DOI 10.1016/0304-3835(94)90154-6; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUN XG, 1995, MOL CELL BIOL, V15, P4489; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WU HY, 1994, J BIOL CHEM, V269, P20067; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	40	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29801	29809		10.1074/jbc.272.47.29801	http://dx.doi.org/10.1074/jbc.272.47.29801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368052	hybrid			2022-12-27	WOS:A1997YG64700062
J	Liu, JL; Blakesley, VA; Gutkind, JS; LeRoith, D				Liu, JL; Blakesley, VA; Gutkind, JS; LeRoith, D			The constitutively active mutant G(alpha 13) transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; G-PROTEINS; NEOPLASTIC TRANSFORMATION; KINASE; G-ALPHA(12); PATHWAYS; GENE; ACTIVATION; MUTATION; ANTIGEN	Insulin-like growth factor-I (IGF-I) receptor plays an important role in normal cell cycle progression and tumor growth, and it is thought to be essential for cellular transformation, To test this hypothesis, we stably transfected a GTPase-deficient mutant human G(alpha 13), which is highly oncogenic when overexpressed in vitro, into R-fibroblasts derived from IGF-I receptor-deficient mice, Northern blots of multiple clones revealed the expression of a 1.8-kilobase pair mutant G(alpha 13) transcript in transfected cells, in addition to the 6-kilobase pair endogenous mRNA, The transfection resulted in a doubling of the expression of G(alpha 13) protein in these cells as assessed by Western blot analysis, The transforming ability of the mutant G(alpha 13) was tested using the soft agar assay, Nontransfected R-cells cultured with 10% fetal bovine serum failed to form colonies after 3 weeks, Most of the mutant G(alpha 13)-expressing clones formed significant numbers of colonies (11-50 colonies/1000 cells plated), Overexpression of the IGF-I receptor enabled R-cells to form colonies (27 colonies), and co transfection of the mutant G(alpha 13) caused a further increase in colony formation (117-153 colonies) in three of five clones analyzed, Apparently G(alpha 13) works through pathways other than mitogen-activated protein kinase and c-Jun N-terminal kinase in transforming R-cells, because their activities were not significantly altered by the mutant G(alpha 13) expression, These results demonstrate that G(alpha 13) can induce cellular transformation through pathways apparently independent of the IGF-I receptor and that activation of the IGF-I receptor signaling pathways, although not essential for the transforming phenotype, enhances the effect of other pathways.	NIDDK, SECT CELLULAR & MOL PHYSIOL, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				BASERGA R, 1995, CANCER RES, V55, P249; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KATO H, 1993, J BIOL CHEM, V268, P2655; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LIU JL, 1995, ENDOCRINOLOGY, V136, P2389, DOI 10.1210/en.136.6.2389; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RESNICOFF M, 1994, CANCER RES, V54, P2218; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TORETSKY JA, 1997, IN PRESS J BIOL CHEM, V272; VALENTINIS B, 1994, ONCOGENE, V9, P825; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WARBURTON C, 1995, RECEPTOR, V5, P35; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zhang YH, 1996, ONCOGENE, V12, P2377	37	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29438	29441		10.1074/jbc.272.47.29438	http://dx.doi.org/10.1074/jbc.272.47.29438			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368001	hybrid			2022-12-27	WOS:A1997YG64700011
J	Swain, SD; Helgerson, SL; Davis, AR; Nelson, LK; Quinn, MT				Swain, SD; Helgerson, SL; Davis, AR; Nelson, LK; Quinn, MT			Analysis of activation-induced conformational changes in p47(phox) using tryptophan fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; NEUTROPHIL NADPH OXIDASE; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; ADENINE-DINUCLEOTIDE PHOSPHATE; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; PLASMA-MEMBRANE	Activation of the neutrophil NADPH oxidase requires translocation of cytosolic proteins p47(phox), P67(phox), and Pac to the plasma membrane or phagosomal membrane, where they assemble with membrane-bound flavocytochrome b, During this process, it appears that p47(phox) undergoes conformational changes, resulting in the ex exposure of binding sites involved in assembly and activation of the oxidase, In the present study, we have directly evaluated activation-induced conformational changes in p47(phox) using tryptophan fluorescence and circular dichroism spectroscopy. Treatment of p47(phox) with amphiphilic agents known to activate the NADPH oxidase (SDS and arachidonic acid) caused a dose dependent quenching in the intrinsic tryptophan fluorescence of p47(phox), whereas treatment with a number of other amphiphilic agents that failed to activate the oxidase had no effect on p47(phox) fluorescence. In addition, the concentration range of activating agents required to induce changes in fluorescence correlated with the concentration range of these agents that induced maximal NADPH oxidase activity in a cell-free assay system. We next determined if activation by phosphorylation caused the same type of conformational changes in p47(phox). Protein kinase C phosphorylation of p47(phox) in vitro resulted in comparable quenching of fluorescence, which also correlated directly with NADPH oxidase activity, Finally, the circular dichroism (CD) spectrum of p47(phox) was significantly changed by the addition of SDS, whereas treatment with a non-activating detergent had no effect on the CD spectrum, These results support the conclusion that activation by amphiphilic agents results in changes in the secondary structure of p47(phox). Thus, our studies provide direct evidence linking conformational changes in p47(phox) to the NADPH oxidase activation/assembly process and also further support the hypothesis that amphiphile-mediated activation of the NADPH oxidase induces changes in p47(phox) that are similar to those mediated by phosphorylation in rico.	MONTANA STATE UNIV,DEPT VET MOL BIOL,BOZEMAN,MT 59717; MONTANA STATE UNIV,DEPT MICROBIOL,BOZEMAN,MT 59717; BAXTER HEALTHCARE CORP,DUARTE,CA 91010	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Baxter International Inc				Quinn, Mark/0000-0001-8114-5073	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042426] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR42426] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOXER GJ, 1985, HOSP PRACT, V40, P69; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COHEN MS, 1994, CLIN INFECT DIS, V18, pS170, DOI 10.1093/clinids/18.Supplement_2.S170; COREY SJ, 1991, J LAB CLIN MED, V118, P343; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DELEO FR, 1997, L LEUKOCYTE BIOL, V60, P677; DELEO GM, 1997, FASEB J, V60, P677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GORG A, 1988, ELECTROPHORESIS, V9, P37, DOI 10.1002/elps.1150090108; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KUZNICKI J, 1995, BIOCHEMISTRY-US, V34, P15389, DOI 10.1021/bi00047a001; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUINN MT, 1992, BLOOD, V79, P2438; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; THELEN M, 1990, BLOOD, V75, P2223; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; WALLACE BA, 1984, ANAL BIOCHEM, V142, P317, DOI 10.1016/0003-2697(84)90471-8; YAMAGUCHI M, 1995, BIOCHEM BIOPH RES CO, V216, P203, DOI 10.1006/bbrc.1995.2611	61	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29502	29510		10.1074/jbc.272.47.29502	http://dx.doi.org/10.1074/jbc.272.47.29502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368011	hybrid			2022-12-27	WOS:A1997YG64700021
J	Pombo, CM; Tsujita, T; Kyriakis, JM; Bonventre, JV; Force, T				Pombo, CM; Tsujita, T; Kyriakis, JM; Bonventre, JV; Force, T			Activation of the Ste20-like oxidant stress response kinase-1 during the initial stages of chemical anoxia-induced necrotic cell death - Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; HYDROGEN-PEROXIDE; PROTEIN-KINASE; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; MESANGIAL CELLS; RENAL INJURY; MAP KINASES; BCL-2	Signal transduction mechanisms activated during the early stages of necrotic cell death are poorly characterized, We have recently identified the Sterile 20 (Ste20)-like oxidant stress response kinase-l, SOK-1, which is a member of the Ste20 kinase family, We report that SOK-1 is markedly activated as early as 20 min after chemical anoxia induced by exposure of Madin-Darby canine kidney or LLC-PK1 renal tubular epithelial cells to 2-deoxyglucose (2-DG) and any one of three inhibitors of the electron transport chain, cyanide (CN), rotenone, or antimycin A. Since oxidant stress activates SOK-I, we postulated that reactive oxygen species (ROS), which are produced by the electron transport chain during chemical anoxia, might be responsible for SOR-I activation, The time course of CN/2-DG-induced SOK-1 activation and of production of ROS, measured in cells loaded with dichlorofluorescein, were compatible with a role for ROS in SOH-l activation, Furthermore, preincubation of LLC-PK, cells with three unrelated scavengers of ROS, pyrrolidine dithiocarbamate, pyruvate, or nordihydroguaiaretic acid, reduced both cellular oxidant stress and activation of SOK-1 by CN/2-DG. An increase in cytosolic free [Ca2+] ([Ca2+](i)) was necessary but not sufficient for CN/2-DG-induced activation of SOK-1, Preincubation of cells with BAPTA-AM prevented activation of SOK-1. Incubation of cells with thapsigargin or the calcium ionophore, A23187, had no effect on SOK-1 activity, but preincubation of cells with either of these agents markedly enhanced CN/2-DG-induced activation of SOK-1 (20-fold versus 7-fold). In summary, chemical anoxia activates SOK-1 via an oxidant stress dependent mechanism that is both critically dependent upon and markedly amplified by an increase in [Ca2+](i). This requirement for dual inputs of oxidant stress and an increase in [Ca2+](i) may prevent inappropriate activation of the kinase by milder degrees of oxidant stress, which are insufficient to generate an increase in [Ca2+](i). The activation of SOK-1 may be one of the cell's earliest responses to inducers of necrotic cell death.	MASSACHUSETTS GEN HOSP E, CARDIAC UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP E, RENAL UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP E, DIABET UNIT, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School			Pombo, Celia M/L-4479-2014	Pombo, Celia M/0000-0003-2541-9468; Force, Thomas/0000-0002-0450-8659	NIDDK NIH HHS [DK50282, DK41513] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513, R55DK050282, R29DK050282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARROLL JM, 1992, J NEUROCHEM, V59, P1836, DOI 10.1111/j.1471-4159.1992.tb11017.x; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FORCE T, 1991, J BIOL CHEM, V266, P4295; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HAJJAR RJ, 1991, J BIOL CHEM, V266, P21589; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KVIETYS PR, 1989, AM J PHYSIOL, V257, pH1640, DOI 10.1152/ajpheart.1989.257.5.H1640; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCCOY CE, 1988, J CLIN INVEST, V82, P1326, DOI 10.1172/JCI113734; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MUSCHEL RJ, 1995, CANCER RES, V55, P995; MYERS KM, 1995, J NEUROCHEM, V65, P2432; NATH KA, 1993, AM J PHYSIOL, V264, pF306, DOI 10.1152/ajprenal.1993.264.2.F306; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SALAHUDEEN AK, 1991, J CLIN INVEST, V88, P1886, DOI 10.1172/JCI115511; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; TURRENS JF, 1990, CLIN ISCHEMIC SYNDRO, P203; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZAGER RA, 1992, J CLIN INVEST, V90, P711, DOI 10.1172/JCI115942; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	61	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29372	29379		10.1074/jbc.272.46.29372	http://dx.doi.org/10.1074/jbc.272.46.29372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361019	hybrid			2022-12-27	WOS:A1997YF68400078
J	Czurylo, EA; Kulikova, N; Dabrowska, R				Czurylo, EA; Kulikova, N; Dabrowska, R			Does calponin interact with caldesmon?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; FLUORESCENT-PROBE; HEAVY-MEROMYOSIN; CHICKEN GIZZARD; F-ACTIN; TROPOMYOSIN; BINDING; PURIFICATION; FLUORIMETRY; FRAGMENTS	The roles of calponin and caldesmon and their interaction in regulation of smooth muscle contraction are controversial, Recently, strong binding between these two proteins has been reported (Graceffa, P., Adam, L. P., and Morgan, K. G. (1996) J. Biol. Chem. 271, 30336-30339), Results in this paper fail to confirm their data and are consistent with the concept of independent functions for calponin and caldesmon. To examine the ability of duck gizzard caldesmon to interact with calponin, three caldesmon derivatives, each containing a different sulfhydryl-specific reporter probe (6-acryloyl-2-dimethylaminonaphtalene, N-(1-pyrenyl)iodoacetamide, and N-iodoacetyl-N'-(5-sulfo-1-naphtylo)ethylenediamine) attached to a single cysteine located in the C-terminal domain, were synthesized, Addition of calponin to labeled caldesmon at both low and physiological salt concentrations did not induce any changes in fluorescence intensity or maximum shift, Under the same conditions, calmodulin and tropomyosin (known to bind to the C terminus of caldesmon) produced substantial changes in these spectral parameters, Gel filtration of an equimolar caldesmon-calponin mixture on a fast protein liquid chromatography Superose-12 column revealed two base-line-separated peaks, the first containing only caldesmon and the second only calponin, thus confirming the lack of any interaction between these two proteins, Also, the addition of calponin did not change the fluorescence parameters of labeled caldesmon in complexes with F-actin and F-actin-tropomyosin.	M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Dabrowska, R (corresponding author), M Nencki Inst Expt Biol, Dept Muscle Biochem, 3 Pasteur St, PL-02093 Warsaw, Poland.							ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; COLLINS J H, 1991, Protein Sequences and Data Analysis, V4, P29; CROSBIE RH, 1995, J MUSCLE RES CELL M, V16, P509, DOI 10.1007/BF00126435; CZURYLO EA, 1993, BIOCHEM J, V293, P363, DOI 10.1042/bj2930363; Czurylo EA, 1997, BIOPHYS J, V72, P835, DOI 10.1016/S0006-3495(97)78717-4; CZURYLO EA, 1991, BIOPHYS CHEM, V40, P181, DOI 10.1016/0301-4622(91)87007-R; DABROWSKA A, 1994, AIRWAYS SMOOTH MUSCL, P31; DABROWSKA R, 1980, COMP BIOCHEM PHYS B, V65, P75, DOI 10.1016/0305-0491(80)90114-5; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHRER SS, 1984, BIOCHEMISTRY-US, V23, P1591, DOI 10.1021/bi00303a001; LU FWM, 1995, BIOCHEMISTRY-US, V34, P11864, DOI 10.1021/bi00037a026; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MARSTON SB, 1991, BIOCHEM J, V279, P1; NORTH AJ, 1994, J CELL SCI, V107, P437; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI K, 1986, BIOCH BIOPHYS RES CO; TAWADA K, 1978, EUR J BIOCHEM, V88, P411, DOI 10.1111/j.1432-1033.1978.tb12463.x; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; VOROTNIKOV AV, 1991, BIOCHEM J, V273, P161, DOI 10.1042/bj2730161; Winder SJ, 1996, CURR TOP CELL REGUL, V34, P33, DOI 10.1016/S0070-2137(96)80002-1; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108	33	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32067	32070		10.1074/jbc.272.51.32067	http://dx.doi.org/10.1074/jbc.272.51.32067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405402	hybrid			2022-12-27	WOS:000071108000021
J	Milgrom, YM; Cross, RL				Milgrom, YM; Cross, RL			Nucleotide-depleted beef heart F-1-ATPase exhibits strong positive catalytic cooperativity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ATP HYDROLYSIS; BINDING-SITES; F1-ATPASE; MECHANISM; ROTATION	Catalytic cooperativity is a central feature of the binding change mechanism for F0F1-ATP synthases, However, in a recent publication (Reynafarje, B. D., and Pedersen, P. L. (1996) J. Biol. Chen. 271, 32546-32550), Reynafarje and Pedersen claim that cooperative effects are an artifact caused by endogenous nucleotides and that when such nucleotides are removed, the multiple catalytic sites on MF1 behave independently during ATP hydrolysis, In contrast to this conclusion, we show here that when ATP is loaded at a single catalytic site on nucleotide-depleted MF1, the rate of product release is accelerated by up to 5 x 10(4)-fold by the binding of ATP at adjacent catalytic sites, Hence, nucleotide-depleted MF1 is not an exception but does in fact show strong cooperative interactions, In addition, evidence is presented supporting a random order for product release during ATP hydrolysis.	SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Cross, RL (corresponding author), SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Syracuse, NY 13210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023152, R37GM023152] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Reynafarje BD, 1996, J BIOL CHEM, V271, P32546, DOI 10.1074/jbc.271.51.32546; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YALAMOVA MV, 1982, BIOCHEM INT, V4, P337	25	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32211	32214		10.1074/jbc.272.51.32211	http://dx.doi.org/10.1074/jbc.272.51.32211			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405423	hybrid			2022-12-27	WOS:000071108000042
J	Schreiber, J; Enderich, J; Sock, E; Schmidt, C; Richter-Landsberg, C; Wegner, M				Schreiber, J; Enderich, J; Sock, E; Schmidt, C; Richter-Landsberg, C; Wegner, M			Redundancy of class III POU proteins in the oligodendrocyte lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR SCIP; DOMAIN GENE; JC VIRUS; FACTOR BRN-2; RAT-BRAIN; EXPRESSION; MYELINATION; OCTAMER; OCT-6	Class III POU proteins are prominent regulators of neural development. Tst-1/Oct6/SCIP, for instance, is essential for terminal differentiation of myelinating Schwann cells in the peripheral nervous system. Although Tst-1/Oct6/SCIP is also expressed in the myelin forming oligodendrocytes of the central nervous system, targeted deletion of Tst-1/Oct6/SCIP failed to reveal a gross alteration of myelination in the central nervous system. To better understand this apparent discrepancy, we examined the expression of POU proteins in both cultured primary oligodendrocytes and in the oligodendrocyte-like CG-4 cell line. These cells expressed Tst-1/Oct6/SCIP, Bm-l, and Brn-2 in significant amounts, indicating that Bm-l and Brn-2 might have the capacity to compensate loss of Tst-1/Oct6/SCIP, We show that Tst-1/Oct6/SCIP, Bm-l, and Brn-2 were all down-regulated during the early phases of oligodendrocyte development both on RNA and protein level. All three POU proteins exhibited similar DNA binding characteristics. When promoters consisting of a single POU protein-binding site adjacent to a TATA box were used as reporters in transient transfections, Bm-l proved to be a weaker transcriptional activator than Tst-1/Oct6/SCIP. In agreement with this, we found the transactivation domain of Bm-l, which we mapped between amino acids 119 and 237, significantly weaker than the transactivation domain of Tst-1/Oct6/SCIP. Taken together, our data imply a partial, but not complete redundancy between POU proteins in oligodendrocytes.	Univ Hamburg, Zentrum Mol Biol, D-20246 Hamburg, Germany; Carl von Ossietzky Univ Oldenburg, Dept Biol, D-26111 Oldenburg, Germany	University of Hamburg; Carl von Ossietzky Universitat Oldenburg	Wegner, M (corresponding author), Univ Hamburg, Zentrum Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.	wegner@plexus.uke.uni-hamburg.de	Schreiber, Jacob/GWC-3164-2022	Wegner, Michael/0000-0002-4586-3294; Sock, Elisabeth/0000-0001-9925-3136				ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HART IK, 1992, GLIA, V6, P310, DOI 10.1002/glia.440060409; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; Mirsky R, 1996, CURR OPIN NEUROBIOL, V6, P89, DOI 10.1016/S0959-4388(96)80013-4; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; PORTER S, 1986, J NEUROSCI, V6, P3070; Renner K, 1996, NUCLEIC ACIDS RES, V24, P4552, DOI 10.1093/nar/24.22.4552; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; RichterLandsberg C, 1996, J NEUROSCI RES, V45, P161, DOI 10.1002/(SICI)1097-4547(19960715)45:2<161::AID-JNR8>3.0.CO;2-8; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; Sock E, 1997, J NEUROCHEM, V68, P1911; Sumiyama K, 1996, J MOL EVOL, V43, P170, DOI 10.1007/PL00006075; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	50	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32286	32293		10.1074/jbc.272.51.32286	http://dx.doi.org/10.1074/jbc.272.51.32286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405434	hybrid			2022-12-27	WOS:000071108000053
J	Xu, SC; Cobb, MH				Xu, SC; Cobb, MH			MEKK1 binds directly to the c-Jun N-terminal kinases stress-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PATHWAY; PHOSPHORYLATION; IDENTIFICATION; DOMAIN; ERK	Mitogen-activated protein (MAP) kinases mediate responses to a wide array of cellular stimuli, These cascades consist of a MAP kinase or extracellular signal-regulated kinase (ERK), activated by a MAP/ERK kinase (MEK), in turn activated by a MEK kinase (MEKK). MEKK1 has been shown to be a strong activator of the c-Jun N-terminal kinase/stress-actived protein kinase (JNK/SAPK) pathway. We report here that JNK/SAPK binds directly to the N-terminal, noncatalytic domain of MEKK1 in vitro and in transfected cells. Immobilized MEKK1-derived peptides extract JNK/SAPK selectively from cell lysates. MEKK1 coimmunoprecipitates with multiple JNK/SAPK isoforms in transfected cells. Expression of the N terminus of MEKK1 lacking the kinase domain increases activation of endogenous JNK/SAPK by MEKK1. The data are consistent with a model in which MEKK1-JNK/SAPK binding facilitates the receipt of signals from upstream inputs and localizes JNK/SAPK to intracellular targets of the pathway.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM56498] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CHOI KY, 1994, CELL, V78, P499; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1996, ONCOGENE, V12, P641; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN A, 1995, SCIENCE, V268, P8286; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	31	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32056	32060		10.1074/jbc.272.51.32056	http://dx.doi.org/10.1074/jbc.272.51.32056			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405400	hybrid			2022-12-27	WOS:000071108000019
J	Sun, WM; Zhang, JZ; Hankinson, O				Sun, WM; Zhang, JZ; Hankinson, O			A mutation in the aryl hydrocarbon receptor (AHR) in a cultured mammalian cell line identifies a novel region of AHR that affects DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; MOUSE HEPATOMA LINE; HELIX-LOOP-HELIX; DIOXIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; GENE; HYDROXYLASE; EXPRESSION	Introduction of a retroviral expression vector far the aryl hydrocarbon receptor (AHR) restores CYPIA1 inducibility to a mutant derivative of the Hepa-1 cell line that is defective in induction of CYP1A1 by ligands for the receptor. An AHR protein with normal ligand binding activity is expressed in the mutant but ligand treatment of mutant cell extract fails to induce binding of the AHR.ARNT (aryl hydrocarbon receptor nuclear translocator) dimer to the xenobiotic responsive element (XRE). ABR cDNAs derived from the mutant encode a protein that is unimpaired in ligand-dependent dimerization with ARNT, but the AHR.ARNT dimer so formed is severely impaired in XRE binding activity. The mutant cDNAs contain a C to G mutation at base 648, causing a cysteine to tryptophan alteration at amino acid 216, located between the PER-ARNT-SIM homology region (PAS) A and PAS B repeats, Introduction of the same mutation in the wild-type AHR sequence by site-directed mutagenesis similarity impaired XRE binding activity. Substitution with the conservative amino acid, serine, had no effect on XRE binding, The tryptophan mutation, but not the wild-type allele, was detectable in genomic DNA of the mutant, The implication that an amino acid within the PAS region may be involved in DNA binding indicates that the DNA binding behavior of AHR may be more anomalous than previously suspected.	UNIV CALIF LOS ANGELES, SCH MED,CTR HLTH SCI,DEPT PATHOL & LAB MED, JONSSON COMPREHEN CANC CTR, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NCI NIH HHS [CA 28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; GUDAS JM, 1987, SOMAT CELL MOLEC GEN, V13, P513, DOI 10.1007/BF01534493; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1994, ADV ENZYME REGUL, V34, P159, DOI 10.1016/0065-2571(94)90015-9; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HANKINSON O, 1981, SOMAT CELL GENET, V7, P373, DOI 10.1007/BF01542983; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOEBEE B, 1988, NUCLEIC ACIDS RES, V16, P8147, DOI 10.1093/nar/16.16.8147; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IRELAND RC, 1995, ARCH BIOCHEM BIOPHYS, V319, P470, DOI 10.1006/abbi.1995.1319; JAIN S, 1994, J BIOL CHEM, V269, P31518; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; KIMURA S, 1987, EMBO J, V6, P1929, DOI 10.1002/j.1460-2075.1987.tb02453.x; LEBEAU MM, 1994, CYTOGENET CELL GENET, V66, P172, DOI 10.1159/000133694; LI H, 1994, J BIOL CHEM, V269, P28098; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MILES C, 1989, MUTAT RES, V227, P97, DOI 10.1016/0165-7992(89)90004-3; MIMURA J, 1994, PHARMACOGENETICS, V4, P349, DOI 10.1097/00008571-199412000-00008; MONTISANO DF, 1985, MOL CELL BIOL, V5, P698, DOI 10.1128/MCB.5.4.698; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; POLAND A, 1994, MOL PHARMACOL, V46, P915; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SOGAWA K, 1995, J CANCER RES CLIN, V121, P612, DOI 10.1007/BF01197779; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; TRASK BJ, 1991, METHOD CELL BIOL, V35, P3; Vasiliou V, 1996, DNA CELL BIOL, V15, P235, DOI 10.1089/dna.1996.15.235; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Zhang JZ, 1996, MOL PHARMACOL, V50, P1454	54	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31845	31854		10.1074/jbc.272.50.31845	http://dx.doi.org/10.1074/jbc.272.50.31845			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395531	hybrid			2022-12-27	WOS:A1997YL41900090
J	WechslerReya, R; Sakamuro, D; Zhang, J; Duhadaway, J; Prendergast, GC				WechslerReya, R; Sakamuro, D; Zhang, J; Duhadaway, J; Prendergast, GC			Structural analysis of the human BIN1 gene - Evidence for tissue-specific transcriptional regulation and alternate RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; HUMAN AMPHIPHYSIN; TUMOR-SUPPRESSOR; PROTEIN; HYBRIDIZATION; CANCER; REGION	BIN1 is a putative tumor suppressor that was identified through its interaction with the MYC oncoprotein. To begin to identify elements of BIN1 whose alteration may contribute to malignancy, we cloned and characterized the human BIN1 gene and promoter, Nineteen exons were identified in a region of >54 kilobases, six of which were alternately spliced in a cell type-specific manner. One alternately spliced exon encodes part of the MYC-binding domain, suggesting that splicing controls the MYC-binding capacity of BIN1 polypeptides. Four other alternately spliced exons encode amphiphysin-related sequences that were included in brain-specific BIN1 species, also termed amphiphysin isoforms or amphiphysin II. The 5'-flanking region of BIN1 is GC-rich and lacks a TATA box but directs transcriptional initiation from a single site, A similar to 0.9-kilobase fragment from this region was sufficient for basal transcription and transactivation by MyoD, which may account for the high levels of BIN1. observed in skeletal muscle. This study lays the foundation for genetic and epigenetic investigations into the role of BIN1 in normal and neoplastic cell regulation.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute								BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; WechslerReya R, 1997, CANCER RES, V57, P3258; WECHSLERREYA R, 1998, IN PRESS MOL CELL BI; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265	18	111	119	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31453	31458		10.1074/jbc.272.50.31453	http://dx.doi.org/10.1074/jbc.272.50.31453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395479	hybrid			2022-12-27	WOS:A1997YL41900038
J	Nieto, C; Espinosa, M; Puyet, A				Nieto, C; Espinosa, M; Puyet, A			The maltose/maltodextrin regulon of Streptococcus pneumoniae - Differential promoter regulation by the transcriptional repressor MalR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; MALTOSE REGULON; GENES; EXPRESSION; OPERON; PURR; OPERATOR	The Streptococcus pneumoniae MalR protein regulates the transcription of two divergent operons, malXCD and malMP, involved in maltosaccharide uptake and utilization, respectively. MalR belongs to the LacI-GalR family of transcription repressors. The protein binds specifically to two operator sequences in the intergenic region between these operons. The affinity of MalR for the malMP binding sequence is higher than for the malXCD site. Results obtained in vivo using transcriptional fusions with reporter genes indicate low repression level of malXCD by MalR when compared with malMP. This behavior may be correlated with the existence of separate induction pathways for maltose, maltotriose, and maltotetraose. The similarities found at the operator sequences and binding domains for MalR and enterococcal repressor proteins suggest that the pneumococcal maltosaccharide regulation system is closely related to several Gram-negative metabolic pathways, but not to the structurally similar Escherichia coli maltose regulon.	Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, E-28040 Madrid, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Puyet, A (corresponding author), Univ Complutense Madrid, Fac Vet, Dept Bioquim & Biol Mol 4, E-28040 Madrid, Spain.		Espinosa, Manuel/M-5282-2019; Nieto, Concha/ABG-2127-2020; Puyet, Antonio/I-4720-2014	Nieto, Concha/0000-0003-0790-3440; Puyet, Antonio/0000-0002-2026-7955				ALBERTI S, 1991, NEW BIOL, V3, P57; ASLANIDIS C, 1990, J BACTERIOL, V172, P2178, DOI 10.1128/jb.172.4.2178-2180.1990; CHAPON C, 1982, J BACTERIOL, V150, P722, DOI 10.1128/JB.150.2.722-729.1982; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; EGAN SM, 1994, J MOL BIOL, V243, P821, DOI 10.1006/jmbi.1994.1684; GEANACOPOULOS M, 1997, J BACTERIOL, V179, P28; GILSON E, 1991, NUCLEIC ACIDS RES, V19, P1375, DOI 10.1093/nar/19.7.1375; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; JAENICKE R, 1990, FEBS LETT, V260, P233, DOI 10.1016/0014-5793(90)80111-U; KIM JH, 1995, J BACTERIOL, V177, P5129, DOI 10.1128/jb.177.17.5129-5134.1995; LACKS S, 1968, GENETICS, V60, P685; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T., 1989, MOL CLONING LAB MANU; Maxam A M, 1980, Methods Enzymol, V65, P499; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; Miller J.H., 1972, EXPT MOL GENETICS; MUIZNIEKS I, 1994, MOL GEN GENET, V242, P90, DOI 10.1007/BF00277352; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PUYET A, 1993, J BIOL CHEM, V268, P25402; PUYET A, 1993, J MOL BIOL, V230, P800, DOI 10.1006/jmbi.1993.1202; PUYET A, 1993, WORLD J MICROB BIOT, V9, P455, DOI 10.1007/BF00328033; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; ROJO F, 1995, METHODS MOL GENET, V6; ROLFES RJ, 1988, J BIOL CHEM, V263, P19653; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; RONALD SL, 1990, GENE, V90, P145, DOI 10.1016/0378-1119(90)90451-V; SCARABEL M, 1995, GENE, V153, P9, DOI 10.1016/0378-1119(94)00660-K; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Schwartz M, 1987, MALTOSE REGULON ESCH; STASSI DL, 1981, P NATL ACAD SCI-BIOL, V78, P7028, DOI 10.1073/pnas.78.11.7028; STASSI DL, 1982, GENE, V20, P359, DOI 10.1016/0378-1119(82)90204-9; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; vanWezel GP, 1997, MOL MICROBIOL, V23, P537, DOI 10.1046/j.1365-2958.1997.d01-1878.x; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WEINRAUCH Y, 1981, MOL GEN GENET, V183, P7, DOI 10.1007/BF00270130	40	45	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30860	30865		10.1074/jbc.272.49.30860	http://dx.doi.org/10.1074/jbc.272.49.30860			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388231	hybrid, Green Published			2022-12-27	WOS:000071640800044
J	Ueda, A; Ishigatsubo, Y; Okubo, T; Yoshimura, T				Ueda, A; Ishigatsubo, Y; Okubo, T; Yoshimura, T			Transcriptional regulation of the human monocyte chemoattractant protein-1 gene - Cooperation of two NF-kappa B sites and NF-kappa B/Rel subunit specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDIOPATHIC PULMONARY FIBROSIS; GROWTH-FACTOR INDUCTION; TUMOR-NECROSIS-FACTOR; IFN-BETA GENE; MESSENGER-RNA; P65 SUBUNIT; ATHEROSCLEROTIC LESIONS; VIRUS INDUCTION; E-SELECTIN; CELL-LINE	Human monocyte chemoattractant protein-1 (human MCP-1) mRNA accumulated in THP-1 cells 2 h after lipopolysaccharide (LPS) stimulation, DNase I footprinting revealed that LPS stimulation induced protein binding to the two closely located NF-kappa B sites, A1 and A2, By electrophoretic gel mobility shift assay and supershift assay, the binding of (p65)(2), c-Rel/p65, p50/p65, and p50/c-Rel to the A2 oligonucleotide probe was detected after LPS stimulation, In contrast, 12-o-tetradecanoylphorbol 13-acetate did not induce a significant amount of MCP-1 mRNA in THP-1 cells 2 h after stimulation, and only p50/p65 bound to the A2 probe, trans Activity of each NF-kappa B/Rel dimer was investigated by transfecting P19 cells with p65, p50, and/or c-Rel expression vectors, and a luciferase construct containing the enhancer region of the human MCP-1 gene, Expression of recombinant p65 or p65 and c-Rel resulted in elevated luciferase activities, indicating that (p65)(2) and c-Rel/p65 had trans-activity, The binding of (p65)(2) and/or c-Rel/p65 to the A2 probe was also detected from 12-o-tetradecanoylphorbol 13-acetate-stimulated HeLa, HOS, and A172 cells in which expression of MCP-1 mRNA was elevated. Finally, the role of the Al site was investigated, Both (p65)(2) and c-Rel/p65 bound to the Al probe by electrophoretic mobility shift assay and a mutation in the A1 or A2 site resulted in a loss of the enhancer activity, These results suggest that the binding of (p65)(2) and c-Rel/p65 to the A1 and A2 sites of this gene is important for the tissue-and stimulus-specific transcription of the human MCP-1 gene.	NCI, Frederick Canc Res & Dev Ctr, Immunopathol Sect, Immunobiol Lab, Frederick, MD 21702 USA; Yokohama City Univ, Sch Med, Dept Internal Med 1, Yokohama, Kanagawa 236, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Yokohama City University	Yoshimura, T (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunopathol Sect, Immunobiol Lab, Bldg 560,Rm 12-71, Frederick, MD 21702 USA.	yoshimur@ncifcrf.gov						AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Kuratsu J, 1996, BRAIN TUMOR, P305; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LI YC, 1994, J BIOL CHEM, V269, P30616; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STAUSS F, 1984, CELL, V37, P889; TAKESHIMA H, 1994, J NEUROSURG, V80, P1056, DOI 10.3171/jns.1994.80.6.1056; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1996, J BIOL CHEM, V271, P20265, DOI 10.1074/jbc.271.34.20265; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1993, J IMMUNOL, V151, P6225; Yoshimura T, 1996, HUMAN CYTOKINES HDB, VII, P198	53	278	280	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31092	31099		10.1074/jbc.272.49.31092	http://dx.doi.org/10.1074/jbc.272.49.31092			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388261	hybrid			2022-12-27	WOS:000071640800074
J	Jiang, Y; Gram, H; Zhao, M; New, LG; Gu, J; Feng, LL; DiPadova, F; Ulevitch, RJ; Han, JH				Jiang, Y; Gram, H; Zhao, M; New, LG; Gu, J; Feng, LL; DiPadova, F; Ulevitch, RJ; Han, JH			Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; MAJOR ACTIVATOR; FISSION YEAST; STRESS; CELLS; PHOSPHORYLATION; IDENTIFICATION; CASCADE; GLOMERULONEPHRITIS	We have cloned and characterized a new member of the p38 group of mitogen-activated protein kinases here termed p38 delta. Sequence comparisons revealed that p38 delta is approximately 60% identical to the other three p38 isoforms but only 40-45% to the other mitogen-activated protein kinase family members. It contains the TGY dual phosphorylation site present in all p38 group members and is activated by a group of extracellular stimuli including cytokines and environmental stresses that also activate the other three known p38 isoforms. However, unlike the other p38 isoforms, the kinase activity of p38 delta is not blocked by the pyridinyl imidazole, 4-(4-fluorophenyl)-2- 2(4-hydroxyphenyl)-5-(4-pyridyl)-imidazole (identicalto SB202190). p38 delta can be activated by MKK3 and MKK6, known activators of the other isoforms. Nonetheless, in-gel kinase assays provide evidence for additional activators. The data presented herein show that p38 delta has many properties that are similar to those of other p38 group members. Nonetheless important differences exist among the four members of the p38 group of enzymes, and thus each may have highly specific, individual contributions to biologic events involving activation of the p38 pathways.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; NOVARTIS PHARMA AG, CH-4002 BASEL, SWITZERLAND	Scripps Research Institute; Novartis			Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM51417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Cano E, 1996, ONCOGENE, V12, P805; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FENG LL, 1993, J AM SOC NEPHROL, V3, P1753; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fujinaka H, 1997, J IMMUNOL, V158, P4978; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MARAIS R, 1993, CELL, V73, P361; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shimizu A, 1996, LAB INVEST, V74, P941; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	46	409	448	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30122	30128		10.1074/jbc.272.48.30122	http://dx.doi.org/10.1074/jbc.272.48.30122			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374491	hybrid			2022-12-27	WOS:A1997YH61300023
J	Thissen, JA; Gross, JM; Subramanian, K; Meyer, T; Casey, PJ				Thissen, JA; Gross, JM; Subramanian, K; Meyer, T; Casey, PJ			Prenylation-dependent association of Ki-Ras with microtubules - Evidence for a role in subcellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; EPITHELIAL-CELLS; BOVINE BRAIN; CYTOSKELETON; MEMBRANE; TUBULIN; IDENTIFICATION; FARNESYL; INVITRO; P21RAS	We recently identified a prenyl peptide-binding protein in microsomal membranes from bovine brain (Thissen, J. A., and Casey, P. J. (1993) J. Biol Chem. 268, 13780-13783), Through a variety of approaches, this binding protein has been identified as the cytoskeletal protein tubulin, Prenyl peptides bind to purified tubulin with a K-d of 40 nM and also bind to tubulin polymerized into microtubules, Microtubule affinity chromatography of extracts from cells in which the prenyl protein pool was metabolically labeled revealed that prenyl proteins bound to the immobilized microtubules; one, a 24-kDa protein, was tentatively identified as a GTP-binding protein. Of several prenylated GTP-binding proteins tested, including Ki-Ras4B, Ha-Ras, RhoB, RhoA, and Rap1B, only Ki-Ras was found to bind significantly to microtubules, and this was in a prenylation-dependent fashion. A potential significance of the interaction of Ki-Ras4B with microtubules was indicated from analysis of the localization of newly synthesized Ki-Ras4B and Ha-Ras, each tagged with green fluorescence protein (GFP). Treatment of NIH-3T3 cells expressing GFP-Ki-Ras with Taxol (paclitaxel) resulted in accumulation of the expressed protein in intracellular locations, whereas in control cells the protein was correctly targeted to the plasma membrane, importantly, such treatment with paclitaxel did not affect the cellular localization of expressed GFP-Ha-Ras. These results indicate that an intact microtubule network may be directly involved in Ki-Ras processing and/or targeting and provide direct evidence for a physiological distinction between Ki-Ras and Ha-Ras in cells. Additionally, the finding that paclitaxel treatment of cells disrupts Ki-Ras trafficking suggests an additional mechanism for the anti-proliferative effects of this drug.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Duke University	Thissen, JA (corresponding author), DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA.			Gross, Jeffrey/0000-0002-9422-6312; Meyer, Tobias/0000-0003-4339-3804; Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM 51457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BARNES G, 1992, MOL BIOL CELL, V3, P29, DOI 10.1091/mbc.3.1.29; Best A, 1996, J BIOL CHEM, V271, P3756; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; EIPPER BA, 1972, P NATL ACAD SCI USA, V69, P2283, DOI 10.1073/pnas.69.8.2283; ENDO A, 1992, J LIPID RES, V33, P1569; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; FAUST J, 1987, J BIOL CHEM, V262, P1996; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; NISHIO K, 1995, INT J CANCER, V63, P688, DOI 10.1002/ijc.2910630514; Olah E, 1996, ANTICANCER RES, V16, P2469; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; RAMASCHI G, 1994, BBA-GEN SUBJECTS, V1199, P20, DOI 10.1016/0304-4165(94)90091-4; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHMIDT RA, 1982, J CELL BIOL, V95, P144, DOI 10.1083/jcb.95.1.144; SIMON JR, 1991, MICRON MICROSC ACTA, V22, P405, DOI 10.1016/0739-6260(91)90058-8; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; THISSEN JA, 1995, METHOD ENZYMOL, V250, P158; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; VOTER WA, 1984, J BIOL CHEM, V259, P430; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	102	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30362	30370		10.1074/jbc.272.48.30362	http://dx.doi.org/10.1074/jbc.272.48.30362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374526	hybrid			2022-12-27	WOS:A1997YH61300058
J	Tommasi, S; Pfeifer, GP				Tommasi, S; Pfeifer, GP			Constitutive protection of E2F recognition sequences in the human thymidine kinase promoter during cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MYB TRANSCRIPTION; IMR-90 DIPLOID FIBROBLASTS; PROTEIN-DNA INTERACTIONS; LIGATION MEDIATED PCR; CCAAT-BINDING PROTEIN; GENE PROMOTER; IN-VIVO; METHYLATION ANALYSIS; GROWTH-REGULATION; TRANS-ACTIVATION	The sequences responsible for S phase-specific induction of the human thymidine kinase (TK) gene have been mapped to a small region that contains putative E2F binding sites, We have analyzed protein-DNA interactions at the TK promoter during cell cycle progression in human fibroblasts using an in vivo footprinting approach, We found 14 protein binding sites that were occupied in vivo, All of the sites (among them two inverted CCAAT boxes and several Spl sites) bound transcription factors constitutively throughout the cell cycle, i.e. none of the factor binding was cell cycle-dependent, An E2F-like site located between nucleotides -97 and -89 relative to the major transcription start site was protected in G(0), G(1), S, and G(2) phases, This cell cycle-independent protection of E2F sequences in the TK promoter differs from the G(0)/G(1)-restricted binding of E2F complexes observed for genes in which the E2F sites function as repressor elements (Tommasi, S., and Pfeifer, G. P. (1995) Mol. Cell. Biol. 15, 6901-6913; Zwicker, J., Liu, N., Engeland, K., Lucibello, F. C., and Muller, R. (1996) Science 271, 1595-1597). A comparison of several genes containing E2F motifs indicates that E2F sites located in proximity to the transcription initiation site (-50 to +20) in TATA-less promoters predominantly function as repressor elements, while in other genes constitutively bound E2F complexes located further upstream mediate activation presumably in conjunction with a functional TATA box.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope				Tommasi, Stella/0000-0001-6897-4985	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Bennett JD, 1996, ONCOGENE, V13, P1073; CHANG ZF, 1995, J BIOL CHEM, V270, P27374, DOI 10.1074/jbc.270.45.27374; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHEN ZF, 1993, CANCER RES, V53, P3253; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim EC, 1996, CELL GROWTH DIFFER, V7, P1741; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIM YK, 1992, J BIOL CHEM, V267, P2723; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIPSON KE, 1995, J CELL BIOCHEM, V57, P711, DOI 10.1002/jcb.240570416; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; MAO XZ, 1995, J CELL BIOCHEM, V57, P701, DOI 10.1002/jcb.240570415; Maxam A M, 1980, Methods Enzymol, V65, P499; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OSWALD F, 1994, ONCOGENE, V9, P2029; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PANG JH, 1993, J BIOL CHEM, V268, P2909; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PLET A, 1992, ONCOGENE, V7, P1847; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wells J, 1996, MOL CELL BIOL, V16, P634; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30483	30490		10.1074/jbc.272.48.30483	http://dx.doi.org/10.1074/jbc.272.48.30483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374541	hybrid			2022-12-27	WOS:A1997YH61300073
J	Wysocki, R; Bobrowicz, P; Ulaszewski, S				Wysocki, R; Bobrowicz, P; Ulaszewski, S			The Saccharomyces cerevisiae ACR3 gene encodes a putative membrane protein involved in arsenite transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE OPERON; ESCHERICHIA-COLI; ARSB PROTEIN; ANION PUMP; MOLECULAR CHARACTERIZATION; LEISHMANIA-TARENTOLAE; NUCLEOTIDE-SEQUENCE; DRUG-RESISTANCE; YEAST; CELLS	The cluster of three genes, ACR1, ACR2, and ACR3, previously was shown to confer arsenical resistance in Saccharomyces cerevisiae, The overexpression of ACR3 induced high level arsenite resistance, The presence of ACR3 together with ACR2 on a multicopy plasmid was conducive to increased arsenate resistance, The function of ACR3 gene has now been investigated. Amino acid sequence analysis of Acr3p showed that this hypothetical protein has hydrophobic character with 10 putative transmembrane spans and is probably located in yeast plasma membrane, We constructed the acr3 null mutation. The resulting disruptants were 5-fold more sensitive to arsenate and arsenite than wild-type cells, The acr3 disruptants showed wild-type sensitivity to antimony, tellurite, cadmium, and phenylarsine oxide, The mechanism of arsenical resistance was assayed by transport experiments using radioactive arsenite, We did not observe any significant differences in the accumulation of (AsO33-)-As-76 wild-type cells, acr1 and acr3 disruptants, However, the high dosage of ACR3 gene resulted in loss of arsenite uptake, These results suggest that arsenite resistance in yeast is mediated by an arsenite transporter (Acr3p).	UNIV WROCLAW, INST MICROBIOL, PL-51148 WROCLAW, POLAND	University of Wroclaw				Wysocki, Robert/0000-0002-3274-2629				Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BROER S, 1993, J BACTERIOL, V175, P3480, DOI 10.1128/jb.175.11.3480-3485.1993; BunYa M, 1996, CURR GENET, V29, P344, DOI 10.1007/s002940050055; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHANG EC, 1989, J BACTERIOL, V171, P6349, DOI 10.1128/jb.171.11.6349-6352.1989; CHEN CM, 1986, J BIOL CHEM, V261, P5030; COLE SPC, 1994, CANCER RES, V54, P5902; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; EHRENHOFERMURRAY AE, 1994, MOL GEN GENET, V244, P287, DOI 10.1007/BF00285456; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HUANG RN, 1995, ENVIRON MOL MUTAGEN, V25, P188, DOI 10.1002/em.2850250304; Huang RN, 1996, TOXICOL APPL PHARM, V136, P243, DOI 10.1006/taap.1996.0031; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; Kaiser C., 1994, METHODS YEAST GENETI; Kochhar TS, 1996, TOXICOL LETT, V84, P37, DOI 10.1016/0378-4274(95)03536-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE TC, 1985, CARCINOGENESIS, V6, P1421, DOI 10.1093/carcin/6.10.1421; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; NOVICK RP, 1968, J BACTERIOL, V95, P1335, DOI 10.1128/JB.95.4.1335-1342.1968; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; Pierce J. S., 1970, Journal of the Institute of Brewing, V76, P442; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SZINICZ L, 1988, ARCH TOXICOL, V61, P444, DOI 10.1007/BF00293690; TAKEMARU K, 1995, MICROBIOL-UK, V141, P323, DOI 10.1099/13500872-141-2-323; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TISA LS, 1990, J BIOL CHEM, V265, P190; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; WU JH, 1992, J BIOL CHEM, V267, P12570	51	176	186	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30061	30066		10.1074/jbc.272.48.30061	http://dx.doi.org/10.1074/jbc.272.48.30061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374482	hybrid			2022-12-27	WOS:A1997YH61300014
J	Hackam, DJ; Rotstein, OD; Zhang, WJ; Demaurex, N; Woodside, M; Tsai, O; Grinstein, S				Hackam, DJ; Rotstein, OD; Zhang, WJ; Demaurex, N; Woodside, M; Tsai, O; Grinstein, S			Regulation of phagosomal acidification - Differential targeting of Na+/H+ exchangers, Na+/K+-ATPases, and vacuolar-type H+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; MYCOBACTERIUM-BOVIS BCG; PROTEIN-KINASE-C; LYSOSOME FUSION; MURINE MACROPHAGES; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; MOUSE STRAINS; AMILORIDE; AVIUM	Vacuolar type (V) ATPases are thought to be the main determinant of phagosomal acidification, In phagosomes containing mycobacteria, which ostensibly impair the delivery of V-ATPases to the phagosomal membrane, the pH would be expected to be near neutral, This prediction was tested by microfluorescence ratio imaging using macrophages from mice susceptible to mycobacterial infection, Although less acidic than their counterparts containing dead bacteria, phagosomes containing live Mycobacteria bovis were nearly 1 pH unit more acidic than the cytosol, suggesting the existence of alternate H+ transport mechanisms, We there fore investigated whether Na+/H+ exchange (NHE) contributes to phagosomal acidification, Immunoblotting, reverse transcriptase-polymerase chain reaction, and pharmacological studies indicated that NHE1 is the predominant isoform of the exchanger in macrophages. Fractionation revealed that NHE1 is incorporated into the phagosomal membrane, and measurements of pH indicated that it is functional in this location, Nevertheless, acidification of the lumen of phagosomes containing either latex beads or live M. bovis was insensitive to (3-methylsulfonyl-4-piperidinobenzoyl)-guanidine methanesulfonate, a potent inhibitor of NHE1, This may have been due to the absence of an appropriate lumen to cytosol Na+ gradient, because the phagosomal membrane was found to be devoid of Na+/K+ pumps, Unexpectedly, the acidification of M. bovis phagosomes was fully reversed by specific inhibitors of the vacuolar H+-ATPase, suggesting that ATPases are present only transiently or in reduced quantities in the phagosomal membrane, Alternatively, acid equivalents accumulated in endosomes by V-ATPases may be delivered to the mycobacterial phagosome by carrier vesicles devoid of ATPases.	UNIV TORONTO, DIV CELL BIOL, HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO HOSP, DEPT SURG, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto				Hackam, David/0000-0001-5195-8807; Demaurex, Nicolas/0000-0002-9933-6772				ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BOUVIER G, 1994, J LEUKOCYTE BIOL, V55, P729, DOI 10.1002/jlb.55.6.729; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; FORGET A, 1981, INFECT IMMUN, V32, P42, DOI 10.1128/IAI.32.1.42-47.1981; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GRINSTEIN S, 1986, AM J PHYSIOL, V250, pC283, DOI 10.1152/ajpcell.1986.250.2.C283; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; Hackam DJ, 1996, ARCH SURG-CHICAGO, V131, P1296; Hackam DJ, 1996, SHOCK, V5, P17, DOI 10.1097/00024382-199601000-00005; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hackam DJ, 1996, J IMMUNOL, V156, P4377; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNE AA, 1991, FEBS LETT, V284, P219, DOI 10.1016/0014-5793(91)80689-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; NANDA A, 1992, J BIOL CHEM, V267, P22740; Oh YK, 1996, INFECT IMMUN, V64, P319, DOI 10.1128/IAI.64.1.319-325.1996; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Russell DG, 1996, J IMMUNOL, V156, P4764; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SIPE DM, 1991, J BIOL CHEM, V266, P3469; STEINBERG TH, 1994, METHOD ENZYMOL, V236, P147; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TEIXEIRA HC, 1995, IMMUNOL LETT, V46, P15, DOI 10.1016/0165-2478(95)00009-T; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; XU SM, 1994, J IMMUNOL, V153, P2568; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	57	122	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29810	29820		10.1074/jbc.272.47.29810	http://dx.doi.org/10.1074/jbc.272.47.29810			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368053	hybrid			2022-12-27	WOS:A1997YG64700063
J	Ahnert, P; Patel, SS				Ahnert, P; Patel, SS			Asymmetric interactions of hexameric bacteriophage T7 DNA helicase with the 5 '- and 3 '-tails of the forked DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZO<A>PYRENE-DNA ADDUCTS INHIBIT; GENE-4 PROTEIN; DEOXYRIBONUCLEIC-ACID; OLIGOMERIC STRUCTURE; STRANDED-DNA; REPLICATION; BINDING; ASSAY	Bacteriophage T7 DNA helicase requires two noncomplementary single-stranded DNA (ssDNA) tails next to a double-stranded DNA (dsDNA) region to initiate DNA unwinding. The interactions of the helicase with the DNA were investigated using a series of forked DNAs. Our results show that the helicase interacts asymmetrically with the two tails of the forked DNA. When the helicase was preassembled on the forked DNA before the start of unwinding, a DNA with 15-nucleotide (nt) 3'-tail and 35-nt 5'-tail was unwound with optimal rates close to 60 base pairs/s at 18 degrees C. When the helicase was not preassembled on the DNA, a >65-nt long 5'-tail was required for maximal unwinding rates of 12 base pairs/s. We show that the helicase interacts specifically with the ssDNA region and maintains contact with both ssDNA strands during DNA unwinding, since conversion of the two ssDNA tails to dsDNA structures greatly inhibited unwinding, and the helicase was unable to unwind past a nick in the dsDNA region. These studies have provided new insights into the mechanism of DNA unwinding. We propose an exclusion model of DNA unwinding in which T7 helicase hexamer interacts mainly with the ssDNA strands during DNA unwinding, encircling the 5'-strand and excluding the 3'-strand from the hole.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Patel, SS (corresponding author), Ohio State Univ, Dept Biochem, 484 W 12Th Ave, Columbus, OH 43210 USA.		Ahnert, Peter/I-8150-2015	Ahnert, Peter/0000-0002-1771-0856	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; HOUSTON P, 1994, P NATL ACAD SCI USA, V91, P5471, DOI 10.1073/pnas.91.12.5471; KORNBERG A, 1992, DNA REPLICATION, P355; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 2002, MOL CLONING LAB MANU; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZHUANG W, 1992, THESIS PURDUE U ANN	39	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32267	32273		10.1074/jbc.272.51.32267	http://dx.doi.org/10.1074/jbc.272.51.32267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405431	hybrid			2022-12-27	WOS:000071108000050
J	Badou, A; Savignac, M; Moreau, M; Leclercq, C; Pasquier, R; Druet, P; Pelletier, L				Badou, A; Savignac, M; Moreau, M; Leclercq, C; Pasquier, R; Druet, P; Pelletier, L			HgCl2-induced interleukin-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CYTOKINE PRODUCTION; MERCURIC-CHLORIDE; IL-4 PRODUCTION; IN-VIVO; NF-AT; ACTIVATION; AUTOIMMUNITY; LYMPHOCYTES; TRANSCRIPTION	Mercuric chloride (HgCl2) induces T helper 2 (Th2) autoreactive anti-class II T cells in Brown Norway rats. These cells produce interleukin (IL)-4 and induce a B cell polyclonal activation that is responsible for autoimmune disease. In Brown Norway rats, HgCl2 triggers early IL-4 mRNA expression both in vivo and in vitro by T cells, which may explain why autoreactive anti-class II T cells acquire a Th2 phenotype. The aim of this study was to explore the transduction pathways by which this chemical operates, By using two murine T cell hybridomas that express IL-4 mRNA upon stimulation with HgCl2, we demonstrate that: 1) HgCl2 acts at the transcriptional level without requiring de novo protein synthesis; 2) HgCl2 induces a protein kinase C-dependent Ca2+ influx through L-type calcium channels; 3) calcium/calcineurin-dependent pathway and protein kinase C activation are both implicated in HgCl2-induced IL-4 gene expression; and 4) HgCl2 can activate directly protein kinase C, which might be one of the main intracellular target for HgCl2. These data are in agreement with an effect of HgCl2 which is independent of antigen-specific recognition. It may explain the T cell polyclonaI activation in the mercury model and the expansion of pathogenic autoreactive anti-class II Th2 cells in this context.	Hop Purpan, Inst Federat Rech 30, INSERM, Unite 28, F-31059 Toulouse, France; Univ Toulouse 3, UMR 5547, CNRS, F-31062 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Badou, A (corresponding author), INSERM, U28, Pavillon Lefebvre,Pl Dr Baylac, F-31059 Toulouse, France.	Abdellah.Badou@purpan.inserm.fr	Leclerc, Catherine/O-6514-2015; Savignac, Magali/K-1757-2014; Pelletier, Lucette/L-2956-2014	Badou, Abdallah/0000-0003-4849-9085				ADORINI L, 1991, J EXP MED, V174, P945, DOI 10.1084/jem.174.4.945; ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; ADORINI L, 1993, J IMMUNOL, V151, P3576; Biancone L, 1996, J EXP MED, V183, P1473, DOI 10.1084/jem.183.4.1473; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; Fillion J, 1997, INT IMMUNOL, V9, P263, DOI 10.1093/intimm/9.2.263; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GAJEWSKI TF, 1989, IMMUNOL REV, V111, P79, DOI 10.1111/j.1600-065X.1989.tb00543.x; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Heo Y, 1996, TOXICOL APPL PHARM, V138, P149, DOI 10.1006/taap.1996.0108; KATO H, 1992, BIOCHEM BIOPH RES CO, V188, P934, DOI 10.1016/0006-291X(92)91145-G; KELLER HU, 1993, BIOCHEM BIOPH RES CO, V194, P1111, DOI 10.1006/bbrc.1993.1936; KUNERTRADEK J, 1990, AGENTS ACTIONS, V29, P254, DOI 10.1007/BF01966455; LAMONT AG, 1990, J IMMUNOL, V145, P1687; Launois P, 1995, EUR J IMMUNOL, V25, P3298, DOI 10.1002/eji.1830251215; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MIURA K, 1995, HANDB EXP PHARMACOL, V115, P163; MOREAU M, 1994, P NATL ACAD SCI USA, V91, P12639, DOI 10.1073/pnas.91.26.12639; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORDLIND K, 1984, INT ALLERGY APPL IMM, V77, P405; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PRIGENT P, 1995, J CLIN INVEST, V96, P1484, DOI 10.1172/JCI118185; Pu MY, 1996, J CELL BIOCHEM, V63, P104; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SAOUDI A, 1995, EUR J IMMUNOL, V25, P1972, DOI 10.1002/eji.1830250726; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOUNG W, 1988, MOL PHARMACOL, V34, P239; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	51	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32411	32418		10.1074/jbc.272.51.32411	http://dx.doi.org/10.1074/jbc.272.51.32411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405450	hybrid			2022-12-27	WOS:000071108000069
J	Nomizu, M; Kuratomi, Y; Song, SY; Ponce, ML; Hoffman, MP; Powell, SK; Miyoshi, K; Otaka, A; Kleinman, HK; Yamada, Y				Nomizu, M; Kuratomi, Y; Song, SY; Ponce, ML; Hoffman, MP; Powell, SK; Miyoshi, K; Otaka, A; Kleinman, HK; Yamada, Y			Identification of cell binding sequences in mouse laminin gamma 1 chain by systematic peptide screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTGROWTH-PROMOTING DOMAIN; CAPILLARY-LIKE STRUCTURES; TERMINAL GLOBULAR DOMAIN; HUMAN-ENDOTHELIAL CELLS; AMINO-ACID-SEQUENCE; EGF-LIKE MOTIF; NEURITE OUTGROWTH; B2 CHAIN; SYNTHETIC PEPTIDES; BASEMENT-MEMBRANE	Laminin-1, a major component of basement membranes, consists of three different chains designated alpha 1, beta 1, and gamma 1 and has diverse biological functions. We have identified cell binding sites on the mouse laminin gamma 1 chain, using systematic screening of 165 overlapping synthetic peptides covering the entire chain. We identified 12 cell binding sequences using HT-1080 human fibrosarcoma and B16-F10 mouse melanoma cells in two independent assays employing peptide-conjugated Sepharose beads and peptide-coated dishes. Four peptides (C-16, C-28, C-64, and C-68) located on the globular domains of the gamma 1 chain were the most active and showed dose-dependent cell attachment. Cell attachment to C-68 was inhibited by EDTA and by anti-alpha(2) beta(1) integrin antibodies. Cell attachment to C-16 and C-64 was partially inhibited by EDTA but was not inhibited by anti-integrin antibodies. EDTA and anti-integrin antibodies did not affect cell attachment to C-28. The four peptides were tested in adhesion and differentiation assays with endothelial, neuronal, and human salivary gland cells. C-16 was the most active for all of the cells, whereas the other three peptides showed cell type specificity in their activities. The active core sequences of C-16, C-28, C-64, and C-68 are YVRL, IRVTLN, TTVKYIFR, and SIKIRGTY, respectively. These sequences are highly conserved among the different species and in the laminin gamma 2 chain. These results suggest that the specific sequences on the laminin gamma 1 chain are biologically active and interact with distinct cell surface receptors.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Fac Pharmaceut Sci, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kyoto University	Yamada, Y (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg30,Rm 405, Bethesda, MD 20892 USA.							BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Bodanszky M., 1983, PEPTIDES, V5, P111; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hoffman M. P., 1995, Molecular Biology of the Cell, V6, p169A; Hoffman MP, 1996, J CELL SCI, V109, P2013; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; NOMIZU M, 1994, J BIOL CHEM, V269, P30386; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OTAKA A, 1995, J ORG CHEM, V60, P3967, DOI 10.1021/jo00118a011; PIERSHBACHER MD, 1984, NATURE, V301, P30; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SKUBITZ APN, 1990, CANCER RES, V50, P7612; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; Takagi Y, 1996, J BIOL CHEM, V271, P18074, DOI 10.1074/jbc.271.30.18074; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814; WUJEK JR, 1990, DEV BRAIN RES, V55, P237, DOI 10.1016/0165-3806(90)90205-D; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L	46	100	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32198	32205		10.1074/jbc.272.51.32198	http://dx.doi.org/10.1074/jbc.272.51.32198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405421	hybrid			2022-12-27	WOS:000071108000040
J	Okazaki, T; Ishikawa, T; Nishimori, S; Igarashi, T; Hata, K; Fujita, T				Okazaki, T; Ishikawa, T; Nishimori, S; Igarashi, T; Hata, K; Fujita, T			Hyperosmolarity-induced gene stimulation is mediated by the negative calcium responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEDULLARY COLLECTING DUCT; PARATHYROID-HORMONE GENE; EXTRACELLULAR CALCIUM; MAMMALIAN-CELLS; PROTEIN; STRESS; ACTIVATION; PROMOTER; REF1	The negative calcium responsive elements of the parathyroid hormone gene bind to a specific set of nuclear proteins in an extracellular calcium (Ca-e(2+))-dependent manner. We have found that one of the negative calcium responsive elements, named oligo B, is found in the 5'-flanking region of such vasoactive genes as the vasopressin and atrial natriuretic polypeptide genes. Furthermore, the oligo B-like sequence in the former gene is conserved throughout evolution, Because expression of some of these vasoactive genes is altered by external stimuli which change cell volume, we examined whether oligo B is involved in gene regulation by hyperosmolarity. Here, we demonstrate that the binding between oligo B and its binding nuclear proteins including a redox factor 1 was reduced by hyperosmolarity generated by sodium chloride but not by urea, Such attenuated binding was reversed by dephosphorylating nuclear proteins by a potato acid phosphatase, suggesting that NaCl treatment elicited phosphorylation of these nuclear proteins to weaken their binding activity to oligo B. Furthermore, these nuclear events led to hyperosmolarity-mediated transcriptional stimulation of the genes bearing this DNA element in the cultured cells.	Univ Tokyo, Sch Med, Dept Internal Med 4, Endocrine Genet & Hyperten Unit,Bunkyo Ku, Tokyo 112, Japan; Mitsubishi Kagaku Bioclin Lab Inc, Itabashi Ku, Tokyo 174, Japan	University of Tokyo; Mitsubishi Kagaku Bio-Clinical Laboratories	Okazaki, T (corresponding author), Univ Tokyo, Sch Med, Dept Internal Med 4, Endocrine Genet & Hyperten Unit,Bunkyo Ku, Tokyo 112, Japan.							BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHEN CJ, 1987, ENDOCRINOLOGY, V121, P958, DOI 10.1210/endo-121-3-958; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOHAN DE, 1993, J CLIN INVEST, V91, P1235, DOI 10.1172/JCI116286; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PU LP, 1995, P NATL ACAD SCI USA, V92, P10653, DOI 10.1073/pnas.92.23.10653; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROBINSON AG, 1990, J CLIN INVEST, V86, P1023, DOI 10.1172/JCI114804; Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624; SATO N, 1990, AM J MED SCI, V299, P309, DOI 10.1097/00000441-199005000-00004; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SZASZI S, 1997, J BIOL CHEM, V272, P16670; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	26	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32274	32279		10.1074/jbc.272.51.32274	http://dx.doi.org/10.1074/jbc.272.51.32274			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405432	hybrid			2022-12-27	WOS:000071108000051
J	Dumoulin, A; Manning, LR; Jenkins, WT; Winslow, RM; Manning, JM				Dumoulin, A; Manning, LR; Jenkins, WT; Winslow, RM; Manning, JM			Exchange of subunit interfaces between recombinant adult and fetal hemoglobins - Evidence for a functional inter-relationship among regions of the tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE HEMOGLOBIN; PROTEIN; SITE; 2,3-DIPHOSPHOGLYCERATE; BINDING; GLOBIN; MUTANT; OXYGEN; YEAST	The inter-relationship between the interior subunit interfaces and the exterior diphosphoglycerate (DPG) binding region of the hemoglobin tetramer and the effects of a specific N-terminal acetylation on tetramer assembly have been evaluated, Tetrameric fetal hemoglobin F in the liganded state was found to dissociate to dimers much less than previously appreciated, i.e, about 70 times less than adult hemoglobin A (K-d = 0.01 mu M and 0.68 mu M, for HbF and HbA, at pH 7.5, respectively) over the pH range 6.2-7.5, whereas HbF(1), in which the N termini of the gamma-chains are acetylated, dissociates like HbA, To determine whether this feature of HbF could be transferred to hemoglobin A, the single amino acid difference in their alpha(1) beta(2)/alpha(1) gamma(2) interfaces and the 4 amino acid differences in their alpha(1) beta(1)/alpha(1) gamma(1) interfaces have been substituted in HbA to those in HbF, This pentasubstituted recombinant HbA/F had the correct molecular weight as determined by mass spectrometry, the expected mobility on isoelectric focusing, the calculated amino acid composition, and normal circular dichroism properties, oxygen binding, and cooperativity, Although HbA/F has the same amino acid side chains that bind DPG as HbA, its diminished response to 2,3-DPG resembled that of HbF. However, its tetramer-dimer dissociation constant (K-d = 0.14 mu M) was between that of HbA and HbF despite the fact that it was composed entirely of HbF subunit interfaces, The results indicate that regions of the tetramer distant from the tetramer-dimer interface influence its dissociation and, reciprocally, that the interfaces affect regions involved in the binding of allosteric regulators, suggesting flexible long range inter-relationships in hemoglobin.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA; INDIANA UNIV, DEPT CHEM, BLOOMINGTON, IN 47405 USA; UNIV CALIF SAN DIEGO, VET AFFAIRS MED CTR, DEPT MED, SAN DIEGO, CA 92161 USA	Northeastern University; Indiana University System; Indiana University Bloomington; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-58512, HL-48018, HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, P01HL058512, P01HL048018, R37HL018819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1965, P NATL ACAD SCI USA, V53, P342, DOI 10.1073/pnas.53.2.342; ACKERS GK, 1975, PROTEINS, V1, P2; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, P NATL ACAD SCI USA, V77, P5130; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BUNN HF, 1974, BIOCHEMISTRY-US, V13, P988, DOI 10.1021/bi00702a024; BUNN HF, 1970, J CLIN INVEST, V49, P1088, DOI 10.1172/JCI106324; CHIANCONE E, 1968, J BIOL CHEM, V243, P1212; CHU AH, 1981, J BIOL CHEM, V256, P1199; CY IP, 1986, ANAL BIOCHEM, V156, P348, DOI 10.1016/0003-2697(86)90264-2; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; EATON WA, 1995, SCIENCE, V268, P1142, DOI 10.1126/science.7539154; FRIER JA, 1977, J MOL BIOL, V112, P97, DOI 10.1016/S0022-2836(77)80158-7; FRONTICELLI C, 1994, BIOPHYS CHEM, V51, P53, DOI 10.1016/0301-4622(94)00028-X; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUEHNS ER, 1964, BIOCHEM J, V92, P444, DOI 10.1042/bj0920444; LONGO LD, 1991, FETAL GAS EXCHANGE L, P1699; MANNING JM, 1997, PROTEIN SCI, V6, P103; Manning LR, 1996, PROTEIN SCI, V5, P775; MILITELLO V, 1991, BIOPHYS CHEM, V39, P161, DOI 10.1016/0301-4622(91)85018-L; MRABET NT, 1986, J BIOL CHEM, V261, P1111; PARK CM, 1973, ANN NY ACAD SCI, V209, P237, DOI 10.1111/j.1749-6632.1973.tb47532.x; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; PERUTZ MF, 1990, MECHANISMS COOPERATI, P7; POYART C, 1978, PFLUG ARCH EUR J PHY, V376, P169, DOI 10.1007/BF00581580; SCALONI A, 1994, J BIOL CHEM, V269, P15076; SCHEEPENS A, 1995, BIOCHEM J, V310, P597, DOI 10.1042/bj3100597; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WILLIAMS RC, 1976, BIOCHEMISTRY-US, V15, P2207, DOI 10.1021/bi00655a028; WIND M, 1976, BIOCHEMISTRY-US, V15, P5161, DOI 10.1021/bi00668a033; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	37	52	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31326	31332		10.1074/jbc.272.50.31326	http://dx.doi.org/10.1074/jbc.272.50.31326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395461	hybrid			2022-12-27	WOS:A1997YL41900020
J	Sleeman, JP; Kondo, K; Moll, J; Ponta, H; Herrlich, P				Sleeman, JP; Kondo, K; Moll, J; Ponta, H; Herrlich, P			Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; RAT-TUMOR; MONOCLONAL-ANTIBODIES; METASTATIC BEHAVIOR; BINDING-PROTEINS; SPLICE VARIANTS; CARCINOMA-CELLS; RECEPTOR CD44; HYALURONATE; PROTEOGLYCAN	Isoforms of the glycoprotein CD44 are cell surface receptors for the glycosaminoglycan hyaluronate. They have been implicated in many biological processes, but their function in these is poorly understood and cannot be explained solely by hyaluronate binding. In the present work we examine the ligand binding properties of alternatively spliced CD44 variant isoforms which are functionally involved in the immune system, embryonic development, and tumor behavior. We shaw that these isoforms bind directly to the purified glycosaminoglycans chondroitin sulfate, heparin, and heparin sulfate, in addition to being able to bind to hyaluronate. Binding to this extended repertoire of glycosaminoglycans by CD44 depends on the inclusion of peptide sequences encoded by the alternatively spliced exons v6 and v7, and occurs both when the CD44 is solubilized from the plasma membrane and when it is expressed on intact cells. A single point mutation in the most N-terminal hyaluronate binding motif of CD44 ablates both hyaluronate and chondroitin sulfate binding, suggesting that glycosaminoglycans are bound through a common motif, and that only one of the hyaluronate binding motifs is responsible for the majority of glycosaminoglycan binding by CD44 on the cell. surface. Taken together, these observations indicate that alternative splicing regulates the ligand binding specificity of CD44 and suggest that structural changes in the CD44 protein have a profound effect on the range of ligands to which this molecule can bind with potentially wide-ranging functional consequences.			Sleeman, JP (corresponding author), FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,POB 3640,D-76021 KARLSRUHE,GERMANY.		Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; KONDO, Kazuhiro/0000-0002-3731-6258				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PONTA H, 1994, INVAS METAST, V14, P82; RUDY W, 1993, CANCER RES, V53, P1262; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; Sleeman JP, 1996, CANCER RES, V56, P3134; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WAINWRIGHT D, 1996, ANN NY ACAD SCI, V758, P345; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	46	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31837	31844		10.1074/jbc.272.50.31837	http://dx.doi.org/10.1074/jbc.272.50.31837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395530	hybrid			2022-12-27	WOS:A1997YL41900089
J	Meyer, T; Carlstedt-Duke, J; Starr, DB				Meyer, T; Carlstedt-Duke, J; Starr, DB			A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RESPONSE ELEMENT; NEGATIVE REGULATION; DNA-BINDING; TRANSCRIPTION; RECEPTOR; COMPLEX; YEAST; PROMOTER; EXPRESSION	The TATA box element is not only important for establishing basal levels of transcription, but it can also be used to modulate cell type or stage specific gene activity. In the case of the human osteocalcin gene, which is transcriptionally repressed by glucocorticoids, a specific binding element for the glucocorticoid receptor (GR) overlaps a noncanonical TATA box, In the present study, the relevance and function of the TATA element in glucocorticoid-mediated repression of the human osteocalcin gene was characterized, Mutating this noncanonical TATA box into a consensus TATA box within the context of the osteocalcin promoter greatly decreased hormone-dependent transcriptional repression by GR. TATA-binding protein (TBP) bound this mutated element much more strongly suggesting a physiologically relevant role for the weak osteocalcin TATA element in the regulation of this bone specific gene. The optimization of the putative transcription factor IIB recognition site did not affect the level of GR-mediated repression. Our results support a model wherein competitive DNA binding of GR and TBP for their overlapping sites explains conditional repression of the osteocalcin gene by glucocorticoids.	Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Huddinge Hosp, Dept Biosci, S-14186 Huddinge, Sweden; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Karolinska Institutet; Karolinska Institutet; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meyer, T (corresponding author), Karolinska Inst, Novum, Huddinge Hosp, Dept Med Nutr, S-14186 Huddinge, Sweden.	thomas.meyer@mednut.ki.se			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL 07731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; DEVOS P, 1994, NUCLEIC ACIDS RES, V22, P1161, DOI 10.1093/nar/22.7.1161; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KALLIO PJ, 1993, ANN NY ACAD SCI, V684, P233, DOI 10.1111/j.1749-6632.1993.tb32295.x; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Pei L, 1996, J BIOL CHEM, V271, P20879; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STARR DB, 1995, J MOL BIOL, V250, P434; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	31	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30709	30714		10.1074/jbc.272.49.30709	http://dx.doi.org/10.1074/jbc.272.49.30709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388207	hybrid			2022-12-27	WOS:000071640800020
J	Xiong, ZH; Ridgley, EL; Enis, D; Olness, F; Ruben, L				Xiong, ZH; Ridgley, EL; Enis, D; Olness, F; Ruben, L			Selective transfer of calcium from an acidic compartment to the mitochondrion of Trypanosoma brucei - Measurements with targeted aequorins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; RAT-LIVER MITOCHONDRIA; IN-VITRO IMPORT; RECOMBINANT AEQUORIN; CA2+ RELEASE; CYTOSOLIC CA2+; CELLS; HOMEOSTASIS; NUCLEAR; PROTEIN	Organelle compartments are used by cells as reservoirs of exchangeable Ca2+ and as Ca2+ buffers, The following study uses recombinant aequorins (CYT-AEQ and MT-AEQ) to measure the dynamics of Ca2+ flux between organelles in procyclic forms of the pathogenic protozoan, Trypanosoma brucei. Emphasis is placed on the exchange between an acidic Ca2+ reservoir and the mitochondrion, The mammalian mitochondrial targeting sequence was functional in trypanosomes as determined by immunoblots, immunolocalizations, and the observation that MT-AEQ was in a compartment whose Ca2+ uptake was inhibited 82% with carbonyl cyanide p-trifluoromethoxyphenylhydrazone and KCN, The resting level of free calcium ion concentration in the mitochondrion ([Ca2+](mit),,,) was slightly higher than that in the cytoplasm ([Ca2+],(cyt)) (400 +/- 50 nM and 290 +/- 40 nM?I, respectively), Melittin (125 nM) disrupted Ca2+ homeostasis by inducing Ca2+ influx across the plasma membrane, [Ca2+](cyt) became slightly elevated to 410 +/- 100 nM, whereas [Ca2+],(mit), was selectively increased approximately la fold, with a broad peak at 4.8 +/- 1.9 mu M. At the peak, the mitochondrion contained approximately three times more free Ca2+ than the cytosol. However, mitochondrial retention of the Ca2+ was transient, Similar selective transport into the mitochondrion was observed when Ca2+ efflux from an acidic compartment was induced with monensin (2 mu g/ml) in the presence of 5 mM EGTA, [Ca2+](cyt) was transiently elevated to 400 +/- 50 nM, whereas [Ca2+],(mit), was elevated to 3.3+/-1.3 mu M. When cells were treated sequentially with monensin (2 mu g/ml) and then melittin (200 nM), mitochondrial Ca2+ transport was normal, However, [Ca2+](cyt),, became elevated to a level that was 1.4-fold higher than with melittin alone, Overall, these data demonstrate that the trypanosome mitochondrion is not a reservoir of exchangeable Ca2+ in the resting cell, However, Ca2+ is selectively channeled to the mitochondrion from the plasma membrane or acidic Ca2+ storage compartment, Additionally, the acidic compartment contributes to maintenance of Ca2+ homeostasis in response to melittin.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; So Methodist Univ, Dept Phys, Dallas, TX 75275 USA	Southern Methodist University; Southern Methodist University	Ruben, L (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.	Iruben@post.smu.edu		Olness, Fredrick/0000-0001-6799-2436	NIAID NIH HHS [AI24627] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BECKER GL, 1980, BIOCHIM BIOPHYS ACTA, V591, P234, DOI 10.1016/0005-2728(80)90155-3; BENAIM G, 1993, BIOCHEM J, V296, P759, DOI 10.1042/bj2960759; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRUN R, 1979, ACTA TROP, V36, P289; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hauser R, 1996, J CELL SCI, V109, P517; Hausler T, 1997, EUR J CELL BIOL, V73, P240; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HECKER H, 1980, PATHOL RES PRACT, V166, P203; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; KENDALL JM, 1990, BIOCHEM BIOPH RES CO, V189, P1008; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Priest JW, 1996, J BIOL CHEM, V271, P20060, DOI 10.1074/jbc.271.33.20060; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; Ruben L, 1996, MOL BIOCHEM PARASIT, V81, P191, DOI 10.1016/0166-6851(96)02707-7; RUBEN L, 1991, J BIOL CHEM, V266, P24351; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Sloof P, 1997, TRENDS MICROBIOL, V5, P189, DOI 10.1016/S0966-842X(97)01034-2; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1993, J BIOL CHEM, V268, P8564; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; WILLIAMSON J, 1981, J PROTOZOOL, V28, P460, DOI 10.1111/j.1550-7408.1981.tb05320.x; WU YM, 1992, BIOCHEM J, V287, P187, DOI 10.1042/bj2870187; Xiong ZH, 1996, MOL BIOCHEM PARASIT, V83, P57, DOI 10.1016/S0166-6851(96)02750-8	48	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31022	31028		10.1074/jbc.272.49.31022	http://dx.doi.org/10.1074/jbc.272.49.31022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388251	hybrid			2022-12-27	WOS:000071640800064
J	Zhou, GS; Seibenhener, ML; Wooten, MW				Zhou, GS; Seibenhener, ML; Wooten, MW			Nucleolin is a protein kinase C-zeta substrate - Connection between cell surface signaling and nucleus in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-INDUCED DIFFERENTIATION; NEURITE OUTGROWTH; BINDING-PROTEIN; EXPRESSION PATTERN; CHO CELLS; PHOSPHORYLATION; ACTIVATION; ISOFORM; LOCALIZATION	We have previously shown that protein kinase C (PKC)-zeta is activated and required for nerve growth factor (NGF)-induced differentiation of rat pheochromocytoma PC12 cells (Wooten, M, W,, Zhou, G., Seibenhener M. L,, and Coleman, E. S, (1994) Cell Growth & Diff. 5, 395-403; Coleman, E, S,, and Wooten, M, W, (1994) J, Mol, Neurosci, 5, 39-57), Here we report the characterization and identification of a 106-kDa nuclear protein as a specific substrate of PKC-zeta, NGF treatment of PC12 cells resulted in translocation of PKC-zeta and coincident phosphorylation of a protein that was localized within the nucleoplasm of nuclei isolated from PC12 cells, Addition of PKC-zeta pseudosubstrate peptide in vitro or myristoylated peptide in vivo diminished phosphorylation of pp106 in a dose-dependent fashion, Likewise, addition of purified PKC-zeta, but neither PKC-alpha nor delta, to nuclear extracts resulted in an incremental increase in the phosphorylation of pp106, Expression of dominant-negative PKC-zeta inhibited NGF-induced phosphorylation of pp106, by comparison overexpression of PKC-zeta enhanced basal phosphorylation without a noticeable effect upon NGF-induced effects, Amino acid sequence analysis of four peptides derived from purified pp106 revealed that this protein was homologous to nucleolin, Using an in vitro reconstitution system, purified nucleolin was likewise shown to be phosphorylated by purified PKC-zeta. The staining intensity of both enzyme and substrate in the nucleus increased upon treatment with NGF, In vivo labeling with P-32(i) and stimulation of PC12 cells with NGF followed by immunoprecipitation with anti-nucleolin antibody corroborated the in vitro approach documenting enhanced phosphorylation of nucleolin by NGF treatment, Taken together, the findings presented herein document that nucleolin is a target of PKC-zeta that serves to relay NGF signals from cell surface to nucleus in PC12 cells.	Auburn Univ, Dept Zool, Auburn, AL 36849 USA	Auburn University System; Auburn University	Wooten, MW (corresponding author), Auburn Univ, Dept Zool, Auburn, AL 36849 USA.	mwwooten@acesag.auburn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033661] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-33661] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1992, MOL BIOL CELL, V3, P323, DOI 10.1091/mbc.3.3.323; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BRADY MJ, 1993, J BIOL CHEM, V268, P17951; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; END D, 1982, J BIOL CHEM, V257, P9223; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; ESCANDEGERAUD ML, 1985, EXP CELL RES, V161, P353, DOI 10.1016/0014-4827(85)90092-8; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HALL FL, 1988, J BIOL CHEM, V263, P4460; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER SE, 1995, DEV BRAIN RES, V85, P239, DOI 10.1016/0165-3806(94)00219-P; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KILEY SC, 1995, J CELL SCI, V108, P1003; KONDRATYEV AD, 1990, FEBS LETT, V264, P75, DOI 10.1016/0014-5793(90)80768-E; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LEHRICH RW, 1994, J BIOL CHEM, V269, P32446; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MCTIGUE M, 1985, J BIOL CHEM, V260, P9047; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SANZ L, 1994, J BIOL CHEM, V269, P10044; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; YU MW, 1980, J BIOL CHEM, V255, P481; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292	69	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31130	31137		10.1074/jbc.272.49.31130	http://dx.doi.org/10.1074/jbc.272.49.31130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388266	hybrid			2022-12-27	WOS:000071640800079
J	Jia, YP; Patel, SS				Jia, YP; Patel, SS			Kinetic mechanism of GTP binding and RNA synthesis during transcription initiation by bacteriophage T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; REVERSE-TRANSCRIPTASE; NUCLEOTIDE; FLUORESCENCE; SEQUENCE; DYNAMICS; FIDELITY	We have used stopped-flow and rapid chemical quench-flow methods to investigate the kinetics of the early steps during transcription initiation by bacteriophage T7 RNA polymerase. Most promoters of T7 RNA polymerase initiate with two GTPs. The kinetics of GTP binding was investigated by monitoring the fluorescence changes resulting from GTP binding to polymerase and fluorescent 2-aminopurine-containing promoter DNA complex. Scheme 1 was determined from studies of T7 Phi 10 promoter at 25 degrees C, where (E.D)(n) represents the polymerase.DNA complex in different conformations. GTP(E) and GTP(I) represent the elongating and initiating GTP molecules incorporated at the +2 and +1 positions, respectively. Our studies show that GTP at the elongation site binds with at least 10-fold tighter affinity than the GTP at the initiation site, Two conformational changes were revealed upon GTP binding to the polymerase-2-aminopurine DNA complex. The first conformational change occurred upon GTP binding to the elongation site. This conformational change was reversible, and studies with partially melted DNA and incorrect NTPs suggested that it may represent a DNA melting and/or base pairing step. A second rate-limiting conformational change whose rate was same as the maximum rate of pppGpG synthesis occurred after two GTPs were bound. As with DNA polymerases, this rate-limiting conformational change probably occurs at each NMP incorporation event and may be involved in proper positioning of the initiation and the elongating GTPs within the polymerase active site to achieve efficient and accurate RNA synthesis.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIGMS NIH HHS [GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Chamberlin M., 1982, ENZYMES, V15, P87; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FOX JJ, 1958, J AM CHEM SOC, V80, P1669, DOI 10.1021/ja01540a041; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P322, DOI 10.1016/S0959-440X(96)80050-9; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; SEN R, 1993, BIOCHEM BIOPH RES CO, V195, P616, DOI 10.1006/bbrc.1993.2090; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; WARD DC, 1969, J BIOL CHEM, V244, P1228; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	25	46	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30147	30153		10.1074/jbc.272.48.30147	http://dx.doi.org/10.1074/jbc.272.48.30147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374495	hybrid			2022-12-27	WOS:A1997YH61300027
J	Lee, KJ; Suh, YA; Cho, YG; Cho, YS; Ha, GW; Chung, KH; Hwang, JH; Yun, YD; Lee, DS; Kim, CM; Sung, YC				Lee, KJ; Suh, YA; Cho, YG; Cho, YS; Ha, GW; Chung, KH; Hwang, JH; Yun, YD; Lee, DS; Kim, CM; Sung, YC			Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT CELLS; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEINS; EXPRESSED PROTEIN; NON-A; GENOME; PURIFICATION; CLEAVAGE; E1; OLIGOMERIZATION	The envelope protein of hepatitis C virus (HCV) is composed of two membrane-associated glycoproteins, E1 and E2. To obtain HCV E2 protein as a secretory form at a high level, we constructed a recombinant chinese hamster ovary (CHO) cell line expressing a C-terminal truncated E2 (E2t) fused to human growth hormone (hGH), CHO/hGHE2t. The hGHE2t fusion protein was purified from the culture supernatant using anti-hGH mAb affinity chromatography at approximately 80% purity. The purified hGHE2t protein appeared to be assembled into oligomers linked by intermolecular disulfide bond(s) when density gradient centrifugation and SDS-polyacrylamide gel electrophoresis were employed. When the purified fusion protein was used for testing its ability to bind to antibodies specific for HCV by enzyme-linked immunosorbent assay, the protein was recognized by antibodies in sera from 90% of HCV-positive patients. Treatment of hGHE2t protein by beta-mercapto-ethanol, but not by heat and SDS, significantly reduced its reactivity to the antibodies of patient sera, suggesting that intermolecular and/or intramolecular disulfide bonds are important for its ability to recognize its specific antibody and that the E2 protein contains discontinuous antigenic epitope(s).	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,CTR BIOFUNCT MOL,SCH ENVIRONM ENGN,POHANG 790784,SOUTH KOREA; KOREA GREEN CROSS CORP,YONGIN,KYUNGGI DO,SOUTH KOREA; MOGAM BIOTECHNOL RES INST,YONGIN,KYUNGGI DO,SOUTH KOREA; KOREA CANC CTR HOSP,SEOUL,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Green Cross Corporation; National Cancer Center - Korea (NCC)								ALLORE RJ, 1984, ANAL BIOCHEM, V137, P523, DOI 10.1016/0003-2697(84)90121-0; CHAKRABARTI S, 1990, VIROLOGY, V178, P134, DOI 10.1016/0042-6822(90)90386-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN DY, 1993, LANCET, V342, P933, DOI 10.1016/0140-6736(93)91983-S; CHO YG, 1993, MOL CELLS, V3, P195; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARADA S, 1995, J GEN VIROL, V76, P1223, DOI 10.1099/0022-1317-76-5-1223; HARLOW E, 1988, ANTIBODIES LAB MANUA, P561; HSU HH, 1993, HEPATOLOGY, V17, P763, DOI 10.1016/0270-9139(93)90149-H; HULST MM, 1993, J VIROL, V67, P5435, DOI 10.1128/JVI.67.9.5435-5442.1993; INOUE Y, 1992, J GEN VIROL, V73, P2151, DOI 10.1099/0022-1317-73-8-2151; JACOB AF, 1996, J GEN VIROL, V77, P1055; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; MATSUURA Y, 1994, VIROLOGY, V205, P141, DOI 10.1006/viro.1994.1629; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NISHIHARA T, 1993, GENE, V129, P207, DOI 10.1016/0378-1119(93)90270-D; OKAMOTO H, 1991, J GEN VIROL, V72, P2696; PACHL C, 1987, J VIROL, V61, P315, DOI 10.1128/JVI.61.2.315-325.1987; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; RUMENAPF T, 1993, J VIROL, V67, P3288; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; SPAETE RR, 1992, VIROLOGY, V188, P819, DOI 10.1016/0042-6822(92)90537-Y; WEILAND E, 1990, J VIROL, V64, P3563, DOI 10.1128/JVI.64.8.3563-3569.1990; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989	38	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30040	30046		10.1074/jbc.272.48.30040	http://dx.doi.org/10.1074/jbc.272.48.30040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374479	hybrid			2022-12-27	WOS:A1997YH61300011
J	Lubin, IM; Healey, JF; Barrow, RT; Scandella, D; Lollar, P				Lubin, IM; Healey, JF; Barrow, RT; Scandella, D; Lollar, P			Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; HEMOPHILIA-A; ANTIBODIES; DOMAIN; PROTEINS; LOCALIZATION; FRAGMENTS; RESIDUES	Antibodies directed to the A2 domain of factor VIII (fVIII) are usually an important component of the polyclonal response in patients who have clinically significant inhibitory antibodies to fVIII. A major determinant of the A2 epitope has been located by homolog scanning mutagenesis using recombinant hybrid human/porcine fVIII molecules to a sequence bounded by Arg(484)-Ile(508) (Healey, J. F., Lubin, I. M., Nakai, H., Saenko, E. L., Hoyer, L. W., Scandella, D., and Lollar, P. (1995) J. Biol. Chem. 270, 14505-14509). Within this region, human residues Arg(484), Pro(485), Tyr(487), Ser(488), Arg(489), Pro(492), Val(495) Phe501, and Ile(508) differ from porcine fVIII. We stably expressed in mammalian cells nine active B-domainless human fVIII molecules containing single alanine substitutions at these sites. Their inhibition by a murine an ti-A2 monoclonal antibody, monoclonal antibody (mAb) 413, and by three A2-specific alloimmune and two A2-specific autoimmune human inhibitor plasmas was measured by the Bethesda assay. The inhibition of Arg(484) --> Ala, Tyr(487) --> Ala, Arg(489) --> Ala, and Arg(492) --> Ala by mAb413 was reduced by greater than 90% compared with wild-type, B-domainless human fVIII. mAb413 inhibited the most severely affected mutant, Arg(489) --> Ala, 0.01% as well as wild-type fVIII, For all five patient plasmas, the Tyr(487) --> Ala mutant displayed the greatest reduction in inhibition. The inhibition of the Tyr(487) --> Ala mutant by these antibodies ranged from 10% to 20% that of wild-type fVIII. The inhibition of the Ser(488) --> Ala, Arg(489) --> Ala, Pro(492) --> Ala, Val(495) --> Ala, Phe(501) --> Ala, and Ile(508) --> Ala mutants by most of the plasmas also was significantly reduced, In contrast, the Arg(484) --> Ala and Pro(485) --> Ala mutants were relatively unaffected. Thus, although mAb413 binds to the same region as human A2 inhibitors, it recognizes a different set of amino acid side chains. The side chains recognized by human A2 inhibitors appear to be similar, despite the differing immune settings that give rise to fVIII alloantibodies and autoantibodies.	EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; AMER RED CROSS, HOLLAND LAB, ROCKVILLE, MD 20855 USA	Emory University; American Red Cross					NHLBI NIH HHS [R01-HL46215, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; Bevington P.R., 1969, DATA REDUCTION ERROR; BRETTLER DB, 1989, ARCH INTERN MED, V149, P1381, DOI 10.1001/archinte.149.6.1381; Brettler DB, 1996, BAILLIERE CLIN HAEM, V9, P319, DOI 10.1016/S0950-3536(96)80066-7; Cohen AJ, 1996, BAILLIERE CLIN HAEM, V9, P331, DOI 10.1016/S0950-3536(96)80067-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FIKSSIGAUD M, 1993, VOX SANG, V64, P210, DOI 10.1111/j.1423-0410.1993.tb03057.x; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; Hay C, 1995, ADV EXP MED BIOL, V386, P143; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; JIN L, 1994, PROTEIN SCI, V3, P2351, DOI 10.1002/pro.5560031219; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KERNOFF PBA, 1984, FACTOR 8 INHIBITORS, P207; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; MORRISON AE, 1993, BLOOD, V81, P1513; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; Shulman N R, 1969, Trans Assoc Am Physicians, V82, P388; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; Zhong D., 1996, Blood, V88, p324A	38	45	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30191	30195		10.1074/jbc.272.48.30191	http://dx.doi.org/10.1074/jbc.272.48.30191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374501	hybrid			2022-12-27	WOS:A1997YH61300033
J	Gilberger, TW; Walter, RD; Muller, S				Gilberger, TW; Walter, RD; Muller, S			Identification and characterization of the functional amino acids at the active site of the large thioredoxin reductase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART LIPOAMIDE DEHYDROGENASE; 2-ELECTRON REDUCED ENZYME; ESCHERICHIA-COLI; GLUTATHIONE-REDUCTASE; DIRECTED MUTAGENESIS; PIG-HEART; DIFFERENTIAL REACTIVITY; CATALYTIC MECHANISM; DISULFIDE; SEQUENCE	The thioredoxin system, composed of the pyridine nucleotide disulfide oxidoreductase thioredoxin reductase, the small peptide thioredoxin, and NADPH as a reducing cofactor, is one of the major thiol-reducing systems of the cell, Recent studies revealed that Plasmodium falciparum and human thioredoxin reductase represent a novel class of enzymes, called large thioredoxin reductases, The large thioredoxin reductases are substantially different from the isofunctional prokaryotic Escherichia coli enzyme, The putative essential amino acids at the catalytic center of large thioredoxin reductase from P, falciparum were determined by using site-directed mutagenesis techniques, To analyze the putative active site cysteines (Cys(88) and Cys(93)) three mutant proteins were constructed substituting alanine or serine residues for cysteine residues, Further, to evaluate the function of His(509) as a putative proton donor/acceptor of large thioredoxin reductase this residue was replaced by either glutamine or alanine, All mutants were expressed in the E. coli system and characterized, Steady state kinetic analysis revealed that the replacement of Cys(88) by either alanine or serine and Cys(93) by alanine resulted in a total loss of enzymatic activity, These results clearly identify Cys(88) and Cys(93) as the active site thiols of large thioredoxin reductase. The replacement of His(509) by glutamine yielded in a 95% loss of thioredoxin reductase activity; replacement by alanine provoked a loss of 97% of enzymatic activity, These results identify His(509) as active site base, but imply that its function can be substituted, although inefficiently, by an alternative proton donor, similar to glutathione reductase, Spectral analysis of wild type P, falciparum thioredoxin reductase revealed a 550-nm absorption band upon reduction which resembles the EH2 form of glutathione reductase and lipoamide dehydrogenase. This spectral feature, recently also reported for the human placenta protein (Arscott, L, D,, Gromer, S,, Schirmer, R, H., Becker K., and Williams, C, H., Jr, (1997) PI oc. Natl, Acad. Sci, U, S, A, 94, 3621-3626), further illustrates the similarity between large thioredoxin reductases and glutathione reductases and stresses the profound differences to small E, coli thioredoxin reductase.	BERNHARD NOCHT INST TROP MED, D-20359 HAMBURG, GERMANY	Bernhard Nocht Institut fur Tropenmedizin				Gilberger, Tim-Wolf/0000-0002-7965-8272				ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; DEONARAIN MP, 1990, P ROY SOC B-BIOL SCI, V241, P179, DOI 10.1098/rspb.1990.0083; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; DISTEFANO MD, 1989, BIOCHEMISTRY-US, V28, P1168, DOI 10.1021/bi00429a035; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Muller S, 1995, MOL BIOCHEM PARASIT, V74, P11, DOI 10.1016/0166-6851(95)02476-X; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; MULROONEY SB, 1994, BIOCHEMISTRY-US, V33, P3148, DOI 10.1021/bi00177a002; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; PAI EF, 1983, J BIOL CHEM, V258, P1752; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; SAHLMAN L, 1984, J BIOL CHEM, V259, P2403; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THORPE C, 1976, J BIOL CHEM, V251, P3553; THORPE C, 1981, BIOCHEMISTRY-US, V20, P1507, DOI 10.1021/bi00509a015; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Wang PF, 1996, BIOCHEMISTRY-US, V35, P4812, DOI 10.1021/bi9526793; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; ZANETTI G, 1967, J BIOL CHEM, V242, P5232	31	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29584	29589		10.1074/jbc.272.47.29584	http://dx.doi.org/10.1074/jbc.272.47.29584			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368022	hybrid			2022-12-27	WOS:A1997YG64700032
J	Kim, J; Kemper, B				Kim, J; Kemper, B			Phenobarbital alters protein binding to the CYP2B1/2 phenobarbital-responsive unit in native chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; TRANSCRIPTIONAL REGULATION; CYTOCHROME-P450 GENES; INDUCTION; SEQUENCE; PROMOTER; COMMON; INVIVO; RNAS	Phenobarbital is a classical inducer of the drug metabolizing cytochrome P450 genes, but the molecular mechanism of induction has not been elucidated, Functional analyses have identified a phenobarbital-responsive unit in the rat CYP2B1/2 and mouse Cyp2b10 genes about -2.3 kilobase pairs from the transcriptional start site, but little or no changes in protein binding to this region were observed in vitro, To examine the role of chromatin structure, protein binding to the phenobarbital-responsive unit assessed by in vitro DNase I footprinting was compared with that assessed by DNase I in vivo footprints in native chromatin, A region centered on a putative nuclear factor-1 site was the major protected region in in vitro footprints, and there were no detectable differences in binding between extracts from control and phenobarbital-treated animals. In contrast, phenobarbital treatment dramatically altered the protection pattern in native chromatin. In control samples a core region of about 25 base pairs (bp) centered on the nuclear factor-1 site was protected, However, after phenobarbital treatment, the protection of this core region was increased, and more dramatically the region of protection was extended 20 bp to either side so that a total of about 60 bp were protected. These results provide the first evidence that phenobarbital treatment alters the composition or architecture of proteins binding to the phenobarbital-responsive unit region and indicate that chromatin structure is important in this process, Because proteins are bound to the region in the untreated animal, the mechanism of induction involves the activation of proteins bound to the region and possibly recruitment of additional regulatory proteins rather than conversion of a closed chromatin structure to an open one that can bind regulatory factors.	UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; CHEN D, 1994, J BIOL CHEM, V269, P5420; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HE JS, 1991, J BIOL CHEM, V266, P7864; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; KIM J, 1991, BIOCHEMISTRY-US, V30, P10287, DOI 10.1021/bi00106a029; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; REMMER H, 1958, NATURWISSENSCHAFTEN, V45, P189, DOI 10.1007/BF00621338; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811	23	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29423	29425		10.1074/jbc.272.47.29423	http://dx.doi.org/10.1074/jbc.272.47.29423			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367997	hybrid			2022-12-27	WOS:A1997YG64700007
J	Liu, Y; Watanabe, H; Nifuji, A; Yamada, Y; Olson, EN; Noda, M				Liu, Y; Watanabe, H; Nifuji, A; Yamada, Y; Olson, EN; Noda, M			Overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression in osteoblastic osteosarcoma ROS17/2.8 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOD FAMILY; DNA-BINDING; PROTEIN; RNA; OSTEOPONTIN; MYOGENESIS; FRAGMENTS; SEQUENCE	Cell differentiation is determined by a certain set of transcription factors such as MyoD in myogenesis, However, transcription factors that play a positive role in phenotypic gene expression in skeletal cells are largely unknown, except the recently identified CBFA1. Scleraxis is a helix-loop-helix-type transcription factor whose transcripts are expressed in sclerotome and in a certain set of skeletal cells; however, nothing is known about its function with regard to the regulation of cell function, To examine possible roles of scleraxis, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells, which express low levels of scleraxis, Scleraxis overexpression enhanced expression of the aggrecan gene, which is not normally expressed at high levels in these osteoblastic cells, Overexpression of scleraxis also increased mRNA levels of type II collagen and osteopontin while suppressing expression of osteoblast phenotype-related genes encoding type I collagen and alkaline phosphatase, Transient transfection experiments indicated that scleraxis enhanced the chloramphenicol acetyltransferase activity of the reporter construct AgCAT-8, which contained an 8-kilobase pair (kb) fragment of the aggrecan gene including both the promoter and its first intron, Deletion analysis identified a 1-kb region that is responsive to scleraxis within the aggrecan gene, This region contains two adjacent E-box sequences, A 29-base pair DNA fragment (AgE) containing these E-box sequences bound to proteins in the ROS17/2.8 cell nuclear extracts as well as to in vitro translated scleraxis, This binding was competed with unlabeled AgE, but not with a mutated E-box DNA sequence (mAgE), indicating the specificity of the binding activity, The AgE binding activity in the ROS17/2.8 cell nuclear extracts was enhanced in the cells overexpressing scleraxis and was supershifted by the antiserum raised against scleraxis, Furthermore, AgE, but not mAgE, conferred responsiveness to scleraxis overexpression to a heterologous promoter, Finally, replacement mutation of the AgE sequence within the 2.5-kb AgCAT-1 construct significantly reduced its responsiveness to scleraxis, These results indicate that overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression via binding to the E box-containing AgE sequence in ROS17/2.8 cells.	TOKYO MED & DENT UNIV,MED RES INST,DIV FUNCT DISORDER RES,DEPT MOL PHARMACOL,CHIYODA KU,TOKYO 101,JAPAN; NIDR,MOL BIOL SECT,NIH,BETHESDA,MD 20892; UNIV TEXAS,SW MED CTR,HARMON CTR BASIC RES CANC,DALLAS,TX 75235	Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIES J, 1980, AM J TROP MED HYG, V29, P1089, DOI 10.4269/ajtmh.1980.29.1089; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P144; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Liu Y, 1996, J ENDOCRINOL, V151, P491, DOI 10.1677/joe.0.1510491; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; SIDDHANTI SR, 1994, J CELL BIOCHEM, V55, P310, DOI 10.1002/jcb.240550307; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	29	61	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29880	29885		10.1074/jbc.272.47.29880	http://dx.doi.org/10.1074/jbc.272.47.29880			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368062	hybrid			2022-12-27	WOS:A1997YG64700072
J	Nielsen, LB; McCormick, SPA; Pierotti, V; Tam, C; Gunn, MD; Shizuya, H; Young, SG				Nielsen, LB; McCormick, SPA; Pierotti, V; Tam, C; Gunn, MD; Shizuya, H; Young, SG			Human apolipoprotein B transgenic mice generated with 207- and 145-kilobase pair bacterial artificial chromosomes - Evidence that a distant 5'-element confers appropriate transgene expression in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BINDING-PROTEIN GENE; HORMONE FUSION GENES; AMINO-ACID SEQUENCE; CIS-ACTING ELEMENTS; BETA-GLOBIN GENE; GUT EPITHELIUM; TYROSINASE GENE; COMPLETE CDNA; HIGH-LEVEL	We reported previously that similar to 80-kilobase pair (kb) P1 bacteriophage clones spanning either the human or mouse apoB gene (clones p158 and p649, respectively) confer apoB expression in the liver of transgenic mice, but not in the intestine, We hypothesized that the absence of intestinal expression was due to the fact that these clones lacked a distant DNA element controlling intestinal expression, To test this possibility, transgenic mice were generated with 145- and 207-kb bacterial artificial chromosomes (BACs) that contained the human apoB gene and more extensive 5'- and 3'-flanking sequences, RNase protection, in situ hybridization, immunohistochemical, and genetic complementation studies revealed that the BAC transgenic mice manifested appropriate apoB gene expression in both the intestine and the liver, indicating that both BACs contained the distant intestinal element, To determine whether the regulatory element was located 5' or 3' to the apoB gene, transgenic mice were generated by co-microinjecting embryos with p158 and either the 5'- or 3'-sequences from the 145-kb BAG. Analysis of these mice indicated that the apoB gene's intestinal element is located 5' to the structural gene, Cumulatively, the transgenic mouse studies suggest that the intestinal element is located between -33 and -70 kb 5' to the apoB gene.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Institute of Technology	Nielsen, LB (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.			Gunn, Michael/0000-0003-4602-0667; Tam-Amersdorfer, Carmen/0000-0003-3123-6342; Young, Stephen/0000-0001-7270-3176; McCormick, Sally/0000-0001-9857-0703	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHEN SH, 1986, J BIOL CHEM, V261, P2918; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; ECCLES S, 1990, New Biologist, V2, P801; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FARESE RV, 1992, J CLIN INVEST, V90, P256, DOI 10.1172/JCI115845; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; Langman J., 1981, MED EMBRYOLOGY; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MATHEW MK, 1988, BIOCHEMISTRY-US, V27, P9204, DOI 10.1021/bi00426a019; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; McCormick SPA, 1996, TRENDS CARDIOVAS MED, V6, P16, DOI 10.1016/1050-1738(95)00125-5; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; Montoliu L, 1996, EMBO J, V15, P6026, DOI 10.1002/j.1460-2075.1996.tb00991.x; PAULWEBER B, 1961, J BIOL CHEM, V266, P24149; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIMON TC, 1993, J BIOL CHEM, V268, P18345; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; WALSH A, 1993, J LIPID RES, V34, P617; Wilcox J N, 1986, Methods Enzymol, V124, P510; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; YOUNG SG, 1986, J BIOL CHEM, V261, P2995; Young Stephen G., 1994, Current Opinion in Lipidology, V5, P94, DOI 10.1097/00041433-199404000-00005	48	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29752	29758		10.1074/jbc.272.47.29752	http://dx.doi.org/10.1074/jbc.272.47.29752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368045	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:A1997YG64700055
J	Almeida, R; Amado, M; David, L; Levery, SB; Holmes, EH; Merkx, G; van Kessel, AG; Rygaard, E; Hassan, H; Bennett, E; Clausen, H				Almeida, R; Amado, M; David, L; Levery, SB; Holmes, EH; Merkx, G; van Kessel, AG; Rygaard, E; Hassan, H; Bennett, E; Clausen, H			A family of human beta 4-galactosyltransferases - Cloning and expression of two novel UDP-galactose: beta-N-acetylglucosamine beta 1,4-galactosyltransferases, beta 4Gal-T2 and beta 4Gal-T3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; MEMBRANE-BOUND FORM; FULL-LENGTH CDNA; GDP-L-FUCOSE; HUMAN GALACTOSYLTRANSFERASE; GENE FAMILY; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; RHEUMATOID-ARTHRITIS; SACCHAROMYCES-CEREVISIAE; DETERMINES EXPRESSION	BLAST analysis of expressed sequence tags (ESTs) using the coding sequence of the human UDP-galactose:beta-N-acetylglucosamine beta 1,4-galactosyltransferase, designated beta 4Gal-T1, revealed a large number of ESTs with identical as well as similar sequences. ESTs with sequences similar to that of beta 4Gal-T1 could be grouped into at least two non-identical sequence sets. Analysis of the predicted amino acid sequence of the novel ESTs with beta 4Gal-T1 revealed conservation of short sequence motifs as well as cysteine residues previously shown to be important for the function of beta 4Gal-T1. The likelihood that the identified ESTs represented novel galactosyltransferase genes was tested by cloning and sequencing of the full coding region of two distinct genes, followed by expression. Expression of soluble secreted constructs in the baculovirus system showed that these genes represented genuine UDP-galactose:beta-N-acetylglucosamine beta 1,4-galactosyltransferases, thus designated beta 4Gal-T2 and beta 4Gal-T3. Genomic cloning of the genes revealed that they have identical genomic organizations compared with beta 4Gal-T1. The two novel genes were located on 1p32-33 and 1q23. The results demonstrate the existence of a family of homologous galactosyltransferases with related functions. The existence of multiple beta 4-galactosyltransferases with the same or overlapping functions may be relevant for interpretation of biological functions previously assigned to beta 4Gal-T1.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Porto, Portugal; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; NW Hosp, Dept Cell Surface Biochem, Seattle, WA 98125 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6050 HB Nijmegen, Netherlands	University of Copenhagen; Universidade do Porto; University System of Georgia; University of Georgia; Radboud University Nijmegen	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.	henrik.clausen@odont.ku.dk	van Kessel, Ad Geurts/A-2810-2010; Bennett, Eric/AAG-6120-2020; David, Leonor/A-4829-2008; Almeida, Raquel/B-9647-2012; clausen, henrik/AAD-8016-2021	Bennett, Eric/0000-0002-4976-0647; David, Leonor/0000-0003-4207-9258; Almeida, Raquel/0000-0002-5622-1633; Clausen, Henrik/0000-0002-0915-5055				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; AXFORD JS, 1994, AUTOIMMUNITY, V17, P157, DOI 10.3109/08916939409014671; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BENDIAK B, 1993, EUR J BIOCHEM, V216, P405, DOI 10.1111/j.1432-1033.1993.tb18158.x; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; BOEGGEMAN EE, 1995, GLYCOCONJUGATE J, V12, P865, DOI 10.1007/BF00731249; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Dennis J W, 1991, Semin Cancer Biol, V2, P411; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; DUBOIS DH, 1995, ADV EXP MED BIOL, V376, P105; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; FURUKAWA K, 1990, INT IMMUNOL, V2, P105, DOI 10.1093/intimm/2.1.105; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KEUSCH J, 1995, GLYCOBIOLOGY, V5, P365, DOI 10.1093/glycob/5.4.365; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KochNolte F, 1997, GENOMICS, V39, P370, DOI 10.1006/geno.1996.4520; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P5335, DOI 10.1021/bi00138a013; LEVERY SB, 1988, CARBOHYD RES, V178, P121, DOI 10.1016/0008-6215(88)80106-X; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1993, BAILLIERE CLIN HAEM, V6, P465, DOI 10.1016/S0950-3536(05)80155-6; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; MOSCARELLO MA, 1985, BIOCHIM BIOPHYS ACTA, V831, P192, DOI 10.1016/0167-4838(85)90035-4; NAKAZAWA K, 1993, J BIOCHEM-TOKYO, V113, P747; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NAKAZAWA K, 1991, EUR J BIOCHEM, V196, P363, DOI 10.1111/j.1432-1033.1991.tb15825.x; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; PAQUET MR, 1984, BIOCHEM J, V218, P745, DOI 10.1042/bj2180745; POWELL JT, 1974, EUR J BIOCHEM, V48, P217, DOI 10.1111/j.1432-1033.1974.tb03759.x; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1997, MOL GLYCOBIOLOGY, P88; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHAPER JH, 1995, ADV EXP MED BIOL, V376, P95; SHAPER JH, 1995, GLYCOCONJUGATE J, V12, P477; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHEARES BT, 1984, J BIOL CHEM, V259, P8045; SHUR BD, 1982, J BIOL CHEM, V257, P6871; SHUR BD, 1988, J BIOL CHEM, V263, P17706; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Uehara K, 1997, EUR J BIOCHEM, V244, P706, DOI 10.1111/j.1432-1033.1997.00706.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1993, J RHEUMATOL, V20, P1282; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YOUAKIM A, 1994, P NATL ACAD SCI USA, V91, P10913, DOI 10.1073/pnas.91.23.10913	85	155	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31979	31991		10.1074/jbc.272.51.31979	http://dx.doi.org/10.1074/jbc.272.51.31979			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405390	Green Published, hybrid			2022-12-27	WOS:000071108000009
J	Kelleher, NL; Nicewonger, RB; Begley, TP; McLafferty, FW				Kelleher, NL; Nicewonger, RB; Begley, TP; McLafferty, FW			Identification of modification sites in large biomolecules by stable isotope labeling and tandem high resolution mass spectrometry - The active site nucleophile of thiaminase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED MULTIPHOTON DISSOCIATION; MULTIPLY-CHARGED IONS; ELECTROSPRAY; PROTEINS; FRAGMENTS; RESONANCE; ANALOGS; PHASE	A widely used procedure for site localization of covalent protein modifications involves proteolysis, partial chromatographic separation of the resulting complex mixture, and tandem mass spectrometry (MS/MS) to identify peptides whose molecular weight (M-r) has been increased appropriately by the modification, As found previously for MS of small molecules, this study shows that protein fragment identification can be greatly simplified by labeling the modification with stable isotopes. Further, the high resolution capabilities of Fourier transform MS make possible the direct identification of CH3/CD3-labeled peptides without chromatographic separation. Although separate Asp-N, Lys-C, and alpha-chymotrypsin digests of thiaminase I (42 kDa) yielded as many as 70 peptides, FTMS identification of the labeled peptide localized the modification site of a mechanism-based inhibitor to Arg(101)-Lys(121), Asp(90)-Gly(122), and Gly(107)-Tyr(119), respectively. The measured mass difference values of the two labels agreed with that expected for CH3/CD3, 3.019 Ha, with a standard deviation of 0.005 Da, providing persuasive identity verification. MS/MS fragmentation narrowed the site to pro(109)-Phe(118) and also caused loss of the derivative with a sulfur atom, uniquely identifying Cys(113) as the thiaminase I active-site nucleophile among the 379 amino acids.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA	Cornell University	McLafferty, FW (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Begley, Tadhg/B-5801-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK044083, R01DK044083, R37DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM016609, R01GM016609, T32GM007273] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [8-T2GM07273, GM16609] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley TP, 1996, NAT PROD REP, V13, P177, DOI 10.1039/np9961300177; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BIEMANN K, 1994, ACCOUNTS CHEM RES, V27, P370, DOI 10.1021/ar00047a008; Blackburn RK, 1997, J AM SOC MASS SPECTR, V8, P483; Campbell S, 1995, J AM CHEM SOC, V117, P12840, DOI 10.1021/ja00156a023; CAPRIOLI RM, 1972, BIOCH APPLICATIONS M, P735; COMISAROW MB, 1974, CHEM PHYS LETT, V25, P282, DOI 10.1016/0009-2614(74)89137-2; Costello CA, 1996, J BIOL CHEM, V271, P3445, DOI 10.1074/jbc.271.7.3445; COX FB, 1943, ORGANIC SYNTHESIS CO, V2, P279; Creighton T.E., 1993, PROTEINS; Deery MJ, 1997, J AM SOC MASS SPECTR, V8, P253, DOI 10.1016/S1044-0305(96)00197-3; EARL JW, 1994, NATURE, V368, P683, DOI 10.1038/368683a0; FUJITA A, 1954, ADV ENZYMOL REL S BI, V15, P389; Gaskell S.J., 1986, MASS SPECTROMETRY BI; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HUTTER JA, 1987, BIOCHEMISTRY-US, V261, P1969; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; Kellner R., 1994, MICROCHARACTERIZATIO; Kurian E, 1997, J AM SOC MASS SPECTR, V8, P8, DOI 10.1016/S1044-0305(97)82228-3; Little DP, 1996, J AM CHEM SOC, V118, P9352, DOI 10.1021/ja9533611; LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004; Loo J.A., 1988, RAPID COMMUN MASS SP, V2, P207; Lundblad R.L., 1991, CHEM REAGENTS PROTEI; Marshall AG, 1996, ACCOUNTS CHEM RES, V29, P307, DOI 10.1021/ar9501481; Marshall AG, 1997, J AM CHEM SOC, V119, P433, DOI 10.1021/ja9630046; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P329, DOI 10.1016/0076-6879(90)93424-J; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Miranker A, 1996, J AM CHEM SOC, V118, P7402, DOI 10.1021/ja9531236; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; MURATA K, 1982, ANN NY ACAD SCI, V378, P146, DOI 10.1111/j.1749-6632.1982.tb31193.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schnier PD, 1996, J AM CHEM SOC, V118, P7178, DOI 10.1021/ja9609157; Schnolzer M, 1996, ELECTROPHORESIS, V17, P945, DOI 10.1002/elps.1150170517; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P229, DOI 10.1016/1044-0305(95)00017-8; SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003; SILVERMAN PB, 1992, ORGANIC CHEM DRUG DE, P178; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; VALASKOVIC GA, 1995, ANAL CHEM, V67, P3802, DOI 10.1021/ac00116a030; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	41	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32215	32220		10.1074/jbc.272.51.32215	http://dx.doi.org/10.1074/jbc.272.51.32215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405424	hybrid			2022-12-27	WOS:000071108000043
J	Li, Y; Asahara, H; Patel, VS; Zhou, S; Linn, S				Li, Y; Asahara, H; Patel, VS; Zhou, S; Linn, S			Purification, cDNA cloning, and gene mapping of the small subunit of human DNA polymerase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; CATALYTIC SUBUNIT; REPAIR SYNTHESIS; HELA-CELLS; REPLICATION; DELTA; IDENTIFICATION; ALPHA; ALIGNMENT	HeLa DNA polymerase epsilon (pol epsilon), possibly involved in both DNA replication and DNA repair, consists of a catalytic subunit of 261 kDa and a tightly bound peptide with a relative molecular mass of 55 kDa. The cDNA of the 261-kDa polypeptide has been independently cloned, sequenced, and then overexpressed in insect cells to give a soluble, but catalytically unstable protein, suggesting that the small subunit of HeLa pol epsilon might be important for stability. HeLa pol epsilon has been isolated by immunoaffinity purification to obtain sequence information which enabled the cloning of a full-length human cDNA encoding the small subunit. The clone encoded nine proteolytic peptides obtained from the subunit. The 59,434-Da predicated polypeptide has 26% identity and 44% homology to the yeast pol epsilon 80-kDa subunit, DPB2, Using fluorescence in situ hybridization, the human pol epsilon p59 locus (DPE2) was assigned to chromosome 14q13-q21.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Barker Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030415] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM30415] Funding Source: Medline; PHS HHS [P30E08196] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aoyagi N, 1997, BIOCHEM BIOPH RES CO, V230, P297, DOI 10.1006/bbrc.1996.5945; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; CHUI G, 1995, THESIS U CALIF, P377; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENIKOFF S, 1995, GENE, V163, P17; HUANG PH, 1995, THESIS U CALIF, P16; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; KESTI T, 1993, J BIOL CHEM, V268, P10238; KESTI T, 1991, J BIOL CHEM, V266, P6336; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NIRANJANAKUMARI S, 1993, J BIOL CHEM, V268, P15557; NISHIDA C, 1988, J BIOL CHEM, V263, P501; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; SZPIRER J, 1994, GENOMICS, V20, P223, DOI 10.1006/geno.1994.1156; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	42	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32337	32344		10.1074/jbc.272.51.32337	http://dx.doi.org/10.1074/jbc.272.51.32337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405441	hybrid			2022-12-27	WOS:000071108000060
J	Liu, GM; Nellaiappan, K; Kagan, HM				Liu, GM; Nellaiappan, K; Kagan, HM			Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues - Implications for homocystinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN CROSS-LINKING; PROTON ABSTRACTION; CHEMICAL PATHOLOGY; RISK FACTOR; PLASMA; ATHEROSCLEROSIS; METABOLISM; DIAMINES; PROTEIN; CELLS	Homocysteine thiolactone, selenohomocysteine lactone, and homoserine lactone were found to be competitive, irreversible inhibitors of lysyl oxidase, with K-I values of 21 +/- 3 mu M, 8.3 +/- 2.2 mu M, and 420 +/- 56 mu M, respectively. The first order rate constants for inactivation (k(2)) of the enzyme varied over a much smaller range, ranging from 0.12 to 0.18 to 0.28 min(-1) for the Se-, thio-, and O-lactones, respectively. Mutually exclusive labeling of the enzyme by [1-C-14]beta-aminopropionitrile, [U-C-14]phenylhydrazine, or [S-35]homocysteine thiolactone was observed. These labeling results, together with the closely similar perturbations of the near UV-visible spectra of lysyl oxidase and of a model of its lysine tyrosylquinone cofactor by the thiolactone, indicate that the lactones likely derivatize and reduce the active site carbonyl cofactor. Substitution with deuterium at the alpha-carbon of the thiolactone caused a deuterium kinetic isotope effect on k(2) of 3.2 +/- 0.2, consistent with the involvement of rate-limiting alpha-proton abstraction during lactone-induced inactivation of the enzyme. The activities of plasma amine oxidase and diamine oxidase were only minimally reduced at concentrations of the sulfur or selenium lactones that fully inhibited lysyl oxidase. Thus, these lactones constitute a new category of mechanism-based inactivators selective for lysyl oxidase. Further, these results may relate to the development of connective tissue defects seen in homocystinuria.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kagan, HM (corresponding author), Boston Univ, Sch Med, Dept Biochem, 80 E Concord St, Boston, MA 02118 USA.				NIAMS NIH HHS [R37 AR 18880] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018880] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baernstein HD, 1934, J BIOL CHEM, V106, P451; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BENESCH R, 1956, J AM CHEM SOC, V78, P1597, DOI 10.1021/ja01589a025; BIRD TA, 1983, BIOCHEM J, V108, P1172; CALLERY PS, 1992, CHEM-BIOL INTERACT, V85, P15, DOI 10.1016/0009-2797(92)90049-Q; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; DAVIDSON VL, 1989, BIOCHEM J, V261, P107, DOI 10.1042/bj2610107; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; FUJIHARA H, 1984, J ORG CHEM, V49, P2819, DOI 10.1021/jo00189a037; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; GACHERU SN, 1988, J BIOL CHEM, V263, P16704; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P46056; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lubec B, 1996, BBA-MOL BASIS DIS, V1315, P159, DOI 10.1016/0925-4439(95)00119-0; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MCCULLY KS, 1994, ANN CLIN LAB SCI, V24, P27; MCCULLY KS, 1976, CANCER RES, V36, P3198; MCCULLY KS, 1989, RES COMMUN CHEM PATH, V59, P107; MENDENHALL W, 1975, INTRO PROBABILITY ST, P250; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; MUDD SH, 1989, RES COMMUN CHEM PATH, V63, P297; MYERS BA, 1985, BIOCHEM J, V229, P153, DOI 10.1042/bj2290153; NAGAN N, 1994, J BIOL CHEM, V269, P22366; NEUMANN R, 1975, J BIOL CHEM, V250, P6362; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P108; SHAH MA, 1993, J BIOL CHEM, V268, P11573; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TANG SS, 1984, J BIOL CHEM, V259, P975; TANG SS, 1989, CONNECT TISSUE RES, V19, P93, DOI 10.3109/03008208909016817; TRACKMAN PC, 1981, ANAL BIOCHEM, V113, P336, DOI 10.1016/0003-2697(81)90086-5; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UELAND PM, 1989, J LAB CLIN MED, V114, P473; VIDAL M, 1986, BIOCHIMIE, V68, P723, DOI 10.1016/S0300-9084(86)80166-3; WALSH C, 1979, ENZYMATIC REACTION M, P86; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P14520; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P8196; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477	49	110	118	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32370	32377		10.1074/jbc.272.51.32370	http://dx.doi.org/10.1074/jbc.272.51.32370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405445	hybrid			2022-12-27	WOS:000071108000064
J	Deng, L; Beigelman, L; MatulicAdamic, J; Karpeisky, A; Gershon, PD				Deng, L; Beigelman, L; MatulicAdamic, J; Karpeisky, A; Gershon, PD			Specific recognition of an rU(2)-N-15-rU motif by VP55, the vaccinia virus poly(A) polymerase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; POLYADENYLATION; NUCLEOTIDE; BINDING; TAIL	VP55, the vaccinia poly(A) polymerase catalytic subunit, interacts with oligonucleotide primers via two uridylate recognition sites (Deng, L., and Gershon, P. D. (1997) EMBO J. 16, 1103-1113), Here, we show that the cognate RNA sequence comprises a 5'-rU(2)-N-15-rU-3' motif (where N = any deoxyribo or ribonucleotide), embedded within oligonucleotide primers 29-30 nucleotides (nt), or greater, in length, Nine residues separate the 3'-most ribouridylate of the optimally positioned motif from the primer 3'-OH. A ribose sugar at the extreme 3'-terminal nucleotide of the primer is absolutely required for VP55's adenylyltransferase activity, but not for stable VP55-RNA interaction, A ribose at position -3 markedly stimulates both adenylyltransferase activity and stable binding. The use of uridine analogs indicated (i) those functional groups of the uracil base which contribute to stable VP55-primer interaction, and (ii) that VP55's ability to discriminate uracil from cytosine stems largely from the requirement for a protonated N3 nitrogen within the pyrimidine ring. The rU(2)-N-15-rU motif was identified within the uridylate-rich 3' end of a naturally occurring vaccinia mRNA, However, oligonucleotides whose only internal uridylates comprised the motif supported only a 3-5-nt processive burst of oligo(A) tail addition, as opposed to the similar to 30-35-nt burst observed with the naturally occurring 3' end.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, HOUSTON, TX 77030 USA; RIBOZYME PHARMACEUT INC, BOULDER, CO 80301 USA	Texas A&M University System				Karpeisky, Alexander/0000-0002-9226-8789	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM51953-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P895, DOI 10.1080/15257779508012497; Burgin AB, 1996, BIOCHEMISTRY-US, V35, P14090, DOI 10.1021/bi961264u; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; Li DN, 1997, EMBO J, V16, P1103, DOI 10.1093/emboj/16.5.1103; MatulicAdamic J, 1996, BIOORG MED CHEM LETT, V6, P373, DOI 10.1016/0960-894X(96)00030-3; MOSS B, 1975, J BIOL CHEM, V250, P4722; MURRAY JB, 1995, BIOCHEM J, V311, P487, DOI 10.1042/bj3110487; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; STROBEL SA, 1994, BIOCHEMISTRY-US, V33, P13824, DOI 10.1021/bi00250a037; SUCK D, 1972, J AM CHEM SOC, V94, P6520, DOI 10.1021/ja00773a041; THOMSON JG, 1995, BIOTECHNIQUES, V19, P416; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	19	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31542	31552		10.1074/jbc.272.50.31542	http://dx.doi.org/10.1074/jbc.272.50.31542			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395491	hybrid			2022-12-27	WOS:A1997YL41900050
J	Fitzsimmons, TJ; McRoberts, JA; Tachiki, KH; Pandol, SJ				Fitzsimmons, TJ; McRoberts, JA; Tachiki, KH; Pandol, SJ			Acyl-coenzyme A causes Ca2+ release in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; COA ESTERS; RYANODINE RECEPTORS; EXOCRINE PANCREAS; CALCIUM; OSCILLATIONS; POOL; ACTIVATION; MECHANISM	The regulation of cytosolic Ca2+ is important for a variety of cell functions. One non-inositol 1,4,5-trisphosphate (IP3) compound that may regulate Ca2+ is palmitoyl-coenzyme A (CoA), a fatty acid-CoA that is reported to cause Ca2+ release from intracellular stores of oocytes, myocytes, and hepatocytes. To study the role of palmitoyl-CoA in the pancreatic acinar cell, rat pancreatic acini were isolated by collagenase digestion, permeablized with streptolysin O, and the release of Ca2+ from internal stores was measured with fura-2. Palmitoyl-CoA released Ca2+ from internal stores (EC50 = 14 mu M). The palmitoyl-CoA-sensitive pool was distinct from, and overlapping with the IP3-sensitive Ca2+ pool. The effects of submaximal doses of IP3 or cyclic ADP-ribose plus palmitoyl-CoA were additive. Fatty acid-CoA derivatives with carbon chain lengths of 16-18 were the most potent and efficacious. Ryanodine and caffeine or elevated resting [Ca2+] sensitized the Ca2+ pool to the actions of palmitoyl-CoA. Fatty acid-CoA levels in pancreatic acini were measured by extraction with 2-propanol/acetonitrile, followed by separation and quantification using reverse phase high performance liquid chromatography, and were found to be 10.17 +/- 0.93 nmol/mg protein. These data suggest the presence of an IP3-insensitive palmitoyl-CoA-sensitive Ca2+ store in pancreatic acinar cells and suggest that palmitoyl-CoA may be needed for Ca2+-induced Ca2+ release.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Fitzsimmons, TJ (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,11301 WILSHIRE BLVD 151,BLDG 258,RM 340,LOS ANGELES,CA 90073, USA.				NIDDK NIH HHS [DK 33010] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033010] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BINDOLI A, 1983, INT J BIOCHEM, V15, P1219, DOI 10.1016/0020-711X(83)90210-0; Chini EN, 1996, AM J PHYSIOL-CELL PH, V270, pC530, DOI 10.1152/ajpcell.1996.270.2.C530; CONNELLY T, 1994, FEBS LETT, V352, P285, DOI 10.1016/0014-5793(94)00969-4; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; FULCERI R, 1994, CELL CALCIUM, V15, P109, DOI 10.1016/0143-4160(94)90049-3; Fulceri R, 1997, BIOCHEM J, V325, P423, DOI 10.1042/bj3250423; FULCERI R, 1993, BIOCHEM J, V295, P663, DOI 10.1042/bj2950663; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOKINNEAVERSON M, 1974, BIOCHEM BIOPH RES CO, V58, P763, DOI 10.1016/S0006-291X(74)80483-3; KAO JPY, 1988, BIOPHYS J, V53, P635, DOI 10.1016/S0006-3495(88)83142-4; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KOLMER M, 1995, BIOCHEM J, V306, P327, DOI 10.1042/bj3060327; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; RICH GT, 1995, BIOCHEM J, V306, P703, DOI 10.1042/bj3060703; RYSSIKORA KE, 1994, J BIOL CHEM, V269, P31607; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737	28	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31435	31440		10.1074/jbc.272.50.31435	http://dx.doi.org/10.1074/jbc.272.50.31435			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395476	hybrid			2022-12-27	WOS:A1997YL41900035
J	Luttrell, LM; Daaka, Y; DellaRocca, GJ; Lefkowitz, RJ				Luttrell, LM; Daaka, Y; DellaRocca, GJ; Lefkowitz, RJ			G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts - Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; FOCAL ADHESION KINASE; MAP KINASE; ANGIOTENSIN-II; SIGNAL-TRANSDUCTION; EGF RECEPTOR; SRC; SEQUESTRATION; PP60(C-SRC)	The Ras-dependent activation of Erk kinases by G protein-coupled receptors (GPCRs) is thought to involve tyrosine phosphorylation of docking proteins that serve as scaffolds for the plasma membrane recruitment of Ras guanine nucleotide exchange factors, such as the Grb2-mSos complex. We have investigated the role of two GPCR-regulated tyrosine phosphoproteins, p125(FAK) (FAK) and Shc, in the Ras-dependent activation of Erk kinases by endogenously expressed GPCRs in Rat 1a fibroblasts, Several lines of evidence suggest that tyrosine phosphorylation of FAK and Shc are independently regulated. The GPCRs for lysophosphatidic acid (LPA), thrombin, and bombesin mediate equivalent increases in FAK tyrosine phosphorylation and FAK-Grb2 association, In contrast, only LPA and thrombin receptors significantly stimulate Shc tyrosine phosphorylation and Shc-Grb2 complex formation. Tyrosine phosphorylation of FAK is pertussis toxin-insensitive, can be mimicked by calcium ionophore, and is inhibited by treatment with cytochalasin D, which depolymerizes the actin cytoskeleton, In contrast, tyrosine phosphorylation of Shc is inhibited by pertussis toxin treatment, is not induced by calcium ionophore, and is insensitive to cytochalasin D, In each case, the rapid stimulation of Erk 1/2 correlates with tyrosine phosphorylation of Shc but not of FAK, The dissociation of FAK-Grb2 complex formation from receptor-mediated activation of Erk 1/2 indicates that recruitment of Grb2-mSos to the plasma membrane is not sufficient to mediate rapid Erk activation, Using four mechanistically distinct inhibitors of clathrin-mediated endocytosis, concanavalin A, hypertonic medium, depletion of intracellular potassium, and monodansylcadaverine, we find that GPCR-mediated Erk 1/2 activation is also endocytosis-dependent. Thus, we propose that an additional step involving vesicle-mediated endocytosis is required for the rapid, Ras-dependent activation of Erk kinases in fibroblasts.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021; Della Rocca, Gregory/AAM-5281-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EGUCHI S, 1996, J BIOL CHEM, V271, P1169; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1995, CANCER SURV, V24, P81; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; YU SS, 1993, J BIOL CHEM, V268, P337	51	165	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31648	31656		10.1074/jbc.272.50.31648	http://dx.doi.org/10.1074/jbc.272.50.31648			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395506	hybrid			2022-12-27	WOS:A1997YL41900065
J	Rybina, IV; Liu, H; Gor, Y; Feinmark, SJ				Rybina, IV; Liu, H; Gor, Y; Feinmark, SJ			Regulation of leukotriene A(4) hydrolase activity in endothelial cells by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-LUNG; SULFIDOPEPTIDE-LEUKOTRIENES; EICOSANOID SYNTHESIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; DE-GRANULATION; GUINEA-PIG; BIOSYNTHESIS; ACID	Endothelial cells contain leukotriene (LT) A(4) hydrolase (LTA-H) as detected by Northern and Western blotting, but several studies have been unable to detect the activity of this enzyme. Since LTA-H could play a hey role in determining what biologically active lipids are generated by activated endothelium during the inflammatory process, we studied possible mechanisms by which this enzyme may be regulated, We find that LTA-H is phosphorylated under basal conditions in human endothelial cells and in this state does not exhibit epoxide hydrolase activity (i.e. conversion of LTA(4) to LTB4). LTA-H purified from endothelial cells is efficiently dephosphorylated by incubation with protein phosphatase-1 in the presence of an LTA-H peptide substrate and not at all in the absence of substrate. Under conditions that lead to dephosphorylation, protein phosphatase-1 activates the epoxide hydrolase activity of LTA-H. Using peptide mapping and site-directed mutagenesis, we have identified serine 415 as the site of phosphorylation of LTA-H by a kinase found in endothelial cell cytosol. In parallel, we have studied a human lung carcinoma cell line that expresses active LTA-H. Although these cells have cytosolic kinases that phosphorylate recombinant LTA-H, they do not target serine 415 and thus do not inhibit LTA-H activity. We believe that LTA-H is regulated in intact cells by a kinase/phosphatase cycle and further that the kinase in endothelial cells specifically recognizes and phosphorylates a regulatory site in the LTA-H.	COLUMBIA UNIV, DEPT PHARMACOL, COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University								BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN KA, 1993, J IMMUNOL METHODS, V163, P13, DOI 10.1016/0022-1759(93)90234-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLAESSON HE, 1984, BIOCHIM BIOPHYS ACTA, V804, P52, DOI 10.1016/0167-4889(84)90098-3; CUNNINGHAM FM, 1980, J PHARM PHARMACOL, V32, P377, DOI 10.1111/j.2042-7158.1980.tb12946.x; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1990, METHOD ENZYMOL, V187, P559; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FEINMARK SJ, 1992, AM REV RESPIR DIS, V146, pS51, DOI 10.1164/ajrccm/146.5_Pt_2.S51; FEINMARK SJ, 1981, FEBS LETT, V136, P141, DOI 10.1016/0014-5793(81)81233-1; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FITZPATRICK F, 1984, J BIOL CHEM, V259, P1403; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FU JY, 1989, BIOCHIM BIOPHYS ACTA, V1006, P121; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GRIMMINGER F, 1990, J IMMUNOL, V144, P1866; GRIMMINGER F, 1990, J EXP MED, V172, P1115, DOI 10.1084/jem.172.4.1115; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; IBE BO, 1988, BIOCHIM BIOPHYS ACTA, V960, P309, DOI 10.1016/0005-2760(88)90039-2; IZUMI T, 1986, BIOCHEM BIOPH RES CO, V135, P139, DOI 10.1016/0006-291X(86)90953-8; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MACLOUF J, 1989, BLOOD, V74, P703; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MANCINI JA, 1995, EUR J BIOCHEM, V231, P65, DOI 10.1111/j.1432-1033.1995.tb20671.x; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEDINA JF, 1988, BIOCHIM BIOPHYS ACTA, V961, P203, DOI 10.1016/0005-2760(88)90115-4; MINAMI M, 1988, FEBS LETT, V229, P279, DOI 10.1016/0014-5793(88)81140-2; MINAMI M, 1987, J BIOL CHEM, V262, P13873; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; OFLAHERTY JT, 1981, BIOCHEM BIOPH RES CO, V101, P1290, DOI 10.1016/0006-291X(81)91587-4; OHISHI N, 1990, J BIOL CHEM, V265, P7520; OHISHI N, 1987, J BIOL CHEM, V262, P10200; OHISHI N, 1990, METHOD ENZYMOL, V187, P286; RADMARK O, 1984, J BIOL CHEM, V259, P2339; Sala A, 1996, FEBS LETT, V388, P94, DOI 10.1016/0014-5793(96)00539-X; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SALA A, 1993, BRIT J PHARMACOL, V110, P1206, DOI 10.1111/j.1476-5381.1993.tb13943.x; Sala A, 1996, BLOOD, V87, P1824; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	48	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31865	31871		10.1074/jbc.272.50.31865	http://dx.doi.org/10.1074/jbc.272.50.31865			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395533	hybrid			2022-12-27	WOS:A1997YL41900092
J	Zhang, WY; Gaynor, PM; Kruth, HS				Zhang, WY; Gaynor, PM; Kruth, HS			Aggregated low density lipoprotein induces and enters surface-connected compartments of human monocyte-macrophages - Uptake occurs independently of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; FOAM-CELL-FORMATION; CULTURED-CELLS; CHOLESTEROL; LDL; PHAGOCYTOSIS; METABOLISM; OXIDATION; MECHANISM; DEGRADATION	Aggregation of low density lipoprotein (LDL) stimulates its uptake by macrophages. We have now shown by electron microscopic and chemical experiments that aggregated LDL (produced by vortexing (VxLDL) or treatment with phospholipase C) induced and became sequestered in large amounts within surface-connected compartments (SCC) of human monocyte-derived macrophages. This occurred through a process different from phagocytosis, Formation of SCC and accumulation of aggregated LDL in SCC are cell-mediated processes that were temperature-dependent (10 x greater cell as association at 37 degrees C than at 4 degrees C) and blocked by cytochalasin D but not by nocodazole, Because of the surface connections of SCC, trypsin could release aggregated EDL from SCC, Degradation of I-125-VxLDL through the SCC pathway showed delayed and a lower rate of degradation (10-55%) compared with nonaggregated I-125-acetylated LDL that did not enter SCC. However, similar to I-125-acetylated LDL degradation, I-125-VxLDL degradation occurred through a chloroquine-sensitive pathway. Uptake of VxLDL into SCC was not mediated by the LDL receptor, Methylation of LDL prevents its binding to the LDL receptor, However, methylated LDL still entered SCC after it was aggregated by vortexing, On the other hand, degradation of I-125-VxLDL was substantially decreased by methylation of LDL and by cholesterol enrichment of macrophages, which decreases macrophage LDL receptor expression, The results suggest that whereas uptake of aggregated LDL into SCC occurs independently of the LDL receptor, movement of aggregated LDL from SCC to lysosomes may depend in part on LDL receptor function. Sequestration into SCC is a novel endocytosis pathway for uptake of aggregated LDL that allows the macrophage to store large amounts of this lipoprotein before it is further processed.	NHLBI,SECT EXPT ATHEROSCLEROSIS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; GAMBLE W, 1978, J LIPID RES, V19, P1068; GIANTURCO SH, 1994, J LIPID RES, V35, P1674; GIANTURCO SH, 1995, CIRCULATION S1, V92, P690; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUYTON JR, 1991, J LIPID RES, V32, P953; HEINECKE JW, 1991, ARTERIOSCLER THROMB, V11, P1643, DOI 10.1161/01.ATV.11.6.1643; HOFF HF, 1993, J LIPID RES, V34, P1919; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; HOFF HF, 1991, LAB INVEST, V64, P254; KAWABE Y, 1994, ARCH BIOCHEM BIOPHYS, V310, P489, DOI 10.1006/abbi.1994.1197; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MORGANELLI PM, 1995, J LIPID RES, V36, P714; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NARUSZEWICZ M, 1994, NUTR METAB CARDIOVAS, V4, P70; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; SHECHTER I, 1981, J LIPID RES, V22, P63; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TERTOV VV, 1992, CIRC RES, V71, P218, DOI 10.1161/01.RES.71.1.218; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	34	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31700	31706		10.1074/jbc.272.50.31700	http://dx.doi.org/10.1074/jbc.272.50.31700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395512	hybrid			2022-12-27	WOS:A1997YL41900071
J	Ostergaard, J; Persiau, G; Davey, MW; Bauw, G; VanMontagu, M				Ostergaard, J; Persiau, G; Davey, MW; Bauw, G; VanMontagu, M			Isolation of a cDNA coding for L-galactono-gamma-lactone dehydrogenase, an enzyme involved in the biosynthesis of ascorbic acid in plants - Purification, characterization, cDNA cloning, and expression in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; TARGETING PEPTIDES; ESCHERICHIA-COLI; SPINACH LEAVES; L-SORBOSONE; KEY ENZYME; MITOCHONDRIAL; OXIDASE; FLAVIN	L-Galactono-gamma-lactone dehydrogenase (EC 1.3.2.3; GLDase), an enzyme that catalyzes the final step in the biosynthesis of L-ascorbic acid was purified 1693-fold from a mitochondrial extract of cauliflower (Brassica oleracea, var. botrytis) to apparent homogeneity with an overall yield of 1.1%, The purification procedure consisted of anion exchange, hydrophobic interaction, gel filtration, and fast protein liquid chromatography, The enzyme had a molecular mass of 56 kDa estimated by gel filtration chromatography and SDS-polyacrylamide gel electrophoresis and showed a pH optimum for activity between pH 8.0 and 8.5, with an apparent K-m of 3.3 mM for L-galactono-gamma-lactone. Based on partial peptide sequence information, polymerase chain reaction fragments were isolated and used to screen a cauliflower cDNA library from which a cDNA encoding GLDase was isolated, The deduced mature GLDase contained 509 amino acid residues with a predicted molecular mass of 57,837 Da, Expression of the cDNA in yeast produced a biologically active protein displaying GLDase activity. Furthermore, we identified a substrate for the enzyme in cauliflower extract, which co-eluted with L-galactono-gamma-lactone by high-performance liquid chromatography, suggesting that this compound is a naturally occurring precursor of L-ascorbic acid biosynthesis in vivo.	STATE UNIV GHENT VIB, GENET LAB, DEPT GENET, B-9000 GHENT, BELGIUM	Flanders Institute for Biotechnology (VIB); Ghent University				Davey, Mark/0000-0002-4633-0991				ARRIGONI O, 1975, NATURE, V256, P513, DOI 10.1038/256513a0; ARRIGONI O, 1996, J BIOL RES B SOC IT, V142, P37; AZZI A, 1981, MEMBRANE PROTEINS LA; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUHMULLER M, 1973, EUR J BIOCHEM, V37, P256, DOI 10.1111/j.1432-1033.1973.tb02983.x; BURNS JJ, 1957, NATURE, V180, P533; CHATTERJEE IB, 1973, SCIENCE, V182, P1271, DOI 10.1126/science.182.4118.1271; CHAUDHURI CR, 1969, SCIENCE, V164, P435, DOI 10.1126/science.164.3878.435; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; COOK RJ, 1985, J BIOL CHEM, V260, P2998; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; EVIDENTE A, 1983, PHYTOCHEMISTRY, V22, P2193, DOI 10.1016/S0031-9422(00)80145-4; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; Goormachtig S, 1995, MOL PLANT MICROBE IN, V8, P816, DOI 10.1094/MPMI-8-0816; HEICK HMC, 1972, CAN J MICROBIOL, V18, P597, DOI 10.1139/m72-094; HELLERMAN L, 1946, J BIOL CHEM, V163, P553; ISHERWOOD FA, 1954, BIOCHEM J, V56, P1; KENNEY WC, 1972, J BIOL CHEM, V247, P4510; KIUCHI K, 1982, BIOCHEMISTRY-US, V21, P5076, DOI 10.1021/bi00263a035; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEUNG CT, 1985, PLANT SCI, V38, P65, DOI 10.1016/0168-9452(85)90081-0; LODI T, 1993, MOL GEN GENET, V238, P315, DOI 10.1007/BF00291989; Loewus F. A., 1988, The biochemistry of plants. A comprehensive treatise. Volume 14. Carbohydrates., P85; LOEWUS MW, 1990, PLANT PHYSIOL, V94, P1492, DOI 10.1104/pp.94.3.1492; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MAPSON LW, 1954, BIOCHEM J, V56, P21, DOI 10.1042/bj0560021; MAPSON LW, 1958, BIOCHEM J, V68, P395, DOI 10.1042/bj0680395; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MINET M, 1992, PLANT J, V2, P417; MINNESITA T, 1956, A REP SHIONOGI RES L, V6, P131; MUTSUDA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1983, DOI 10.1271/bbb.59.1983; NICK JA, 1986, PLANT SCI, V46, P181, DOI 10.1016/0168-9452(86)90190-1; NISHIKIMI M, 1976, ARCH BIOCHEM BIOPHYS, V175, P427, DOI 10.1016/0003-9861(76)90530-0; OBA K, 1995, J BIOCHEM, V117, P120, DOI 10.1093/oxfordjournals.jbchem.a124697; OBA K, 1994, PLANT CELL PHYSIOL, V35, P473; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; SAITO K, 1990, PLANT PHYSIOL, V94, P1496, DOI 10.1104/pp.94.3.1496; SINGER TP, 1950, ARCH BIOCHEM, V27, P348; TAKAHASHI T, 1976, AGR BIOL CHEM TOKYO, V40, P121, DOI 10.1080/00021369.1976.10861999; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; Wright CI, 1944, J BIOL CHEM, V155, P315	48	107	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30009	30016		10.1074/jbc.272.48.30009	http://dx.doi.org/10.1074/jbc.272.48.30009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374475	hybrid			2022-12-27	WOS:A1997YH61300007
J	Sica, A; Dorman, L; Viggiano, V; Cippitelli, M; Ghosh, P; Rice, N; Young, HA				Sica, A; Dorman, L; Viggiano, V; Cippitelli, M; Ghosh, P; Rice, N; Young, HA			Interaction of NF-kappa B and NFAT with the interferon-gamma promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; HUMAN INTERLEUKIN-4 GENE; DNA-BINDING SUBUNIT; IFN-GAMMA; NUCLEAR FACTOR; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; IMMUNE INTERFERON; MESSENGER-RNA; LYMPHOCYTE-T	Interferon-gamma (IFN-gamma) is a pleiotropic lymphokine whose production is restricted to activated T cells and NK cells. Along with other cytokines, IFN-gamma gene expression is inhibited by the immunosuppressant cyclosporin A. We have previously identified an intronic enhancer region (C3) of the IFN-gamma gene that binds the NF-kappa B protein c-Rel and that shows partial DNA sequence homology with the cyclosporin A-sensitive NFAT binding site and the 3'-half of the NF-kappa B consensus site. Sequence analysis of the IFN-gamma promoter revealed the presence of two additional C3-related elements (C3-1P and C3-3P). In addition, an NF-kappa B site (IFN-gamma kappa B) was identified within the promoter region. Based on this observation, we have analyzed the potential role of NF-kappa B and NFAT family members in regulating IFN-gamma transcription. Electrophoretic mobility shift assay analysis demonstrated that after T cell activation, the p50 and p65 NF-kappa B subunits bind specifically to the newly identified IFN-gamma kappa B and C3-related sites. In addition, we identified the NFAT proteins as a component of the inducible complexes that bind to the C3-3P site. Site-directed mutagenesis and transfection studies demonstrate that calcineurin-inducible transcriptional factors enhance the transcriptional activity of the IFN-gamma promoter through the cyclosporin-sensitive C3-3P site, whereas NF-kappa B proteins functionally interact with the C3-related sites. In addition, when located downstream to the beta-galactosidase gene driven by the IFN-gamma promoter, the intronic C3 site worked in concert with both the IFN-gamma kappa B and the C3-3P site to enhance gene transcription. These results demonstrate that the coordinate activities of NFAT and NF-kappa B proteins are involved in the molecular mechanisms controlling IFN-gamma gene transcription.	NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,EXPT IMMUNOL LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Sica, A (corresponding author), IST RIC FARMACOL MARIO NEGRI,DEPT IMMUNOL & CELL BIOL,VIA ERITREA 62,MILAN,ITALY.		Sica, Antonio/AAB-9546-2020; Cippitelli, Marco/AAF-4857-2021; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Young, Howard/0000-0002-3118-5111				ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Barbulescu K, 1997, EUR J IMMUNOL, V27, P1098, DOI 10.1002/eji.1830270509; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; Campbell PM, 1996, TRANSPLANTATION, V61, P933, DOI 10.1097/00007890-199603270-00016; CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DIMARZIO P, 1994, J EXP MED, V179, P1731, DOI 10.1084/jem.179.5.1731; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FOX HS, 1991, J IMMUNOL, V146, P4362; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUPTA SL, 1990, INT J CELL CLONING, V8, P92, DOI 10.1002/stem.5530080709; Howie SEM, 1996, J INVEST DERMATOL, V106, P1218, DOI 10.1111/1523-1747.ep12348507; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; Kanno T, 1996, J IMMUNOL, V157, P5277; KASAHARA T, 1983, J IMMUNOL, V130, P1784; KEVIN WB, 1993, P NATL ACAD SCI USA, V90, P9707; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAMKHIOUED B, 1996, ANN NY ACAD SCI, V797, P203; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYAKH L, 1977, MOL CELL BIOL, V17, P2475; MATSUDA I, 1994, BIOCHEM BIOPH RES CO, V199, P439, DOI 10.1006/bbrc.1994.1248; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; Webber S, 1997, INT ARCH ALLERGY IMM, V113, P275, DOI 10.1159/000237571; WILLIAMS CMM, 1995, IMMUNOLOGY, V86, P244; WILLIAMS JG, 1993, J SURG RES, V54, P79, DOI 10.1006/jsre.1993.1013; XU Z, 1996, SCIENCE, V273, P794; YE JP, 1995, J LEUKOCYTE BIOL, V58, P225, DOI 10.1002/jlb.58.2.225; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YOUNG HA, 1987, J IMMUNOL, V139, P724; YOUNG LLD, 1996, CELL IMMUNOL, V168, P133	55	361	369	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30412	30420		10.1074/jbc.272.48.30412	http://dx.doi.org/10.1074/jbc.272.48.30412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374532	hybrid			2022-12-27	WOS:A1997YH61300064
J	Wrenger, S; Hoffmann, T; Faust, J; MrestaniKlaus, C; Brandt, W; Neubert, K; Kraft, M; Olek, S; Frank, R; Ansorge, S; Reinhold, D				Wrenger, S; Hoffmann, T; Faust, J; MrestaniKlaus, C; Brandt, W; Neubert, K; Kraft, M; Olek, S; Frank, R; Ansorge, S; Reinhold, D			The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; HUMAN LYMPHOCYTE-T; VIRUS TYPE-III; CORRELATION SPECTROSCOPY; COHERENCE TRANSFER; ROTATING FRAME; PROLIFERATION; PROTEIN; INHIBITION; CD26	Evidence exists that the human immunodeficiency virus-1 (HIV-1) transactivator Tat occurs extracellularly and is involved in the immunosuppression of non-HIV-1-infected T cells of acquired immunodeficiency syndrome (AIDS) patients, The mechanism of this immunosuppressive activity of Tat has been controversially discussed, Interestingly, Tat binds to the T cell activation marker CD26, which has been shown to play a key role in the regulation of growth of lymphocytes and to inhibit its dipeptidyl peptidase IV (DpIV) activity, Here we show that the N-terminal nonapeptide MDPVDPNIE of Tat is a competitive inhibitor of DP TV and suppresses DNA synthesis of tetanus toxoid-stimulated peripheral blood mononuclear cells, Amino acid exchanges at positions 5 and 6 strongly weaken these effects. H-1 nuclear magnetic resonance and molecular dynamics simulations of Tat(1-9), I-5-Tat(1-9), and L-6-Tat(1-9) suggest a similar backbone conformation for Tat(1-9) and L-6-Tat(1-9). The solution conformation of I-5-Tat(1-9) considerably differs from the other two. However, Tat(1-9) fits into our previously proposed active site model of DP TV in contrast to I-5-Tat(1-9) and L-6-Tat(1-9), Conformational alterations with regard to the parent peptide and spatial hindrances between these both compounds and DP TV can explain the loss of inhibitory activity. Our data suggest that the N-terminal residues of HIV-1 Tat do interact directly with the active site of DPIV and that DP TV does mediate Tat's immunosuppressive effects.	UNIV MAGDEBURG,INST EXPT INTERNAL MED,CTR INTERNAL MED,D-39120 MAGDEBURG,GERMANY; UNIV HALLE WITTENBERG,INST BIOCHEM,DEPT BIOCHEM & BIOTECHNOL,D-06120 HALLE,GERMANY; UNIV HEIDELBERG,CTR MOL BIOL,D-69120 HEIDELBERG,GERMANY	Otto von Guericke University; Martin Luther University Halle Wittenberg; Ruprecht Karls University Heidelberg				Wrenger, Sabine/0000-0002-9733-6162				AUE WP, 1976, J CHEM PHYS, V64, P229; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDT W, 1995, INT J PEPT PROT RES, V46, P494; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GASTEIGER J, 1985, ANGEW CHEM, V97, P699; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; KRAFT M, 1994, PEPTIDES 1994, P349; LANE C, 1985, NEW ENGL J MED, V131, P79; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MEYAARD L, 1992, EUR J IMMUNOL, V22, P2729, DOI 10.1002/eji.1830221038; MULLER L, 1979, MOL PHYS, V38, P963, DOI 10.1080/00268977900102161; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; Reinhold D, 1996, IMMUNOBIOLOGY, V195, P119, DOI 10.1016/S0171-2985(96)80010-6; REINHOLD D, 1994, IMMUNOBIOLOGY, V192, P121, DOI 10.1016/S0171-2985(11)80412-2; Schmitz T, 1996, J CLIN INVEST, V97, P1545, DOI 10.1172/JCI118577; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SCHON E, 1989, SCAND J IMMUNOL, V29, P127, DOI 10.1111/j.1365-3083.1989.tb01108.x; SCHON E, 1991, BIOL CHEM H-S, V372, P305, DOI 10.1515/bchm3.1991.372.1.305; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wrenger S, 1996, FEBS LETT, V383, P145, DOI 10.1016/0014-5793(96)00221-9	35	60	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30283	30288		10.1074/jbc.272.48.30283	http://dx.doi.org/10.1074/jbc.272.48.30283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374514	hybrid			2022-12-27	WOS:A1997YH61300046
J	Ezura, Y; Tournay, O; Nifuji, A; Noda, M				Ezura, Y; Tournay, O; Nifuji, A; Noda, M			Identification of a novel suppressive vitamin D response sequence in the 5'-flanking region of the murine Id1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORAMPHENICOL-ACETYL-TRANSFERASE; RETINOID-X-RECEPTOR; LOOP-HELIX PROTEIN; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSCRIPTIONAL REPRESSION; HORMONE-RECEPTOR; 24-HYDROXYLASE GENE; NEGATIVE REGULATION; DNA-SEQUENCES; KINASE-C	Vitamin D promotes differentiation of cells either by simply enhancing phenotypic gene expression and/or by suppressing expression of inhibitors of differentiation. previously, we reported that expression of a gene encoding Idl, a negative type helix-loop-helix transcription factor, was transcriptionally suppressed by 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) (1). To identify the sequence required for the negative regulation by 1,25(OH)(2)D-3, a 1,5-kilobase 5'-flanking region of murine Idl gene was examined by transiently transfecting luciferase reporter constructs into ROS17/2.8 osteoblastic cells. The transcriptional activity of this construct was repressed by 10(-8) hz 1,25(OH)(3)D-3. Deletion analysis revealed that a 57-base pair (bp) upstream response sequence (URS) (-1146/-1090) was required for the suppression by 1,25(OH)(2)D-3. This sequence conferred negative responsiveness to 1,25(OH)(2)D-3 to a heterologous SV40 promoter. The 57-bp URS contained not only Egr-1 consensus sequence (2) but also four direct repeats of a heptamer sequence (C/A)CAGCCC. Electrophoresis mobility shift assay revealed that the 57-bp URS formed specific nuclear protein-DNA complexes, which were neither competed by previously known positive and negative vitamin D response elements nor supershifted by anti-vitamin D receptor antibody, suggesting the absence of vitamin D receptor in these complexes. These results indicate the involvement of the novel 57-bp sequence in the vitamin D suppression of Idl gene transcription.	TOKYO MED & DENT UNIV, MED RES INST, DEPT MOL PHARMACOL, TOKYO 101, JAPAN; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	Tokyo Medical & Dental University (TMDU); Memorial Sloan Kettering Cancer Center			Nifuji, Akira/AAX-7907-2021; Ezura, Yoichi/L-9485-2016	Nifuji, Akira/0000-0002-8182-4380; 				ALROY I, 1995, MOL CELL BIOL, V15, P5789; Ausubel F.M., 1987, CURRENT PROTOCOLS MO, P241; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BERTHOLD A, 1990, BIOMED BIOCHIM ACTA, V49, P1243; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARR FE, 1994, J BIOL CHEM, V269, P4175; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HAUSSLER MR, 1995, BONE, V17, pS33, DOI 10.1016/8756-3282(95)00205-R; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P1533, DOI 10.1210/me.9.11.1533; Sakoda K, 1996, BIOCHEM BIOPH RES CO, V219, P31, DOI 10.1006/bbrc.1996.0176; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wang DS, 1996, J BONE MINER RES, V11, P472; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	51	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29865	29872		10.1074/jbc.272.47.29865	http://dx.doi.org/10.1074/jbc.272.47.29865			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368060	hybrid			2022-12-27	WOS:A1997YG64700070
J	Newberry, EP; Boudreaux, JM; Towler, DA				Newberry, EP; Boudreaux, JM; Towler, DA			Stimulus-selective inhibition of rat osteocalcin promoter induction and protein-DNA interactions by the homeodomain repressor Msx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT MICE; GENE; GROWTH; BONE; TRANSCRIPTION; ELEMENT; CALCIFICATION; EXPRESSION; RECEPTORS; MUTATION	Osteocalcin (OC) is a matrix calcium-binding protein expressed in osteoblasts and odontoblasts undergoing mineralization. OC expression is up-regulated in part by signals initiated by basic fibroblast growth factor (FGF2), cyclic AMP or forskolin (FSK), and calcitriol via defined elements and DNA-protein interactions in the OC promoter, We identified the OC gene as a target for transcriptional suppression by Msx2, a homeodomain transcription factor that controls ossification in the developing skull, in this study, we examine the effects of Msx2 expression on OC promoter activation (luciferase reporter) by FGF2/FSK and calcitriol in MC3T3-E1 osteoblasts, Expression of Msx2 decreases basal activity of the 1-kilobase (-1050 to +32) rat OC promoter by 80%; however, the promoter is still inducible 3-fold by calcitriol, By contrast, OC promoter induction by FGF2/FSK is completely abrogated by Msx2, Because intrinsic Msx2 DNA binding activity is not required for the Msx2 suppressor function, we assessed whether Msx2 represses OC activation by regulating DNA-protein interactions at the FGF2 response element (OCFRE) and compared these interactions with those occurring at the calcitriol response element (VDRE), Treatment of MC3T3-E1 cells with FGF2/FSK or calcitriol up-regulates specific DNA-protein interactions at the OCFRE or VDRE, respectively, as detected by gel shift assay, Preincubation of crude nuclear extracts with recombinant glutathione S-transferase (GST)-Msx2 dose-dependently inhibits OCFRE DNA binding activity, whereas GST has no effect, Msx2 itself does not bind the OCFRE. Residues 132-148 required for Msx2 core suppressor function in transfection assays are also required to inhibit OCFRE DNA binding activity, By contrast, GST-Msx2 has no effect on calcitriol-regulated DNA-protein interactions at the VDRE, Using gel shift as an assay, the OCFRE DNA-binding protein OCFREB was purified to about 50% homogeneity from MG63 osteosarcoma cells, Recombinant Msx2 inhibits purified OCFREB DNA binding activity, whereas the Msx2 variant lacking residues 132-148 is inactive, Thus, Msx2 abrogates up-regulation of the OC promoter by FGF2/FSK in part by inhibiting OCFREB binding to the OCFRE.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV METAB & BONE & MINERAL DIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Newberry, EP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV ENDOCRINOL,BOX 8103,660 S EUCLID,ST LOUIS,MO 63110, USA.		Boudreaux, Jeanne/AAU-8580-2020	Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731, T32AR007033] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07033, AR43731] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149; DEMAY MB, 1992, MOL ENDOCRINOL, V6, P557, DOI 10.1210/me.6.4.557; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODIG M, 1996, J BONE MINER RES S1, V11, pS260; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy Patricia, 1996, P183; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hoffmann HM, 1996, J CELL BIOCHEM, V61, P310, DOI 10.1002/(SICI)1097-4644(19960501)61:2<310::AID-JCB14>3.0.CO;2-P; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Marks Sandy C. Jr., 1996, P3; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Stein Gary S., 1996, P69; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Towler Dwight A., 1996, P1173; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	36	42	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29607	29613		10.1074/jbc.272.47.29607	http://dx.doi.org/10.1074/jbc.272.47.29607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368026	hybrid			2022-12-27	WOS:A1997YG64700036
J	Paz, K; Hemi, R; LeRoith, D; Karasik, A; Elhanany, E; Kanety, H; Zick, Y				Paz, K; Hemi, R; LeRoith, D; Karasik, A; Elhanany, E; Kanety, H; Zick, Y			Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; P55 TNF-RECEPTOR; CELL-DEATH; KINASE-ACTIVITY; AMINO-ACIDS; SUBSTRATE-1; PROTEIN; SPHINGOMYELINASE; RESISTANCE	Tumor necrosis factor alpha (TNF alpha) or chronic hyperinsulinemia that induce insulin resistance trigger increased Ser/Thr phosphorylation of the insulin receptor (Hi) and of its major insulin receptor substrates, IRS-1 and IRS-2. To unravel the molecular basis for this uncoupling in insulin signaling, we undertook to study the interaction of Ser/Thr-phosphorylated IRS-1 and IRS-2 with the insulin receptor. We could demonstrate that, similar to IRS-1, IRS-2 also interacts with the juxtamembrane (JM) domain (amino acids 943-984) but not with the carboxyl-terminal region (amino acids 1245-1331) of IR expressed in bacteria as His(6) fusion peptides, Moreover, incubation of rat hepatoma Fao cells with TNF alpha, bacterial sphingomyelinase, or other Ser(P)/Thr(P)-elevating agents reduced insulin-induced Tyr phosphorylation of IRS-I and IRS-2, markedly elevated their Ser(P)/Thr(P) levels, and significantly reduced their ability to interact with the JM region of IR. Withdrawal of TNF alpha for periods as short as 30 min reversed its inhibitory effects on IR-IRS interactions, Similar inhibitory effects were obtained when Fao cells were subjected to prolonged (20-60 min) pretreatment with insulin, Incubation of the cell extracts with alkaline phosphatase reversed the inhibitory effects of insulin. These findings suggest that insulin resistance is associated with enhanced Ser/Thr phosphorylation of IRS-1 and IRS-S, which impairs their interaction with the JIVE region of IR. Such impaired interactions abolish the ability of IRS-1 and IRS-2 to undergo insulin-induced Tyr phosphorylation and further propagate the insulin receptor signal. Moreover, the reversibility of the TNF alpha effects and the ability to mimic its action by exogenously added sphingomyelinase argue against the involvement of a proteolytic cascade in mediating the acute inhibitory effects of TNF alpha on insulin action.	WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, INST ENDOCRINOL, IL-52621 TEL HASHOMER, ISRAEL; NIH, DIABET BRANCH, BETHESDA, MD 20982 USA; ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70400 NESS ZIONA, ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012					AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COHEN SA, 1986, NATURE, V320, P769, DOI 10.1038/320769a0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTH RA, 1994, HORM RES, V41, P51, DOI 10.1159/000183961; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Skolnik Edward Y., 1996, Cytokine and Growth Factor Reviews, V7, P161, DOI 10.1016/1359-6101(96)00021-4; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZICK Y, 1983, J BIOL CHEM, V258, P75; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	44	420	440	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29911	29918		10.1074/jbc.272.47.29911	http://dx.doi.org/10.1074/jbc.272.47.29911			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368067	hybrid			2022-12-27	WOS:A1997YG64700077
J	Bettati, S; Mozzarelli, A				Bettati, S; Mozzarelli, A			T state hemoglobin binds oxygen noncooperatively with allosteric effects of protons, inositol hexaphosphate, and chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADULT HEMOGLOBIN; SOL-GEL ENCAPSULATION; HYBRID HEMOGLOBINS; SINGLE-CRYSTALS; MOLECULAR CODE; COOPERATIVITY; MODEL; STEREOCHEMISTRY; MECHANISMS; BIOSENSORS	Hemoglobin is the paradigm of allosteric proteins. Over the years, cooperative oxygen binding has been explained by different models predicting that the T state of hemoglobin binds oxygen either noncooperatively or with some degree of cooperativity or with strong cooperativity. Therefore, a critical test that discriminates among models is to determine the oxygen binding by the T state of hemoglobin. Fixation of hemoglobin in the T state has been achieved either by crystallization from polyethylene glycol solutions or by encapsulation in wet porous silica gels. Hemoglobin crystals bind oxygen noncooperatively with reduced affinity compared with solution, with no Bohr effect and with no influence of other allosteric effecters. In this study, we have determined accurate oxygen-binding curves to the T state of hemoglobin in silica gels with the same microspectrophotometric apparatus and multiwavelengths analysis used in crystal experiments. The T state of hemoglobin in silica gels binds oxygen noncooperatively with an affinity and a Bohr effect similar to those observed in solution for the binding of the first oxygen molecule. Other allosteric effecters such as inositol hexaphosphate, bezafibrate, and chloride significantly affect oxygen affinity. Therefore, T state hemoglobins that are characterized by strikingly different functional properties share the absence of cooperativity in the binding of oxygen. These findings are fully consistent with the Monod, Wyman, and Changeux model and with most features of Perutz's stereochemical model, but they are not consistent with models of both Koshland and Ackers.	Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy	University of Parma	Mozzarelli, A (corresponding author), Univ Parma, Inst Biochem Sci, I-43100 Parma, Italy.		Mozzarelli, Andrea/C-3615-2014; Bettati, Stefano/V-9975-2018	Mozzarelli, Andrea/0000-0003-3762-0062; Bettati, Stefano/0000-0001-6787-0594				ABRAHAM DJ, 1992, J MOL BIOL, V227, P480, DOI 10.1016/0022-2836(92)90902-V; Ackers GK, 1997, BIOCHEMISTRY-US, V36, P10822, DOI 10.1021/bi971382x; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Ariga O, 1996, J FERMENT BIOENG, V82, P341, DOI 10.1016/0922-338X(96)89147-1; ASAKURA T, 1978, P NATL ACAD SCI USA, V75, P5462, DOI 10.1073/pnas.75.11.5462; Bettati S, 1996, PROTEINS, V25, P425, DOI 10.1002/(SICI)1097-0134(199608)25:4<425::AID-PROT3>3.3.CO;2-A; BETTATI S, 1998, IN PRESS J BIOL CHEM, V273; BLYTH DJ, 1995, ANALYST, V120, P2725, DOI 10.1039/an9952002725; BRINKER CJ, 1990, SOL GEL SCI PHYSICS; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; CHUNG KE, 1995, ANAL CHEM, V67, P1505, DOI 10.1021/ac00105a004; DAVE BC, 1994, ANAL CHEM, V66, pA1120, DOI 10.1021/ac00094a001; DVORAK JA, 1971, EXP CELL RES, V68, P144, DOI 10.1016/0014-4827(71)90596-9; Edelstein SJ, 1996, J MOL BIOL, V257, P737, DOI 10.1006/jmbi.1996.0198; EDELSTEIN SJ, 1975, ANNU REV BIOCHEM, V44, P209, DOI 10.1146/annurev.bi.44.070175.001233; ELLERBY LM, 1992, SCIENCE, V255, P1113, DOI 10.1126/science.1312257; Henry ER, 1997, BIOCHEMISTRY-US, V36, P6511, DOI 10.1021/bi9619177; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; Imai K., 1982, ALLOSTERIC EFFECTS H; KAVANAUGH JS, 1995, J MOL BIOL, V248, P136, DOI 10.1006/jmbi.1995.0207; KISTER J, 1987, J BIOL CHEM, V262, P12085; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LINDSTROM TR, 1972, P NATL ACAD SCI USA, V69, P1707, DOI 10.1073/pnas.69.7.1707; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mozzarelli A, 1996, J BIOL CHEM, V271, P3627; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Mozzarelli A, 1997, PROTEIN SCI, V6, P484; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; NARANG U, 1994, ANAL CHEM, V66, P3139, DOI 10.1021/ac00091a023; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; POYART CF, 1978, EUR J BIOCHEM, V87, P75, DOI 10.1111/j.1432-1033.1978.tb12353.x; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P6411, DOI 10.1021/bi00076a014; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; Shen CY, 1997, J AM CHEM SOC, V119, P1304, DOI 10.1021/ja961867t; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 1997, BIOCHEMISTRY-US, V36, P4375, DOI 10.1021/bi970009m; SHIBAYAMA N, 1986, J MOL BIOL, V192, P331, DOI 10.1016/0022-2836(86)90368-2; SHIBAYAMA N, 1995, BIOCHEMISTRY-US, V34, P4773, DOI 10.1021/bi00014a035; SHTELZER S, 1994, BIOTECHNOL APPL BIOC, V19, P293; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0; WU SG, 1994, APPL BIOCHEM BIOTECH, V47, P11, DOI 10.1007/BF02788671	57	129	130	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32050	32055		10.1074/jbc.272.51.32050	http://dx.doi.org/10.1074/jbc.272.51.32050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405399	hybrid			2022-12-27	WOS:000071108000018
J	Gruic-Sovulj, I; Ludemann, HC; Hillenkamp, F; Weygand-Durasevic, I; Kucan, Z; Peter-Katalinic, J				Gruic-Sovulj, I; Ludemann, HC; Hillenkamp, F; Weygand-Durasevic, I; Kucan, Z; Peter-Katalinic, J			Detection of noncovalent tRNA-aminoacyl-tRNA synthetase complexes by matrix-assisted laser desorption/ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; SACCHAROMYCES-CEREVISIAE; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; GENETIC-CODE; YEAST; RECOGNITION; BINDING	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-MS) was used for the study of complexes formed by yeast seryl-tRNA synthetase (SerRS) and tyrosyl-tRNA synthetase (TyrRS) with tRNA(Ser) and tRNA(Tyr). Cognate and noncognate complexes were easily distinguished due to a large mass difference between the two tRNAs, Both homodimeric synthetases gave MS spectra indicating intact desorption of dimers. The spectra of synthetase-cognate tRNA mixtures showed peaks of free components and peaks assigned to complexes, Noncognate complexes were also detected. In competition experiments, where both tRNA species were mixed with each enzyme only cognate alpha(2).tRNA complexes were observed. Only cognate alpha(2).tRNA(2) complexes were detected with each enzyme. These results demonstrate that MALDI-MS can be used successfully for accurate mass and, thus, stoichiometry determination of specific high molecular weight noncovalent protein-nucleic acid complexes.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Univ Zagreb, Fac Sci, Dept Chem, Zagreb 10000, Croatia	University of Munster; University of Zagreb	Peter-Katalinic, J (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.	jkp@uni-muenster.de						ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CARTER P, 1986, P NATL ACAD SCI USA, V83, P1189, DOI 10.1073/pnas.83.5.1189; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Cheng XH, 1996, ANAL BIOCHEM, V239, P35, DOI 10.1006/abio.1996.0287; CHOW CM, 1993, J BIOL CHEM, V268, P12855; Cohen LRH, 1997, J AM SOC MASS SPECTR, V8, P1046, DOI 10.1016/S1044-0305(97)00148-7; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1995, CURR OPIN STRUC BIOL, V5, P48, DOI 10.1016/0959-440X(95)80008-O; DESSEN P, 1982, J MOL BIOL, V154, P603, DOI 10.1016/S0022-2836(82)80017-X; DESSEN P, 1982, J MOL BIOL, V159, P651, DOI 10.1016/0022-2836(82)90106-1; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Glocker MO, 1996, J MASS SPECTROM, V31, P1221, DOI 10.1002/(SICI)1096-9888(199611)31:11<1221::AID-JMS410>3.0.CO;2-P; GruicSovulj I, 1997, NUCLEIC ACIDS RES, V25, P1859, DOI 10.1093/nar/25.9.1859; HARTLEIN M, 1995, J MOL EVOL, V40, P519; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; HILLENKAMP F, 1996, IN PRESS NATO ADV RE; IBBA M, 1995, FEBS LETT, V358, P293, DOI 10.1016/0014-5793(94)01454-9; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; KUCAN Z, 1973, J BIOCHEM, V73, P811; LECCHI P, 1995, J AM SOC MASS SPECTR, V6, P972, DOI 10.1016/1044-0305(95)00524-H; MAXWELL IH, 1968, BIOCHEMISTRY-US, V7, P2629, DOI 10.1021/bi00847a027; Mazauric MH, 1996, EUR J BIOCHEM, V241, P814, DOI 10.1111/j.1432-1033.1996.00814.x; Meinnel Thierry, 1995, P251; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8; PACHMANN U, 1978, NUCLEIC ACIDS RES, V5, P975, DOI 10.1093/nar/5.3.975; PLOHL M, 1988, BIOCHIMIE, V70, P637, DOI 10.1016/0300-9084(88)90247-7; PRAMANIK BN, 1996, P 44 ASMS C MASS SPE; RIESNER D, 1976, EUR J BIOCHEM, V68, P71, DOI 10.1111/j.1432-1033.1976.tb10765.x; RIGLER R, 1971, FEBS LETT, V11, P320; Rogers M J, 1990, Prog Nucleic Acid Res Mol Biol, V39, P185, DOI 10.1016/S0079-6603(08)60627-3; ROSINKE B, 1995, J MASS SPECTROM, V30, P1462, DOI 10.1002/jms.1190301012; RUBELJ I, 1990, EUR J BIOCHEM, V193, P783, DOI 10.1111/j.1432-1033.1990.tb19400.x; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; SUZUKI T, 1994, NUCLEIC ACIDS RES, V22, P115, DOI 10.1093/nar/22.2.115; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; TANG XD, 1995, ANAL CHEM, V67, P4542, DOI 10.1021/ac00120a018; VINCENT C, 1995, NUCLEIC ACIDS RES, V23, P1113, DOI 10.1093/nar/23.7.1113; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; WOODS AS, 1995, ANAL CHEM, V67, P4462, DOI 10.1021/ac00120a005; ZACCAI G, 1979, J MOL BIOL, V129, P483, DOI 10.1016/0022-2836(79)90508-4; Zhu YF, 1996, RAPID COMMUN MASS SP, V10, P1591, DOI 10.1002/(SICI)1097-0231(199610)10:13<1591::AID-RCM715>3.0.CO;2-W; Zhu YF, 1996, RAPID COMMUN MASS SP, V10, P383, DOI 10.1002/(SICI)1097-0231(199602)10:3<383::AID-RCM485>3.0.CO;2-W	53	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32084	32091		10.1074/jbc.272.51.32084	http://dx.doi.org/10.1074/jbc.272.51.32084			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405405	hybrid			2022-12-27	WOS:000071108000024
J	Hanada, K; Hara, T; Nishijima, M; Kuge, O; Dickson, RC; Nagiec, MM				Hanada, K; Hara, T; Nishijima, M; Kuge, O; Dickson, RC; Nagiec, MM			A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HAMSTER OVARY CELLS; LONG-CHAIN BASES; BIOSYNTHESIS; MUTANT; SACCHAROMYCES; GENE; LOCALIZATION; ALIGNMENT; CLONING	Serine palmitoyltransferase (SPT; EC 2.3.1.50) catalyzes the initial step dedicated to sphingolipid biosynthesis and is thought to be a key enzyme for regulating cellular sphingolipid content. For SPT activity, the yeast Saccharomyces cerevisiae requires two genes, LCB1 and LCB2. We isolated mammalian LCB1 cDNA homologs from mouse and Chinese hamster ovary (CHO) cells and an LCB2 cDNA homolog from CHO cells. The mammalian LCB1 proteins are predicted to have about 35% amino acid identity to the yeast Lcb1 protein, whereas the CHO LCB2 protein is predicted to have about 40% amino acid identity to the yeast Lcb2 protein. Northern blot analysis of mRNA isolated from various mouse tissues revealed that the tissue distribution of both LCB1 and LCB2 messengers followed a similar pattern. Transfection of an SPT-defective CHO mutant strain with a CHO LCB1-expressing plasmid restored both SPT activity and de novo sphingolipid synthesis to the wild type levels, whereas transfection of the mutant strain with a CHO LCB2-expressing plasmid did not exhibit any recovery effects, indicating that the SPT defect in the mutant cells is specifically complemented by the CHO LCB1 homolog. Furthermore, when the SPT-defective mutant cells were transfected with a plasmid encoding a His(6)-tagged CHO LCB1 protein, SPT activity bound to a Ni2+-immobilized resin. These results indicate that the CHO LCB1 homolog encodes a component of SPT.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 162, Japan; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	National Institute of Infectious Diseases (NIID); University of Kentucky; University of Kentucky	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 162, Japan.			Kuge, Osamu/0000-0003-4962-3519; Hanada, Kentaro/0000-0003-1383-2781				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANADA K, 1990, J BIOL CHEM, V265, P22137; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HORI T, 1993, PROG LIPID RES, V32, P25, DOI 10.1016/0163-7827(93)90003-F; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1985, J LIPID RES, V26, P617; Merrill Jr A. H., 1996, BIOCH LIPIDS LIPOPRO, P309; MUKHERJEE JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P24, DOI 10.1016/0167-4838(90)90097-Y; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; WELLS GB, 1983, J BIOL CHEM, V258, P200; ZHAO C, 1994, J BIOL CHEM, V269, P21480; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	36	114	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32108	32114		10.1074/jbc.272.51.32108	http://dx.doi.org/10.1074/jbc.272.51.32108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405408	hybrid			2022-12-27	WOS:000071108000027
J	Aspinwall, CA; Brooks, SA; Kennedy, RT; Lakey, JRT				Aspinwall, CA; Brooks, SA; Kennedy, RT; Lakey, JRT			Effects of intravesicular H+ and extracellular H+ and Zn2+ on insulin secretion in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLARY CELLS; INDIVIDUAL CHROMAFFIN CELLS; VESICLE FUSION; AMPEROMETRIC DETECTION; QUANTAL SECRETION; GRANULE MATRIX; CHROMOGRANIN-A; TIME-COURSE; B-CELL; RELEASE	The effects of extracellular Zn2+ and pH and intravesicular pH on insulin and 5-hydroxytryptamine (5-HT) secretion from pancreatic beta cells were investigated. Insulin and 5-HT secretion from single cells was detected by amperometry as a series of current spikes corresponding to detection of multimolecular packets secreted by exocytosis. Spike width was used as a measure of the kinetics of clearance from the cell and the area of spikes as a measure of amount released. Changes in extracellular pH from 6.9 to 7.9 caused insulin spikes to become narrower with no change in area, whereas the same treatments had no effect on 5-HT secretion. Treatment of cells with Bafilomycin A(1) or N-ethylmaleimide, both of which are expected to increase intravesicular pH by inhibiting V-type H+-ATPase, had no effect on 5-HT secretion but caused insulin spikes to become more narrow. These results indicate that exposure to high pH, whether intravesicular or extracellular, accelerates release of insulin during exocytosis without affecting the amount of insulin released. Increasing extracellular Zn2+ concentration from 0 to 25 mu M increased the width and decreased the area of insulin spikes without affecting 5-HT secretion. Zn2+ effects were likely exerted through a common-ion effect on Zn2+-insulin dissociation. It was concluded that intravesicular storage conditions and extracellular ions can affect free insulin concentration in the vicinity of beta cells during secretion.	UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611; UNIV ALBERTA,DEPT SURG,COMPREHENS TISSUE CTR,EDMONTON,AB T6H 2R8,CANADA	State University System of Florida; University of Florida; University of Alberta			Kennedy, Robert/G-9095-2016	Kennedy, Robert/0000-0003-2447-7471; Aspinwall, Craig/0000-0002-4359-5812	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046960] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46960-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT DW, 1994, J MEMBRANE BIOL, V138, P113; BERSON SA, 1966, AM J MED, V40, P676, DOI 10.1016/0002-9343(66)90148-3; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BONNER FW, 1979, CHEM-BIOL INTERACT, V27, P343, DOI 10.1016/0009-2797(79)90137-6; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHEN MD, 1995, BIOL TRACE ELEM RES, V50, P119, DOI 10.1007/BF02789414; CHEN TK, 1994, ANAL CHEM, V66, P3031, DOI 10.1021/ac00091a007; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CIOLKOWSKI EL, 1992, J AM CHEM SOC, V114, P2815, DOI 10.1021/ja00034a009; COORE HG, 1969, BIOCHEM J, V111, P107, DOI 10.1042/bj1110107; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; EPAND RM, 1985, MOL PHARMACOL, V27, P366; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; Hazelwood R.L., 1989, ENDOCRINE PANCREAS; HELMERHORST E, 1986, ARCH BIOCHEM BIOPHYS, V245, P238, DOI 10.1016/0003-9861(86)90210-9; HUANG L, 1995, P NATL ACAD SCI USA, V92, P608; HURLEY LS, 1969, AM J CLIN NUTR, V22, P1332; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KELLY RS, 1986, ANAL CHIM ACTA, V187, P79, DOI 10.1016/S0003-2670(00)82900-1; KENNEDY RT, 1993, ANAL CHEM, V65, P1882, DOI 10.1021/ac00062a012; Kennedy RT, 1996, J AM CHEM SOC, V118, P1795, DOI 10.1021/ja953271w; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; NANAVATI C, 1993, SCIENCE, V259, P963, DOI 10.1126/science.8438154; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Paras CD, 1997, ELECTROANAL, V9, P203, DOI 10.1002/elan.1140090303; PARAS CD, 1995, ANAL CHEM, V67, P3633, DOI 10.1021/ac00116a003; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; SMITH P, 1994, J PHYSIOL-LONDON, V475P, pP157; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; TANFORD C, 1954, J AM CHEM SOC, V76, P2170, DOI 10.1021/ja01637a036; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; WARNOCK GL, 1994, PANCREATIC ISLET TRA, V1, P81; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Xu G, 1996, BIOCHEM J, V318, P623, DOI 10.1042/bj3180623; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; ZHOU Z, 1995, P NATL ACAD SCI USA, V92, P6938, DOI 10.1073/pnas.92.15.6938; Zhou Z, 1996, J BIOL CHEM, V271, P270, DOI 10.1074/jbc.271.1.270; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447	62	81	82	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31308	31314		10.1074/jbc.272.50.31308	http://dx.doi.org/10.1074/jbc.272.50.31308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395458	hybrid			2022-12-27	WOS:A1997YL41900017
J	Kappeler, F; Klopfenstein, DRC; Foguet, M; Paccaud, JP; Hauri, HP				Kappeler, F; Klopfenstein, DRC; Foguet, M; Paccaud, JP; Hauri, HP			The recycling of ERGIC-53 in the early secretory pathway - ERGIC-53 carries a cytosolic endoplasmic reticulum exit determinant interacting with COPII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; GTP-BINDING-PROTEINS; TRANSPORT VESICLES; MEMBRANE-PROTEIN; COATED VESICLES; BETA-COP; TRANSMEMBRANE PROTEINS; MONOCLONAL-ANTIBODIES; LEGUMINOUS LECTINS; BREFELDIN-A	Further investigation of the targeting of the intracellular membrane lectin endoplasmic reticulum (ER)-Golgi intermediate compartment-53 (ERGIC-53) by site-directed mutagenesis revealed that its lumenal and transmembrane domains together confer ER retention. In addition we show that the cytoplasmic domain is required for exit from the ER indicating that ERGIC-53 carries an ER-exit determinant. Two phenylalanines at the C terminus are essential for ER-exit. Thus, ERGIC-53 contains determinants for ER retention as well as anterograde transport which, in conjunction with a dilysine ER retrieval signal, control the continuous recycling of ERGIC-53 in the early secretory pathway, In vitro binding studies revealed a specific phenylalanine-dependent interaction between an ERGIC-53 cytosolic tail peptide and the COPII coat component Sec23p. These results suggest that the ER-exit of ERGIC-53 is mediated by direct interaction of its cytosolic tail with the Sec23p.Sec24p complex of COPII and that protein sorting at the level of the ER occurs by a mechanism similar to receptor-mediated endocytosis or Golgi to ER retrograde transport.	UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND; UNIV GENEVA,MED CTR,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Basel; University of Geneva								AHLE S, 1989, J BIOL CHEM, V264, P20089; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANHYKH SI, 1997, J CELL BIOL, V138, P1; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARQUHAR MG, 1997, GOLGI APPARATUS, P63; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HAURI HP, 1997, HDB PHYSIOL 14, P605; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WADA I, 1991, J BIOL CHEM, V266, P19599; WHITNEY JA, 1995, CELL, V83, P703	79	222	226	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31801	31808		10.1074/jbc.272.50.31801	http://dx.doi.org/10.1074/jbc.272.50.31801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395526	hybrid			2022-12-27	WOS:A1997YL41900085
J	Suzuki, M; Raab, G; Moses, MA; Fernandez, CA; Klagsbrun, M				Suzuki, M; Raab, G; Moses, MA; Fernandez, CA; Klagsbrun, M			Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; SELECTIN ADHESION MOLECULE; DIPHTHERIA-TOXIN RECEPTOR; PHORBOL-ESTER; FACTOR-ALPHA; TRANSMEMBRANE FORM; TISSUE INHIBITOR; T-LYMPHOCYTES; MESSENGER-RNA; SURFACE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is synthesized as a membrane-anchored precursor that is cleaved to release the soluble mature growth factor. The two forms are active as juxtacrine and paracrine/autocrine growth factors, respectively, The enzymes that process the HB EGF transmembrane form are unknown, Accordingly, an in vitro assay was established using a fusion protein in which alkaline phosphatase (AP) replaced the transmembrane and cytoplasmic domains of HB-EGF (HB-EGF JM-AP). The fusion protein was anchored to agarose beads coated with anti-AP antibodies, Several matrix metalloproteinases (MMPs) were tested for the ability to release soluble HB-EGF in the in vitro system. MMP-3 released soluble 12-kDa immunoreactive and mitogenic HB-EGF within 30 min. On the other hand neither MMP-2 nor MMP-9 had any cleavage activities. A non-cleavable mutant was prepared by replacing the juxtamembrane (JM) region of HB-EGF with the JM region of CD4. The mutant HB-EGF, which in its full-length form was as active a juxtacrine growth factor as was the wild type HB-EGF in vivo, was not cleaved by MMP-3 in the in vitro assay. The C-terminal portion of the cleaved HB-EGF JM-AP that remained attached to the anti-AP beads was N-terminally sequenced and the MMP-3 cleavage site was determined to be Glu(151)-Asn(152), a site within the JM domain. MMP-3 treatment also released soluble HB-EGF in vivo from MC2 cells expressing transmembrane HB-EGF precursor, at a level of about 2-fold above control. It was concluded that MMP-3 cleaves HB-EGF at a specific site in the JM domain and that this enzyme might regulate the conversion of HB-EGF from being a juxtacrine to a paracrine/autocrine growth factor.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NATL INST BIOSCI & HUMAN TECHNOL,BIOSIGNALING DEPT,TSUKUBA,IBARAKI 305,JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; National Institute of Advanced Industrial Science & Technology (AIST)			Suzuki, Masashi/M-1696-2018	Suzuki, Masashi/0000-0002-7218-0923	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47397] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bini A, 1996, BIOCHEMISTRY-US, V35, P13056, DOI 10.1021/bi960730c; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; Couet J, 1996, J BIOL CHEM, V271, P4545; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hosono T, 1996, FEBS LETT, V381, P115, DOI 10.1016/0014-5793(96)00081-6; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Knox JB, 1997, CIRCULATION, V95, P205, DOI 10.1161/01.CIR.95.1.205; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; ONO M, 1994, J BIOL CHEM, V269, P31315; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; PIERCE JH, 1994, SCIENCE, V91, P2890; POWELL PP, 1993, AM J PATHOL, V143, P784; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Raab G, 1996, DEVELOPMENT, V122, P637; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; UNEMORI EN, 1994, EXP CELL RES, V210, P166, DOI 10.1006/excr.1994.1025; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wiesen JF, 1996, ENZYME PROTEIN, V49, P174, DOI 10.1159/000468624; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	67	259	270	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31730	31737		10.1074/jbc.272.50.31730	http://dx.doi.org/10.1074/jbc.272.50.31730			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395517	hybrid			2022-12-27	WOS:A1997YL41900076
J	Zhao, JK; Trewhella, J; Corbin, J; Francis, S; Mitchell, R; Brushia, R; Walsh, D				Zhao, JK; Trewhella, J; Corbin, J; Francis, S; Mitchell, R; Brushia, R; Walsh, D			Progressive cyclic nucleotide-induced conformational changes in the cGMP-dependent protein kinase studied by small angle X-ray scattering in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP BINDING DOMAINS; CRYSTAL-STRUCTURE; PREDICTED STRUCTURES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CATALYTIC SUBUNIT; DELETION MUTANT; TERMINAL DOMAIN; TROPONIN-C; SITES	Small angle scattering data from bovine lung type I alpha cGRSP-dependent protein kinase (PKG) in the absence of cGMP show the protein to have a highly asymmetric structure with a radius of gyration (R-g) of 45 Angstrom and a maximum linear dimension (d(max)) of 165 Angstrom. The addition of cGMP induces a marked conformational change in PKG. The R-g and d(max) increase 25-30%, and the protein's mass moves further away from the center of mass; this results in an even more asymmetric structure, Fourier transform infrared spectroscopy data suggest that the conformational change induced by cGMP binding is primarily due to a topographical movement of the structural domains of PKG rather than to secondary structural changes within one or more of the individual domains. Each monomer of the dimeric PKG contains one high and one low affinity cGMP-binding site. A prominent increase in the asymmetry of PKG occurs with binding to high affinity cGMP-binding sites alone, but the full domain movements require the binding to both sets of sites, These conformational changes occurring in PKG with the progressive binding of cGMP to both sets of cGMP-binding sites correlate with past data, which have indicated that cGMP binding to both sets of sites is required for the fall activation of the enzyme, These results provide the first quantitative measurement of the overall PKG structure, as well as an assessment of the structural events that accompany the activation of a protein kinase upon binding a small molecular weight ligand.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA; UNIV CALIF DAVIS, DEPT BIOL CHEM, DAVIS, CA 95616 USA	Vanderbilt University; University of California System; University of California Davis	Zhao, JK (corresponding author), LOS ALAMOS NATL LAB, DIV CHEM SCI & TECHNOL, LOS ALAMOS, NM 87545 USA.		Zhao, Jinkui/B-7872-2013	Zhao, Jinkui/0000-0002-7756-1952; Trewhella, Jill/0000-0002-8555-6766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013613, R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13613, DK40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1985, BIOCHEMISTRY-US, V24, P2163, DOI 10.1021/bi00330a009; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; Corbin J D, 1978, Adv Cyclic Nucleotide Res, V9, P159; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DONG A, 1992, BIOCHEMISTRY-US, V31, P182, DOI 10.1021/bi00116a027; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; Feigin L. A., 1987, STRUCTURE ANAL SMALL, P25, DOI DOI 10.1007/978-1-4757-6624-0; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P322; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; Glatter O., 1982, SMALL ANGLE XRAY SCA, P17; Guinier A., 1939, ANN PHYS-NEW YORK, V11, P161, DOI DOI 10.1051/ANPHYS/193911120161; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON DA, 1993, BIOCHEMISTRY-US, V32, P6402, DOI 10.1021/bi00076a013; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KREUGER JK, 1997, BIOCH, V36, P6017; KRINGBAUM WR, 1970, BIOCHEMISTRY-US, V9, P1216; KUO JF, 1970, J BIOL CHEM, V245, P2493; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LEHMANN MS, 1984, BIOCHEMISTRY-US, V23, P1939, DOI 10.1021/bi00304a008; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; SU Y, 1993, J MOL BIOL, V230, P1091, DOI 10.1006/jmbi.1993.1224; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; ZACCAI G, 1986, J MOL BIOL, V190, P97, DOI 10.1016/0022-2836(86)90078-1; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	61	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31929	31936		10.1074/jbc.272.50.31929	http://dx.doi.org/10.1074/jbc.272.50.31929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395542	hybrid			2022-12-27	WOS:A1997YL41900101
J	Clum, S; Ebner, KE; Padmanabhan, R				Clum, S; Ebner, KE; Padmanabhan, R			Cotranslational membrane insertion of the serine proteinase precursor NS2B-NS3(Pro) of dengue virus type 2 is required for efficient in vitro processing and is mediated through the hydrophobic regions of NS2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER VIRUS; PROTEASE DOMAIN; NONSTRUCTURAL PROTEINS; STRUCTURAL PROTEINS; VIRAL REPLICATION; POLYPROTEIN PRECURSOR; ENDOPLASMIC-RETICULUM; CLEAVAGE SITE; NS3 PROTEIN; IN-VITRO	Polyprotein processing of dengue virus type 2, a positive strand RNA virus, is carried out by the host signal peptidase and a novel two-component viral proteinase of the serine proteinase family, NS2B/NS3(Pro), in the endoplasmic reticulum, Using an in vitro processing system, we examined the cis and trans cleavages of the 2B/3 and 4B/5 sites by NS2B/NS3(Pro), respectively, Lysates of BHK-21 cells coexpressing NS2B and NS3(Pro) mediated trans cleavage of the 4B/5 site in vitro, and the protease activity was associated with the membrane fraction, To study the role of membranes in the protease activity of NS2B/NS3(Pro), labeled precursors, NS2B-NS3(Pro) and the mutant ndNS2B-NS3(Pro) in which the functional hydrophilic domain of NS2B was deleted, were analyzed using a coupled in vitro transcription/translation system (TnT), The results showed that cotranslational addition of microsomal membranes to the TnT reaction markedly enhanced the cis cleavage of the 2B/3 site in a dose-dependent manner, NS2B synthesized in the presence of membranes also facilitated trans cleavage of the 2B/3 site in the mutant precursor, The cleavage products, NS2B and NS3(Pro), were membrane-associated, Furthermore, this membrane requirement was dictated by the hydrophobic regions of NS2B, Deletion of hydrophobic regions of NS2B, leaving only the conserved hydrophilic domain of 40 amino acids, resulted in highly efficient processing of the 2B-3 site in vitro in the absence of microsomal membranes.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032078, R21AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Chen H, 1997, Methods Mol Biol, V62, P199; COTTEN M, 1995, VIROLOGY, V213, P494, DOI 10.1006/viro.1995.0022; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573; KAPOOR M, 1995, J BIOL CHEM, V270, P1910; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P6218, DOI 10.1073/pnas.90.13.6218; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; PREUGSCHAT F, 1991, VIROLOGY, V185, P689, DOI 10.1016/0042-6822(91)90540-R; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PREUGSCHAT F, 1991, J VIROL, V65, P4749, DOI 10.1128/JVI.65.9.4749-4758.1991; PUGACHEV KV, 1993, FEBS LETT, V328, P115, DOI 10.1016/0014-5793(93)80977-3; RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; YAMSHCHIKOV VF, 1993, VIROLOGY, V192, P38, DOI 10.1006/viro.1993.1006; YAMSHCHIKOV VF, 1994, J VIROL, V68, P5765, DOI 10.1128/JVI.68.9.5765-5771.1994; ZHANG L, 1993, GENE, V129, P197, DOI 10.1016/0378-1119(93)90269-9; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	44	160	169	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30715	30723		10.1074/jbc.272.49.30715	http://dx.doi.org/10.1074/jbc.272.49.30715			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388208	hybrid			2022-12-27	WOS:000071640800021
J	Duan, HW; Lin, CY; Mazzone, T				Duan, HW; Lin, CY; Mazzone, T			Degradation of macrophage ApoE in a nonlysosomal compartment - Regulation by sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; HEPARAN-SULFATE PROTEOGLYCANS; UBIQUITIN-PROTEASOME PATHWAY; BONE-MARROW TRANSPLANTATION; HUMAN APOLIPOPROTEIN-E; E-DEFICIENT MICE; GOLGI-APPARATUS; NIEMANN-PICK; REMNANT LIPOPROTEINS; PROTEIN-DEGRADATION	Macrophage derived apoE has been shown to play an important role in the susceptibility of the vessel wall to atherosclerosis. Previous studies have shown that macrophage sterol content modulates apoE synthesis and secretion, associated with a large transcriptional response of the apoE gene, The current studies were undertaken to evaluate the existence of additional posttranscriptional regulatory loci for the effect of sterols on apoE synthesis and secretion, Using a macrophage cell line transfected to constitutively express an apoE cDNA to facilitate detection of a post-transcriptional regulatory locus, we demonstrated that preincubations in 25-hydroxycholesterol and cholesterol lead to increased apoE secretion in pulse/chase experiments, Examination of cell lysates in these experiments showed that apoE not secreted by control cells was degraded and not detectable, suggesting that the preincubation in sterols increased secretion by decreasing degradation of newly synthesized apoE, The measurement of total protein and apoE degradation in cell fractions revealed an intermediate density fraction that degraded significant amounts of newly synthesized total protein and newly synthesized apoE, In this fraction, degradation of total protein and apoE was unaffected by chloroquine but was substantially reduced by N-acetyl-Leu-Leu-nor-leucinal plus N-acetyl-Leu-Leu-methioninal or by lacta-cystin, suggesting the involvement of proteasomes, Preincubation in sterol/oxysterol or acetylated low density lipoprotein did not modify total protein degradation by this fraction but inhibited apoE degradation, Similar results were obtained using intermediate density fractions isolated from human monocyte-derived macrophages, The results of our studies indicate that newly synthesized apoE in the macrophage can be degraded in an intermediate density nonlysosomal cellular compartment, which is sensitive to proteasomal inhibitors. Alteration of cellular lipid homeostasis by preincubation in sterol/oxysterol or acetylated low density lipoprotein inhibits apoE, but not total protein, degradation in this fraction, Inhibition of the degradation of apoE in this fraction likely contributes to the increased apoE secretion observed in sterol-enriched cells.	Rush Med Coll, Dept Med, Chicago, IL 60612 USA; Rush Med Coll, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University	Mazzone, T (corresponding author), Rush Med Ctr, 1653 W Congress Pkwy, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Cader AA, 1997, J LIPID RES, V38, P981; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COXEY RA, 1993, J LIPID RES, V34, P1165; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DENG JT, 1995, J LIPID RES, V36, P2129; Dick LR, 1997, J BIOL CHEM, V272, P182; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; HAMILTON RL, 1991, J LIPID RES, V32, P529; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HONGWEI D, 1995, J CLIN INVEST, V96, P915; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LANGE Y, 1988, J BIOL CHEM, V263, P9366; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1997, J BIOL CHEM, V272, P13000, DOI 10.1074/jbc.272.20.13000; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; STAUDERMAN ML, 1993, J LIPID RES, V34, P190; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANGIVERSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P256, DOI 10.1016/0005-2760(85)90163-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WERB Z, 1989, AM J PATHOL, V134, P661; Wu XJ, 1996, J LIPID RES, V37, P1198; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	49	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31156	31162		10.1074/jbc.272.49.31156	http://dx.doi.org/10.1074/jbc.272.49.31156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388269	hybrid			2022-12-27	WOS:000071640800082
J	Kim, YM; Talanian, RV; Billiar, TR				Kim, YM; Talanian, RV; Billiar, TR			Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; WILD-TYPE P53; S-NITROSYLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; HEPATIC DAMAGE; C-ELEGANS; SYNTHASE; EXPRESSION	Nitric oxide (NO) has emerged as an important endogenous inhibitor of apoptosis, and here we report that NO prevents hepatocyte apoptosis initiated by the removal of growth factors or exposure to TNF alpha or anti-Fas antibody, We postulated that the mechanism of the inhibition of apoptosis by NO would include an effect on caspase-3-like protease activity, Caspase-3-like activity increased coincident with apoptosis due to all three stimuli, and treatment with the caspase-3-like protease inhibitor N-acetyl-Asp-Glu-Val-Asp-aldehyde inhibited both proteolytic activity and apoptosis, Endogenous or exogenous sources of NO prevented the increase in caspase-3-like activity in hepatocytes. Exposure of purified recombinant caspase-3 to an NO or NO+ donor inhibited proteolytic activity, Dithiothreitol (DTT), but not glutathione, reversed the inhibition of recombinant caspase-3 by NO, When lysates from cells stimulated to express inducible NO synthase or cells exposed to NO donors were incubated in DTT, caspase-3-like activity increased to about 55% of cells not exposed to a source of NO. Similarly, administration of an NO donor to rats treated with TNF alpha and D-galactosamine also prevented the increase in caspase-3-like activity as measured in liver homogenates. The effect of the NO donor was reversed by about 50% if the homogenate was incubated with DTT, TNF alpha-induced apoptosis and caspase-3-like activity were also reduced in cultured hepatocytes exposed to 8-bromo-cGMP, and both effects were inhibited by the cGMP-dependent kinase inhibitor KT5823, The suppression in caspase-3-like activity in hepatocytes exposed to an NO donor was partially blocked by an inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one, (ODQ), while the incubation of these lysates in DTT almost completely restored caspase-3-like activity to the level of TNF alpha-treated controls. These data indicate that NO prevents apoptosis in hepatocytes by either directly or indirectly inhibiting caspase-3-like activation via a cGMP-dependent mechanism and by direct inhibition of caspase-3-like activity through protein S-nitrosylation.	Univ Pittsburgh, Coll Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Coll Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; BASF Biores Corp, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; BASF	Billiar, TR (corresponding author), A1010 Presbyterian Univ Hosp, 200 Lothrop St, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R37GM044100, R01GM037753, R01GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37753, GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1016/0270-9139(95)90212-0; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COBBS CS, 1995, CANCER RES, V55, P727; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HARBRECHT BG, 1994, AM J PHYSIOL, V266, pG1004, DOI 10.1152/ajpgi.1994.266.6.G1004; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; Ientile R, 1996, FEBS LETT, V379, P82, DOI 10.1016/0014-5793(95)01490-X; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuo PC, 1996, IMMUNOLOGY, V87, P647, DOI 10.1046/j.1365-2567.1996.468592.x; LEIST M, 1995, AM J PATHOL, V146, P1220; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MartinSanz P, 1996, HEPATOLOGY, V23, P1200; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; Mohr S, 1996, J BIOL CHEM, V271, P4209; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; POSPISIL R, 1995, P NATL ACAD SCI USA, V92, P6961, DOI 10.1073/pnas.92.15.6961; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; REAP EA, 1995, J IMMUNOL, V154, P936; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEPPERMAN BL, 1993, AM J PHYSIOL, V265, pG214, DOI 10.1152/ajpgi.1993.265.2.G214; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WOOD KS, 1987, J BIOL CHEM, V262, P5020; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	73	760	783	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31138	31148		10.1074/jbc.272.49.31138	http://dx.doi.org/10.1074/jbc.272.49.31138			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388267	hybrid			2022-12-27	WOS:000071640800080
J	Babnigg, G; Bowersox, SR; Villereal, ML				Babnigg, G; Bowersox, SR; Villereal, ML			The role of pp60(c-src) in the regulation of calcium entry via store-operated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	6th International Cell Biology Meeting	DEC 07-11, 1996	SAN FRANCISCO, CA				NIH 3T3 CELLS; C-SRC; TYROSINE PHOSPHORYLATION; DEPENDENT SUPPRESSION; KINASE; PROTEIN; TRANSFORMATION; FIBROBLASTS; RECEPTOR; INFLUX	In many cell types, G protein-coupled receptors stimulate a transient Ca2+ release from internal stores followed by a sustained, capacitative Ca2+ entry, which is mediated by store-operated channels (SOCs), Although it is clear that SOCs are activated by depletion of internal Ca2+ stores, the mechanism for this process is not well understood, Previously, we have reported that inhibitors of tyrosine kinase activity block the bradykinin-and thapsigarin-stimulated Ca2+ entry in fibroblasts, suggesting that a tyrosine kinase activity may be involved in relaying the message from the empty internal Ca2+ stores to the plasma membrane Ca2+ channel (Lee, K.-M., Toscas, K,, and Villereal, RI, L, (1993) J, Biol, Chem, 268, 9945-9948), We also have demonstrated that bradykinin activates the nonreceptor tyrosine kinase c-src (Lee, K.-M., and Villereal, hi. L, (1996) Am. J, Physiol. 270, C1430-C1437). We investigated whether c-src plays a role in the regulation of SOCs by monitoring capacitative Ca2+ entry in 3T3-like embryonic fibroblast lines derived from either wild type or src(-)/src(-) (Src(-)) transgenic mice, We report that Ca2+ entry, following store depletion by either bradykinin or thapsigargin, is dramatically lower in Src-fibroblasts than in wild type fibroblasts. The level of capacitative Ca2+ entry in Src(-) cells is restored to nearly normal levels by transfecting Src-cells with chicken c-src, These data suggest that c-src may play a major role in the regulation of SOCs.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago					NIGMS NIH HHS [GM54500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONACCORSI L, 1995, FEBS LETT, V364, P83, DOI 10.1016/0014-5793(95)00369-K; BYRON KL, 1992, J BIOL CHEM, V267, P108; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lee KM, 1996, AM J PHYSIOL-CELL PH, V270, pC1430, DOI 10.1152/ajpcell.1996.270.5.C1430; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LIN PH, 1995, ONCOGENE, V10, P401; MEUCCI O, 1995, BIOCHEM BIOPH RES CO, V209, P630, DOI 10.1006/bbrc.1995.1546; MILLER BA, 1994, CELL CALCIUM, V16, P481, DOI 10.1016/0143-4160(94)90078-7; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	23	54	57	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29434	29437		10.1074/jbc.272.47.29434	http://dx.doi.org/10.1074/jbc.272.47.29434			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	YG647	9368000	hybrid			2022-12-27	WOS:A1997YG64700010
J	Degroote, S; LoGuidice, JM; Strecker, G; Ducourouble, MP; Roussel, P; Lamblin, G				Degroote, S; LoGuidice, JM; Strecker, G; Ducourouble, MP; Roussel, P; Lamblin, G			Characterization of an N-acetylglucosamine-6-O-sulfotransferase from human respiratory mucosa active on mucin carbohydrate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE RESIDUES; CYSTIC-FIBROSIS GENE; L-SELECTIN; LINKED OLIGOSACCHARIDES; ENZYMATIC SULFATION; LEWIS-X; SULFOTRANSFERASE; BIOSYNTHESIS; LIGAND; CELLS	A microsomal GlcNAc-6-O-sulfotransferase activity from human bronchial mucosa, able to transfer a sulfate group from adenosine 3'-phosphate 5'-phosphosulfate onto methyl-N-acetylglucosaminides or terminal N-acetylglucosamine residues of carbohydrate chains from human respiratory mucins, has been characterized. The reaction products containing a terminal HO3S-6GlcNAc were identified by high performance anion-exchange chromatography. Using methyl-beta-N-acetylglucosaminide as a substrate, the optimal activity was obtained with 0.1% Triton X-100, 30 mM NaF, 20 mM Mn2+, 5 mM AMP in a 30 mM MOPS (3-(N-morpholino) propanesulfonic acid) buffer at pH 6.7, The apparent K-m values for adenosine 3'-phosphate 5'-phosphosulfate and methyl-beta-N-acetylglucosaminide were observed at 9.1 x 10(-6) M and 0.54 x 10(-3) M, respectively. The enzyme had more affinity for carbohydrate chains with a terminal GlcNAc residue than for methyl-beta-N-acetylglucosaminide; it was unable to catalyze the transfer of sulfate to position 6 of the GlcNAc residue contained in a terminal Gal beta 1-4GlcNAc sequence. However, oligosaccharides with a nonreducing terminal HO3S-6GlcNAc were substrates for a beta 1-4 galactosyltransferase from human bronchial mucosa. These data point out that GlcNAc-6-O-sulfotransferase must act before beta 1-4 galactosylation in mucin-type oligosaccharide biosynthesis.	INSERM, U377, F-59045 LILLE, FRANCE; UNIV SCI & TECHNOL LILLE, CNRS, UMR 111, F-59650 VILLENEUVE DASCQ, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			GUIDICE, Jean-Marc LO/O-3177-2017	GUIDICE, Jean-Marc LO/0000-0003-3486-6809; Groux-Degroote, Sophie/0000-0002-9964-6519				BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Boat T F, 1976, Mod Probl Paediatr, V19, P141; CACAN R, 1995, METHODS GLYCONJUGATE, P201; CARNOY C, 1993, AM J RESP CELL MOL, V9, P323, DOI 10.1165/ajrcmb/9.3.323; CARTER SR, 1988, J BIOL CHEM, V263, P11977; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P2925, DOI 10.1021/bi00009a024; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; DELUCA S, 1968, J BIOL CHEM, V243, P2725; DOSANJH A, 1994, AM J PHYSIOL, V266, pC360, DOI 10.1152/ajpcell.1994.266.2.C360; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GOSO Y, 1993, GLYCOCONJUGATE J, V10, P226, DOI 10.1007/BF01209822; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOIBY N, 1988, CHEST, V94, pS97, DOI 10.1378/chest.94.2_Supplement.97S; JAIN RK, 1995, CARBOHYD RES, V268, P279, DOI 10.1016/0008-6215(94)00323-8; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; Lamblin G, 1976, Mod Probl Paediatr, V19, P153; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAZATIN JO, 1994, GLYCOSYLATION DIS, V1, P263; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MILLER RR, 1979, ARCH BIOCHEM BIOPHYS, V198, P31, DOI 10.1016/0003-9861(79)90392-8; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; Porchet N, 1995, BIOCHEM SOC T, V23, P800, DOI 10.1042/bst0230800; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Roussel P, 1996, GLYCOPROTEINS DIS, P351; ROUSSEL P, 1996, ENV IMPACT AIRWAYS I, V93, P437; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; SLOMIANY A, 1988, ARCH ORAL BIOL, V33, P669, DOI 10.1016/0003-9969(88)90122-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; STRECKER G, 1992, BIOCHIMIE, V74, P39, DOI 10.1016/0300-9084(92)90182-E; SUZUKI S, 1960, J BIOL CHEM, V235, P257; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANKUIK JA, 1987, FEBS LETT, V221, P150, DOI 10.1016/0014-5793(87)80370-8; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WHITTEMORE RM, 1986, ARCH BIOCHEM BIOPHYS, V249, P464, DOI 10.1016/0003-9861(86)90023-8; Zhang YL, 1995, J CLIN INVEST, V96, P2997, DOI 10.1172/JCI118372	49	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29493	29501		10.1074/jbc.272.47.29493	http://dx.doi.org/10.1074/jbc.272.47.29493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368010	hybrid			2022-12-27	WOS:A1997YG64700020
J	Salerno, JC; Harris, DE; Irizarry, K; Patel, B; Morales, AJ; Smith, SME; Martasek, P; Roman, LJ; Masters, BSS; Jones, CL; Weissman, BA; Lane, P; Liu, Q; Gross, SS				Salerno, JC; Harris, DE; Irizarry, K; Patel, B; Morales, AJ; Smith, SME; Martasek, P; Roman, LJ; Masters, BSS; Jones, CL; Weissman, BA; Lane, P; Liu, Q; Gross, SS			An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-TRANSFER; L-ARGININE; PROTEIN; IDENTIFICATION; BIOSYNTHESIS; FLAVOPROTEIN; SEQUENCES; EVOLUTION; REDUCTASE	Nitric oxide synthases (NOSs) are classified functionally, based an whether calmodulin binding is Ca2+-dependent (cNOS) or Ca2+-independent (iNOS). This key dichotomy has not been defined at the molecular level, Here we show that cNOS isoforms contain a unique polypeptide insert in their FMN binding domains which is not shared with iNOS or other related flavoproteins. Previously identified autoinhibitory domains in calmodulin-regulated enzymes raise the possibility that the polypeptide insert is the autoinhibitory domain of cNOSs. Consistent with this possibility, three-dimensional molecular modeling suggested that the insert originates from a site immediately adjacent to the calmodulin binding sequence, Synthetic peptides derived from the 45-amino acid insert of endothelial NOS were found to potently inhibit binding of calmodulin and activation of cNOS isoforms, This inhibition was associated with peptide binding to NOS, rather than free calmodulin, and inhibition could be reversed by increasing calmodulin concentration, In contrast, insert-derived peptides did not interfere with the arginine site of cNOS, as assessed from [H-3]N-G-nitro-L-arginine binding, nor did they potently effect iNOS activity, Limited proteolysis studies showed that calmodulin's ability to gate electron flow through cNOSs is associated with displacement of the insert polypeptide; this is the first specific calmodulin-induced change in NOS conformation to be identified, Together, our findings strongly suggest that the insert is an autoinhibitory control element, docking with a site on cNOSs which impedes calmodulin binding and enzymatic activation, The autoinhibitory control element molecularly defines cNOSs and offers a unique target for developing novel NOS activators and inhibitors.	CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021; RENSSELAER POLYTECH INST,DEPT BIOL,TROY,NY 12180; AENEAS BIOTECHNOL,TROY,NY 12180; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM BIOCHEM & STRUCT BIOL,NEW YORK,NY 10021	Cornell University; Rensselaer Polytechnic Institute; University of Texas System; University of Texas Health San Antonio; Cornell University			salerno, john c/A-2595-2014; Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444; Lane, Paul/0000-0003-1595-3237	NHLBI NIH HHS [HL 30050, HL 44603, HL 50656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL050656, R01HL030050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; Gross SS, 1996, METHOD ENZYMOL, V268, P159; GROSS SS, 1992, J BIOL CHEM, V267, P25722; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IMPARL JM, 1995, ARCH BIOCHEM BIOPHYS, V318, P3780; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KIM JJ, 1996, FLAVINS FLAVOPROTEIN, P455; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857	33	211	217	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29769	29777		10.1074/jbc.272.47.29769	http://dx.doi.org/10.1074/jbc.272.47.29769			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368047	Green Accepted, hybrid			2022-12-27	WOS:A1997YG64700057
J	Stewart, DB; Nelson, WJ				Stewart, DB; Nelson, WJ			Identification of four distinct pools of catenins in mammalian cells and transformation-dependent changes in catenin distributions among these pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; KIDNEY EPITHELIAL-CELLS; E-CADHERIN EXPRESSION; BETA-CATENIN; ALPHA-CATENIN; ADHESION MOLECULES; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; COMPLEX-FORMATION	Catenins are cytoplasmic proteins that were initially identified in a complex with cadherins, a superfamily of transmembrane glycoproteins important for cell adhesion in normal and disease states, We have used gel filtration to identify four complexes of catenins in extracts from normal and transformed epithelial cells, In normal Madin-Darby canine kidney epithelial cells, a significant fraction of alpha- and beta-catenin and plakoglobin co-elute with cadherin in a high molecular weight complex (complex I), A portion of alpha-catenin and the remainder of beta-catenin and plakoglobin co-elute in a high molecular weight complex that does not contain cadherin (complex II). The remainder of alpha-catenin elutes in a low molecular weight fraction (complex III). In extracts from two colon carcinoma cell lines, HCT116 and SW480, beta-catenin elutes in an additional low molecular weight pool (complex IV) not present in Madin-Darby canine kidney cell extracts, In two subclones derived from SW480 cells, SW-E8 and SW-R2, beta-catenin is distributed evenly between high and low molecular weight pools in SW-ES cells, whereas it elutes primarily in the low molecular weight pool (complex TV) in SW-RB cells, These changes in beta-catenin elution profiles correlate with an increase in transformed phenotype and decreased cell-cell adhesion in the SW-RP cells.	STANFORD UNIV, BECKMAN CTR,DEPT CELLULAR & MOL PHYSIOL,MED CTR, SCH MED, STANFORD, CA 94305 USA	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035527, R01GM035527] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45573] Funding Source: Medline; NIGMS NIH HHS [GM 35527] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; DORUDI S, 1993, AM J PATHOL, V142, P981; GAMALLO C, 1993, AM J PATHOL, V142, P987; GUMBINER BM, 1993, J CELL SCI, P155; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Larue L, 1996, DEVELOPMENT, V122, P3185; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NELSON WJ, 1992, COLD SPRING HARB SYM, V57, P621, DOI 10.1101/SQB.1992.057.01.068; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OKA H, 1993, CANCER RES, V53, P1696; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1993, DEVELOPMENT, P163; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SHORE EM, 1991, J BIOL CHEM, V266, P19672; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TOMITA N, 1992, CANCER RES, V52, P6840; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632	63	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29652	29662		10.1074/jbc.272.47.29652	http://dx.doi.org/10.1074/jbc.272.47.29652			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368032	hybrid			2022-12-27	WOS:A1997YG64700042
J	Aoki, K; Taguchi, H; Shindo, Y; Yoshida, M; Ogasahara, K; Yutani, K; Tanaka, N				Aoki, K; Taguchi, H; Shindo, Y; Yoshida, M; Ogasahara, K; Yutani, K; Tanaka, N			Calorimetric observation of a GroEL-protein binding reaction with little contribution of hydrophobic interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; APO-ALPHA-LACTALBUMIN; CHAPERONIN GROEL; PORCINE PEPSIN; ATP; STABILITY; CONSTANTS	Binding of Escherichia coli chaperonin, GroEL, to substrate proteins with non-native structure, reduced alpha-lactalbumin (rLA) and denatured pepsin, were analyzed by isothermal titration calorimetry at various temperatures in the presence of salt (0.2 M KCI). Both proteins bound to GroEL with 1:1 stoichiometry and micromolar affinity at all temperatures tested. However, thermodynamic properties of their binding to GroEL are remarkably different from each other. While heat capacity changes (Delta Cp) of rLA-GroEL binding showed large negative values, -4.19 kJ mol(-1) K-1, that of denatured pepsin-GroEL binding was only -0.2 kJ mol(-1) K-1. These values strongly indicate that the hydrophobic interaction is a major force of rLA-GroEL binding but not so for denatured pepsin-GroEL binding. When salt was omitted hom the solution, the affinity and Delta Cp of the rLA-GroEL binding reaction were not significantly changed whereas denatured pepsin lost affinity to GroEL. Thus, in the non-native protein-GroEL binding reaction, thermodynamic properties, as well as the effect of salt, differ from protein to protein and hydrophobic interaction may not always be a major driving force.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan	Tokyo Institute of Technology; Osaka University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, 4259 Nagatsuta,R-1, Yokohama, Kanagawa 226, Japan.		taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDTS JF, 1990, AM LAB, V22, P30; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FORMISANO S, 1977, P NATL ACAD SCI USA, V74, P3340, DOI 10.1073/pnas.74.8.3340; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gorovits BM, 1997, J BIOL CHEM, V272, P32; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hoshino M, 1996, J MOL BIOL, V262, P575, DOI 10.1006/jmbi.1996.0536; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KUWAJIMA K, 1975, J BIOCHEM-TOKYO, V78, P205; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LIN XL, 1993, PROTEIN SCI, V2, P1383, DOI 10.1002/pro.5560020903; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PRIVALOV PL, 1981, J MOL BIOL, V152, P455; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	31	61	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32158	32162		10.1074/jbc.272.51.32158	http://dx.doi.org/10.1074/jbc.272.51.32158			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405415	hybrid			2022-12-27	WOS:000071108000034
J	Blount, P; Schroeder, MJ; Kung, C				Blount, P; Schroeder, MJ; Kung, C			Mutations in a bacterial mechanosensitive channel change the cellular response to osmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PATCH-CLAMP; ION CHANNELS; FUNCTIONAL RECONSTITUTION; QUANTITATIVE MEASUREMENTS; ACTIVATED CHANNELS; BACILLUS-SUBTILIS; GIANT LIPOSOMES; MEMBRANE; TRANSPORT	MscL is a channel found in bacterial plasma membranes that opens a large pore in response to mechanical stress. Here we demonstrate that some mutations within this channel protein (K31D and K31E) evoke a cellular phenotype in which the growth rate is severely depressed. Increasing the osmolarity of the growth medium partially rescues this "slowed growth" phenotype and decreases an abnormal cytosolic potassium loss observed in cells expressing the mutants. In addition, upon sudden decrease in osmolarity (osmotic downshock) more cytoplasmic potassium is released from cells expressing the mutants than cells expressing wild-type MscL. After osmotic downshock, all cells remained viable; hence, the differences in potassium efflux observed are not due to cell lysis but instead appear to be an exaggeration of the normal response to this sudden change in environmental osmolarity. Patch clamp studies in native bacterial membranes substantiate the hypothesis that these mutant channels are more sensitive to mechanical stresses, especially at voltages approaching those estimated for bacterial membrane potentials. These data are consistent with a crucial role for MscL in the adaptation to large osmotic downshock and suggest that if the normally tight regulation of MscL gating is disrupted, cell growth can be severely inhibited.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Blount, P (corresponding author), Univ Wisconsin, Dept Mol Biol, 1525 Linden Dr, Madison, WI 53706 USA.	plblount@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47856] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1981, BIOCHEM J, V200, P573, DOI 10.1042/bj2000573; BERRIER C, 1992, FEBS LETT, V306, P251, DOI 10.1016/0014-5793(92)81011-A; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Booth I. R., 1996, HDB BIOL PHYS, V2, P693; BOOTH IR, 1980, BIOCHEM J, V188, P467, DOI 10.1042/bj1880467; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; CUI C, 1995, J MEMBRANE BIOL, V144, P31; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAMILL OP, 1994, TRENDS NEUROSCI, V17, P439, DOI 10.1016/0166-2236(94)90125-2; Harold F. M., 1986, VITAL FORCE STUDY BI; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MARTINAC B, 1992, ADV COMP ENV PHYSL, V10, P3; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1979, EUR J BIOCHEM, V95, P1, DOI 10.1111/j.1432-1033.1979.tb12934.x; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; RUTHE HJ, 1985, BIOCHIM BIOPHYS ACTA, V819, P105, DOI 10.1016/0005-2736(85)90200-7; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; TSAPIS A, 1977, BIOCHIM BIOPHYS ACTA, V469, P1, DOI 10.1016/0005-2736(77)90320-0; WALSBY AE, 1986, FEMS MICROBIOL LETT, V39, P45; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V	43	95	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32150	32157		10.1074/jbc.272.51.32150	http://dx.doi.org/10.1074/jbc.272.51.32150			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405414	hybrid			2022-12-27	WOS:000071108000033
J	Nibbs, RJB; Wylie, SM; Yang, JY; Landau, NR; Graham, GJ				Nibbs, RJB; Wylie, SM; Yang, JY; Landau, NR; Graham, GJ			Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CELL-LINE; CYTOKINE FAMILY; HIV-1 ENTRY; MIP-1-ALPHA; LIGAND; LESTR/FUSIN; MIP-1-BETA	Members of the chemokine family of chemotactic peptides interact with their target cells through heptahelical cell surface receptors, An understanding of the biochemistry and expression patterns of these receptors is therefore central to our overall understanding of the roles played by chemokines in both physiological and pathological processes, To date, eight receptors for the beta-chemokine subfamily have been described, We have recently cloned a novel murine beta-chemokine receptor and report here the identification and characterization of a highly homologous human gene termed human D6 (hD6). This is a promiscuous beta-chemokine receptor and appears to be able to bind the majority of members of the beta-chemokine family. It is, however, specific for this family and shows no detectable affinity for members of the alpha-chemokine or the C or CXXXC chemokines, Unlike the majority of other chemokine receptors, human D6 does not appear to be able to flux calcium following ligand binding, thus it is currently not clear if this novel receptor is indeed a signaling receptor. Human D6 is expressed in a range of tissues including hemopoietic cells although it appears not to be ubiquitously expressed in hemopoietic cells. Human D6, unlike some other beta-chemokine receptors, appears not to be able to function as an entry co-factor for human immunodeficiency virus type 1 (HIV)1 on CD4-expressing cells.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Beatson Institute; Rockefeller University	Graham, GJ (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Graham, Gerard/D-1240-2009	Graham, Gerard/0000-0002-7801-204X; Nibbs, Robert/0000-0002-8150-0044				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; GAO JL, 1994, J BIOL CHEM, V269, P28539; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, J BIOL CHEM, V269, P17730; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LIU R, 1996, CELL, V86, P867; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	39	193	206	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32078	32083		10.1074/jbc.272.51.32078	http://dx.doi.org/10.1074/jbc.272.51.32078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405404	hybrid			2022-12-27	WOS:000071108000023
J	Wigle, JT; Demchyshyn, L; Pratt, MAC; Staines, WA; Salih, M; Tuana, BS				Wigle, JT; Demchyshyn, L; Pratt, MAC; Staines, WA; Salih, M; Tuana, BS			Molecular cloning, expression, and chromosomal assignment of sarcolemmal-associated proteins - A family of acidic amphipathic alpha-helical proteins associated with the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; CALCIUM CHANNELS; LEUCINE ZIPPER; RECEPTOR GENE; COILED-COIL; CARCINOMA; MUSCLE; HETERODIMER; MECHANISM; REGIONS	Two overlapping cDNAs encoding a novel sarcolemmal associated protein (SLAP) were isolated from a cardiac cDNA expression library by immunoscreening with anti-sarcolemmal antibodies, Further characterization of these clones showed that they belonged to a family of related cDNAs that potentially encode polypeptides of 37, 46, and 74 kDa designated SLAP1, SLAP2, and SLAP3, respectively, The SLAP3 transcript was ubiquitously expressed, whereas SLAP1 and SLAP2 transcripts were predominantly expressed in cardiac, soleus, and smooth muscle, SLAP was encoded by a single gene that mapped to chromosome 3p14.3-21.2, and the various transcripts are likely generated by alternative splicing, The primary structure of SLAP predicted that it would have large regions of coiled-coil structure including an 11-heptad acidic amphipathic alpha-helical segment, The carboxyl-terminal region of the SLAP proteins was predicted to have a transmembrane domain, although there was no discernible signal sequence, SLAPs could only be solubilized from cardiac membrane with detergents suggesting that they were integral membrane proteins, Subcellular distribution studies showed that MYC epitope-tagged SLAP localized to regions of juxtaposition between neighboring cell membranes although an intracellular pool of the protein was also present in cells undergoing apparent cleavage, Immunohistochemical localization of SLAP in cardiac muscle revealed that SLAP associated with the sarcolemma and also displayed a reticular pattern of staining that resembled the transverse tubules and the sarcoplasmic reticulum, The SLAPs define a new family of tail-anchored membrane proteins that exhibit tissue-specific expression and are uniquely situated to serve a variety of roles through their coiled-coil motifs.	Univ Ottawa, Dept Pharmacol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Anat & Neurobiol, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa	Tuana, BS (corresponding author), Univ Ottawa, Dept Pharmacol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684; Staines, Willim/0000-0002-7288-5026				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; EVAN GI, 1985, MOL CELL BIOL, V5, P387; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIBI K, 1992, ONCOGENE, V7, P445; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LI ZP, 1993, J BIOL CHEM, V268, P11489; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Meng HP, 1996, J BIOL CHEM, V271, P12364, DOI 10.1074/jbc.271.21.12364; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1991, SCIENCE, V254, P646; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUANA BS, 1987, MOL CELL BIOCHEM, V76, P173; TUANA BS, 1991, BIOCHIM BIOPHYS ACTA, V1091, P236, DOI 10.1016/0167-4889(91)90067-8; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	50	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32384	32394		10.1074/jbc.272.51.32384	http://dx.doi.org/10.1074/jbc.272.51.32384			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405447	hybrid			2022-12-27	WOS:000071108000066
J	Kinoshita, A; Greenwel, P; Tanaka, S; DiLiberto, M; Yoshioka, H; Ramirez, F				Kinoshita, A; Greenwel, P; Tanaka, S; DiLiberto, M; Yoshioka, H; Ramirez, F			A transcription activator with restricted tissue distribution regulates cell-specific expression of alpha 1(XI) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; GENE-EXPRESSION; PROMOTER; BINDS; IDENTIFICATION; SEQUENCE; ELEMENTS; PROTEIN	Different regulatory programs are likely to control expression of the alpha 1(XI) collagen (COL11A1) gene in cartilaginous and non-cartilaginous tissues and in coordination with different collagen genes Here, we report the identification of a cis-acting element that is required for constitutive and tissue-specific activity of the proximal COL11A1 promoter, The element binds an apparently novel activator whose expression is restricted mostly, but not exclusively, to cells of mesenchymal origin, Transient transfection experiments using wild-type and mutant constructs demonstrated the critical contribution of a 45-base pair upstream element (FP9) to promoter activity, The same functional tests and DNA binding assays narrowed down the critical portion of FP9 to a 20-base pair sequence, which consists of an imperfect palindrome with strong homology to the GATA consensus motif. Despite being able to bind GATA proteins in vitro, FP9 is actually recognized by a distinct similar to 100-kDa polypeptide (FP9C) probably belonging to the zinc-finger family of transcription factors. FP9C binding was mostly identified in nuclei from cells of mesenchymal origin, including those actively engaged in COL11A1 transcription, A positive correlation was also established between the level of FP9C binding and the degree of cell differentiation in vitro, Thus, FP9C represents an unusual example of tissue-specific and differentiation-related transcription factor with overlapping expression in hard and soft connective tissues.	CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; OKAYAMA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,OKAYAMA 565,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Okayama University					PHS HHS [R37-38648] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BOAST S, 1990, J BIOL CHEM, V265, P13351; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Hay ED., 1991, CELL BIOL EXTRACELLU, P7; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LACKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1421; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; ROSSERT JA, 1995, J CELL BIOL, V123, P1421; Sambrook J., 1983, MOL CLONING LAB MANU; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TRUTER S, 1992, J BIOL CHEM, V267, P25389; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsumaki N, 1996, J CELL BIOL, V134, P1573, DOI 10.1083/jcb.134.6.1573; YOSHIOKA H, 1995, J BIOL CHEM, V270, P418, DOI 10.1074/jbc.270.1.418	36	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31777	31784		10.1074/jbc.272.50.31777	http://dx.doi.org/10.1074/jbc.272.50.31777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395523	hybrid, Green Published			2022-12-27	WOS:A1997YL41900082
J	Soker, S; GollamudiPayne, S; Fidder, H; Charmahelli, H; Klagsbrun, M				Soker, S; GollamudiPayne, S; Fidder, H; Charmahelli, H; Klagsbrun, M			Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF(165)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; FACTOR VEGF; TYROSINE KINASE; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; RECEPTOR SYSTEM; BINDING-SITES; FACTOR FAMILY; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells (EC) in vitro and a major regulator of angiogenesis in vivo. VEGF(121) and VEGF(165) are the most abundant of the five known VEGF isoforms. The structural difference between these two is the presence in VEGF(165) of 44 amino acids encoded by exon 7 lacking in VEGF(121). It was previously shown that VEGF(165) and VEGF(121) both bind to KDR/Flk-1 and Flt-1 but that VEGF(165) binds in addition to a novel receptor (Soker, S., Bidder, Il., Neufeld, G., and Klagsbrun, M. (1996) J. Biol. Chem. 271, 5761-5767). The binding of VEGF(165) to this VEGF(165)-specific receptor (VEGF(165)R) is mediated by the exon 7-encoded domain. To investigate the biological role of this domain further, a glutathione S-transferase fusion protein corresponding to the VEQF(165) exon 7-encoded domain was prepared. The fusion protein inhibited binding of I-125-VEGF(165) to VEGF(165)R on human umbilical vein-derived EC (HUVEC) and MDA-MB-231 tumor cells. The fusion protein also inhibited significantly I-125-VEGF(165) binding to KDR/Flk-1 on HUVEC but not on porcine EC which express KDR/Flk-1 alone. VEGF(165) had a 2-fold higher mitogenic activity for HUVEC than did VEGF(121). The exon 7 fusion protein inhibited VEGF(165)-induced HUVEC proliferation by 60% to about the level stimulated by VEGF(121). Unexpectedly, the fusion protein also inhibited HUVEC proliferation in response to VEGF(121). Deletion analysis revealed that a core inhibitory domain exists within the C-terminal 23-amino acid portion of the exon 7-encoded domain and that a cysteine residue at position 22 in exon 7 is critical for inhibition. It was concluded that the exon 7-encoded domain of VEGF(165) enhances its mitogenic activity for HUVEC by interacting with VEGF(165)R and modulating KDR/Flk-1-mediated mitogenicity indirectly and that exon 7-derived peptides may be useful VEGF antagonists in ansogenesis-associated diseases.	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIOTHERAPY,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BRIER G, 1992, DEVELOPMENT, V114, P521; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAKAMOTO N, 1991, CANCER RES, V51, P903; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Strawn LM, 1996, CANCER RES, V56, P3540; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	54	164	190	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31582	31588		10.1074/jbc.272.50.31582	http://dx.doi.org/10.1074/jbc.272.50.31582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395496	hybrid			2022-12-27	WOS:A1997YL41900055
J	de Rocquigny, H; Petitjean, P; Tanchou, V; Decimo, D; Drouot, L; Delaunay, T; Darlix, JL; Roques, BP				de Rocquigny, H; Petitjean, P; Tanchou, V; Decimo, D; Drouot, L; Delaunay, T; Darlix, JL; Roques, BP			The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; CELL-CYCLE; NUCLEAR-LOCALIZATION; VIRION INCORPORATION; ANNEALING ACTIVITIES; H-1-NMR STRUCTURE; GENE-PRODUCT; IN-VITRO; BINDING	The 96-amino acid protein Vpr functions as a regulator of cellular processes involved in human immunodeficiency virus, type 1 (HIV-1) life cycle, in particular by interrupting cells division in the G(2) phase, Incorporation of Vpr in the virion was reported to be mediated by the C-terminal domain of the pr55(Gag) polyprotein precursor, which includes NCp7, a protein involved in the genomic RNA encapsidation and p6, a protein required for particle budding, To precisely define the Gag and Vpr sequences involved in this protein-protein interaction, NCp7, p6, and Vpr as well as a series of derived peptides were synthesized using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry, Binding assays were carried out by Far Western experiments and by competition studies using (52-96)Vpr immobilized onto agarose beads, The results show that interaction between NCp7 and Vpr occurs in vitro by a recognition mechanism requiring the zinc fingers of NCp7 and the last 16 amino acids of Vpr, Moreover, NCp10, the equivalent of NCp7 in Moloney murine leukemia virus but not polysine inhibits Vpr-NCp7 complexation, Interestingly enough, Vpr was found to interact with Gag, NCp15, and NCp7 but not with mature p6 in vitro. In vive mutations in NCp7 zinc fingers in an HIV-1 molecular clone led to viruses with important defects in Vpr encapsidation. Together, these results suggest that NCp7 cooperates with p6 to induce Vpr encapsidation in HIV-1 mature particles, The NCp7-Vpr complex could also be important for interaction of Vpr with cellular proteins involved in cell division.	UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, F-75270 Paris 06, France; Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon, France; Inst Sante Rech Med, F-69364 Lyon, France; INRA, Dept Virol & Immunol Mol, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Roques, BP (corresponding author), UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, 4 Ave Observ, F-75270 Paris 06, France.		LUC, DARLIX JEAN/AAE-9268-2020	Decimo, Didier/0000-0002-0390-1205				Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CARRIERE C, 1995, J VIROL, V69, P2366; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; Colgan J, 1996, J VIROL, V70, P4299, DOI 10.1128/JVI.70.7.4299-4310.1996; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEMENE H, 1994, J BIOMOL NMR, V4, P153, DOI 10.1007/BF00175244; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DONG CZ, 1997, IN PRESS J PEPTIDES, V49; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GORELICK RJ, 1996, RETROVIRUSES 1996S R, P356; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; GRASMASSE H, 1990, INT J PEPT PROT RES, V36, P219; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LAVALLEE C, 1994, J VIROL, V68, P1926; Li MS, 1996, BIOCHEM BIOPH RES CO, V218, P352, DOI 10.1006/bbrc.1996.0061; LIM THY, 1997, FEBS LETT, V401, P197; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; ROQUES BP, IN PRESS BIOCHIMIE P; Sato A, 1996, VIROLOGY, V220, P208, DOI 10.1006/viro.1996.0302; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; SOUTH TL, 1993, PROTEIN SCI, V2, P3; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; TANCHOU V, 1994, AIDS RES HUM RETROV, V10, P983, DOI 10.1089/aid.1994.10.983; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; ZHANG YQ, 1995, J VIROL, V69, P5716, DOI 10.1128/JVI.69.9.5716-5722.1995; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	53	65	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30753	30759		10.1074/jbc.272.49.30753	http://dx.doi.org/10.1074/jbc.272.49.30753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388214	hybrid			2022-12-27	WOS:000071640800027
J	Gnatt, A; Fu, JH; Kornberg, RD				Gnatt, A; Fu, JH; Kornberg, RD			Formation and crystallization of yeast RNA polymerase II elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION; ESCHERICHIA-COLI; TERNARY COMPLEXES; INITIATION; DNA; PROTEIN; PURIFICATION; CLEAVAGE; TEMPLATE; INVITRO	Minimal templates were devised for the efficient generation of yeast RNA polymerase II transcription elongation complexes. A 33-base pair DNA with a 15-residue dC tail at one 3'-end supported the formation of a complex containing the polymerase paused at nucleotide 11 of the duplex region and an RNA of 14-16 residues. The same template could yield an arrested complex with the enzyme at nucleotide 13-15 and RNA of 15-17 residues. These complexes were stable for at least a week under various conditions and could be resolved by gel electrophoresis or purified by ion exchange chromatography. The purified paused complex formed crystals capable of x-ray diffraction to 3.5 Angstrom resolution. The complex remained active in the crystal and, in the presence of nucleoside triphosphates, could efficiently extend the transcript in situ.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NCI NIH HHS [5T32CA09151] Funding Source: Medline; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM49985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DUAN RD, 1995, SCIENCE, V269, P1402; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1994, NAT STRUCT BIOL, V1, P195, DOI 10.1038/nsb0394-195; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GU WG, 1993, J BIOL CHEM, V268, P25604; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Maniatis T., 1982, MOL CLONING LAB MANU; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30799	30805		10.1074/jbc.272.49.30799	http://dx.doi.org/10.1074/jbc.272.49.30799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388221	hybrid			2022-12-27	WOS:000071640800034
J	Zhang, P; Liu, B; Kang, SW; Seo, MS; Rhee, SG; Obeid, LM				Zhang, P; Liu, B; Kang, SW; Seo, MS; Rhee, SG; Obeid, LM			Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; SACCHAROMYCES-CEREVISIAE; CELL-DEATH; FACTOR ADF; GENE; INDUCTION; REDUCTASE; CANCER; YEAST; LOCALIZATION	Thioredoxin peroxidase (TPx) is a member of a newly discovered family of proteins that are conserved from yeast to mammals and to which natural killer enhancing factor belongs. These proteins are antioxidants that function as peroxidases only when coupled to a sulfhydryl reducing system, The physiological function of TPx in cells is not yet known, Here we demonstrate that when the human TPx II, a member of this family, is stably overexpressed in Molt-4 leukemia cells, it protects from apoptosis induced by serum deprivation, ceramide, or etoposide. TPx II, like Bcl-2, is able to inhibit release of cytochrome c from mitochondria to cytosol, and it inhibits lipid peroxidation in cells, TPx II, unlike Bcl-2, could prevent hydrogen peroxide accumulation in cells, suggesting that it functions upstream of Bcl-2 in the protection from apoptosis and may be implicated as an endogenous regulator of apoptosis.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Vet Affairs Geriatr Res Educ & Clin Ctr, Durham, NC 27710 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obeid, LM (corresponding author), Duke Univ, Med Ctr, Dept Med, Box3345, Durham, NC 27710 USA.			obeid, lina/0000-0002-0734-0847	NIA NIH HHS [1R29-AG-12467] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAKER MS, 1989, MED HYPOTHESES, V29, P187, DOI 10.1016/0306-9877(89)90193-X; BANKSON DD, 1993, CLIN LAB MED, V13, P463, DOI 10.1016/S0272-2712(18)30449-9; BREDESEN DE, 1996, NEUROLOGY S, V47, P38; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; GASDASKA PY, 1994, BBA-GENE STRUCT EXPR, V1218, P292, DOI 10.1016/0167-4781(94)90180-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JENNER P, 1996, NEUROLOGY S3, V47, P161; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUDA M, 1991, J IMMUNOL, V147, P3837; Othmane Kamel Ben, 1992, Nature Genetics, V2, P315; PAHL P, 1995, GENOMICS, V26, P602, DOI 10.1016/0888-7543(95)80183-M; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SATCH T, 1996, J BIOCHEM-TOKYO, V120, P540; SHAU HG, 1994, IMMUNOGENETICS, V40, P129; SHAU HY, 1993, CELL IMMUNOL, V147, P1, DOI 10.1006/cimm.1993.1043; SHAU HY, 1994, BIOCHEM BIOPH RES CO, V199, P83, DOI 10.1006/bbrc.1994.1197; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STADTMAN ER, 1993, TOXICOL IND HEALTH, V9, P187, DOI 10.1177/0748233793009001-213; Wang JX, 1997, BLOOD, V89, P2480, DOI 10.1182/blood.V89.7.2480; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	41	331	339	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30615	30618		10.1074/jbc.272.49.30615	http://dx.doi.org/10.1074/jbc.272.49.30615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388194	hybrid			2022-12-27	WOS:000071640800007
J	Hirose, Y; Manley, JL				Hirose, Y; Manley, JL			Creatine phosphate, not ATP, is required for 3' end cleavage of mammalian pre-mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA POLYADENYLATION; LATE TRANSCRIPTION UNIT; POLY(A) ADDITION SITE; SPECIFICITY FACTOR; POLY(A)-BINDING PROTEIN; PROCESSING FACTORS; AAUAAA SEQUENCE; 160-KD SUBUNIT; POLYMERASE-II; GLOBIN GENE	The poly(A) tail of a mammalian mRNA is generated by endonucleolytic cleavage and poly(A) addition, Previous studies conducted with nuclear extracts suggested an ATP requirement for the cleavage step, We have reexamined the cofactor requirement, initially with the SV40 late pre-mRNA, which requires for cleavage four protein factors, cleavage and polyadenylation specificity factor, cleavage stimulation factor, cleavage factor I, and cleavage factor II. Using highly purified preparations of these factors, which lacked detectable creatine phosphokinase and ATPase activities, creatine phosphate (CP) was, surprisingly, found to be sufficient to promote efficient cleavage, Although other phosphate compounds substituted poorly or not at all for CP, another phosphoguanidine, arginine phosphate, was fully functional. Notably, ATP was neither necessary nor sufficient, and could in fact inhibit the reaction. Treatment of the purified factors with hexokinase plus glucose (to deplete any contaminating ATP) was without effect, as was addition of EDTA, Using P-32-labeled CP, we found that neither hydrolysis of CP nor phosphate transfer from CP occurred during the cleavage reaction. CP also allowed cleavage of the adenovirus 2 L3 pre-mRNA, However, in this case, ATP both enhanced the reaction and influenced the precise site of cleavage, perhaps reflecting the requirement of poly(A) polymerase for cleavage of this RNA, These results indicate that ATP is not essential for 3' pre-mRNA cleavage and that CP or a related compound can function as a necessary cofactor.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CANDE WZ, 1983, NATURE, V304, P557, DOI 10.1038/304557a0; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; ENNOR AH, 1958, PHYSIOL REV, V38, P631, DOI 10.1152/physrev.1958.38.4.631; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; Gilmartin GM, 1996, J VIROL, V70, P1775, DOI 10.1128/JVI.70.3.1775-1783.1996; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KOONS SJ, 1982, EXP CELL RES, V140, P401, DOI 10.1016/0014-4827(82)90130-6; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; LYZLOVA SN, 1991, PHOSPHAGEN KINASES, P1; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANOS P, 1993, DEV NEUROSCI-BASEL, V15, P271, DOI 10.1159/000111344; MANOS P, 1992, J COMP NEUROL, V326, P273, DOI 10.1002/cne.903260209; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MOORE CL, 1988, MOL CELL BIOL, V8, P226, DOI 10.1128/MCB.8.1.226; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; PRESCOTT JC, 1992, J BIOL CHEM, V267, P8175; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RMEGSEGGER U, 1996, J BIOL CHEM, V271, P6107; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SPERRY AO, 1986, MOL CELL BIOL, V6, P4734, DOI 10.1128/MCB.6.12.4734; STEFANO JE, 1988, MOL CELL BIOL, V8, P2052, DOI 10.1128/MCB.8.5.2052; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317; ZHANG F, 1987, MOL CELL BIOL, V7, P3277, DOI 10.1128/MCB.7.9.3277; Zhao J, 1997, J BIOL CHEM, V272, P10831	67	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29636	29642		10.1074/jbc.272.47.29636	http://dx.doi.org/10.1074/jbc.272.47.29636			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368030	hybrid			2022-12-27	WOS:A1997YG64700040
J	Jaitner, BK; Becker, J; Linnemann, T; Herrmann, C; Wittinghofer, A; Block, C				Jaitner, BK; Becker, J; Linnemann, T; Herrmann, C; Wittinghofer, A; Block, C			Discrimination of amino acids mediating Ras binding from noninteracting residues affecting Raf activation by double mutant analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HA-RAS; PROTEIN-KINASE; IN-VITRO; PLASMA-MEMBRANE; DOMAIN; IDENTIFICATION; TRANSFORMATION; P21(RAS); COMPLEX; INTERFACE	The contribution of residues outside the Has binding domain of Raf (RafRBD) to Ras-Raf interaction and Ras-dependent Raf activation has remained unresolved. Here, we utilize a double mutant approach to identify complementary interacting amino acids that are involved in Ras-Raf interaction and activation. Biochemical analysis demonstrates that Raf-Arg(59) and Raf-Arg(67) from RafRBD are interacting residues complementary to Ras-Glu(37) located in the Ras effector region. Raf-Arg(59) and Raf-Arg(67) also mediate interaction with Ras-Glu(37) in Has-dependent Raf activation, The characteristics observed here can be used as criteria for a role of residues from other regions of Raf in Ras-Raf interaction and activation. We developed a quantitative two-hybrid system as a tool to investigate the effect of point mutations on protein-protein interactions that elude biochemical analysis of bacterially expressed proteins. This assay shows that Raf-Ser(257) in the RafCR2 domain does not contribute to Ras-Raf interaction and that the Raf-S257L mutation does not restore Raf binding to Ras-E37G, Yet, Raf-S257L displays high constitutive kinase activity and further activation by Ras-G12V/E37G is still impaired as compared with activation by Ras-G12V, This strongly suggests that the RafCR2 domain is an independent domain involved in the control of Raf activity and a common mechanism for constitutively activating mutants may be the interference with the inactive ground state of the kinase.	MAX PLANCK INST MOL PHYSIOL, ABT STRUKTURELLE BIOL, D-44026 DORTMUND, GERMANY	Max Planck Society								BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SCHEFFLER JE, 1994, BIOCHEMISTRY-US, V35, P22340; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29927	29933		10.1074/jbc.272.47.29927	http://dx.doi.org/10.1074/jbc.272.47.29927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368069	hybrid			2022-12-27	WOS:A1997YG64700079
J	Fuchs, SY; Xie, B; Adler, V; Fried, VA; Davis, RJ; Ronai, Z				Fuchs, SY; Xie, B; Adler, V; Fried, VA; Davis, RJ; Ronai, Z			c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; DELTA-DOMAIN; UV IRRADIATION; IN-VIVO; V-JUN; PHOSPHORYLATION; STRESS; BINDING; DEGRADATION; INDUCTION	Regulatory proteins are often ubiquitinated, depending on their phosphorylation status as well as on their association with ancillary proteins that serve as adapters of the ubiquitination machinery, We previously demonstrated that c-Jun is targeted for ubiquitination by its association with inactive c-Jun NH2-terminal kinase (JNK), Phosphorylation by activated JNK protects c-Jun from ubiquitination, thus by prolonging its half-life, In the study reported here, we determined the ability of JNK to target ubiquitination of its other substrates (Elk1 and activating transcription factor 2 (ATF2)) and associated proteins (ATF2 and JunB), We demonstrate that phosphorylation by JNK protects ATF2, but not Elk1, from JNK-targeted ubiquitination. We also show that association of inactive JNK with JunB or ATF2 is necessary to target them for ubiquitination, Unlike its targeting of c-Jun, JNK requires additional cellular components, yet to be identified, to target the ubiquitination of ATF2., Elk1 is phosphorylated by JNK, but JNK neither associates with nor targets Elk1 for ubiquitination. The implications for the dual role of JNK in the regulation of ubiquitination and stability of c-Jun, ATF2, and JunB in normally growing versus stressed cells are discussed.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Worcester, MA 01605 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York Medical College; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA-59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; Bocco JL, 1996, ONCOGENE, V12, P1971; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAI TN, 1995, ONCOGENE, V10, P849; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Fuchs SY, 1996, ONCOGENE, V13, P1531; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	41	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32163	32168		10.1074/jbc.272.51.32163	http://dx.doi.org/10.1074/jbc.272.51.32163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405416	hybrid			2022-12-27	WOS:000071108000035
J	AlAoukaty, A; Rolstad, B; Maghazachi, AA				AlAoukaty, A; Rolstad, B; Maghazachi, AA			Functional coupling of NKR-P1 receptors to various heterotrimeric G proteins in rat interleukin-2-activated natural killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING EVENTS; T-LYMPHOCYTES; GENE-COMPLEX; CLASS-I; CLONING; KINASE; NK; INVOLVEMENT; INHIBITION; MOLECULE	NKR-P1 molecules constitute a family of type II membrane receptors in natural killer (NK) cells that preferentially activate NK cell killing and release of interferon-gamma from these cells. Here, we demonstrate that anti NKR-P1 enhances GTP binding in rat interleukin-2- activated NK cell membranes; GTP binding to G(i3)alpha, G(s) alpha, G(q,11)alpha and G(z) alpha increased noticeably in these cell membranes after treatment with anti-NKR-P1. Western blot analysis of membrane proteins prepared from interleukin-2-activated NK cells reveals the presence of G(i1,2)alpha, G(i3)alpha, G(o) alpha, G(s) alpha, G(q,11)alpha, G(z) alpha, and G(12)alpha, but not G(13)alpha. However, only alpha(i3), alpha(s), alpha(q,11), and alpha(z), but not alpha(i1,2), alpha(o), alpha(12), or alpha(13) subunits when immunoprecipitated with the appropriate anti-G protein antibodies, are associated with NKR-P1 when immunoblotted with anti-NKR-P1. Reciprocally, NKR-P1 immunoprecipitated with anti-NKR-P1 is associated with alpha(i3), alpha(s), alpha(q,11), and alpha(z) immunoblotted with anti-G proteins. These results are the first to demonstrate the physical and functional coupling of NKR-P1 to the heterotrimeric G proteins in NK cells.			AlAoukaty, A (corresponding author), UNIV OSLO, DEPT ANAT, INST BASIC MED SCI, POB 1105 BLINDERN, N-0317 OSLO, NORWAY.			Maghazachi, Azzam/0000-0002-3310-678X				AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; ALAOUKATY A, 1994, BLOOD, V83, P1299; Biron Christine A., 1996, Methods (Orlando), V9, P379, DOI 10.1006/meth.1996.0043; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; DAVIES P, 1994, J CELL PHYSIOL, V159, P399, DOI 10.1002/jcp.1041590303; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GIORDA R, 1992, SCIENCE, V147, P1701; HISASHI A, 1996, J EXP MED, V183, P2391; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; Lanier L L, 1995, Semin Immunol, V7, P75, DOI 10.1006/smim.1995.0011; LANIER LL, 1994, J IMMUNOL, V153, P2417; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Litosch I, 1996, BIOCHEM J, V319, P173, DOI 10.1042/bj3190173; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maghazachi AA, 1997, BIOCHEM BIOPH RES CO, V236, P270, DOI 10.1006/bbrc.1997.6937; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MAGHAZACHI AA, 1994, J BIOL CHEM, V269, P6796; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; Moretta L, 1996, J CLIN IMMUNOL, V16, P243, DOI 10.1007/BF01541388; NAPER C, 1995, EUR J IMMUNOL, V25, P1249, DOI 10.1002/eji.1830250518; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PITCHER JA, 1995, CELL, V83, P821; PROCOPIO ADG, 1991, J IMMUNOL, V146, P3550; RAULET DH, 1992, NATURE, V358, P21, DOI 10.1038/358021a0; RYAN JC, 1992, J IMMUNOL, V149, P1631; RYAN JC, 1991, J IMMUNOL, V147, P3244; Ryan JC, 1997, IMMUNOL REV, V155, P79, DOI 10.1111/j.1600-065X.1997.tb00941.x; SEBOK K, 1993, J IMMUNOL, V150, P1524; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TING AT, 1992, J BIOL CHEM, V267, P23957; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	41	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31604	31608		10.1074/jbc.272.50.31604	http://dx.doi.org/10.1074/jbc.272.50.31604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395499	hybrid			2022-12-27	WOS:A1997YL41900058
J	Chin, D; Winkler, KE; Means, AR				Chin, D; Winkler, KE; Means, AR			Characterization of substrate phosphorylation and use of calmodulin mutants to address implications from the enzyme crystal structure of calmodulin-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; RAT-BRAIN; PEPTIDE COMPLEX; PURIFICATION; RECOGNITION; ACTIVATION; BINDING; IDENTIFICATION; SPECIFICITIES; RESIDUES	Calcium/calmodulin (CaM) directly activates CaM-dependent protein kinase I (CaMKI) by binding to the enzyme and indirectly promotes the phosphorylation and synergistic activation of CaMKI by an exogenous kinase. We have evaluated the initial CaM-dependent activation of the unphosphorylated form of CaMKI, The kinetics of bacterially expressed human CaMKI show that the peptide syntide-2 is a relatively poor substrate, whereas the synapsin site-1 peptide is 17-fold more specific. The peptide ADR1G is 400-fold more specific than syntide-2, and its catalytic rate is among the highest reported for a kinase peptide substrate. To understand how CaM activates CaMKI, we have characterized the activation of the enzyme by CaM mutants with substitutions at hydrophobic residues. The point mutant M124Q located in the C-terminal domain of CaM produced a 57-fold increase in the CaM activation constant for CaMKI and suggests the involvement of methionine 124 in an important hydrophobic interaction with tryptophan 303 of CaMKI. Substituting two, three, and five hydrophobic residues in the N-terminal domain of CaM increased the CaM activation constant for CaMKI by 10-190-fold and lowered the maximal enzyme activity by more than 80%. Two of these N-terminal mutants of CaM do not affect the K-m for peptide substrate but instead produce a 5-10-fold higher K-m for ATP. This result demonstrates the critical role of the N-terminal domain of CaM in regulating the access of ATP to CaMKI.	DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Dixon M., 1979, ENZYMES, Vthird; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INOUE S, 1995, BIOCHEM BIOPH RES CO, V215, P861, DOI 10.1006/bbrc.1995.2543; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KEMP BE, 1994, PROTEIN KINASES, P30; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P23851; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	35	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31235	31240		10.1074/jbc.272.50.31235	http://dx.doi.org/10.1074/jbc.272.50.31235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395448	hybrid			2022-12-27	WOS:A1997YL41900007
J	Yamaguchi, A; Urano, T; Goi, T; Feig, LA				Yamaguchi, A; Urano, T; Goi, T; Feig, LA			An eps homology (EH) domain protein that binds to the Ral-GTPase target, RalBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; TYROSINE KINASE SUBSTRATE; ACTIVATING PROTEIN; PUTATIVE EFFECTOR; SH3 DOMAIN; VESICLES; IDENTIFICATION; ENDOCYTOSIS; INTERACTS; GENE	Ral proteins constitute a family of small GTPases that can be activated by Ras in cells, In the GTP-bound state, Ral proteins bind to RalBP1, a GTPase-activating protein for CDC42 and Rac GTPases. We have used the two-hybrid system in yeast to clone a cDNA for a novel similar to 85-kDa protein that can bind to an additional site on RalBP1, This newly identified protein contains an Eps homology (EH) domain, which was first detected in the epidermal growth factor (EGF) receptor substrate Eps15. Recently, the EH domain of Eps15 has been shown to bind to proteins containing an asparagine-proline-phenylalanine motif. Moreover, EH domains have been found in proteins involved in endocytosis and/or actin cytoskeleton regulation. The RalBP1 associated Eps-homology domain protein, Reps1, is tyrosine-phosphorylated in response to EGF stimulation of cells. In addition, Reps1 has the capacity to form a complex with the SH3 domains of the adapter proteins Crk and Grb2, which may link Reps1 to an EGF-responsive tyrosine kinase. Thus, Reps1 may coordinate the cellular actions of activated EGF receptors and Ral-GTPases.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University				Urano, Takeshi/0000-0003-3383-3554	NIGMS NIH HHS [GM47707] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; BENMERAH A, 1996, J BIOL CHEM, V271, P28727; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMKEY R, 1991, J BIOL CHEM, V266, P9703; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Iannolo G, 1997, CANCER RES, V57, P240; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	41	102	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31230	31234		10.1074/jbc.272.50.31230	http://dx.doi.org/10.1074/jbc.272.50.31230			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395447	hybrid			2022-12-27	WOS:A1997YL41900006
J	Athlan, ES; Mushynski, WE				Athlan, ES; Mushynski, WE			Heterodimeric associations between neuronal intermediate filament proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFILAMENT TRIPLET PROTEINS; COILED-COIL; NF-L; MOLECULAR MASSES; ALPHA-INTERNEXIN; EXPRESSION; POLYPEPTIDES; PERIPHERIN; INVITRO; SUBUNIT	Formation of protein dimers involving alpha-internexin, peripherin, and the neurofilament (NF) proteins NFH, NFM, and NFL was investigated by partial renaturation of various combinations of individually purified subunits in buffered 2 M urea, Oligomers that were formed were resolved by "blue" native electrophoresis (Schagger, H.,, Cramer, W., A., and von Jagow, G. (1994) Anal, Biochem. 217, 220-230) modified to include urea in the polyacrylamide gels, Combining this method with Western blot analysis, disulfide cross-linking, and SDS-polyacrylamide gel electrophoresis in the second dimension showed that NFL readily forms significant amounts of heterodimer with NFH, NFM, alpha-internexin, or peripherin in the presence of 2 M urea, alpha-Internexin and peripherin also formed heterodimers with NFH or NFM under these conditions, The modified version of blue native gel electrophoresis described here may be useful in monitoring the impact of post-translational modifications and mutations on the dimerization of intermediate filament proteins.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Mushynski, WE (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Athlan ES, 1997, J NEUROSCI RES, V47, P300; BRAGG PD, 1975, ARCH BIOCHEM BIOPHYS, V167, P311, DOI 10.1016/0003-9861(75)90467-1; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; CARDEN MJ, 1986, BIOCHEM J, V234, P587, DOI 10.1042/bj2340587; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHADAN S, 1994, J NEUROCHEM, V62, P1894; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHIU FC, 1989, NEURON, V2, P1435, DOI 10.1016/0896-6273(89)90189-X; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COHLBERG JA, 1995, J BIOL CHEM, V270, P9334, DOI 10.1074/jbc.270.16.9334; COHLBERG JA, 1987, J BIOL CHEM, V262, P17009; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLIEGNER KH, 1994, J COMP NEUROL, V342, P161, DOI 10.1002/cne.903420202; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; Giasson BI, 1997, NEUROSCI LETT, V229, P77, DOI 10.1016/S0304-3940(97)00425-4; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PARYSEK LM, 1991, J NEUROSCI RES, V30, P80, DOI 10.1002/jnr.490300110; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; *SIGM, 1988, SIGM TECHN B; SOKOLOFF RL, 1981, ANAL BIOCHEM, V118, P138, DOI 10.1016/0003-2697(81)90169-X; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun DM, 1997, J NEUROCHEM, V68, P917; WEBER K, 1969, J BIOL CHEM, V244, P4406; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; ZACKROFF RV, 1982, P NATL ACAD SCI-BIOL, V79, P754, DOI 10.1073/pnas.79.3.754	47	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31073	31078		10.1074/jbc.272.49.31073	http://dx.doi.org/10.1074/jbc.272.49.31073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388258	hybrid			2022-12-27	WOS:000071640800071
J	Barone, LM; Shih, C; Wasserman, BP				Barone, LM; Shih, C; Wasserman, BP			Mercury-induced conformational changes and identification of conserved surface loops in plasma membrane aquaporins from higher plants - Topology of PMIP31 from Beta vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(1,3)-BETA-GLUCAN CALLOSE SYNTHASE; TONOPLAST INTRINSIC PROTEIN; WATER CHANNEL PROTEINS; CELL CHIP28 PROTEIN; ARABIDOPSIS-THALIANA; VACUOLAR MEMBRANE; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; EXPRESSION; FAMILY	Aquaporins are integral membrane proteins occurring in mammals, plants, and microorganisms, which serve as channels that permit the bidirectional passage of water through cellular membranes, Higher plants contain abundant levels of aquaporins in both the tonoplast and plasma membrane, Aquaporins contain six transmembrane segments with three surface loops located at the apoplastic face of the membrane and two loops at the cytosolic side, In this study, we probed the topology of plasma membrane aquaporins to determine the effects of divalent cations on aquaporin conformation, and to identify structural features that distinguish plasma membrane intrinsic proteins from tonoplast intrinsic proteins, Plasma membrane vesicles from storage tissue of Beta vulgaris L. were subjected to limited proteolysis, and proteolytic fragmentation patterns were detected using affinity-purified antibodies recognizing aquaporins of 31-kDa, In its native membrane-associated state, the 31 aquaporin band, PMIP31, was refractory to proteolysis by trypsin, However,mercuric compounds specifically induced a conformational change resulting in the exposure of a proteolytic cleavage site and formation of a unique 22-kDa proteolytic fragment (p22), N-terminal sequence analysis of p22 established its identity as an aquaporin-derived fragment, Topological studies using sealed right-side-out plasma membrane vesicles established that the proteolytic cleavage site is located at surface loop C, the second apoplastic loop, immediately preceding the sequence Gly-Gly-Gly-Ala-Asn, The Gly-Gly-Gly-Ala-Asn-X-X-X-X-Gly-Tyr motif of loop C and a 14 amino acid motif in apoplastic loop E, Thr-Gly-Ile-Thr-Asn-Pro-Ala-Arg-Ser-Leu/Phe-Gly-Ala-Ala-Ile/Val-Ile/Val-Phe/Tyr-Asn are completely conserved in all known higher plant aquaporins of plasma membrane origin and are not present in any of the known tonoplast intrinsic proteins. These results demonstrate that the two highly conserved plasma membrane intrinsic protein surface loops are structural features that clearly distinguish plasma membrane from tonoplast aquaporins.	Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick	Wasserman, BP (corresponding author), Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08903 USA.	wasserman@aesop.rutgers.edu						AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P8827; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CHRISPEELS MJ, 1994, PLANT PHYSIOL, V105, P9, DOI 10.1104/pp.105.1.9; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; Daniels MJ, 1996, PLANT CELL, V8, P587, DOI 10.1105/tpc.8.4.587; FARINAS J, 1993, BIOCHEMISTRY-US, V32, P11857, DOI 10.1021/bi00095a014; FRAY RG, 1994, PLANT MOL BIOL, V24, P539, DOI 10.1007/BF00024122; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; INOUE K, 1995, PLANT MOL BIOL, V28, P1089, DOI 10.1007/BF00032669; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; Johansson I, 1996, PLANT CELL, V8, P1181, DOI 10.1105/tpc.8.7.1181; JOHNSON KD, 1990, PLANT CELL, V2, P525, DOI 10.1105/tpc.2.6.525; JOHNSON KD, 1992, PLANT PHYSIOL, V100, P1787, DOI 10.1104/pp.100.4.1787; KALDENHOFF R, 1993, PLANT MOL BIOL, V23, P1187, DOI 10.1007/BF00042352; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESNIAK W, 1994, BIOCHEMISTRY-US, V33, P13678, DOI 10.1021/bi00250a018; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; NIELSEN S, 1995, KIDNEY INT, V48, P1057, DOI 10.1038/ki.1995.389; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; QI X, 1996, PLANT PHYSIOL, V112, P861; QI XQ, 1995, PLANT PHYSIOL, V108, P387, DOI 10.1104/pp.108.1.387; Robinson DC, 1996, PLANT PHYSIOL, V111, P645, DOI 10.1104/pp.111.2.645; TANG WJY, 1993, ANTIBODIES CELL BIOL, P95; Umbach AL, 1996, J BIOL CHEM, V271, P25019, DOI 10.1074/jbc.271.40.25019; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WASSERMAN BP, 1989, MOD METHOD PLANT, V10, P1; WASSERMAN BP, 1996, MOD METHOD PLANT, V17, P181; WU A, 1993, PLANT J, V4, P683, DOI 10.1046/j.1365-313X.1993.04040683.x; WU AY, 1991, PLANT PHYSIOL, V97, P684, DOI 10.1104/pp.97.2.684; YAMADA S, 1995, PLANT CELL, V7, P1129, DOI 10.1105/tpc.7.8.1129; YAMAGUCHISHINOZAKI K, 1992, PLANT CELL PHYSIOL, V33, P217, DOI 10.1093/oxfordjournals.pcp.a078243; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	53	45	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30672	30677		10.1074/jbc.272.49.30672	http://dx.doi.org/10.1074/jbc.272.49.30672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388202	hybrid			2022-12-27	WOS:000071640800015
J	Mhaouty-Kodja, S; Bouet-Alard, R; Limon-Boulez, I; Maltier, JP; Legrand, C				Mhaouty-Kodja, S; Bouet-Alard, R; Limon-Boulez, I; Maltier, JP; Legrand, C			Molecular diversity of adenylyl cyclases in human and rat myometrium - Correlation with global adenylyl cyclase activity during mid- and term pregnancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHORBOL ESTER TREATMENT; CALCIUM INHIBITION; MESSENGER-RNA; MUSCLE-CELLS; EXPRESSION; PROTEIN; BRAIN; RECEPTOR; PROGESTERONE	Expression and regulation of myometrial adenylyl cyclases (AC) were studied during pregnancy, Hybridization of poly(A)(+) RNA with specific cDNA probes for enzyme types I-IX indicated 1) the presence of transcripts encoding types II-VI and type IX in rat and human, and type VII in rat and 2) the absence of detectable mRNA for types I and VIII in both species, No substantial change was observed in the amount of specific mRNA and basal AC activity from mid-pregnancy to term, However, activation of the alpha(2)-adrenergic receptor/G(i) protein pathway resulted in potentiation of G(s)-stimulated AC activity at mid-pregnancy but not at term (Mhaouty, S., Cohen-Tannoudji, J,, Bouet-Alard, R,, Limon-Boulez, I., Maltier, J, P,, and Legrand, C, (1995) J, Biol, Chem. 270, 11012-11016), We demonstrate in the present work that beta gamma scavengers transducin-alpha and QEHA peptide abolished this positive input, On the other hand, increasing submicromolar concentrations of free Ca2+, a situation that mimics late term, reduced the forskolin-stimulated AC activity with an IC50 of 3.9 mu M. Thus, the presence in myometrium of AC II family (types II, IV, VII) confers ability to G inhibitory proteins to stimulate enzyme activity via beta gamma complexes at mid-pregnancy, whereas expression of AC III, V, and VI isoforms confers to the myometrial AC system a high sensitivity to inhibition by Ca2+-dependent processes at term. These data suggest that in the pregnant myometrium, the expression of different species of AC with distinct regulatory properties provides a mechanism for integrating positively or negatively the responses to various hormonal inputs existing either during pregnancy or in late term.	Univ Paris 06, Reprod Physiol Lab, CNRS, URA 1449, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Legrand, C (corresponding author), Univ Paris 06, Reprod Physiol Lab, CNRS, URA 1449, 4 Pl Jussieu, F-75252 Paris 05, France.		Limon, Isabelle/P-2750-2017; Limon, Isabelle/AAJ-6169-2020	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Mhaouty-Kodja, Sakina/0000-0001-9743-5243				BARBER R, 1988, SEC MESS PHOSPHOPROT, V12, P59; BREUILLER M, 1990, J CLIN ENDOCR METAB, V70, P1299, DOI 10.1210/jcem-70-5-1299; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COHEN-TANNOUDJI J, 1995, BIOL REPROD, V53, P55, DOI 10.1095/biolreprod53.1.55; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1994, CELL SIGNAL, V6, P823, DOI 10.1016/0898-6568(94)90016-7; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; ESPINASSE I, 1995, J MOL CELL CARDIOL, V27, P1789, DOI 10.1016/0022-2828(95)90002-0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FURUYAMA T, 1993, MOL BRAIN RES, V19, P165, DOI 10.1016/0169-328X(93)90163-J; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HOUDEAU E, 1994, CELL TISSUE RES, V277, P579; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LASKER RD, 1982, ARCH BIOCHEM BIOPHYS, V216, P345, DOI 10.1016/0003-9861(82)90220-X; LEGRAND C, 1986, J REPROD FERTIL, V76, P415, DOI 10.1530/jrf.0.0760415; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MAGOCSI M, 1991, BIOCHIM BIOPHYS ACTA, V1063, P7, DOI 10.1016/0005-2736(91)90346-A; MAKA FDK, 1990, GYNECOL OBSTET INVES, V30, P169; Marjamaki A, 1997, J BIOL CHEM, V272, P16466, DOI 10.1074/jbc.272.26.16466; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; NELSON CA, 1986, J BIOL CHEM, V261, P3469; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PIASCIK MT, 1995, ARCH BIOCHEM BIOPHYS, V241, P28; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; STRITTMATTER S, 1980, P NATL ACAD SCI-BIOL, V77, P6344, DOI 10.1073/pnas.77.11.6344; TANFIN Z, 1991, FEBS LETT, V278, P4, DOI 10.1016/0014-5793(91)80070-J; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; VIVAT V, 1992, J BIOL CHEM, V267, P7975; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; WEILAND T, 1992, J BIOL CHEM, V267, P20791; WENG G, 1996, J BIOL CHEM, V2271, P26445; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zimmermann G, 1996, J BIOL CHEM, V271, P27161, DOI 10.1074/jbc.271.43.27161	47	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31100	31106		10.1074/jbc.272.49.31100	http://dx.doi.org/10.1074/jbc.272.49.31100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388262	hybrid			2022-12-27	WOS:000071640800075
J	Toretsky, JA; Kalebic, T; Blakesley, V; LeRoith, D; Helman, LJ				Toretsky, JA; Kalebic, T; Blakesley, V; LeRoith, D; Helman, LJ			The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUND-CELL TUMORS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; T(1122) TRANSLOCATION; CHIMERIC TRANSCRIPTS; EWING SARCOMA; GENE; PROTEIN; FUSION; PHOSPHATASE	Ewing's family of tumors is characterized by a well described reciprocal translocation, t(11;22)(q24;q12), which produces a fusion protein (EWS/FLI-1) that transforms mouse fibroblasts. The EWS/FLI-1 fusion protein has been shown to act as a potent chimeric transcription factor. Overexpression of insulin like growth factor-I receptor (IGF-IR) has been implicated in many tumor models as playing a role in cell growth and tumorigenesis. In addition, blockade of the IGF-IR inhibits the growth of Ewing's family of tumors cells. Therefore, we first studied whether the presence of the IGF-IR is required for transformation by the EWS/FLI-1 fusion protein. To perform this study, we used two previously described fibroblast cell lines, R- and W, derived from an IGF-IR knockout mouse and a wild-type littermate, respectively. Neither W nor R-cells without the fusion protein formed soft agar colonies. However, W clones expressing the fusion message (WF cells) formed soft agar colonies, whereas R-clones expressing the fusion message (R-F cells) did not form soft agar colonies. Because the IGF-IR is required for EWS/FLI-1 transformation, we chose to investigate whether altered signaling occurs from the IGF-IR when the EWS/FLI-1 fusion is present. WF cells demonstrated a greater degree of ligand-stimulated insulin receptor substrate-1 phosphorylation when compared with W cells, suggesting that expression of the EWS/FLI-1 fusion protein alters the IGF-IR signaling pathway.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Toretsky, JA (corresponding author), Univ Maryland, Dept Pediat Hematol Oncol, 22 S Greene St,Rm N5E16, Baltimore, MD 21201 USA.	jt@helix.nih.gov						BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; DAmbrosio C, 1996, ONCOGENE, V12, P371; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOCKHORNDWORNICZAK B, 1994, VIRCHOWS ARCH, V425, P107, DOI 10.1007/BF00230345; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; FURLANETTO RW, 1993, CANCER RES, V53, P2522; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RUBIN R, 1995, LAB INVEST, V73, P311; Scotlandi K, 1996, CANCER RES, V56, P4570; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	40	182	188	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30822	30827		10.1074/jbc.272.49.30822	http://dx.doi.org/10.1074/jbc.272.49.30822			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388225	hybrid			2022-12-27	WOS:000071640800038
J	Anderson, KM; Roshak, A; Winkler, JD; McCord, M; Marshall, LA				Anderson, KM; Roshak, A; Winkler, JD; McCord, M; Marshall, LA			Cytosolic 85-kDa phospholipase A(2)-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; GROUP-II PHOSPHOLIPASE-A2; MESSENGER-RNA LEVELS; MESANGIAL CELLS; PROSTAGLANDIN BIOSYNTHESIS; GENE-EXPRESSION; SYNOVIAL-FLUID; A(2); RAT; GROWTH	Recent evidence suggests that arachidonic acid (AA) may be involved in regulating cellular proliferation, The predominant mechanism of AA release from cellular phospholipids is via phospholipase A(2) (PLA(2)) hydrolysis, The purpose of this study was to examine the roles of the distinct 14-kDa and 85-kDa PLA(2) enzymes in human coronary artery vascular smooth muscle cell (hCAVSMC) proliferation, Cultured hCAVSMCs proliferate in the presence of growth medium with a typical doubling time of 30-40 h, grow at a slower proliferative rate upon reaching confluency (day 8), and eventually undergo contact inhibition of growth (day 10), Neither Type II 14-kDa PLA(2) activity nor mass changed over a 10-day culture period, In contrast, 85-kDa PLA(2) protein activity and mRNA decreased as time in culture progressed. This reduction in 85-kDa PLA(2) correlated with reductions in DNA synthesis and suggested a possible association between 85-kDa PLA(2) and proliferation, To directly evaluate the role of the 85-kDa PLA(2) in proliferation we examined the effects of an 85-kDa PLA(2) inhibitor (AACOCF(3)) and 85-kDa PLA(2) antisense oligonucleotides on proliferation. Both reagents dose dependently inhibited proliferation, whereas a 14-kDa PLA(2) inhibitor (SB203347), a calcium-independent PLA(2) inhibitor (HELSS), all 85-kDa sense oligonucleotide, and a nonrelevant scrambled control oligonucleotide had no effect, The mechanism by which 85-kDa PLA(2) influences cellular proliferation remains unclear. Inhibition of 85-kDa PLA(2) activity produced neither phase-specific cell cycle arrest nor apoptosis (fluorescence-activated cell sorter analysis). Addition of AA (20 mu M) attenuated the effects of both AACOCF(3) and 85-kDa antisense oligonucleotides implicating AA as a key mediator in cellular proliferation However, although prostaglandin E-2 (PGE(2)) was present in the culture medium, it peaked early (day 3) in culture, and indomethacin had no effect on cellular proliferation indicating that hCAVSMC proliferation was not mediated through PGE(2). These data provide the first direct evidence that PLA(2) is involved in control of VSMC proliferation and indicate that 85-kDa PLA(2)-mediated liberation of AA is critical for cellular proliferation.	SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOPHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	Anderson, KM (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,POB 1539,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							AMAEGADZIE BY, 1993, GENE AMST, V128, P307; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARSAGI D, 1986, SCIENCE, V233, P1062; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BRINKMAN HJM, 1990, THROMB HAEMOSTASIS, V63, P291; CAMEJO EH, 1995, CIRCULATION S1, V92, P424; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHAPMAN RS, 1995, CYTOMETRY, V20, P245, DOI 10.1002/cyto.990200308; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Corda D, 1996, ANTICANCER RES, V16, P1341; CROWL RM, 1991, J BIOL CHEM, V266, P2647; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GORCZYCA W, 1993, CANCER RES, V53, P1945; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IVANDIC B, 1996, CIRCULATION S1, V94, P1; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KERR JS, 1989, BIOCHEM BIOPH RES CO, V165, P1079, DOI 10.1016/0006-291X(89)92712-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1990, PHOSPHOLIPASE A2, P35; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LIN LL, 1992, J BIOL CHEM, V267, P23451; Liu Y, 1997, BBA-MOL CELL RES, V1355, P270, DOI 10.1016/S0167-4889(96)00148-6; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; OKA S, 1991, J BIOL CHEM, V266, P9956; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V248, P1; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1996, CORONARY RESTENOSIS, P5; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SPRARAGEN SC, 1962, CIRC RES, V11, P329, DOI 10.1161/01.RES.11.2.329; STADEL JM, 1993, J MOL RECOGNIT, V5, P145; SUNG CP, 1994, J PHARMACOL EXP THER, V271, P429; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WAITE M, 1996, BIOCH LIPIDS LIPOPRO, P211; WOJTASZEK PA, 1995, FEBS LETT, V367, P228, DOI 10.1016/0014-5793(95)00556-O	72	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30504	30511		10.1074/jbc.272.48.30504	http://dx.doi.org/10.1074/jbc.272.48.30504			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374544	hybrid			2022-12-27	WOS:A1997YH61300076
J	Rintamaki, E; Salonen, M; Suoranta, UM; Carlberg, I; Andersson, B; Aro, EM				Rintamaki, E; Salonen, M; Suoranta, UM; Carlberg, I; Andersson, B; Aro, EM			Phosphorylation of light-harvesting complex II and photosystem II core proteins shows different irradiance-dependent regulation in vivo - Application of phosphothreonine antibodies to analysis of thylakoid phosphoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOTOINHIBITION; PHOTOSYNTHESIS; DEGRADATION; CHLOROPLASTS; DEACTIVATION; D1-PROTEIN; MEMBRANES	An immunological approach using a polyclonal phosphothreonine antibody is introduced for the analysis of thylakoid protein phosphorylation in vivo, Virtually the same photosystem II (PSII) core phosphoproteins (D1, D2, CP43, and the psbH gene product) and the light-harvesting chlorophyll a/b complex II (LHCII) phosphopolypeptides (LHCB1 and LHCB2), as earlier identified by radiolabeling experiments, were recognized in both pumpkin and spinach leaves, Notably, the PSII core proteins and LHCII polypeptides were found to have a different phosphorylation pattern in vivo with respect to increasing irradiance. Phosphorylation of the PSII core proteins in leaf discs attained the saturation level at the growth light intensity, and this level was also maintained at high irradiances, Maximal phosphorylation of LHCII polypeptides only occurred at low light intensities, far below the growth irradiance, and then drastically decreased at higher irradiances. These observations are at variance with traditional studies in vitro, where LHCII shows a light-dependent increase in phosphorylation, which is maintained even at high irradiances, Only a slow restoration of the phosphorylation capacity for LHCII polypeptides at the low light conditions occurred in vivo after the high light-induced inactivation, Furthermore, if thylakoid membranes were isolated from the high light-inactivated leaves, no restoration of LHCII phosphorylation took place in vitro, However, both the high light-induced inactivation and low light-induced restoration of LHCII phosphorylation seen in vivo could be mimicked in isolated thylakoid membranes by incubating with reduced and oxidized diothiothreitol, respectively, We propose that stromal components are involved in the regulation of LHCII phosphorylation in vivo, and inhibition of LHCII phosphorylation under increasing irradiance results from reduction of the thiol groups in the LHCII kinase.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University	Rintamaki, E (corresponding author), UNIV TURKU,DEPT BIOL,FIN-20014 TURKU,FINLAND.		Rintamaki, Eevi/T-6903-2017; Andersson, Bertil/C-9328-2009; Aro, Eva-Mari/Q-8664-2017	Rintamaki, Eevi/0000-0002-1353-3995; Aro, Eva-Mari/0000-0002-2922-1435				Allen J. F., 1981, NATURE, V291, P21; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BUCHANAN BB, 1992, PHOTOSYNTH RES, V33, P147, DOI 10.1007/BF00039177; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; Carlberg I, 1996, PHOTOSYNTH RES, V47, P145, DOI 10.1007/BF00016177; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; FRID D, 1992, J BIOL CHEM, V267, P25908; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GAL A, 1990, J BIOL CHEM, V265, P19742; HAMMER MF, 1997, PLANT PHYSIOL, V133, P227; Hast T, 1996, J PHOTOCH PHOTOBIO B, V36, P313, DOI 10.1016/S1011-1344(96)07383-6; HIND G, 1995, BIOCHEMISTRY-US, V34, P8157, DOI 10.1021/bi00025a022; HORTON P, 1985, PLANTA, V165, P37, DOI 10.1007/BF00392209; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Kettunen R, 1997, EUR J BIOCHEM, V247, P441, DOI 10.1111/j.1432-1033.1997.00441.x; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON UK, 1987, BIOCHIM BIOPHYS ACTA, V894, P59, DOI 10.1016/0005-2728(87)90212-X; MCCORMAC DJ, 1994, BBA-BIOENERGETICS, V1187, P301, DOI 10.1016/0005-2728(94)90004-3; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MILLNER PA, 1982, J BIOL CHEM, V257, P1736; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; SCHEIBE R, 1987, PHYSIOL PLANTARUM, V71, P393, DOI 10.1111/j.1399-3054.1987.tb04362.x; SCHUSTER G, 1986, J CELL BIOL, V103, P71, DOI 10.1083/jcb.103.1.71; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225	35	199	209	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30476	30482		10.1074/jbc.272.48.30476	http://dx.doi.org/10.1074/jbc.272.48.30476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374540	hybrid			2022-12-27	WOS:A1997YH61300072
J	Sweet, DH; Wolff, NA; Pritchard, JB				Sweet, DH; Wolff, NA; Pritchard, JB			Expression closing and characterization of ROAT1 - The basolateral organic anion transporter in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PARA-AMINOHIPPURATE TRANSPORT; RENAL PROXIMAL TUBULE; MEMBRANE-VESICLES; FUNCTIONAL EXPRESSION; TRANSMEMBRANE PROTEINS; P-AMINOHIPPURATE; CLONING; NA+; URATE	Expression cloning in Xenopus laevis oocytes was used to isolate an organic anion transport protein from rat kidney, A cDNA library was constructed from size-fractionated poly(A)(+) RNA and screened for probenecid-sensitive transport of p-aminohippurate (PAH), A 2,227-base pair cDNA clone containing a 1,656-base pair open reading frame coding for a peptide 551 amino acids long was isolated and named ROAT1, ROAT1-mediated transport of 50 mu M [H-3]PAH was independent of imposed changes in membrane potential, Transport was significantly inhibited at 4 degrees C, or upon incubation with other organic anions, but nea, by the organic cation tetraethyl-ammonium, by the multidrug resistance ATPase inhibitor cyclosporin A, or by urate, External glutarate and alpha-ketoglutarate (1 mM), both counterions for basolateral PAH exchange, also inhibited transport, suggesting that ROAT1 is functionally similar to the basolateral PAH carrier. Consistent with this conclusion, PAH uptake was trans-stimulated in oocytes preloaded with glutarate, whereas the dicarboxylate methylsuccinate, which is not accepted by the basolateral exchanger, did not trans-stimulate. Finally, ROAT1-mediated PAH transport was saturable, with an estimated K-m of 70 mu M. Each of these properties is identical to those previously described for the basolateral alpha-ketoglutarate/PAH exchanger in isolated membrane vesicles or intact renal tubules.	NIEHS,LAB PHARMACOL & CHEM,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Sweet, Douglas H/H-7914-2013	Sweet, Douglas H/0000-0002-8911-9184				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; CHATSUDTHIPONG V, 1992, AM J PHYSIOL, V263, pF384, DOI 10.1152/ajprenal.1992.263.3.F384; COADY MJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P130, DOI 10.1016/0003-9861(90)90622-6; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; CSERZO M, 1994, J MOL BIOL, V243, P388, DOI 10.1006/jmbi.1994.1666; FRITZSCH G, 1984, PFLUG ARCH EUR J PHY, V400, P250, DOI 10.1007/BF00581555; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V978, P249, DOI 10.1016/0005-2736(89)90122-3; GASSER R, 1988, MOL PHARMACOL, V33, P22; *GEN COMP GROUP, 1996, GCG WISC PACK VERS 9; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLOHAN PD, 1975, J PHARMACOL EXP THER, V195, P22; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; MARTINEZ F, 1990, AM J PHYSIOL, V258, pF1145, DOI 10.1152/ajprenal.1990.258.5.F1145; MILLER DS, 1993, AM J PHYSIOL, V264, pR882, DOI 10.1152/ajpregu.1993.264.5.R882; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PRITCHARD JB, 1990, J PHARMACOL EXP THER, V255, P969; PRITCHARD JB, 1995, J PHARMACOL EXP THER, V274, P1278; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SWEET DH, 1996, FASEB J*, V10, pA127; ULLRICH KJ, 1987, PFLUG ARCH EUR J PHY, V409, P229, DOI 10.1007/BF00583470; WERNER D, 1991, AM J PHYSIOL, V261, pF265, DOI 10.1152/ajprenal.1991.261.2.F265; WERNER D, 1990, J PHARMACOL EXP THER, V252, P792; WOLFF NA, 1992, MOL CELL BIOCHEM, V114, P35	40	368	378	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30088	30095		10.1074/jbc.272.48.30088	http://dx.doi.org/10.1074/jbc.272.48.30088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374486	hybrid			2022-12-27	WOS:A1997YH61300018
J	Whitlow, M; Howard, AJ; Stewart, D; Hardman, KD; Kuyper, LF; Baccanari, DP; Fling, ME; Tansik, RL				Whitlow, M; Howard, AJ; Stewart, D; Hardman, KD; Kuyper, LF; Baccanari, DP; Fling, ME; Tansik, RL			X-ray crystallographic studies of Candida albicans dihydrofolate reductase - High resolution structures of the holoenzyme and an inhibited ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; BINDING; TRIMETHOPRIM; METHOTREXATE; SEQUENCE; ENZYME; CRYSTALLIZATION	The recent rise in systemic fungal infections has created a need for the development of new antifungal agents, As part of an effort to provide therapeutically effective inhibitors of fungal dihydrofolate reductase (DHFR), we have cloned, expressed, purified, crystallized, and determined the three-dimensional structure of Candida albicans DHFR. The 192-residue enzyme, which was expressed in Escherichia coli and purified by methotrexate affinity and cation exchange chromatog raphy, was 27% identical to human DHFR, Crystals of C. albicans DHFR were grown as the holoenzyme complex and as a ternary complex containing a pyrroloquinazoline inhibitor. Both complexes crystallized with two molecules in the asymmetric unit in space group P2(1). The final structures had R-factors of 0.199 at 1.85 Angstrom resolution and 0.155 at 1.60-Angstrom resolution, respectively. The enzyme fold was similar to that of bacterial and vertebrate DHFR, and the binding of a nonselective diaminopyrroloquinazoline inhibitor and the interactions of NADPH with protein were typical of ligand binding to other DHFRs. However, the width of the active site cleft of C. albicans DHFR was significantly larger than that of the human enzyme, providing a basis for the design of potentially selective inhibitors.	GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709; GENEX CORP,DEPT PROT ENGN,GAITHERSBURG,MD 20877	GlaxoSmithKline								AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; Agarwal RC, 1981, REFINEMENT PROTEIN S, P24; BACCANARI DP, 1989, J BIOL CHEM, V264, P1100; BACCANARI DP, 1981, J BIOL CHEM, V256, P1738; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BEVAN AW, 1985, EUR BIOPHYS J BIOPHY, V11, P211; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Brooks R. G., 1987, Antimicrobial Agents Annual, V2, P297; CHAMPNESS JN, 1994, STRUCTURE, V2, P915, DOI 10.1016/S0969-2126(94)00093-X; CHAN JH, 1995, J MED CHEM, V38, P3608, DOI 10.1021/jm00018a021; CHEUNG HTA, 1986, BIOCHEMISTRY-US, V25, P1925, DOI 10.1021/bi00356a014; COCCO L, 1983, ARCH BIOCHEM BIOPHYS, V226, P567, DOI 10.1016/0003-9861(83)90326-0; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DALY S, 1994, GENE, V147, P115, DOI 10.1016/0378-1119(94)90049-3; DELVES CJ, 1993, PROTEIN EXPRES PURIF, V4, P16, DOI 10.1006/prep.1993.1003; EDWARDS JE, 1991, NEW ENGL J MED, V324, P1060, DOI 10.1056/NEJM199104113241511; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREISHEIM JH, 1984, FOLATE ANTAGONISTS T, V1, P69; FRENKEL J. K., 1957, ANTIBIOT AND CHE MOTHER, V7, P630; GILLILAND GL, 1984, METHOD ENZYMOL, V104, P370; GODSON GN, 1967, BIOCHIM BIOPHYS ACTA, V149, P476, DOI 10.1016/0005-2787(67)90175-X; Graybill JR, 1996, CLIN INFECT DIS, V22, pS166, DOI 10.1093/clinids/22.Supplement_2.S166; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HITCHINGS GH, 1989, DESIGN ENZYME INHIBI, P343; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASS EH, 1982, REV INFECT DIS, V4, P196; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; KUYPER IF, 1990, PROTEIN DESIGN DEV N, P297; KUYPER LF, 1985, J MED CHEM, V28, P303, DOI 10.1021/jm00381a008; Kuyper LF, 1996, J MED CHEM, V39, P892, DOI 10.1021/jm9505122; KUYPER LF, 1989, COMPUTER AIDED DRUG, P327; Leoung G. S., 1989, OPPORTUNISTIC INFECT; MASTERS JN, 1983, GENE, V21, P59, DOI 10.1016/0378-1119(83)90147-6; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MILLS J, 1990, SCI AM, V263, P50, DOI 10.1038/scientificamerican0890-50; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; RAMACHANDRAN GN, 1966, BIOPHYS J, V6, P849, DOI 10.1016/S0006-3495(66)86699-7; ROTH B, 1989, DRUGS FUTURE, V14, P249; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; STAMMERS DK, 1987, FEBS LETT, V218, P178, DOI 10.1016/0014-5793(87)81042-6; STERNBERG S, 1994, SCIENCE, V266, P1632, DOI 10.1126/science.7702654; STONE D, 1979, J BIOL CHEM, V254, P480; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; WALSH TJ, 1990, DIAGN MICR INFEC DIS, V13, P37, DOI 10.1016/0732-8893(90)90051-V; WARNOCK DW, 1995, J ANTIMICROB CHEMOTH, V36, P73, DOI 10.1093/jac/36.suppl_B.73; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398	54	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30289	30298		10.1074/jbc.272.48.30289	http://dx.doi.org/10.1074/jbc.272.48.30289			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374515	hybrid			2022-12-27	WOS:A1997YH61300047
J	Woodring, PJ; Garrison, JC				Woodring, PJ; Garrison, JC			Expression, purification, and regulation of two isoforms of the inositol 1,4,5-trisphosphate 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYACRYLAMIDE-GEL ELECTROPHORESIS; V-SRC ONCOGENE; RAT-BRAIN; MOLECULAR-CLONING; HUMAN-PLATELETS; SMOOTH-MUSCLE; IDENTIFICATION; STIMULATION; FIBROBLASTS	The level of inositol 1,4,5-trisphosphate in the cytoplasm is tightly regulated by two enzymes, the inositol 1,4,5,5-phosphatase and the inositol 1,4,5-trisphosphate 3-kinase. Two isoforms of the inositol 1,4,5-trisphosphate S-kinase have been identified, the A form and the B form. The regulatory properties of the two isoforms were compared following overexpression and purification of the proteins from a v-src transformed mammalian cell line. The highly purified, recombinant inositol 1,4,5-trisphosphate 3-kinases were differentially regulated by calcium/calmodulin and via phosphorylation by protein kinase C or the cyclic AMP-dependent protein kinase. Both enzymes had similar affinities for inositol 1,4,5-trisphosphate (K-m 2-5 mu m). Calcium/calmodulin stimulated the activity of isoform A about 2.5-fold, whereas the activity of isoform B was increased 20-fold. The cyclic AMP-dependent protein kinase phosphorylated the inositol 1,4,5-trisphosphate 3-kinase A to the extent of 0.9 mol/mol and isoform B to 1 mol/mol. Protein kinase C phosphorylated isoform A to the extent of 2 mol/mol and isoform B to 2.7 mol/mol. Phosphorylation of isoform A by the cyclic AMP-dependent protein kinase caused a 2.5-fold increase in its activity when assayed in the absence of calcium/calmodulin, whereas phosphorylation by protein kinase C decreased activity by 72%. The activity of isoform B in the absence of calcium/calmodulin was not affected by phosphorylation using either kinase. When assayed in the presence of calcium/calmodulin, phosphorylation of isoform A by the cyclic AMP-dependent protein kinase increased activity 1.5-fold, whereas phosphorylation of isoform B decreased activity by 45%. Phosphorylation of either isoform A or B by protein kinase C resulted in a 70% reduction of calcium/calmodulin-stimulated activity. Differential expression and regulation of the two inositol 1,4,5-trisphosphate 3-kinase isoforms provides multiple mechanisms for regulating the cytosolic level of inositol 1,4,5-trisphosphate in cells.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,CANC RES CTR,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [P01-CA 40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLA T, 1991, J BIOL CHEM, V266, P24719; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BIDEN TJ, 1988, BIOCHEM J, V256, P697, DOI 10.1042/bj2560697; BIDEN TJ, 1988, BIOCHEM J, V251, P435, DOI 10.1042/bj2510435; Bornstein P, 1977, Methods Enzymol, V47, P132; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Communi D, 1997, EMBO J, V16, P1943, DOI 10.1093/emboj/16.8.1943; CONIGRAVE A, 1992, CELL SIGNAL, V4, P303, DOI 10.1016/0898-6568(92)90070-O; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DSANTOS CS, 1994, CELL SIGNAL, V6, P335, DOI 10.1016/0898-6568(94)90038-8; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; HOGAN SP, 1994, CELL SIGNAL, V6, P233, DOI 10.1016/0898-6568(94)90081-7; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; KING WG, 1989, J BIOL CHEM, V264, P6070; LEE SY, 1990, J BIOL CHEM, V265, P9434; LIN A, 1993, ARCH BIOCHEM BIOPHYS, V303, P412, DOI 10.1006/abbi.1993.1303; LIN AN, 1990, BIOCHEM BIOPH RES CO, V170, P1371, DOI 10.1016/0006-291X(90)90546-Y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; MATTINGLY RR, 1991, J BIOL CHEM, V266, P15144; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEARS SB, 1989, BIOCHEM J, V260, P313, DOI 10.1042/bj2600313; SIM SS, 1990, J BIOL CHEM, V265, P10367; Soriano S, 1997, FEBS LETT, V403, P1, DOI 10.1016/S0014-5793(96)01516-5; TAKAZAWA K, 1991, BIOCHEM J, V280, P125, DOI 10.1042/bj2800125; TAKAZAWA K, 1995, J ENDOCRINOL, V144, P527, DOI 10.1677/joe.0.1440527; TAKAZAWA K, 1990, BIOCHEM J, V268, P213, DOI 10.1042/bj2680213; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; Thomas S, 1996, BIOCHEM J, V319, P713, DOI 10.1042/bj3190713; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; WANG XL, 1995, BIOCHEM J, V308, P1009, DOI 10.1042/bj3081009; Woodring PJ, 1996, BIOCHEM J, V319, P73, DOI 10.1042/bj3190073; YAMAGUCHI K, 1988, BIOCHEM J, V251, P129, DOI 10.1042/bj2510129	46	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30447	30454		10.1074/jbc.272.48.30447	http://dx.doi.org/10.1074/jbc.272.48.30447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374536	hybrid			2022-12-27	WOS:A1997YH61300068
J	Fu, J; Ren, MD; Kreibich, G				Fu, J; Ren, MD; Kreibich, G			Interactions among subunits of the oligosaccharyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; PROTEIN COMPLEX; RIBOPHORIN-I; MOLECULAR-CLONING; RIBOSOME BINDING; YEAST; MEMBRANE; POLYPEPTIDES; IDENTIFICATION	The mammalian oIigosaccharyltransferase (OST) is an oligomeric complex composed of three membrane proteins of the endoplasmic reticulum: ribophorin I (RI), ribophorin II (RII), and OST48. In addition, sequence homology between the Ost2 subunit of the yeast OST complex and Dad1 (defender against apoptotic death) suggests that Dad1 may represent a fourth subunit of the mammalian OST complex. In attempts to elucidate the structural organization of this complex, we have studied the interactions among its subunits. Using the yeast two-hybrid system, we have shown that the luminal domains of RI and RII (Ra and RIIL, respectively) interacted with the luminal domain of OST48 (OST48L), but no direct interaction was observed between RIL and RIIL. These results were confirmed by biochemical assays. Deletion analyses using the yeast two-hybrid system showed that subdomain of RIL or RIIL adjacent to the respective transmembrane domains interacted with OST48L. Of the three equal length subdomains of OST48L, the one at the N terminus and the one next to the transmembrane domain interacted with RIL. None of these three subdomains of OST48L interacted with RIIL. The yeast two-hybrid assay also revealed affinity between the cytoplasmically located N-terminal region of Dad1 and the short cytoplasmic tail of OST48, thus placing Dad1 firmly into the OST complex. Tn addition, we found a homotypic interaction between the cytoplasmic domains of RI, which may play a role in the formation of the oligomeric array formed by components of the translocation machinery.	NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; AUSUBEL FM, 1992, SHORT PROTOCOLS MOLB; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Garabedian Michael J., 1993, Methods (Orlando), V5, P138, DOI 10.1006/meth.1993.1018; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KARAOGLU D, 1995, PROTEIN KINESIS DYNA, P83; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KUMAR V, 1994, J BIOL CHEM, V269, P13451; LIU F, 1995, MOL CELL BIOL, V15, P3479; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; SABATINI DD, 1995, METABOLIC BASIS INHE, V1, P459; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29687	29692		10.1074/jbc.272.47.29687	http://dx.doi.org/10.1074/jbc.272.47.29687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368036	hybrid			2022-12-27	WOS:A1997YG64700046
J	Perou, CM; Leslie, JD; Green, W; Li, LT; Ward, DM; Kaplan, J				Perou, CM; Leslie, JD; Green, W; Li, LT; Ward, DM; Kaplan, J			The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ARTIFICIAL CHROMOSOMES; COMPLEMENTATION; IDENTIFICATION; COMPARTMENTS; MACROPHAGES; ENDOCYTOSIS; MUTATION; DEFECT	The human autosomal recessive disorder Chediak-Higashi syndrome and its murine homologue beige are associated with the formation of giant lysosomes that cluster near the perinuclear region of cells, We prepared a polyclonal antiserum against a glutathione S-transferase-Beige fusion protein and demonstrated by Western analysis that the beige gene encodes a protein of 400 kDa that is expressed in cultured murine fibroblasts as well as most mouse tissues, The protein was not detected in either cultured fibroblasts or mouse tissues from two different beige mutants, Cultured fibroblasts transformed with multiple copies of yeast artificial chromosomes that contain the full-length beige gene showed much higher levels of Beige protein than either wild type fibroblasts or mouse tissues. Subcellular fractionation experiments demonstrated that the Beige protein was cytosolic and, under the conditions of isolation, had no measurable membrane association, Cultured mouse fibroblasts in which the Beige protein was overexpressed had smaller than normal lysosomes that were more peripherally distributed than in control cells, These findings, coupled with earlier published results, suggest that the Beige protein regulates lysosomal fission.	UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	NCI NIH HHS [5 P30 CA 42014] Funding Source: Medline; NHLBI NIH HHS [HL26922] Funding Source: Medline; NIDDK NIH HHS [T32DK07115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026922, R37HL026922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1987, AM J PEDIAT HEMATOL, V9, P42; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; BURKHARDT JK, 1993, EXP MED, V178, P1945; EDELSON PJ, 1978, J EXP MED, V147, P77, DOI 10.1084/jem.147.1.77; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; Kelley E. M, 1957, MOUSE NEWS LETT, V16, P36; MCVEYWARD D, 1997, IN PRESS CELL BIOL; MURPHY RF, 1985, P NATL ACAD SCI USA, V82, P8523, DOI 10.1073/pnas.82.24.8523; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLIVER C, 1975, LAB INVEST, V32, P17; Perou CM, 1997, GENOMICS, V42, P366, DOI 10.1006/geno.1997.4740; Perou CM, 1996, P NATL ACAD SCI USA, V93, P5905, DOI 10.1073/pnas.93.12.5905; PEROU CM, 1993, SOMAT CELL MOLEC GEN, V19, P459, DOI 10.1007/BF01233251; PEROU CM, 1993, J CELL SCI, V106, P99; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Perou CM, 1997, GENOMICS, V39, P136, DOI 10.1006/geno.1996.4478; SPICER SS, 1981, FED PROC, V40, P1451; SRIVASTAVA AK, 1991, GENE, V103, P53, DOI 10.1016/0378-1119(91)90390-W; WARD DM, 1995, J CELL BIOL, V129, P1229, DOI 10.1083/jcb.129.5.1229; WILSON RB, 1989, METHOD CELL BIOL, V31, P293	21	95	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29790	29794		10.1074/jbc.272.47.29790	http://dx.doi.org/10.1074/jbc.272.47.29790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368050	hybrid			2022-12-27	WOS:A1997YG64700060
J	Adachi, H; Tsujimoto, M; Arai, H; Inoue, K				Adachi, H; Tsujimoto, M; Arai, H; Inoue, K			Expression cloning of a novel scavenger receptor from human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; PROTEIN; MACROPHAGES; CHOLESTEROL; METABOLISM; ARTERIES; BINDING	Scavenger receptors mediate the endocytosis of chemically modified lipoproteins, such as acetylated low density lipoprotein (Ac-LDL) and oxidized LDL (Ox-LDL), and have been implicated in the pathogenesis of atherosclerosis. The evidence that endothelial cells possess scavenger receptor activity is substantial, and this property is widely used in the isolation of endothelial cells from vascular tissues. In the current study, we have isolated, by expression cloning, the cDNA encoding a novel type of scavenger receptor expressed by endothelial cells (SREC), which mediates the binding and degradation of Ac-LDL. The primary structure of the molecule has no significant homology to other types of scavenger receptors, including the recently cloned endothelial cell Ox-LDL receptor, a member of the C-type lectin family. The cDNA encodes a protein of 830 amino acids with a calculated molecular mass of 85,735 Da (mature peptide). Chinese hamster ovary cells stably expressing SREC bound I-125-labeled Ac-LDL with high affinity (K-d = 3.0 mu g/ml, approximately 1.7 nM) and degraded them via an endocytic pathway. Association of DiII-Ac-LDL were effectively inhibited by Ox-LDL, malondialdehyde-modified LDL, dextran sulfate, and polyinosinic acid, but not by natural LDL and heparin. The cloned receptor has several characteristic domain structures, including an N-terminal extracellular domain with five epidermal growth factor-like cysteine pattern signatures and an unusually long C-terminal cytoplasmic domain (391 amino acids) composed of a Ser/Pro-rich region followed by a Gly-rich region.	UNIV TOKYO,GRAD SCH PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	Adachi, H (corresponding author), RIKEN,INST PHYS & CHEM RES,BIOORGAN CHEM LAB,2-1 HIROSAWA,WAKO,SAITAMA 35101,JAPAN.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARENDT RM, 1990, CIRCULATION, V82, P248; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROMQUIST MC, 1984, P NATL ACAD SCI USA, V81, P7363; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FUKASAWA M, 1995, J BIOL CHEM, V270, P1921, DOI 10.1074/jbc.270.4.1921; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; KODOMA T, 1990, NATURE, V343, P531; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; PALKAMA T, 1993, CLIN EXP IMMUNOL, V92, P353; ROHER L, 1990, NATURE, V343, P570; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; STANTON LW, 1992, J BIOL CHEM, V267, P22446; VANHINSBERGH VWM, 1983, ARTERIOSCLEROSIS, V3, P547, DOI 10.1161/01.ATV.3.6.547; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	25	150	155	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31217	31220		10.1074/jbc.272.50.31217	http://dx.doi.org/10.1074/jbc.272.50.31217			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395444	hybrid			2022-12-27	WOS:A1997YL41900003
J	Lanyi, JK				Lanyi, JK			Mechanism of ion transport across membranes - Bacteriorhodopsin as a prototype for proton pumps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSFORM INFRARED-SPECTROSCOPY; X-RAY-DIFFRACTION; PROTEIN CONFORMATION CHANGE; CYTOCHROME-C-OXIDASE; RETINAL SCHIFF-BASE; PH-INDICATOR DYES; STRUCTURAL-CHANGES; NATRONOBACTERIUM-PHARAONIS; 2.8-ANGSTROM RESOLUTION; EXTRACELLULAR SURFACE				Lanyi, JK (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697, USA.		Lanyi, Janos/C-3808-2011					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALEXIEV U, 1994, BIOCHEMISTRY-US, V33, P13693, DOI 10.1021/bi00250a020; BALASHOV SP, 1995, BIOCHEMISTRY-US, V34, P8820, DOI 10.1021/bi00027a034; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BAMBERG E, 1993, P NATL ACAD SCI USA, V90, P639, DOI 10.1073/pnas.90.2.639; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; BROWN LS, 1994, BIOCHEMISTRY-US, V33, P12001, DOI 10.1021/bi00206a001; Brown LS, 1997, P NATL ACAD SCI USA, V94, P5040, DOI 10.1073/pnas.94.10.5040; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; BROWN LS, 1993, BIOPHYS J, V65, P124, DOI 10.1016/S0006-3495(93)81064-6; Brown LS, 1995, BIOPHYS J, V69, P2103, DOI 10.1016/S0006-3495(95)80081-0; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; CAO Y, 1993, BIOCHEMISTRY-US, V32, P1981, DOI 10.1021/bi00059a015; CAO Y, 1995, BIOPHYS J, V68, P1518, DOI 10.1016/S0006-3495(95)80324-3; DANON A, 1976, BIOCHIM BIOPHYS ACTA, V423, P133, DOI 10.1016/0005-2728(76)90107-9; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P11120, DOI 10.1073/pnas.92.24.11120; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DRUCKMANN S, 1982, BIOCHEMISTRY-US, V21, P4953, DOI 10.1021/bi00263a019; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; FAHMY K, 1989, J MOL STRUCT, V214, P257, DOI 10.1016/0022-2860(89)80017-1; FISCHER WB, 1994, BIOCHEMISTRY-US, V33, P12757, DOI 10.1021/bi00209a005; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HAN BG, 1994, BIOPHYS J, V67, P1179, DOI 10.1016/S0006-3495(94)80586-7; Hatanaka M, 1996, BIOCHEMISTRY-US, V35, P6308, DOI 10.1021/bi952973v; Haupts U, 1997, BIOCHEMISTRY-US, V36, P2, DOI 10.1021/bi962014g; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; HEGEMANN P, 1987, EMBO J, V6, P259, DOI 10.1002/j.1460-2075.1987.tb04748.x; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; KANDORI H, 1995, J AM CHEM SOC, V117, P2118, DOI 10.1021/ja00112a036; Karlin A, 1997, P NATL ACAD SCI USA, V94, P5508, DOI 10.1073/pnas.94.11.5508; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KHORANA HG, 1993, P NATL ACAD SCI USA, V90, P1166, DOI 10.1073/pnas.90.4.1166; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; LANYI JK, 1995, NATURE, V375, P461, DOI 10.1038/375461a0; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; MAEDA A, 1992, BIOCHEMISTRY-US, V31, P462, DOI 10.1021/bi00117a023; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MICHEL H, 1980, BIOCHEMISTRY-US, V19, P4615, DOI 10.1021/bi00561a012; MILLER A, 1990, BIOCHIM BIOPHYS ACTA, V1020, P57, DOI 10.1016/0005-2728(90)90093-J; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; Oesterhelt D, 1995, ISR J CHEM, V35, P475; ORLANDI G, 1979, CHEM PHYS LETT, V64, P370, DOI 10.1016/0009-2614(79)80534-5; OTTO H, 1989, P NATL ACAD SCI USA, V86, P922; PEYBAYPEYROULA E, 1997, SCIENCE, V277, P1676; Richter HT, 1996, BIOPHYS J, V71, P3392, DOI 10.1016/S0006-3495(96)79532-2; Richter HT, 1996, BIOCHEMISTRY-US, V35, P15461, DOI 10.1021/bi9612430; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; ROUSSO I, 1995, BIOCHEMISTRY-US, V34, P12059, DOI 10.1021/bi00037a049; SASAKI J, 1995, SCIENCE, V269, P73, DOI 10.1126/science.7604281; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHERRER P, 1994, BIOCHEMISTRY-US, V33, P13684, DOI 10.1021/bi00250a019; SOUVIGNIER G, 1992, BIOPHYS J, V63, P1393, DOI 10.1016/S0006-3495(92)81722-8; Spudich JL, 1996, CURR OPIN CELL BIOL, V8, P452, DOI 10.1016/S0955-0674(96)80020-2; Subramaniam S, 1997, P NATL ACAD SCI USA, V94, P1767, DOI 10.1073/pnas.94.5.1767; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VARO G, 1995, BIOCHEMISTRY-US, V34, P12161, DOI 10.1021/bi00038a009; Varo G, 1996, BIOPHYS J, V70, P461, DOI 10.1016/S0006-3495(96)79589-9; Varo G, 1996, BIOCHEMISTRY-US, V35, P6604, DOI 10.1021/bi9601159; VARO G, 1995, BIOCHEMISTRY-US, V34, P14490, DOI 10.1021/bi00044a027; VARO G, 1995, BIOPHYS J, V68, P2062, DOI 10.1016/S0006-3495(95)80385-1; VARO G, 1991, BIOCHEMISTRY-US, V30, P5016, DOI 10.1021/bi00234a025; VARO G, 1995, BIOCHEMISTRY-US, V34, P14500, DOI 10.1021/bi00044a028; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; Weidlich O, 1996, BIOCHEMISTRY-US, V35, P10807, DOI 10.1021/bi960780h; Xu D, 1995, BIOPHYS J, V69, P2745, DOI 10.1016/S0006-3495(95)80146-3; ZIMANYI L, 1992, BIOCHEMISTRY-US, V31, P8535, DOI 10.1021/bi00151a022; ZIMANYI L, 1992, PHOTOCHEM PHOTOBIOL, V56, P1049, DOI 10.1111/j.1751-1097.1992.tb09728.x; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010	84	167	168	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31209	31212		10.1074/jbc.272.50.31209	http://dx.doi.org/10.1074/jbc.272.50.31209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395442	hybrid			2022-12-27	WOS:A1997YL41900001
J	Xie, Z; Price, D				Xie, Z; Price, D			Drosophila factor 2, an RNA polymerase II transcript release factor, has DNA-dependent ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI REP; ELONGATION COMPLEXES; GENE-EXPRESSION; TERMINATION; PROTEIN; RHO; PURIFICATION; HYDROLYSIS; HELICASE	Drosophila factor 2 has been identified as a component of negative transcription elongation factor (N-TEF) that causes the release of RNA polymerase II transcripts in an ATP-dependent manner (Xie, Z. and Price D. H. (1996) J. Biol. Chem. 271, 11043-11046). We show here that the transcript release activity of factor 2 requires ATP or dATP and that adenosine 5'-O-(thiotriphosphate) (ATP gamma S), adenosine 5'-(beta,gamma-imino)triphosphate (AMP-PNP), or other NTPs do not support the activity, Factor 2 demonstrated a strong DNA-dependent ATPase activity that correlated with its transcript release activity, At 20 mu g/ml DNA, the ATPase activity of factor 2 had an apparent K-m(ATP) Of 28 mu M and an estimated K-cat of 140 min(-1). Factor 2 caused the release of nascent transcripts. associated with elongation complexes generated by RNA polymerase II on a dC-tailed template, Therefore, no other protein cofactors are required for the transcript release activity of factor 2, Using the dC-tailed template assay, it was found that renaturation of the template was required for factor 2 function.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KUMAR KA, 1993, J BIOL CHEM, V268, P26162; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; Verhage RA, 1997, MOL GEN GENET, V254, P284, DOI 10.1007/s004380050417; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	33	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31902	31907		10.1074/jbc.272.50.31902	http://dx.doi.org/10.1074/jbc.272.50.31902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395538	hybrid			2022-12-27	WOS:A1997YL41900097
J	Laune, D; Molina, F; Ferrieres, G; Mani, JC; Cohen, P; Simon, D; Bernardi, T; Piechaczyk, M; Pau, B; Granier, C				Laune, D; Molina, F; Ferrieres, G; Mani, JC; Cohen, P; Simon, D; Bernardi, T; Piechaczyk, M; Pau, B; Granier, C			Systematic exploration of the antigen binding-activity of synthetic peptides isolated from the variable regions of immunoglobulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; 3-DIMENSIONAL STRUCTURE; LIGHT-CHAINS; LYSOZYME; FRAGMENT; COMPLEMENTARITY; COMPLEXES; AFFINITY; SITES	Sets of short (12 residues) cellulose-bound synthetic overlapping peptides derived from the sequences of the variable regions of the heavy and light chains of three different antibodies (an anti-thyroglobulin antibody, the HyHEL-5 anti-lysozyme antibody, and an anti-angiotensin II antibody) were used to systematically assess the antigen binding capacity of peptides from the antibody paratope outside their natural molecular context. Peptides enclosing one or several of the complementarity determining region (CDR) residues had antigen binding activity, although the most active peptides were not necessarily those bearing the greatest number of CDR residues. Several residues from the framework region, preceding or following the CDR, were found to play a role in binding. Affinity constants from 4.1 x 10(-7) to 6.7 x 10(-8) M-1 for the soluble form of 9 lysozyme-binding dodecapeptides were measured by BIAcore analysis. Alanine scanning of lysozyme-binding hexapeptides from the HyHEL-5 sequence identified 38 residues important for binding, of which 22 corresponded to residues that had been shown by x-ray crystallography to be at the interface between HyHEL-5 and lysozyme. Our results could be of interest for the rational identification of biologically active peptides derived from antibody sequences and in providing an experimental basis for mutagenesis of the antibody paratope.	Fac Pharm Montpellier, CNRS, UMR 9921, F-34000 Montpellier, France; Sanofi Rech, F-34000 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Sanofi-Aventis; Sanofi France	Granier, C (corresponding author), Fac Pharm Montpellier, CNRS, UMR 9921, Ave Charles Flahault, F-34000 Montpellier, France.	granier@pharma.univ-montpl.fr	GRANIER, Claude/A-8841-2008; Molina, Franck/E-8419-2011; Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598				AMIT A, 1986, NATURE, V313, P156; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; DAVIES D, 1990, ANNU REV BIOCHEM, V50, P439; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; LEVI M, 1993, P NATL ACAD SCI USA, V90, P4373; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; Molina F, 1996, PEPTIDE RES, V9, P151; Noel D, 1996, J IMMUNOL METHODS, V193, P177, DOI 10.1016/0022-1759(96)00043-9; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PIECHACZYK M, 1985, HYBRIDOMA, V4, P351; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; SARAGOVI UH, 1992, IMMUNOMETHODS, V1, P5; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIMON D, 1992, CLIN CHEM, V38, P1963; TAUB R, 1989, J BIOL CHEM, V264, P259; TRIFILIEFF E, 1991, MOL IMMUNOL, V28, P889, DOI 10.1016/0161-5890(91)90053-M; WELLING GW, 1991, J CHROMATOGR, V548, P235, DOI 10.1016/S0021-9673(01)88605-2; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WILSON IA, 1994, RES IMMUNOL, V145, P73, DOI 10.1016/S0923-2494(94)80049-9; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	36	58	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30937	30944		10.1074/jbc.272.49.30937	http://dx.doi.org/10.1074/jbc.272.49.30937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388240	hybrid			2022-12-27	WOS:000071640800053
J	Maddox, BK; Keene, DR; Sakai, LY; Charbonneau, NL; Morris, NP; Ridgway, CC; Boswell, BA; Sussman, MD; Horton, WA; Bachinger, HP; Hecht, JT				Maddox, BK; Keene, DR; Sakai, LY; Charbonneau, NL; Morris, NP; Ridgway, CC; Boswell, BA; Sussman, MD; Horton, WA; Bachinger, HP; Hecht, JT			The fate of cartilage oligomeric matrix protein is determined by the cell type in the case of a novel mutation in pseudoachondroplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ENDOPLASMIC-RETICULUM; PERICENTROMERIC REGION; GENETIC-LINKAGE; COLLAGEN; COMP; CHROMOSOME-19; BINDING; IX; THROMBOSPONDIN-1	We have identified a novel missense mutation in a pseudoachondroplasia (PSACH) patient in one of the type III repeats of cartilage oligomeric matrix protein (COMP), Enlarged lamellar rough endoplasmic reticulum vesicles were shown to contain accumulated COMP along with type IX collagen, a cartilage-specific component. COMP was secreted and assembled normally into the extracellular matrix of tendon, demonstrating that the accumulation of COMP in chondrocytes was a cell-specific phenomenon. We believe that the intracellular storage of COMP causes a nonspecific aggregation of cartilage-specific molecules and results in a cartilage matrix deficient in required structural components leading to impaired cartilage growth and maintenance, These data support a common pathogenetic mechanism behind two clinically related chondrodysplasias, PSACH and multiple epiphyseal dysplasia.	Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA; Shriners Hosp Crippled Children, Houston, TX 77225 USA	Oregon Health & Science University; Oregon Health & Science University; University of Texas System	Horton, WA (corresponding author), Shriners Hosp Crippled Childrens, Res Dept, Portland, OR 97201 USA.							Beck K, 1996, J BIOL CHEM, V271, P21566, DOI 10.1074/jbc.271.35.21566; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; BRIGGS MD, 1994, AM J HUM GENET, V55, P678; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; COOPER RR, 1973, J BONE JOINT SURG AM, VA 55, P475, DOI 10.2106/00004623-197355030-00003; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Horton William A., 1993, P641; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Maddox BK, 1997, MATRIX BIOL, V16, P93, DOI 10.1016/S0945-053X(97)90038-X; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MAYNARD JA, 1972, LAB INVEST, V26, P40; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OEHLMANN R, 1994, AM J HUM GENET, V54, P3; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1984, J BONE JOINT SURG AM, V66A, P817, DOI 10.2106/00004623-198466060-00002; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; WARMAN ML, 1994, GENOMICS, V23, P158, DOI 10.1006/geno.1994.1472	33	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30993	30997		10.1074/jbc.272.49.30993	http://dx.doi.org/10.1074/jbc.272.49.30993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388247	hybrid			2022-12-27	WOS:000071640800060
J	Li, L; Karlsson, OP; Wieslander, A				Li, L; Karlsson, OP; Wieslander, A			Activating amphiphiles cause a conformational change of the 1,2-diacylglycerol 3-glucosyltransferase from Acholeplasma laidlawii membranes according to proteolytic digestion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ANIONIC PHOSPHOLIPIDS; PHASE-EQUILIBRIA; LIPID REGULATION; ENZYME	1,2-Diacylglycerol 3-glucosyltransferase synthesizes the major nonbilayer-prone lipid monoglucosyldiacylglycerol (MGlcDAG) in the membrane of Acholeplasma laidlawii, which is important for the spontaneous curvature, and is a regulatory site for the lipid surface charge density, A potential connection between activity and a conformational change of this enzyme, governed by essential lipid activators, was studied with purified MGlcDAG synthase in different lipid aggregates, Critical fractions of anionic phospholipids 1,2-dioleoyl-phosphatidylglycerol (DOPG) and 1,2-dioleoyl-phosphatidylserine (DOPG) were essential for the restoration of enzyme activity, while the zwitterionic 1,2-dioleoyl-phosphatidylcholine (DOPC) and the uncharged di glucosyldiacylglycerol (DGlcDAG) were not, Proteolytic resistance had a very good correlation with the enzyme activity in various lipid CHAPS mixed micelles. Anionic lipids DOPG and DOPS could protect the exposed MGlcDAG:synthase from digestion, whereas DOPC and DGlcDAG could not, Similar features were observed in liposome bilayers, Likewise, the detergent dodecylphosphoglycerol (PGD), with a phosphatidylglycerol-Like headgroup, could also stimulate the MGlcDAG synthase activity efficiently with a concomitant protection toward proteolytic digestion, Neither proteolytic resistance nor restored enzyme activity was observed using soluble glycerol 3-phosphate, It is concluded that in addition to critical amounts, both the negatively charged headgroup and hydrophobic chains of the activator amphiphiles, but not a certain aggregate curvature, seem necessary for a proper conformation and the resulting active state of the MGlcDAG synthase.	UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN	Umea University								Andersson AS, 1996, BIOCHEMISTRY-US, V35, P11119, DOI 10.1021/bi960561w; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold U, 1996, EUR J BIOCHEM, V237, P862, DOI 10.1111/j.1432-1033.1996.0862p.x; BandorowiczPikula J, 1996, MOL MEMBR BIOL, V13, P241; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; CHRISTIANSSON A, 1985, J BIOL CHEM, V260, P3984; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; DAHLQVIST A, 1995, BIOCHEMISTRY-US, V34, P13381, DOI 10.1021/bi00041a015; DEJONGH HHJ, 1995, FEBS LETT, V360, P255, DOI 10.1016/0014-5793(95)00115-P; IMAI T, 1995, BBA-PROTEIN STRUCT M, V1246, P189, DOI 10.1016/0167-4838(94)00195-M; Jones PC, 1996, MOL MEMBR BIOL, V13, P53, DOI 10.3109/09687689609160575; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NYSTROM S, 1992, EUR J BIOCHEM, V204, P231, DOI 10.1111/j.1432-1033.1992.tb16629.x; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SMITH PF, 1969, J BACTERIOL, V99, P480, DOI 10.1128/JB.99.2.480-486.1969; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; Webb T, 1997, BIOCHEM J, V321, P83, DOI 10.1042/bj3210083; WIESLANDER A, 1977, BIOCHIM BIOPHYS ACTA, V466, P336, DOI 10.1016/0005-2736(77)90229-2	27	7	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29602	29606		10.1074/jbc.272.47.29602	http://dx.doi.org/10.1074/jbc.272.47.29602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368025	hybrid			2022-12-27	WOS:A1997YG64700035
J	Lotfi, CFP; Todorovic, Z; Armelin, HA; Schimmer, BP				Lotfi, CFP; Todorovic, Z; Armelin, HA; Schimmer, BP			Unmasking a growth-promoting effect of the adrenocorticotropic hormone in Y1 mouse adrenocortical tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; SIGNALING PATHWAYS; PHORBOL ESTER; ADRENAL-CELLS; ANTISENSE RNA; CYCLIC-AMP; FOS; ACTH; MONOPHOSPHATE	The adrenocorticotropic hormone (ACTH) inhibits the growth of Y1 mouse adrenocortical tumor cells as well as normal adrenocortical cells in culture but stimulates adrenocortical cell growth in vivo. In this study, we investigated this paradoxical effect of ACTH on cell proliferation in Y1 adrenal cells and have unmasked a growth promoting effect of the hormone. Y1 cells were arrested in the G(1) phase of the cell cycle by serum starvation and monitored for progression through S phase by measuring [H-3]thymidine incorporation into DNA and by measuring the number of nuclei labeled with bromodeoxyuridine. Y1 cells were stimulated to progress through S phase and to divide after a brief pulse of ACTH (up to 2 h), This effect of ACTH appeared to be cAMP independent, since ACTH also induced cell cycle progression in Kin-8, a Y1 mutant with defective cAMP-dependent protein kinase activity, The growth-promoting effect of ACTH in Y1 was preceded by the rapid activation of p44 and p42 mitogen-activated protein kinases and by the accumulation of c-FOS protein, In contrast, continuous treatment with ACTH (14 h) inhibited cell cycle progression in Y1 cells by a cAMP-dependent pathway. The inhibitory effect of ACTH mapped to the midpoint of G,, Together, the results demonstrate a dual effect of ACTH on cell cycle progress, a cAMP-independent growth-promoting effect early in G(1) possibly mediated by mitogen-activated protein kinase and c-FOS, and a cAMP-dependent inhibitory effect at mid-G(1). It is suggested that the growth-inhibitory effect of ACTH at mid-G(1) represents an ACTH-regulated check point that limits cell cycle progression.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto	Lotfi, CFP (corresponding author), UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05599970 SAO PAULO, BRAZIL.		Armelin, Hugo/P-4390-2015; Lotfi, Claudimara/B-7354-2011	Armelin, Hugo/0000-0001-9557-0804; Lotfi, Claudimara/0000-0002-9881-7099				Armelin HA, 1996, ENDOCR RES, V22, P373, DOI 10.1080/07435809609043721; ARMELIN MCS, 1977, J CELL PHYSIOL, V93, P1, DOI 10.1002/jcp.1040930102; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; GILL GN, 1977, J CELL PHYSIOL, V92, P65, DOI 10.1002/jcp.1040920109; GOSPODAROWICZ D, 1975, ENDOCRINOLOGY, V97, P102, DOI 10.1210/endo-97-1-102; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Holzwarth MA, 1996, ENDOCR RES, V22, P401, DOI 10.1080/07435809609043724; HORNSBY PJ, 1985, ENDOCR RES, V10, P259; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KIMURA E, 1983, REV BRAS GENET, V6, P211; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUDLOW JE, 1980, P NATL ACAD SCI-BIOL, V77, P2767, DOI 10.1073/pnas.77.5.2767; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MASUI H, 1971, P NATL ACAD SCI USA, V68, P3206, DOI 10.1073/pnas.68.12.3206; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Mitani F, 1996, ENDOCR RES, V22, P421, DOI 10.1080/07435809609043728; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SCHIMMER BP, 1985, ENDOCR RES, V11, P199, DOI 10.1080/07435808509032978; SCHIMMER BP, 1976, MOL CELL ENDOCRINOL, V4, P263, DOI 10.1016/0303-7207(76)90060-5; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCHIMMER BP, 1989, DRUG RESISTANCE MAMM, V1, P185; SCHIMMER BP, 1981, FUNCTIONALLY DIFFERE, P61; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VIARD I, 1994, J STEROID BIOCHEM, V50, P219, DOI 10.1016/0960-0760(94)90125-2; WEIDMAN ER, 1977, J CELL PHYSIOL, V90, P91, DOI 10.1002/jcp.1040900112; WIDMAIER EP, 1985, MOL CELL ENDOCRINOL, V43, P181, DOI 10.1016/0303-7207(85)90082-6; YASUMURA Y, 1966, CANCER RES, V26, P529	41	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29886	29891		10.1074/jbc.272.47.29886	http://dx.doi.org/10.1074/jbc.272.47.29886			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368063	hybrid			2022-12-27	WOS:A1997YG64700073
J	Sirrenberg, C; Endres, M; Becker, K; Bauer, MF; Walther, E; Neupert, W; Brunner, M				Sirrenberg, C; Endres, M; Becker, K; Bauer, MF; Walther, E; Neupert, W; Brunner, M			Functional cooperation and stoichiometry of protein translocases of the outer and inner membranes of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; PRECURSOR PROTEINS; PROCESSING PEPTIDASE; INTERMEMBRANE SPACE; NEUROSPORA-CRASSA; RECEPTOR-SITES; CONTACT SITES; IMPORT; TRANSPORT; MACHINERY	The qualitative relationship between preprotein translocases in the mitochondrial outer and inner membranes was determined by both a functional analysis and a determination of characteristic components of the translocases. Translocation contact sites of isolated mitochondria were saturated with intermediates of a matrix-targeted precursor of the beta-subunit of the F-1-ATPase (pF(1) beta), and import of preproteins into the different mitochondrial subcompartments was monitored, A strong inhibition (75-95%) was observed for preproteins with an N-terminal matrix targeting signal, indicating that a significant portion of the contact sites was blocked by accumulated F-1 beta. Insertion of preproteins into the outer membrane and import into the intermembrane space of preproteins without matrix targeting signals was inhibited by about 45%, indicating that functional outer membrane translocases were available despite saturation of contact sites, Similarly, import of members of the mitochondrial carrier family into the inner membrane was only partly inhibited (40-50%), demonstrating that functional Tim22 translocases were available to cooperate with the Tom machinery in the import of carrier proteins, The stoichiometry of Tom40, Tim23, and Tim22 in mitochondria was determined to be 5:1:0.22, We conclude that translocases of the outer membrane are present in excess over translocases of the inner membrane.			Sirrenberg, C (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BAUER MF, 1996, HDB BIOL PHYSICS, V2, P791; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Dekker PJT, 1996, BIOL CHEM, V377, P535; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MEYER A, 1993, J CELL BIOL, V121, P1233; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RASSOW J, 1990, NUCLEIC ACIDS RES, V18, P4922, DOI 10.1093/nar/18.16.4922; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; VANDERKLEI IJ, 1994, MICROSC RES TECHNIQ, V27, P284, DOI 10.1002/jemt.1070270404	27	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29963	29966		10.1074/jbc.272.47.29963	http://dx.doi.org/10.1074/jbc.272.47.29963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368075	hybrid			2022-12-27	WOS:A1997YG64700085
J	Sparrow, LG; McKern, NM; Gorman, JJ; Strike, PM; Robinson, CP; Bentley, JD; Ward, CW				Sparrow, LG; McKern, NM; Gorman, JJ; Strike, PM; Robinson, CP; Bentley, JD; Ward, CW			The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FIBRONECTIN TYPE-III; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; MESSENGER-RNA; ALPHA-SUBUNIT; BETA-SUBUNIT; PROTEINS; KINASE	The human insulin receptor is a homodimer consisting of two monomers linked by disulfide bonds, Each monomer comprises an alpha-chain that is entirely extracellular and a beta-chain that spans the cell membrane, The alpha-chain has a total of 37 cysteine residues, most of which form intrachain disulfide bonds, whereas the beta-chain contains 10 cysteine residues, four of which are in the extracellular region, There are two classes of disulfide bonds in the insulin receptor, those that can be reduced under mild reducing conditions to give alpha-beta monomers (class I) and those that require stronger reducing conditions (class II), The number of class I disulfides is small and includes the alpha-alpha dimer bond Cys(524), In this report we describe the use of cyanogen bromide and protease digestion of the exon 11 plus form of the receptor ectodomain to identify disulfide linkages between the beta-chain residues Cys(798) and Cys(807) and between the alpha-chain Cys(647) and the beta-chain Cys(872), The latter bond is the sole alpha-beta link in the molecule and implies a side-by-side alignment of the two fibronectin III domains of the receptor, Also presented is evidence for additional alpha-alpha dimer bond(s) involving at least one of the cysteine residues of the triplet at positions 682, 683, and 685, Evidence is also presented to show that Cys(884) exists as a buried thiol in the soluble ectodomain.	CSIRO,DIV MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA; CSIRO,BIOMOL RES INST,PARKVILLE,VIC 3052,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)								BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BILAN PJ, 1994, BIOCHEM BIOPH RES CO, V205, P1891, DOI 10.1006/bbrc.1994.2891; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHIACCHIA KB, 1991, BIOCHEM BIOPH RES CO, V176, P1178, DOI 10.1016/0006-291X(91)90409-Z; Cosgrove L, 1995, PROTEIN EXPRES PURIF, V6, P789, DOI 10.1006/prep.1995.0010; CZECH MP, 1981, TRENDS BIOCHEM SCI, V6, P222, DOI 10.1016/0968-0004(81)90081-5; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURONIO V, 1988, J BIOL CHEM, V263, P5436; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; Kabat EA, 1991, SEQUENCES PROTEINS I; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RIDGE KD, 1988, P NATL ACAD SCI USA, V85, P9489, DOI 10.1073/pnas.85.24.9489; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Sparrow LG, 1997, PROTEIN PEPTIDE LETT, V4, P271; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WIELAND T, 1972, PEPTIDES 72, P38; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; XU QY, 1990, J BIOL CHEM, V265, P18673	40	87	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29460	29467		10.1074/jbc.272.47.29460	http://dx.doi.org/10.1074/jbc.272.47.29460			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368005	hybrid			2022-12-27	WOS:A1997YG64700015
J	Zhou, LX; Chen, H; Lin, CH; Cong, LN; McGibbon, MA; Sciacchitano, S; Lesniak, MA; Quon, MJ; Taylor, SI				Zhou, LX; Chen, H; Lin, CH; Cong, LN; McGibbon, MA; Sciacchitano, S; Lesniak, MA; Quon, MJ; Taylor, SI			Insulin receptor substrate-2 (IRS-2) can mediate the action of insulin to stimulate translocation of GLUT4 to the cell surface in rat adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; ACTIVATION; MICE; PROTEIN; DOMAIN; KINASE; BINDS	Insulin receptor substrates-1 and -2 (IRS-1 and -2) are important substrates of the insulin receptor tyrosine kinase, Previous studies have focused upon the role of IRS-1 in mediating the actions of insulin, In the present study, we demonstrate that IRS-2 can mediate translocation of the insulin responsive glucose transporter GLUT4 in a physiologically relevant target cell for insulin action, Co-immunoprecipitation experiments performed on cell lysates derived from freshly isolated rat adipose cells incubated in the presence or absence of insulin indicated that twice as much phosphatidylinositol 3-kinase was associated with endogenous IRS-1 as with IRS-2 after insulin stimulation, When rat adipose cells in primary culture were transfected with expression vectors for IRS-1 or IRS-2, we observed 40-fold over-expression of human IRS-1 or murine IRS-2. In addition, anti-phosphotyrosine immunoblotting experiments confirmed that the recombinant substrates were phosphorylated in response to insulin stimulation, To examine the role of IRS-2 in insulin-stimulated translocation of GLUT4, we studied the effects of overexpression of IRS-1 and -2 on translocation of a co-transfected epitope-tagged GLUT4 (GLUT4-HA). Overexpression of IRS-1 or IRS-2 in adipose cells resulted in a significant increase in the basal level of cell surface GLUT4 (in the absence of insulin). Interestingly, at maximally effective concentrations of insulin (60 nM), the level of cell surface GLUT4 in cells overexpressing IRS-1 or -2 significantly exceeded the maximal recruitment observed in the control cells (160 and 135% of control, respectively; p < 0.003), Our data directly demonstrate that IRS-2, like IRS-1, is capable of participating in insulin signal transduction pathways leading to the recruitment of GLUT4, Thus, IRS-2 may provide an alternative pathway for critical metabolic actions of insulin.	NHLBI,HYPERTENS ENDOCRINE BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zhou, LX (corresponding author), NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892, USA.		Quon, Michael/B-1970-2008; Sciacchitano, Salvatore/AAM-5895-2020	Sciacchitano, Salvatore/0000-0003-1492-5365; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	38	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29829	29833		10.1074/jbc.272.47.29829	http://dx.doi.org/10.1074/jbc.272.47.29829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368055	hybrid			2022-12-27	WOS:A1997YG64700065
J	Bortner, CD; Hughes, FM; Cidlowski, JA				Bortner, CD; Hughes, FM; Cidlowski, JA			A primary role for K+ and Na+ efflux in the activation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; VOLUME; FAS; THYMOCYTES	Cell shrinkage is a major characteristic of apoptosis, but the mechanism and role of this process in cell death are poorly understood. The primary factor that controls volume regulation in all cells is ions, and thus we have examined the movement of ions at the single cell level in lymphocytes during apoptosis, Activation of the death program with several stimuli that act through independent pathways to stimulate apoptosis results in a synchronous shift of cells from a normal cell size to a shrunken cell size. Only the shrunken cells exhibit DNA fragmentation and an approximate 4-fold elevation of caspase-3-like activity. Analysis of K+ and Na+ ion content of individual cells by flow cytometry revealed that the intracellular ionic strength of apoptotic cells decreased substantially from their non-shrunken counterparts. Additionally, we show apoptosis is enhanced under conditions where the intracellular K+ concentration is diminished and that apoptosis is inhibited when K+ efflux is prevented. These data show that the efflux of ions, primarily potassium, plays a necessary and perhaps a pivotal role in the cell death program.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019; Hughes, Francis M/G-8036-2017	Cidlowski, John A/0000-0003-1420-0516; Hughes, Francis/0000-0003-3776-3653				ALHABORI M, 1994, INT J BIOCHEM, V26, P319, DOI 10.1016/0020-711X(94)90052-3; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAUSSINGER D, 1994, AM J PHYSIOL, V267, pE343, DOI 10.1152/ajpendo.1994.267.3.E343; HOFFMANN EK, 1987, CURR TOP MEMBR TRANS, V30, P125; HUGHES FM, 1997, J BIOL CHEM, V272; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MINTA A, 1989, J BIOL CHEM, V264, P19449; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NORMAN MR, 1977, CANCER RES, V37, P3785; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THOMAS N, 1981, MOL CELL ENDOCRINOL, V22, P71, DOI 10.1016/0303-7207(81)90103-9; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	26	476	491	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32436	32442		10.1074/jbc.272.51.32436	http://dx.doi.org/10.1074/jbc.272.51.32436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405453	hybrid			2022-12-27	WOS:000071108000072
J	Ren, HM; Allison, WS				Ren, HM; Allison, WS			Photoinactivation of the F-1-ATPase from spinach chloroplasts by dequalinium is accompanied by derivatization of methionine beta 183	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; NUCLEOTIDE-BINDING-SITES; BOVINE HEART MITOCHONDRIAL-F1-ATPASE; ADENOSINE-TRIPHOSPHATASE; QUINACRINE MUSTARD; GAMMA-SUBUNIT; EPSILON-SUBUNIT; ATPASE ACTIVITY; BACILLUS PS3; H+-ATPASE	In contrast to the F-1-ATPases from bovine mitochondria and the thermophilic Bacillus PS3, which are reversibly inhibited by dequalinium in the absence of irradiation, the Mg2+-ATPase activity of heat- or dithiothreitol-activated chloroplast F-1 (CF1) from spinach chloroplasts is slightly stimulated by dequalinium. Conversely, dequalinium is a partial inhibitor (maximal inhibition is 85-90%) of the Ca2+-ATPase of CF1 activated by heat, dithiothreitol, or octylglucoside. The Mg2+- and Ca2+-ATPase activities of CF1 respond differently in the presence of lauryl dimethylamine oxide (LDAO) in the assay medium. Whereas the Mg2+-ATPase activity of heat-or dithiothreitol-activated CF1 is stimulated up to 14-fold by increasing concentrations of LDAO, the Ca2+-ATPase is inhibited in a biphasic manner by increasing concentrations of LDAO. In the presence of LDAO, dequalinium does not stimulate the heat-activated Mg2+-ATPase over that promoted by LDAO alone. That dequalinium slightly stimulates Mg2+-ATPase activity although it inhibits Ca2+-ATPase activity can be reconciled by assuming that dequalinium binds to two sites in CF1, a stimulatory site that also binds LDAO and an inhibitory site. By acting as a partial inhibitor of the Mg2+-ATPase activity that it activates, the combined effect of dequalinium is modest stimulation. Irradiation of heat-or dithiothreitol-activated CF1 or the alpha(3) beta(3) gamma subcomplex of CF1 in the presence of 12 mu M dequalinium led to rapid photoinactivation. ATP and ADP, separately or in combination with Mg2+, protect against photoinactivation. After photoinactivating the alpha(3) beta(3) gamma subcomplex of CF1 with [C-14]dequalinium, tryptic and peptic digests of the isolated, derivatized beta subunit were fractionated by high performance liquid chromatography. Sequencing of the isolated, radioactive tryptic and peptic peptides revealed that Met(beta 183), which is at or near the catalytic site, is derivatized in a single beta subunit when CF1 is photoinactivated with [C-14]dequalinium.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Allison, WS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDREWS WW, 1984, BIOCHEM BIOPH RES CO, V123, P1040, DOI 10.1016/S0006-291X(84)80238-7; ANTHON GE, 1986, BIOCHIM BIOPHYS ACTA, V848, P92, DOI 10.1016/0005-2728(86)90164-7; ARANA JL, 1982, J BIOL CHEM, V257, P1125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; BRUIST MF, 1982, BIOCHEMISTRY-US, V21, P3370, DOI 10.1021/bi00257a019; BULLOUGH DA, 1989, BIOCHIM BIOPHYS ACTA, V975, P377, DOI 10.1016/S0005-2728(89)80346-9; BULLOUGH DA, 1989, J BIOL CHEM, V264, P9155; CHAZOTTE B, 1982, BIOCHIM BIOPHYS ACTA, V680, P310, DOI 10.1016/0005-2728(82)90144-X; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3823, DOI 10.1021/bi00821a023; FENG Y, 1985, ARCH BIOCHEM BIOPHYS, V238, P61; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GROTH G, 1995, BIOCHEMISTRY-US, V34, P8589, DOI 10.1021/bi00027a008; Helenius A, 1979, Methods Enzymol, V56, P734; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4846, DOI 10.1021/bi952913p; JAGENDORF AT, 1982, METHODS CHLOROPLAST, P881; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KAGAWA Y, 1981, BIOCHEM BIOPH RES CO, V100, P1370, DOI 10.1016/0006-291X(81)91975-6; LAIKIND PK, 1983, J BIOL CHEM, V258, P1700; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; MCCARTY RE, 1968, J BIOL CHEM, V243, P129; MICHEL L, 1992, FEBS LETT, V313, P90, DOI 10.1016/0014-5793(92)81191-N; MORIYAMA Y, 1995, FEBS LETT, V359, P69, DOI 10.1016/0014-5793(95)00013-Y; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; NELSON N, 1972, J BIOL CHEM, V247, P6506; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PALATINI P, 1982, MOL PHARMACOL, V21, P415; PATRIE WJ, 1984, J BIOL CHEM, V259, P1121; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PICK U, 1982, BIOCHEMISTRY-US, V21, P6144, DOI 10.1021/bi00267a019; Racker E., 1971, METHOD ENZYMOL, V23, P547; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; SAKURAI H, 1981, J BIOCHEM, V90, P95, DOI 10.1093/oxfordjournals.jbchem.a133473; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VALLEJOS RH, 1977, BIOCHIM BIOPHYS ACTA, V459, P20, DOI 10.1016/0005-2728(77)90004-4; VAMBUSTA.VK, 1965, J BIOL CHEM, V240, P2660; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; VITSEVA OI, 1990, BIOCHEMISTRY-MOSCOW, V61, P251; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WIEKER HJ, 1987, BIOCHIM BIOPHYS ACTA, V892, P108, DOI 10.1016/0005-2728(87)90253-2; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013	49	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32294	32300		10.1074/jbc.272.51.32294	http://dx.doi.org/10.1074/jbc.272.51.32294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405435	hybrid			2022-12-27	WOS:000071108000054
J	Shinoda, K; Morishita, Y; Sasaki, K; Matsuda, Y; Takahashi, I; Nishi, T				Shinoda, K; Morishita, Y; Sasaki, K; Matsuda, Y; Takahashi, I; Nishi, T			Enzymatic characterization of human alpha 1,3-fucosyltransferase Fuc-TVII synthesized in a B cell lymphoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; ACCEPTOR SPECIFICITY; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; SUBSTRATE SPECIFICITIES; LEUKOCYTE TRAFFICKING; DETERMINES EXPRESSION; SELECTIN LIGAND	The human alpha 1,3-fucosyltransferase, Fuc-TVII, a key enzyme in the biosynthesis of selectin ligands, was expressed as a soluble protein-A chimeric form in a human B cell lymphoma cell line, Namalwa KJM-1, and purified using IgG-Sepharose. The enzymatic properties of recombinant soluble Fuc-TVII were then examined. Its enzyme activity was highest at pH 7.5, and the presence of 25 mM Mn2+ was required for full activity. Fuc-TVII exhibits an acceptor specificity restricted to alpha 2,3-sialylated type 2 oligosaccharides, and the apparent K-m values for alpha 2,3-sialyl lacto-N-neotetraose and GDP-fucose were 3.08 mM and 16.4 mu M, respectively. The inhibitory effects of various nucleotides on the activity of Fuc-TVII reflected its donor specificity for the nucleotide portion of GDP. Fuc-TVII was demonstrated to be useful for the synthesis of a sialyl Lewis x hexasaccharide from lacto-N-neotetraose in combination with an alpha 2,3-sialyltransferase, ST3Gal IV. Polyethylene glycols enhanced the thermal stability of Fuc-TVII, leading to increased formation of the reaction product.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan	Kyowa Kirin Ltd	Nishi, T (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.							BORSIG L, 1995, BIOCHEM BIOPH RES CO, V210, P14, DOI 10.1006/bbrc.1995.1621; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; DELBOURG MF, 1993, BIOTECHNOL LETT, V15, P157, DOI 10.1007/BF00133016; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; Fukuda M., 1992, CELL SURFACE CARBOHY; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAYASHIDA K, 1992, J FERMENT BIOENG, V73, P239, DOI 10.1016/0922-338X(92)90170-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; JAENICKE R, 1987, BIOL CHEM H-S, V368, P871, DOI 10.1515/bchm3.1987.368.2.871; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIYAJI H, 1990, CYTOTECHNOLOGY, V4, P173, DOI 10.1007/BF00365098; Miyamoto D, 1995, BIOCHEM BIOPH RES CO, V217, P852, DOI 10.1006/bbrc.1995.2850; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VALKI A, 1994, P NATL ACAD SCI USA, V91, P7390; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	34	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31992	31997		10.1074/jbc.272.51.31992	http://dx.doi.org/10.1074/jbc.272.51.31992			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405391	hybrid			2022-12-27	WOS:000071108000010
J	Chu, DM; Corbin, JD; Grimes, KA; Francis, SH				Chu, DM; Corbin, JD; Grimes, KA; Francis, SH			Activation by cyclic GMP binding causes an apparent conformational change in cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; BOVINE AORTA; I-BETA; CIRCULAR-DICHROISM; TERMINAL DOMAIN; CAMP; PURIFICATION; SEQUENCE; ISOZYMES; ANALOGS	Cyclic nucleotide binding activates cyclic nucleotide-dependent protein kinases, but the molecular mechanism is unknown. In the present studies, cGMP binding to type I alpha or type I beta cGMP-dependent protein kinase (PKG) caused (i) a large electronegative charge shift of each enzyme on ion exchange chromatography, (ii) an increase in the Stokes radius (>3 Angstrom) of each enzyme, and (iii) a decreased mobility of type I beta PKG on native gel electrophoresis, These physical changes were not detected in the monomeric form of type I beta PKG upon activation by cGMP, However, the results of partial proteolysis of type I alpha PKG revealed some degree of cGMP-induced conformational change within the PKG-monomer, since cGMP binding protects the PKG-monomer against chymotryptic cleavage, The altered sensitivity to proteolysis occurs at Met-200, which is located between the B and C alpha-helices in the high affinity site (site A), and implies that the cGMP-induced structural perturbations in this region may participate in activation of dimeric PKG, The cGMP-induced conformational effects observed using the physical separation methods are likely to reflect altered interactions within the dimeric PKG that are caused by structural alterations within the subunits.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOL BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University					NIDDK NIH HHS [DK40029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARPENTER FH, 1972, J BIOL CHEM, V247, P5580; COBB CE, 1987, J BIOL CHEM, V262, P16566; COHN EJ, 1943, PROTEINS AMINO ACIDS, P424; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LINCOLN TM, 1988, J BIOL CHEM, V263, P17632; MIGLIETTA LAP, 1988, J BIOL CHEM, V263, P16096; PORATH J, 1959, NATURE, V183, P1657, DOI 10.1038/1831657a0; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCATCHARD G, 1962, J AM CHEM SOC, V84, P127, DOI 10.1021/ja00861a001; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1982, P NATL ACAD SCI-BIOL, V79, P7679, DOI 10.1073/pnas.79.24.7679; WOLFE L, 1987, J BIOL CHEM, V262, P16906; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	40	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31922	31928		10.1074/jbc.272.50.31922	http://dx.doi.org/10.1074/jbc.272.50.31922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395541	hybrid			2022-12-27	WOS:A1997YL41900100
J	Dean, N; Zhang, YB; Poster, JB				Dean, N; Zhang, YB; Poster, JB			The VRG4 gene is required for GDP-mannose transport into the lumen of the Golgi in the yeast, Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE-N-ACETYLGLUCOSAMINE; ROUGH ENDOPLASMIC-RETICULUM; PROTEIN GLYCOSYLATION; GUANOSINE DIPHOSPHATASE; SPHINGOLIPIDS; MUTANTS; PHOSPHATE; APPARATUS; VESICLES; FAMILY	In the yeast Saccharomyces cerevisiae, glycoproteins and sphingolipids are modified in the Golgi by the addition of mannose residues. The critical mannosyl donor for these reactions is the nucleotide sugar, GDP-mannose, whose transport into the Golgi from the cytoplasm is required for mannosylation. This transport reaction has been well characterized, but the nucleotide sugar transporter has yet to be identified in yeast, VRG4 is an essential gene whose product is required for a number of Golgi-specific functions, including glycosylation and the organization of the endomembrane system. Here, data are presented that demonstrate that the primary role of Vrg4p is in the transport of GDP-mannose into the Golgi. The vrg4 mutation causes a general impairment in mannosylation, affecting N-linked and O-linked glycoprotein modifications as well as the mannosylation of sphingolipids. By using an in vitro assay, vrg4 mutants were shown to be specifically defective in the transport of GDP-mannose into Golgi vesicles. The Vrg4 protein localizes to the Golgi complex in a pattern that suggests a wide distribution throughout the Golgi. Vrg4p displays homology to other putative nucleotide sugar transporters, suggesting that the VRG4 gene encodes a Golgi GDP-mannose transporter. As Vrg4p is essential, these results suggest that a complete lack of mannosylation of glycoproteins in the Golgi leads to inviability. Alternatively, the essential function of Vrg4p in yeast involves its effect on sphingolipids, which would imply a critical role for mannosylinositol phosphorylceramides or mannosyl diphosphoinositol ceramides on growth and viability.			Dean, N (corresponding author), SUNY STONY BROOK, INST CELL & DEV BIOL, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.				NIGMS NIH HHS [GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; COTTAREL G, 1995, CURR GENET, V28, P380, DOI 10.1007/BF00326437; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANIKENNULAT C, 1995, GENETICS, V140, P933; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lussier M, 1997, J BIOL CHEM, V272, P15527, DOI 10.1074/jbc.272.24.15527; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Neiman AM, 1997, GENETICS, V145, P637; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PATTON JL, 1992, ARCH BIOCHEM BIOPHYS, V292, P70, DOI 10.1016/0003-9861(92)90052-X; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Poster JB, 1996, J BIOL CHEM, V271, P3837; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; Sherman F., 1983, METHODS YEAST GENETI; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SMITH SW, 1974, J BIOL CHEM, V249, P3395; WAECHTER CJ, 1973, J BIOL CHEM, V248, P7570; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WU WI, 1993, J BIOL CHEM, V268, P13830	41	115	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31908	31914		10.1074/jbc.272.50.31908	http://dx.doi.org/10.1074/jbc.272.50.31908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395539	hybrid			2022-12-27	WOS:A1997YL41900098
J	Dobrosotskaya, I; Guy, RK; James, GL				Dobrosotskaya, I; Guy, RK; James, GL			MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SYNAPSE-ASSOCIATED PROTEIN; NMDA RECEPTOR SUBUNITS; WW DOMAIN; PSD-95 FAMILY; PDZ DOMAIN; BINDING; HOMOLOG; SAP90; GENE	Membrane-associated guanylate kinase (MAGUK) proteins participate in the assembly of multiprotein complexes on the inner surface of the plasma membrane at regions of cell-cell contact. MAGUKs are characterized by three types of protein-protein interaction modules: the PDZ domain, the Src homology 3 (SH3) domain, and the guanylate kinase (GuK) domain. The arrangement of these domains is conserved in all previously known MAGUKs: either one or three PDZ domains in the NH2-terminal half, followed by the SH3 domain, followed by a COOH-terminal GuK domain. In this report, we describe the cDNA cloning and subcellular distribution of MAGI-1, a MAGUK with three unique structural features: 1) the GuK domain is at the NH2 terminus, 2) the SH3 domain is replaced by two WW domains, and 3) it contains five PDZ domains, MAGI-1 mRNA was detected in several adult mouse tissues. Sequence analysis of overlapping cDNAs revealed the existence of three splice variants that are predicted to encode MAGI-1 proteins with different COOH termini. The longest variant, MAGI-1c, contains three bipartite nuclear localization signals in its unique COOH-terminal sequence and was found predominantly in the nucleus of Madin-Darby canine kidney cells. A shorter form lacking these signals was found primarily in membrane and cytoplasmic fractions. This distribution, which is reminiscent of that seen for the tight junction protein ZO-1, suggests that MAGI-1 may participate in the transmission of regulatory signals from the cell surface to the nucleus.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Guy, Rodney/J-7107-2013	Guy, Rodney/0000-0002-9638-2060	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUB O, 1996, CURR BIOL, V4, P495; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	51	164	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31589	31597		10.1074/jbc.272.50.31589	http://dx.doi.org/10.1074/jbc.272.50.31589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395497	hybrid			2022-12-27	WOS:A1997YL41900056
J	Ray, K; Fan, GF; Goldsmith, PK; Spiegel, AM				Ray, K; Fan, GF; Goldsmith, PK; Spiegel, AM			The carboxyl terminus of the human calcium receptor - Requirements for cell-surface expression and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; MUTATIONS; RAT; PROTEINS	The G-protein-coupled calcium receptor plays a key role in extracellular calcium homeostasis. To examine the role of the membrane-spanning domains and the similar to 200-residue cytoplasmic carboxyl terminus of the calcium receptor-in cell-surface expression and signal transduction, we transfected HEK-293 cells with a series of truncation and carboxyl-terminal missense mutants and analyzed expression by immunoblotting, glycosidase digestion, intact cell immunoassay, and extracellular calcium-stimulated phosphoinositide hydrolysis assay. Two truncation mutants terminating at residues 706 and 802 within the second and third intracellular loops, respectively, were not properly glycosylated, failed to reach the cell-surface, and showed no calcium response, indicating that mutant receptors with the full extracellular domain but only three or five transmembrane domains are improperly folded and/or processed. Truncation mutants terminating at residues 888 and 903 within the carboxyl terminus were equivalent to the wild type in all assays, whereas mutants truncated at residues 865 and 874 showed no response to calcium, despite only similar to 25% reduction in cell-surface expression. Mutants with a full-length carboxyl terminus but with residues between positions 874 and 888 replaced with alanines showed either no (Ala(875), Ala(876), and Ala(879)) or significantly reduced (Ala(881)-Ala(883)) calcium response at levels of cell-surface expression equivalent to those of the wild-type receptor. These results indicate that deletion of the majority of the carboxyl terminus is compatible with normal processing, cell-surface expression, and signal transduction of the receptor. The truncation and alanine substitution mutants identify a small region between residues 874 and 888 critical for normal signal transduction by the receptor.	NIDDK,METAB DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; CHANG W, 1996, 10 INT C END JUN 12, P725; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Heymann JAW, 1997, P NATL ACAD SCI USA, V94, P4966, DOI 10.1073/pnas.94.10.4966; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KIFOR O, 1990, J BONE MINER RES, V5, P1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720	22	107	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31355	31361		10.1074/jbc.272.50.31355	http://dx.doi.org/10.1074/jbc.272.50.31355			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395465	hybrid			2022-12-27	WOS:A1997YL41900024
J	StraussSoukup, JK; Maher, LJ				StraussSoukup, JK; Maher, LJ			Role of asymmetric phosphate neutralization in DNA bending by PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOMAL DNA; RECOGNITION; COMPLEX	The PU.1 transcription factor is a member of the Ets family of DNA binding proteins, PU.1 binds to DNA via a loop-helix-loop domain and functions in the differentiation of hematopoietic cells, The structure of a PU.1-DNA complex was recently reported (Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R., and Ely, K. (1996) Nature 380, 456-460). The DNA in this complex is deformed by 8 degrees as it curves around the protein, The pattern of electrostatic contacts between PU.1, and its DNA binding site suggests that laterally asymmetric phosphate neutralization accompanies PU.1 binding, Because of our previous studies showing that such neutralization can induce bending in naked DNA, we have explored the effect of phosphate neutralization by substituting neutral methylphosphonate internucleoside linkages at relevant positions within DNA containing the PU.1 binding sequence, Consistent with the prediction that DNA will collapse toward its partially neutralized surface, DNA neutralized at seven positions to simulate PU.1 binding is observed to bend by 28 degrees. The directions of DNA curvature are slightly different in the co-crystal versus the partially neutralized duplexes, The electrostatic component of the binding energy appears more than enough to account for the DNA bending observed in the PU.1-DNA complex.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Mayo Clinic; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NIGMS NIH HHS [GM47814, GM54411] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814, R01GM054411] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; HOGREFE RI, 1993, NUCLEIC ACIDS RES, V21, P2031, DOI 10.1093/nar/21.9.2031; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Strauss JK, 1996, P NATL ACAD SCI USA, V93, P9515, DOI 10.1073/pnas.93.18.9515; Strauss JK, 1996, CHEM BIOL, V3, P671, DOI 10.1016/S1074-5521(96)90135-0; StraussSoukup JK, 1997, BIOCHEMISTRY-US, V36, P8692, DOI 10.1021/bi9705467	14	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31570	31575		10.1074/jbc.272.50.31570	http://dx.doi.org/10.1074/jbc.272.50.31570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395494	hybrid			2022-12-27	WOS:A1997YL41900053
J	Traub, O; Monia, BP; Dean, NM; Berk, BC				Traub, O; Monia, BP; Dean, NM; Berk, BC			PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; SHEAR-STRESS; MAP KINASE; ALPHA EXPRESSION; GENE-EXPRESSION; FLOW; CALCIUM; INHIBITION; RAF	Mechano-sensitive regulation of endothelial cells (EC) function by shear stress is critical for flow-induced vasodilation and gene expression. Previous studies by our laboratory demonstrated that shear stress activates the 44- and 42-kDa extracellular signal-regulated kinases (ERK1/2) in EC in a time-and force-dependent manner. ERK1/2 activation was inhibited by protein kinase C (PKC) down-regulation with phorbol 12,13-dibutyrate (1 mu M for 24 h) but not by calcium chelation with BAPTA-AM (acetoxymethyl ester of BAPTA) (75 mu M for 30 min), suggesting that a novel PKC isoform (delta, epsilon, eta, theta) mediates shear stress-induced ERK1/2 activation. Western blotting with PKC isoform-specific antibodies demonstrated expression of PKC-alpha, -epsilon, and -zeta isoforms in EC. PKC-epsilon was specifically inhibited by transfection with antisense PKC-epsilon phosphorothioate oligonucleotides (1,000 nM for 6 h). Antisense treatment decreased PKC-epsilon protein levels by 80 +/- 13% after 72 h and completely inhibited shear stress-stimulated ERK1/2 activation. Scrambled PKC-epsilon oligonucleotides and antisense PKC-alpha and PKC-zeta oligonucleotides had no effect on ERK1/2 activity. PKC-epsilon appeared specific for mechano-sensitive ERK1/2 activation, as antisense PKC-epsilon oligonucleotides did not inhibit ERK1/2 activation by EGF or bradykinin but did inhibit ERK1/2 activation upon EC adhesion to fibronectin. These results define a pathway for shear stress-mediated ERK1/2 activation and establish a new function for PKC-epsilon as part of a mechano-sensitive signal transduction pathway in EC.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195; ISIS PHARMACEUT,DEPT MOL PHARMACOL,CARLSBAD,CA 92008	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Isis Pharmaceuticals Inc				Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007266] Funding Source: NIH RePORTER; NHLBI NIH HHS [IH PO1 HL18645] Funding Source: Medline; NIGMS NIH HHS [NIGM-GM07266] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1996, MOL PHARMACOL, V50, P522; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; CACACE AM, 1993, ONCOGENE, V8, P2095; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; CORSON MA, 1993, CIRCULATION, V88, P183; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DEAN NM, 1994, J BIOL CHEM, V269, P16416; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Girard Peggy R., 1993, Frontiers of Medical and Biological Engineering, V5, P31; HERSHENSON MB, 1995, J BIOL CHEM, V270, P19908, DOI 10.1074/jbc.270.34.19908; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; UEMATSU M, 1993, CIRCULATION, V88, P184; VUORI K, 1993, J BIOL CHEM, V268, P21459; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; Young SW, 1996, FEBS LETT, V384, P181, DOI 10.1016/0014-5793(96)00287-6; YU SM, 1996, J CELL BIOL, V50, P1000	45	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31251	31257		10.1074/jbc.272.50.31251	http://dx.doi.org/10.1074/jbc.272.50.31251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395450	hybrid			2022-12-27	WOS:A1997YL41900009
J	Anand-Apte, B; Zetter, BR; Viswanathan, A; Qiu, RG; Chen, J; Ruggieri, R; Symons, M				Anand-Apte, B; Zetter, BR; Viswanathan, A; Qiu, RG; Chen, J; Ruggieri, R; Symons, M			Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; TRANSFORMATION; CELLS; BINDING; SCATTER; RHO; CHEMOTAXIS; TRANSCRIPTION; FIBROBLASTS	Directed cell migration is essential for a variety of important biological processes ranging from development and angiogenesis to metastasis. Ras plays a pivotal role in the signaling cascade that governs chemotaxis of fibroblasts toward platelet-derived growth factor-BB (PDGF-BB), Ras activates multiple downstream pathways, which include the extracellular signal-regulated kinase (ERK), Rac, and Ral signaling cascades, We therefore investigated the role of the Rac and ERK pathways in cell migration, We showed that migration of fibroblasts toward PDGF-BB is inhibited by expression of dominant negative Asn-17 Rad. Blocking of the ERK pathway by either expression of dominant negative Ala-218/Ala-222-mitogen-activated protein kinase kinase (A218/A222-MEK1) or by a MEK-specific inhibitor did not inhibit migration toward PDGF-BB, In contrast, migration toward soluble fibronectin was suppressed by inhibition of the ERK pathway but not by Asn-17 Rad expression, These results indicate that directed cell migration mediated by different receptor classes in response to different ligands differentially utilizes the Rac and ERK pathways and suggest that Rac might play a critical role in pathological processes such as angiogenesis and metastasis.	ONYX Pharmaceut, Richmond, CA 94806 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Symons, M (corresponding author), ONYX Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.	msymons@onyx-pharm.com		viswaanathan, akila/0000-0002-1896-2924	NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornfeldt KE, 1996, TRENDS CARDIOVAS MED, V6, P143, DOI 10.1016/1050-1738(96)00038-2; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRONNERFRASER M, 1995, TRENDS GENET, V11, P423, DOI 10.1016/S0168-9525(00)89136-2; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Godwin SL, 1997, J BIOL CHEM, V272, P11307; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHagan RC, 1996, ONCOGENE, V13, P1323; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHLAEPFER DD, 1994, NATURE, V372, P786; STOKES CL, 1991, J THEOR BIOL, V152, P377, DOI 10.1016/S0022-5193(05)80201-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WENNSTROM S, 1994, ONCOGENE, V9, P651; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILKINSON PC, 1988, METHOD ENZYMOL, V162, P3; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	46	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30688	30692		10.1074/jbc.272.49.30688	http://dx.doi.org/10.1074/jbc.272.49.30688			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388204	hybrid			2022-12-27	WOS:000071640800017
J	Balasubramanian, K; Chandra, J; Schroit, AJ				Balasubramanian, K; Chandra, J; Schroit, AJ			Immune clearance of phosphatidylserine-expressing cells by phagocytes - The role of beta(2)-glycoprotein I in macrophage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-GLYCOPROTEIN-I APOLIPOPROTEIN-H; LOW-DENSITY-LIPOPROTEIN; RED-BLOOD-CELLS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; APOPTOTIC CELLS; BINDING; MEMBRANE; PROTEIN; AUTOANTIBODIES	The function of beta(2)-glycoprotein I (beta(2)GPI), a 50-kDa serum glycoprotein, is not completely understood but has been suggested to be involved in the regulation of thrombosis (Brighten, T. A., Hogg, P, J,, Dal, Y,-P,, Murray, B, H., Choing, B, H,, and Chesterman, C, N, (1996) Br, J. Haematol, 93, 185-194) and the clearance of phosphatidylserine (PS)-expressing cells (Chonn, A., Semple S, C,, and Cullis P, R, (1995) J, Biol, Chem. 270, 25845-25849). To further understand the role of this protein, we characterized the ability of beta(2)GPI to interact with PS vesicles and influence their uptake by macrophages in vitro. beta(2)GPI bound to and precipitated vesicles containing anionic but not zwitterionic phospholipids in a gel diffusion assay, beta(2)GPI also inhibited the procoagulant activity of PS liposomes, In vitro phagocytosis studies showed 20-fold greater uptake of PS liposomes over phosphatidylcholine liposomes. This enhanced uptake was maintained even after PS was "shielded" with beta(2)GPI and further increased upon the addition of beta(2)GPI antibodies, Similar to liposomes, PS-expressing apoptotic thymocytes and lipid symmetric red blood cell ghosts bound beta(2)GPI. Macrophage uptake of these cells was also maintained or enhanced in the presence of beta(2)GPI and further increased upon the addition of beta(2)GPI antibodies, It is concluded that beta(2)GPI can play a critical role in hemostasis by influencing both thrombosis and the clearance of PS-expressing cells.	Univ Texas, MD Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schroit, AJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cell Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.				NIDDK NIH HHS [DK 41714] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brighton TA, 1996, BRIT J HAEMATOL, V93, P185, DOI 10.1046/j.1365-2141.1996.446981.x; CHONN A, 1995, J BIOL CHEM, V270, P25845, DOI 10.1074/jbc.270.43.25845; CINES DB, 1995, J CLIN IMMUNOL S, V15, P86; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fukasawa M, 1996, EXP CELL RES, V222, P246, DOI 10.1006/excr.1996.0030; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; HAGIHARA Y, 1995, J BIOCHEM-TOKYO, V118, P129, DOI 10.1093/oxfordjournals.jbchem.a124867; HUNT J, 1994, J IMMUNOL, V152, P653; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; NIMPF J, 1986, BIOCHIM BIOPHYS ACTA, V884, P142, DOI 10.1016/0304-4165(86)90237-0; OOSTING JD, 1993, BLOOD, V81, P2618; POLTZ E, 1979, FEBS LETT, V102, P183; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROUBEY RAS, 1995, J IMMUNOL, V154, P954; ROUBEY RAS, 1994, BLOOD, V84, P2854; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHOUSBOE I, 1979, BIOCHIM BIOPHYS ACTA, V579, P396, DOI 10.1016/0005-2795(79)90067-9; SCHROIT AJ, 1983, BIOCHEMISTRY-US, V22, P3617, DOI 10.1021/bi00284a012; STEINKASSERER A, 1991, BIOCHEM J, V277, P387, DOI 10.1042/bj2770387; Sugi T, 1996, THROMB RES, V84, P97, DOI 10.1016/0049-3848(96)00165-X; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	31	137	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31113	31117		10.1074/jbc.272.49.31113	http://dx.doi.org/10.1074/jbc.272.49.31113			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388264	hybrid			2022-12-27	WOS:000071640800077
J	Bomer, U; Meijer, M; Guiard, B; Dietmeier, K; Pfanner, N; Rassow, J				Bomer, U; Meijer, M; Guiard, B; Dietmeier, K; Pfanner, N; Rassow, J			The sorting route of cytochrome b(2) branches from the general mitochondrial import pathway at the preprotein translocase of the inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; C PEROXIDASE; MATRIX HSP70; SIGNAL; PRESEQUENCE; TRANSPORT; COMPLEX	Cytochrome b(2) is synthesized in the cytosol with a bipartite presequence. The first part of the presequence targets the protein to mitochondria and mediates translocation into the mitochondrial matrix compartment; the second part contains the sorting signal that is required for delivery of the protein to the intermembrane space, The localization of the structures that recognize the sorting signal is unclear, Here we show that upon import in vivo, the sorting signal of cytochrome b(2) causes an early divergence from the general matrix import pathway and thereby prevents translocation of a folded C-terminal domain into mitochondria. By co-immunoprecipitations we find that translocation intermediates of cytochrome b(2) are associated with Tim23, a component of the inner membrane protein import machinery, Cytochrome b(2) constructs with an alteration in the sorting signal are mistargeted to the matrix of wildtype mitochondria, In mitochondria containing a mutant form of Tim23, however, the translocation of the altered sorting signal across the inner membrane is inhibited, and cytochrome b(2) is correctly sorted to the intermembrane space, We suggest that the sorting signal of cytochrome b(2) is recognized within the inner membrane in close vicinity to Tim23.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY; BIOCTR AMSTERDAM, INST MOL CELL BIOL, NL-1098 SM AMSTERDAM, NETHERLANDS; UNIV PARIS 06, CNRS, CTR GENET MOL, F-91190 GIF SUR YVETTE, FRANCE	University of Freiburg; University of Amsterdam; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay			Pfanner, Nikolaus/AAV-7878-2021					Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Ausubel FM, 1988, MOL REPROD DEV; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Bomer U, 1996, J MOL BIOL, V262, P389, DOI 10.1006/jmbi.1996.0522; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; CUTHRIE C, 1991, METHODS ENZYMOLOGY G, V194, P1; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; Horst M, 1996, PROTEIN SCI, V5, P759; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; ONO H, 1995, J BIOL CHEM, V270, P16932, DOI 10.1074/jbc.270.28.16932; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1997, IN PRESS ANN REV CEL, V13; PON L, 1991, MOL CELLULAR BIOL YE, V1, P333; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rassow J, 1996, CURR BIOL, V6, P115, DOI 10.1016/S0960-9822(02)00437-2; REID GA, 1982, J BIOL CHEM, V257, P3068; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; RYAN KR, 1993, J BIOL CHEM, V268, P23743; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	65	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30439	30446		10.1074/jbc.272.48.30439	http://dx.doi.org/10.1074/jbc.272.48.30439			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374535	Green Published, hybrid			2022-12-27	WOS:A1997YH61300067
J	Fanen, P; Labarthe, R; Garnier, F; Benharouga, M; Goossens, M; Edelman, A				Fanen, P; Labarthe, R; Garnier, F; Benharouga, M; Goossens, M; Edelman, A			Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect - Analysis of C225R-CFTR and R1066C-CFTR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS; REGULATOR; CFTR; CHANNEL; RESIDUES; LOOP	We have previously screened the cystic fibrosis transmembrane conductance regulator (CFTR) gene and identified new disease-causing mutations. C225R and R1066C are both associated with pancreatic insufficiency, but the former mutation is associated with mild and unusual lung disease, whereas the latter is associated with severe lung disease, In the present study, we expressed these mutants heterologously in HeLa cells, and we analyzed protein synthesis by immunoprecipitation and chloride channel function by using a halide-sensitive fluorescent dye, 6-methoxy-N-ethylquinolinium, Immunoprecipitation and functional studies showed that cells transfected with C225R-CFTR exhibit cAMP-dependent chloride fluxes; C225R-CFTR protein is poorly expressed but fully glycosylated and can be compared with R117H-CFTR. R1066C-CFTR protein is not correctly processed and, unlike Delta F508-CFTR, this defect cannot be corrected by reduced temperature or overexpression in butyrate-treated cells; defective processing may occur at a different step in the biosynthetic pathway, These results point to two different mechanisms underlying the same pancreatic status and suggest that it is unwise to use pancreatic sufficiency and insufficiency to define mild and severe cystic fibrosis (CF) disease, respectively, Finally, the experimental model described here may be helpful to predict the pulmonary status of CF patients bearing mutations located in putative membrane-spanning domains of the CFTR protein.	FAC MED NECKER ENFANTS MALAD,INSERM,U467,F-75015 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U468,F-94010 CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Garnier, Fabien/O-7950-2016	Fanen, Pascale/0000-0002-3273-5349; Garnier, Fabien/0000-0002-7749-952X				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; HIPPER A, 1995, FEBS LETT, V374, P312, DOI 10.1016/0014-5793(95)01132-X; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Sheppard DN, 1996, J BIOL CHEM, V271, P14995, DOI 10.1074/jbc.271.25.14995; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	17	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30563	30566		10.1074/jbc.272.48.30563	http://dx.doi.org/10.1074/jbc.272.48.30563			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374552	hybrid			2022-12-27	WOS:A1997YH61300084
J	Fichard, A; Tillet, E; Delacoux, F; Ruggiero, F				Fichard, A; Tillet, E; Delacoux, F; Ruggiero, F			Human recombinant alpha 1(V) collagen chain - Homotrimeric assembly and subsequent processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS SYNDROME; V COLLAGEN; CORNEAL FIBRILLOGENESIS; STRUCTURAL-ANALYSIS; TRIPLE-HELIX; B-CHAINS; EXPRESSION; CELLS; MUTATION; INVITRO	Human embryonic kidney cells (293-EBNA) have been transfected with the full length human alpha 1 chain of collagen V using an episomal vector, High yields (15 mu g/ml) of recombinant collagen were secreted in the culture medium, In presence of ascorbate, the alpha 1(V) collagen is correctly folded into a stable triple helix as shown by electron microscopy and pepsin resistance, Circular dichroism data confirm the triple helix conformation and indicate a melting temperature of 37.5 degrees C for the recombinant homotrimer, The major secreted form is a 250-kDa polypeptide (alpha 1FL), N-terminal sequencing and collagenase digestion indicate that alpha 1FL retains the complete N-propeptide but lacks the C-propeptide. However, alpha 1FL might undergo a further N-terminal trimming into a form (alpha 1TH) corresponding to the main triple-helix domain plus the major part of the NC2 domain, This processing is different from the one of the heterotrimeric (alpha 1(V))(2) alpha 2(V) and could have some physiological relevance, Analysis of cell homogenates indicates the presence of a 280-kDa polypeptide that is disulfide-linked through its C-terminal globular domain, This C-propeptide is rapidly cleaved after secretion in the medium, giving the first evidence of a C-terminal processing of recombinant fibrillar collagens, Rotary shadowing observations not only confirm the presence of a globular domain at the N-terminal end of the molecule but reveal the presence of a kink within the triple helix in a region poor in iminoacids. This region could represent a target for proteases, Together with the thermal stability data, these results might explain the low amount of (alpha 1(V))(3) recovered from tissues.	UNIV LYON 1,INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1				Tillet, Emmanuelle/0000-0002-0076-8007; RUGGIERO, Florence/0000-0003-2915-5359				ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BENTZ H, 1978, EUR J BIOCHEM, V92, P563, DOI 10.1111/j.1432-1033.1978.tb12778.x; BIRK DE, 1990, J CELL SCI, V95, P649; BROEK DL, 1985, J BIOL CHEM, V260, P555; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FICHARD A, 1994, MATRIX BIOL, V14, P515; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GEDDIS AE, 1993, MATRIX, V13, P339; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HARALSON MA, 1984, ARCH BIOCHEM BIOPHYS, V229, P509, DOI 10.1016/0003-9861(84)90182-6; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LI Y, 1995, CELL, V80, P1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4129, DOI 10.1021/bi00823a015; Ruggiero F, 1996, INVEST OPHTH VIS SCI, V37, P1749; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Tomita M, 1995, BIOCHEM J, V312, P847, DOI 10.1042/bj3120847; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733	40	67	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30083	30087		10.1074/jbc.272.48.30083	http://dx.doi.org/10.1074/jbc.272.48.30083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374485	hybrid			2022-12-27	WOS:A1997YH61300017
J	Costache, M; Apoil, PA; Cailleau, A; Elmgren, A; Larson, G; Henry, S; Blancher, A; Iordachescu, D; Oriol, R; Mollicone, R				Costache, M; Apoil, PA; Cailleau, A; Elmgren, A; Larson, G; Henry, S; Blancher, A; Iordachescu, D; Oriol, R; Mollicone, R			Evolution of fucosyltransferase genes in vertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; FUCOSYL-TRANSFERASE GENES; SIALYL-LEWIS-X; GDP-L-FUCOSE; MOLECULAR-CLONING; ELAM-1 LIGAND; EXPRESSION; SEQUENCE; ANTIGEN	Cloning and expression of chimpanzee FUT3, FUT5, and FUT6 genes confirmed the hypothesis that the gene duplications at the origin of the present human cluster of genes occurred between: (i) the great mammalian radiation 80 million years ago and (ii) the separation of man and chimpanzee 10 million years ago, The phylogeny of fucosyltransferase genes was completed by the addition of the FUT8 family of alpha(1,6)fucosyltransferase genes, which are the oldest genes of the fucosyltransferase family. By analysis of data banks, a new FUT8 alternative splice expressed in human retina was identified, which allowed mapping the human FUT8 gene to 14q23. The results suggest that the fucosyltransferase genes have evolved by successive duplications, followed by translocations, and divergent evolution from a single ancestral gene.	UNIV PARIS 11, INSERM, U178, F-94807 VILLEJUIF, FRANCE; CHU PURPAN, LAB IMMUNOGENET MOL, F-31059 TOULOUSE, FRANCE; GOTHENBURG UNIV, DEPT CLIN CHEM & TRANSFUS MED, S-41345 GOTHENBURG, SWEDEN; AUCKLAND INST TECHNOL, GLYCOSCI RES CTR, AUCKLAND 1020, NEW ZEALAND; UNIV BUCHAREST, DEPT BIOCHEM, BUCHAREST 75201, ROMANIA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; University of Gothenburg; Auckland University of Technology; University of Bucharest			Larson, Göran/AAF-3404-2019; Costache, Marieta D/F-2806-2016	Costache, Marieta D/0000-0002-8103-3693; APOIL, POL ANDRE/0000-0002-1057-4919				Breton C, 1996, GLYCOBIOLOGY, V6, pR7; BRETON C, 1998, IN PRESS GLYCOBIOLOG; CANDELIER JJ, 1993, LAB INVEST, V69, P449; Cohney S, 1996, IMMUNOGENETICS, V44, P76, DOI 10.1007/BF02602660; Costache M, 1997, TRANSFUS CLIN BIOL, V4, P367, DOI 10.1016/S1246-7820(97)80042-0; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; Fitch W.M., 1970, EVOL BIOL, V4, P67; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GERSTEN KM, 1994, THESIS U MICHIGAN AN; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOD AH, 1992, VOX SANG, V62, P180, DOI 10.1111/j.1423-0410.1992.tb01195.x; Gosselin S, 1996, BIOORGAN MED CHEM, V4, P2023, DOI 10.1016/S0968-0896(97)81455-1; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; ReguigneArnould I, 1996, CR ACAD SCI III-VIE, V319, P783; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626	43	86	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29721	29728		10.1074/jbc.272.47.29721	http://dx.doi.org/10.1074/jbc.272.47.29721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368041	hybrid			2022-12-27	WOS:A1997YG64700051
J	vandenWijngaard, PWJ; Vredenberg, WJ				vandenWijngaard, PWJ; Vredenberg, WJ			A 50-picosiemens anion channel of the chloroplast envelope is involved in chloroplast protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; ION CHANNELS; MEMBRANE; TRANSLOCATION	Single channel recordings were used to investigate the changes on the pea chloroplast envelope during protein import, In the inside-out patch configuration a 50-picosiemens (pS) anion channel of the chloroplast envelope membrane was identified, The open time probability of the channel was decreased by the addition of the wild type precursor protein of ferredoxin (wt-prefd) to the pipette-filling solution in the presence of 0.5 mM ATP. In the absence of ATP or in the presence of 50 mu M ATP, wt-prefd did not affect the open time probability of the channel, A deletion mutant of prefd, Delta 6-14-prefd, which is inactive in in vitro import, was also unable to affect the open time probability of the 50-pS anion channel, In the presence of 100 mu M ATP, wt-prefd decreased the open time probability of the channel to a lesser extent, as did the transit peptide alone, It is concluded that the 50 pS anion channel could be part of the protein import machinery of the inner membrane. In addition the precursor protein under im port conditions induced burst-like increases of the envelope conductivity. The implication of both responses for the chloroplast protein import process are discussed.			vandenWijngaard, PWJ (corresponding author), AGR UNIV WAGENINGEN,DEPT PLANT PHYSIOL,ARBORETUMLAAN 4,NL-6703 BD WAGENINGEN,NETHERLANDS.							BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FUKS B, 1995, J BIOL CHEM, V270, P9947, DOI 10.1074/jbc.270.17.9947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heiber T, 1995, BIOCHEMISTRY-US, V34, P15906, DOI 10.1021/bi00049a005; Heinemann Stefan H., 1995, P53; KESSLER F, 1994, SCIENCE, V266, P1033; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Lu Y, 1997, J BIOL CHEM, V272, P13555, DOI 10.1074/jbc.272.21.13555; MI F, 1994, PLANT PHYSIOL, V105, P955, DOI 10.1104/pp.105.3.955; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; POTTOSIN II, 1992, FEBS LETT, V308, P87, DOI 10.1016/0014-5793(92)81057-S; POTTOSIN II, 1993, FEBS LETT, V330, P211, DOI 10.1016/0014-5793(93)80275-Y; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; THEG SM, 1989, J BIOL CHEM, V264, P6730; VREDENBERG W, 1995, BBA-BIOENERGETICS, V1230, P77, DOI 10.1016/0005-2728(95)00036-I	21	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29430	29433		10.1074/jbc.272.47.29430	http://dx.doi.org/10.1074/jbc.272.47.29430			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367999	hybrid			2022-12-27	WOS:A1997YG64700009
J	Backlund, M; Johansson, I; Mkrtchian, S; IngelmanSundberg, M				Backlund, M; Johansson, I; Mkrtchian, S; IngelmanSundberg, M			Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CULTURED RABBIT HEPATOCYTES; HEAT-SHOCK PROTEIN; AH DIOXIN RECEPTOR; HYDROXYLASE INDUCTION; ENZYME-ACTIVITY; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; HUMAN KERATINOCYTES	We have investigated mechanisms of omeprazole (OME)-mediated induction of CYP1A1 and CYP3A, using the rat hepatoma H4IIE cell line, in comparison with mechanisms exerted by traditional aryl hydrocarbon receptor (AhR) ligands such as benso(a)pyrene (B(a)P) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). OME did not bind specifically to AhR, and it could not activate the AhR complex in rat cytosol to a xenobiotic-responsive element (XRE)-binding form in vitro. Genistein, a tyrosine kinase inhibitor, and daidzein, an inhibitor of casein kinase II, efficiently inhibited OME-mediated but not B(a)P-or TCDD-mediated induction of CYP1A1, as monitored at the transcriptional, mRNA, and protein levels as well as by analysis of activation of XRE-luciferase reporter constructs transfected into H4IIE cells. The protease inhibitor N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) and lavendustin A also had similar OME-specific effects. In addition, insulin pretreatment caused an almost complete inhibition of OME-dependent CYP1A1 induction but only partially affected TCDD and B(a)P-mediated induction of CYPIA1. Staurosporine, an inhibitor of protein kinase C, impaired the induction by both B(a)P and OME. OME caused an approximately 2-fold increase in the level of CYP3A expression, but all inhibitors used were ineffective in preventing this induction. Gel shift analysis with radiolabeled XRE and specific peptide antibodies toward AhR and aryl hydrocarbon receptor nuclear translocator protein (Arnt) revealed an OME-mediated translocation of the AhR.Arnt complex into the nuclei. Genistein inhibited the specific nuclear XRE binding caused by OME, but it potentiated the formation of the TCDD-induced XRE.AhR complex. Although daidzein was able to effectively inhibit the OME-stimulated CYP1A1 gene transcription, it did not influence the OME-dependent AhR.XRE complex formation, The data are consistent with a mechanism for OME-mediated induction of CYP1A1 that involves activation of the AhR complex via intracellular signal transduction systems and that is distinct from induction mediated by AhR ligands.	KAROLINSKA INST, INST ENVIRONM MED, DIV MOL TOXICOL, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet			Ingelman-Sundberg, Magnus/ABD-9302-2021	Mkrtchian, Souren/0000-0001-9801-2736				AIX L, 1994, BIOCHEM BIOPH RES CO, V202, P1483, DOI 10.1006/bbrc.1994.2098; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHEN YT, 1980, BIOCHEM BIOPH RES CO, V143, P343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384; Daujat M, 1996, EUR J BIOCHEM, V237, P642, DOI 10.1111/j.1432-1033.1996.0642p.x; DAUJAT M, 1992, BIOCHEM BIOPH RES CO, V188, P820, DOI 10.1016/0006-291X(92)91130-I; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; Dzeletovic N, 1997, J BIOL CHEM, V272, P12705, DOI 10.1074/jbc.272.19.12705; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; GIELEN JE, 1972, J BIOL CHEM, V247, P7591; GLEIZES C, 1991, BIOCHEM PHARMACOL, V41, P1813, DOI 10.1016/0006-2952(91)90119-P; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GRADIN K, 1994, J BIOL CHEM, V269, P23800; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HIGASHI K, 1994, BBA-MOL CELL RES, V1221, P29, DOI 10.1016/0167-4889(94)90212-7; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; JURUTKA PW, 1993, BIOCHEMISTRY-US, V32, P8184, DOI 10.1021/bi00083a019; KIKUCHI H, 1995, ARCH BIOCHEM BIOPHYS, V316, P649, DOI 10.1006/abbi.1995.1085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; Lindros KO, 1997, J PHARMACOL EXP THER, V280, P506; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONNELL WM, 1992, GASTROENTEROLOGY, V103, P1509, DOI 10.1016/0016-5085(92)91171-Y; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; OWENS IS, 1975, MOL PHARMACOL, V11, P94; OWENS IS, 1976, BIOCHEM PHARMACOL, V25, P805, DOI 10.1016/0006-2952(76)90151-9; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PUGA A, 1992, FASEB J, V6, P777, DOI 10.1096/fasebj.6.2.1311272; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ReyGrobellet X, 1996, BIOCHEM BIOPH RES CO, V220, P789, DOI 10.1006/bbrc.1996.0482; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SADEK CM, 1994, J BIOL CHEM, V269, P31505; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; SOUHAILIELAMRI H, 1988, TOXICOL APPL PHARM, V92, P141, DOI 10.1016/0041-008X(88)90236-0; STRUHL K, 1990, CURRENT PROTOCOLS MO	51	109	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31755	31763		10.1074/jbc.272.50.31755	http://dx.doi.org/10.1074/jbc.272.50.31755			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395520	hybrid			2022-12-27	WOS:A1997YL41900079
J	Inoue, K; Dreyfuss, BW; Kindle, KL; Stern, DB; Merchant, S; Sodeinde, OA				Inoue, K; Dreyfuss, BW; Kindle, KL; Stern, DB; Merchant, S; Sodeinde, OA			Ccs1, a nuclear gene required for the post-translational assembly of chloroplast c-type cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; CHLAMYDOMONAS-REINHARDTII; B(6)F COMPLEX; COMPLEMENTARY-DNA; HEME ATTACHMENT; BF COMPLEX; EXPRESSION; BIOGENESIS; SEQUENCE; MUTATIONS	Nuclear genes play important regulatory roles in the biogenesis of the photosynthetic apparatus of eukaryotic cells by encoding factors that control steps ranging from chloroplast gene transcription to post-translational processes, However, the identities of these genes and the mechanisms by which they govern these processes are largely unknown. By using glass bead-mediated transformation to generate insertional mutations in the nuclear genome of Chlamydomonas reinhardtii, we have generated four mutants that are defective in the accumulation of the cytochrome b(6)f complex. One of them, strain abf3, also fails to accumulate holocytochrome c(6). We have isolated a gene, Ccs1, from a C. reinhardtii genomic library that complements both the cytochrome b(6)f and cytochrome c(6) deficiencies in abf3. The predicted protein product displays significant identity with Ycf44 from the brown alga Odontella sinensis, the red alga Porphyra purpurea, and the cyanobacterium Synechocystis strain PCC 6803 (25-33% identity), In addition, we note limited sequence similarity with ResB of Bacillus subtilis and an open reading frame in a homologous operon in Mycobacterium leprae (11-12% identity). On the basis of the pleiotropic e-type cytochrome deficiency in the ccs1 mutant, the predicted plastid localization of the protein, and its relationship to candidate cytochrome biosynthesis proteins in Gram-positive bacteria, we conclude that Ccs1 encodes a protein that is required for chloroplast c-type holocytochrome formation.	PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90095 USA; CORNELL UNIV, PLANT SCI CTR, ITHACA, NY 14853 USA; CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Los Angeles; Cornell University; Cornell University; Boyce Thompson Institute for Plant Research			Stern, David B/H-7852-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594, F32GM017483, R01GM048350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17483, GM48350, GM00594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARKAN A, 1995, PHYSIOL PLANTARUM, V93, P163, DOI 10.1034/j.1399-3054.1995.930123.x; BECKMAN DL, 1992, GENE DEV, V6, P268, DOI 10.1101/gad.6.2.268; BENDALL DS, 1986, FEBS LETT, V203, P31, DOI 10.1016/0014-5793(86)81430-2; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHEN XM, 1993, EMBO J, V12, P3627, DOI 10.1002/j.1460-2075.1993.tb06036.x; Cramer WA, 1997, PHYSIOL PLANTARUM, V100, P852, DOI 10.1111/j.1399-3054.1997.tb00011.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; GAL A, 1990, CURRENT RES PHOTOSYN, V2, P779; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; HILL KL, 1991, J BIOL CHEM, V266, P15060; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; IMBAULT P, 1988, GENE, V73, P397, DOI 10.1016/0378-1119(88)90504-5; Kaneko T, 1996, DNA Res, V3, P109; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; Li HH, 1996, J BIOL CHEM, V271, P31283, DOI 10.1074/jbc.271.49.31283; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MATSUMOTO T, 1991, PLANT CELL PHYSIOL, V32, P863; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1987, J BIOL CHEM, V262, P9062; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; QUINN J, 1998, IN PRESS METHODS ENZ; QUINN JM, 1995, PLANT CELL, V7, P623, DOI 10.1105/tpc.7.5.623; RAMSEIER TM, 1991, J BIOL CHEM, V266, P7793; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNELL RA, 1993, GENETICS, V134, P737; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; SHEPHERD HS, 1983, CELL, V32, P99, DOI 10.1016/0092-8674(83)90500-7; SODEINDE OA, 1993, P NATL ACAD SCI USA, V90, P9199, DOI 10.1073/pnas.90.19.9199; SOROKIN A, 1993, MOL MICROBIOL, V10, P385, DOI 10.1111/j.1365-2958.1993.tb02670.x; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; TAM LW, 1993, GENETICS, V135, P375; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; WAFFENSCHMIDT S, 1993, PLANT CELL, V5, P809, DOI 10.1105/tpc.5.7.809; Xie ZY, 1996, J BIOL CHEM, V271, P4632; YOUNGBLOM J, 1984, MOL CELL BIOL, V4, P2686, DOI 10.1128/MCB.4.12.2686; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	67	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31747	31754		10.1074/jbc.272.50.31747	http://dx.doi.org/10.1074/jbc.272.50.31747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395519	hybrid			2022-12-27	WOS:A1997YL41900078
J	Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH				Latham, GJ; Bacheller, DJ; Pietroni, P; vonHippel, PH			Structural analyses of gp45 sliding clamp interactions during assembly of the bacteriophage T4 DNA polymerase holoenzyme .3. The gp43 DNA polymerase binds to the same face of the sliding clamp as the clamp loader	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; III HOLOENZYME; REPLICATION COMPLEX; TRACKING PROTEIN; SUBUNIT; PROCESSIVITY; ENHANCEMENT; HYDROLYSIS; MECHANISM; PROMOTER	In the preceding paper (Latham, G. J., Bacheller, D. J., Pietroni, P., and von Hippel, P. H. (1997) J. Biol. Chem. 272, 31677-31684), we demonstrated that the T4 gp44/62-ATP clamp loader binds to the C-terminal face of the gp45 sliding clamp. Here we extend these results by exploring the structural relationship between the gp43 polymerase and the gp45 sliding clamp, Using fluorescence intensity and polarization techniques, as well as photo-cross-linking methods, we present evidence that gp43, like gp44/62, binds to the C-terminal face of gp45, In addition, we show that g43 binds to the gp45 clamp in two distinct interaction modes, depending on the presence or absence of template-primer DNA. When template-primer DNA is present, gp43 binds tightly to gp45 to form the highly processive DNA polymerase holoenzgme, Gp43 also binds to gp45 in the absence of template-primer DNA, but this interaction is more than 100 times weaker than gp43-gp45 binding on DNA. Specific interactions between gp43 and the C-terminal face of gp45 are maintained in both modes of binding. These results underscore the pivotal role of template-primer DNA in modulating the strength of protein-protein interactions during DNA synthesis and provide additional insight into the structural requirements of the replication process.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R01GM029158, R37GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Fu TJ, 1996, EMBO J, V15, P4414, DOI 10.1002/j.1460-2075.1996.tb00814.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NEWPORT JW, 1980, MECHANISTIC STUDIES, P485; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; SANDERS GM, 1995, EMBO J, V14, P3966, DOI 10.1002/j.1460-2075.1995.tb00068.x; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; TinkerKulberg RL, 1996, EMBO J, V15, P5032, DOI 10.1002/j.1460-2075.1996.tb00883.x; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	30	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31685	31692		10.1074/jbc.272.50.31685	http://dx.doi.org/10.1074/jbc.272.50.31685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395510	hybrid			2022-12-27	WOS:A1997YL41900069
J	Umayahara, Y; Ji, CH; Centrella, M; Rotwein, P; McCarthy, TL				Umayahara, Y; Ji, CH; Centrella, M; Rotwein, P; McCarthy, TL			CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts - Identification of a novel cyclic AMP signaling pathway in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; MESSENGER-RIBONUCLEIC-ACID; CAMP RESPONSE ELEMENT; PARATHYROID-HORMONE; PROSTAGLANDIN E(2); ENRICHED CULTURES; MOLECULAR CHARACTERIZATION; TYROSINE PHOSPHORYLATION; HYPOPHYSECTOMIZED RATS; CELLS	Insulin-like growth factor-I (IGF-I) plays a key role in skeletal growth by stimulating bone cell replication and differentiation. We previously showed that prostaglandin E-2 (PGE(2)) and other cAMP-activating agents enhanced IGF-I gene transcription in cultured primary rat osteoblasts through promoter 1, the major IGF-I promoter, and identified a short segment of the promoter, termed HS3D, that was essential for hormonal regulation of IGF-I gene expression, We now demonstrate that CCAAT/enhancer-binding protein (C/EBP) delta is a major component of a PGE(2)-stimulated DNA-protein complex involving HS3D and find that C/EBP delta transactivates IGF-I promoter 1 through this site, Competition gel shift studies first indicated that a core C/EBP half-site (GCAAT) was required for binding of a labeled HS3D oligomer to osteoblast nuclear proteins. Southwestern blotting add UV-cross-linking studies showed that the HS3D probe recognized a similar to 35-kDa nuclear protein, and antibody supershift assays indicated that C/EBP delta comprised most of the PGE(2)-activated gel-shifted complex, C/EBP delta was detected by Western immunoblotting in osteoblast nuclear extracts after treatment of cells with PGE(2). An HS3D oligonucleotide competed effectively with a high affinity C/EBP site from the rat albumin gene for binding to osteoblast nuclear proteins, Cotransfection of osteoblast cell cultures with a C/EBP delta expression plasmid enhanced basal and PGE(2)-activated IGE-I promoter 1-luciferase activity but did not stimulate a reporter gene lacking an HS3D site, By contrast, an expression plasmid for the related protein, C/EBP beta, did not alter basal IGF-I gene activity but did increase the response to PGE,. In osteoblasts and in COS-7 cells, C/EBP delta, but not C/EBP beta, transactivated a reporter gene containing four tandem copies of HS3D fused to a minimal promoter; neither transcription factor stimulated a gene with four copies of an HS3D mutant that was unable to bind osteoblast nuclear proteins. These results identify C/EBP delta as a hormonally activated inducer of IGF-I gene transcription in osteoblasts and show that the HS3D element within IGF-I promoter 1 is a high affinity binding site for this protein.	OREGON HLTH SCI UNIV,DEPT MED,DIV MOL MED,PORTLAND,OR 97201; YALE UNIV,SCH MED,SECT PLAST SURG,NEW HAVEN,CT 06520	Oregon Health & Science University; Yale University			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NICHD NIH HHS [5-PO1-HD20805] Funding Source: Medline; NIDDK NIH HHS [5-RO1-DK37449, 5-RO1-DK47421] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK037449] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CHODOSH LA, 1997, CURRENT PROTOCOLS MO; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOURNIER T, 1995, J IMMUNOL, V155, P2123; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; JEE WSS, 1990, BONE MINER, V15, P175; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KACHRA Z, 1991, ENDOCRINOLOGY, V128, P1723, DOI 10.1210/endo-128-4-1723; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LIN T, 1994, ENDOCRINOLOGY, V134, P2142, DOI 10.1210/en.134.5.2142; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1993, ADV EXPT MED BIOL, P407; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; Osada S, 1996, J BIOL CHEM, V271, P3891; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; POLL V, 1990, CELL, V63, P643; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUSSELL SM, 1985, ENDOCRINOLOGY, V116, P2563, DOI 10.1210/endo-116-6-2563; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOTTNER A, 1987, J ENDOCRINOL, V112, P123, DOI 10.1677/joe.0.1120123; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	48	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31793	31800		10.1074/jbc.272.50.31793	http://dx.doi.org/10.1074/jbc.272.50.31793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395525	hybrid			2022-12-27	WOS:A1997YL41900084
J	Fournier, T; Fadok, V; Henson, PM				Fournier, T; Fadok, V; Henson, PM			Tumor necrosis factor-alpha inversely regulates prostaglandin D-2 and prostaglandin E-2 production in murine macrophages - Synergistic action of cyclic amp on cyclooxygenase-2 expression and prostaglandin E-2 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; RENAL MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; ENDOPEROXIDE SYNTHASE-1; GENE-EXPRESSION; PHOSPHOLIPASE A(2); BLOOD MONOCYTES; MESSENGER-RNA; PHORBOL ESTER; MAST-CELLS	Increased synthesis of insulin-like growth factor-1 is induced in murine macrophages by prostaglandin E-2 (PGE(2),) and tumor necrosis factor-alpha (TNF alpha). Accordingly, we have investigated mechanisms regulating synthesis of PGE(2), that might contribute to autocrine/paracrine effects on insulin-like growth factor-1 production. In response to zymosan, TNF alpha specifically induced a 5-fold increase in PGE(2), synthesis, at the same time decreasing PGD(2), production in a reciprocal fashion. Activators of cyclic AMP-dependent protein kinase (PKA), such as PGE(2), itself or dibutyryl cyclic AMP, did not modify PGE(2), production by themselves but potentiated the TNF alpha-induced increase in PGE(2),; this effect required both RNA and protein synthesis, No significant change in arachidonate release or production of other eicosanoids was observed. The inducible form of cyclooxygenase-a (COX2) but not of the constitutive form COX1 was implicated in the generation of both PGE(2), and PGD(2), in these cells by use of specific inhibitors and effects of dexamethasone. Neither COX1 nor COX2 protein levels were affected by TNF alpha or PKA activators used alone, whereas in association, marked up-regulation of COX2 mRNA and protein was observed. Incubations of cells carried out with PGH(2), demonstrated that PGE(2), synthase activity was increased after a TNF alpha pretreatment. Taken together, our results suggest that TNF alpha induced a switch from the PGD(2), to PGE(2), synthesis pathway by regulating PGE(2), synthase expression and/or activity and that activators of PKA markedly potentiated the TNF alpha-induced increase in PGE(2), through up-regulation of COX2 gene expression.	Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Fournier, T (corresponding author), Fac Xavier Bichat, INSERM, U408, BP 416, F-75870 Paris 18, France.		Fournier, Thierry C/E-5836-2016	Fournier, Thierry/0000-0002-7515-339X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353, P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27353, HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGARWAL BB, 1993, LYMPHOKINE CYTOK RES, V12, P149; ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; ANTOINE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139, DOI 10.1016/0005-2760(92)90299-B; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BETZ M, 1991, J IMMUNOL, V146, P108; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BONNEY RJ, 1980, BIOCHIM BIOPHYS ACTA, V633, P410, DOI 10.1016/0304-4165(80)90199-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; CHU E, 1993, J CLIN IMMUNOL, V13, P49, DOI 10.1007/BF00920635; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; DIAZ A, 1993, J BIOL CHEM, V268, P10364; ELIAS JA, 1985, AM REV RESPIR DIS, V131, P94; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURNIER T, 1995, J IMMUNOL, V155, P2123; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GREWE M, 1992, BIOL CHEM H-S, V373, P655, DOI 10.1515/bchm3.1992.373.2.655; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HEMPEL SL, 1994, AM J PHYSIOL, V266, pC1392, DOI 10.1152/ajpcell.1994.266.5.C1392; HENSON PM, 1994, ANN NY ACAD SCI, V725, P298, DOI 10.1111/j.1749-6632.1994.tb39813.x; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; KELLY RW, 1986, PROSTAG LEUKOTR ESS, V24, P1, DOI 10.1016/0262-1746(86)90201-5; KELNER MJ, 1994, BIOCHEM BIOPH RES CO, V198, P298, DOI 10.1006/bbrc.1994.1042; KONIECZKOWSKI M, 1993, J CLIN INVEST, V92, P2425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LASZLO DJ, 1993, AM J PATHOL, V143, P587; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MUHL H, 1992, FEBS LETT, V301, P190, DOI 10.1016/0014-5793(92)81245-H; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; PACE JL, 1985, J IMMUNOL, V134, P977; PFEILSCHIFTER J, 1989, BIOCHEM BIOPH RES CO, V159, P385, DOI 10.1016/0006-291X(89)90003-X; PFEILSCHIFTER J, 1991, BIOCHEM J, V273, P199, DOI 10.1042/bj2730199; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RICHES DWH, 1988, J IMMUNOL, V141, P180; ROPER RL, 1990, J IMMUNOL, V145, P2644; RUSSELL SW, 1984, J LEUKOCYTE BIOL, V35, P291; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SPATZ M, 1993, PROSTAG LEUKOTR ESS, V49, P789, DOI 10.1016/0952-3278(93)90027-T; TAFFET SM, 1981, J IMMUNOL, V126, P424; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640	58	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31065	31072		10.1074/jbc.272.49.31065	http://dx.doi.org/10.1074/jbc.272.49.31065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388257	hybrid			2022-12-27	WOS:000071640800070
J	Spiecker, M; Peng, HB; Liao, JK				Spiecker, M; Peng, HB; Liao, JK			Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-SELECTIN; ACTIVATION; GENE; PHOSPHORYLATION; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; TRANSCRIPTION; MECHANISM; PROTEIN; PATHWAY	The induction of vascular cell adhesion molecule-1 (VCAM-1) expression by tumor necrosis factor (TNF)-alpha requires the activation of nuclear factor-kappa B (NF-kappa B) via a process involving the phosphorylation and degradation of its cytoplasmic inhibitor, I kappa B alpha. We have shown that nitric oxide (NO) decreases VCAM-1 expression via inhibition of NF-kappa B activation. To determine how NO inhibits NF-kappa B, we studied the fate of I kappa B alpha following TNF-alpha stimulation in the presence of NO donors S-nitrosoglutathione and sodium nitroprusside, Activation of NF-kappa B by TNF-alpha occurred within 15 min and coincided with rapid degradation of I kappa B alpha, Go-treatment with NO donors did not prevent I kappa B alpha phosphorylation or degradation, However, after 2 h of TNF-alpha stimulation, NO donors inhibited NF-kappa B activation and augmented I kappa B alpha resynthesis and nuclear translocation by 2.5- and 3-fold, respectively, This correlated with a 75% reduction in TNF-alpha-induced VCAM-1 expression. In a time-dependent manner, NO donors alone caused the nuclear translocation of I kappa B alpha. TO confirm that NO donors have similar effects as endogenously derived NO, murine macrophage-like cells, RAW264.,7, were co-cultured with endothelial cells, Induction of RAW264.,7-derived NO inhibited lipopolysaccharide-induced endothelial VCAM-1 expression, which was reversed by the NO synthase inhibitor N-omega-monomethyl-L-arginine. These findings indicate that NO inhibits NF-kappa B activation and VCAM-1 expression by increasing the expression and nuclear translocation of I kappa B alpha.	Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, JK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 221 Longwood Ave,LMRC-316, Boston, MA 02115 USA.	jkliao@bics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009650, R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, HL-09650] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLINS T, 1995, FASEB J, V9, P1; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MACKAY CR, 1993, IMMUNOL TODAY, V14, P99, DOI 10.1016/0167-5699(93)90205-Y; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Pierce JW, 1996, J IMMUNOL, V156, P3961; RASBAND W, 1993, NIH IMAGE VERSION 1; Read MA, 1996, J IMMUNOL, V157, P3472; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V10, P4159	31	208	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30969	30974		10.1074/jbc.272.49.30969	http://dx.doi.org/10.1074/jbc.272.49.30969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388244	hybrid			2022-12-27	WOS:000071640800057
J	Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Krett, N; Halgren, R; Rosen, S; Kufe, D; Kharbanda, S; Anderson, K				Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Krett, N; Halgren, R; Rosen, S; Kufe, D; Kharbanda, S; Anderson, K			Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DEATH; CED-3; ICE; ACTIVATION; INHIBITION; PROTEASES; CLEAVAGE; KINASE; P35	Cytochrome c is a mitochondrial protein that induces apoptosis when accumulated in the cytosol in response to diverse stress inducers. This protein has also been shown to cause apoptosis when added to cell free extracts. In this report, we studied the role of cytochrome c (cyto-c) in dexamethasone (Dex), anti-Fas monoclonal antibody (mAb), and ionizing radiation-induced apoptosis in multiple myeloma cells, The results demonstrate that ionizing radiation-induced apoptosis is associated with an increase in cytosolic cyto-c levels, whereas apoptosis induced by Dex or anti Fas mAb has no detectable effect on cyto-e release. By contrast, caspase-3 was activated in response to all of these agents. Thus, our findings suggest that Dex or anti-Fas mAb-induced apoptosis is not accompanied by cyto-c release and that there are at least two different pathways leading to activation of caspases and induction of apoptosis in multiple myeloma cells that can be distinguished by accumulation of cytosolic cyto-c.	NORTHWESTERN UNIV,SCH MED,ROBERT H LURIE CANC CTR,CHICAGO,IL 60611	Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Chauhan, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT ADULT ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.			Ogata, Atsushi/0000-0003-3944-3442	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GOLDMANLEIKIN RE, 1989, J LAB CLIN INVEST, V113, P345; HARDIN J, 1994, BLOOD, V84, P3063; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MOALLI PA, 1992, BLOOD, V79, P213; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; WILLIE AH, 1980, INT REV CYTOL, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	24	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29995	29997		10.1074/jbc.272.48.29995	http://dx.doi.org/10.1074/jbc.272.48.29995			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374472	hybrid			2022-12-27	WOS:A1997YH61300004
J	Gavrilova, O; Barr, V; MarcusSamuels, B; Reitman, M				Gavrilova, O; Barr, V; MarcusSamuels, B; Reitman, M			Hyperleptinemia of pregnancy associated with the appearance of a circulating form of the leptin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; BINDING-PROTEIN; WEIGHT; SERUM; MICE; EXPRESSION; RODENT; HUMANS; RNA	Leptin is a hormone produced in adipose cells that regulates energy expenditure, food intake, and adiposity, In mice, we observed that circulating leptin levels increase 20-40-fold during pregnancy, Pregnant ob/ob females had no detectable serum leptin, demonstrating that the heterozygous conceptus was not the source of the leptin. However, leptin RNA and protein levels in maternal adipose tissue were not elevated, The circulating leptin was in a high molecular weight complex, suggesting that the rise in leptin was due to expression of a binding protein, Indeed, quantitative assays of serum leptin binding capacity revealed a 40-fold increase, coincident with the rise in serum leptin, Leptin binding activity reached a capacity of 207 +/- 15 nmol/liter of serum at day 18 of gestation, and half-maximal binding was observed with similar to 3 nM leptin, The binding protein was purified and partially sequenced, revealing sequence identity to the extracellular domain of the leptin receptor, We found that the placenta produces large amounts of the OB-Re isoform of leptin receptor mRNA, which encodes a soluble binding protein, Thus, the extreme hyperleptinemia of late pregnancy is attributable to binding of the leptin by a secreted form of the leptin receptor made by the placenta.	NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BARR VA, 1997, ENDOCRINOLOGY, V38, P4463; BAUMANN G, 1995, EXP CLIN ENDOCR DIAB, V103, P2, DOI 10.1055/s-0029-1211322; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BEHAN DP, 1995, FRONT NEUROENDOCRIN, V16, P362, DOI 10.1006/frne.1995.1013; BI S, 1997, IN PRESS J BIOL CHEM, V272; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS FM, 1987, MOL BIOL EVOL, V4, P242; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cumin F, 1996, INT J OBESITY, V20, P1120; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HEANEY ML, 1993, BLOOD, V82, P1945, DOI 10.1182/blood.V82.7.1945.bloodjournal8271945; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; HYTTEN FE, 1991, CLIN PHYSL OBSTET, P196; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON JJ, 1986, P NUTR SOC, V45, P71, DOI 10.1079/PNS19860037; Schubring C, 1996, EUR J PEDIATR, V155, P830, DOI 10.1007/BF02002918; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; SMITHBERG M., 1957, JOUR HEREDITY, V48, P97; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TALAMANTES F, 1994, P SOC EXP BIOL MED, V206, P254; TARGAGLIA LA, 1995, CELL, V83, P1263; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	198	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30546	30551		10.1074/jbc.272.48.30546	http://dx.doi.org/10.1074/jbc.272.48.30546			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374549	hybrid			2022-12-27	WOS:A1997YH61300081
J	Bakker, H; Friedmann, I; Oka, S; Kawasaki, T; Nifantev, N; Schachner, M; Mantei, N				Bakker, H; Friedmann, I; Oka, S; Kawasaki, T; Nifantev, N; Schachner, M; Mantei, N			Expression cloning of a cDNA encoding a sulfotransferase involved in the biosynthesis of the HNK-1 carbohydrate epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONYL GLYCOLIPIDS; CELL-ADHESION MOLECULES; NERVOUS-SYSTEM; DEVELOPMENTAL EXPRESSION; L2/HNK-1 CARBOHYDRATE; SULFOGLUCURONYL GLYCOLIPIDS; HNK-1-REACTIVE ANTIGENS; GENE FAMILY	The HNK-1 carbohydrate epitope is expressed on several neural adhesion glycoproteins and as a glycolipid, and is involved in cell. interactions, The structural element of the epitope common to glycoproteins and glycolipids has been determined to be sulfate-3-GlcA beta 1-->3Gal beta 1-->4GlcNAc. The glucuronyltransferase and sulfotransferase are considered to be the key enzymes in the biosynthesis of this epitope because the rest of the structure occurs often in glycoconjugates. Here we describe the isolation of the rat sulfotransferase cDNA via an expression cloning strategy, The clone finally isolated predicts a protein of 356 amino acids, uith characteristics of a type II transmembrane protein and with no sequence similarity to other known sulfotransferases, Both the enzyme expressed as a soluble fusion protein and homogenates of cells transfected with the full-length cDNA could transfer sulfate from a sulfate donor to acceptor substrates containing terminal glucuronic acid.	ETH HONGGERBERG,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 60601,JAPAN; RUSSIAN ACAD SCI,ND ZELINSKII ORGAN CHEM INST,MOSCOW 117913,RUSSIA; UNIV HAMBURG,ZENTRUM MOL NEUROBIOL,D-20246 HAMBURG,GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; Kyoto University; Russian Academy of Sciences; Zelinsky Institute of Organic Chemistry; University of Hamburg; University Medical Center Hamburg-Eppendorf			Bakker, Hans/AAA-1623-2020; Nifantiev, Nikolay E/O-6579-2015; Bakker, Hans/A-1787-2017	Bakker, Hans/0000-0002-1364-9154; Nifantiev, Nikolay E/0000-0002-0727-4050; Bakker, Hans/0000-0002-1364-9154				ABO T, 1981, J IMMUNOL, V127, P1024; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CUMMINGS L, 1993, BIOCHEM BIOPH RES CO, V195, P814, DOI 10.1006/bbrc.1993.2118; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HOLLEY JA, 1987, DEV NEUROSCI-BASEL, V9, P105, DOI 10.1159/000111613; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; ILYAS AA, 1984, BIOCHEM BIOPH RES CO, V122, P1206, DOI 10.1016/0006-291X(84)91220-8; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LOW K, 1994, EUR J NEUROSCI, V6, P1773, DOI 10.1111/j.1460-9568.1994.tb00570.x; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MARTINI R, 1994, J NEUROSCI, V14, P7180; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OKA S, 1992, J BIOL CHEM, V267, P22711; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WERNECKE H, 1985, J NEUROIMMUNOL, V9, P115, DOI 10.1016/S0165-5728(85)80012-6; Yuen CT, 1997, J BIOL CHEM, V272, P8924	39	98	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29942	29946		10.1074/jbc.272.47.29942	http://dx.doi.org/10.1074/jbc.272.47.29942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368071	hybrid			2022-12-27	WOS:A1997YG64700081
J	Heydemann, A; Boehmler, JH; Simon, MC				Heydemann, A; Boehmler, JH; Simon, MC			Expression of two myeloid cell-specific genes requires the novel transcription factor, c-fes expression factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR PROMOTER; PROTEIN-TYROSINE KINASE; SCAVENGER RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; CHICKEN LYSOZYME GENE; HL-60 LEUKEMIA-CELLS; TRANSGENIC MICE; FACTOR PU.1; T-CELLS; GRANULOCYTIC DIFFERENTIATION	The protein product of the c-fes proto-oncogene has been implicated in the normal development of myeloid cells (macrophages and granulocytes). We have previously shown that 151 base pairs of c-fes 5'-flanking sequences are sufficient for myeloid cell-specific expression and include functional binding sites for Spl, PU.1, and a novel nuclear factor (Heydemann, A., Juang, G., Hennessy, K., Parmacek, M. S., and Simon, M. C. (1996) Mol, Cell Biol, 16, 1676-1686), This novel hematopoietic transcription factor, termed FEF (c-fes expression factor), binds to a cis-acting element that is located at nucleotides -9 to -4 of the c-fes promoter between two Ets binding sites (at -19 to -15 and -4 to +1) which bind PU.1. We now show that a FEF binding site exists in the myeloid cell-specific regulatory region of a second gene, the -2.7-kilobase pair enhancer of chicken lysozyme. The lysozyme FEF site is immediately 5' to a PU.1 site, analogous to their arrangement in the c-fes promoter, and allows the formation of a preliminary FEF consensus site, 5'-GAAT(C/G)A-3'. This consensus site does not match any sites for known transcription factors. Importantly, although PU.1 binds immediately 3' of the FEF site in both the c-fes promoter and the chicken lysozyme enhancer (CLE), we show that they bind independently, The FEF sites are required for high levels of transcription by both the CLE and the c-fes promoter in transient transfection experiments, Importantly, elimination of the CLE FEF site abolishes all transcriptional activity of this enhancer element, Mutation of the adjacent PU.1 site in either the c-fes promoter or the CLE, reduces activity by approximately 50%. Therefore, transcription of both lysozyme and fee in myeloid cells requires FEF and PU.1. UV cross-linking experiments show that the FEF binding activity consists of a single 70-kDa protein in both human and murine cell lines, FEF binding activity is not affected by antibodies that specifically recognize a number of cloned transcription factors, Collectively, these data indicate that we have identified a novel transcription factor that is functionally important for the expression of at least two myeloid cell-specific genes.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago			Simon, Celeste/AAG-3941-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ALCALAY M, 1990, ONCOGENE, V5, P267; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; CARE A, 1994, ONCOGENE, V9, P739; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EICHBAUM Q, 1994, GENOMICS, V22, P656, DOI 10.1006/geno.1994.1445; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREZ M, 1981, CELL, V25, P743, DOI 10.1016/0092-8674(81)90182-3; He YF, 1996, BBA-GENE STRUCT EXPR, V1306, P179, DOI 10.1016/0167-4781(96)00005-X; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; KONIMATO Y, 1995, MOL CELL BIOL, V15, P59; LANFRANCONE L, 1989, INT J CANCER, P35; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAYGALLET D, 1995, ONCOGENE, V11, P303; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sippel A E, 1987, Results Probl Cell Differ, V14, P255; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YATES KE, 1995, ONCOGENE, V10, P1239; YU G, 1988, MOL PHARMACOL, V33, P384; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	52	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29527	29537		10.1074/jbc.272.47.29527	http://dx.doi.org/10.1074/jbc.272.47.29527			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368014	hybrid			2022-12-27	WOS:A1997YG64700024
J	Hsu, MH; Chiang, SC; Ye, RD; Prossnitz, ER				Hsu, MH; Chiang, SC; Ye, RD; Prossnitz, ER			Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PERTUSSIS TOXIN; CHEMOATTRACTANT RECEPTORS; NEUTRAL ENDOPEPTIDASE; HUMAN-NEUTROPHILS; EXPRESSION; INHIBITION; MEMBRANE; CALCIUM; PROTEIN	The human N-formyl peptide receptor (FPR) is a member of the family of leukocyte, G protein-coupled, chemoattractant receptors, To determine the role(s) of receptor phosphorylation in FPR processing and formylmethionylleucylphenylalanine (fMLF) mediated chemotaxis, we utilized U937 cells expressing the recombinant wild type receptor and a mutant form of the FPR, This mutant, which lacks all of the serine and threonine residues in the C terminus of the receptor, Delta ST, has recently been shown to produce a receptor capable of fMLF binding and G protein activation but was demonstrated not to undergo fMLF-dependent phosphorylation or desensitization of the calcium mobilization response upon repeated exposure to agonist (Prossnitz, E. R. (1997) J. Biol. Chem. 272, 15213-15219). In this report, we examined the role of receptor phosphorylation in FPR internalization and leukocyte chemotaxis. Whereas the wild type receptor was rapidly internalized upon stimulation, the phosphorylation-deficient mutant was not, remaining entirely on the cell surface, In addition, contrary to the hypothesis that receptor processing and recycling are required for chemotaxis, we found no defect in the ability of the mutant FPR to migrate up a concentration gradient of fMLF. These results indicate that phosphorylation of the FPR is a necessary step in receptor internalization but that receptor phosphorylation, desensitization, and internalization are not required for chemotaxis,	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI33503, AI36357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R01AI033503, R56AI033503, R29AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BECKER EL, 1972, J IMMUNOL, V108, P396; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; HUU TP, 1979, BIOMEDICINE, V30, P121; KEW RR, 1997, L LEUKOCYTE BIOL, V61, P329; LAD PM, 1986, FEBS LETT, V200, P91, DOI 10.1016/0014-5793(86)80517-8; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; PAINTER RG, 1995, J LEUKOCYTE BIOL, V58, P468, DOI 10.1002/jlb.58.4.468; PEREZ HD, 1982, J IMMUNOL, V129, P2718; PEREZ HD, 1986, J IMMUNOL, V136, P1803; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; SCHIFFMANN E, 1975, J IMMUNOL, V114, P1831; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WILDE MW, 1989, J BIOL CHEM, V264, P190; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9; ZIGMOND SH, 1989, AM J RESP CELL MOL, V1, P451, DOI 10.1165/ajrcmb/1.6.451; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	28	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29426	29429		10.1074/jbc.272.47.29426	http://dx.doi.org/10.1074/jbc.272.47.29426			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367998	hybrid			2022-12-27	WOS:A1997YG64700008
J	MacLean, DW; Meedel, TH; Hastings, KEM				MacLean, DW; Meedel, TH; Hastings, KEM			Tissue-specific alternative splicing of ascidian troponin I isoforms - Redesign of a protein isoform-generating mechanism during chordate evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC TROPONIN; TRANSGENIC MICE; DEVELOPMENTAL EXPRESSION; STRIATED MUSCLES; MESSENGER-RNA; NEURAL CREST; CDNA CLONE; RAT-HEART; GENE; SLOW	In vertebrates, troponin I (TnI) exists as shorter and longer isoforms encoded by distinct genes expressed in skeletal and cardiac muscle, respectively. We report that the protochordate ascidian Ciona intestinalis expresses a homologous set of shorter and longer TnI isoforms in body wall muscle and heart, respectively. The heart-specific segment of the ascidian longer TnI isoform shares several sequence features with vertebrate cardiac TnI but lacks the protein kinase A phosphorylation sites implicated in sympatho-adrenal control of cardiac function, In contrast with vertebrates, the ascidian longer and shorter TnI isoforms are produced from a single gene by tissue-specific alternative RNA splicing; remarkably, the molecular mechanism of TnI isoform generation has been entirely reworked during ascidian/vertebrate evolution. Because alternative splicing is the more probable chordate ancestral condition, the long/cardiac versus short/somatic muscle pattern of TnI: isoforms likely existed before the occurrence of the gene duplication events that created the vertebrate TnI gene family. Thus, gene duplication was apparently not the primary engine of isoform diversity in this aspect of TnI gene family evolution; rather, it simply provided an alternative (transcriptional) means of maintaining a previously established system of isoform diversity and tissue specificity based on alternative RNA splicing.	McGill Univ, Dept Biol, Montreal, PQ H3A 2B4, Canada; Rhode Isl Coll, Dept Biol, Providence, RI 02908 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Hastings, KEM (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.							ARAKI I, 1994, ROUX ARCH DEV BIOL, V203, P320, DOI 10.1007/BF00457803; AUSONI S, 1994, J BIOL CHEM, V269, P339; AUSONI S, 1991, DEVELOPMENT, V112, P1041; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BANERJEEBASU S, 1994, GENE, V145, P241, DOI 10.1016/0378-1119(94)90013-2; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; Berrill N.J., 1955, ORIGIN VERTEBRATES; CORIN SJ, 1994, J BIOL CHEM, V269, P10651; DRYSDALE TA, 1994, DEV BIOL, V165, P432, DOI 10.1006/dbio.1994.1265; ENDO T, 1981, J BIOCHEM, V89, P1599, DOI 10.1093/oxfordjournals.jbchem.a133355; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GOODBODY I, 1974, ADV MAR BIOL, V12, P1; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; Guenet JL, 1996, MAMM GENOME, V7, P13, DOI 10.1007/s003359900004; HALLAUER PL, 1993, DEVELOPMENT, V119, P691; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HOLLAND PWH, 1994, DEVELOPMENT, P125; JIANG HB, 1994, J BIOL CHEM, V269, P55; KATZ MJ, 1983, BIOL BULL-US, V164, P1, DOI 10.2307/1541186; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEVITT LK, 1995, DNA CELL BIOL, V14, P599, DOI 10.1089/dna.1995.14.599; LITMAN GW, 1993, MOL BIOL EVOL, V10, P60; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; Meedel TH, 1997, DEVELOPMENT, V124, P1711; MEEDEL TH, REPROD BIOL INVERTEB, V8; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; Ohno S., 1970, EVOLUTION GENE DUPLI; OHNO S, 1974, PROTOCHORDATA CYCLOS; OHTA T, 1989, GENOME, V31, P304, DOI 10.1139/g89-048; PERRY SV, 1994, MYOLOGY BASIC CLIN, V1, P529; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SABRY MA, 1989, J MUSCLE RES CELL M, V10, P85, DOI 10.1007/BF01739858; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	40	35	36	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32115	32120		10.1074/jbc.272.51.32115	http://dx.doi.org/10.1074/jbc.272.51.32115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405409	hybrid			2022-12-27	WOS:000071108000028
J	Roullet, JB; Luft, UC; Xue, H; Chapman, J; Bychkov, R; Roullet, CM; Luft, FC; Haller, H; McCarron, DA				Roullet, JB; Luft, UC; Xue, H; Chapman, J; Bychkov, R; Roullet, CM; Luft, FC; Haller, H; McCarron, DA			Farnesol inhibits L-type Ca2+ channels in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CALCIUM CHANNELS; MEVALONATE AVAILABILITY; DIHYDROPYRIDINE AGONIST; SIGNAL-TRANSDUCTION; RESISTANCE ARTERIES; CA-2+; RAT; REDUCTASE; IDENTIFICATION	Earlier experiments with animal and human arteries have shown that farnesol, a natural 15-carbon (C-15) isoprenoid, is an inhibitor of vasoconstriction (Roullet, J.-B., Xue, H., Chapman, J., McDougal, P., Roullet, C. M., and McCarron, D. A. (1996) J. Clin. Invest. 97, 2384-2390). We report here that farnesol reduced KCl- and norepinephrine-dependent cytosolic Ca2+ transients in fura-2-loaded intact arteries. An effect on Ca2+ signaling was also observed in cultured aortic smooth muscle cells (A10 cells). In these cells, farnesol reduced KCl-induced [Ca2+](i) transients and mimicked the inhibitory effect of Ca2+-free medium on the [Ca2+](i) response to both 12,13-phorbol myristate acetate, a protein kinase C activator, and thapsigargin, a specific endoplasmic reticulum ATPase inhibitor. Perforated patch-clamp experiments further showed in two vascular smooth muscle cell lines (A10 and A7r5), a reversible, dose-dependent inhibitory effect of farnesol on L-type Ca2+ currents (IC50 = 2.2 mu M). Shorter (C-10, geraniol) and longer (C-20, geranylgeraniol) isoprenols were inactive. L-type Ca2+ channel blockade also occurred under tight (gigaohm) seal configuration using cell-attached, single-channel analysis, thus suggesting a possible action of farnesol from within the intracellular space. We finally demonstrated that farnesol did not affect Ca2+-sensitive pathways implicated in smooth muscle contraction, as tested with alpha-toxin permeabilized arteries. Altogether, our results indicate that farnesol is an inhibitor of vascular smooth muscle Ca2+ signaling with plasma membrane Ca2+ channel blocker properties. The data have implications for the endogenous and pharmacological regulation of vascular tone by farnesol or farnesol analogues.	Oregon Hlth & Sci Univ, Dept Nephrol Hypertens & Clin Pharmacol, Portland, OR 97201 USA; Max Delbruck Ctr Mol Med, Franz Volhard Klin, D-13122 Berlin, Germany	Oregon Health & Science University; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Roullet, JB (corresponding author), Oregon Hlth & Sci Univ, Dept Nephrol Hypertens & Clin Pharmacol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	roulletj@ohsu.edu		Luft, Friedrich/0000-0002-8635-1199				ADANY I, 1994, CANCER LETT, V79, P175, DOI 10.1016/0304-3835(94)90257-7; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BIAN K, 1995, HYPERTENSION, V25, P110, DOI 10.1161/01.HYP.25.1.110; Bostedor RG, 1997, J BIOL CHEM, V272, P9197; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BUKOSKI RD, 1990, J HYPERTENS, V8, P37, DOI 10.1097/00004872-199001000-00007; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gollasch M, 1996, AM J PHYSIOL-CELL PH, V271, pC842, DOI 10.1152/ajpcell.1996.271.3.C842; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; GONZALESPACANOW.D, 1988, J BIOL CHEM, V263, P1304; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JENSEN PE, 1994, EXP BIOL M, P23; JIANG MJ, 1987, AM J PHYSIOL, V253, pH1365, DOI 10.1152/ajpheart.1987.253.6.H1365; Keller RK, 1996, ARCH BIOCHEM BIOPHYS, V328, P324, DOI 10.1006/abbi.1996.0180; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOTHAPALLI R, 1994, BIOCHEM PHARMACOL, V47, P1909, DOI 10.1016/0006-2952(94)90322-0; MARKS TN, 1990, PFLUG ARCH EUR J PHY, V417, P433, DOI 10.1007/BF00370664; MCCREERY MJ, 1978, NEUROPHARMACOLOGY, V17, P451, DOI 10.1016/0028-3908(78)90050-3; MCEWEN BF, 1985, J CELL BIOL, V100, P1922, DOI 10.1083/jcb.100.6.1922; Meigs TE, 1996, J BIOL CHEM, V271, P7916, DOI 10.1074/jbc.271.14.7916; MIRONNEAU J, 1995, CELL SIGNAL, V7, P471, DOI 10.1016/0898-6568(95)00014-G; MIRONNEAU J, 1995, PFLUEGERS ARCH, V430, P590; NG LL, 1994, CIRC RES, V74, P173, DOI 10.1161/01.RES.74.2.173; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; NISHIMURA J, 1990, AM J PHYSIOL, V259, pH2, DOI 10.1152/ajpheart.1990.259.1.H2; OBrien ML, 1996, CARCINOGENESIS, V17, P185, DOI 10.1093/carcin/17.2.185; Ohanian V, 1996, CIRC RES, V78, P806, DOI 10.1161/01.RES.78.5.806; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; ROULLET JB, 1993, P NATL ACAD SCI USA, V90, P11728, DOI 10.1073/pnas.90.24.11728; ROULLET JB, 1995, J CLIN INVEST, V96, P239, DOI 10.1172/JCI118027; Roullet JB, 1996, J CLIN INVEST, V97, P2384, DOI 10.1172/JCI118682; ROULLET JB, 1996, AM J HYPERTENS, V9, P81; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VOZIYAN PA, 1995, BIOCHEM BIOPH RES CO, V212, P479, DOI 10.1006/bbrc.1995.1995; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; XIONG ZL, 1994, PFLUG ARCH EUR J PHY, V428, P105, DOI 10.1007/BF00374847; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1988, J BIOL CHEM, V263, P9887; YAZLOVITSKAYA EM, 1995, CANCER LETT, V88, P179, DOI 10.1016/0304-3835(94)03635-V	55	59	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32240	32246		10.1074/jbc.272.51.32240	http://dx.doi.org/10.1074/jbc.272.51.32240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405427	hybrid			2022-12-27	WOS:000071108000046
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			Activation of stress-activated protein kinase c-Jun N-terminal kinase, but not NF-kappa B, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN; PHOSPHORYLATION; IDENTIFICATION; APOPTOSIS; CASCADE; DEATH; LIGHT; ERK	A key step by which tumor necrosis factor (TNF) signals the activation of nuclear factor-kappa B (NF-kappa B) and the stress-activated protein kinase (SAPK, also called c-Jun N-terminal kinase or JNK) is the recruitment to the TNF receptor of TNF receptor-associated factor 2 (TRAF2). However, the subsequent steps in TRAF2-induced SAPK and NF-kappa B activation remain unresolved. Here we report the identification of a TNF-responsive serine/threonine protein kinase termed GCK related (GCKR) that likely signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase kinase 1 (MEKK1) to activate the SAPK pathway. TNF, TRAF2, and ultraviolet (UV) light, which in part uses the TNF receptor signaling pathway, all increased GCKR activity. A TRAF2 mutant, which inhibits both TRAF2-induced NF-kappa B and SAPK activation, blocked TNF-induced GCKR activation. Finally, interference with GCKR expression impeded TRAF2- and TNF-induced SAPK activation but not that of NF-kappa B. This suggests a divergence in the TNF signaling pathway that leads to SAPK and NF-kappa B activation, which is located downstream of TRAF2 but upstream of GCKR.	NIAID, Immunoregulat Lab, B Cell Mol Immunol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, B Cell Mol Immunol Sect, Bldg 10,Rm 11B-13,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.		Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; EZOE K, 1994, ONCOGENE, V9, P935; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; YAN MH, 1994, NATURE, V372, P798	34	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32102	32107		10.1074/jbc.272.51.32102	http://dx.doi.org/10.1074/jbc.272.51.32102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405407	hybrid			2022-12-27	WOS:000071108000026
J	Pearce, DA; Sherman, F				Pearce, DA; Sherman, F			Differential ubiquitin-dependent degradation of the yeast apo-cytochrome c isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PROTEIN-DEGRADATION; AMINO-ACID REPLACEMENTS; SACCHAROMYCES-CEREVISIAE; IN-VIVO; SYNTHETIC OLIGONUCLEOTIDES; HEME LYASE; ISO-1-CYTOCHROME-C; ENDOCYTOSIS; GENE; PROTEOLYSIS	The yeast Saccharomyces cerevisiae contains two forms of cytochrome c, iso-1- and iso-2-cytochrome c, which are encoded by the nuclear genes CYC1 and CYC7, respectively, The cytochromes c are synthesized in the cytosol, imported into mitochondria, and subsequently modified by the covalent attachment of heme through the action of cytochrome c heme lyase, which is encoded by CYC3. Apo-iso-2-cytochrome c but not apo-iso-1-cytochrome c was observed in cyc3(-) mutants. Furthermore, pulse-chase experiments previously demonstrated that the lack of apo-iso-1-cytochrome c was due to its rapid degradation. We report herein that this degradation of apo-iso-1-cytochrome c is dependent on ubiquitination and on the action of the proteasome. Diminished degradation of apo-iso-1-cytochrome c was observed in pre2-2 and pre1-1 mutants having altered proteasome subunits; in ubc1, ubc4, and ubc5 strains lacking one or more of the ubiquitin-conjugating enzymes; and in strains blocked in multi-ubiquitination by overproduction of the abnormal ubiquitin-K48R ubiquitin. In addition, we have used epitope-tagged ubiquitin to demonstrate that apo-iso-1-cytochrome c but not apo-iso-2-cytochrome c is ubiquitinated. Furthermore, the degradation of apo-iso-1-cytochrome c was diminished when the N-terminaI region was replaced with the N-terminal region of apo-iso-2-cytochrome c, indicating that this region may be the target for degradation. We suggest that ubiquitin-dependent degradation of apo-iso-1-cytochrome c is part of the regulatory process controlling the preferential expression of the iso-cytochromes c.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BERROTERAN RW, 1991, ARCH BIOCHEM BIOPHYS, V288, P261, DOI 10.1016/0003-9861(91)90193-M; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HICKEY DR, 1991, J BIOL CHEM, V266, P11686; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4021; HOCHSTRASSER M, 1990, CELL, V61, P507; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P278; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MATNER RR, 1983, J BIOL CHEM, V257, P9811; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; PEARCE DA, 1995, MOL GEN GENET, V249, P155, DOI 10.1007/BF00290361; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; REID GA, 1983, METHOD ENZYMOL, V97, P324; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER PW, 1987, ENVIRON ENTOMOL, V16, P368, DOI 10.1093/ee/16.2.368; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1971, ANNU REV GENET, V5, P257, DOI 10.1146/annurev.ge.05.120171.001353; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104	54	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31829	31836		10.1074/jbc.272.50.31829	http://dx.doi.org/10.1074/jbc.272.50.31829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395529	hybrid			2022-12-27	WOS:A1997YL41900088
J	Napierala, M; Krzyzosiak, WJ				Napierala, M; Krzyzosiak, WJ			CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER RNAPHE; TRIPLET REPEAT; RIBOSOMAL-RNA; HUMAN-DISEASE; DYSTROPHY MUTATION; ESCHERICHIA-COLI; MOLECULAR-BASIS; CTG REPEATS; DNA	We show that CUG repeats form "slippery" hairpins in their natural sequence context of the myotonin kinase gene transcript. This novel type of RNA structure is characterized by strong S-1 and T-1 nuclease and lead cleavages in the terminal loop and by mild lead cleavages in the hairpin stem. The latter effect indicates a relaxed metastable structure of the stem. (CUG)(5) repeats do not form any detectable secondary structure, whereas hairpins of increasing stability are formed by (CUG)(11), (CUG)(21), and (CUG)(49). The potential role of the RNA hairpin structure in the pathogenesis of myotonic dystrophy is discussed.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@man.poznan.pl						BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; Bhagwati S, 1996, BIOCHEM BIOPH RES CO, V228, P55, DOI 10.1006/bbrc.1996.1615; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CIESIOLKA J, 1992, EUR J BIOCHEM, V204, P575, DOI 10.1111/j.1432-1033.1992.tb16670.x; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GACY AM, 1995, CELL, V81, P533; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Harris S, 1996, HUM MOL GENET, V5, P1417, DOI 10.1093/hmg/5.Supplement_1.1417; HUMMERICH H, 1995, ELECTROPHORESIS, V16, P1698, DOI 10.1002/elps.11501601282; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KNAPP G, 1989, METHOD ENZYMOL, V180, P192; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Mariappan SVS, 1996, NUCLEIC ACIDS RES, V24, P775, DOI 10.1093/nar/24.4.775; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; NEVILLE CE, 1994, HUM MOL GENET, V3, P45; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; RUBIN JR, 1983, J BIOMOL STRUCT DYN, V1, P639, DOI 10.1080/07391102.1983.10507471; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; VARANI G, 1994, RNA PROTEIN INTERACT, P1; Wahl MC, 1996, NAT STRUCT BIOL, V3, P24, DOI 10.1038/nsb0196-24; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; Wang YX, 1996, NUCLEIC ACIDS RES, V24, P2666, DOI 10.1093/nar/24.14.2666; WATKINS WS, 1995, HUM MOL GENET, V4, P1485, DOI 10.1093/hmg/4.9.1485; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	130	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31079	31085		10.1074/jbc.272.49.31079	http://dx.doi.org/10.1074/jbc.272.49.31079			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388259	hybrid			2022-12-27	WOS:000071640800072
J	Wu, C; Lytvyn, V; Thomas, DY; Leberer, E				Wu, C; Lytvyn, V; Thomas, DY; Leberer, E			The phosphorylation site for Ste20p-like protein kinases is essential for the function of myosin-I in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; CDC42; IDENTIFICATION; PURIFICATION; LOCALIZATION; FILOPODIA; SEQUENCE; GTPASES; ACID; RAC	The budding yeast Saccharomyces cerevisiae has two functionally redundant myosin-I isoforms encoded by the MYO3 and MYO5 genes. The function shared by these myosin proteins is required for proper yeast budding, Serine residue 357 in the head domain of Myo3p, conserved among myosin-I proteins including yeast Myo5p, was identified as a unique phosphorylation site for the serine/threonine protein kinase Ste20p and its closely related isoform Cla4p. These protein kinases share a function that is also essential for budding. Replacement of serine 357 with alanine disrupted the in vivo function of Myo3p, whereas this function was maintained by changing the serine residue to aspartate, This mutant version failed to compensate the growth defect of cells which lack both Ste20p and Cla4p, suggesting that myosin-I is not the only essential target of these protein kinases, Our results suggest that phosphorylation of the head domain by Ste20p-like protein kinases plays an essential role in the function of myosin-I in yeast cells.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada	National Research Council Canada	Leberer, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIKORSKI RS, 1989, GENETICS, V122, P19; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	33	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30623	30626		10.1074/jbc.272.49.30623	http://dx.doi.org/10.1074/jbc.272.49.30623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388196	hybrid			2022-12-27	WOS:000071640800009
J	Biffo, S; Sanvito, F; Costa, S; Preve, L; Pignatelli, R; Spinardi, L; Marchisio, PC				Biffo, S; Sanvito, F; Costa, S; Preve, L; Pignatelli, R; Spinardi, L; Marchisio, PC			Isolation of a novel beta(4) integrin-binding protein (p27(BBP)) expressed in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; ALPHA(6)BETA(4) INTEGRIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; HEMIDESMOSOME FORMATION; PYLORIC ATRESIA; BETA-4 SUBUNIT; NUCLEAR MATRIX; ADHESION; ALPHA-6-BETA-4	The integrin beta(4) has a long cytodomain necessary for hemidesmosome formation. A yeast two-hybrid screen using beta(4) cytodomain uncovered a protein called p27(BBP) that represents a beta(4) interactor. Both in yeast and in vitro, p27(BBP) binds the two NH2-terminal fibronectin type III modules of beta(4), a region required for signaling and hemidesmosome formation, Sequence analysis of p27(BBP) revealed that p27(BBP) was not previously known and has no homology with any isolated mammalian protein, bat 85% identical to a yeast gene product of unknown function, Expression studies by Northern analysis and in situ hybridization showed that, in vivo, p27(BBP) mRNA is highly expressed in epithelia and proliferating embryonic epithelial cells, An antibody raised against p27(BBP) COOH-terminal domain showed that all beta(4)-containing epithelial cell lines expressed p27(BBP). The p27(BBP) protein is insoluble and present in the intermediate filament pool, Furthermore, subcellular fractionation indicated the presence of p27(BBP) both in the cytoplasm and in the nucleus, Confocal analysis of cultured cells showed that part of p27(BBP) immunoreactivity was both nuclear and in the membrane closely apposed to beta(4). These results suggest that the p27(BBP) is an in vivo interactor of beta(4), possibly linking beta(4) to the intermediate filament cytoskeleton.	UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; SAN RAFFAELE SCI INST,DEPT PATHOL,I-20132 MILAN,ITALY	University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Biffo, S (corresponding author), SAN RAFFAELE SCI INST,DEPT BIOL & TECHNOL RES,DIBIT,VIA OLGETTINA 58,I-20132 MILAN,ITALY.		Spinardi, Laura/I-6925-2015	Spinardi, Laura/0000-0002-4619-853X; biffo, stefano/0000-0002-3780-1050	Telethon [762, 826] Funding Source: Medline	Telethon(Fondazione Telethon)		BROCCOLI D, 1991, GENOMICS, V10, P68, DOI 10.1016/0888-7543(91)90485-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; DECHANT G, 1993, DEVELOPMENT, V119, P545; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Giancotti FG, 1996, J CELL SCI, V109, P1165; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KOZAK M, 1982, J MOL BIOL, V156, P807, DOI 10.1016/0022-2836(82)90143-7; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; NATALI PG, 1992, J CELL SCI, V103, P1243; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; Niessen CM, 1996, J CELL SCI, V109, P1695; Niessen CM, 1997, MOL BIOL CELL, V8, P555, DOI 10.1091/mbc.8.4.555; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Penman J, 1997, P NATL ACAD SCI USA, V94, P3732, DOI 10.1073/pnas.94.8.3732; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Sambrook J., 1989, MOL CLONING LAB MANU, V2, P32; SONNENBERG A, 1990, J CELL SCI, V96, P207; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SWAFFIELD J, 1995, CURRENT PROTOCOLS MO; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	41	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30314	30321		10.1074/jbc.272.48.30314	http://dx.doi.org/10.1074/jbc.272.48.30314			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374518	hybrid			2022-12-27	WOS:A1997YH61300050
J	Khurana, S; Arpin, M; Patterson, R; Donowitz, M				Khurana, S; Arpin, M; Patterson, R; Donowitz, M			Ileal microvillar protein villin is tyrosine-phosphorylated and associates with PLC-gamma(1) - Role of cytoskeletal rearrangement in the carbachol-induced inhibition of ileal NaCl absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-ABSORBING CELLS; BRUSH-BORDER; F-ACTIN; DEPENDENT MANNER; EPITHELIAL-CELLS; FILAMENTS; GELSOLIN; TRANSLOCATION; MEMBRANE; BINDING	In ileal absorptive cells, carbachol inhibits NaCl absorption and its component brush border Na+/H+ exchanger, acting via basolateral membrane receptors, This carbachol effect involves (i) activation of brush border phosphatidylinositol 4,5-bisphosphate-specific phospholipase C (PLC) activity and brush border but not basolateral membrane translocation of PLC-gamma(1) (Khurana, S., Kreydiyyeh, S., Aronzon, A., Hoogerwerf, W. A., Rhee, S. G., Donowitz, M., and Cohen, M. E. (1996) Biochem, J. 313, 509-518); and (ii) brush border tyrosine kinase(s) because mucosal but not serosal addition of the tyrosine kinase inhibitor genistein prevents the carbachol-induced inhibition of NaCl absorption and brush border Na+/H+ exchange, In the present work we identify a pool of villin (a brush border actin-binding protein) in the microvillus membrane fraction of rabbit ileum; this pool of villin is tyrosine-phosphorylated and associates with brush border membrane PLC-gamma(1), Villin is present both in the Triton X-100-soluble and -insoluble fractions of the brush border, The Triton X-100-soluble pool is approximately 4-fold smaller than the brush border pool of villin that is present in the Triton X-100- insoluble fraction, Only the villin present in the Triton X-100-soluble fraction of ileal villus brush border associates with PLC-gamma(1), and is tyrosine phosphorylated. Carbachol increases the tyrosine phosphorylation of villin rapidly (as early as 30 s) and transiently, Carbachol also increases the amount of tyrosine-phosphorylated villin that associates with PLC-gamma(1), These studies demonstrate that carbachol effects on NaCl absorption are accompanied by an increase in brush border PLC-gamma(1), association with villin and an increase in tyrosine phosphorylation of villin, To study the role of cytoskeletal rearrangement in carbachol-induced inhibition of NaCl absorption, we used the F-actin stabilizing drug jasplakinolide. Jasplakinolide prevents the carbachol inhibition of ileal Nacl absorption, This suggests that F-actin severing is necessary for carbachol to inhibit ileal villus NaCl absorption, Since villin is known to sever actin, these studies suggest a role for villin in the signaling cascade that begins at the basolateral membrane with carbachol binding to its receptor and ends at the apical membrane in inhibition of NaCl absorption.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; INST CURIE,F-75231 PARIS,FRANCE	Johns Hopkins University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Khurana, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,ROSS 925,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.			Khurana, Seema/0000-0002-6884-810X	NATIONAL CANCER INSTITUTE [R01CA047135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47135] Funding Source: Medline; NIDDK NIH HHS [P01 DK 44484, R01 DK 26523] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BOOTH AG, 1976, J CELL SCI, V21, P449; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GOLIGORSKY MS, 1986, J MEMBRANE BIOL, V92, P151, DOI 10.1007/BF01870704; HIRST BH, 1985, BIOCHEM J, V231, P641, DOI 10.1042/bj2310641; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; HOWE CL, 1980, J CELL BIOL, V85, P916, DOI 10.1083/jcb.85.3.916; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; JAISER F, 1996, 29 ANN M AM SOC NEPH, P1310; Janecki A, 1997, FASEB J, V11, P2971; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; KLUMPERMAN J, 1991, EUR J CELL BIOL, V54, P76; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P648, DOI 10.1083/jcb.92.3.648; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; MOOSEKER MS, 1980, J CELL BIOL, V87, P809, DOI 10.1083/jcb.87.3.809; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanford C., 1973, HYDROPHOBIC EFFECT; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30115	30121		10.1074/jbc.272.48.30115	http://dx.doi.org/10.1074/jbc.272.48.30115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374490	hybrid			2022-12-27	WOS:A1997YH61300022
J	Li, S; Kim, M; Hu, YL; Jalali, S; Schlaepfer, DD; Hunter, T; Chien, S; Shyy, JYJ				Li, S; Kim, M; Hu, YL; Jalali, S; Schlaepfer, DD; Hunter, T; Chien, S; Shyy, JYJ			Fluid shear stress activation of focal adhesion kinase - Linking to mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTOR; ADAPTER PROTEIN; BINDING-SITE; SH3 DOMAIN; KAPPA-B; RAS	Shear stress, the tangential component of hemodynamic forces, activates the extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) signal transduction pathways in cultured vascular endothelial cells to induce the transcriptional activation of many immediate early genes. It appears that integrins, protein-tyrosine kinases, and the structural integrity of actin are important factors involved in these shear stress-induced responses. The underlying molecular events were investigated by the application of a shear stress of 12 dyn/cm(2) on bovine aortic endothelial cells (BAEC), We found that such a shear stress increased the tyrosine phosphorylation and the kinase activity of focal adhesion kinase (FAK) and its association with growth factor receptor binding protein 2 (Grb2) in a rapid and transient manner, suggesting that FAK may be linked to these mitogen-activated protein kinase signaling pathways through a Grb2.Son of sevenless (Sos) complex, FAK(F397Y), which encodes a dominant negative mutant of FAK, attenuated the shear stress-induced kinase activity of Myc epitope-tagged ERK2 and hemagglutinin epitope-tagged JNK1. Delta mSos1, encoding a dominant negative mutant of Sos in which the guanine nucleotide exchange domain has been deleted, also attenuated shear stress activation of Myc-ERK2 and hemagglutinin-JNK1, Pretreating the confluent BAEC monolayers with a blocking type antivitronectin receptor monoclonal antibody had similar inhibitory effects in these shear stress-activated ERKs and JNKs. Confocal microscopic observation further demonstrated that FAK tended to cluster with vitronectin receptor near the abluminal side of the sheared BAEC. These results demonstrate that FAK signaling is critical in the shear stress-induced dual activation of ERK and JNK.	UNIV CALIF SAN DIEGO, DEPT BIOENGN, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, INST BIOMED ENGN, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; Salk Institute				Li, Song/0000-0002-4760-8828	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056707, R01HL019454, R01HL056707, P01HL043026] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56707, HL19454, HL43026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; JALALI S, 1997, FASEB J, V11, pA18; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li YS, 1996, MOL CELL BIOL, V16, P5947; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malek AM, 1996, J CELL SCI, V109, P713; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NEREM RM, 1993, J CARDIOVASC PHARM, V21, pS6; PARSONS JT, 1994, J CELL SCI, P109; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293	51	335	346	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30455	30462		10.1074/jbc.272.48.30455	http://dx.doi.org/10.1074/jbc.272.48.30455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374537	hybrid			2022-12-27	WOS:A1997YH61300069
J	Spataro, V; Toda, T; Craig, R; Seeger, M; Dubiel, W; Harris, AL; Norbury, C				Spataro, V; Toda, T; Craig, R; Seeger, M; Dubiel, W; Harris, AL; Norbury, C			Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MAMMALIAN-CELL LINES; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; ATPASE SUBUNIT; CDNA CLONING; IN-VIVO; C-JUN	We have investigated the usefulness of the fission yeast Schizosaccharomyces pombe as a model organism for the discovery of novel modes of drug resistance in human cells, In fission yeast, overexpression of the essential pad1(+) gene confers pleiotropic drug resistance through a pathway involving an AP-1 transcription factor encoded by pap1(+), We have identified POH1, a human pad1 homologue that can substitute fully for pad1(+) and induce AP-1-dependent drug resistance in fission yeast, POH1 also confers P-glycoprotein-independent resistance to taxol (paclitaxel), doxorubicin, 7-hydroxy-staurosporine, and ultraviolet Light when transiently overexpressed in mammalian cells, Poh1 is a previously unidentified component of the human 26 S proteasome, a multiprotein complex that degrades proteins targeted for destruction by the ubiquitin pathway. Hence, Poh1 is part of a conserved mechanism that determines cellular susceptibility to cytotoxic agents, perhaps by influencing the ubiquitin-dependent proteolysis of transcription factors.	UNIV OXFORD, JOHN RADCLIFFE HOSP,INST MOL MED, IMPERIAL CANC RES FUND,MOL ONCOL LAB, OXFORD OX3 9DS, ENGLAND; IMPERIAL CANC RES FUND, CELL REGULAT LAB, LONDON WC2A 3PX, ENGLAND; HUMBOLDT UNIV BERLIN, CHARITE, INST BIOCHEM, D-10117 BERLIN, GERMANY	University of Oxford; Cancer Research UK; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Dubiel, Wolfgang/0000-0002-3393-0701				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DEXTER D, 1994, GENETICS, V136, P505; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREY M, 1994, CURR GENET, V25, P469, DOI 10.1007/BF00351788; Harlow E., 1988, ANTIBODIES LAB MANUA; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Kaye SB, 1995, AM J MED, V99, pS40, DOI 10.1016/S0002-9343(99)80285-X; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SHIMANUKI M, 1995, J CELL SCI, V108, P569; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, BIOCHEM BIOPH RES CO, V210, P600, DOI 10.1006/bbrc.1995.1701; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; USUI T, 1995, GENE, V161, P93, DOI 10.1016/0378-1119(95)00229-Y; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367	42	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30470	30475		10.1074/jbc.272.48.30470	http://dx.doi.org/10.1074/jbc.272.48.30470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374539	hybrid			2022-12-27	WOS:A1997YH61300071
J	Antoine, M; Reimers, K; Dickson, C; Kiefer, P				Antoine, M; Reimers, K; Dickson, C; Kiefer, P			Fibroblast growth factor 3, a protein with dual subcellular localization, is targeted to the nucleus and nucleolus by the concerted action of two nuclear localization signals and a nucleolar retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT; FACTOR FAMILY; TRANSLOCATION SEQUENCE; MITOGENIC ACTIVITY; ONCOGENE INT-2; MULTIPLE ROLES; XENOPUS-LAEVIS; MESSENGER-RNA; EXPRESSION; RECEPTOR	The major isoform of fibroblast growth factor 3 (FGF3) is initiated from a CUG codon, and the resultant product is distributed to the nucleus/nucleolus and secretory pathway. This dual subcellular localization is achieved in part by the competing effects of two classical intracellular targeting signals located near the amino terminus, At the extreme amino terminus is a short stretch of 29 amino acids before a signal peptide necessary for translocation into the endoplasmic reticulum, which is next to an adjacent bipartite nuclear localization signal. The carboxyl-terminal region of FGF3 is also implicated in nuclear/nucleolar localization. We describe here the characterization of carboxyl-terminal signals by showing they are capable of directing a heterologous protein, beta-galactosidase, to the nucleus. Furthermore, appending both the amino-and carboxyl terminal domains onto beta-galactosidase, reproduces the dual subcellular localization properties of FGF3. Nuclear uptake of FGF3 appears to be signal-mediated since it binds to karyopherin alpha, the nuclear localization signal binding subunit of a heterodimeric receptor of the nuclear import machinery. The import of FGF3 into the nucleus is energy-dependent, and the inhibition of this process has demonstrated the importance of the nucleolar retention signal in nucleoplasmic and nucleolar accumulation.	RUHR UNIV BOCHUM,FAK MED,INST HYG & MIKROBIOL,ABT MED MIKROBIOL VIROL,D-44780 BOCHUM,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Ruhr University Bochum; Cancer Research UK								ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kiefer P, 1996, GENE, V168, P211, DOI 10.1016/0378-1119(95)00736-9; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; PETERS G, 1991, SEMIN VIROL, V2, P319; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	52	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29475	29481		10.1074/jbc.272.47.29475	http://dx.doi.org/10.1074/jbc.272.47.29475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368007	hybrid			2022-12-27	WOS:A1997YG64700017
J	Kim, JS; Pabo, CO				Kim, JS; Pabo, CO			Transcriptional repression by zinc finger peptides - Exploring the potential for applications in gene therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; CRYSTAL-STRUCTURE; SELECTION; SEQUENCE; PROTEIN; COMPLEX; RECOGNITION; UPSTREAM; ELEMENT; DOMAINS	A series of studies were performed to determine whether zinc finger peptides could efficiently repress transcription from RNA polymerase Il promoters in vivo and to determine how such repression might depend on the position of the zinc finger binding site with respect to those of the TATA box or the initiator element. Promoter constructs were prepared with Zif268 binding sites inserted at various positions, and the activity of a reporter gene was measured in transfection studies. We found that the peptide containing the three zinc fingers of Zif268 could efficiently repress activated transcription when bound to a site near the TATA box (19-fold repression) or when bound to a site near the initiator element (18-fold repression). Repression was even more effective when the zinc finger peptide was bound to both of these sites (63-fold repression). Novel zinc finger peptides that had been selected via phage display also served as repressors of activated transcription, but repression with these proteins was somewhat less efficient than with the Zif268 peptide.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306				Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MCBRYANT SJ, 1995, J MOL BIOL, V250, P315, DOI 10.1006/jmbi.1995.0379; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	28	48	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29795	29800		10.1074/jbc.272.47.29795	http://dx.doi.org/10.1074/jbc.272.47.29795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368051	hybrid			2022-12-27	WOS:A1997YG64700061
J	Craddock, BL; Welham, MJ				Craddock, BL; Welham, MJ			Interleukin-3 induces association of the protein-tyrosine phosphatase SHP2 and phosphatidylinositol 3-kinase with a 100-kDa tyrosine-phosphorylated protein in hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; STEEL FACTOR; P85 SUBUNIT; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; FAMILY MEMBERS	We have observed previously the co-immunoprecipitation of the p85 subunit of phosphatidylinositol-3 kinase (PI3K) and SHP2 in murine lymphohemopoietic cells after stimulation with interleukin-3. We have investigated this interaction in more detail and now report the identification of a potentially novel 100-kDa protein (termed p100), which is inducibly phosphorylated on tyrosine after interleukin-3 treatment and which co-immunoprecipitates with both p85 PI3K and SHP2. The Src homology region 2 domains of both p85 and SHP2 appear to mediate their interactions with p100. Sequential precipitation analyses suggest that these interactions are direct and do not involve Grb2, and that the same p100 protein, or a portion of it, interacts with both p85 and SHP2, implying that p100 may serve to link these two proteins. Far Western blotting with both full-length p85 and isolated p85 Src homology region 2 domains supports this view, Interestingly, p100 also appears to be a substrate for the SHP2 phosphatase activity. In addition, p100 is precipitated by Grb2-glutathione S-transferase fusion proteins, an interaction largely mediated by the Grb2 SH3 domains, p100 appears to be distinct from JAK2, Vav, STATE, and c-Cbl, Although largely cytosolic, p100 can be detected associated with SHP2 and PI3K in crude membrane fractions after interleukin-3 stimulation. We propose that p100 plays a role as an adaptor molecule, linking PI3K and SHP2 in IL-3 signaling.	UNIV BATH, DEPT PHARM & PHARMACOL, PHARMACOL GRP, BATH BA2 7AY, AVON, ENGLAND	University of Bath								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; DURONIO V, 1992, EXP HEMATOL, V20, P505; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liu L, 1997, J BIOL CHEM, V272, P10998; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; OKUDA K, 1992, BLOOD, V79, P2880; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TOKER A, 1994, J BIOL CHEM, V269, P32358; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	76	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29281	29289		10.1074/jbc.272.46.29281	http://dx.doi.org/10.1074/jbc.272.46.29281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361008	hybrid			2022-12-27	WOS:A1997YF68400067
J	Gilchrist, CA; Gray, DA; Baker, RT				Gilchrist, CA; Gray, DA; Baker, RT			A ubiquitin-specific protease that efficiently cleaves the ubiquitin-proline bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; GLUTATHIONE-S-TRANSFERASE; FIBROBLAST GROWTH-FACTOR; SHORT-LIVED PROTEIN; DEGRADATION SIGNAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; GENE; EXPRESSION	Ubiquitin is a small eukaryotic protein that is synthesized naturally as one of several fusion proteins, which are processed by ubiquitin-specific proteases to release free ubiquitin. The expression of heterologous proteins as fusions to ubiquitin in either prokaryotic or eukaryotic hosts often dramatically enhances their yield, and allows the exposure of any amino acid following cleavage of ubiquitin. The single exception is when proline is the amino acid immediately following ubiquitin; the ubiquitin-proline bond is poorly cleaved by presently studied ubiquitin-specific proteases. We show that the mouse ubiquitin-specific protease Unp, and its human homolog Unph, can efficiently cleave the ubiquitin-proline bond in ubiquitin fusion proteins of different sizes. N-terminal sequencing of the cleavage products reveals that cleavage occurs precisely at the ubiquitin-proline junction. The biological significance of this cleavage activity is unclear, as ubiquitin-proline fusions do not occur naturally. However, it may indicate a different catalytic mechanism for these ubiquitin-specific proteases and/or that they can cleave ubiquitin-like proteins. Unp and Unph thus represent versatile ubiquitin-specific proteases for cleaving ubiquitin-fusion proteins in biotechnology and basic research, regardless of both the amino acid immediately following ubiquitin, and the size of the fusion partner.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; Ottawa Reg Canc Ctr, Canc Res Grp, Ottawa, ON K1H 8L6, Canada	Australian National University; John Curtin School of Medical Research; University of Ottawa; Ottawa Hospital Research Institute	Baker, RT (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, GPO Box 334, Canberra, ACT 2601, Australia.	Rohan.Baker@anu.edu.au	; /U-3554-2018	Gilchrist, Catherine/0000-0002-7467-7933; /0000-0002-8634-4984				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALIN P, 1985, FEBS LETT, V182, P319, DOI 10.1016/0014-5793(85)80324-0; Amerik AY, 1997, EMBO J, V16, P4826; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; Baker RT, 1996, CURR OPIN BIOTECH, V7, P541, DOI 10.1016/S0958-1669(96)80059-0; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; BENCHEKROUN MT, 1993, BRIT J PHARMACOL, V109, P902, DOI 10.1111/j.1476-5381.1993.tb13705.x; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRAY DA, 1995, ONCOGENE, V10, P2179; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; LOWE G, 1971, BIOCHEM J, V124, P107, DOI 10.1042/bj1240107; LOWE G, 1971, BIOCHEM J, V124, P117, DOI 10.1042/bj1240117; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MAULE AG, 1991, PARASITOLOGY, V102, P309, DOI 10.1017/S0031182000062648; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schlesinger M J, 1987, Oxf Surv Eukaryot Genes, V4, P77; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YOO Y, 1989, J BIOL CHEM, V264, P17078	49	44	47	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32280	32285		10.1074/jbc.272.51.32280	http://dx.doi.org/10.1074/jbc.272.51.32280			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405433	hybrid			2022-12-27	WOS:000071108000052
J	Kakinoki, Y; Somers, J; Brautigan, DL				Kakinoki, Y; Somers, J; Brautigan, DL			Multisite phosphorylation and the nuclear localization of phosphatase inhibitor 2-green fluorescent protein fusion protein during S phase of the cell growth cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CASEIN KINASE-II; AMINO-ACID-SEQUENCE; PHOSPHOPROTEIN PHOSPHATASE; ESCHERICHIA-COLI; SYNERGISTIC PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; MODULATOR INHIBITOR-2; SITE; EXPRESSION	Human phosphatase inhibitor 2 (Inh2) is a phosphoprotein that complexes with type 1 protein phosphatase, and its expression peaks during S phase and mitosis during the cell cycle. Localization of Inh2 was visualized in HS68 human fibroblasts by fusing Inh2 to green fluorescent protein (GFP). During G(1) phase, Inh2-GFP was localized in the cytoplasm, and as cells progressed into S phase Inh2-GFP accumulated in the nucleus, Known phosphorylation sites of Inh2 at Thr-72, Ser-86, and Ser120/121 were each replaced with alanine. None of the mutated Inh2-GFP proteins accumulated in the nucleus during S phase, indicating that all of these phosphorylation sites were required, Mutation of two lysine residues in a putative nuclear localization sequence in Inh2 also prevented the Inh2-GFP fusion protein from accumulating in the nucleus during S phase. Recombinant Inh2 was phosphorylated by kinases in cytosols prepared from G(1) and S phase cells, The amount of Inh2 kinase attributed to casein kinase 2, based on inhibition by heparin, increased 2.6-fold from G(1) to S phase, In addition, kinases in G(1) versus S phase cytosols produced distinct Inh2 phosphopeptides. The results indicate that changes in phosphorylation of Inh2 are involved in intracellular redistribution of the protein during the cell cycle.	Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Brautigan, DL (corresponding author), Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Box 577,Hosp W 7196, Charlottesville, VA 22908 USA.	db8g@virginia.edu			NIGMS NIH HHS [GM-56362] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BALLOU LM, 1985, CURR TOP CELL REGUL, V27, P183; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; BOLLEN M, 1994, FEBS LETT, V344, P196, DOI 10.1016/0014-5793(94)00391-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAUTIGAN DL, 1991, ADV PROTEIN PHOSPHAT, V6, P375; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CANNON JF, 1994, GENETICS, V136, P485; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P211; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAN CSM, 1995, ADV PROTEIN PHOSPHAT, V9, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1985, FEBS LETT, V183, P430, DOI 10.1016/0014-5793(85)80824-3; FOULKES JG, 1980, EUR J BIOCHEM, V105, P195, DOI 10.1111/j.1432-1033.1980.tb04489.x; Gerdes HH, 1996, FEBS LETT, V389, P44, DOI 10.1016/0014-5793(96)00586-8; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PARK IK, 1994, J BIOL CHEM, V269, P28919; PARK IK, 1994, J BIOL CHEM, V269, P944; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VANDENHEEDE JR, 1981, J BIOL CHEM, V256, P5894; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS JP, 1995, J CELL BIOCHEM, V57, P415, DOI 10.1002/jcb.240570307; YANG SD, 1981, J BIOL CHEM, V256, P231; YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9; ZHANG ZJ, 1994, ARCH BIOCHEM BIOPHYS, V308, P37, DOI 10.1006/abbi.1994.1005; ZHANG ZJ, 1992, BIOCHEM BIOPH RES CO, V186, P1168, DOI 10.1016/0006-291X(92)90869-M	56	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32308	32314		10.1074/jbc.272.51.32308	http://dx.doi.org/10.1074/jbc.272.51.32308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405437	hybrid			2022-12-27	WOS:000071108000056
J	McDonald, KK; Zharikov, S; Block, ER; Kilberg, MS				McDonald, KK; Zharikov, S; Block, ER; Kilberg, MS			A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the ''arginine paradox''	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; PLASMA-MEMBRANE; DEPENDENT RELAXATION; SEROTONIN TRANSPORT; RELAXING FACTOR; CELLS; RELEASE; ARTERY; PALMITOYLATION; PURIFICATION	Immunohistochemistry of porcine pulmonary artery endothelial cells (PAEC) with antibodies specific for caveolin, endothelial nitric-oxide synthase (eNOS), and the arginine transporter (CAT1) demonstrates that all of these proteins co-localize in plasma membrane caveolae. When incubated with solubilized PAEC plasma membrane proteins, eNOS-specific antibody immunoprecipitates CAT1-mediated arginine transport. These results document the existence of a caveolar complex between CAT1 and eNOS in PAEC that provides a mechanism for the directed delivery of substrate arginine to eNOS. Direct transfer of extracellular arginine to membrane-bound eNOS accounts for the ''arginine paradox'' and explains why caveolar localization of eNOS is required for optimal nitric oxide production by endothelial cells.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOL BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, CTR STRUCT BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, DEPT MED, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, GAINESVILLE VA MED CTR, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Zharikov, Sergey/G-1636-2011; Zharikov, Sergey/A-2981-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL052136, R01HL052136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52136] Funding Source: Medline; NIDDK NIH HHS [DK-28374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; BAYDOUN AR, 1990, BIOCHEM BIOPH RES CO, V173, P940, DOI 10.1016/S0006-291X(05)80876-9; BHAT GB, 1990, AM J RESP CELL MOL, V3, P363, DOI 10.1165/ajrcmb/3.4.363; BHAT GB, 1992, AM J RESP CELL MOL, V6, P633, DOI 10.1165/ajrcmb/6.6.633; BLOCK ER, 1995, AM J PHYSIOL-LUNG C, V269, pL574, DOI 10.1152/ajplung.1995.269.5.L574; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Closs EI, 1996, AMINO ACIDS, V11, P193, DOI 10.1007/BF00813860; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; EDDAHIBI S, 1992, AM J PHYSIOL, V263, pL194, DOI 10.1152/ajplung.1992.263.2.L194; FAFOURNOUX P, 1989, J BIOL CHEM, V264, P4805; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOLD ME, 1989, BIOCHEM BIOPH RES CO, V164, P714, DOI 10.1016/0006-291X(89)91518-0; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Kurz S, 1997, J CLIN INVEST, V99, P369, DOI 10.1172/JCI119166; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; McDonald KK, 1997, BBA-BIOMEMBRANES, V1324, P133, DOI 10.1016/S0005-2736(96)00226-X; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MONCADA S, 1991, PHARMACOL REV, V43, P109; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; ROSSITCH E, 1991, J CLIN INVEST, V87, P1295, DOI 10.1172/JCI115132; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SIMIONESCU M, 1987, PULMONARY ENDOTHELIU, P35; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; TAYLOR PD, 1994, BRIT J PHARMACOL, V113, P801, DOI 10.1111/j.1476-5381.1994.tb17064.x; TEITEL JM, 1986, J CELL PHYSIOL, V128, P329, DOI 10.1002/jcp.1041280227; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; ZHARIKOV SI, 1997, IN PRESS BIOCH BIOPH	51	382	391	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31213	31216		10.1074/jbc.272.50.31213	http://dx.doi.org/10.1074/jbc.272.50.31213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395443	hybrid			2022-12-27	WOS:A1997YL41900002
J	Ratcliffe, MJ; Rubin, LL; Staddon, JM				Ratcliffe, MJ; Rubin, LL; Staddon, JM			Dephosphorylation of the cadherin-associated p100/p120 proteins in response to activation of protein kinase C in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; ADHESION MOLECULE UVOMORULIN; TIGHT JUNCTION PERMEABILITY; GLYCOGEN-SYNTHASE KINASE-3; EPIDERMAL GROWTH-FACTOR; BETA-CATENIN COMPLEX; TYROSINE PHOSPHORYLATION; SELECTIVE INHIBITOR; MDCK CELLS; PARACELLULAR PERMEABILITY	Protein kinase C signaling pathways have been implicated in the disruption of intercellular junctions, but mechanisms are not clear. p100 and p120 are members of the Armadillo family of proteins and are localized to cellular adherens junctions. In strain I Madin-Darby canine kidney cells, protein kinase C activation leads to disruption of tight junctions and an increase in permeability of cell monolayers. We show that this permeability increase is accompanied by dephosphorylation of p100/p120 on serine and threonine residues, The dephos phorylation of these proteins can also be induced by the kinase inhibitors staurosporine, KT5926, and G(o) double over dot 6976. Treatment of cells with phosphatase inhibitors induced hyperphosphorylation of p100 and p120. Thus, p100 and p120 participate in a regulatable cycle of serine/threonine phosphorylation and dephosphorylation. Protein kinase C must act, directly or indirectly, by perturbing this phosphorylation cycle, by inhibition of a p100/p120 kinase and/or activation of a phosphatase. These data clearly show that p100 and p120 are targets of a novel protein kinase C signaling pathway. Dephosphorylation of these proteins precedes the permeability increase across epithelial cell monolayers seen in response to phorbol esters, raising the possibility that this pathway may play a role in the modulation of intercellular junctions.	UCL, EISAI LONDON RES LABS LTD, LONDON WC1E 6BT, ENGLAND	Eisai Co Ltd; University of London; University College London				Rubin, Lee/0000-0002-8658-841X				AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOWNING JR, 1991, ONCOGENE, V6, P607; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GOODE N, 1992, J BIOL CHEM, V267, P16878; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HASHIMOTO Y, 1991, BIOCHEM BIOPH RES CO, V181, P423, DOI 10.1016/S0006-291X(05)81436-6; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KLEINSCHROTH J, 1995, BIOORG MED CHEM LETT, V5, P55, DOI 10.1016/0960-894X(94)00458-R; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCarthy KM, 1996, J CELL SCI, V109, P2287; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIERCE SB, 1995, DEVELOPMENT, V121, P755; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SOLER AP, 1993, EXP CELL RES, V207, P398, DOI 10.1006/excr.1993.1207; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STADDON JM, 1995, J CELL SCI, V108, P609; STENSON WF, 1993, AM J PHYSIOL, V265, pG955, DOI 10.1152/ajpgi.1993.265.5.G955; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	77	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31894	31901		10.1074/jbc.272.50.31894	http://dx.doi.org/10.1074/jbc.272.50.31894			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395537	hybrid			2022-12-27	WOS:A1997YL41900096
J	Rice, WJ; Green, NM; MacLennan, DH				Rice, WJ; Green, NM; MacLennan, DH			Site-directed disulfide mapping of helices M4 and M6 in the Ca2+ binding domain of SERCA1a, the Ca2+ ATPase of fast twitch skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CROSS-LINKING; AMINO-ACIDS; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE DOMAIN; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; CALCIUM-BINDING; CA2+-ATPASE; CA-2+-ATPASE	In an attempt to define the spatial relationships among SERCA1a transmembrane helices M4, M5, M6, and M8, involved in Ca2+ binding, all six cysteine residues were removed from predicted transmembrane sequences by substitution with Ser or Ala. The cysteine-depleted protein retained 44% of wild type Ca2+ transport activity. Pairs of cysteine residues were then reintroduced to determine whether their juxtaposition would result in the formation of disulfide cross-links between transmembrane helices. In initial studies de signed to map the juxtaposition of Ca2+ binding residues, Cys was substituted for Glu(309) or Gly(310) in transmembrane sequence M4, in combination with the substitution of Cys for Glu(771) in M5; for Asn(796), Thr(789), or Asp(800) in M6; or for Glu(908) in M8. These double mutants all retained the capacity to form a phosphoenzyme intermediate from P-i (but not from ATP in the presence of Ca2+), and in all but mutants E309C/N796C and G310C/N796C, phosphoenzyme formation was insensitive to 100 mu M Ca2+. These results support the view that both Glu(309) and Asn(796) contribute to Ca2+ binding site II, which is not required for conversion of E-2, the substrate for P-i phosphorylation, to E-1. Cross linking in mutants E309C/N796C and G310C/D800C established reference points for the orientation of M4 and M6 relative to each other and provided the basis for the prediction of potential additional cross-links. Strong links were formed with the pairs T317C/A804C and T317C/L807C near the cytoplasmic ends of the two helices and with A305C/L792C and A305C/L793C near the lumenal ends. These combined results support the conclusion that M4 and M6 form a right-handed coiled-coil structure that forms part of the pathway of Ca2+ translocation. In addition to providing a possible explanation for the mutation sensitivity of several pairs of residues in these helices, the proposed association of M4 and M6 supports a new model for the orientation of the two Ca2+ binding sites among transmembrane helices M4, M5, and M6.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A6, CANADA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	University of Toronto; University of Toronto; MRC National Institute for Medical Research				Rice, William/0000-0002-5187-255X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039280] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 39280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GF, 1994, J BIOL CHEM, V269, P29920; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; ROSS DC, 1987, J BIOL CHEM, V262, P2042; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; STEWART PS, 1974, J BIOL CHEM, V249, P985; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	51	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31412	31419		10.1074/jbc.272.50.31412	http://dx.doi.org/10.1074/jbc.272.50.31412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395473	hybrid			2022-12-27	WOS:A1997YL41900032
J	Vega, RB; Kelly, DP				Vega, RB; Kelly, DP			A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; TRANSCRIPTION FACTORS; TRANSGENIC MICE; C/EBP-ALPHA; PPAR-GAMMA; EXPRESSION; TISSUE; CELLS; DEHYDROGENASE; SUPERFAMILY	Little is known about the factors involved in the brown adipocyte gene regulatory program. In contrast to the white adipocyte, the brown adipocyte is characterized by abundant mitochondria and high level expression of mitochondrial fatty acid beta-oxidation enzymes. Previous studies in transgenic mice have shown that the brown adipose-enriched expression of a key beta-oxidation enzyme, medium chain acyl-coenzyme A dehydrogenase (MCAD), requires cis-acting elements located within the proximal promoter region of the MCAD gene. The levels of mRNA encoding MCAD and several other beta-oxidation cycle enzymes were coordinately induced during differentiation of brown adipocytes in culture. Expression of transgenes comprised of MCAD gene promoter fragments fused to chloramphenicol acetyltransferase reporters in differentiating brown adipocytes revealed that a known nuclear receptor response element (NRRE-1) was required for the transcriptional induction of the MCAD gene during brown adipocyte differentiation. Electrophoretic mobility shift assays and antibody recognition studies identified distinct brown adipocyte differentiation stage-specific, NRRE-1-protein complexes; the orphan nuclear receptors, chicken ovalbumin upstream promoter transcription factors I and II, were identified as major the NRRE-1 binding proteins in the pre-adipocyte, whereas the estrogen-related receptor alpha (ERR alpha) bound NRRE-1 in extracts prepared from differentiated brown adipocytes. DNA binding studies performed with a series of NRRE-1 mutant probes indicated that ERR alpha was capable of binding two distinct sites within NRRE-1, each of which conform to the known ERR alpha monomeric binding consensus. The expression of ERR alpha paralleled NRRE-1 binding activities and MCAD expression during brown adipocyte differentiation, cardiac development, and among a variety of adult mouse tissues. These results identify a new class of ERR alpha target genes and implicate ERR alpha and chicken ovalbumin upstream promoter transcription factor in the control of a pivotal metabolic pathway during brown adipocyte differentiation.	WASHINGTON UNIV,SCH MED,CARDIOVASC RES CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Kelly, Daniel/ABG-2056-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45416] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beinert H., 1963, ENZYMES, P447; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BREMER J, 1984, FATTY ACID OXIDATION, P13; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Disch DL, 1996, MOL CELL BIOL, V16, P4043; FLUERY C, 1997, NAT GENET, V15, P269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	34	132	142	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31693	31699		10.1074/jbc.272.50.31693	http://dx.doi.org/10.1074/jbc.272.50.31693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395511	hybrid			2022-12-27	WOS:A1997YL41900070
J	Bauerfeind, R; Takei, K; De Camilli, P				Bauerfeind, R; Takei, K; De Camilli, P			Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; ADRENAL CHROMAFFIN CELLS; PROTEIN-KINASE-C; SYNAPTIC VESICLES; ACTIN CYTOSKELETON; BREAST-CANCER; DYNAMIN-I; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; TRIGGERED EXOCYTOSIS	Amphiphysin I is an abundant presynaptic protein that interacts via its COOH-terminal src homology 3 (SH3) domain with the GTPase dynamin I and the inositol-5-phosphatase synaptojanin., Both dynamin I and synaptojanin I have a putative role in synaptic vesicle recycling and undergo rapid dephosphorylation in rat brain synaptosomes stimulated to secrete by a depolarizing stimulus, We show here that amphiphysin I also undergoes constitutive phosphorylation and stimulationdependent dephosphorylation, Dephosphorylation of amphiphysin I requires extracellular Ca2+ and is unaffected by pretreatment of synaptosomes with tetanus toxin, Thus, Ca2+ influx, but not synaptic vesicle exocytosis, is required for dephosphorylation. Dephosphorylation of amphiphysin I, like dephosphorylation of dynamin I and synaptojanin I, is inhibited by cyclosporin A and FK-506 (0.5 mu M), two drugs that specifically block the Ca2+/calmodulin-dependent phosphatase 2B calcineurin, but not by okadaic acid (1 mu M), which blocks protein phosphatases 1 and 2B. We also show by immunogold electron microscopy immunocytochemistry that amphiphysin I is localized in the nerve terminal cytomatrix and is partially associated with endocytic intermediates, These include the clathrin-coated buds and dynamin-coated tubules, which accumulate in nerve terminal membranes incubated in the presence of guanosine 5'-3-O-(thio)triphosphate. These data support the hypothesis that amphiphysin I, dynamin I, and syaptojanin I are physiological partners in some step(s) of synaptic vesicle endocytosis, We hypothesize that the parallel Ca2+-dependent calcineurin-dependent dephosphorylation of amphiphysin I and of its two major binding proteins is part of a process that primes the nerve terminal for endocytosis in response to a burst of exocytosis.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu		Takei, Kohji/0000-0002-6555-9425	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; CREUTZ CE, 1984, NATURE, V308, P208, DOI 10.1038/308208a0; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; Gad H., 1995, Society for Neuroscience Abstracts, V21, P332; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KLEE CB, 1990, FID RES FDN, V4, P95; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Kuromi H, 1997, NEUROSCI RES, V27, P101, DOI 10.1016/S0168-0102(96)01132-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNDIGI O, 1997, IN PRESS J NEUROSCI; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NEMOTO Y, 1997, IN PRESS J BIOL CHEM; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONGRAFENSTEIN H, 1993, J MEMBRANE BIOL, V134, P1; WANG JKT, 1988, J NEUROSCI, V8, P281; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	65	131	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30984	30992		10.1074/jbc.272.49.30984	http://dx.doi.org/10.1074/jbc.272.49.30984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388246	hybrid			2022-12-27	WOS:000071640800059
J	Benkirane, M; Jin, DY; Chun, RF; Koup, RA; Jeang, KT				Benkirane, M; Jin, DY; Chun, RF; Koup, RA; Jeang, KT			Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5 Delta 32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; RECEPTOR; ENTRY; GENE; LESTR/FUSIN; MIP-1-ALPHA; INDIVIDUALS; PROGRESSION; REPLICATION; MIP-1-BETA	Human chemokine receptor 5 (CCRB) functions as a co-receptor for Human immunodeficiency virus (HIV-1) infection, CCR5 is a seven-transmembrane cell surface receptor, Recently, a naturally occurring mutation of CCRB, ccr5 Delta 32, has been described, A small number of Caucasians are homozygously ccr5 Delta 32/ccr5 Delta 32, while a larger number of individuals are heterozygously CCR5/ccr5 Delta 32. The ccr5 Delta 32/ccr5 Delta 32 genotype has been linked to a phenotype that is "highly" protected from HIV-1 infection, On the other hand, several studies have shown that the CCR5/ccr5 Delta 32 genotype confers "relative" protection from AIDS with onset of disease being delayed by 2-4 years, Although it is known that peripheral blood lymphocytes from heterozygous individuals (CCR5/ccr5 Delta 32) support ex vivo HTV-1 replication at a reduced level compared with CCR5/CCR5 cells, the molecular basis for this observation is unknown, Here we report on events that post-translationally modify CCRB, We show that CCR5 progresses through the endoplasmic reticulum prior to appearing on the cell surface, Mature CCRB can be post-translationally modified by phosphorylation and/or co-translationally by multimerization, By contrast, mutant ccr5 Delta 32, although retaining the capacity for multimerization, was incapable of being phosphorylated. ccr5 Delta 32 heterocomplexes with CCR5, and this interaction retains CCR5 in the endoplasmic reticulum resulting in reduced cell surface expression, Thus, co-expression in cells of ccr5 Delta 32 with CCR5 produces a trans-inhibition by the former of ability by the latter to support HIV-1 infection, Taken together, our findings suggest CCR5/ccr5 Delta 32 heterodimerization as a molecular explanation for the delayed onset of AIDS in CCR5/ccr5 Delta 32 individuals.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX 75235 USA; Ctr Rech Biochim Macromol, CNRS, ERS 0155, Montpellier, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Benkirane, M (corresponding author), NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008; Chun, Rene/A-9415-2010	Chun, Rene/0000-0002-0190-0807	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035522, R01AI042397, R01AI035522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35522, AI42397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; WU BL, 1997, J EXP MED, V185, P1681	27	306	315	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30603	30606		10.1074/jbc.272.49.30603	http://dx.doi.org/10.1074/jbc.272.49.30603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388191	hybrid			2022-12-27	WOS:000071640800004
J	de Chaves, EIP; Rusinol, AE; Vance, DE; Campenot, RB; Vance, JE				de Chaves, EIP; Rusinol, AE; Vance, DE; Campenot, RB; Vance, JE			Role of lipoproteins in the delivery of lipids to axons during axonal regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-A-I; PERIPHERAL-NERVE; CHOLESTEROL-SYNTHESIS; MEMBRANE-LIPIDS; SCHWANN-CELLS; SCIATIC-NERVE; RECEPTORS; MYELIN	Nerve fiber elongation involves the input of lipids to the growing axons. Since cell bodies are often a great distance from the regenerating tips, alternative sources of lipids have been proposed. We previously demonstrated that axonal synthesis of phosphatidylcholine is required for axonal growth (Posse de Chaves, E., Vance, D. E., Campenot, R. B. and Vance, J. E. (1995) J. Cell Biol, 128, 913-918; Posse de Chaves, E., Vance, D. E., Campenot, R. B. and Vance, J. E. (1995) Biochem, J. 312, 411-417), In contrast, cholesterol is not made in axons. We now show that when compartmented cultures of rat sympathetic neurons are incubated with pravastatin, in the absence of exogenously supplied lipids, cholesterol synthesis is inhibited and axonal growth is impaired. The addition of cholesterol to the axons or cell bodies of neurons treated with this inhibitor restores normal axonal elongation. Similarly, a supply of cholesterol via lipoproteins restores normal axonal growth. In contrast, lipoproteins do not provide axons with sufficient phosphatidylcholine for normal elongation when axonal phosphatidylcholine synthesis is inhibited. Thus, our studies support the idea that during axonal regeneration lipoproteins can be taken up by axons from the microenvironment and supply sufficient cholesterol, but not phosphatidylcholine, for growth, We also show that neither apoE nor apoA-I within the lipoproteins is essential for axonal growth.	Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol & Anat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Lipid & Lipoprot Res Grp, Edmonton, AB T6G 2S2, Canada.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALBERTS B, 1989, MOL BIOL CELL, P1059; BEUCHE W, 1984, J NEUROCYTOL, V13, P767, DOI 10.1007/BF01148493; BOIRON F, 1993, J NEUROCHEM, V60, P320, DOI 10.1111/j.1471-4159.1993.tb05854.x; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROUSSEAU T, 1993, CLIN CHEM, V39, P960; CAMPENOT RB, 1991, J NEUROSCI, V11, P1126; CAMPENOT RB, 1989, NEURON, V3, P733, DOI 10.1016/0896-6273(89)90242-0; CAMPENOT RB, 1992, CELL CELL INTERACTIO, P275; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; FALKENBACH A, 1990, MED HYPOTHESES, V33, P57, DOI 10.1016/0306-9877(90)90085-S; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOODRUM JF, 1993, J NEUROCHEM, V60, P1564, DOI 10.1111/j.1471-4159.1993.tb03322.x; GOODRUM JF, 1995, J NEUROCHEM, V64, P408; GOODRUM JF, 1991, J NEUROCHEM, V56, P2082, DOI 10.1111/j.1471-4159.1991.tb03469.x; GOODRUM JF, 1990, J NEUROCHEM, V54, P1709, DOI 10.1111/j.1471-4159.1990.tb01225.x; GOODRUM JF, 1994, J NEUROSCI, V14, P357; GOULD RM, 1987, J NEUROCHEM, V48, P1121, DOI 10.1111/j.1471-4159.1987.tb05636.x; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; ISHIBASHI S, 1993, HORM METAB RES, V25, P82, DOI 10.1055/s-2007-1002048; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; LEDEEN RW, 1992, MOL NEUROBIOL, V6, P179, DOI 10.1007/BF02780551; LEDEEN RW, 1985, PHOSPHOLIPIDS NERVOU, P135; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MULLER HW, 1986, J CELL BIOL, V102, P393, DOI 10.1083/jcb.102.2.393; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; NAKAYA N, 1986, ATHEROSCLEROSIS, V61, P125, DOI 10.1016/0021-9150(86)90071-7; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POPKO B, 1993, J NEUROCHEM, V60, P1155, DOI 10.1111/j.1471-4159.1993.tb03268.x; RAWLINS FA, 1970, LAB INVEST, V22, P237; RAWLINS FA, 1972, J CELL BIOL, V52, P615, DOI 10.1083/jcb.52.3.615; ROTHE T, 1991, J NEUROCHEM, V57, P2016, DOI 10.1111/j.1471-4159.1991.tb06417.x; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; SNIPES GJ, 1983, SOC NEUR ABSTR, V9, P52; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; VANCE JE, 1994, J NEUROCHEM, V62, P329; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; WEISGRABER KH, 1980, J LIPID RES, V21, P316; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	48	132	133	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30766	30773		10.1074/jbc.272.49.30766	http://dx.doi.org/10.1074/jbc.272.49.30766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388216	hybrid			2022-12-27	WOS:000071640800029
J	Gray, MO; Karliner, JS; Mochly-Rosen, D				Gray, MO; Karliner, JS; Mochly-Rosen, D			A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART; INTRACELLULAR RECEPTOR; VENTRICULAR MYOCYTES; GENE-EXPRESSION; STRESS PROTEIN; ISOZYME; CARDIOMYOCYTES; LOCALIZATION; TRANSLOCATION; INCREASES	Protein kinase C activation is thought to protect cardiac tissue from subsequent ischemic injury by a process termed preconditioning, The protein kinase C isozyme that mediates preconditioning has not yet been identified, Using a cell culture model of hypoxic preconditioning, we found that cardiac myocyte viability after 9 h of hypoxia was increased by more than 50% over control, Preconditioning activated protein kinase C isozymes as evidenced by translocation from one cell compartment to another as follows: there was a a,l-fold increase in epsilon-protein kinase C activation, a 2.8-fold increase in delta-protein kinase C activation, and no increase in beta(1)-protein kinase C activation, 4 beta-Phorbol la-myristate 13-acetate mimicked hypoxic preconditioning, increasing myocyte survival after prolonged hypoxia by 34% compared with control, We previously identified an epsilon-protein kinase C-selective antagonist, epsilon V1-2 peptide, that inhibits epsilon-protein kinase C translocation and function in cardiac myocytes (Johnson, J, A., Gray, M. O., Chen, C.-H,, and Mochly-Rosen, D. (1996) J, Biol, Chem, 271, 24962-24966), epsilon V1-2 peptide abolished hypoxic preconditioning and phorbol ester mediated cardiac protection, Therefore, preconditioning can be induced in this culture model, and activation of epsilon-protein kinase C is critical for cardiac myocyte protection.	Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94121 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Karliner, JS (corresponding author), Vet Affairs Med Ctr, Cardiol Sect, 111C,4150 Clement St, San Francisco, CA 94121 USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL025847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52141, HL-25847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREW EC, 1995, AM J PHYSIOL-HEART C, V269, pH1370, DOI 10.1152/ajpheart.1995.269.4.H1370; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CLERK A, 1995, AM J PHYSIOL-HEART C, V269, pH1087, DOI 10.1152/ajpheart.1995.269.3.H1087; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1995, J MOL CELL CARDIOL, V27, P2473, DOI 10.1006/jmcc.1995.0235; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; Henry P, 1996, CIRC RES, V78, P161, DOI 10.1161/01.RES.78.1.161; HU KL, 1995, CIRCULATION, V92, P2259, DOI 10.1161/01.CIR.92.8.2259; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; IRONS CE, 1992, J BIOL CHEM, V267, P5211; Jiang TR, 1996, CIRC RES, V78, P724, DOI 10.1161/01.RES.78.4.724; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Morris SD, 1996, J CLIN INVEST, V97, P706, DOI 10.1172/JCI118468; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; PRYZKLENK K, 1995, CIRCULATION, V92, P1546; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; ROCHASINGH KJ, 1991, J CLIN INVEST, V88, P204, DOI 10.1172/JCI115279; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; YAMASHITA N, 1994, J CLIN INVEST, V94, P2193, DOI 10.1172/JCI117580; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	41	328	345	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30945	30951		10.1074/jbc.272.49.30945	http://dx.doi.org/10.1074/jbc.272.49.30945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388241	hybrid			2022-12-27	WOS:000071640800054
J	Lee, FJS; Huang, CF; Yu, WL; Buu, LM; Lin, CY; Huang, MC; Moss, J; Vaughan, M				Lee, FJS; Huang, CF; Yu, WL; Buu, LM; Lin, CY; Huang, MC; Moss, J; Vaughan, M			Characterization of an ADP-ribosylation factor-like 1 protein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; PHOSPHOLIPASE-D ACTIVITY; CHOLERA-TOXIN; GOLGI MEMBRANES; NUCLEOTIDE-BINDING; ARF PROTEINS; FACTOR-I; SELECTIVE AMPLIFICATION; DROSOPHILA-MELANOGASTER; ENDOPLASMIC-RETICULUM	ADP-ribosylation factors (ARFs) are highly conserved similar to 20-kDa guanine nucleotide-binding proteins that enhance the ADP-ribosyltransferase activity of cholera toxin and are believed to participate in vesicular transport in both exocytic and endocytic pathways. Several ARF-like proteins (ARLs) have been cloned from Drosophila, rat, and human; however, the biological functions of ARLs are unknown. We have identified a yeast gene (ARL1) encoding a protein that is structurally related (>60% identical) to human, rat, and Drosophila ARL1. Biochemical analyses of purified recombinant yeast ARL1 (yARL1) protein revealed properties similar to those ARF and ARL1 proteins, including the ability to bind and hydrolyze GTP. Like other ARLs, recombinant yARL1 protein did not stimulate cholera toxin-catalyzed auto-ADP-ribosylation. yARL1 was not recognized by antibodies against mammalian ARLs or yeast ARFs. Anti-yARL1 antibodies did not cross-react with yeast ARFs, but did react with human ARLs. On subcellular fractionation, yARL1, similar to yARF1, was localized to the soluble fraction. The amino terminus of yARL1, like that of ARF, was myristoylated. Unlike Drosophila Arl1, yeast ARL1 was not essential for cell viability. Like rat ARL1, yARL1 might be associated in part with the Golgi complex. However, yARL1 was not required for endoplasmic reticulum-to-Golgi protein transport, and it may offer an opportunity to define an ARL function in another kind of vesicular trafficking, such as the regulated secretory pathway.	Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 10764, Taiwan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Taiwan University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, FJS (corresponding author), Natl Taiwan Univ, Sch Med, Inst Mol Med, 7 Chung Shan S Rd, Taipei 10764, Taiwan.			LEE, FANG-JEN/0000-0002-2167-2426; HUANG, MIN-CHUAN/0000-0002-0704-3447				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LEE FJS, 1992, J BIOL CHEM, V267, P24441; Lee FJS, 1997, MOL BIOCHEM PARASIT, V87, P217, DOI 10.1016/S0166-6851(97)00061-3; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; LEE FJS, 1994, J BIOL CHEM, V269, P21555; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Lowe SL, 1996, J CELL SCI, V109, P209; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; MURTAGH JJ, 1993, BIOCHEMISTRY-US, V32, P6011, DOI 10.1021/bi00074a012; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1992, J BIOL CHEM, V267, P3922; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEISS O, 1989, J BIOL CHEM, V264, P21066; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; WHITNEY JA, 1995, CELL, V83, P703; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	78	68	72	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30998	31005		10.1074/jbc.272.49.30998	http://dx.doi.org/10.1074/jbc.272.49.30998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388248	hybrid			2022-12-27	WOS:000071640800061
J	Yamamoto, T; Horikoshi, M				Yamamoto, T; Horikoshi, M			Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; YEAST; ACTIVATION; SINGLE; GCN5P; GENES	Tip60, originally isolated as an HIV-1-Tat interactive protein, contains an evolutionarily conserved domain with yeast silencing factors, We demonstrate here direct biochemical evidence that this domain of Tip60 has histone acetyltransferase activity, The purified recombinant effectively acetylates H2A, H3, and H4 but not H2B of core histone mixtures, This substrate specificity has not been observed among histone acetyltransferases analyzed to date. These results indicate that Tip60 is a histone acetyltransferase with a novel property, suggesting that Tip60 and its related factors may introduce a distinct alteration on chromatin.	Univ Tokyo, Inst Mol & Cellular Biol, Dept Cellular Biol, Dev Biol Lab,Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Horikoshi, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biol, Dept Cellular Biol, Dev Biol Lab,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Yamamoto, Tohru/A-3801-2012	Yamamoto, Tohru/0000-0002-1652-0233				Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yamamoto T, 1997, GENES CELLS, V2, P245, DOI 10.1046/j.1365-2443.1997.1180316.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	24	198	201	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30595	30598		10.1074/jbc.272.49.30595	http://dx.doi.org/10.1074/jbc.272.49.30595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388189	hybrid			2022-12-27	WOS:000071640800002
J	Yamasaki, K; Daiho, T; Saino, T; Kanazawa, T				Yamasaki, K; Daiho, T; Saino, T; Kanazawa, T			Modification of histidine 5 in sarcoplasmic reticulum Ca2+-ATPase by diethyl pyrocarbonate causes strong inhibition of formation of the phosphoenzyme intermediate from inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; CA-2+-DEPENDENT CONFORMATIONAL CHANGE; ADENOSINE-TRIPHOSPHATASE; TIGHT-BINDING; ACTIVE-SITE; HIGH-AFFINITY; CA-2+ PUMP; CALCIUM; VANADATE; PHOSPHORYLATION	Sarcoplasmic reticulum vesicles were modified with diethyl pyrocarbonate (DEPC), a histidine-modifying reagent, Phosphoenzyme formation from P-i in the Ca2+-ATPase (reversal of hydrolysis of the phosphoenzyme intermediate) was almost completely inhibited by this modification, Tight binding of F- and Mg2+ and high affinity binding of vanadate in the presence of Mg2+, both of which produce transition state analogs for phosphoenzyme formation from the magnesium-enzyme-phosphate complex, were also inhibited, Formation of the phosphoenzyme from acetyl phosphate in the forward reaction was only weakly inhibited, but hydrolysis of the phosphoenzyme was strongly inhibited, The enzyme was protected by tight binding of F- and Mg2+ or by high affinity binding of vanadate in the presence of Mg2+ against the DEPC-induced inhibition of phosphoenzyme formation from P-i. The enzyme was also pro tected by tight binding of F- and Mg2+ against the DEPC-induced inhibition of phosphoenzyme hydrolysis, Peptide mapping of the tryptic digests, detection of peptides containing DEPC-modified histidine by UV absorption at 240 nm, amino acid analysis, sequencing, and mass spectrometry showed that His-5 was a single major residue protected by the above transition state analogs against the modification with DEPC, These results indicate that modification of His-Fi with DEPC is responsible for the DEPC induced inhibition of phosphoenzyme formation from P-i and of phosphoenzyme hydrolysis and suggest that His-5 is located in or very close to the catalytic site in the transition state for phosphoenzyme formation from the magnesium-enzyme-phosphate complex and is likely involved in the catalytic process of this reaction step.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan	Asahikawa Medical College	Kanazawa, T (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan.	kanazawa@asahikawa-med.ac.jp		Saino, Tomoyuki/0000-0001-6360-9516				ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; Christendat D, 1996, BIOCHEMISTRY-US, V35, P4468, DOI 10.1021/bi9525637; COAN C, 1990, J BIOL CHEM, V265, P5376; COFFEY RL, 1975, ARCH BIOCHEM BIOPHYS, V170, P37, DOI 10.1016/0003-9861(75)90095-8; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DEMEIS L, 1982, J BIOL CHEM, V257, P4993; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; INESI G, 1984, J BIOL CHEM, V259, P996; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; KOLASSA N, 1979, FEBS LETT, V108, P495, DOI 10.1016/0014-5793(79)80596-7; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundblad RL., 1995, TECHNIQUES PROTEIN M; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARTINEZAZORIN F, 1995, BIOCHEM J, V309, P499, DOI 10.1042/bj3090499; MARTONOSI A, 1973, COLD SPRING HARB SYM, V37, P455, DOI 10.1101/SQB.1973.037.01.057; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; Miles E W, 1977, Methods Enzymol, V47, P431; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PUCELL A, 1971, J BIOL CHEM, V246, P3389; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; REITHMEIER RAF, 1981, J BIOL CHEM, V256, P5957; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; TENU JP, 1976, J BIOL CHEM, V251, P4322; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129; YAMASAKI K, 1991, J BIOCHEM, V110, P915, DOI 10.1093/oxfordjournals.jbchem.a123689; YU BP, 1974, BIOCHEMISTRY-US, V13, P5083, DOI 10.1021/bi00722a004	51	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30627	30636		10.1074/jbc.272.49.30627	http://dx.doi.org/10.1074/jbc.272.49.30627			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388197	hybrid			2022-12-27	WOS:000071640800010
J	Zhang, ZX; Jones, S; Hagood, JS; Fuentes, NL; Fuller, GM				Zhang, ZX; Jones, S; Hagood, JS; Fuentes, NL; Fuller, GM			STAT3 acts as a co-activator of glucocorticoid receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHASE RESPONSE FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTOR; INTERLEUKIN-6 RECEPTOR; FUNCTIONAL ANTAGONISM; PROTEIN-INTERACTION; HORMONE RECEPTORS; DNA-BINDING; GENE	Interleukin 6 (IL-6) and glucocorticoids are important mediators of inflammatory and immunological responses. Glucocorticoids are known to synergistically enhance IL-B-mediated cellular responses. We now show that IL-6 also has a synergistic effect upon glucocorticoid signaling, In particular, IL-6-activated STAT3 associates with ligand-bound glucocorticoid receptor to form a transactivating/signaling complex, which can function through either an IL-6-responsive element or a glucocorticoid-responsive element. These findings reveal a new level of interaction between these two crucial signaling cascades and indicate that activated STAT3 can also act as a transcriptional co-activator without direct association with its DNA binding motif.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Div Pulm, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Fuller, GM (corresponding author), Univ Alabama, Dept Cell Biol, BHSB Suite 680, Birmingham, AL 35294 USA.		Jones, Simon Arnett/Q-7017-2018	Jones, Simon Arnett/0000-0001-7297-9711; Zhang, Zhixin/0000-0003-3924-1082				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ausubel FM, 1988, MOL REPROD DEV; BAUMANN H, 1990, J BIOL CHEM, V265, P20390; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; Duncan SA, 1997, DEV DYNAM, V208, P190, DOI 10.1002/(SICI)1097-0177(199702)208:2<190::AID-AJA6>3.0.CO;2-D; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMAI E, 1993, J BIOL CHEM, V268, P5353; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; NAKAJIMA K, 1996, EMBO J, V15, P3051; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STAHL N, 1995, SCIENCE, V267, P5; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang ZX, 1997, BIOCHEM BIOPH RES CO, V237, P90, DOI 10.1006/bbrc.1997.7082; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	47	187	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30607	30610		10.1074/jbc.272.49.30607	http://dx.doi.org/10.1074/jbc.272.49.30607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388192	hybrid			2022-12-27	WOS:000071640800005
J	Couet, J; Sargiacomo, M; Lisanti, MP				Couet, J; Sargiacomo, M; Lisanti, MP			Interaction of a receptor tyrosine kinase, EGF-R, with caveolins - Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MEMBRANE-PROTEIN; CELLS; INTERNALIZATION; LOCALIZATION; PURIFICATION; SEQUENCE; DOMAINS	Caveolin, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes. We and others have suggested that caveolin functions as a scaffolding protein to organize and concentrate certain caveolin-interacting signaling molecules within caveolae membranes. In this regard, it has been shown that a 20-amino acid membrane-proximal region of the cytosolic NH2-terminal domain of caveolin is sufficient to mediate the interaction of caveolin with signaling proteins, namely G-proteins, Src-Like kinases, eNOS, and H-Ras. This caveolin-derived protein domain has been termed the caveolin scaffolding domain. Binding of the caveolin-scaffolding domain functionally suppresses the activity of G-protein alpha subunits, eNOS, and Src-Like kinases, suggesting that caveolin binding may also play a negative regulatory role in signal transduction. Here, we report the direct interaction of caveolin with a growth factor receptor, EGF-R, a known caveollae-associated receptor tyrosine kinase. Two consensus caveolin binding motifs have been previously defined using phage display technology. One of these motifs is present within the conserved kinase domains of most known receptor tyrosine kinases (termed region IX). We now show that this caveolin binding motif within the kinase domain of the EGF-R can mediate the interaction of the EGF-R with the scaffolding domains of caveolins 1 and 3 but not with caveolin 2, In addition, the scaffolding do mains of caveolins 1 and 3 both functionally inhibit the autophosphorylation of the EGF-R kinase in vitro. Importantly, this caveolin mediated inhibition of the EGF-R kinase could be prevented by the addition of an EGF-R-derived peptide that (i) contains a well conserved caveolin binding motif and (ii) is located within the kinase domain of the EGF-R and most known receptor tyrosine kinases. Similar results were obtained with protein kinase C, a serine/threonine kinase, suggesting that caveolin may function as a general kinase inhibitor, The implications of our results are discussed within the context of caveolae-mediated signal transduction. In this regard, caveolae-coupled signaling might explain how linear signaling pathways can branch and interconnect extensively, forming a signaling module or network.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; UNIV LAVAL, LAVAL HOSP RES CTR, Ste Foy, PQ G1V 4G5, CANADA; IST SUPER SANITA, DEPT HEMATOL & ONCOL, I-00161 ROME, ITALY	Yeshiva University; Albert Einstein College of Medicine; Laval University; Istituto Superiore di Sanita (ISS)			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X; Couet, Jacques/0000-0001-5409-8689				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gleizes PE, 1996, EUR J CELL BIOL, V71, P144; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	37	529	545	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30429	30438		10.1074/jbc.272.48.30429	http://dx.doi.org/10.1074/jbc.272.48.30429			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374534	hybrid			2022-12-27	WOS:A1997YH61300066
J	Gremlich, S; Bonny, C; Waeber, G; Thorens, B				Gremlich, S; Bonny, C; Waeber, G; Thorens, B			Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE ACTIVITY; DEPENDENT DIABETES-MELLITUS; LONG-TERM EXPOSURE; HOMEOBOX FACTOR; FACTOR STF-1; BETA-CELLS; GENE; HOMEODOMAIN; TRANSCRIPTION; ACTIVATION	IDX-1 (islet/duodenum homeobox-1) is a transcription factor expressed in the duodenum and pancreatic beta and delta cells, It is required for embryonic development of the pancreas and transactivates the Glut2, glucokinase, insulin, and somatostatin genes, Here we show that exposure of isolated rat pancreatic islets to palmitic acid induced a similar to 70% decrease in IDX-1 mRNA and protein expression as well as 40 and 65% decreases in the binding activity of IDX-1 for its cognate cis-regulatory elements of the Glut2 and insulin promoters, respectively, The inhibitory effect of palmitic acid required its mitochondrial oxidation since it was prevented by the carnitine palmitoyltransferase I inhibitor bromopalmitic acid, The palmitic acid effect on IDX-1 was correlated with decreases in GLUT2 and glucokinase expression of 40 and 25%, respectively, at both the mRNA and protein levels, Insulin and somatostatin mRNA expression was also decreased by 40 and 60%, whereas glucagon mRNA expression was not modified, After 48 h of exposure to fatty acids, total islet insulin, somatostatin, and glucagon contents were decreased by 85, 55, and 65%, respectively, At the same time, total hormone release was strongly stimulated (13-fold) for glucagon, whereas its was only marginally increased for insulin and somatostatin (1.5- and 1.7-fold, respectively), These results indicate that elevated fatty acid levels 1) negatively regulate Idx-1 expression; 2) decrease the expression of genes transactivated by IDX-1 such as those for GLUT2, glucokinase, insulin, and somatostatin; and 3) lead to an important increase in glucagon synthesis and secretion, Fatty acids thus have pleiotropic effects on pancreatic islet gene expression, and the negative control of Idx-1 expression may be an initial event in the development of these multiple defects.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; UNIV LAUSANNE HOSP,DEPT INTERNAL MED B,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)				Waeber, Gerard/0000-0003-4193-788X				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lu M, 1996, ENDOCRINOLOGY, V137, P2959, DOI 10.1210/en.137.7.2959; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ORRIELD MF, 1996, DEVELOPMENT CAMB, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SAMOLS E, 1991, ENDOCRINE PANCREAS, P93; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	43	202	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30261	30269		10.1074/jbc.272.48.30261	http://dx.doi.org/10.1074/jbc.272.48.30261			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374511	hybrid			2022-12-27	WOS:A1997YH61300043
J	Lally, ET; Kieba, IR; Sato, A; Green, CL; Rosenbloom, J; Korostoff, J; Wang, JF; Shenker, BJ; Ortlepp, S; Robinson, MK; Billings, PC				Lally, ET; Kieba, IR; Sato, A; Green, CL; Rosenbloom, J; Korostoff, J; Wang, JF; Shenker, BJ; Ortlepp, S; Robinson, MK; Billings, PC			RTX toxins recognize a beta 2 integrin on the surface of human target cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTINOBACILLUS-ACTINOMYCETEMCOMITANS LEUKOTOXIN; THURINGIENSIS DELTA-ENDOTOXINS; BRUSH-BORDER MEMBRANE; ALPHA-SUBUNIT; EXPRESSION; LFA-1; DOMAIN; SPECIFICITY; RECEPTORS; HEMOLYSIN	Actinobacillus actinomycetemcomitans leukotoxin and Escherichia coli alpha-hemolysin are RTX toxins that kill human immune cells. We have obtained a monoclonal antibody (295) to a cell surface molecule present on toxin-sensitive HL60 cells that can inhibit cytolysis by both RTX toxins. Utilization of this monoclonal antibody for immunoaffinity purification of detergent-solubilized target cell membranes yielded two polypeptide chains of approximate molecular masses of 100 and 170 kDa. Microsequencing of tryptic peptides from the two proteins showed complete homology with CD11a and CD18, the two subunits of the beta 2 integrin, lymphocyte function-associated antigen 1 (LFA-1). Anti-CD11a and CD18 monoclonal antibodies also inhibited RTX toxin-mediated cytolysis. Direct binding experiments demonstrated the ability of an immobilized RTX to bind LFA-1 heterodimers present in a deter gent lysate of human HL60 target cells. Transfection of CD11a and CD18 integrin genes into a cell line (K562) that is not sensitive to either RTX toxin resulted in LFA-1 expressing cells, KL/4, that were sensitive to both toxins. These experiments identify LFA-1 as a cell surface recep- tor that mediates toxicity of members of this family of pore-forming toxins.	UNIV OHU,SCH DENT MED,DEPT ORAL SURG 1,KORIYAMA,FUKUSHIMA 963,JAPAN; CELLTECH LTD,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd	Lally, ET (corresponding author), UNIV PENN,LEON LEVY RES CTR ORAL BIOL,4010 LOCUST ST,PHILADELPHIA,PA 19104, USA.		Korostoff, Jonathan/GRO-5722-2022; Korostoff, Jonathan/AAM-1691-2021		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008239] Funding Source: NIH RePORTER; NIDCR NIH HHS [5 P50 DE08239-10, R01 DE09517-06] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BROGAN JM, 1994, INFECT IMMUN, V62, P501, DOI 10.1128/IAI.62.2.501-508.1994; CARRERA AC, 1988, J IMMUNOL, V141, P1919; CAVALIERI SJ, 1984, MICROBIOL REV, V48, P326, DOI 10.1128/MMBR.48.4.326-343.1984; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; LALLY ET, 1994, J BIOL CHEM, V269, P31289; LALLY ET, 1989, BIOCHEM BIOPH RES CO, V159, P256, DOI 10.1016/0006-291X(89)92431-5; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LEAR JD, 1995, BBA-BIOMEMBRANES, V1238, P34, DOI 10.1016/0005-2736(95)00086-I; LIAN CJ, 1989, INFECT IMMUN, V57, P3377, DOI 10.1128/IAI.57.11.3377-3382.1989; LO RYC, 1985, INFECT IMMUN, V50, P667, DOI 10.1128/IAI.50.3.667-671.1985; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; MOBLEY HLT, 1991, INFECT IMMUN, V59, P2036, DOI 10.1128/IAI.59.6.2036-2042.1991; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PATTUS F, 1990, EXPERIENTIA, V46, P180; REED JC, 1997, LYMPHOID SYSTEM; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SCHNUR RA, 1990, J IMMUNOL, V144, P4765; SIMPSON DL, 1988, INFECT IMMUN, V56, P1162, DOI 10.1128/IAI.56.5.1162-1166.1988; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STRATHDEE CA, 1989, J BACTERIOL, V171, P916, DOI 10.1128/jb.171.2.916-928.1989; Taichman N S, 1987, Oral Microbiol Immunol, V2, P97, DOI 10.1111/j.1399-302X.1987.tb00270.x; TAICHMAN NS, 1984, J PERIODONTAL RES, V19, P133, DOI 10.1111/j.1600-0765.1984.tb00802.x; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; 1987, LEUC TYP, V3	41	212	219	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30463	30469		10.1074/jbc.272.48.30463	http://dx.doi.org/10.1074/jbc.272.48.30463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374538	hybrid			2022-12-27	WOS:A1997YH61300070
J	Morales, A; GarciaRuiz, C; Miranda, M; Mari, M; Colell, A; Ardite, E; FernandezCheca, JC				Morales, A; GarciaRuiz, C; Miranda, M; Mari, M; Colell, A; Ardite, E; FernandezCheca, JC			Tumor necrosis factor increases hepatocellular glutathione by transcriptional regulation of the heavy subunit chain of gamma-glutamylcysteine synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; ACTIVATOR INHIBITOR TYPE-2; ALPHA-INDUCED APOPTOSIS; REDUCED GLUTATHIONE; FACTOR CYTOTOXICITY; OXIDATIVE STRESS; CELL-DEATH; TNF; INDUCTION	Tumor necrosis factor (TNF) is an inflammatory cytokine that causes cell injury by generation of oxidative stress, Since glutathione (GSH) is a key cellular antioxidant that detoxifies reactive oxygen species, the purpose of our work was to examine the regulation of cellular GSH, the expression of heavy subunit chain of gamma-glutamylcysteine synthetase (gamma-GCS-HS), and control of intracellular generation of reactive oxygen species in cultured rat hepatocytes treated with TNF. Exposure of cells to TNF (10,000 units/ml) resulted in depletion of cellular GSH levels (50-70%) and overproduction of hydrogen peroxide (2-3-fold) and lipid peroxidation, However, cells treated with lower doses of TNF (250-500 units/ml) exhibited increased levels of GSH (60-80% over control). TNF treatment increased (70-100%) the levels of gamma-GCS-HS mRNA, the catalytic subunit of the regulating enzyme in GSH biosynthesis. Furthermore, intact nuclei isolated from hepatocytes treated with TNF transcribed the gamma-GCS-HS gene to a greater extent than control cells, indicating that TNF regulates gamma-GCS-HS at the transcriptional level. The capacity to synthesize GSH de novo determined in cell-free extracts incubated with GSH precursors was greater (50-70%) in hepatocytes that were treated with TNF; however, the activity of GSH synthetase remained unaltered by TNF treatment indicating that TNF selectively increased the activity of gamma-GCS. Despite activation of nuclear factor-kappa B (NF-kappa B) by TNF, this transcription factor was not required for TNF-induced transcription of gamma-GCS-HS as revealed by deletion constructs of the gamma-GCS-HS promoter subcloned in a chloramphenicol acetyltransferase reporter vector and transfected into HepG2 cells, In contrast, a construct containing AP-1 like/metal response regulatory elements increased chloramphenicol acetyltransferase activity upon exposure to TNF. Thus, TNF increases hepatocellular GSH levels by transcriptional regulation of gamma-GCS-HS gene, probably through AP-1/metal response element-like binding site(s) in its promoter, which may constitute a protective mechanism in the control of oxidative stress induced by inflammatory cytokines.	UNIV BARCELONA,HOSP CLIN & PROV,CSIC,LIVER UNIT,INST INVEST BIOMED,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,SERV BIOQUIM,E-08036 BARCELONA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona			MARI, MONTSERRAT/M-2871-2019; Morales, Albert/E-2988-2013; Mari, Montserrat/A-7376-2013; Colell, Anna/N-8710-2014; miranda, merce/H-7467-2017; Fernández-Checa, José Carlos/L-8342-2014	Morales, Albert/0000-0001-8702-2269; Mari, Montserrat/0000-0002-6116-3247; Colell, Anna/0000-0001-5236-1834; miranda, merce/0000-0001-6214-1042; Fernández-Checa, José Carlos/0000-0003-3422-2990	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009526] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09526] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRACH MA, 1993, MOL CELL BIOL, V13, P4824; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG787; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FEINGOLD KR, 1988, BIOCHEM BIOPH RES CO, V153, P576, DOI 10.1016/S0006-291X(88)81134-3; FernandezCheca JC, 1996, SEMIN LIVER DIS, V16, P147, DOI 10.1055/s-2007-1007228; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HILL DB, 1995, HEPATOLOGY, V21, P1114, DOI 10.1002/hep.1840210434; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KUMAR S, 1991, J BIOL CHEM, V266, P20960; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MING SM, 1994, J BIOL CHEM, V269, P26512; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WALLACH D, 1984, J IMMUNOL, V132, P2464; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAN N, 1990, J BIOL CHEM, V265, P1588; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; YAO KS, 1995, CANCER RES, V55, P4367; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	53	126	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30371	30379		10.1074/jbc.272.48.30371	http://dx.doi.org/10.1074/jbc.272.48.30371			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374527	hybrid			2022-12-27	WOS:A1997YH61300059
J	Barkett, M; Xue, D; Horvitz, HR; Gilmore, TD				Barkett, M; Xue, D; Horvitz, HR; Gilmore, TD			Phosphorylation of I kappa B-alpha inhibits its cleavage by caspase CPP32 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SPLEEN-CELLS; V-REL ONCOGENE; INDUCED APOPTOSIS; PROTEOLYSIS; ACTIVATION; DEATH; TRANSFORMATION	I kappa B proteins function as direct regulators of Rel/NF-kappa B transcription complexes. We show that the cell-death protease CPP32 (caspase-3) in vitro specifically cleaved chicken and human I kappa B-alpha at a conserved Asp-Ser sequence. This cleavage site appears to be identical to the site at which chicken I kappa B-alpha is cleaved in vivo in temperature-sensitive v-Rel-transfarmed chicken spleen cells undergoing apoptosis. Other caspases, namely interleukin-1 beta-converting enzyme (caspase-1) and Ich-1 (caspase-2), did not cleave I kappa B-alpha. CPP32 also cleaved mammalian I kappa B-beta in vitro at the analogous Asp-Ser sequence. Cleavage of I kappa B-alpha by CPP32 was blocked by serine phosphorylation of I kappa B-alpha. Cleavage of I kappa B-alpha by a CPP32-like protease could generate a constitutive inhibitor of Rel transcription complexes. This report provides evidence for a direct biochemical interaction between the NF-kappa B signaling pathway and a cell-death protease signaling pathway.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215; MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Boston University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				XUE, DING/0000-0002-8429-8136	NCI NIH HHS [CA47763] Funding Source: Medline; NCRR NIH HHS [RR11397] Funding Source: Medline; NIGMS NIH HHS [GM08291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rodriguez MS, 1996, ONCOGENE, V12, P2425; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	23	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29419	29422		10.1074/jbc.272.47.29419	http://dx.doi.org/10.1074/jbc.272.47.29419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367996	hybrid			2022-12-27	WOS:A1997YG64700006
J	Fire, E; Brown, CM; Roth, MG; Henis, YI; Petersen, NO				Fire, E; Brown, CM; Roth, MG; Henis, YI; Petersen, NO			Partitioning of proteins into plasma membrane microdomains - Clustering of mutant influenza virus hemagglutinins into coated pits depends on the strength of the internalization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; LYSOSOMAL ACID-PHOSPHATASE; TYROSINE KINASE-ACTIVITY; LOW-DENSITY-LIPOPROTEIN; DI-LEUCINE MOTIF; CYTOPLASMIC DOMAIN; MDCK CELLS; IN-VITRO	Internalization of membrane proteins involves their recruitment into plasma membrane clathrin-coated pits, with which they are thought to interact by binding to AP-2 adaptor protein complexes, To investigate the interactions of membrane proteins with coated pits at the cell surface, we applied image correlation spectroscopy to measure directly and quantitatively the clustering of influenza hemagglutinin (HA) protein mutants carrying specific cytoplasmic internalization signals. The HA system enables direct comparison between isolated internalization signals, because HA itself is excluded from coated pits, The studies presented here provide, for the first time, a direct quantitative measure for the degree of clustering of membrane proteins in coated pits at the cell surface, The degree of clustering depended on the strength of the internalization signal and on the integrity of the clathrin lattices and correlated with the internalization rates of the mutants, The clustering of the HA mutants fully correlated with their ability to co-precipitate alpha-adaptin from whole cells, the first such demonstration for a membrane protein that is not a member of the epidermal growth factor receptor family. Furthermore, both the clustering in coated pits and the co-precipitation with alpha-adaptin were dramatically reduced in the cold, suggesting that low temperature can interfere with the sorting of proteins into coated pits. In addition to the specific results reported here, the general applicability of the image correlation spectroscopy approach to study any process involving the clustering or oligomerization of membrane receptors at the cell surface is discussed.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT NEUROBIOCHEM, IL-69978 TEL AVIV, ISRAEL; UNIV WESTERN ONTARIO, DEPT CHEM, LONDON, ON N6A 5B7, CANADA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Tel Aviv University; Western University (University of Western Ontario); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Brown, Claire/B-1498-2008	Brown, Claire/0000-0003-1622-663X; Roth, Michael/0000-0002-9056-332X; Henis, Yoav/0000-0002-1408-3877	NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CROW EL, 1960, STATISTICS MANUAL, P60; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EHRENBERG M, 1976, Q REV BIOPHYS, V9, P69, DOI 10.1017/S003358350000216X; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; FIRE E, 1995, J BIOL CHEM, V270, P21075, DOI 10.1074/jbc.270.36.21075; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1993, BIOMEMBRANES PHYSICA, V1, P279; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERSEN NO, 1986, BIOPHYS J, V49, P809, DOI 10.1016/S0006-3495(86)83709-2; PETERSEN NO, 1993, BIOPHYS J, V65, P1135, DOI 10.1016/S0006-3495(93)81173-1; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Schmid SL, 1993, CURR OPIN CELL BIOL, V5, P621, DOI 10.1016/0955-0674(93)90131-9; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Wiseman P., 1995, THESIS U W ONTARIO L; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	73	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29538	29545		10.1074/jbc.272.47.29538	http://dx.doi.org/10.1074/jbc.272.47.29538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368015	hybrid			2022-12-27	WOS:A1997YG64700025
J	Guthrie, CR; Skalhegg, BS; McKnight, GS				Guthrie, CR; Skalhegg, BS; McKnight, GS			Two novel brain-specific splice variants of the murine C beta gene of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; EXPRESSION; MYRISTYLATION; ISOFORMS; CELLS; MUTATIONS; CLONING; FORM	We have previously characterized two murine cAMP-dependent protein kinase catalytic subunit genes, C alpha and C beta 1. Targeted disruption of the C beta 1 promoter revealed two splice variants of the C beta catalytic subunit gene (designated C beta 2 and C beta 3) that continue to be expressed. These variants arise from unique promoters and are brain specific. C beta 2 is expressed in several discrete areas in the limbic system, These include the lateral septum, the bed nucleus of the stria terminalis, the ventral medial hypothalamus, and the amygdala, In the neocortex, expression is highest in cortical areas such as the prefrontal and insular cortex that are associated limbic structures, By contrast, C beta 1 is most highly expressed in the cortex and hippocampus and is also present in all non-neuronal tissues examined, C beta 3 is expressed at very low levels with wide distribution throughout the brain, Both the C beta 2 and C beta 3 variants are enzymatically active and induce gene expression in transient transfections with a cAMP response element-reporter construct, This activity is inhibited by protein kinase A regulatory subunits, the protein kinase inhibitor, and the chemical inhibitor H-89. We also demonstrate that C beta 1 is myristoylated at the amino terminus like the C alpha isoform, but neither C beta 2 nor C beta 3 is myristoylated, The discrete expression of C beta variants in the brain suggests specific functional roles in neuronal signaling.	UNIV WASHINGTON,DEPT PHARMACOL,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07312] Funding Source: Medline; NIGMS NIH HHS [GM32875] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; ANJARD C, 1993, BIOCHEMISTRY-US, V32, P9532, DOI 10.1021/bi00088a003; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHELEY S, 1991, BIOCHEMISTRY-US, V30, P10246, DOI 10.1021/bi00106a024; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; CUMMINGS DE, 1994, MAMM GENOME, V5, P701, DOI 10.1007/BF00426076; FRANKLIN KBJ, 1997, MOUSE BAIN STEREOTAX; GABELLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; LIU FC, 1995, J NEUROSCI, V15, P2367, DOI 10.1523/JNEUROSCI.15-03-02367.1995; MELENDEZ A, 1995, GENETICS, V141, P1507; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; THOMAS J, 1991, J BIOL CHEM, V266, P10906; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	31	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29560	29565		10.1074/jbc.272.47.29560	http://dx.doi.org/10.1074/jbc.272.47.29560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368018	hybrid			2022-12-27	WOS:A1997YG64700028
J	Li, LW; Ernsting, BR; Wishart, MJ; Lohse, DL; Dixon, JE				Li, LW; Ernsting, BR; Wishart, MJ; Lohse, DL; Dixon, JE			A family of putative tumor suppressors is structurally and functionally conserved in humans and yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE	In Saccharomyces cerevisiae the CDC14 gene is essential for cell cycle progression, Strains carrying the cdc14-1(ts) allele enter the cell cycle and arrest at restrictive temperatures, We have identified two human cDNAs encoding proteins which share sequence identity to the yeast CDC14p. The cell cycle arrest in cdc14-1(ts) can be specifically complemented by the human cDNAs suggesting that they are functionally equivalent to the yeast CDC14 gene, Another clone identified in the search for human CDC14-like proteins corresponded to the putative tumor suppressor gene PTEN/MMAC1 (phosphatase and tensin homologue deleted on chromo same 10 or mutated in multiple advanced cancers 1), Analysis of the PTEN/MMAC1 showed that it did not complement the cdc14-1(ts) allele and that it is more closely related to the yeast open reading frame YNL128W. Human CDC14p and PTEN/MMAC1 were expressed as recombinant proteins, and both were shown to have kinetic properties characteristic of dual specific phosphatases, The human CDC14p was localized in the nucleus while PTEN/MMAC1 has been reported to be localized in the cytoplasm, Our results suggest that CDC14 and YNL128W/PTEN/MMAC1 represent two related, but distinct, families of human and yeast phosphatases.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Li, Liwu/0000-0001-8870-5299	NCI NIH HHS [CA09676] Funding Source: Medline; NIGMS NIH HHS [5T32GM08322-07] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATSCHUL SF, 1990, J MOL BIOL, V215, P403; Ernsting BR, 1997, J BIOL CHEM, V272, P9332; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MEYERS, 1997, P NATL ACAD SCI USA, V94, P9052; PALMER RE, 1990, GENETICS, V125, P763; Shirayama M, 1996, MOL GEN GENET, V251, P176; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STONE RL, 1994, J BIOL CHEM, V269, P31323; WAN J, 1992, J BIOL CHEM, V267, P11274; WILAND A, 1997, J BIOL CHEM, V271, P33486	16	137	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29403	29406		10.1074/jbc.272.47.29403	http://dx.doi.org/10.1074/jbc.272.47.29403			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367992	hybrid			2022-12-27	WOS:A1997YG64700002
J	Madsen, CS; Regan, CP; Owens, GK				Madsen, CS; Regan, CP; Owens, GK			Interaction of CArG elements and a GC-rich repressor element in transcriptional regulation of the smooth muscle myosin heavy chain gene in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; LIGATION-MEDIATED PCR; C-FOS; PROMOTER ELEMENTS; ALTERED EXPRESSION; ISOFORM DIVERSITY; PROTEIN-BINDING; DNA; IDENTIFICATION; ATHEROSCLEROSIS	We have previously shown that maximal expression of the rat smooth muscle myosin heavy chain (SM-MHC) gene in cultured rat aortic smooth muscle cells (SMCs) required the presence of a highly conserved domain (nucleotides -1321 and -1095) that contained two positive acting serum response factor (SRF) binding elements (CArG boxes 1 and 2) and a negative-acting GC-rich element that was recognized by Spl (Madsen, C. S., Hershey, J. C., Hautmann, M. B., White, S. L., and Owens, G. K. (1997) J. Biol. Chem, 272, 6332-6340). In this study, to better understand the functional role of these three cis elements, we created a series of SM-MHC reporter-gene constructs in which each element was mutated either alone or in combination with each other and tested them for activity in transient transfection assays using primary cultured rat aortic SMCs. Results demonstrated that the most proximal SRF binding element (CArG-boxl) was active in the absence of CArG-box2, but only upon removal of the GC-rich repressor, In contrast, regardless of sequence context, CArG-box2 was active only when CArG-boxl was present, We further demonstrated using electrophoretic mobility shift assays that Sp1 binding to the GC-rich repressor element did not prevent SRF binding to the adjacent CArG-box2. Thus, unlike other proteins reported to inhibit SRF activity, the repressor activity associated with the GC-rich element does not appear to function through direct inhibition of SRF binding, As a first step toward understanding the importance of these elements in vivo, we performed in vivo footprinting on the intact rat aorta, We demonstrated that both CArG boxes and the GC-rich element were bound by protein within the animal, Additionally, using the rat carotid injury model we showed that Sp1 protein was significantly increased in SMCs located within the myointimal lesion, suggesting that increased expression of this putative repressor factor may contribute to the decreased SM MHC expression within SMCs found in myointimal lesions.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Virginia				Regan, Chris/0000-0002-3201-5878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL038854, T32HL007284] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL07284, P01-HL19242, R01-HL38854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FRID MG, 1993, J VASC RES, V30, P279, DOI 10.1159/000159007; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERRING BP, 1997, AM J PHYSIOL, V41, pC1394; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; Holifield B, 1996, J CLIN INVEST, V97, P814, DOI 10.1172/JCI118481; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KELLEY CA, 1994, CAN J PHYSL PHARM, V72, P12351; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kim SW, 1996, MOL CELL BIOL, V16, P4465; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; KUROO M, 1989, J BIOL CHEM, V264, P18272; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIANO JM, 1993, AM J PATHOL, V142, P715; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SHARROCKS AD, 1995, NUCLEIC ACIDS RES, V23, P2442, DOI 10.1093/nar/23.13.2442; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SUZUKI J, 1995, TRANSPLANT P, V27, P578; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANTANABE M, 1996, CIRC RES, V78, P978; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297	59	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29842	29851		10.1074/jbc.272.47.29842	http://dx.doi.org/10.1074/jbc.272.47.29842			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368057	hybrid			2022-12-27	WOS:A1997YG64700067
J	Balsinde, J; Balboa, MA; Dennis, EA				Balsinde, J; Balboa, MA; Dennis, EA			Antisense inhibition of group VI Ca2+-independent phospholipase A(2) blocks phospholipid fatty acid remodeling in murine P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; BROMOENOL LACTONE; CELLS; TRIACYLGLYCEROL; BIOSYNTHESIS; MOBILIZATION; GENERATION; ENZYMES	A major issue in lipid signaling relates to the role of particular phospholipase A(2) isoforms in mediating receptor-triggered responses, This has been difficult to study because of the lack of isoform specific inhibitors, Based on the use of the Group VI Ca2+-independent phospholipase A(2) (iPLA(2)) inhibitor bromoenol lactone (EEL), we previously suggested a role for the iPLA(2) in mediating phospholipid fatty acid turnover (Balsinde, J,, Bianco, I, D,, Ackermann, E, J,, Conde-Frieboes, K., and Dennis, E, A. (1995) Proc, Natl, Acad, Sci, U, S, A, 92: 8527-8531), We have now further evaluated the role of the iPLA(2) in phospholipid remodeling by using antisense RNA technology, We show herein that inhibition of iPLA(2) expression by a specific antisense oligonucleotide decreases both the steady-state levels of lysophosphatidylcholine and the capacity of the cell to incorporate arachidonic acid into membrane phospholipids. These effects correlate with a decrease in both iPLA(2) activity and protein in the antisense-treated cells. Collectively these data provide further evidence that the iPLA(2) plays a major role in regulating phospholipid fatty acyl turnover in P388D(1) macrophages. In stark contrast, experiments with activated cells confirmed that the iPLA(2) does not play a significant role in receptor-coupled arachidonate mobilization in these cells, as manifested by the lack of an effect of the iPLA(2) antisense oligonucleotide on PAF-stimulated arachidonate release.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298	NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ASMIS R, 1994, ANN NY ACAD SCI, V744, P1, DOI 10.1111/j.1749-6632.1994.tb52718.x; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLANK ML, 1995, BIOCHEM BIOPH RES CO, V210, P1052, DOI 10.1006/bbrc.1995.1763; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHILTON FH, 1987, BIOCHEM BIOPH RES CO, V145, P1126, DOI 10.1016/0006-291X(87)91554-3; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dillon DA, 1997, J BIOL CHEM, V272, P10361; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; KUWAE T, 1990, J BIOL CHEM, V265, P5002; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567	25	186	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29317	29321		10.1074/jbc.272.46.29317	http://dx.doi.org/10.1074/jbc.272.46.29317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361012	Green Published, hybrid			2022-12-27	WOS:A1997YF68400071
J	Baek, SH; Kwak, JY; Lee, SH; Lee, T; Ryu, SH; Uhlinger, DJ; Lambeth, JD				Baek, SH; Kwak, JY; Lee, SH; Lee, T; Ryu, SH; Uhlinger, DJ; Lambeth, JD			Lipase activities of p37, the major envelope protein of vaccinia virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE ACTIVATION; PHOSPHOLIPASE-D; DIACYLGLYCEROL KINASE; MEMBRANE-FUSION; INHIBITION; IDENTIFICATION; POLYPEPTIDE; MECHANISM; VESICLES; SYSTEM	p37, the major protein of the extracellular enveloped form of vaccinia virus, is involved in the biogenesis of the viral double membrane and in egress of virus from the cell, p37 was expressed as a glutathione S-transferase fusion protein and was purified to homogeneity by silver staining using glutathione-agarose, Sephacryl S-200, and DEAE-cellulose chromatography, Incubation of p37 with phosphatidylcholine labeled in the fatty acyl side chains resulted in the production of multiple lipid products that were identified by thin layer chromatography and mass spectrometry as diacylglycerol, free fatty acid, monoacylglycerol, and lysophosphatidylcholine, Lipid-metabolizing activities colocalized with p37-containing fractions throughout the chromatographic steps, p37 also metabolized phosphatidylethanolamine efficiently, but it had less activity toward phosphatidylinositol and little or no activity toward phosphatidylserine, The purified enzyme also metabolized triacylglycerol to diacylglycerol but was inactive toward sn-1,2-diacylglycerol. p37 was also expressed in insect cells as a poly-His fusion protein; cell lysates and partially purified proteins also generated products expected from phospholipase C and A activities, Thus, p37 is a broad specificity lipase with phospholipase C, phospholipase A, and triacylglycerol lipase activities.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Emory University; Pohang University of Science & Technology (POSTECH)	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			Ryu, Sung Ho/0000-0003-0913-3048	NCI NIH HHS [CA46508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; Cao JX, 1997, VIRUS RES, V48, P11, DOI 10.1016/S0168-1702(96)01422-0; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Heller M, 1978, Adv Lipid Res, V16, P267; KARLI UO, 1990, P NATL ACAD SCI USA, V87, P5912, DOI 10.1073/pnas.87.15.5912; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MORORA S, 1995, BIOCHEMISTRY-US, V34, P11062; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; PAYNE L, 1978, J VIROL, V27, P28, DOI 10.1128/JVI.27.1.28-37.1978; PAYNE LG, 1979, J VIROL, V31, P147, DOI 10.1128/JVI.31.1.147-155.1979; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; Ponting CP, 1996, PROTEIN SCI, V5, P914; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SCHMUTZ C, 1995, VIROLOGY, V213, P19, DOI 10.1006/viro.1995.1542; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P3703, DOI 10.1021/bi00435a012; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; ULAETO D, 1995, J GEN VIROL, V76, P103, DOI 10.1099/0022-1317-76-1-103; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WAITE M, 1996, BIOCH LIPIDS LIPOPRO, P211; WALSH JP, 1995, J BIOL CHEM, V270, P28647, DOI 10.1074/jbc.270.48.28647; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P211; [No title captured]	36	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32042	32049		10.1074/jbc.272.51.32042	http://dx.doi.org/10.1074/jbc.272.51.32042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405398	hybrid			2022-12-27	WOS:000071108000017
J	Hiraki, Y; Inoue, H; Iyama, K; Kamizono, A; Ochiai, M; Shukunami, C; Iijima, S; Suzuki, F; Kondo, J				Hiraki, Y; Inoue, H; Iyama, K; Kamizono, A; Ochiai, M; Shukunami, C; Iijima, S; Suzuki, F; Kondo, J			Identification of chondromodulin I as a novel endothelial cell growth inhibitor - Purification and its localization in the avascular zone of epiphysical cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CAROTID-ARTERY; PLATELET FACTOR-IV; VASCULARIZED MESENCHYME; ANGIOGENESIS INHIBITOR; TUBULAR MORPHOGENESIS; TUMOR ANGIOGENESIS; CHONDROCYTES; EXPRESSION; INVITRO; NEOVASCULARIZATION	Cartilage is unique among tissues of mesenchymal origin in that it is resistant to vascular invasion due to an intrinsic angiogenic inhibitor, During endochondral bone formation, however, calcified cartilage formed in the center of the cartilaginous bone rudiment allows vascular invasion, which initiates the replacement of cartilage by bone, The transition of cartilage from the angioresistant to the angiogenic status thus plays a key role in bone formation, However, the molecular basis of this phenotypic transition of cartilage has been obscure, We report here purification of an endothelial cell growth inhibitor from a guanidine extract of bovine epiphyseal cartilage, The N-terminal amino acid sequence indicated that the inhibitor was identical to chondromodulin I (ChM-I), a cartilage-specific growth-modulating factor, Purified ChM-I inhibited DNA synthesis and proliferation of vascular endothelial cells as well as tube morphogenesis in vitro, Expression of ChM-I cDNA in COS7 cells indicated that mature ChM-I molecules were secreted from the cells after post-translational modifications and cleavage from the transmembrane precursor at the predicted processing signal, Recombinant ChM-I stimulated DNA synthesis and proteoglycan synthesis of cultured growth plate chondrocytes, but inhibited tube morphogenesis of endothelial cells, In situ hybridization and immunohistochemical studies indicated that ChM-I is specifically expressed in the avascular zone of cartilage in developing bone, but not present in calcifying cartilage, These results suggest a regulatory role of ChM-I in vascular invasion during endochondral bone formation.	Osaka Univ, Fac Dent, Dept Biochem, Suita, Osaka 565, Japan; Kumamoto Univ, Sch Med, Univ Hosp, Dept Surg Pathol, Kumamoto 860, Japan; Mitsubishi Chem Corp, Res Ctr, Yokohama, Kanagawa 227, Japan	Osaka University; Kumamoto University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Hiraki, Y (corresponding author), Osaka Univ, Fac Dent, Dept Biochem, 1-8 Yamadaoka, Suita, Osaka 565, Japan.		Ochiai, Masanori/A-4372-2012; Shukunami, Chisa/G-2887-2019	Ochiai, Masanori/0000-0002-0022-347X; Shukunami, Chisa/0000-0001-5616-6761				ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BROWN RA, 1987, BONE MINER, V3, P143; BROWN RA, 1992, BONE MINER, V17, P49, DOI 10.1016/0169-6009(92)90709-M; DIMUZIO MT, 1987, J RHEUMATOL, V14, P45; EISENSTEIN R, 1973, AM J PATHOL, V73, P765; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GELB DE, 1990, ENDOCRINOLOGY, V127, P1941, DOI 10.1210/endo-127-4-1941; GOETZ IE, 1985, IN VITRO CELL DEV B, V21, P172, DOI 10.1007/BF02621355; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HAGIWARA H, 1984, THROMB RES, V33, P363, DOI 10.1016/0049-3848(84)90075-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1996, J BIOL CHEM, V271, P22657, DOI 10.1074/jbc.271.37.22657; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; KANAYASU T, 1989, BIOCHEM BIOPH RES CO, V159, P572, DOI 10.1016/0006-291X(89)90032-6; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; KUETTNER KE, 1976, BIOCHEM BIOPH RES CO, V72, P40, DOI 10.1016/0006-291X(76)90957-8; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NEAME PJ, 1990, J BIOL CHEM, V265, P9628; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; SCHENK RK, 1968, ACTA ANAT, V69, P1; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SORGENTE N, 1975, LAB INVEST, V32, P217; SUZUKI F, 1987, METHOD ENZYMOL, V146, P313; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKIGAWA M, 1985, CELL BIOL INT REP, V9, P619, DOI 10.1016/0309-1651(85)90054-2; TAKIGAWA M, 1988, J BONE MINER METAB, V6, P83; TWAL WO, 1994, J BONE MINER RES, V9, P1737; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	46	160	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32419	32426		10.1074/jbc.272.51.32419	http://dx.doi.org/10.1074/jbc.272.51.32419			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405451	hybrid			2022-12-27	WOS:000071108000070
J	Jiang, DY; Hatahet, Z; Melamede, RJ; Kow, YW; Wallace, SS				Jiang, DY; Hatahet, Z; Melamede, RJ; Kow, YW; Wallace, SS			Characterization of Escherichia coli endonuclease VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; APURINIC APYRIMIDINIC SITES; FPG PROTEIN; SUBSTRATE-SPECIFICITY; BASE-EXCISION; DAMAGED DNA; SACCHAROMYCES-CEREVISIAE; G.C->T.A TRANSVERSIONS; IONIZING-RADIATION	Escherichia coli endonuclease VIII (endo VIII) was identified as an enzyme that, like endonuclease III (endo III), removes radiolysis products of thymine including thymine glycol, dihydrothymine, beta-ureidoisobutyric acid, and urea from double-stranded plasmid or phage DNA and cleaves the DNA strand at abasic (AP) sites (Melamede, R. J., Hatahet, Z., Kow, Y. W., Ide., H., and Wallace, S. S. (1994) Biochemistry 33, 1255-1264). Using apparently homogeneous endo Vm protein, we now show that endo MI removes from double-stranded oligodeoxyribonucleotides the stable oxidative products of cytosine, 5-hydroxycytosine and 5-hydroxyuracil. Endo VIII cleaved the damage-containing DNA strand by beta,delta-elimination as does formamidopyrimidine DNA glycosylase (Fpg). Like Fpg, endo VIII also excised the 5'-terminal deoxyribose phosphate from an endonuclease IV (endo TV) pre-incised AP site. Thus, in addition to amino acid sequence homology (Jiang, D., Hatahet, Z., Blaisdell, J., Melamede, R. J., and Wallace, S. S. (1997) J. Bacteriol 179, 3773-3782), endo VIII shares a number of catalytic properties with Fpg. In addition, endo WI specifically bound to oligodeoxynucleotides containing a reduced AP site with a stoichiometry of 1:1 for protein to DNA with an apparent equilibrium dissociation constant of 3.9 nM. Like Fpg and endo III, the DNase I footprint was small with contact sites primarily on the damage-containing strand; unlike Fpg and endo III, the DNA binding of endo VIII to DNA was asymmetric, 3' to the reduced AP site.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Stafford Hall, Burlington, VT 05405 USA.	swallace@zoo.uvm.edu		Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [R37CA033657] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOORSTEIN RJ, 1989, BIOCHEMISTRY-US, V28, P6164, DOI 10.1021/bi00441a007; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; Cadenas E., 1995, OXIDATIVE STRESS ANT, P1, DOI 10.1007/978-1- 4615-9689-9_1; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; EVANS J, 1993, MUTAT RES, V175, P41; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; GATES FT, 1977, J BIOL CHEM, V252, P2802; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HATAHET Z, 1993, NUCLEIC ACIDS RES, V21, P1563, DOI 10.1093/nar/21.7.1563; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MOSBAUGH DW, 1982, J BIOL CHEM, V257, P575; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3723; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NOLLING J, 1992, NUCLEIC ACIDS RES, V24, P6501; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; RADMAN M, 1976, J BIOL CHEM, V251, P1438; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STRNISTE GF, 1975, P NATL ACAD SCI USA, V72, P1997, DOI 10.1073/pnas.72.6.1997; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VERLY WG, 1974, P NATL ACAD SCI USA, V71, P2273, DOI 10.1073/pnas.71.6.2273; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; WEISS B, 1981, ENZYMES, P203; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	66	138	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32230	32239		10.1074/jbc.272.51.32230	http://dx.doi.org/10.1074/jbc.272.51.32230			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405426	hybrid			2022-12-27	WOS:000071108000045
J	JahnenDechent, W; Schinke, T; Trindl, A; MullerEsterl, W; Sablitzky, F; Kaiser, S; Blessing, M				JahnenDechent, W; Schinke, T; Trindl, A; MullerEsterl, W; Sablitzky, F; Kaiser, S; Blessing, M			Cloning and targeted deletion of the mouse fetuin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; GROWTH-FACTOR-BETA; INSULIN-RECEPTOR; HUMAN ALPHA-2-HS-GLYCOPROTEIN; ALPHA(2)-MACROGLOBULIN GENE; ALPHA-MACROGLOBULINS; RAT FETUIN; STEM-CELLS; INHIBITOR; MICE	We proposed that the alpha(2)-Heremans Schmid glycoprotein/fetuin family of serum proteins inhibits unwanted mineralization. To test this hypothesis in animals, we cloned the mouse fetuin gene and generated mice lacking fetuin. The gene consists of seven exons and six introns. The cystatin-like domains D1 and D2 of mouse fetuin are encoded by three exons each, whereas a single terminal exon encodes the carboxyl-terminal domain D3. The promoter structure is well conserved between rat and mouse fetuin genes within the regions shown to bind transcription factors in the rat system. Expression studies demonstrated that mice homozygous for the gene deletion lacked fetuin protein and that mice heterozygous for the null mutation produced roughly half the amount of fetuin protein produced by wild-type mice. Fetuin-deficient mice were fertile and showed no gross anatomical abnormalities. However, the serum inhibition of apatite formation was compromised in these mice as well as in heterozygotes. In addition, some homozygous fetuin-deficient female ex-breeders developed ectopic microcalcifications in soft tissues. These results corroborate a role for fetuin in serum calcium homeostasis. The fact that generalized ectopic calcification did not occur in fetuin-deficient mice proves that additional inhibitors of phase separation exist in serum.	BOEHRINGER INGELHEIM FORSCHERGRP, SFB 311, D-55101 MAINZ, GERMANY; UCL, SCH MED, DEPT MED, LONDON W1P 8BT, ENGLAND	Boehringer Ingelheim; University of London; University College London; UCL Medical School	JahnenDechent, W (corresponding author), UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, D-55099 MAINZ, GERMANY.		Sablitzky, Fred/A-2276-2011; Jahnen-Dechent, Willi/A-7608-2011	Sablitzky, Fred/0000-0001-9718-1546; Jahnen-Dechent, Willi/0000-0003-1315-4407				AKHOUNDI C, 1994, J BIOL CHEM, V269, P15925; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; BLUMENTHAL NC, 1975, CALC TISS RES, V18, P81, DOI 10.1007/BF02546228; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dziegielewska K., 1995, MOL BIOL INTELLIGENC; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FALQUERHO L, 1991, GENE, V98, P209, DOI 10.1016/0378-1119(91)90175-B; FALQUERHO L, 1992, NUCLEIC ACIDS RES, V20, P1983, DOI 10.1093/nar/20.8.1983; GARNETT J, 1990, BIOCHEM J, V266, P863; HAYASE T, 1992, BIOCHEMISTRY-US, V31, P4915, DOI 10.1021/bi00135a024; HEERZE LD, 1992, J BIOL CHEM, V267, P25810; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOGAN BL, 1995, MANIPULATING MOUSE E; JAHNENDECHENT W, 1994, EUR J BIOCHEM, V226, P59, DOI 10.1111/j.1432-1033.1994.tb20026.x; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P502; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KOIDE T, 1988, THROMB RES, P91; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KUMBLA L, 1991, FASEB J, V5, P2971, DOI 10.1096/fasebj.5.14.1721594; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECAM A, 1992, CELL, V68, P8, DOI 10.1016/0092-8674(92)90201-M; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKAY PAZ, 1996, MOL CELL BIOL, V16, P4024; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; Nawratil P, 1996, J BIOL CHEM, V271, P31735, DOI 10.1074/jbc.271.49.31735; Neuman W. F., 1980, FUNDAMENTAL CLIN BON, P83; Ohnishi T, 1997, EUR J BIOCHEM, V243, P753, DOI 10.1111/j.1432-1033.1997.00753.x; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; RAUTH G, 1992, EUR J BIOCHEM, V204, P523, DOI 10.1111/j.1432-1033.1992.tb16663.x; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAUNDERS NR, 1994, HISTOCHEMISTRY, V102, P457, DOI 10.1007/BF00269578; Schinke T, 1997, FEBS LETT, V412, P559, DOI 10.1016/S0014-5793(97)00827-2; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SCHULTZE HE, 1962, NATURWISSENSCHAFTEN, V49, P15, DOI 10.1007/BF00632835; SELBY PB, 1987, STAIN TECHNOL, V62, P143, DOI 10.3109/10520298709107984; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SRINIVAS PR, 1993, MOL ENDOCRINOL, V7, P1445, DOI 10.1210/me.7.11.1445; SULLENBARGER BA, 1995, BLOOD, V86, P135, DOI 10.1182/blood.V86.1.135.bloodjournal861135; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; Webb DJ, 1996, J BIOL CHEM, V271, P24982, DOI 10.1074/jbc.271.40.24982; WESTWOOD SA, 1988, ELECTROPHORESIS, V9, P432, DOI 10.1002/elps.1150090816; YAMAMOTO K, 1993, J BIOL CHEM, V268, P17750; YANG FM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P149, DOI 10.1016/0167-4781(92)90522-2	54	211	224	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31496	31503		10.1074/jbc.272.50.31496	http://dx.doi.org/10.1074/jbc.272.50.31496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395485	hybrid			2022-12-27	WOS:A1997YL41900044
J	Klinge, CM; Silver, BF; Driscoll, MD; Sathya, G; Bambara, RA; Hilf, R				Klinge, CM; Silver, BF; Driscoll, MD; Sathya, G; Bambara, RA; Hilf, R			Chicken ovalbumin upstream promoter transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; MONOCLONAL-ANTIBODIES; NUCLEAR RECEPTORS; COUP-TF; POLYCLONAL ANTIBODIES; HORMONE RECEPTORS; ORPHAN RECEPTORS; DNA; PURIFICATION; SUPERFAMILY	Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) was identified as a low abundance protein in bovine uterus that co-purified with estrogen receptor (ER) in a ligand-independent manner and was separated from the ER by its lower retention on estrogen response element (ERE)-Sepharose. In gel mobility shift assays, COUP-TF bound as an apparent dimer to ERE and ERE half-sites. COUP-TF bound to an ERE half-site with high affinity, K-d = 1.24 nM. In contrast, ER did not bind a single ERE half-site. None of the class II nuclear receptors analyzed, i.e. retinoic acid receptor, retinoid X receptor, thyroid receptor, peroxisome proliferator-activated receptor, or vitamin D receptor, were constituents of the COUP-TF.DNA binding complex detected in gel mobility shift assays. Direct interaction of COUP-TF with ER was indicated by GST ''pull-down'' and co-immunoprecipitation assays. The nature of the ER ligand influenced COUP-TF-ERE half-site binding. When ER was liganded by the antiestrogen 4-hydroxytamoxifen (4-OHT), COUP-TF-half-site interaction decreased. Conversely, COUP-TF transcribed and translated in vitro enhanced the ERE binding of purified estradiol (E-2)-liganded ER but not 4-OHT-liganded ER. Co-transfection of ER-expressing MCF-7 human breast cancer cells with an expression vector for COUP-TFI resulted in a dose-dependent inhibition of E-2-induced expression of a luciferase reporter gene under the control of three tandem copies of EREc38. The ability of COUP-TF to bind specifically to EREs and half-sites, to interact with ER, and to inhibit E-2-induced gene expression suggests COUP-TF regulates ER action by both direct DNA binding competition and through protein-protein interactions.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	Klinge, CM (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM & MOL BIOL,LOUISVILLE,KY 40292, USA.			Klinge, Carolyn/0000-0002-3358-4378	NICHD NIH HHS [HD24459] Funding Source: Medline; NIEHS NIH HHS [1P20 ES06832-12] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P20ES006832] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; Anolik JH, 1996, J STEROID BIOCHEM, V59, P413, DOI 10.1016/S0960-0760(96)00129-X; ANOLIK JH, 1995, BIOCHEMISTRY-US, V34, P2511, DOI 10.1021/bi00008a015; ANOLIK JH, 1993, J STEROID BIOCHEM, V46, P713, DOI 10.1016/0960-0760(93)90312-K; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Driscoll MD, 1996, J STEROID BIOCHEM, V58, P45, DOI 10.1016/0960-0760(96)00015-5; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FENG JQ, 1995, J BIOL CHEM, V270, P28364, DOI 10.1074/jbc.270.47.28364; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Graumann K, 1996, J STEROID BIOCHEM, V57, P293, DOI 10.1016/0960-0760(95)00274-X; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HERSCROFT NJ, 1997, BIOTECHNIQUES, V22, P224; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOOPES BC, 1992, J BIOL CHEM, V267, P11589; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKEDA M, 1994, BIOCHEM MOL BIOL INT, V33, P447; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, MOL CELL BIOL, V15, P5858; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Klinge CM, 1997, NUCLEIC ACIDS RES, V25, P1903, DOI 10.1093/nar/25.10.1903; KLINGE CM, 1992, J STEROID BIOCHEM, V43, P249, DOI 10.1016/0960-0760(92)90159-G; Klinge CM, 1996, J STEROID BIOCHEM, V57, P51, DOI 10.1016/0960-0760(95)00246-4; Klinge CM, 1996, STEROIDS, V61, P278, DOI 10.1016/0039-128X(95)00219-G; KLINGE CM, 1992, CANCER RES, V52, P1073; KLINGE CM, 1987, CANCER RES, V47, P2852; KLINGE CM, 1992, ONCOL RES, V4, P1073; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lin BC, 1997, J BIOL CHEM, V272, P9860; LUDWIG LB, 1990, MOL ENDOCRINOL, V4, P1027, DOI 10.1210/mend-4-7-1027; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; ONATE SA, 1995, SCIENCE, V270, P1354; PAVLIK EJ, 1976, J STEROID BIOCHEM, V7, P357, DOI 10.1016/0022-4731(76)90095-9; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; PEALE FV, 1989, BIOCHEMISTRY-US, V28, P8671, DOI 10.1021/bi00448a001; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; Sambrook J., 2002, MOL CLONING LAB MANU; SAUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAISH A, 1989, ENDOCRINOLOGY, V125, P172, DOI 10.1210/endo-125-1-172; TRAISH AM, 1990, STEROIDS, V55, P551, DOI 10.1016/0039-128X(90)90051-C; TRAISH AM, 1990, STEROIDS, V55, P196, DOI 10.1016/0039-128X(90)90017-6; TRAISH AM, 1995, STEROIDS, V60, P467, DOI 10.1016/0039-128X(95)00061-T; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; YANG N, 1996, J BIOL CHEM, V271, P5796	71	96	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31465	31474		10.1074/jbc.272.50.31465	http://dx.doi.org/10.1074/jbc.272.50.31465			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395481	hybrid			2022-12-27	WOS:A1997YL41900040
J	Racine-Samson, L; Rockey, DC; Bissell, DM				Racine-Samson, L; Rockey, DC; Bissell, DM			The role of alpha 1 beta 1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; COLLAGEN MATRIX REORGANIZATION; SINUSOIDAL ENDOTHELIAL-CELLS; HUMAN SMOOTH-MUSCLE; RAT-LIVER; MURINE DEVELOPMENT; GENE-EXPRESSION; IN-VITRO; FIBROSIS; LIPOCYTES	An unresolved question in wound contraction concerns the identity of integrins mediating the attachment of tissue myofibroblasts to matrix in the injury site. Previous studies with cell lines have focussed on alpha 1 beta 1 and alpha 2 beta 1, the principal collagen-binding integrins, but have yielded conflicting data. We have examined this issue in wound healing in the liver, isolating the myofibroblast population (activated stellate cells) and quantitating expression of the alpha 1 and alpha 2 integrin subunits during the in vivo injury. Normal stellate cells displayed alpha 1 but no detectable alpha 2. During injury, alpha 1 expression was maintained; alpha 2 became detectable at the mRNA level but at all times was <8% of alpha 1 mRNA. Contraction of collagen lattices, studied with 24-h cultured cells and initiated by endothelin 1, was blocked 70% by anti-alpha 1 and 30% by anti-alpha 2 (both significant, p < 0.05). The inhibition by anti-alpha 2, which was unexpected, was attributable to culture-induced change in integrin expression; both the mRNA and protein for alpha 2 increased strikingly within 24 h of plating stellate cells on a collagen gel. We conclude that alpha 1 beta 1 is the sole integrin utilized by contracting myofibroblasts in vivo. Although alpha 2 beta 1 is capable of mediating contraction, its expression by myofibroblasts occurs largely, if not exclusively, in response to culture.	Univ Calif San Francisco, Dept Med, Gastrointestinal Unit, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Liver Ctr Lab, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Bissell, DM (corresponding author), Univ Calif San Francisco, Dept Med, Gastrointestinal Unit, Box 0538, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031198, R37DK031198, P30DK026743, R01DK050574] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31198, DK 50574, DK 26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAKOKKO L, 1987, BIOCHEM J, V244, P75, DOI 10.1042/bj2440075; BALLARDINI G, 1988, VIRCHOWS ARCH B, V56, P45, DOI 10.1007/BF02890000; BELKIN VM, 1990, J CELL BIOL, V111, P2159, DOI 10.1083/jcb.111.5.2159; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Carloni V, 1996, GASTROENTEROLOGY, V110, P1127, DOI 10.1053/gast.1996.v110.pm8613002; CARVER W, 1995, J CELL PHYSIOL, V165, P425, DOI 10.1002/jcp.1041650224; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COUVELARD A, 1993, AM J PATHOL, V143, P738; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P1233; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; INGHAM KC, 1989, J BIOL CHEM, V264, P16977; IRLE C, 1980, J SUBMICR CYTOL PATH, V12, P209; IRVING MG, 1984, GASTROENTEROLOGY, V87, P1233; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KOUNTOURAS J, 1984, BRIT J EXP PATHOL, V65, P305; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MENDRICK DL, 1995, LAB INVEST, V72, P367; MENDRICK DL, 1993, LAB INVEST, V69, P690; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rockey DC, 1996, HEPATOLOGY, V24, P233; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; TURNER DC, 1989, J NEUROSCI, V9, P3287; VOLPES R, 1993, AM J PATHOL, V142, P1483; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624; ZUTTER MM, 1990, AM J PATHOL, V137, P113	44	141	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30911	30917		10.1074/jbc.272.49.30911	http://dx.doi.org/10.1074/jbc.272.49.30911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388237	hybrid			2022-12-27	WOS:000071640800050
J	Sagawa, K; Kimura, T; Swieter, M; Siraganian, RP				Sagawa, K; Kimura, T; Swieter, M; Siraganian, RP			The protein-tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule PECAM-1 (CD31)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; GROWTH-FACTOR RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; FC-GAMMA-RIIB; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; SH2 DOMAINS; MONOCLONAL-ANTIBODIES; MAST-CELL; IN-VIVO	Aggregation of many cell-surface receptors results in tyrosine phosphorylation of numerous proteins. We previously observed the tyrosine phosphorylation of the platelet/endothelial cell adhesion molecule, PECAM-1 (CD31), after Fc epsilon RI stimulation in rat basophilic leukemia RBL-2H3 cells. Here we found that PECAM-1 was also transiently tyrosine-phosphoryated after adherence of these cells to fibronectin, Similarly aggregation of the T cell receptor on Jurkat cells also induced this tyrosine phosphorylation, The protein-tyrosine phosphatase SHP-2 is a widely expressed cytosolic enzyme with two Src homology 2 (SH2) domains. SHP-2, but not the related protein-tyrosine phosphatase SHP-1, associated with PECAM-1. This association of the two proteins correlated with the extent of the tyrosine phosphorylation of PECAM-1. A fusion protein containing the two SH2 domains of SHP-2 precipitated PECAM-1 from cell lysates and also directly bound to phosphorylated PECAM-1, In immune precipitate phosphatase assays, there was tyrosine dephosphorylation of PECAM-1, Therefore, integrin and immune receptor activation results in tyrosine phosphorylation of PECAM-1 and the binding of the protein-tyrosine phosphatase SHP-2, which could regulate receptor-mediated signaling in cells.	NIDR, Receptors & Signal Transduct Sect, OIIB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Siraganian, RP (corresponding author), NIDR, Receptors & Signal Transduct Sect, OIIB, NIH, Bldg 10,Rm 1N106, Bethesda, MD 20892 USA.	rs53x@nih.gov						Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERMAN ME, 1995, J IMMUNOL, V154, P299; Berman ME, 1996, J IMMUNOL, V156, P1515; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DEFRANCO AL, 1995, SCIENCE, V268, P263, DOI 10.1126/science.7716518; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; KIMURA T, 1997, IN PRESS J IMMUNOL, V159; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MULLER WA, 1995, J LEUKOCYTE BIOL, V57, P523, DOI 10.1002/jlb.57.4.523; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; SKUBITZ KM, 1994, J IMMUNOL, V152, P5902; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SWIETER M, 1995, J IMMUNOL, V155, P5330; TAN XH, 1993, J BIOL CHEM, V268, P6835; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	66	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31086	31091		10.1074/jbc.272.49.31086	http://dx.doi.org/10.1074/jbc.272.49.31086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388260	hybrid			2022-12-27	WOS:000071640800073
J	Bi, S; Gavrilova, O; Gong, DW; Mason, MM; Reitman, M				Bi, S; Gavrilova, O; Gong, DW; Mason, MM; Reitman, M			Identification of a placental enhancer for the human leptin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE OBESE GENE; BINDING PROTEIN-ALPHA; OB GENE; TRANSCRIPTION FACTOR; PROMOTER ACTIVITY; HUMAN CHORIOCARCINOMA; ADIPOSE-CELLS; GROWTH-FACTOR; SUBUNIT GENE; FOOD-INTAKE	Leptin is a hormone that regulates metabolic efficiency, energy expenditure, and food intake. Leptin is produced chiefly in adipose cells, but in humans, mRNA encoding leptin is also present in the placenta. Here we elucidate the basis for placental leptin production. The same promoter is used for adipose and placental transcription. An upstream enhancer functions in the JEG-3 and JAR choriocarcinoma cell lines but not in adipocytes or HeLa cells. The minimal positive acting region is 60 base pairs in length. This region is within a MER11 repetitive element, suggesting that human placental expression of leptin is the result of insertion of this element. Binding analyses demonstrated three protein binding sites, designated placental leptin enhancer elements (PLE)1, PLE2, and PLE3. PLE2 binds Sp1. Enhancer activity was reduced by mutation of the PLE1 or PLE3 sites but was unaffected by alteration of PLE2. Proteins binding to PLE3 were present in JEG-3 and human placental nuclear extracts but not in extracts from non-placental sources. Upon triplication, the PLE3 element was a strong enhancer in choriocarcinoma cells but not in HeLa cells. The protein binding to the PLE3 motif appears to be a novel, placenta-specific transcription factor.	NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Reitman, Marc/B-4448-2013; Gong, Dawei/AAB-4283-2020	Reitman, Marc/0000-0002-0426-9475; bi, sheng/0000-0002-2441-0528				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAMBERGER AM, 1995, J CLIN ENDOCR METAB, V80, P2021, DOI 10.1210/jc.80.7.2021; Butte NF, 1997, J CLIN ENDOCR METAB, V82, P585, DOI 10.1210/jc.82.2.585; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; CHEN HW, 1995, DNA CELL BIOL, V14, P681, DOI 10.1089/dna.1995.14.681; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Gong DW, 1996, J BIOL CHEM, V271, P3971; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Heckert LL, 1996, J BIOL CHEM, V271, P31650, DOI 10.1074/jbc.271.49.31650; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Lee BJ, 1996, MOL CELL ENDOCRINOL, V118, P9, DOI 10.1016/0303-7207(95)03758-6; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Mounzih K, 1997, ENDOCRINOLOGY, V138, P1190, DOI 10.1210/en.138.3.1190; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; NG YK, 1994, DEVELOPMENT, V120, P3257; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Scatena CD, 1996, ENDOCRINOLOGY, V137, P3000, DOI 10.1210/en.137.7.3000; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; SMITHBERG M., 1957, JOUR HEREDITY, V48, P97; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; Stephanou A, 1996, J MOL ENDOCRINOL, V16, P221, DOI 10.1677/jme.0.0160221; TODA K, 1995, J STEROID BIOCHEM, V53, P181, DOI 10.1016/0960-0760(95)00032-U; Trayhurn P, 1996, BIOCHEM BIOPH RES CO, V228, P605, DOI 10.1006/bbrc.1996.1704; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WADA N, 1993, J BIOL CHEM, V268, P14003; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	151	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30583	30588		10.1074/jbc.272.48.30583	http://dx.doi.org/10.1074/jbc.272.48.30583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374555	hybrid			2022-12-27	WOS:A1997YH61300087
J	Lai, MT; DiCera, E; Shafer, JA				Lai, MT; DiCera, E; Shafer, JA			Kinetic pathway for the slow to fast transition of thrombin - Evidence of linked ligand binding at structurally distinct domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; PROCOAGULANT; FIBRINOGEN; INHIBITION; ENZYME	The kinetic pathway for the Na+ -induced slow --> fast transition of thrombin was characterized, The slow form was shown to consist of two conformers in a 3:1 ratio (E-s2:E-s1) at 5 degrees C, pH 7.4, Gamma/2 0.3.E-s2 binds Na+ 3 orders of magnitude faster than does E-s1. The small molecule active site-directed inhibitor L-371,912, and the exosite I binding ligand hirugen, like Na+, bind selectively to E-s2 and induce the slow --> fast conversion of thrombin. The slow --> fast transition is limited by the rate of conversion of E-s1 to E-s2 (k similar to 28 s(-1) at 5 degrees C), Replacement of Arg-221a or Lys-224 at the Na+ binding site with Ala appears to selectively alter the slow form and reduce the apparent affinity of the mutants for Na+ and L-371,912, This replacement, however, has little effect on the affinity for the inhibitor in the presence of saturating concentrations of Na+, The kinetically linked ligand binding at the Na+ binding site, exosite I, and the active site of thrombin characterized in the present study indicates the basis for the plasticity of this important enzyme, and suggests the possibility that the substrate specificity and, therefore, the procoagulant and anticoagulant activities of thrombin may be subject to allosteric regulation by as yet unidentified physiologically important effecters.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	Lai, MT (corresponding author), MERCK RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FERSHT A, 1984, ENZYME STRUCTURE MEC, P121; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; LEWIS SD, 1993, THROMB RES, V70, P173, DOI 10.1016/0049-3848(93)90158-K; LEWIS SD, 1995, THROMB HAEMOSTASIS, V74, P1107; LUNDBLAD RL, 1985, THROMB RES, V37, P53, DOI 10.1016/0049-3848(85)90032-5; Lyle TA, 1997, BIOORG MED CHEM LETT, V7, P67, DOI 10.1016/S0960-894X(96)00583-5; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SUZUKI K, 1983, J BIOCHEM-TOKYO, V96, P455; VILLANUEVA GB, 1983, THROMB RES, V29, P489, DOI 10.1016/0049-3848(83)90344-4; WALKER FJ, 1984, SEMIN THROMB HEMOST, V10, P131, DOI 10.1055/s-2007-1004415; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; ZHANG E, 1997, BIOPHYS CHEM, V63, P18	24	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30275	30282		10.1074/jbc.272.48.30275	http://dx.doi.org/10.1074/jbc.272.48.30275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374513	hybrid			2022-12-27	WOS:A1997YH61300045
J	Yanai, K; Saito, T; Hirota, K; Kobayashi, H; Murakami, K; Fukamizu, A				Yanai, K; Saito, T; Hirota, K; Kobayashi, H; Murakami, K; Fukamizu, A			Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; BLOOD-PRESSURE REGULATION; FACTOR USF; HUMAN HYPERTENSION; MULTIPLE FORMS; GENE; IDENTIFICATION; REGION; RENIN; EXPRESSION	Recent genetic studies indicate that several molecular variants discovered in angiotensinogen (AG), the precursor of vasoactive octapeptide angiotensin II, could potentially be responsible for inherited predisposition to human blood pressure variation, We have previously shown that a ubiquitously expressed nuclear factor, AGCF1, bound to AGCE1 (AG core promoter element 1 including the core nucleotides, CTCGTG, CTC-type) located between the TATA box and transcription initiation site (positions -25 to -1) is an authentic regulator of human AG transcription, In the present study, we showed that AGCF1 has biologically and immunologically similar properties to those of a helix-loop-helix nuclear factor USF1 and examined the effects of two other naturally occurring molecular variants (ATCGTG, ATC-type and ATTGTG, ATT-type) found in the AGCE1 position on the human AG transcriptional activity, Competitive gel-shift and transfection experiments demonstrated that the transcriptional activity for the CTC- and ATC-type promoters was 2.5 times higher than that for the ATT-type through the alteration of AGCF1-binding affinity, These results suggest the possible involvement of USF1 as a component in AGCF1 formation and the potential importance of AGCE1 variation in blood pressure regulation through human AG expression.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,MOL FUNCT LAB,TSUKUBA,IBARAKI 305,JAPAN; NATL FOOD RES INST,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan			fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				ARGRIMSSON R, 1993, NAT GENET, V4, P114; CARTHEW RW, 1987, GENE DEV, V1, P978; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doria A, 1996, HYPERTENSION, V27, P1134, DOI 10.1161/01.HYP.27.5.1134; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FASOLA AF, 1968, J APPL PHYSIOL, V25, P410, DOI 10.1152/jappl.1968.25.4.410; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1995, TRENDS ENDOCRIN MET, V6, P279, DOI 10.1016/1043-2760(95)00156-5; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HYDER SM, 1992, J BIOL CHEM, V267, P18047; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KAMITANI A, 1995, HYPERTENSION, V25, P950, DOI 10.1161/01.HYP.25.5.950; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4458; LIFTON RP, 1995, P NATL ACAD SCI USA, V92, P8545, DOI 10.1073/pnas.92.19.8545; LYNCH KR, 1991, HYPERTENSION, V17, P263, DOI 10.1161/01.HYP.17.3.263; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Sato N, 1997, HYPERTENSION, V30, P321, DOI 10.1161/01.HYP.30.3.321; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; TAMURA K, 1992, JPN HEART J, V33, P113; WALKER WG, 1979, HYPERTENSION, V1, P473; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981	44	49	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30558	30562		10.1074/jbc.272.48.30558	http://dx.doi.org/10.1074/jbc.272.48.30558			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374551	hybrid			2022-12-27	WOS:A1997YH61300083
J	Bourgeois, L; BrillardBourdet, M; Deperthes, D; Juliano, MA; Juliano, L; Tremblay, RR; Dube, JY; Gauthier, F				Bourgeois, L; BrillardBourdet, M; Deperthes, D; Juliano, MA; Juliano, L; Tremblay, RR; Dube, JY; Gauthier, F			Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN GLANDULAR KALLIKREIN; PROTEIN-C INHIBITOR; RAT-SUBMAXILLARY-GLAND; SUICIDE SUBSTRATE; SEMINAL PLASMA; HUMAN SEMEN; PURIFICATION; EXPRESSION; SITE	The third human tissue kallikrein to be identified, hK2, could be an alternate or complementary marker to kallikrein hK3 (prostate-specific antigen) for prostate diseases, Most of the hK2 in seminal plasma forms an inactive complex with protein C inhibitor (PCI), a serpin secreted by seminal vesicles, As serpin inhibitors behave as suicide substrates that are cleaved early in the interaction with their target enzyme, and kallikreins have different sensitivities to serpin inhibitors, we prepared a series of substrates with intramolecularly quenched fluorescence based on the sequences of the serpin reactive loops, They were used to compare the substrate specificities of hK1 and hK2, which both have trypsin-like specificity, and thus differ from chymotrypsin-like hK3, The serpin-derived peptides behaved as kallikrein substrates whose sensitivities reflected the specificity of the parent inhibitory proteins, Substrates derived from PCI were the most sensitive for both hK1 and hK2 with specificity constants of about 10(7) M-1.s(-1). Those derived from antithrombin III and alpha(2)-antiplasmin were more specific for hK2 while a kallistatin-derived substrate was specifically cleaved by hK1, hK1 and hK2 substrates of greater specificity were obtained using chimeric peptides based on the sequence of serpin reactive loops, The main difference between specificities of hK1 and hK2 arise because hK2 can accommodate positively charged as well as small residues at P-2 and requires an arginyl residue at P-1, Thus, unlike hK1, hK2 does not cleave kininogen derived substrates overlapping the region of N-terminal insertion of bradykinin in human kininogens.	UNIV TOURS, ENZYMOL & PROT CHEM LAB, CNRS, EP 117, F-37032 TOURS, FRANCE; CHUL, RES CTR, HORMONAL BIOREGULAT LAB, Ste Foy, PQ, CANADA; UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT BIOPHYS, SAO PAULO, BRAZIL	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Laval University; Universidade Federal de Sao Paulo (UNIFESP)			Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822				Alves LC, 1996, PEPTIDE RES, V9, P92; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BRIDON DP, 1995, UROLOGY, V45, P801, DOI 10.1016/S0090-4295(99)80087-9; BRILLARDBOURDET M, 1995, BBA-PROTEIN STRUCT M, V1246, P47, DOI 10.1016/0167-4838(94)00179-K; Catalona WJ, 1996, PROSTATE, P64; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432-1033.1994.tb18597.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; Deperthes D, 1996, J ANDROL, V17, P659; Deperthes D, 1995, BBA-GEN SUBJECTS, V1245, P311, DOI 10.1016/0304-4165(95)00118-2; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; ESPANA F, 1995, EUR J BIOCHEM, V234, P641, DOI 10.1111/j.1432-1033.1995.641_b.x; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; Frenette G, 1997, BBA-GEN SUBJECTS, V1334, P109, DOI 10.1016/S0304-4165(96)00080-3; GEIGER R, 1981, METHOD ENZYMOL, V80, P466; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IRIE A, 1986, BIOCHEM INT, V13, P375; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Komiyama T, 1996, PROTEIN SCI, V5, P874; Kumar A, 1996, CANCER RES, V56, P5397; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LILJA H, 1992, CANCER, V70, P230, DOI 10.1002/1097-0142(19920701)70:1+<230::AID-CNCR2820701310>3.0.CO;2-Y; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MOREAU T, 1992, J BIOL CHEM, V267, P10045; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PIMENTA DC, 1997, IN PRESS BIOCH J; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; SAEDI MS, 1995, MOL CELL ENDOCRINOL, V109, P237, DOI 10.1016/0303-7207(95)03508-5; SHORI DK, 1992, BIOCHEM PHARMACOL, V43, P1209, DOI 10.1016/0006-2952(92)90494-4; Tremblay RR, 1997, AM J PATHOL, V150, P455; VIHINEN M, 1994, BIOCHEM BIOPH RES CO, V204, P1251, DOI 10.1006/bbrc.1994.2597; WANG MC, 1979, INVEST UROL, V17, P159; Young CYF, 1996, PROSTATE, P17; YU JX, 1994, J BIOL CHEM, V269, P18843; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	44	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29590	29595		10.1074/jbc.272.47.29590	http://dx.doi.org/10.1074/jbc.272.47.29590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368023	hybrid			2022-12-27	WOS:A1997YG64700033
J	Braun, P; Persson, B; Kaback, HR; vonHeijne, G				Braun, P; Persson, B; Kaback, HR; vonHeijne, G			Alanine insertion scanning mutagenesis of lactose permease transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LAC CARRIER PROTEIN; POLYTOPIC MEMBRANE-PROTEIN; METAL-BINDING SITES; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; CARBOXYL TERMINUS; SEQUENCE; EXPRESSION; PROXIMITY	A priori, single residue insertions into transmembrane helices are expected to be highly disruptive to protein structure and function. We have carried out a systematic analysis of the phenotypes associated with Ala insertions into transmembrane helices in lactose permease, a multispanning Escherichia coli inner membrane protein, Insertion of alanine into the center of 7 transmembrane helices was found to abolish stable integration of lactose permease into the membrane or uphill lactose transport. A more detailed Ala insertion scan was made of transmembrane helix III. The results pinpoint a central region of similar to 2 helical turns that is crucial for lactose permease stability and/or activity. A Trp scan in this region identified 2 residues essential for lactose permease stability. From these results, it appears that transmembrane helices have differential sensitivities to single residue insertions and that such mutations may be useful for identifying structurally and/or functionally important helix segments.	VAXJO UNIV,DEPT ENGN & NAT SCI,S-35195 VAXJO,SWEDEN; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MOL GENET & MICROBIOL,LOS ANGELES,CA 90095	Linnaeus University; Vaxjo University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Braun, P (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FOSTER DL, 1983, J BIOL CHEM, V258, P31; Goswitz VC, 1996, J BIOL CHEM, V271, P21927, DOI 10.1074/jbc.271.36.21927; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HEINZ DW, 1994, J MOL BIOL, V236, P869, DOI 10.1006/jmbi.1994.1195; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; KABACK HR, 1994, J EXP BIOL, V196, P183; KABACK HR, 1996, HDB BIOL PHYS, V2, P203; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MCKENNA E, 1992, P NATL ACAD SCI USA, V89, P11954, DOI 10.1073/pnas.89.24.11954; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; ROEPE PD, 1989, P NATL ACAD SCI USA, V86, P3992, DOI 10.1073/pnas.86.11.3992; SAHINTOTH M, 1994, PROTEIN SCI, V3, P2302, DOI 10.1002/pro.5560031215; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SHARP LL, 1995, P NATL ACAD SCI USA, V92, P7946, DOI 10.1073/pnas.92.17.7946; STOCHAJ U, 1988, J BACTERIOL, V170, P2639, DOI 10.1128/jb.170.6.2639-2645.1988; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; VIITANEN PV, 1985, BIOCHEMISTRY-US, V24, P7628, DOI 10.1021/bi00347a020; Wallin E, 1997, PROTEIN SCI, V6, P808; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; Wu JH, 1996, P NATL ACAD SCI USA, V93, P10123, DOI 10.1073/pnas.93.19.10123	38	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29566	29571		10.1074/jbc.272.47.29566	http://dx.doi.org/10.1074/jbc.272.47.29566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368019	hybrid			2022-12-27	WOS:A1997YG64700029
J	Caccuri, AM; Antonini, G; Nicotra, M; Battistoni, A; LoBello, M; Board, PG; Parker, MW; Ricci, G				Caccuri, AM; Antonini, G; Nicotra, M; Battistoni, A; LoBello, M; Board, PG; Parker, MW; Ricci, G			Catalytic mechanism and role of hydroxyl residues in the active site of theta class glutathione S-transferases - Investigation of Ser-9 and Tyr-113 in a glutathione S-transferase from the Australian sheep blowfly, Lucilia cuprina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI-BI MECHANISM; KINETICS; FLEXIBILITY; MUTAGENESIS; ISOMERASE; MUTATION; BINDING; P1-1; RAT; PI	Spectroscopic and kinetic studies have been performed on the Australian sheep blowfly Lucilia cuprina glutathione S-transferase (Lucilia GST; EC 2.5.1.18) to clarify its catalytic mechanism, Steady state kinetics of Lucilia GST are non-Michaelian, but the quite hyperbolic isothermic binding of GSH suggests that a steady state random sequential Bi Ri mechanism is consistent with the anomalous kinetics observed. The rate-limiting step of the reaction is a viscosity-dependent physical event, and stopped-flow experiments indicate that product release is rate-limiting, Spectroscopic and kinetic data demonstrate that Lucilia GST is able to lower the pK(a) of the bound GSH from 9.0 to about 6.5. Based on crystallographic suggestions, the role of two hydroxyl residues, Ser-9 and Tyr-113, has been investigated. Removal of the hydroxyl group of Ser-9 by site-directed mutagenesis raises the pK(a) of bound GSH to about 7.6, and a very low turnover number (about 0.5% of that of wild type) is observed. This inactivation may be explained by a strong contribution of the Ser-9 hydroxyl group to the productive binding of GSH and by an involvement in the stabilization of the ionized GSH. This serine residue is highly conserved in the Theta class GSTs, so the present findings may be applicable to all of the family members, Tyr-113 appears not to be essential for the GSH activation. Stopped-flow data indicate that removal of the hydroxyl group of Tyr-113 does not change the rate-limiting step of reaction but causes an increase of the rate constants of both the formation and release of the GSH conjugate, Tyr-113 resides on alpha-helix 4, and its hydroxyl group hydrogen bonds directly to the hydroxyl of Tyr-105, This would reduce the flexibility of a protein region that contributes to the electrophilic substrate binding site; segmental motion of alpha-helix 4 possibly modulates different aspects of the catalytic mechanism of the Lucilia GST.	UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY; CHILDRENS HOSP,IRCCS BAMBIN GESU,I-00165 ROME,ITALY; UNIV AQUILA,DEPT BASIC & APPL BIOL,I-67010 LAQUILA,ITALY; UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI,I-00185 ROME,ITALY; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOL GENET GRP,CANBERRA,ACT 2601,AUSTRALIA; ST VINCENTS INST MED RES,IAN POTTER FDN PROT CRYTALLOG LAB,FITZROY,VIC 3065,AUSTRALIA	University of Rome Tor Vergata; IRCCS Bambino Gesu; University of L'Aquila; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research			Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022; Battistoni, Andrea/A-4778-2016	Parker, Michael W/0000-0002-3101-1138; Battistoni, Andrea/0000-0003-4085-7917; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961				Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1991, ITAL J BIOCHEM, V40, P304; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; Habig W H, 1981, Methods Enzymol, V77, P398; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LIU SX, 1992, J BIOL CHEM, V267, P4296; LoBello M, 1997, BIOCHEMISTRY-US, V36, P6207, DOI 10.1021/bi962813z; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MILLER J, 1968, REACTION MECH ORGANI, V8, P137; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Segel IH, 1975, ENZYME KINETICS, P460; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Zheng YJ, 1997, J AM CHEM SOC, V119, P1523, DOI 10.1021/ja961667h	38	63	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29681	29686		10.1074/jbc.272.47.29681	http://dx.doi.org/10.1074/jbc.272.47.29681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368035	hybrid			2022-12-27	WOS:A1997YG64700045
J	Ito, H; Okamoto, K; Nakayama, H; Isobe, T; Kato, K				Ito, H; Okamoto, K; Nakayama, H; Isobe, T; Kato, K			Phosphorylation of alpha B-crystallin in response to various types of stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TUMOR-NECROSIS-FACTOR; NON-LENTICULAR TISSUES; KINASE CASCADE; RAPID PHOSPHORYLATION; IMMUNOREACTIVE ALPHA; CHAPERONE ACTIVITY; MAPKAP KINASE-2; PHORBOL ESTER; OKADAIC ACID	Phosphorylation of alpha B-crystallin, a member of the hsp27 family, in human glioma (U373 MG) cells was stimulated by exposure of the cells to various stimuli, which included heat, arsenite, phorbol 12-myristate 13-acetate (PMA), okadaic acid, H2O2, anisomycin, and high concentrations of NaCl or sorbitol, but not in response to agents that elevated intracellular levels of cyclic AMP. Cells exposed to PMA together with okadaic acid yielded three bands of P-32-labeled alpha B-crystallin when immunoprecipitated samples were subjected to electrophoresis on an isoelectric focusing gel. All of the phosphorylated residues were identified as serine, an indication that three different serine residues can act as sites of phosphorylation in alpha B-crystallin. Structural analysis by mass spectrometry revealed that phosphorylation of alpha B-crystallin occurred at serines 19, 45, and 59. Dithiothreitol and staurosporine selectively inhibited the phosphorylation induced by arsenite and the phorbol ester, respectively, SB202190, an inhibitor of p38 mitogen-activated protein (MAP) kinase, suppressed the phosphorylation induced by arsenite, anisomycin, H2O2, sorbitol, NaCl, and heat shock, but not that induced by PMA and okadaic acid, The PMA-induced phosphorylation was selectively suppressed by an inhibitor of p44 MAP kinase kinase, PD98059, Although PMA and arsenite preferentially stimulated the phosphorylation of Ser-45 and Ser-59, respectively, as determined with antibodies that recognized the respective phosphorylated forms of alpha B-crystallin, all three sites were phosphorylated in response to each stimulus, These results suggest that p38 MAP kinase or p44 MAP kinase might be involved in the signal transduction cascade that leads to the phosphorylation of alpha B-crystallin, The phosphorylation of alpha B-crystallin was also enhanced in the heart and diaphragm when rats were exposed to heat stress (42 degrees C for 20 min).	AICHI HUMAN SERV CTR,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,HACHIOJI,TOKYO 19203,JAPAN	Tokyo Metropolitan University			Isobe, Toshiaki/Q-9279-2017	Ito, Hidenori/0000-0002-6527-477X				ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNARDINI F, 1995, BIOCHEM BIOPH RES CO, V208, P742, DOI 10.1006/bbrc.1995.1400; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUY GR, 1992, J BIOL CHEM, V267, P1846; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; Nakayama H, 1996, J CHROMATOGR A, V730, P279, DOI 10.1016/0021-9673(95)00974-4; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; VOORTER CEM, 1989, FEBS LETT, V259, P50; WANG KY, 1995, EXP EYE RES, V61, P115; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YOSHITAKE S, 1979, EUR J BIOCHEM, V101, P395, DOI 10.1111/j.1432-1033.1979.tb19731.x	48	180	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29934	29941		10.1074/jbc.272.47.29934	http://dx.doi.org/10.1074/jbc.272.47.29934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368070	hybrid			2022-12-27	WOS:A1997YG64700080
J	Kersten, S; Reczek, PR; Noy, N				Kersten, S; Reczek, PR; Noy, N			The tetramerization region of the retinoid X receptor is important for transcriptional activation by the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; NUCLEAR HORMONE RECEPTORS; ACID RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; LIGAND-BINDING; DIRECT REPEATS; CO-REPRESSOR; ALL-TRANS; DEPENDENT TRANSACTIVATION	The retinoid X receptor (RXR), a member of the superfamily of hormone nuclear receptors, is a ligand-inducible transcription factor that is activated by the vitamin A derivative 9-cis-retinoic acid. We previously showed that RXR self-associates into tetramers with a high affinity and that ligand binding induces rapid dissociation of receptor tetramers to smaller species. Here, the RXR region that is responsible for mediating tetramer formation is identified. It is shown that this interface, which we term the ''tetramerization domain,'' critically contains two consecutive phenylalanine residues located at the C-terminal region of the receptor. Mutation of these residues is sufficient to disrupt RXR tetramers without affecting the overall fold of the protein or interfering with ligand binding, dimer formation, or DNA binding by the receptor. Nevertheless, the tetramer-impaired mutant was found to be transcriptionally defective. The newly characterized tetramerization domain and the previously identified main dimerization interface of RXR act autonomously to affect separate intersubunit interactions that, overall, lead to formation of tetramers, Protein-protein interactions mediated by the tetramerization domain, but not those that involve the dimerization interface, are disrupted following ligand binding by RXR Overall, these data attest to the specificity of the interaction and implicate the tetramerization interface in playing a direct role in regulating transcriptional activation by RXR.	CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA; BRISTOL MYERS SQUIBB CO, BUFFALO, NY 14213 USA	Cornell University; Bristol-Myers Squibb			Kersten, Sander/A-1116-2011	Kersten, Sander/0000-0003-4488-7734	NCI NIH HHS [CA68150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; BORTELL R, 1993, P NATL ACAD SCI USA, V90, P2300, DOI 10.1073/pnas.90.6.2300; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; Kersten S, 1997, J BIOL CHEM, V272, P12771, DOI 10.1074/jbc.272.19.12771; Kizaki M, 1996, BLOOD, V87, P1977; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Law Simon W., 1994, Gene Expression, V4, P77; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Lin BC, 1997, J BIOL CHEM, V272, P9860; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Nagy L, 1996, J BIOL CHEM, V271, P4355; ONATE SA, 1995, SCIENCE, V270, P1354; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; REDFERN CPF, 1995, EUR J CANCER, V31A, P486, DOI 10.1016/0959-8049(95)00066-R; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VuDac N, 1996, MOL CELL BIOL, V16, P3350; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	77	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29759	29768		10.1074/jbc.272.47.29759	http://dx.doi.org/10.1074/jbc.272.47.29759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368046	hybrid			2022-12-27	WOS:A1997YG64700056
J	Olson, MW; Gervasi, DC; Mobashery, S; Fridman, R				Olson, MW; Gervasi, DC; Mobashery, S; Fridman, R			Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; GELATINASE-A; PROTEOLYTIC ACTIVITY; PROGELATINASE-A; ACTIVATION; MECHANISM; CONSTANTS	The dissociation constants (K-d) of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2, for the active and latent forms of matrix metalloproteinase (MMP)-2 and MMP-9 were evaluated using surface plasmon resonance (SPR) and enzyme inhibition studies, SPR analysis shows biphasic kinetics with high (nM) and low (mu M) affinity binding sites of TIMP-2 and TIMP-1 for MMP-2 (72- and 62-kDa species) and MMP-9 (92- and 82-kDa species), respectively, In contrast, binding data of TIMP-8 to an MMP-2 45-kDa active form lacking the C-terminal domain and to an MMP-2 C-terminal domain (CTD) fragment displays monophasic kinetics with K-d values of 315 and 60 nM, respectively, This suggests that the CTD contains the high affinity binding site, whereas the catalytic domain contains the low affinity site. Also, binding of TIMP-2 to pro-MMP-2 is stronger at both the high and low affinity sites than the corresponding binding of TIMP-2 to the MMP-2 62-kDa form demonstrating the importance of the N-terminal prodomain. In addition, the K-d value of TIMP-1 for the MMP-2 62-kDa species is 28.6 nn at the high affinity site, yet neither the MMP-2 45-kDa species nor the CTD interacts with TIMP-1. Enzyme inhibition studies demonstrate that TIMPs are slow binding inhibitors with monophasic inhibition kinetics, This suggests that a single binding event results in enzyme inhibition, The kinetic parameters for the onset of inhibition are fast (k(on) -10(5) M-1 s(-1)) with slow off rates (k(off) similar to 10(-3) s(-1)). The inhibition constants (K-i) are in the 10(-7)-10(-9) hr range and correlate with the values determined by SPR.	WAYNE STATE UNIV,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,KARMANOS CANC INST,DETROIT,MI 48201; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48201	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University					NCI NIH HHS [CA-61986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BROWN PD, 1990, CANCER RES, V50, P6184; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1995, CANCER RES, V55, P2548; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICK BR, 1978, CAN J BIOCHEM CELL B, V56, P1055, DOI 10.1139/o78-166; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISBON AM, 1995, NAT STRUCT BIOL, V11, P938; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	28	241	250	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29975	29983		10.1074/jbc.272.47.29975	http://dx.doi.org/10.1074/jbc.272.47.29975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368077	hybrid			2022-12-27	WOS:A1997YG64700087
J	Panzenboeck, U; Raitmayer, S; Reicher, H; Lindner, H; Glatter, O; Malle, E; Sattler, W				Panzenboeck, U; Raitmayer, S; Reicher, H; Lindner, H; Glatter, O; Malle, E; Sattler, W			Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HYDROGEN-PEROXIDE-CHLORIDE; SELECTIVE UPTAKE; ESTER HYDROPEROXIDES; CELLULAR CHOLESTEROL; GAS-CHROMATOGRAPHY; REACTION-PRODUCTS; FATTY-ACIDS; HUMAN SERUM	Myeloperoxidase (MPO), a protein secreted by activated phagocytes, may be a potential candidate for the generation of modified/oxidized lipoproteins in vivo via intermediate formation of HOCl, a powerful oxidant. During the present study, the effects of reagent NaOCl and OCl- generated by the MPO/H2O2/Cl- system on physicochemical and metabolic properties of high density lipoprotein (HDL) subclass 3 (HDL3) were investigated, Up to a molar oxidant:lipoprotein ratio of approximately 30:1, apolipoprotein A-I (apoA-I), the major HDL3 apolipoprotein component, represented the preferential target for OCl- attach (consuming 35-76% of the oxidant), thereby protecting HDL3 fatty acids (consuming between 17 and 30% of the oxidant) against OCl--mediated modification. At molar oxidant:HDL3 ratios greater than or equal to 60:1, we have observed pronounced consumption of HDL3 unsaturated fatty acids with concomitant formation of fatty acid chlorohydrins. Modification of HDL3 in the presence of the MPO/H2O2/Cl- system resulted in amino acid oxidation in a manner comparable with that found with reagent NaOCl only, Treatment of HDL3 with reagent NaOCl as well as modification by the MPO/H2O2/Cl- system resulted in significantly enhanced turnover rates of HDL3 by mouse peritoneal macrophages, an effect that was not a result of HDL3 aggregation as judged by dynamic and static light-scattering experiments, In comparison with native HDL3, the degradation by macrophages was enhanced by 4- and 15-fold when HDL3 was modified with reagent NaOCl or the MPO/H2O2/Cl- system, Finally, the ability of HDL3 to promote cellular cholesterol efflux from macrophages was significantly diminished after modification with reagent NaOCl. Collectively, these results demonstrate that the modification of HDL3 by hypochlorite (added as reagent or generated by the MPO/H2O2/Cl- system) transformed an antiatherogenic lipoprotein particle into a modified lipoprotein with characteristics similar to lipoproteins commonly thought to initiate foam cell formation in vivo.	GRAZ UNIV,DEPT BIOCHEM MED,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,DEPT PHYS CHEM,A-8010 GRAZ,AUSTRIA	University of Graz; University of Graz			Malle, Ernst/D-3071-2013	Panzenbock, Ute/0000-0002-0545-6758				BANKA CL, 1994, J BIOL CHEM, V269, P10288; Banka CL, 1996, CURR OPIN LIPIDOL, V7, P139, DOI 10.1097/00041433-199606000-00005; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622; Cogny A, 1996, BIOCHEM J, V314, P285, DOI 10.1042/bj3140285; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; FOOTE CS, 1981, NATURE, V301, P715; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; GUERTIN F, 1995, BIOCHEM BIOPH RES CO, V212, P1, DOI 10.1006/bbrc.1995.1927; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; HAZEN SL, 1996, J CLIN INVEST, V98, P1; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAESBERG B, 1993, ARTERIOSCLER THROMB, V13, P133, DOI 10.1161/01.ATV.13.1.133; KATRANTZIS M, 1991, FREE RADICAL BIO MED, V10, P101, DOI 10.1016/0891-5849(91)90003-L; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; LAMPERT MB, 1983, BLOOD, V62, P645; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Malle E, 1997, AM J PATHOL, V150, P603; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MURAKAMI M, 1986, BIOCHEM BIOPH RES CO, V137, P29, DOI 10.1016/0006-291X(86)91171-X; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PANASENKO OM, 1994, FREE RADICAL BIO MED, V16, P143, DOI 10.1016/0891-5849(94)90137-6; Panzenboeck U, 1997, J LIPID RES, V38, P239; PARKS JS, 1979, J BIOL CHEM, V254, P6716; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Rifici VA, 1996, BBA-LIPID LIPID MET, V1299, P87, DOI 10.1016/0005-2760(95)00198-0; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; SATTLER W, 1996, LIPIDS, V12, P1303; SEGREST JP, 1992, J LIPID RES, V33, P141; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; VANDENBERG J, 1994, METHOD ENZYMOL, V233, P639; VANDENBERG JJM, 1993, J LIPID RES, V34, P2005; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	61	89	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29711	29720		10.1074/jbc.272.47.29711	http://dx.doi.org/10.1074/jbc.272.47.29711			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368040	hybrid			2022-12-27	WOS:A1997YG64700050
J	Chamberlain, LH; Burgoyne, RD				Chamberlain, LH; Burgoyne, RD			The molecular chaperone function of the secretory vesicle cysteine string proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; ATPASE ACTIVITY; J-DOMAIN; SUBSTRATE-BINDING; ENDOPLASMIC-RETICULUM; SYNAPTIC VESICLES; NMR STRUCTURE; REPLICATION; DROSOPHILA	The ''J'' domains of eukaryotic DnaJ-like proteins specify interaction with various Hsp70s. The conserved tripeptide, HPD, present in all J domains has been shown to be important for the interaction between yeast and bacterial DnaJ/Hsp70 protein pairs. We have characterized mutations in the HPD motif of the synaptic vesicle protein cysteine-string protein (Csp). Mutation of the histidine (H43Q) or aspartic acid (D45A) residues of this motif reduced the ability of Csp to stimulate the ATPase activity of mammalian Hsc70, The H43Q and D45A mutant proteins were not able to stimulate the ATPase activity of Hsc70 to any significant extent. The mutant proteins were characterized by competition assays, tryptic digestion analysis, and direct binding analysis from which it was seen that these proteins were defective in binding to Hsc70. Thus, the HPD motif of Csp is required for binding to Hsc70. We also analyzed the interaction between Csp and a model substrate protein, denatured firefly luciferase. Both Csp1 and the C-terminally truncated isoform Csp2 were able to prevent aggregation of heat-denatured luciferase, and they also cooperated with Hsc70 to prevent aggregation. In addition, complexes of Csp1 or Csp2 with Hsc70 and luciferase were isolated, confirming that these proteins interact and that Csps can bind directly to denatured proteins. Csp1 and Csp2 isoforms must differ in some aspect other than interaction with Hsc70 and substrate protein. These results show that both Csp1 and Csp2 can bind a partially unfolded protein and act as chaperones, This suggests that Csps may have a general chaperone function in regulated exocytosis.	UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFANO C, 1989, J BIOL CHEM, V264, P10709; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1362; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Kwon OJ, 1996, MOL BIOL CELL, V7, P2599; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MASTROGIACOMO A, 1995, MOL BRAIN RES, V28, P12, DOI 10.1016/0169-328X(94)00172-B; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Pupier S, 1997, J NEUROSCI, V17, P2722; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	42	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31420	31426		10.1074/jbc.272.50.31420	http://dx.doi.org/10.1074/jbc.272.50.31420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395474	hybrid			2022-12-27	WOS:A1997YL41900033
J	Friedman, JE; Sun, Y; Ishizuka, T; Farrell, CJ; McCormack, SE; Herron, LM; Hakimi, P; Lechner, P; Yun, JS				Friedman, JE; Sun, Y; Ishizuka, T; Farrell, CJ; McCormack, SE; Herron, LM; Hakimi, P; Lechner, P; Yun, JS			Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN-RECEPTOR SUBSTRATE-1; TISSUE-SPECIFIC EXPRESSION; GROWTH-HORMONE GENE; DIETARY-REGULATION; RESPONSE UNIT; PEPCK GENE; RESISTANCE; PROMOTER; MUSCLE	The molecular mechanisms underlying increased hepatic phosphoenolpyruvate carboxykinase (PEPCK) gene transcription and gluconeogenesis in type II diabetes are largely unknown, To examine the involvement of glucocorticoids and the cis-acting insulin response sequence (IRS, -416/-407) in the genetically obese db/db mouse model, we generated crosses between C57BL/KsJ-db/+ mice and transgenic mice that express -460 or -2000 base pairs of the rat PEPCK gene promoter containing an intact or mutated IRS, linked to a reporter gene. Transgenic mice expressing the intact PEPCK(460)-CRP (C-reactive protein) transgene bred to near homozygosity at the db locus were obese, hyperinsulinemic, and developed fasting hyperglycemia (389 +/- 26 mg/100 ml) between 4 and 10 weeks of age, Levels of CRP reporter gene expression were increased 2-fold despite severe hyperinsulinemia compared with non-diabetic non-obese transgenic mice, Reporter gene expression was also increased 2-fold in transgenic obese diabetic db/db mice bearing a mutation in the IRS, -2000(IRS)-hGx, compared with non-obese non-diabetic transgenic 2000(IRS)-hGx mice. Treatment of obese diabetic db/db transgenic mice with the glucocorticoid receptor blocker RU 486 decreased plasma glucose by 50% and reduced PEPCK, GLUT2, glucose-6-phosphatase, tyrosine aminotransferase, CRP, and hGx reporter gene expression to levels similar to those of non-obese normoglycemic transgenic mice, Taken together, these results establish that -460 bp of 5'-flanking sequence is sufficient to mediate the induction of PEPCK gene transcription in genetically obese db/db mice during the development of hyperglycemia, The results further demonstrate that the mechanism underlying increased expression of gluconeogenic enzymes in the db/db mouse requires the action of glucocorticoids and occurs independently of factors acting through the PEPCK IRS (-416/-407) promoter binding site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45107	Case Western Reserve University; University System of Ohio; Ohio University	Friedman, JE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.		Hakimi, Parvin/AAB-1643-2021		NIDDK NIH HHS [DK50272] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050272] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARDUS C, 1993, DIABETES CARE, V16, P228, DOI 10.2337/diacare.16.1.228; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1982, DIABETES, V31, P1; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1990, J CLIN INVEST, V86, P2038, DOI 10.1172/JCI114940; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HOFMANN CA, 1992, ENDOCRINOLOGY, V130, P735, DOI 10.1210/en.130.2.735; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KUSUNOKI M, 1995, DIABETES, V44, P718, DOI 10.2337/diabetes.44.6.718; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANGLEY SC, 1990, AM J PHYSIOL, V259, pR539, DOI 10.1152/ajpregu.1990.259.3.R539; LEITER EH, 1987, J IMMUNOL, V10, P3224; Lin CS, 1995, IMMUNOL CELL BIOL, V73, P521, DOI 10.1038/icb.1995.82; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; Ludwig DS, 1996, J CLIN ENDOCR METAB, V81, P503, DOI 10.1210/jc.81.2.503; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NOGUCHI T, 1993, FEBS LETT, V328, P145, DOI 10.1016/0014-5793(93)80982-Z; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKADA S, 1992, AM J PHYSIOL, V262, pR1106, DOI 10.1152/ajpregu.1992.262.6.R1106; OLEFSKY JM, 1981, DIABETES, V30, P148, DOI 10.2337/diab.30.2.148; PATEL YM, 1994, J BIOL CHEM, V269, P5619; RESHEF L, 1960, METABOLISM, V9, P551; ROESLER WJ, 1985, MOL CELL BIOCHEM, V92, P99; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SHAFRIR E, 1988, FRONTIERS DIABETES R, P304; SHIMOMURA Y, 1987, HORM METAB RES, V19, P295, DOI 10.1055/s-2007-1011804; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; WILLIAMSSON JR, 1966, P NATL ACAD SCI USA, V6, P247; YANG SH, 1995, BIOCHEM J, V310, P375, DOI 10.1042/bj3100375	41	93	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31475	31481		10.1074/jbc.272.50.31475	http://dx.doi.org/10.1074/jbc.272.50.31475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395482	hybrid			2022-12-27	WOS:A1997YL41900041
J	Higashida, H; Yokoyama, S; Hashii, M; Taketo, M; Higashida, M; Takayasu, T; Ohshima, T; Takasawa, S; Okamoto, H; Noda, M				Higashida, H; Yokoyama, S; Hashii, M; Taketo, M; Higashida, M; Takayasu, T; Ohshima, T; Takasawa, S; Okamoto, H; Noda, M			Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RYANODINE RECEPTOR; CA2+ RELEASE; SIGNAL TRANSDUCTION; INSULIN-SECRETION; CD38; CALCIUM; ACETYLCHOLINE; ACTIVATION; HYDROLYSIS	Cyclic ADP-ribose (cADP-ribose) is an endogenous modulator of ryanodine-sensitive Ca2+ release channels. An unsolved question is whether or not cADP-ribose mediates intracellular signals from hormone or neurotransmitter receptors. The first step in this study was to develop a TLC method to measure ADP-ribosyl cyclase, by which conversion of [H-3]NAD(+) to [H-3]cADP-ribose was confirmed in COS-7 cells overexpressing human CD38. A membrane fraction of NG108-15 neuroblastoma x glioma hybrid cells possessed ADP-ribosyl cyclase activity measured by TLC. Carbamylcholine increased this activity by 2.6-fold in NG108-15 cells overexpressing mi or m3 muscarinic acetylcholine receptors (mAChRs), but inhibited it by 30-52% in cells expressing m2 and/or m4 mAChRs. Both of these effects were mimicked by GTP, Pretreatment of cells with cholera toxin blocked the activation, whereas pertussis toxin blocked the inhibition. Application of carbamylcholine caused significant decreases in NAD(+) concentrations in untreated m1-transformed NG108-15 cells, but an increase in cholera toxin-treated cells. These results suggest that mAChRs couple to ADP-ribosyl cyclase within cell membranes via trimeric G proteins and can thereby control cellular function by regulating cADP-ribose formation.	KANAZAWA UNIV,SCH MED,DEPT LEGAL MED,KANAZAWA,ISHIKAWA 920,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN; KYUSHU UNIV,SCH MED,DEPT PHYSIOL,FUKUOKA 812,JAPAN	Kanazawa University; Tohoku University; Kyushu University	Higashida, H (corresponding author), KANAZAWA UNIV,SCH MED,NEUROINFORMAT RES INST,DEPT BIOPHYS,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.		higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; Genazzani AA, 1997, J BIOL CHEM, V272, P7669, DOI 10.1074/jbc.272.12.7669; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Higashida H, 1996, FEBS LETT, V379, P236, DOI 10.1016/0014-5793(95)01516-7; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HIGASHIDA H, 1982, J CELL PHYSIOL, V110, P107, DOI 10.1002/jcp.1041100202; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; Mathes C, 1996, J NEUROSCI, V16, P1702; MATSUZAWA H, 1975, P NATL ACAD SCI USA, V72, P3472, DOI 10.1073/pnas.72.9.3472; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MESZAROS V, 1995, BIOCHEM BIOPH RES CO, V210, P452, DOI 10.1006/bbrc.1995.1681; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Noda M, 1996, J LIPID MEDIAT CELL, V14, P175, DOI 10.1016/0929-7855(96)00523-8; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOHGO A, 1994, J BIOL CHEM, V269, P28555; Tohgo A, 1997, J BIOL CHEM, V272, P3879, DOI 10.1074/jbc.272.7.3879; Vu CQ, 1996, J BIOL CHEM, V271, P4747; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; YOKOYAMA S, 1994, BIOCHEM BIOPH RES CO, V200, P634, DOI 10.1006/bbrc.1994.1495; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	46	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31272	31277		10.1074/jbc.272.50.31272	http://dx.doi.org/10.1074/jbc.272.50.31272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395453	hybrid			2022-12-27	WOS:A1997YL41900012
J	Mann, CJ; Troussard, AA; Yen, FT; Hannouche, N; Najib, J; Fruchart, JC; Lotteau, V; Andre, P; Bihain, BE				Mann, CJ; Troussard, AA; Yen, FT; Hannouche, N; Najib, J; Fruchart, JC; Lotteau, V; Andre, P; Bihain, BE			Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; LDL-RECEPTOR; APO-CIII; HIGH-AFFINITY; LIPASE; HYPERTRIGLYCERIDEMIA; METABOLISM; GENE; PROTEIN	ApoC-III overexpression in mice results in severe hypertriglyceridemia due primarily to a delay in the clearance of triglyceride-rich lipoproteins. We have, in primary cultures of rat hepatocytes, characterized a lipolysis-stimulated receptor (LSR), The apparent number of LSR that are available on rat liver plasma membranes is negatively correlated with plasma triglyceride concentrations measured in the fed state, We therefore proposed that the primary physiological role of the LSR is to contribute to the cellular uptake of triglyceride-rich lipoproteins. We have now tested the effect of apoC-III on the binding of triglyceride rich lipoproteins to LSR, Supplementation of I-125-very low density lipoprotein (VLDL) with apoC-III inhibited the LSR-mediated binding, internalization, and degradation of I-125-VLDL in primary cultures of rat hepatocytes. Studies using isolated rat liver plasma membranes showed that enrichment of human VLDL and chylomicrons with synthetic or purified human apoC-III decreased their binding to the LSR by about 40%, Supplementation of triglyceride-rich lipoproteins under the same conditions with human apoC-II had no such inhibitory effect, despite the fact that this apoprotein bound as efficiently as apoC-III to these particles. Preincubation of LDL with apoC-III did not modify its binding to LSR, Partitioning studies using I-125-apoC-III showed that this lack of effect was due to apoC-III's inability to efficiently associate with LDL. Purified human apoC-III1 was as efficient as the synthetic nonsialylated form of apoC-III in inhibiting binding of VLDL to LSR, However, despite a 2-fold greater binding of apoC-III2 to VLDL, this isoform was a less efficient inhibitor of the binding of VLDL to LSR than apoC-III1 or nonsialylated apoC-III, Desialylation of apoC-III2 by treatment with neuraminidase increased the inhibition of VLDL binding to LSR to a level similar to that observed with apoC-III1 and nonsialylated apoC-III. We propose that apoC-III regulates in part the rate of removal of triglyceride-rich particles by inhibiting their binding to the ESR, and that the level of inhibition is determined by the degree of apoC-III sialylation.	INSERM,U391,F-35043 RENNES,FRANCE; INST PASTEUR,SERLIA,F-59019 LILLE,FRANCE; INSERM,U325,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)			Yen, Frances T/G-9175-2014; André, Patrice/M-8139-2014; lotteau, vincent/M-8143-2014	Yen, Frances T/0000-0001-8740-4304; André, Patrice/0000-0002-5834-7395; Lotteau, Vincent/0000-0003-0997-3282				AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHAIN BE, 1989, J BIOL CHEM, V264, P17316; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CAMPS L, 1991, J LIPID RES, V32, P1877; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P1881, DOI 10.1021/bi00406a013; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; DallingaThie GM, 1996, J LIPID RES, V37, P136; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; FORTE TM, 1984, J CLIN INVEST, V74, P1601, DOI 10.1172/JCI111576; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1977, INT CELL BIOL 1976 1, P639; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JACKSON RL, 1986, METHOD ENZYMOL, V128, P288; JACKSON RL, 1986, BIOCHIM BIOPHYS ACTA, V875, P211, DOI 10.1016/0005-2760(86)90170-0; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MANN CJ, 1995, BIOCHEMISTRY-US, V35, P10421; Markwell M A, 1981, Methods Enzymol, V72, P296; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; MCCONATHY WJ, 1992, J LIPID RES, V33, P995; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORELL AG, 1966, J BIOL CHEM, V241, P3745; QUARFORDT SH, 1982, J BIOL CHEM, V257, P4642; Sanan DA, 1997, J LIPID RES, V38, P1002; SCHACHTER NS, 1996, J CLIN INVEST, V98, P846; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; WALLINDER L, 1979, BIOCHIM BIOPHYS ACTA, V575, P166, DOI 10.1016/0005-2760(79)90142-5; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WICK U, 1995, CLIN GENET, V47, P184; WINDLER E, 1985, J LIPID RES, V26, P556; YANG CY, 1993, J LIPID RES, V34, P1311; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017	48	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31348	31354		10.1074/jbc.272.50.31348	http://dx.doi.org/10.1074/jbc.272.50.31348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395464	hybrid			2022-12-27	WOS:A1997YL41900023
J	Alonso, MA; Fan, L; Alarcon, B				Alonso, MA; Fan, L; Alarcon, B			Multiple sorting signals determine apical localization of a nonglycosylated integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; ANCHORED PROTEINS; RECEPTOR COMPLEX; ANTIGEN RECEPTOR; MDCK CELLS; N-GLYCANS; TRANSPORT; SUBUNITS; SURFACE; CHAIN	In polarized cells, newly synthesized proteins are sorted in the trans-Golgi network and from there delivered to either the apical or basolateral membranes, Madin-Darby canine kidney (MDCK) cells have been widely used as a model system 60 study sorting determinants to the apical and basolateral surfaces, Whereas sorting signals for basolateral transmembrane proteins seem to reside in their cytoplasmic domains, apical determinants appear to reside in the N-glycans of secretory proteins or in the glycolipid tails of glycosylphosphatidylinositol-linked proteins, We show in this study that a surface-expressed form of CD3-epsilon, a nonglycosylated type I membrane protein, is exclusively targeted to the apical membrane in MDCK cells by a glycolipid-independent transport pathway, Deletion of the cytoplasmic tail does not affect its distribution, whereas deletion of the transmembrane domain results in secretion from both surfaces although still predominantly through the apical membrane, The transmembrane domain of CD3-epsilon appended to rat growth hormone, a secretory protein that lacks apical and basolateral determinants, promotes basolateral localization of the chimeric protein, However, a growth hormone chimera containing both the transmembrane and cytoplasmic domains of CD3-epsilon resulted in localization to the apical and basolateral membranes, These results suggest there are multiple determinants in CD3-epsilon that affect its distribution in polarized MDCK cells, Whereas the transmembrane domain contains a basolateral determinant, the ectodomain and the cytoplasmic domain contain apical determinants.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alarcon, B (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain.		Alarcon, Balbino/N-9648-2016; Alonso, Miguel A/J-3945-2016	Alarcon, Balbino/0000-0001-7820-1070; Alonso, Miguel A/0000-0002-7001-8826				ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; BORST J, 1983, EUR J IMMUNOL, V13, P576, DOI 10.1002/eji.1830130712; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Harlow E., 1988, ANTIBODIES LAB MANUA; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; PESSANO S, 1985, EMBO J, V4, P337, DOI 10.1002/j.1460-2075.1985.tb03634.x; PETTEY CL, 1987, J BIOL CHEM, V262, P4854; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	30	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30748	30752		10.1074/jbc.272.49.30748	http://dx.doi.org/10.1074/jbc.272.49.30748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388213	hybrid			2022-12-27	WOS:000071640800026
J	Ottilie, S; Diaz, JL; Horne, W; Chang, J; Wang, Y; Wilson, G; Chang, S; Weeks, S; Fritz, LC; Oltersdorf, T				Ottilie, S; Diaz, JL; Horne, W; Chang, J; Wang, Y; Wilson, G; Chang, S; Weeks, S; Fritz, LC; Oltersdorf, T			Dimerization properties of human BAD - Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-X-L proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HOMOLOG BAK; APOPTOSIS; INHIBITION; BCL-X(L); GENE; DISTINCT; BH1	Bad, an inducer of programmed cell death, was recently isolated from a mouse cDNA library by its ability to bind to the anti-apoptotic protein BCL-2. Sequence analysis suggested that Bad was a member of the BCL-2 gene family that encodes both inducers and inhibitors of programmed cell death. To further analyze the role of BAD in the network of homo- and heterodimers formed by the BCL-2 family, we have cloned the human homologue of BAD and assessed its biological activity and its interactions with wild type and mutant BCL-2 family proteins. Our results indicate that the human BAD protein, like its mouse homologue, is able to induce apoptosis when transfected into mammalian cells. Furthermore, in yeast two-hybrid assays as well as quantitative in vitro interaction assays, human Bad interacted with BCL-2 and BCL-X-L. Sequence alignments of human BAD revealed the presence of a BH-3 homology domain as seen in other BCL-2 family proteins, Peptides derived from this domain were able to completely inhibit the dimerization of BAD with BCL-X-L. Thus, as previously shown for BAX, BAK, BCL-2, and BCL-X-L, the BH3 domain of BAD is required for its dimerization with other BCL-2 family proteins. BAD was further analyzed for its ability to bind to various mutants of BCL-2 and BCL-X-L that have lost the ability to bind BAX and BAK, some of which retain biological activity and some of which do not. Surprisingly, all of the mutated BCL-2 and BCL-X-L proteins analyzed strongly interacted with human BAD. Our data thus indicate that mutations in BCL-2 and BCL-X-L can differentially affect the heterodimeric binding of different death-promoting proteins and have implications concerning the relationship between heterodimerization and biological activity.	IDUN Pharmaceut Inc, La Jolla, CA 92037 USA		Oltersdorf, T (corresponding author), IDUN Pharmaceut Inc, 11085 N Torrey Pines Rd, La Jolla, CA 92037 USA.							BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Diaz JL, 1997, J BIOL CHEM, V272, P11350; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; JACOBSON MD, 1994, CURR BIOL, V4, P3337; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; Maniatis T., 1982, MOL CLONING LAB MANU; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ottilie S, 1997, J BIOL CHEM, V272, P16955, DOI 10.1074/jbc.272.27.16955; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426	31	127	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30866	30872		10.1074/jbc.272.49.30866	http://dx.doi.org/10.1074/jbc.272.49.30866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388232	hybrid			2022-12-27	WOS:000071640800045
J	Koyama, Y; Yamamoto, T; Kondo, D; Funaki, H; Yaoita, E; Kawasaki, K; Sato, N; Hatakeyama, K; Kihara, I				Koyama, Y; Yamamoto, T; Kondo, D; Funaki, H; Yaoita, E; Kawasaki, K; Sato, N; Hatakeyama, K; Kihara, I			Molecular cloning of a new aquaporin from rat pancreas and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIP28 WATER CHANNEL; KIDNEY COLLECTING DUCT; INTRINSIC PROTEIN; TRANSPORT WATER; MIP FAMILY; MEMBRANE; CDNA; EXPRESSION; LOCALIZATION; PERMEABILITY	A new water channel (aquaporin-8, gene symbol AQP8) was isolated from rat pancreas and liver by homology cloning, Ribonuclease protection assay showed intense expression of the gene in pancreas and liver, less intense in colon and salivary gland, and negligible in other organs, The full-length cDNA was obtained by ligation of similar to 1.4-kilobase (kb) cDNA isolated from the rat liver cDNA library to similar to 0.5 kb of the 5' end fragment obtained by the rapid amplification of cDNA ends method, A major transcript of similar to 1.45 kb was demonstrated in liver and colon by Northern blot analysis. Expression of the cRNA in Xenopus oocytes markedly enhanced osmotic water permeability in a mercury-sensitive manner, indicating a water channel function of this molecule, The open reading frame encoded a 263-amino acid protein with a predicted molecular size of 28 kDa. Hydropathy analysis represented six membrane-spanning domains and five connecting loops containing two sites of NPA motif as preserved in other aquaporins, Unlike other mammalian aquaporins, AQP8 has an unusual structure with a long N terminus and a short C terminus, which are found in plant aquaporin, gamma-tonoplast intrinsic protein, By in situ hybridization, AQP8 mRNA expression was assumed in hepatocytes, acinal cells of pancreas and salivary gland, and absorptive colonic epithelial cells, The physiological role(s) of AQP8 remain to be elucidated.	NIIGATA UNIV, SCH MED, INST NEPHROL, DEPT PATHOL, NIIGATA 951, JAPAN; NIIGATA UNIV, SCH MED, DEPT SURG 1, NIIGATA 951, JAPAN	Niigata University; Niigata University								AGRE P, 1993, AM J PHYSIOL, V265, pF463; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DOUBILET H, 1961, AM J GASTROENTEROL, V35, P499; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; Preston G M, 1993, Methods Mol Biol, V15, P317, DOI 10.1385/0-89603-244-2:317; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Yamamoto T, 1997, AM J PHYSIOL-RENAL, V272, pF198, DOI 10.1152/ajprenal.1997.272.2.F198; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	29	143	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30329	30333		10.1074/jbc.272.48.30329	http://dx.doi.org/10.1074/jbc.272.48.30329			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374520	hybrid			2022-12-27	WOS:A1997YH61300052
J	Tschanz, CL; Noy, N				Tschanz, CL; Noy, N			Binding of retinol in both retinoid-binding sites of interphotoreceptor retinoid-binding protein (IRBP) is stabilized mainly by hydrophobic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-EPITHELIUM; FATTY-ACIDS; PHOTORECEPTORS; RHODOPSIN; MECHANISM; RELEASE	Interphotoreceptor retinoid-binding protein (IRBP) is an ocular protein which is believed to participate in the visual cycle by mediating transport of retinoids between pigment epithelium and photoreceptor cells, The molecular mechanism underlying the ability of IRBP to target particular retinoids to the specific cells that are their sites of action and metabolism is not completely clear, and little information is available regarding the structure of the protein's multiple ligand-binding sites, IRBP possesses two retinoid-binding sites, and it was reported that binding of the visual chromophore, Il cis-retinal, in one of these sites, but not in the other, is tightly regulated by another IRBP ligand, docosahexaenoic acid (Chen, Y., Houghton, L. A., Brenna, J. T., and Noy, N. (1996) J. Biol. Chem. 271, 20507), The two sites are thus functionally distinct, Here, the thermodynamic parameters governing the interactions of retinol with the IRBP retinoid-binding sites were measured, The data demonstrate that the interactions of retinol with both sites are stabilized mainly by hydrophobic interactions, and that the hydroxyl head group of retinol is not involved in formation of protein-ligand complexes, Nevertheless, the data indicate that the two sites are structurally distinct, and that binding of retinol in them occurs by remarkably different modes of interactions.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University					NATIONAL EYE INSTITUTE [R01EY009296] Funding Source: NIH RePORTER; NEI NIH HHS [EY09296] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, J BIOL CHEM, V260, P4850; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BORST DE, 1989, J BIOL CHEM, V264, P1115; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FONG SL, 1988, J BIOL CHEM, V263, P15330; FONG SL, 1984, J BIOL CHEM, V259, P6534; HO MTP, 1989, J BIOL CHEM, V264, P928; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; PUTILINA T, 1993, BIOCHEMISTRY-US, V32, P3797, DOI 10.1021/bi00065a036; ROSS PD, 1981, BIOCHEMISTRY-US, V90, P2096; SAARI JC, 1985, J BIOL CHEM, V260, P195; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; Saari John C., 1994, P351	29	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30201	30207		10.1074/jbc.272.48.30201	http://dx.doi.org/10.1074/jbc.272.48.30201			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374503	hybrid			2022-12-27	WOS:A1997YH61300035
J	Ying, SX; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Swiergiel, J; Roth, MR; Conrad, GW; Kao, WWY				Ying, SX; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Swiergiel, J; Roth, MR; Conrad, GW; Kao, WWY			Characterization and expression of the mouse lumican gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; MACULAR CORNEAL-DYSTROPHY; COMPLETE CDNA CLONING; V COLLAGEN; STRUCTURAL IMPLICATIONS; GENOMIC ORGANIZATION; GLYCOSAMINOGLYCANS; FIBRILLOGENESIS; SEQUENCE; CELLS	Lumican is one of the major keratan sulfate proteoglycans (KSPG) in vertebrate corneas. We previously cloned the murine lumican cDNA. This study determines the structure of murine lumican gene (Lum) and its expression during mouse embryonic developments. The mouse lumican gene was isolated from a bacterial artificial chromosome mouse genomic DNA library and characterized by polymerase chain reaction and Southern hybridization. The lumican gene spans 6.9 kilobase pairs of mouse genome. The gene consists of three exons and two introns. Exon 1 constitutes 88 bases (b) of untranslated sequence. Exon 2 is 883 b and contains most of the coding sequence of lumican mRNA, and exon 3 has 152 b of coding sequence and 659 b of 3' noncoding sequence. The mouse lumican gene has a TATCA element, a presumptive TATA box, which locates 27 b 5'-upstream from the transcription initiation site, Northern hybridization and in situ hybridization indicate that ill early stages of embryonic development, day 7 post coitus the embryo expresses little or no lumican, Thereafter, different levels of lumican mRNA can be detected in various organ systems, such as cornea stroma, dermis, cartilage, heart, lung, and kidney. The cornea and heart are the two tissues that have the highest expression in adult. Immunoblotting studies found that KSPG core proteins became abundant in the cornea and sclera by postnatal day 10 but that sulfated KSPG could not be detected until after the eyes open. These results indicate that. lumican is widely distributed in most interstitial connective tissues, The modification of lumican with keratan sulfates in cornea is concurrent with eye opening and may contribute to corneal transparency.	UNIV CINCINNATI, DEPT OPHTHALMOL, CINCINNATI, OH 45267 USA; KANSAS STATE UNIV, DIV BIOL, MANHATTAN, KS 66502 USA	University System of Ohio; University of Cincinnati; Kansas State University					NEI NIH HHS [EY 10556, EY00952, EY 09368] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY010556, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Cai CX, 1996, EXP EYE RES, V63, P193, DOI 10.1006/exer.1996.0108; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; EDWARD DP, 1988, ARCH OPHTHALMOL-CHIC, V106, P1579, DOI 10.1001/archopht.1988.01060140747049; FARRELL RA, 1973, J PHYSIOL-LONDON, V233, P589, DOI 10.1113/jphysiol.1973.sp010325; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Funderburgh JL, 1996, INVEST OPHTH VIS SCI, V37, P2989; FUNDERBURGH JL, 1989, KERATAN SULPHATE CHE, P39; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; HAHN RA, 1992, DEVELOPMENT, V115, P383; HART GW, 1976, J BIOL CHEM, V251, P6513; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KAO WWY, 1979, J BIOL CHEM, V254, P2234; KAO WWY, 1983, J BIOL CHEM, V258, P7779; Kresse H, 1994, EXS, V70, P73; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LINSENMAYER TF, 1990, ANN NY ACAD SCI, V580, P143, DOI 10.1111/j.1749-6632.1990.tb17926.x; LIU CY, 1994, J BIOL CHEM, V269, P24627; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MEIER S, 1973, DEV BIOL, V35, P318, DOI 10.1016/0012-1606(73)90027-4; MEIER S, 1974, P NATL ACAD SCI USA, V71, P2310, DOI 10.1073/pnas.71.6.2310; MELLES GRJ, 1995, CURR EYE RES, V14, P809, DOI 10.3109/02713689508995803; Moyer PD, 1996, DIFFERENTIATION, V60, P31, DOI 10.1046/j.1432-0436.1996.6010031.x; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; Quantock AJ, 1996, BIOPHYS J, V70, P1966, DOI 10.1016/S0006-3495(96)79761-8; RAWE IM, 1992, HISTOCHEM J, V24, P311, DOI 10.1007/BF01046162; Ruggiero F, 1996, INVEST OPHTH VIS SCI, V37, P1749; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; VIGNERON M, 1984, EMBO J, V3, P2373, DOI 10.1002/j.1460-2075.1984.tb02142.x; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002	48	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30306	30313		10.1074/jbc.272.48.30306	http://dx.doi.org/10.1074/jbc.272.48.30306			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374517	hybrid			2022-12-27	WOS:A1997YH61300049
J	Arlotta, P; Rustighi, A; Mantovani, F; Manfioletti, G; Giancotti, V; Tell, G; Damante, G				Arlotta, P; Rustighi, A; Mantovani, F; Manfioletti, G; Giancotti, V; Tell, G; Damante, G			High mobility group I proteins interfere with the homeodomains binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; HMGI-C; TRANSCRIPTION FACTORS; CIRCULAR-DICHROISM; NUCLEAR PROTEINS; THYROID-CELLS; CDC2 KINASE; E-SELECTIN; EXPRESSION; SEQUENCE	Homeodomains (HDs) constitute the DNA binding domain of several transcription factors that control cell differentiation and development in a wide variety of organisms, Most HDs recognize sequences that contain a 5'-TAAT-3' core motif, However, the DNA binding specificity of HD containing proteins does not solely determine their biological effects, and other molecular mechanisms should be responsible for their ultimate functional activity, Interference by other factors in the HD/DNA interaction could be one of the processes by which HD-containing proteins achieve the functional complexity required for their effects on the expression of target genes, Using gel-retardation assay, we demonstrate that two members of the high mobility group I (HMGI) family of nuclear proteins (HMGI-C and HMGY) can bind to a subset of HD target sequences and inhibit HDs from binding to the same sequences, The inhibition of the HD/DNA interaction occurs while incubating HPGI-C with DNA either before or after the addition of the HD, The reduced half-life of the HD DNA complex in the presence of HMGI-C, and the shift observed in the CD spectra recorded upon HMGI-C binding to DNA, strongly suggest that structural modifications of the DNA are responsible for the inhibition of the HD DNA complex formation, Moreover, by co-transfection experiments we provide evidence that this inhibition can occur also in vivo, The data reported here would suggest that HMGI proteins may be potential regulators of the function of HD-containing proteins and that they are able to interfere with the access of the HD to their target genes.	UNIV UDINE,DIPARTIMENTO SCI & TECNOL BIOMED,I-33100 UDINE,ITALY; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34100 TRIESTE,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Trieste			Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Tell, Gianluca/0000-0001-8845-6448				ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BROWN DG, 1990, EMBO J, V9, P1329, DOI 10.1002/j.1460-2075.1990.tb08242.x; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DELSAL G, 1994, BIOTECHNIQUES, V16, P134; DORMAN BP, 1973, P NATL ACAD SCI USA, V70, P255, DOI 10.1073/pnas.70.1.255; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY DM, 1978, BIOPOLYMERS, V17, P145, DOI 10.1002/bip.1978.360170111; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; IVANOV VI, 1974, J MOL BIOL, V87, P817, DOI 10.1016/0022-2836(74)90086-2; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kaufman T C, 1990, Adv Genet, V27, P309; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANDEL R, 1976, NUCLEIC ACIDS RES, V3, P1839, DOI 10.1093/nar/3.8.1839; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Sreenath TL, 1996, P NATL ACAD SCI USA, V93, P9636, DOI 10.1073/pnas.93.18.9636; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	60	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29904	29910		10.1074/jbc.272.47.29904	http://dx.doi.org/10.1074/jbc.272.47.29904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368066	hybrid			2022-12-27	WOS:A1997YG64700076
J	Lim, YP; Low, BC; Ong, SH; Guy, GR				Lim, YP; Low, BC; Ong, SH; Guy, GR			Growth factors stimulate tyrosine dephosphorylation of p75 and its dissociation from the SH2 domain of Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SWISS 3T3 CELLS; ADAPTER PROTEIN; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; DNA-SYNTHESIS; KAPPA-B; RECEPTOR; RAS; KINASE	The growth factor receptor binding protein (Grb2) has a key role in initiating the mitogen-activated protein kinase signaling cascade in major cell regulatory pathways. The binding of proteins to the SH2 domain of Grb2 has been reported to occur mainly after they are tyrosine-phosphorylated following receptor activation. Using an in vitro binding assay, immunoprecipitation, and Far Western techniques, we report that in quiescent cells a 75-kDa protein binds directly to the SH2 domain of Grb2. All of the tyrosine-phosphorylated p75 protein co-localizes with Grb2.Sos complex in the cytosolic fraction of the cell in vivo and undergoes tyrosine dephosphorylation when cells are treated with mitogenic ligands such as epidermal, platelet derived, and fibroblast growth factors, endothelin-1, and bombesin but not tumor necrosis factor-alpha, interferon-alpha and -gamma, interleukein-6, and leukemic inhibitory factor, which are either cell growth inhibitory or not significantly mitogenic. The dephosphorylation of p75 and the ensuing dissociation from Grb2 is rapid, occurring within 30 s following mitogenic stimulation by ligands such as epidermal growth factor, suggesting p75 to be an early component in the signal transduction pathways involving Grb2.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 119076, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAmbrosio C, 1996, ONCOGENE, V12, P371; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SU J, 1994, J BIOL CHEM, V269, P18731; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VIRDEE K, 1994, BBA-MOL CELL RES, V1224, P489, DOI 10.1016/0167-4889(94)90286-0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29892	29898		10.1074/jbc.272.47.29892	http://dx.doi.org/10.1074/jbc.272.47.29892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368064	hybrid			2022-12-27	WOS:A1997YG64700074
J	Ferguson, AT; Vertino, PM; Spitzner, JR; Baylin, SB; Muller, MT; Davidson, NE				Ferguson, AT; Vertino, PM; Spitzner, JR; Baylin, SB; Muller, MT; Davidson, NE			Role of estrogen receptor gene demethylation and DNA methyltransferase DNA adduct formation in 5-aza-2 '-deoxycytidine-induced cytotoxicity in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID LEUKEMIAS; CPG ISLAND; EPITHELIAL-CELLS; SUPPRESSOR GENE; COLON-CANCER; METHYLATION; EXPRESSION; HYPOMETHYLATION; INHIBITION; MECHANISM	The cytosine analog 5-aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase, Its cytotoxicity has been attributed to several possible mechanisms including reexpression of growth suppressor genes and formation of covalent adducts between DNA methyltransferase and 5-aza-2'-deoxycytidine-substituted DNA which may lead to steric inhibition of DNA function, In this study, we use a panel of human breast cancer cell lines as a model system to examine the relative contribution of two mechanisms, gene reactivation and adduct formation. Estrogen receptor-negative cells, which have a hypermethylated estrogen receptor gene promoter, are more sensitive than estrogen receptor-positive cells and underwent apoptosis in response to 5-aza-2-deoxycytidine. For the first time, we show that reactivation of a gene silenced by methylation, estrogen receptor, plays a major role in this toxicity in one estrogen receptor-negative cell line as treatment of the cells with anti-estrogen-blocked cell death, However, drug sensitivity of other tumor cell lines correlated best with increased levels of DNA methyltransferase activity and formation DNA DNA methyltransferase adducts as analyzed in situ. Therefore, both reexpression of genes like estrogen receptor and formation of covalent enzyme DNA adducts can play a role in 5-aza-2'-deoxycytidine toxicity in cancer cells.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, Atlanta, GA 30335 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Johns Hopkins University; Johns Hopkins Medicine; Emory University; University System of Ohio; Ohio State University	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [P30CA016058, U01CA063185, R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63185, CA 43318, CA 16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1988, CANCER RES, V40, P277; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; CHABOT GG, 1983, BIOCHEM PHARMACOL, V32, P1327, DOI 10.1016/0006-2952(83)90293-9; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; CHRISTMAN JK, 1985, J BIOL CHEM, V260, P4059; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FERGUSON AT, 1995, CANCER RES, V55, P2279; FERGUSON AT, 1994, J VIROL, V68, P4274, DOI 10.1128/JVI.68.7.4274-4286.1994; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; HERMAN JG, 1995, CANCER RES, V55, P4525; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HUANG Y, 1991, J BIOL CHEM, V266, P17424; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Issa JPJ, 1996, CANCER RES, V56, P973; JABLONKA E, 1985, CHROMOSOMA, V93, P152, DOI 10.1007/BF00293162; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; MCCLOSKEY DE, 1995, CANCER RES, V55, P3233; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; PINTO A, 1984, BLOOD, V64, P922; PINTO A, 1993, LEUKEMIA, V7, P51; SANTI D, 1984, P NATL ACAD SCI USA, V81, P6996; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004	43	136	140	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32260	32266		10.1074/jbc.272.51.32260	http://dx.doi.org/10.1074/jbc.272.51.32260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405430	hybrid			2022-12-27	WOS:000071108000049
J	Leibel, RL; Chung, WK; Chua, SC				Leibel, RL; Chung, WK; Chua, SC			The molecular genetics of rodent single gene obesities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN OB GENE; BROWN ADIPOSE-TISSUE; LEPTIN RECEPTOR; OBESE GENE; AGOUTI GENE; TRANSGENIC MICE; NEUROPEPTIDE-Y; OB/OB MICE; ECTOPIC EXPRESSION; MISSENSE MUTATION		Columbia Univ Coll Phys & Surg, Dept Pediat, Div Mol Genet, New York, NY 10032 USA	Columbia University	Leibel, RL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, Div Mol Genet, Russ Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.				NIDDK NIH HHS [DK47473, DK52431, DK26687] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047473, R01DK052431, P30DK026687] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BOULANGE A, 1979, J LIPID RES, V20, P857; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chagnon YC, 1997, OBES RES, V5, P115, DOI 10.1002/j.1550-8528.1997.tb00651.x; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chung WK, 1996, GENOME RES, V6, P1192, DOI 10.1101/gr.6.12.1192; Chung WK, 1997, GENOMICS, V41, P332, DOI 10.1006/geno.1997.4672; Chung WK, 1996, GENOME RES, V6, P431, DOI 10.1101/gr.6.5.431; Clement K, 1996, DIABETES, V45, P687, DOI 10.2337/diabetes.45.5.687; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; Considine RV, 1996, BIOCHEM BIOPH RES CO, V220, P735, DOI 10.1006/bbrc.1996.0473; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DEVENPORT L, 1990, PHYSIOL BEHAV, V47, P1221, DOI 10.1016/0031-9384(90)90375-E; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; Duggirala R, 1996, AM J HUM GENET, V59, P694; Echwald SM, 1997, BIOCHEM BIOPH RES CO, V233, P248, DOI 10.1006/bbrc.1997.6430; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; ERICKSON JC, 1996, NATURE, V381, P414; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GREEN ED, 1995, GENOME RES, V5, P5, DOI 10.1101/gr.5.1.5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HIMMSHAGEN J, 1985, ANNU REV NUTR, V5, P69, DOI 10.1146/annurev.nu.05.070185.000441; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; JOOSTEN HFP, 1974, METABOLISM, V23, P59, DOI 10.1016/0026-0495(74)90104-8; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LAMOREUX ML, 1973, STUDY GENE INTERACTI; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibel RL, 1997, NAT GENET, V16, P218, DOI 10.1038/ng0797-218; Leiter EH, 1997, DIABETES REV, V5, P131; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; Murakami T, 1997, BIOCHEM BIOPH RES CO, V231, P26, DOI 10.1006/bbrc.1996.6030; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; POOLE TW, 1976, DEV BIOL, V48, P377, DOI 10.1016/0012-1606(76)90098-1; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; SMITH CK, 1985, AM J PHYSIOL, V249, pR13, DOI 10.1152/ajpregu.1985.249.1.R13; Smith FJ, 1996, NATURE, V382, P307, DOI 10.1038/382307a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Takaya K, 1996, BIOCHEM BIOPH RES CO, V225, P75, DOI 10.1006/bbrc.1996.1133; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; THOMPSON DB, 1995, DIABETES, V44, P478, DOI 10.2337/diabetes.44.4.478; TOKUYAMA K, 1987, AM J PHYSIOL, V252, pE202, DOI 10.1152/ajpendo.1987.252.2.E202; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WHITE D, 1997, IN PRESS P NATL ACAD; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; Xu W, 1995, Obes Res, V3, P559; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	93	231	236	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					31937	31940		10.1074/jbc.272.51.31937	http://dx.doi.org/10.1074/jbc.272.51.31937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405382	hybrid			2022-12-27	WOS:000071108000001
J	So, T; Ito, H; Koga, T; Watanabe, S; Ueda, T; Imoto, T				So, T; Ito, H; Koga, T; Watanabe, S; Ueda, T; Imoto, T			Depression of T-cell epitope generation by stabilizing hen lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN-PRESENTING CELLS; DISULFIDE BONDS; THERMAL INACTIVATION; QUATERNARY STRUCTURE; TOLERANCE INDUCTION; TRANSITION-STATE; GROWTH-FACTOR; CROSS-LINKS; PROTEINS	Conformational stability of proteins is an important factor that determines their resistance/susceptibility to proteolytic digestion. Intracellular proteolysis is the key step in antigen presentation events for protein antigens; hence, it is likely that increasing protein stability reduces the antigenicity of proteins, We prepared three hen egg white lysozyme derivatives possessing different stabilities by chemical modification to clarify the relationship between conformational stability and the antigenicity of the protein, One of the derivatives was conformationally unstabilized by removing one intramolecular disulfide bond, whereas the two others were stabilized by the addition of an intramolecular crosslink. The antigenicity of these derivatives was evaluated using hen egg white lysozyme-specific T-cell hybridoma cells and a B-lymphoma cell line, A20, as antigen-presenting cells. With an increase in conformational stability, the T-cell response decreased. However, the reduction was not derived from the inefficiency of internalization to A20 cells nor the alteration of antigenicity by chemical modifications. Moreover, from analyses of their susceptibility to proteolysis and the kinetics of presentation of the T-cell epitope, it was confirmed that increasing protein stability led to the depression of T-cell epitope generation by increasing resistance to proteolysis. These results have an important implication in devising a new strategy for manipulating T-cell response by the stability of protein antigen.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81282, Japan; Kyushu Univ, Sch Dent, Dept Biochem, Fukuoka 81282, Japan	Kyushu University; Kyushu University	Imoto, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81282, Japan.		So, Takanori/R-6175-2019	So, Takanori/0000-0003-3004-8526				ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BEDDELL CR, 1975, J MOL BIOL, V97, P643, DOI 10.1016/S0022-2836(75)80064-7; Beernink PT, 1996, P NATL ACAD SCI USA, V93, P5374, DOI 10.1073/pnas.93.11.5374; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CHILLER JM, 1971, SCIENCE, V171, P813, DOI 10.1126/science.171.3973.813; COLLINS DS, 1991, J IMMUNOL, V147, P4054; COOPER A, 1992, J MOL BIOL, V225, P939, DOI 10.1016/0022-2836(92)90094-Z; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DIMENT S, 1988, J BIOL CHEM, V263, P6901; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; GILLIS S, 1978, J IMMUNOL, V120, P2027; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Imoto T, 1997, CELL MOL LIFE SCI, V53, P215, DOI 10.1007/PL00000593; IMOTO T, 1974, BIOCHIM BIOPHYS ACTA, V336, P264, DOI 10.1016/0005-2795(74)90403-6; IMOTO T, 1973, J MOL BIOL, V80, P637, DOI 10.1016/0022-2836(73)90201-5; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; Janssen R, 1996, INT IMMUNOL, V8, P829, DOI 10.1093/intimm/8.6.829; JENSEN PE, 1993, J IMMUNOL, V150, P3347; JOHNSON RE, 1978, BIOCHEMISTRY-US, V17, P1479, DOI 10.1021/bi00601a019; JOHNSON RE, 1990, PROTEIN ENG, V3, P325; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KIM KJ, 1979, J IMMUNOL, V122, P549; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LEVICH JD, 1987, J IMMUNOL, V138, P3675; LEVICH JD, 1985, J IMMUNOL, V135, P873; LEVINE TP, 1992, P NATL ACAD SCI USA, V89, P8342, DOI 10.1073/pnas.89.17.8342; LIN SH, 1984, BIOCHEMISTRY-US, V23, P5504, DOI 10.1021/bi00318a019; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATTHYSSENS GE, 1972, EUR J BIOCHEM, V26, P449, DOI 10.1111/j.1432-1033.1972.tb01786.x; MCCOY KL, 1993, J IMMUNOL, V151, P6757; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PACE CN, 1984, BIOCHEM J, V219, P411, DOI 10.1042/bj2190411; PACE CN, 1988, J BIOL CHEM, V263, P11820; PARKS DE, 1980, J IMMUNOL, V124, P1230; POLAND DC, 1965, BIOPOLYMERS, V3, P373; RADFORD SE, 1991, BIOCHEM J, V273, P211, DOI 10.1042/bj2730211; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROUAS N, 1993, J IMMUNOL, V150, P782; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2489; So T, 1996, IMMUNOL LETT, V49, P91, DOI 10.1016/0165-2478(95)02488-3; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; UEDA T, 1985, BIOCHEMISTRY-US, V24, P6316, DOI 10.1021/bi00343a042; YAMADA H, 1993, J BIOCHEM-TOKYO, V114, P398, DOI 10.1093/oxfordjournals.jbchem.a124188; YAMADA H, 1994, J BIOCHEM-TOKYO, V116, P852, DOI 10.1093/oxfordjournals.jbchem.a124606	55	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32136	32140		10.1074/jbc.272.51.32136	http://dx.doi.org/10.1074/jbc.272.51.32136			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405412	hybrid			2022-12-27	WOS:000071108000031
J	Breault, DT; Lichtler, AC; Rowe, DW				Breault, DT; Lichtler, AC; Rowe, DW			COL1A1 transgene expression in stably transfected osteoblastic cells - Relative contributions of first intron, 3'-flanking sequences, and sequences derived from the body of the human COL1A1 minigene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN GENE; PUTATIVE REGULATORY SEQUENCES; 3' UNTRANSLATED REGION; I PROCOLLAGEN COL1A1; 1ST INTRON; MESSENGER-RNA; DIFFERENTIAL UTILIZATION; 3'-UNTRANSLATED REGION; CHROMATIN STRUCTURE; CULTURED-CELLS	Collagen reporter gene constructs have be used to identify cell-specific sequences needed for transcriptional activation, The elements required for endogenous levels of COL1A1 expression, however, have not been elucidated, The human COL1A1 minigene is expressed at high levels and likely harbors sequence elements required for endogenous levels of activity, Using stably transfected osteoblastic Pyla cells, me studied a series of constructs (pOBColCAT) designed to characterize further the elements required for high level of expression. pOBColCAT, which contains the COL1A1 first intron, was expressed at 50-100-fold higher levels than ColCAT 3.6, which lacks the first intron. This difference is best explained by improved mRNA processing rather than a transcriptional effect, Furthermore, variation in activity observed with the intron deletion constructs is best explained by altered mRNA splicing, Two major regions of the human COL1A1 minigene, the 3'-flanking sequences and the minigene body, were introduced into pOBColCAT to assess both transcriptional enhancing activity and the effect on mRNA stability, Analysis of the minigene body, which includes the first five exons and introns fused with the terminal six introns and exons, revealed an orientation-independent 5-fold increase in CAT activity, In contrast the 3'-flanking sequences gave rise to a modest 61% increase in CAT activity, Neither region increased the mRNA half-life of the parent construct, suggesting that CAT-specific mRNA instability elements may serve as dominant negative regulators of stability. This study suggests that other sites within the body of the COL1A1 minigene are important for high expression, e.g. during periods of rapid extracellular matrix production.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,L5090,FARMINGTON,CT 06030	University of Connecticut			Breault, David/HDN-6048-2022					Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER CC, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P75; BARKSDALE SK, 1995, MOL CELL BIOL, V15, P2962; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BEDALOV A, 1994, J BIOL CHEM, V269, P4903; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; Breault D, 1996, MATRIX BIOL, V15, P62, DOI 10.1016/S0945-053X(96)90141-9; BREINDL M, 1984, CELL, V38, P9, DOI 10.1016/0092-8674(84)90521-X; DIEGELMANN RF, 1972, DEV BIOL, V28, P443, DOI 10.1016/0012-1606(72)90028-0; FALL PM, 1994, J BONE MINER RES, V9, P1935; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERGET T, 1989, MOL CELL BIOL, V9, P2828, DOI 10.1128/MCB.9.7.2828; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; Liska Deann J., 1992, Gene Expression, V2, P379; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MAATTA A, 1995, BBA-GENE STRUCT EXPR, V1260, P294, DOI 10.1016/0167-4781(94)00207-J; MAATTA A, 1993, BIOCHEM J, V295, P691; MANLEY JL, 1994, GENE DEV, V8, P259, DOI 10.1101/gad.8.3.259; MOEN RC, 1979, J BIOL CHEM, V254, P3526; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RAISZ LG, 1993, MOL ENDOCRINOL, V7, P17, DOI 10.1210/me.7.1.17; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SALVATORI R, 1992, BIOTECHNIQUES, V13, P510; SEGEL IH, 1976, BIOCH CALCULATIONS, P297; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31241	31250		10.1074/jbc.272.50.31241	http://dx.doi.org/10.1074/jbc.272.50.31241			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395449	hybrid			2022-12-27	WOS:A1997YL41900008
J	Roychowdhury, S; Rasenick, MM				Roychowdhury, S; Rasenick, MM			G protein beta 1 gamma 2 subunits promote microtubule assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; CYTOPLASMIC MICROTUBULES; REGULATORY PROTEIN; GTP-BINDING; TUBULIN; RECEPTORS; DOMAINS; CELLS; ASSOCIATION	alpha and beta gamma subunits of G proteins are thought to transduce signals from cell surface receptors to intracellular effector molecules. G(alpha) and G(beta gamma) have also been implicated in cell growth and differentiation, perhaps due to their association with cytoskeletal components. In this report G(beta gamma) is shown to modulate the cytoskeleton by regulation of microtubule assembly, Specificity among beta gamma species exists, as beta 1 gamma 2 stimulates microtubule assembly, and beta 1 gamma 1 is without any effect. Furthermore, a mutant beta 1 gamma 2, beta 1 gamma 2(C68S), which does not undergo prenylation and subsequent carboxyl-terminal processing on the gamma subunit, does not stimulate the formation of microtubules. beta immunoreactivity was detected exclusively in the microtubule fraction after assembly in the presence of beta 1 gamma 2, suggesting a preferential association with microtubules rather than soluble tubulin. Crude microtubule fractions from ovine brain contain G(beta gamma), and electron tron microscopy reveals a specific association with microtubules. The decoration of microtubules by G(beta gamma) appears to be strikingly similar to the periodic pattern observed for microtubule-associated proteins, suggesting a similar site of activation of microtubule assembly by both agents. It is suggested that reformation of the cytoskeleton represents an additional cellular process mediated by G(beta gamma).	UNIV ILLINOIS,DEPT PSYCHIAT,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roychowdhury, S (corresponding author), UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,M-C 901,835 S WOLCOTT AVE,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 39595, MH 00669] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Avila J, 1990, MICROTUBULE PROTEINS, V1st; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns RG, 1996, TRENDS CELL BIOL, V6, P297, DOI 10.1016/0962-8924(96)10024-6; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; Dustin P., 1984, MICROTUBULES; FUKUDA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658A0; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOSAWA T, 1995, J BIOL CHEM, V270, P1734; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEIBER D, 1993, J BIOL CHEM, V268, P3833; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LI QW, 1994, J BIOL CHEM, V269, P31777; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIN CT, 1992, LAB INVEST, V67, P770; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NEER EJ, 1994, PROTEIN SCI, V3, P3; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; PURICH DL, 1984, ADV PROTEIN CHEM, V36, P133, DOI 10.1016/S0065-3233(08)60297-1; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; Ravindra R, 1996, J CELL BIOCHEM, V61, P392, DOI 10.1002/(SICI)1097-4644(19960601)61:3<392::AID-JCB6>3.3.CO;2-M; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; SAGA CR, 1995, BIOCHEMISTRY-US, V34, P7409; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIMON M, 1991, SCIENCE, V252, P8002; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yan K, 1996, J NEUROCHEM, V66, P1489; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	46	72	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31576	31581		10.1074/jbc.272.50.31576	http://dx.doi.org/10.1074/jbc.272.50.31576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395495	hybrid			2022-12-27	WOS:A1997YL41900054
J	Zheng, GX; Blumenthal, KM; Ji, YG; Shardy, DL; Cohen, SB; Stavnezer, E				Zheng, GX; Blumenthal, KM; Ji, YG; Shardy, DL; Cohen, SB; Stavnezer, E			High affinity dimerization by ski involves parallel pairing of a novel bipartite alpha-helical domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COIL LEUCINE-ZIPPER; ELECTROSTATIC REPULSIONS; SECONDARY STRUCTURE; ONCOGENE; PROTEINS; GCN4; ACTIVATION; STABILITY; ACCURACY; FAMILY	c-Ski protein possesses a C-terminal dimerization domain that was deleted during the generation of v-ski, and has been implicated in the increased potency of c-ski in cellular transformation compared with the viral gene. The domain is predicted to consist of an extended alpha-helical segment made up of two motifs: a tandem repeat (TR) consisting of five imperfect repeats of 25 residues each and a leucine zipper (LZ) consisting of six heptad repeats. We have examined the structure and dimerization of TR or LZ individually or the entire TR-LZ domain. Using a quenched chemical cross-linking method, we show that the TR dimerizes with moderate efficiency (K-d = 4 x 10(-6) M), whereas LZ dimerizes poorly (K-d > 2 x 10(-5) M). However, the entire TR-LZ domain dimerizes efficiently (K-d = 2 x 10(-8) M), showing a cooperative effect of the two motifs, CD analyses indicate that all three proteins contain predominantly helices. Limited proteolysis of the TR-LZ dimer indicates that the two helical motifs are linked by a small loop. Interchain disulfide bond formation indicates that both the LZ and TR helices are oriented in parallel. We propose a model for the dimer interface in the TR region consisting of discontinuous clusters of hydrophobic residues forming ''leucine buttons.''	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	Case Western Reserve University; University of Cincinnati					NCI NIH HHS [CA43600] Funding Source: Medline; NHLBI NIH HHS [HL51555] Funding Source: Medline; NIGMS NIH HHS [GM48676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P552; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; KENAR KT, 1995, PROTEIN SCI, V4, P1934, DOI 10.1002/pro.5560040929; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; KOHN WD, 1995, PROTEIN SCI, V4, P237; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NAGASE T, 1993, J BIOL CHEM, V268, P13710; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SLEEMAN JP, 1993, ONCOGENE, V8, P67; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; STURAVE P, 1989, MOL CELL BIOL, V9, P1989; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1991, ONCOGENE, V6, P353; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31855	31864		10.1074/jbc.272.50.31855	http://dx.doi.org/10.1074/jbc.272.50.31855			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395532	hybrid			2022-12-27	WOS:A1997YL41900091
J	Dustin, ML; Golan, DE; Zhu, DM; Miller, JM; Meier, W; Davies, EA; van der Merwe, PA				Dustin, ML; Golan, DE; Zhu, DM; Miller, JM; Meier, W; Davies, EA; van der Merwe, PA			Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-3; MHC CLASS-II; CYTOPLASMIC DOMAIN; RECEPTOR; BINDING; LFA-3; CD48; ACTIVATION; MOBILITY; PROTEIN	The mechanism by which low affinity adhesion molecules function to produce stable cell-cell adhesion is unknown. In solution, the interaction of human CD2 with its ligand CD58 is of low affinity (500 mM(-1)) and the interaction of rat CD2 with its ligand CD48 is of still lower affinity (40 mM(-1)). At the molecular level, however, the two systems are likely to be topologically identical. Fluorescently labeled glycosylphosphatidylinositol-anchored CD48 and CD58 were prepared and incorporated into supported phospholipid bilayers, in which the ligands were capable of free lateral diffusion, Quantitative fluorescence imaging was used to study the binding of cell surface human and rat CD2 molecules to the fluorescent ligands in contact areas between Jurkat cells and the bilayers. These studies provide two major conclusions. First, CD2/ligand interactions cooperate to align membranes with nanometer precision leading to a physiologically effective two-dimensional affinity. This process does not require the intact cytoplasmic tail of CD2. Second, the degree of membrane alignment that can be achieved by topologically similar receptors deteriorates with decreasing affinity. This suggests an affinity limit for the ability of this mode of cooperativity to achieve stable cell-cell adhesion at approximately 10 mM(-1).	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Biogen Inc, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Biol Chem & Mol Pharmacol,Hematol Oncol Div, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Hematol Oncol Div, Boston, MA 02115 USA; Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England	Washington University (WUSTL); Washington University (WUSTL); Biogen; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oxford	Dustin, ML (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.		van der Merwe, P. Anton/F-8539-2011; Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASASNOVA SJM, 1997, NATURE, V387, P312; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; IZZARD CS, 1976, J CELL SCI, V21, P129; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; LIU SJ, 1995, BIOPHYS J, V68, P459, DOI 10.1016/S0006-3495(95)80207-9; MEGE JL, 1986, J THEOR BIOL, V119, P147, DOI 10.1016/S0022-5193(86)80070-4; Melton E, 1996, EUR J IMMUNOL, V26, P2952, DOI 10.1002/eji.1830261222; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; Trinkaus J. P., 1984, CELLS ORGANS FORCES; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VARHAGEN AM, 1996, EUR J IMMUNOL, V26, P2841; WARD MD, 1994, BIOPHYS J, V67, P2522, DOI 10.1016/S0006-3495(94)80742-8; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368	51	161	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30889	30898		10.1074/jbc.272.49.30889	http://dx.doi.org/10.1074/jbc.272.49.30889			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388235	hybrid			2022-12-27	WOS:000071640800048
J	Ramirez, MT; Zhao, XL; Schulman, H; Brown, JH				Ramirez, MT; Zhao, XL; Schulman, H; Brown, JH			The nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; ALPHA-ADRENERGIC STIMULATION; CALCIUM INFLUX; CELLS; PHOSPHORYLATION; IDENTIFICATION; VOLTAGE; PATHWAY; OVEREXPRESSION; ACTIVATION	Cultured neonatal ventricular myocytes display features of myocardial hypertrophy including increased cell size, myofilament organization, and reexpression of the embryonic gene for atrial natriuretic factor (ANF). KN-93, an inhibitor of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase II), blocked the induction of these responses by the alpha(1)-adrenergic receptor agonist phenylephrine, whereas its inactive analog KN-92 did not, To directly determine whether CaM kinase II could regulate ANF gene expression, we transiently expressed each of three isoforms of CaM kinase II ((alpha, delta(B), and delta(C)) along with an ANF promoter/luciferase reporter gene. The delta(B) isoform markedly increased luciferase gene expression, whereas comparable levels of the delta(C) and alpha isoforms were ineffective, Expression of delta(B)-CaM kinase II also potentiated phenylephrine-mediated ANF gene expression, and this effect was blocked by KN-93 but not by KN-92, The ability of delta(B)-CaM kinase II to transactivate a truncated ANF promoter, containing a serum response element (SRE) required for phenylephrine inducible gene expression, was lost when this SRE was mutated. The delta(B) isoform of CaM kinase II has been shown to exhibit nuclear localization, Coexpression of the non-nuclear delta(C) or alpha isoforms, which can form multimers with the delta(B) isoform, prevented the nuclear localization of delta(B)-CaM kinase II and also blocked its effects on ANF reporter gene and protein expression, In addition, a chimeric alpha-CaM kinase II which contains the nuclear localization signal of the delta(B) isoform was able to induce ANF reporter gene expression, albeit to a lesser extent than delta(B)-CaM kinase II, These data are the first to assign a function to the delta(B) isoform of CaM kinase II and to link its nuclear localization to subsequent activation of cardiac gene expression.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NIGMS NIH HHS [GM40600] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SAMAREL AM, 1992, AM J PHYSIOL, V263, pC642, DOI 10.1152/ajpcell.1992.263.3.C642; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Wang Y, 1996, MOL CELL BIOL, V16, P5915; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659	34	168	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31203	31208		10.1074/jbc.272.49.31203	http://dx.doi.org/10.1074/jbc.272.49.31203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388275	hybrid			2022-12-27	WOS:000071640800088
J	Ozers, MS; Hill, JJ; Ervin, K; Wood, JR; Nardulli, AM; Royer, CA; Gorski, J				Ozers, MS; Hill, JJ; Ervin, K; Wood, JR; Nardulli, AM; Royer, CA; Gorski, J			Equilibrium binding of estrogen receptor with DNA using fluorescence anisotropy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTORS; CONFORMATIONAL CHANGE; NUMERICAL-ANALYSIS; STEROID-HORMONES; AMINO-ACIDS; DOMAIN; LIGAND	Interaction of estrogen receptor (ER) with DNA sequences known as estrogen response elements (ERE) is required for estrogen regulation of the expression of target genes, To characterize the affinity and specificity of ER interaction with ERE sequences in vitro under equilibrium conditions, fluorescence anisotropy assays were performed using recombinant, purified ER and a fluorescein-labeled 35 base pair oligonucleotide bearing an idealized palindromic ERE, In buffer containing 100 mM KCl, the baculovirus-expressed, purified human EW bound with similar affinity to the consensus ERE and a mutant ERE with a single base pair change per half site. Above 225 mM KCl, ER exhibited discrimination between the consensus and mutated ERE targets, Between 225 and 275 mM KCl, binding to the consensus ERE was independent of salt concentration and occurred with an equilibrium dissociation constant (Rd) Of 1.8 +/- 0.6 nM, whereas binding to the mutant ERE was not detected at ER concentrations below 100 nn under the same conditions. At 300 mM KCl, the K-d for the consensus ERE increased approximately 25-fold, suggesting complex salt concentration dependence, Both estrogen-occupied and unoccupied ER bound to the consensus ERE sequence with similar affinity, indicating that estrogen affects ER activity at a step other than DNA binding, Unlike the full-length ER, the recombinant DNA binding domain of ER did not discriminate between the consensus and mutated ERE sequences even at buffer salt concentrations greater than 200 mM NaCl, suggesting that ER sequences outside the DNA binding domain may be important in promoting specific binding.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; PANVERA CORP,MADISON,WI 53711; UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Illinois System; University of Illinois Urbana-Champaign			Royer, Catherine A/E-5266-2016; Wood, Jennifer R/S-3213-2019	Royer, Catherine A/0000-0002-2670-3391; Wood, Jennifer R/0000-0001-9337-5837	NICHD NIH HHS [HD08192, HD07259, HD31299] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008192, R29HD031299, T32HD007259, R37HD008192] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; FRITSCH M, 1993, BIOCHEMISTRY-US, V32, P14000, DOI 10.1021/bi00213a033; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; HANSEN JC, 1986, J BIOL CHEM, V261, P13990; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; LUNDEEN S, 1996, HDB ENDOCRINOLOGY, P121; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MURDOCH FE, 1991, BIOCHEMISTRY-US, V30, P10838, DOI 10.1021/bi00109a005; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; ROYER CA, 1993, ANAL BIOCHEM, V210, P91, DOI 10.1006/abio.1993.1155; ROYER CA, 1992, METHOD ENZYMOL, V210, P481; ROYER CA, 1990, ANAL BIOCHEM, V191, P287, DOI 10.1016/0003-2697(90)90221-T; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	46	75	79	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30405	30411		10.1074/jbc.272.48.30405	http://dx.doi.org/10.1074/jbc.272.48.30405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374531	hybrid			2022-12-27	WOS:A1997YH61300063
J	Pochart, P; Woltering, D; Hollingsworth, NM				Pochart, P; Woltering, D; Hollingsworth, NM			Conserved properties between functionally distinct MutS homologs in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE MSH2; DNA-BASE PAIRS; MISMATCH REPAIR; DUPLEX OLIGONUCLEOTIDES; SPECIFICALLY BINDS; ESCHERICHIA-COLI; 2-HYBRID SYSTEM; HOP1 GENE; PROTEIN; HETERODIMER	In the yeast Saccharomyces cerevisiae there are five nuclear MutS homologs that act in two distinct processes. MSH2, 3, and 6 function in mismatch repair in both vegetative and meiotic cells, whereas MSH4 and MSH5 act specifically to facilitate crossovers between homologs during meiosis. Coimmunoprecipitation as well as two-hybrid experiments indicate that the Msh4 and Msh5 proteins form a hetero-oligomeric structure similar to what is observed for the Msh proteins involved in mismatch repair. Mutation of conserved amino acids in the NTP binding and putative helix-turn-helix domains of Msh5p abolish function but are still capable of interaction with Msh4p, suggesting that NTP binding plays a role downstream of hetero-oligomer formation. No hetero-oligomers are observed between the mismatch repair MutS proteins (Msh2p and Msh6p) and either Msh4p or Msh5p. These results indicate that one level of functional specificity between the mismatch repair and meiotic crossover MutS homologs in yeast is provided by the ability to form distinct hetero-oligomers.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,INST CELL & DEV BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50717, R01 GM050717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; CHI NW, 1994, J BIOL CHEM, V269, P29984; CROUSE GF, 1997, MISMATCH REPAIR SYST; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HAWLEY RS, 1987, EXCHANGE CHROMOSOMAL, P497; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLLINGSWORTH NM, 1993, GENETICS, V133, P785; Hollingsworth NM, 1997, GENETICS, V147, P33; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PROLLA TA, 1994, NATURE, V265, P1091; REENAN RAG, 1992, GENETICS, V132, P975; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	37	100	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30345	30349		10.1074/jbc.272.48.30345	http://dx.doi.org/10.1074/jbc.272.48.30345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374523	hybrid			2022-12-27	WOS:A1997YH61300055
J	Waltz, SE; McDowell, SA; Muraoka, RS; Air, EL; Flick, LM; Chen, YQ; Wang, MH; Degen, SJF				Waltz, SE; McDowell, SA; Muraoka, RS; Air, EL; Flick, LM; Chen, YQ; Wang, MH; Degen, SJF			Functional characterization of domains contained in hepatocyte growth factor-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; RECEPTOR TYROSINE KINASE; SCATTER FACTOR; KRINGLE DOMAINS; MESSENGER-RNA; MET RECEPTOR; HUMAN-SERUM; GENE; EXPRESSION; RON	To delineate the functional protein domains necessary for the biological activity of hepatocyte growth factor-like protein (HGFL), we created various site-directed and deletion mutated cDNAs coding for this protein, Wild-type and mutated versions of HGFL were produced after transfection of the corresponding cDNAs into tissue culture cells, The biological importance of the domains within HGFL was then examined by addition of recombinant wild-type or mutant forms of HGFL to assays aimed at elucidating regions involved in the stimulation of DNA synthesis, the induction of shape changes in macrophages, and the ability to stimulate cell scattering, Mutant proteins lacking the serine protease-like domain (light chain) were not biologically active in any of the assays tested and could not compete with wild-type HGFL in cell scattering experiments. These data, in addition to direct enzyme-linked immunosorbent assay analyses, suggest that the light chain may play an important role in the interaction of HGFL with its receptor, Ron, Elimination of the proposed protease cleavage site between the heavy and light chains (by mutation of Arg-483 to Glu) produced a protein with activity comparable to wild-type HGFL, Further studies with this mutated protein uncovered an additional proteolytic cleavage site that produces biologically active protein. Deletion of the various kringle domains or the amino-terminal hairpin loop had various effects in the multiple assays, These data suggest that the heavy chain may play a pivotal role ill determining the functional aspects of HGFL.	CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,GRAD PROGRAM DEV BIOL,CINCINNATI,OH 45229; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV PULM MED,DETROIT,MI 48201	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Wayne State University				Waltz, Susan/0000-0003-3572-4642	NHLBI NIH HHS [HL07527] Funding Source: Medline; NIDDK NIH HHS [DK09466, DK47003] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEZERRA JA, 1994, BIOCHEM BIOPH RES CO, V203, P666, DOI 10.1006/bbrc.1994.2234; BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HAN S, 1993, HEPATOCYTE GROWTH FA, P61; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEE HS, 1995, BIOCHEM BIOPH RES CO, V210, P1017, DOI 10.1006/bbrc.1995.1758; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; QUANTIN B, 1995, DEV DYNAM, V204, P383, DOI 10.1002/aja.1002040405; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P230; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WALTZ SE, IN PRESS ONCOGENE; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	44	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30526	30537		10.1074/jbc.272.48.30526	http://dx.doi.org/10.1074/jbc.272.48.30526			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374547	hybrid			2022-12-27	WOS:A1997YH61300079
J	Boulay, G; Zhu, X; Peyton, M; Jiang, MS; Hurst, R; Stefani, E; Birnbaumer, L				Boulay, G; Zhu, X; Peyton, M; Jiang, MS; Hurst, R; Stefani, E; Birnbaumer, L			Cloning and expression of a novel Mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the G(q) class of G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; MUSCARINIC ACETYLCHOLINE-RECEPTOR; THYROTROPIN-RELEASING-HORMONE; PANCREATIC ACINAR-CELLS; STORE DEPLETION; PERTUSSIS-TOXIN; MAST-CELLS; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; HUMAN PLATELETS	Hormonal stimulation of G(q)-protein coupled receptors triggers Ca2+ mobilization from internal stores, This is followed by a Ca2+ entry through the plasma membrane, Drosophila Trp and Trpl proteins have been implicated in Ca2+ entry and three mammalian homologues of Drosophila Trp/Trpl, hTrp1, hTrp3 and bTrp4 (also bCCE) have been cloned and expressed, Using mouse brain RNA as template, we report here the polymerase chain reaction-based cloning and functional expression of a novel Trp, mTrp6, The cDNA encodes a protein of 930 amino acids, the sequence of which is 36.8, 36.3, 43.1, 38.6, and 74.1% identical to Drosophila Trp and Trpl, bovine Trp4, and human Trp1 and Trp3, respectively, Transient expression of mTrp6 in COS.M6 cells by transfection of the full-length mTrp6 cDNA increases Ca2+ entry induced by stimulation of co-transfected M5 muscarinic acetylcholine receptor with carbachol (CCh), as seen by dual wavelength fura 2 fluorescence ratio measurements, The mTrp6-mediated increase in Ca2+ entry activity was blocked by SKF-96365 and La3+. Ca2+ entry activity induced by thapsigargin was similar in COS cells transfected with or without the mTrp6 cDNA, The thapsigargin-stimulated Ca2+ entry could not be further stimulated by CCh in control cells but was markedly increased in mTrp6-transfected cells, Records of whole cell transmembrane currents developed in response to voltage ramps from -80 to +40 mV in control HEK cells and HEK cells stably expressing mTrp6 revealed the presence of a muscarinic receptor responsive non-selective cation conductance in Trp6 cells that was absent in control cells, Our data support the hypothesis that mTrp6 encodes an ion channel subunit that mediates Ca2+ entry stimulated by a G-protein coupled receptor, but not Ca2+ entry stimulated by intracellular Ca2+ store depletion.	UNIV CALIF LOS ANGELES,SCH MED,DEPT ANESTHESIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST BRAIN RES,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Boulay, Guylain/D-9773-2010; Peyton, Michael/A-8728-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45198] Funding Source: Medline; NIGMS NIH HHS [GM54235] Funding Source: Medline; FDA HHS [BM16733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS		ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAREW MA, 1995, J PHYSIOL-LONDON, V486, P349, DOI 10.1113/jphysiol.1995.sp020817; CHINO M, 1995, J BIOL CHEM, V270, P1149; CHOW SC, 1993, BIOCHEM J, V293, P395, DOI 10.1042/bj2930395; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; Dasgupta S., 1996, Society for Neuroscience Abstracts, V22, P1028; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harlow E., 1988, ANTIBODIES LAB MANUA; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU Y, 1994, BIOCHEM BIOPH RES CO, V132, P346; Innamorati G, 1996, MOL PHARMACOL, V50, P467; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; SAGE SO, 1994, TRENDS PHARMACOL SCI, V15, P282, DOI 10.1016/0165-6147(94)90007-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; STBRID G, 1993, J BIOL CHEM, V268, P21486; SUSS E, 1989, J GEN PHYSIOL, V94, P465, DOI 10.1085/jgp.94.3.465; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU XZS, 1997, CELL, V89, P1154; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	73	275	291	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29672	29680		10.1074/jbc.272.47.29672	http://dx.doi.org/10.1074/jbc.272.47.29672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368034	hybrid			2022-12-27	WOS:A1997YG64700044
J	Lingueglia, E; deWeille, JR; Bassilana, F; Heurteaux, C; Sakai, H; Waldmann, R; Lazdunski, M				Lingueglia, E; deWeille, JR; Bassilana, F; Heurteaux, C; Sakai, H; Waldmann, R; Lazdunski, M			A modulatory subunit of acid sensing ion channels in brain and dorsal root ganglion cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; EPITHELIAL SODIUM-CHANNEL; CAENORHABDITIS-ELEGANS; HOMOLOGOUS SUBUNITS; MEMBRANE TOPOLOGY; RAT; EXPRESSION; RECEPTOR; CLONING; PROTONS	MDEG1 is a cation channel expressed in brain that belongs to the degenerin/epithelial Na+ channel superfamily, It is activated by the same mutations which cause neurodegeneration in Caenorhabditis elegans if present in the degenerins DEG-1, MEC-4, and MEC-10. MDEG1 shares 67% sequence identity with the recently cloned proton gated cation channel ASIC (acid sensing ion channel), a new member of the family which is present in brain and in sensory neurons, We have now identified MDEG1 as a proton-gated channel with properties different from those of ASIC, MDEG1 requires more acidic pH values for activation and has slower inactivation kinetics, In addition, we have cloned from mouse and rat brain a splice variant form of the MDEG1 channel which differs in the first 236 amino acids, including the first transmembrane region, This new membrane protein, which has been called MDEG2, is expressed in both brain and sensory neurons, MDEG2 is activated neither by mutations that bring neurodegeneration once introduced in C. elegans degenerins nor by low pH, However, it can associate both with MDEG1 and another recently cloned H+-activated channel DRASIC to form heteropolymers which display different kinetics, pH dependences, and ion selectivities, Of particular interest is the subunit combination specific for sensory neurons, MDEG2/DRASIC. In response to a drop in pH, it gives rise to a biphasic current with a sustained current which discriminates poorly between Na+ and K+, like the native H+-gated current recorded in dorsal root ganglion cells, This sustained current is thought to be required for the tonic sensation of pain caused by acids.	INST PHARMACOL MOL & CELLULAIRE, CNRS, UPR 411, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; HEURTEAUX, Catherine/M-4947-2016; de Weille, Jan R/F-8103-2014; LINGUEGLIA, Eric/F-5509-2013	Waldmann, Rainer/0000-0002-4599-2926; HEURTEAUX, Catherine/0000-0002-9741-9777; de Weille, Jan R/0000-0002-0505-3166; LINGUEGLIA, Eric/0000-0003-3902-3405				Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARDIAANOVEROS J, 1997, P ANTL ACAD SCI US, V94, P1459; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; Hall DH, 1997, J NEUROSCI, V17, P1033; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; STEEN KH, 1995, J NEUROSCI, V15, P3982; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0	31	412	432	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29778	29783		10.1074/jbc.272.47.29778	http://dx.doi.org/10.1074/jbc.272.47.29778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368048	hybrid			2022-12-27	WOS:A1997YG64700058
J	Shi, Y; Sullivan, SK; Pitterle, DM; Kennington, EA; Graff, JM; Blackshear, PJ				Shi, Y; Sullivan, SK; Pitterle, DM; Kennington, EA; Graff, JM; Blackshear, PJ			Mechanisms of MARCKS gene activation during Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; MIDBLASTULA TRANSITION; LAEVIS EMBRYOGENESIS; CALMODULIN-BINDING; CELLULAR SUBSTRATE; IN-VIVO; EXPRESSION	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a high affinity cellular substrate for protein kinase C, The MARCKS gene is under multiple modes of transcriptional control, including cytokine- and transformation-dependent, cell-specific, and developmental regulation, This study evaluated the transcriptional control of MARCKS gene expression during early development of Xenopus laevis, Xenopus MARCKS was highly conserved with its mammalian and avian homologues; its mRNA and protein were abundant in the maternal pool and increased after the mid-blastula transition (MBT). The Xenopus MARCKS gene was similar to those of other species, except that a second intron interrupted the 5'-untranslated region. By transiently transfecting XTC-2 cells and microinjecting Xenopus embryos with reporter gene constructs containing serial deletions of 5'-flanking MARCKS sequences, we identified a 124-base pair minimal promoter that was critical for promoter activity, Developmental gel shift assays revealed that a CBF/NF-Y/CP-1-like factor and an Sp1-like factor bound to this region in a manner correlating with the onset of Xenopus MARCKS transcription at MBT. Mutations in the promoter that abolished binding of these two factors also completely inhibited transcriptional activation of the MARCKS gene at MBT, The binding sites for these two factors are highly conserved in the human and mouse MARCKS promoters, suggesting that these elements might also regulate MARCKS transcription in other species. These studies not only increase our knowledge of the transcriptional regulation of the MARCKS genes but also have implications for the mechanisms responsible for zygotic activation of the Xenopus genome at MBT.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,SECT DIABET & METAB, DIV ENDOCRINOL METAB & NUTR,DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,SECT DIABET & METAB, DIV ENDOCRINOL METAB & NUTR,DEPT BIOCHEM, DURHAM, NC 27710 USA; ROCKEFELLER UNIV, LAB CARDIAC MEMBRANE PHYSIOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, CTR DEV BIOL, DALLAS, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; Blackshear PJ, 1996, DEV BRAIN RES, V96, P62, DOI 10.1016/S0165-3806(96)00097-1; BRAKENHOFF RH, 1991, NUCLEIC ACIDS RES, V19, P1279, DOI 10.1093/nar/19.6.1279; BRENNAN SM, 1991, MOL REPROD DEV, V30, P293, DOI 10.1002/mrd.1080300403; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MODAK SP, 1993, ONCOGENE, V8, P645; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; OVSENEK N, 1991, DEV BIOL, V145, P323, DOI 10.1016/0012-1606(91)90130-U; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMBROOK JE, 1989, MOL CLONING LB MANUA; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMITH JC, 1991, METHOD CELL BIOL, V36, P635; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416	60	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29290	29300		10.1074/jbc.272.46.29290	http://dx.doi.org/10.1074/jbc.272.46.29290			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361009	hybrid			2022-12-27	WOS:A1997YF68400068
J	Takeuchi, Y; Suzawa, M; Kikuchi, T; Nishida, E; Fujita, T; Matsumoto, T				Takeuchi, Y; Suzawa, M; Kikuchi, T; Nishida, E; Fujita, T; Matsumoto, T			Differentiation and transforming growth factor-beta receptor down-regulation by collagen-alpha 2 beta 1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; COLLAGEN MESSENGER-RNA; MC3T3-E1 CELLS; MAP KINASE; TRANSDUCTION PATHWAYS; EXTRACELLULAR-MATRIX; ALKALINE-PHOSPHATASE; INVITRO; BINDING; PHOSPHORYLATION	Interaction of type I collagen (COL(I)) with alpha 2 beta 1 integrin causes differentiation and transforming growth factor (TGF)-beta receptor down-regulation in osteoblastic cells (Takeuchi, Y,, Nakayama, K,, and Matsumoto, T, (1996) J, Biol, Chem, 271, 3938-3644), The TGF-beta receptor down-regulation enables cells to escape from the inhibition of differentiation by TGF-beta. To clarify how the cell-matrix interaction regulates these phenotypic changes, signaling pathways were examined in murine MC3T3-E1 cells, Attachment of cells to COL(I) stimulated tyrosine phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK), a mitogen-activated protein kinase (MAPK), and enhanced MAPK activity, Inhibition of tyrosine kinase by herbimycin A, destruction of focal adhesion by cytochalasin D, or overexpression of antisense FAK mRNA prevented the activation of ERK/MAPK and the increase in alkaline phosphatase (ALP) activity. Transient expression of a MAPK-specific phosphatase, CL100, also sup pressed the elevation of ALP activity, In addition, introduction of a constitutively active MAPK kinase enhanced ALP activity in the absence of collagen production, TGF-beta receptor down-regulation was abrogated by treatments that inactivate FAK, whereas the expression of CL100 had no effect, These results demonstrate that COL(I)-alpha 2 beta 1 integrin interaction facilitates differentiation and down-regulates TGF-beta receptors via the activation of FAK and its diverse downstream signals, These signaling pathways may play an important role in the sequential differentiation of osteoblasts during bone formation.	KYOTO UNIV, INST VIRUS RES, KYOTO 60601, JAPAN	Kyoto University	Takeuchi, Y (corresponding author), UNIV TOKYO, SCH MED, DEPT INTERNAL MED 4, BUNKYO KU, 3-28-6 MEJIRODAI, TOKYO 112, JAPAN.							CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HEINO J, 1989, J BIOL CHEM, V264, P21806; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO T, 1991, BONE, V12, P27, DOI 10.1016/8756-3282(91)90051-J; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARSONS JT, 1994, J CELL SCI, P109; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; TSAO H, 1990, J BIOL CHEM, V265, P15471; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	36	267	278	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29309	29316		10.1074/jbc.272.46.29309	http://dx.doi.org/10.1074/jbc.272.46.29309			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361011	hybrid			2022-12-27	WOS:A1997YF68400070
J	McMahon, LG; Nakano, H; Levy, MD; Gregory, JF				McMahon, LG; Nakano, H; Levy, MD; Gregory, JF			Cytosolic pyridoxine-beta-D-glucoside hydrolase from porcine jejunal mucosa - Purification, properties, and comparison with broad specificity beta-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; POLYACRYLAMIDE-GEL ELECTROPHORESIS; GAUCHERS-DISEASE; RICE BRAN; IN-VITRO; PYRIDOXINE-5'-BETA-D-GLUCOSIDE; GLUCOCEREBROSIDASE; VITAMIN-B6; HYDROLYSIS; PROTEIN	During studies of the nutritional utilization of pyridoxine 5'-beta-D-glucoside, a major form of vitamin B6 in plants, we detected two cytosolic beta-glucosidases in jejunal mucosa. As expected, one was broad specificity beta-glucosidase that hydrolyzed aryl beta-D-glycosides but not pyridoxine beta-D-glucoside. We also found a previously unknown enzyme, designated pyridoxine-beta-D-glucoside hydrolase, that efficiently hydrolyzed pyridoxine beta-D-glucoside. These were separated and purified as follows: broad specificity beta-glucosidase 1460-fold and pyridoxine-beta-D-glucoside hydrolase 36,500-fold, Purified pyridoxine-beta-D-glucoside hydrolase did not hydrolyze any of the aryl glycosides tested but did hydrolyze cellobiose and lactose. Pyridoxine-beta-D-glucoside hydrolase exhibited a pH optimum of 5.5 and apparent molecular mass of 130 kDa by SDS-polyacrylamide gel electrophoresis and 160 kDa by nondenaturing gel filtration, in contrast to 60 kDa for native and denatured broad specificity beta-glucosidase. Glucono-delta-lactone was a strong inhibitor of both enzymes. Ionic and nonionic detergents were inhibitory for each enzyme. Conduritol B epoxide, a potent inhibitor of lysosomal acid beta-glucosidase, inhibited pyridoxine-beta-D-glucoside hydrolase but not broad spec- ificity beta-glucosidase, but both were inhibited by the mechanism-based inhibitor 2-deoxy-2-fluoro-beta-D-glucosyl fluoride. Our findings indicate major differences between these two cytosolic beta-glucosidases. Studies addressing the role of vitamin B6 nutrition in regulating the activity and its consequences regarding pyridoxine glucoside bioavailability are in progress.	Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Gregory, JF (corresponding author), Univ Florida, Dept Food Sci & Human Nutr, POB 110370, Gainesville, FL 32611 USA.	jfgy@gnv.ifas.ufl.edu		Gregory, Jesse/0000-0002-9976-2085	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037481] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37481] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AERTS JMFG, 1985, EUR J BIOCHEM, V150, P565, DOI 10.1111/j.1432-1033.1985.tb09058.x; AERTS JMFG, 1986, ANAL BIOCHEM, V154, P655, DOI 10.1016/0003-2697(86)90043-6; BANKS MA, 1994, J NUTR BIOCHEM, V5, P238, DOI 10.1016/0955-2863(94)90042-6; BANKS MA, 1994, J NUTR, V124, P406, DOI 10.1093/jn/124.3.406; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONCHIE J, 1967, BIOCHEM J, V102, P929, DOI 10.1042/bj1020929; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; DANIELS LB, 1982, CLIN CHEM, V28, P569; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; DEPETRO JJ, 1987, THESIS U PITTSBURGH; GARFIN DE, 1990, METHOD ENZYMOL, V182, P459; GLEW RH, 1976, BIOCHIM BIOPHYS ACTA, V422, P179, DOI 10.1016/0005-2744(76)90018-8; GLEW RH, 1988, LAB INVEST, V58, P5; GLEW RH, 1993, BETAGLUCOSIDASES BIO, P93; GOPALAN V, 1992, J BIOL CHEM, V267, P14027; GOPALAN V, 1989, BIOCHEM J, V262, P541, DOI 10.1042/bj2620541; GOPALAN V, 1989, J BIOL CHEM, V264, P15418; GRABOWSKI GA, 1993, ACS SYM SER, V533, P66; GREGORY JF, 1987, J AGR FOOD CHEM, V35, P76, DOI 10.1021/jf00073a018; GREGORY JF, 1991, J NUTR, V121, P177, DOI 10.1093/jn/121.2.177; Gregory JF, 1997, METHOD ENZYMOL, V280, P58; HARA A, 1979, BIOCHIM BIOPHYS ACTA, V582, P412, DOI 10.1016/0304-4165(79)90133-8; Hays WS, 1996, BIOCHEM J, V319, P829, DOI 10.1042/bj3190829; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; HO MW, 1973, BIOCHEM J, V136, P821, DOI 10.1042/bj1360821; INK SL, 1986, J AGR FOOD CHEM, V34, P857, DOI 10.1021/jf00071a024; IWAMI K, 1986, NUTR RES, V6, P407, DOI 10.1016/S0271-5317(86)80181-6; KABIR H, 1983, J FOOD SCI, V48, P1422, DOI 10.1111/j.1365-2621.1983.tb03506.x; KANFER JN, 1975, BIOCHEM BIOPH RES CO, V67, P85, DOI 10.1016/0006-291X(75)90286-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCO KL, 1985, ARCH BIOCHEM BIOPHYS, V236, P669, DOI 10.1016/0003-9861(85)90672-1; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; LEABACK DH, 1968, BIOCHEM BIOPH RES CO, V32, P1025, DOI 10.1016/0006-291X(68)90132-0; MARET A, 1981, EUR J BIOCHEM, V115, P455; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCARTER JD, 1994, BIOCHEM J, V301, P343, DOI 10.1042/bj3010343; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAKANO H, 1995, J NUTR, V125, P2751; Nakano H, 1997, J NUTR, V127, P1508, DOI 10.1093/jn/127.8.1508; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PENTCHEV PG, 1973, J BIOL CHEM, V248, P5256; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P1983; PETERS SP, 1976, ARCH BIOCHEM BIOPHYS, V175, P569, DOI 10.1016/0003-9861(76)90547-6; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; POCSI I, 1988, BIOCHEM J, V256, P139, DOI 10.1042/bj2560139; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; ROCKLIN RD, 1983, J LIQ CHROMATOGR, V6, P1577, DOI 10.1080/01483918308064876; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TANAKA A, 1986, J BIOCHEM-TOKYO, V100, P1379, DOI 10.1093/oxfordjournals.jbchem.a121844; TRUMBO PR, 1990, P SOC EXP BIOL MED, V195, P240; TRUMBO PR, 1988, J NUTR, V118, P1336, DOI 10.1093/jn/118.11.1336; TRUMBO PR, 1988, J NUTR, V118, P179; WALASZEK Z, 1982, CARBOHYD RES, V106, P193, DOI 10.1016/S0008-6215(00)81073-3; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; YASUMOTO K, 1977, AGR BIOL CHEM TOKYO, V41, P1061, DOI 10.1080/00021369.1977.10862620	55	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32025	32033		10.1074/jbc.272.51.32025	http://dx.doi.org/10.1074/jbc.272.51.32025			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405396	hybrid			2022-12-27	WOS:000071108000015
J	Mori, K; Tobimatsu, T; Hara, T; Toraya, T				Mori, K; Tobimatsu, T; Hara, T; Toraya, T			Characterization, sequencing, and expression of the genes encoding a reactivating factor for glycerol-inactivated adenosylcobalamin-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; CITROBACTER-FREUNDII; ESCHERICHIA-COLI; COENZYME; CLONING; ENTEROBACTERIACEAE; 1,2-PROPANEDIOL; FERMENTATION	Diol dehydratase undergoes suicide inactivation by glycerol during catalysis involving irreversible cleavage of the Go-G bond of adenosylcobalamin. In permeabilized Klebsiella oxytoca and Klebsiella pneumoniae cells, the glycerol-inactivated holoenzyme or the enzyme-cyanocobalamin complex is rapidly activated by the exchange of the inactivated coenzyme or cyanocobalamin for free adenosylcobalamin in the presence of ATP and Mg2+ (Honda, S., Toraya, T., and Fukui, S. (1980) J. Bacteriol. 143, 1458-1465; Ushio, K., Honda, S., Toraya, T., and Fukui, S. (1982) J. Nutr. Sci. Vitaminol. 28, 225-236). Permeabilized Escherichia coli cells co-expressing the diol dehydratase genes with two open reading frames in the 3'-flanking region were capable; of reactivating glycerol-inactivated diol dehydratase as well as activating the enzyme-cyanocobalamin complex in situ in the presence of free adenosylcobalamin, ATP, and Mg2+. These open reading frames, designated as ddrA and ddrB genes, were identified as the genes of a putative reactivating factor for inactivated diol dehydratase. The genes encoded polypeptides consisting of 610 and 125 amino acid residues with predicted molecular weights of 64,266 and 13,620, respectively. Go-expression of the open reading frame in the 5'-flanking region was stimulatory but not obligatory for conferring the reactivating activity upon E. coli. Thus, the product of this gene was considered not an essential component of the reactivating factor.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 700, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 700, Japan.		Mori, Koichi/ABC-7268-2021; MORI, Koichi/B-2567-2011; TOBIMATSU, Takamasa/B-2646-2011	Mori, Koichi/0000-0001-8865-2107; 				BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V17, P2218; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FORAGE RG, 1982, J BACTERIOL, V151, P591, DOI 10.1128/JB.151.2.591-599.1982; FORAGE RG, 1982, J BACTERIOL, V149, P413, DOI 10.1128/JB.149.2.413-419.1982; FORAGE RG, 1979, BIOCHIM BIOPHYS ACTA, V569, P249, DOI 10.1016/0005-2744(79)90060-3; HONDA S, 1980, J BACTERIOL, V143, P1458, DOI 10.1128/JB.143.3.1458-1465.1980; HOSOI N, 1978, J FERMENT TECHNOL, V56, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAYA AA, 1977, BIOCHIM BIOPHYS ACTA, V484, P236, DOI 10.1016/0005-2744(77)90128-0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER Z, 1966, ACTA BIOCHIM POL, V13, P311; Seyfried M, 1996, J BACTERIOL, V178, P5793, DOI 10.1128/jb.178.19.5793-5796.1996; SHIBUI T, 1988, AGR BIOL CHEM TOKYO, V52, P983; Tobimatsu T, 1996, J BIOL CHEM, V271, P22352, DOI 10.1074/jbc.271.37.22352; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; TORAYA T, 1978, J BACTERIOL, V135, P726, DOI 10.1128/JB.135.2.726-729.1978; TORAYA T, 1979, J BACTERIOL, V139, P39, DOI 10.1128/JB.139.1.39-47.1979; Toraya T., 1982, B12, P233; USHIO K, 1982, J NUTR SCI VITAMINOL, V28, P225; Walter D, 1997, J BACTERIOL, V179, P1013, DOI 10.1128/jb.179.4.1013-1022.1997	30	57	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32034	32041		10.1074/jbc.272.51.32034	http://dx.doi.org/10.1074/jbc.272.51.32034			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405397	hybrid			2022-12-27	WOS:000071108000016
J	Angermayr, M; Bandlow, W				Angermayr, M; Bandlow, W			The type of basal promoter determines the regulated or constitutive mode of transcription in the common control region of the yeast gene pair GCY1/RIO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SITE-SPECIFIC MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; ACTIVATION; ELEMENT; DNA; SEQUENCES; COMPLEX	The yeast genes, GCY1 and RIO1, are transcribed divergently from the 869-base pair intergenic region, GCY1 is inducible by galactose about 25-fold due to Gal4p-binding to a single UAS(GAL), whereas RIO1 is constitutively expressed, GCY1 has a TATA box obeying the consensus TATAAA, whereas the RIO1 5'-upstream region lacks such a motif. In vitro mutagenesis of the TATA motif of GCY1, on the one hand, and introduction of a TATA-element into the promoter of RIO1, on the other hand, as well as inversion of the intergenic region have revealed that transcription of GCY1 and RIO1 is only regulated by Gal4p when a consensus TATA motif is included in their core promoters but not in its absence, The data imply that only transcription complexes that assemble at a consensus TATA box are compatible with specific transactivators, such as Gal4p. As a result, the adjacent gene is subject to regulated expression. By contrast, if a consensus TATA sequence is absent, the initiation complex does not respond to regulatory transcription factors, and consequently, the respective gene is constitutively transcribed. On the other hand, we show that two blocks of homo-oligomeric (dA.dT) sequences do not function as boundary sequences that might confine regulatory action of Gal4p to GCY1.	UNIV MUNICH,INST GENET & MIKROBIOL,D-80638 MUNICH,GERMANY	University of Munich								AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERMANN H, 1992, GENE, V119, P137, DOI 10.1016/0378-1119(92)90079-5; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; Maniatis T., 1982, MOL CLONING; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1994, J BIOL CHEM, V269, P23135; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; SAKURAI H, 1996, FEBS LETT, V39, P113; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YOCUM RR, 1984, MOL CELL BIOL, V4, P1984	41	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31630	31635		10.1074/jbc.272.50.31630	http://dx.doi.org/10.1074/jbc.272.50.31630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395503	hybrid			2022-12-27	WOS:A1997YL41900062
J	Chan, VC; Ramshaw, JAM; Kirkpatrick, A; Beck, K; Brodsky, B				Chan, VC; Ramshaw, JAM; Kirkpatrick, A; Beck, K; Brodsky, B			Positional preferences of ionizable residues in Gly-X-Y triplets of the collagen triple-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSTATIC INTERACTIONS; CHAIN CONFORMATION; MOLECULAR PACKING; MODEL PEPTIDES; COILED COILS; STABILIZATION; ENERGETICS; PROTEINS; ORIGINS; DESIGN	Collagens contain a high amount of charged residues involved in triple-helix stability, fibril formation, and ligand binding. The contribution of charged residues to stability was analyzed utilizing a host-guest peptide system with a single Gly-X-Y triplet embedded within Ac(Gly-Pro-Hyp)(3)-Gly-X-Y-(Gly-Pro-Hyp)(4)-Gly-Gly-NH2. The ionizable residues Arg, Lys, Glu, and Asp were incorporated into the X position of Gly-X-Hyp; in the Y position of Gly-Pro-Y; or as pairs of oppositely charged residues occupying X and Y positions, The Gly-X-Hyp peptides had similar thermal stabilities, only marginally less stable than Gly-Pro-Hyp, whereas Gly-Pro-Y peptides showed a wide thermal stability range (T-m = 30-45 degrees C). The stability of peptides with oppositely charged residues in the X and Y positions appears to reflect simple additivity of the individual residues, except when X is occupied by a basic residue and Y = Asp, The side chains of Glu, Lys, and Arg have the potential to form hydrogen bonds with available peptide backbone carbonyl groups within the triple-helix, whereas the shorter Asp side chain does not, This may relate to the unique involvement of Asp residues in energetically favorable ion pair formation. These studies clarify the dependence of triple-helix stability on the identity, position, and ionization state of charged residues.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; CSIRO,DEPT MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Beck, Konrad/AAX-1351-2020; Ramshaw, John AM/A-9411-2011	Beck, Konrad/0000-0001-5098-9484; Ramshaw, John A.M./0000-0002-2131-3685	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19626] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANSAL M, 1978, INT J PEPT PROT RES, V11, P73; BELLA J, 1995, STRUCTURE, V3, P893, DOI 10.1016/S0969-2126(01)00224-6; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BRODSKY B, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P55; BROWN EM, 1993, J AM LEATHER CHEM AS, V88, P2; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DOYLE BB, 1974, BIOCHEM BIOPH RES CO, V60, P858, DOI 10.1016/0006-291X(74)90320-9; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; Fields GB, 1996, BIOPOLYMERS, V40, P345, DOI 10.1002/(SICI)1097-0282(1996)40:4<345::AID-BIP1>3.0.CO;2-W; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; HOFMANN H, 1980, J MOL BIOL, V141, P293, DOI 10.1016/0022-2836(80)90182-5; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HULMES DJS, 1973, J MOL BIOL, V79, P137, DOI 10.1016/0022-2836(73)90275-1; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER K, 1995, PROTEIN PROFILE, V2, P491; KATZ EP, 1992, J MOL BIOL, V228, P963, DOI 10.1016/0022-2836(92)90878-N; KATZ EP, 1990, BIOPOLYMERS, V29, P791, DOI 10.1002/bip.360290413; LI ST, 1975, J MOL BIOL, V98, P835, DOI 10.1016/S0022-2836(75)80015-5; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SALEM G, 1975, FEBS LETT, V51, P94, DOI 10.1016/0014-5793(75)80861-1; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; TRAUB W, 1976, FEBS LETT, V68, P245, DOI 10.1016/0014-5793(76)80446-2; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; Wada A, 1976, Adv Biophys, P1; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WALLACE DG, 1990, BIOPOLYMERS, V29, P1015, DOI 10.1002/bip.360290613; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	40	80	82	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31441	31446		10.1074/jbc.272.50.31441	http://dx.doi.org/10.1074/jbc.272.50.31441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395477	hybrid, Green Accepted			2022-12-27	WOS:A1997YL41900036
J	Cheng, YS; Champliaud, MF; Burgeson, RE; Marinkovich, MP; Yurchenco, PD				Cheng, YS; Champliaud, MF; Burgeson, RE; Marinkovich, MP; Yurchenco, PD			Self-assembly of laminin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; MUSCULAR-DYSTROPHY; HEPARIN-BINDING; SHORT ARM; CHAIN; EXPRESSION; ADHESION; NETWORK; GENE; KERATINOCYTES	The alpha, beta, and gamma subunits of basement membrane laminins can combine into different heterotrimeric molecules with either three full short arms (e.g. laminins-1-4), or molecules containing one (laminins-6-9) or more (laminin-5) short arm truncations. Laminin-1 (alpha 1 beta 1 gamma 1), self-assembles through a calcium-dependent thermal gelation requiring binding interactions between N-terminal short arm domains, forming a meshwork polymer thought to contribute to basement membrane architecture (Yurchenco, P. D., and Cheng, Y. S. (1993) J. Biol. Chem. 268, 17286-17299). However, it has been unclear whether other isoforms share this property, and if so, which ones. To begin to address this, we evaluated laminin-2 (alpha 2 beta 1 gamma 1), laminin-4 (alpha 2 beta 2 gamma 1), laminin-5 (alpha 3A beta 3 gamma 2), and laminin-6 (alpha 3A beta 1 gamma 1). The first two isoforms were found to self-aggregate in a concentration- and temperature-dependent manner and a close self-assembly relationship among laminins-1, -2, and -4 were demonstrated by: (a) polymerization of all three proteins was inhibited by EDTA and laminin-1 short arm fragments, (b) polymerization of laminin-1 was inhibited by fragments of laminins-2 and -4, (c) laminin-2 and, to a lesser degree, laminin-4, even well below their own critical concentration, co-aggregated with laminin-1, evidence for co-polymerization. Laminin-5, on the other hand, neither polymerized nor co-polymerized with laminin-1. Laminin-6 failed to co-aggregate with laminin-l at all concentrations evaluated, evidence for a lack of a related self-assembly activity. The data support the hypothesis that all three short arms are required for self-assembly and suggest that the short arm domain structure of laminin isoforms affect their architecture-forming properties in basement membranes.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL & LAB MED,PISCATAWAY,NJ 08854; PALO ALTO VET AFFAIRS HLTH CARE SYST,DIV DERMATOL,PALO ALTO,CA 94061; STANFORD UNIV,SCH MED,DEPT DERMATOL,STANFORD,CA 94305; HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,CUTANEOUS BIOL RES CTR,CHARLESTOWN,MA 02129	Rutgers State University New Brunswick; Rutgers State University Medical Center; Stanford University; Harvard University				Yurchenco, Peter/0000-0003-0387-2317	NIAMS NIH HHS [P01-AR-44012, R01-AR 35689] Funding Source: Medline; NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035689, P01AR044012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Engvall E, 1996, J CELL BIOCHEM, V61, P493; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; Mayer U., 1994, EXTRACELLULAR MATRIX, P389, DOI [10.1016/B978-0-12-775170-2.50017-2, DOI 10.1016/B978-0-12-775170-2.50017-2]; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miquel C, 1996, EXP CELL RES, V224, P279, DOI 10.1006/excr.1996.0138; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; Yurchenco PD., 1994, EXTRACELLULAR MATRIX, P351	30	198	202	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31525	31532		10.1074/jbc.272.50.31525	http://dx.doi.org/10.1074/jbc.272.50.31525			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395489	hybrid			2022-12-27	WOS:A1997YL41900048
J	Crosbie, RH; Heighway, J; Venzke, DP; Lee, JC; Campbell, KP				Crosbie, RH; Heighway, J; Venzke, DP; Lee, JC; Campbell, KP			Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; CONGENITAL FIBROSIS; EXTRAOCULAR-MUSCLES; GENE; CHROMOSOME-12; SARCOLEMMA; LINKAGE	The dystrophin-glycoprotein complex is a multisubunit protein complex that spans the sarcolemma and forms a link between the subsarcolemmal cytoskeleton and the extracellular matrix. Primary mutations in the genes encoding the proteins of this complex are associated with several forms of muscular dystrophy. Here we report the cloning and characterization of sarcospan, a unique 25-kDa member of this complex. Topology algorithms predict that sarcospan contains four transmembrane spanning helices with both N- and C-terminal domains located intracellularly. Phylogenetic analysis reveals that sarcospan's arrangement in the membrane as well as its primary sequence are similar to that of the tetraspan superfamily of proteins. Sarcospan co-localizes and co-purifies with the dystrophin-glycoprotein complex, demonstrating that it is an integral component of the complex. We also show that sarcospan expression is dramatically reduced in muscle from patients with Duchenne muscular dystrophy. This suggests that localization of sarcospan to the membrane is dependent on proper dystrophin expression. The gene encoding sarcospan maps to human chromosome 12p11.2, which falls within the genetic locus for congenital fibrosis of the extraocular muscle, an autosomal dominant muscular dystrophy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,MANCHESTER M20 9BX,LANCS,ENGLAND	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Campbell, Kevin/0000-0003-2066-5889; Venzke, David/0000-0001-8180-9562				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; ENGLE EC, 1995, AM J HUM GENET, V57, P1086; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; SCOTT AF, 1994, GENOMICS, V20, P227, DOI 10.1006/geno.1994.1157; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; WILLIAMS KR, 1997, IN PRESS TECHNIQUES, V6; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; [No title captured]	21	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31221	31224		10.1074/jbc.272.50.31221	http://dx.doi.org/10.1074/jbc.272.50.31221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395445	hybrid, Green Submitted			2022-12-27	WOS:A1997YL41900004
J	Vivaudou, M; Chan, KW; Sui, JL; Jan, LY; Reuveny, E; Logothetis, DE				Vivaudou, M; Chan, KW; Sui, JL; Jan, LY; Reuveny, E; Logothetis, DE			Probing the G-protein regulation of GIRK1 and GIRK4, the two subunits of the K-ACh channel, using functional homomeric mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; MUSCARINIC POTASSIUM CHANNEL; GTP-BINDING PROTEINS; INWARD-RECTIFIER; I-KACH; XENOPUS OOCYTES; RECTIFICATION; EXPRESSION; CLONING; RESIDUE	In heart, G-protein-activated channels are complexes of two homologous proteins, GIRK1 and GIRK4. Expression of either protein alone results in barely active or non-active channels, making it difficult to assess the individual contribution of each subunit to the channel complex. The residue Phe(137), located within the H5 region of GIRK1, is critical to the synergy between GIRK1 and GIRK4 (Chan, K. W., Sui, J. L., Vivaudou, M., and Logothetis, D. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14193-14198). By modifying this residue or the matching residue of GIRK4, Ser(143), we have been able to generate mutant proteins that produced large inwardly rectifying, G-protein-modulated currents when expressed alone in Xenopus oocytes. The enhanced activity of the heterologous expression of each of two active mutants, GIRK1(F137S) and GIRK4(S143T), was not caused by association with an endogenous oocyte channel subunit, and these mutants did not display apparent differences in the ability to localize to the cell surface compared with their wild-type counterparts. when these functional mutant channels were compared individually with wild-type heteromeric channels, they responded with only small differences to a number of maneuvers involving coexpression with muscarinic receptors, G-protein beta gamma subunits, wild-type or mutated G-protein alpha subunits, and active protomers of pertussis toxin. These experiments, which confirmed the crucial, though not exclusive, role of G beta gamma in regulating channel activity, demonstrated that GIRK1(F137S) and GIRK4(S143T), and by extrapolation their wild-type counterparts, interact in a qualitatively similar way with G-protein subunits. These findings suggest that functionally important sites of interaction with G-proteins are likely to be located within the homologous regions of GIRK1 and GIRK4 rather than within the divergent terminal regions. They also raise the question of the functional advantage of a heteromeric over homomeric design for G-protein-gated channels.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Weizmann Institute of Science			Vivaudou, Michel/C-5338-2008	Vivaudou, Michel/0000-0002-9777-3127; Jan, Lily/0000-0003-3938-8498	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; SUI JL, 1988, IN PRESS ADV 2 MESSP; VIVAUDOU M, 1997, BIOPHYS J, V72, P11; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	35	127	130	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31553	31560		10.1074/jbc.272.50.31553	http://dx.doi.org/10.1074/jbc.272.50.31553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395492	hybrid			2022-12-27	WOS:A1997YL41900051
J	Zeng, YC; Bannon, G; Thomas, VH; Rice, K; Drake, R; Elbein, A				Zeng, YC; Bannon, G; Thomas, VH; Rice, K; Drake, R; Elbein, A			Purification and specificity of beta 1,2-xylosyltransferase, an enzyme that contributes to the allergenicity of some plant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ATOPIC-DERMATITIS; GLYCANS; IGE; ANTIBODIES; CHALLENGES; POLLEN; VENOM; WHEAT	The enzyme that transfers D-xylose from UDP-xylose to the beta-linked mannose of plant N-linked oligosaccharides was purified about 51,000-fold to apparent homogeneity from soybean microsomes. On SDS gels, two proteins of 56 and 59 kDa were detected and both were labeled to the same extent by the photoaffinity label, 5-N-3-UDP-[P-32]xylose. Labeling of both proteins was inhibited by cold UDP-xylose, but not by UDP-glucose. The amount of 5-N-3-UDP-[P-32]xylose that bound to the two protein bands was greatly increased in the presence of oligosaccharide accepters. The best acceptor for xylose transfer and for stimulation of UDP-xylose binding was GlcNAc(2)Man(3)GlcNAc(2)-T, but GlcNAc(1)Man(3)GlcNAc(2), with the GlcNAc on the 3-branch, was also a good acceptor and a good stimulator. A number of other N-linked oligosaccharides were poor accepters, especially those with galactose units at the nonreducing termini, Many of the properties of this enzyme have been described, and the product of the reaction of UDP-xylose and GlcNAc(2)Man(3)(GlcNAc)(2) was characterized as GlcNAc beta 1, 2Man alpha 1,6(GlcNAc beta 1,2Man alpha 1,3) (Xyl beta 1,2)Man beta 1,4GlcNA c(2)-T by chemical and NMR methods.	UNIV ARKANSAS MED SCI,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205; UNIV MICHIGAN,COLL PHARM,DEPT MED CHEM,ANN ARBOR,MI 48109	University of Arkansas System; University of Arkansas Medical Sciences; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; BERZOKSKY JA, 1985, SCIENCE, V219, P932; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P172; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; DIXON RA, 1985, PLANT CELL CULTURE; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; GARCIACASADO G, 1995, FEBS LETT, V364, P36, DOI 10.1016/0014-5793(95)00355-D; HANSEN MY, 1994, ALLERGY, V49, P235, DOI 10.1111/j.1398-9995.1994.tb02655.x; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; KYOSSEV ZN, 1995, EUR J BIOCHEM, V228, P109, DOI 10.1111/j.1432-1033.1995.0109o.x; MULDER H, 1995, EUR J BIOCHEM, V232, P272, DOI 10.1111/j.1432-1033.1995.tb20809.x; RODGERS MW, 1992, BIOCHEM J, V288, P817, DOI 10.1042/bj2880817; SILVA M, 1994, ARCH BIOCHEM BIOPHYS, V312, P151; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TEZUKA K, 1992, EUR J BIOCHEM, V203, P401, DOI 10.1111/j.1432-1033.1992.tb16564.x; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857	23	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31340	31347		10.1074/jbc.272.50.31340	http://dx.doi.org/10.1074/jbc.272.50.31340			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395463	hybrid			2022-12-27	WOS:A1997YL41900022
J	Zha, HB; Reed, JC				Zha, HB; Reed, JC			Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; BCL-X(L); HOMODIMERIZATION; CHEMOTHERAPY; INHIBITION; EXPRESSION; APOPTOSIS; DISTINCT; SURVIVAL; DOMAINS	The pro-apoptotic protein Bax can homodimerize with itself and heterodimerize with the anti-apoptotic protein Bcl-2, but the significance of these protein-protein interactions remains unclear. Alanine substitution mutations were created in a well conserved IGDE motif found within the BH3 domain of Bax (residues 66-69) and the resulting mutant Bax proteins were tested for ability to homodimerize with themselves and to heterodimerize with Bcl-2, Correlations were made with cell death induction by these mutants of Bax both in mammalian cells where Bax may function through several mechanisms, and in yeast where Bax may exert its lethal actions through a more limited repertoire of mechanisms perhaps related to its ability to form ion channels in intracellular membranes, Two of the mutants, Bax(D68A) and Bax(E69A), retained the ability to homodimerize but failed to interact with Bcl-2 as determined by yeast two-hybrid assays and co-immunoprecipitation analysis using transfected mammalian cells, The Bax(E69A) protein exhibited a lethal phenotype in yeast, which could be specifically suppressed by co-expression of Bcl-2, despite its failure to dimerize with Bcl-2, Both the Bax(D68A) and Bax(E69A) proteins induced apoptosis when overexpressed in human 293 cells, despite an inability to bind to Bcl-2, Moreover, co-expression of Bcl-2 with Bax(D68A) and Bax(E69A) rescued mammalian cells from apoptosis, In contrast, a mutant of Bax lacking the IGDE motif, Bax(Delta IGDE), was incapable of either homodimerizing with itself or heterodimerizing with Bcl-2 and was inactive at promoting cell death in either yeast or mammalian cells, Although failing to interact with Bcl-2, the Bax(D68A) and Bax(E69A) mutants retained the ability to bind to Bid, a putative Bax-activating member of the Bcl-2 family, and collaborated with Bid in inducing apoptosis, When taken together with previous observations, these findings indicate that (i) Bax can induce apoptosis in mammalian cells irrespective of heterodimerization with Bcl-2 and (ii) Bcl-2 can rescue both mammalian cells and yeast from the lethal effects of Bax without heterodimerizing with it, However, these results do not exclude the possibility that BH3-dependent homodimerization of Bax or interactions with Bax activators such as Bid may either assist or be required for the cell death-inducing mechanism of this protein.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Diaz JL, 1997, J BIOL CHEM, V272, P11350; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1996, J BIOL CHEM, V271, P32073, DOI 10.1074/jbc.271.50.32073; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494	31	145	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31482	31488		10.1074/jbc.272.50.31482	http://dx.doi.org/10.1074/jbc.272.50.31482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395483	hybrid, Green Published			2022-12-27	WOS:A1997YL41900042
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGING TREATMENTS; EPIDERMAL GROWTH-FACTOR; ACTIN STRESS FIBERS; C-JUN; SIGNALING PATHWAY; MAMMALIAN-CELLS; CDC42 GTPASES; ACTIVATION; INDUCTION; INHIBITOR	The small GTPase RhoB is immediate-early inducible by DNA damaging treatments and thus part of the early response of eukaryotic cells to genotoxic stress. To investigate the regulation of this cellular response, we isolated the gene for rhoB from a mouse genomic Library, Sequence analysis of the rhoB gene showed that its coding region does not contain introns, The promoter region of rhoB harbors regulatory elements such as TATA, CAAT, and Sp1 boxes but not consensus sequences for AP-1, Elk-1, or c-Jun/ATF-2. The rhoB promoter was activated by UV irradiation, but not by 12-O-tetradecanoylphorbol-13-acetate treatment. rhoB promoter deletion constructs revealed a fragment of 0.17 kilobases in size which was sufficient in eliciting the UV response. This minimal promoter fragment contains TATA and CAAT boxes but no other known regulatory elements, Neither MEK inhibitor PD98059 nor p38 kinase inhibitor SB203580 blocked stimulation of rhoB by UVC (UV Light, 254 nm) which indicates that ERK or p38 mitogen-activated protein (MAP) kinase are not involved in the UV induction of rhoB, Also, phosphatidylinositol 3-kinase inhibitor wortmannin, which blocks UV stimulation of both JNK and p38 MAP kinase, did not inhibit rhoB activation. Furthermore, activation of JNK by interleukin-1 beta did not affect rhoB expression. These data indicate that JNK is not involved in the regulation of rhoB, Overexpression of wild-type Rac as well as the Rho guanine-dissociation inhibitor caused activation of rhoB, Wild-type RhoB inhibited both basal and UV stimulated rhoB promoter activity, indicating a negative regulatory feedback by RhoB itself, The data provide evidence both for a signal transduction pathway independent of JNK, ERK, and p38 MAP kinase to be involved in the induction of rhoB by genotype stress, and furthermore, indicate autoregulation of rhoB.			Fritz, G (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P201; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KAINA B, 1990, DNA REPAIR MECHANISM, P149; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	63	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30637	30644		10.1074/jbc.272.49.30637	http://dx.doi.org/10.1074/jbc.272.49.30637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388198	hybrid			2022-12-27	WOS:000071640800011
J	Karow, JK; Chakraverty, RK; Hickson, ID				Karow, JK; Chakraverty, RK; Hickson, ID			The Bloom's syndrome gene product is a 3 '-5 ' DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; GENOME STABILITY; WERNER SYNDROME; HOMOLOG; CLONING; SGS1; EXPRESSION; INTERACTS; DISEASE; PROTEIN	Bloom's syndrome (BS) is an autosomal recessive condition characterized by short stature, immunodeficiency, and a greatly elevated frequency of many types of cancer. The gene mutated in BS, BLM, encodes a protein containing seven "signature" motifs conserved in a wide range of DNA and RNA helicases, BLM is most closely related to the subfamily of DEXH box-containing DNA helicases of which the prototypical member is Escherichia coli RecQ, To analyze its biochemical properties, me have overexpressed an oligohistidine-tagged version of the BLM gene product in Saccharomyces cerevisiae and purified the protein to apparent homogeneity using nickel chelate affinity chromatography. The recombinant BLM protein possesses an ATPase activity that is strongly stimulated by either single or double-stranded DNA. Moreover, BLM exhibits ATP-and Mg2+-dependent DNA helicase activity that displays 3'-5' directionality. Because many of the mutations in BS individuals are predicted to truncate the BLM protein and thus eliminate the "helicase" motifs or map to conserved positions within these motifs, our data strongly suggest that these mutations will disable the 3'-5' helicase function of the BLM protein.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.		Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X; Chakraverty, Ronjon/0000-0003-2301-2664				AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Duguet M, 1997, J CELL SCI, V110, P1345; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Lombard DB, 1996, TRENDS GENET, V12, P283, DOI 10.1016/0168-9525(96)30065-6; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; PURANAM LL, 1994, J BIOL CHEM, V269, P29838; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; THWEATT R, 1993, BIOESSAYS, V15, P421, DOI 10.1002/bies.950150609; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WASSERMAN RA, 1993, CANCER RES, V53, P3591; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	22	318	324	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30611	30614		10.1074/jbc.272.49.30611	http://dx.doi.org/10.1074/jbc.272.49.30611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388193	hybrid			2022-12-27	WOS:000071640800006
J	Lin, RZ; Hu, ZW; Chin, JH; Hoffman, BB				Lin, RZ; Hu, ZW; Chin, JH; Hoffman, BB			Heat shock activates c-Src tyrosine kinases and phosphatidylinositol 3-kinase in NIH3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; MAPKAP KINASE-2; S6 KINASE; FACTOR-I; PHOSPHORYLATION; CELLS; RECEPTORS; STRESS; CASCADE	There is increasing evidence that cellular responses to stress are in part regulated by protein kinases, although specific mechanisms are not well defined, The purpose of these experiments was to investigate potential upstream signaling events activated during heat shock in NIH3T3 fibroblasts. Experiments were designed to ask whether heat shock activates p60 c-Src tyrosine kinase or phosphatidylinositol 3-kinase (PI 3-kinase). Using in vitro protein kinase activity assays, it was demonstrated that heat shock stimulates c-Src and PI 3-kinase activity in a time-dependent manner, Also, there was increased PI 3-kinase activity in anti-phosphotyrosine and anti-c-Src immunoprecipitated immunocomplexes from heated cells, Heat shock activated mitogen-activated protein kinase (MAPK) and p70 S6 kinase (S6K) in these cells, The role of PI 3-kinase in regulating heat shock activation of MAPK and p70 S6K was investigated using wortmannin, a specific pharmacological inhibitor of PI 3-kinase. The results demonstrated that wortmannin inhibited heat shock activation of p70 S6K but only partially inhibited heat activation of MAPK, A dominant negative Raf mutant inhibited activation of MAPK by heat shock but did not inhibit heat shock stimulation of p70 S6K. Genistein, a tyrosine kinase inhibitor, and suramin, a growth factor receptor inhibitor, both inhibited heat shock stimulation of MAPK activity and tyrosine phosphorylation of MAPK. Furthermore, a selective epidermal growth factor receptor (EGFR) inhibitor, tryphostin AG1478, and a dominant negative EGFR mutant also inhibited heat shock activation of MAPK. Heat shock induced EGFR phosphorylation. These results suggest that early up stream signaling events in response to heat stress may involve activation of PI 3-kinase and tyrosine kinases, such as c-Src, and a growth factor receptor, such as EGFR; activation of important downstream pathways, such as MAPK and p70 S6K, occur by divergent signaling mechanisms similar to growth factor stimulation.	Stanford Univ, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care System, Palo Alto, CA 94394 USA; Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94394 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Geriatric Research Education & Clinical Center	Hoffman, BB (corresponding author), Vet Affairs Med Ctr, 3801 Miranda Ave,GRECC 182B, Palo Alto, CA 94304 USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Huot J, 1996, CANCER RES, V56, P273; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MAHER PA, 1989, J CELL BIOL, V108, P2029, DOI 10.1083/jcb.108.6.2029; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; Rao GN, 1996, ONCOGENE, V13, P713; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; YANO H, 1993, J BIOL CHEM, V268, P25846	31	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31196	31202		10.1074/jbc.272.49.31196	http://dx.doi.org/10.1074/jbc.272.49.31196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388274	hybrid			2022-12-27	WOS:000071640800087
J	Lu, M; Farrell, PJ; Johnson, R; Iatrou, K				Lu, M; Farrell, PJ; Johnson, R; Iatrou, K			A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC ACTIN GENE; DNA-REPLICATION; HOMOLOGOUS DNA; EARLY PROMOTER; SV40 ENHANCER; RECOMBINANT BACULOVIRUSES; ORGYIA-PSEUDOTSUGATA; PUTATIVE ORIGINS; BINDING-PROTEIN; EXPRESSION	It has been previously reported that baculovirus homologous regions, the regions of baculovirus genomes that contain the origins of DNA replication, can augment the expression of a small number of baculovirus genes in vitro, We are now reporting that a region of the genome of Bombyx mori nuclear polyhedrosis virus (BmNPV) containing the homologous region 3 (HR3) acts as an enhancer for the promoter of a nonviral gene, the cytoplasmic actin gene of the silkmoth B. mori. Incorporation of the HR3 sequences of BmNPV into an actin promoter based expression cassette results in an augmentation of transgene expression in transfected cells by two orders of magnitude relative to the control re combinant expression cassette, This increase is due to a corresponding increase in the rate of transcription from the actin promoter and not to replication of the expression cassette and occurs only when the HR3 element is linked to the expression cassette in cis, A comparable degree of enhancement in the activity of the silkworm actin promoter occurs also in heterologous lepidopteran cells, Concomitant supplementation of transfected cells with the BmIE1 trans-activator, which was previously shown to be capable of functioning in vitro as a transcriptional co-activator of the cytoplasmic actin gene promoter, results in more than a 1,000-fold increase in the level of expression of recombinant proteins placed under the control of the actin gene promoter, These findings provide the foundation for the development of a nonlytic insect cell expression system for continuous high-level expression of recombinant proteins. Such a system should provide levels of expression of recombinant proteins comparable to those obtained from baculovirus expression systems and should also have the additional advantage of continuous production in a cellular environment that, in contrast to that generated by a baculovirus infection, supports continuously proper posttranslational modifications of recombinant proteins and the capability of expression of proteins from genomic as well as cDNA sequences.	Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	University of Calgary	Iatrou, K (corresponding author), Univ Calgary, Dept Med Biochem, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Johnson, Russell/0000-0002-5850-9059				AHRENS CH, 1995, VIROLOGY, V207, P572, DOI 10.1006/viro.1995.1119; ARIF BM, 1984, EMBO J, V3, P525, DOI 10.1002/j.1460-2075.1984.tb01841.x; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; CARSON DD, 1991, J VIROL, V65, P945, DOI 10.1128/JVI.65.2.945-951.1991; COCHRAN MA, 1983, J VIROL, V45, P961, DOI 10.1128/JVI.45.3.961-970.1983; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DICKSON JA, 1991, J VIROL, V65, P4006, DOI 10.1128/JVI.65.8.4006-4016.1991; GRUSS P, 1981, P NATL ACAD SCI-BIOL, V78, P943, DOI 10.1073/pnas.78.2.943; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1991, J VIROL, V65, P3676, DOI 10.1128/JVI.65.7.3676-3680.1991; GUARINO LA, 1987, J VIROL, V61, P2091, DOI 10.1128/JVI.61.7.2091-2099.1987; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; HAMMOCK BD, 1977, ANAL BIOCHEM, V82, P573, DOI 10.1016/0003-2697(77)90196-8; HOOPES RR, 1991, P NATL ACAD SCI USA, V88, P4513, DOI 10.1073/pnas.88.10.4513; IATROU K, 1985, J VIROL, V54, P436, DOI 10.1128/JVI.54.2.436-445.1985; JOHNSON R, 1992, VIROLOGY, V190, P815, DOI 10.1016/0042-6822(92)90919-G; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; KOGAN PH, 1994, J VIROL, V68, P813, DOI 10.1128/JVI.68.2.813-822.1994; KOOL M, 1993, J GEN VIROL, V74, P2661, DOI 10.1099/0022-1317-74-12-2661; KOOL M, 1993, VIROLOGY, V192, P94, DOI 10.1006/viro.1993.1011; KUZIO J, 1984, VIROLOGY, V139, P185, DOI 10.1016/0042-6822(84)90339-8; LEISY DJ, 1993, VIROLOGY, V196, P722, DOI 10.1006/viro.1993.1529; Lu ML, 1997, GENE, V185, P69, DOI 10.1016/S0378-1119(96)00632-4; Lu ML, 1996, J GEN VIROL, V77, P3135, DOI 10.1099/0022-1317-77-12-3135; Lu ML, 1996, VIROLOGY, V218, P103, DOI 10.1006/viro.1996.0170; MAEDA S, 1990, J GEN VIROL, V71, P1851, DOI 10.1099/0022-1317-71-8-1851; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; MOUNIER N, 1991, INSECT BIOCHEM, V21, P293, DOI 10.1016/0020-1790(91)90019-B; NISSEN MS, 1989, J VIROL, V63, P493, DOI 10.1128/JVI.63.2.493-503.1989; PEARSON M, 1992, SCIENCE, V257, P1382, DOI 10.1126/science.1529337; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SHERIDAN PL, 1995, J BIOL CHEM, V270, P4575, DOI 10.1074/jbc.270.9.4575; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; THEILMANN DA, 1992, VIROLOGY, V187, P97, DOI 10.1016/0042-6822(92)90298-4	37	88	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30724	30728		10.1074/jbc.272.49.30724	http://dx.doi.org/10.1074/jbc.272.49.30724			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388209	hybrid			2022-12-27	WOS:000071640800022
J	Rohr, O; Aunis, D; Schaeffer, E				Rohr, O; Aunis, D; Schaeffer, E			COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat in human microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; HUMAN BRAIN-CELLS; HIV-1 INFECTION; GENE-EXPRESSION; IN-VITRO; RECEPTOR SUPERFAMILY; POSITIVE REGULATION; TRANSGENIC MICE; NEURONAL CELLS	We have recently reported that chicken ovalbumin upstream promoter transcription factor (COUP-TF) activates human immunodeficiency virus type 1 (HIV-1) gene transcription in glial and neuronal cells. Here, we have examined the role of COUP-TF in microglial cells, the major target cells for HIV-1 infection in brain. We show that COUP-TF activates gene expression from both the lymphotropic LAI and the macrophage-tropic JR-FL HIV-1 strains, Although COUP-TF binds to the -352/-320 nuclear receptor responsive element of the long terminal repeat, it functions as a transcriptional activator by acting on the -68/+29 minimal promoter. This region is a direct target of transcription factors Sp1 and Sp3. We report the discovery and features of a physical and functional interplay between COUP-TF and Sp1. Our cotransfection experiments provide evidence for a functional synergism between Sp1 and COUP-TF leading to enhanced transcriptional activity of the HIV-1 long terminal repeat through the Sp1 element, In contrast, Sp3 functions as a repressor of Sp1- or COUP-TF-induced activation. We further demonstrate that COUP-TF and Sp1 are capable of physically interacting, via the DNA-binding domain of COUP-TF, in vitro and in the cell, These findings reveal how the novel interplay of Sp1 and COUP-TF families of transcription factors regulate HIV-1 gene expression.	INSERM, Unite 338, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Schaeffer, E (corresponding author), INSERM, Unite 338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				Albright AV, 1996, VIROLOGY, V217, P211, DOI 10.1006/viro.1996.0108; BUSY JM, 1995, VIROLOGY, V210, P361; CANONNEHERGAUX F, 1995, J VIROL, V69, P6634, DOI 10.1128/JVI.69.11.6634-6642.1995; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KIMURA A, 1993, J BIOL CHEM, V268, P11125; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kurth J, 1996, J VIROL, V70, P7686, DOI 10.1128/JVI.70.11.7686-7694.1996; Leng X, 1996, MOL CELL BIOL, V16, P2332; LI YC, 1994, J BIOL CHEM, V269, P30616; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOSES AV, 1994, J VIROL, V68, P298, DOI 10.1128/JVI.68.1.298-307.1994; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PERRY VH, 1994, J LEUKOCYTE BIOL, V56, P399, DOI 10.1002/jlb.56.3.399; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; Portegies P, 1991, AIDS, V5 Suppl 2, pS211, DOI 10.1097/00002030-199101001-00029; Power SC, 1996, MOL CELL BIOL, V16, P778; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Sawaya BE, 1996, J BIOL CHEM, V271, P22895, DOI 10.1074/jbc.271.37.22895; Sawaya BE, 1996, J BIOL CHEM, V271, P23572, DOI 10.1074/jbc.271.38.23572; SAWAYA BE, 1995, NUCLEIC ACIDS RES, V23, P2206, DOI 10.1093/nar/23.12.2206; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; Strizki JM, 1996, J VIROL, V70, P7654, DOI 10.1128/JVI.70.11.7654-7662.1996; SUNE C, 1995, J VIROL, V69, P6572; TAYLOR JP, 1994, ADV NEUROIMMUNOL, V4, P291, DOI 10.1016/S0960-5428(06)80270-6; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	50	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31149	31155		10.1074/jbc.272.49.31149	http://dx.doi.org/10.1074/jbc.272.49.31149			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388268	Green Published, hybrid			2022-12-27	WOS:000071640800081
J	Verdone, L; Cesari, F; Denis, CL; Di Mauro, E; Caserta, R				Verdone, L; Cesari, F; Denis, CL; Di Mauro, E; Caserta, R			Factors affecting Saccharomyces cerevisiae ADH2 chromatin remodeling and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL DEHYDROGENASE-II; IN-VIVO; REGULATED TRANSCRIPTION; ACTIVATE TRANSCRIPTION; PHO5 PROMOTER; RNA-SYNTHESIS; DNA-SEQUENCE; N-TERMINI; YEAST; NUCLEOSOME	The chromatin structure of the Saccharomyces cerevisiae ADH2 gene is modified during the switch from repressing (high glucose) to derepressing (low glucose) conditions of growth. Loss of protection toward micrococcal nuclease cleavage for the nucleosomes covering the TATA box and the RNA initiation sites (-1 and +1, respectively) is the major modification taking place and is strictly dependent on the presence of the transcriptional activator ADR1. To identify separate functions involved in the transition from a repressed to a transcribing promoter, we have analyzed the ADH2 chromatin organization in various genetic backgrounds. Deletion of the CCR4 gene coding for a general transcription factor impaired ADH2 expression without affecting chromatin remodeling, Growing yeast at 37 degrees C also resulted in chromatin remodeling at the ADH2 locus even under glucose repressing conditions. However, although this temperature-induced remodeling was dependent on the ADR1 protein, no ADH2 mRNA was observed. In addition, inactivating RNA polymerase II (and therefore, elongation) was found to have no effect on the ability to reconfigure nucleosomes. Taken together, these data indicate that chromatin remodeling by itself is insufficient to induce transcription at the ADH2 promoter.	Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, CNR, Ctr Studio Acidi Nucl, I-00185 Rome, Italy; Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, Fdn Inst Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; University System Of New Hampshire; University of New Hampshire	Caserta, R (corresponding author), Univ Rome La Sapienza, Dipartimento Genet & Biol Mol, CNR, Ctr Studio Acidi Nucl, I-00185 Rome, Italy.		Verdone, Loredana/AGG-5450-2022	Caserta, Micaela/0000-0003-1647-5118; Verdone, Loredana/0000-0002-8854-1068	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041215] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; BUTTINELLI M, 1995, P NATL ACAD SCI USA, V92, P10747, DOI 10.1073/pnas.92.23.10747; BUTTINELLI M, 1995, METH MOL G, V6, P168; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CASERTA M, 1996, BIOESSAYS, V18, P947; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; DENIS CL, 1986, MOL CELL BIOL, V6, P4026, DOI 10.1128/MCB.6.11.4026; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; FASHER KD, 1993, J MOL BIOL, V231, P658; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GANDREAU L, 1997, CELL, V89, P55; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LINXWEILER W, 1985, CELL, V42, P281; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pereira GG, 1996, EUR J BIOCHEM, V238, P181, DOI 10.1111/j.1432-1033.1996.0181q.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Surridge C, 1996, NATURE, V380, P287, DOI 10.1038/380287a0; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; vanHolde K, 1996, BIOESSAYS, V18, P697, DOI 10.1002/bies.950180903; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENDITTI S, 1988, BIOCHIM BIOPHYS ACTA, V951, P139, DOI 10.1016/0167-4781(88)90034-6; VENDITTI S, 1994, MOL GEN GENET, V242, P100, DOI 10.1007/BF00277353; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Verdone L, 1996, MOL CELL BIOL, V16, P1978; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wolffe AP, 1996, CURR BIOL, V6, P234, DOI 10.1016/S0960-9822(02)00465-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	60	32	33	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30828	30834		10.1074/jbc.272.49.30828	http://dx.doi.org/10.1074/jbc.272.49.30828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388226	hybrid			2022-12-27	WOS:000071640800039
J	Bjorkhem, I; Lutjohann, D; Breuer, O; Sakinis, A; Wennmalm, A				Bjorkhem, I; Lutjohann, D; Breuer, O; Sakinis, A; Wennmalm, A			Importance of a novel oxidative mechanism for elimination of brain cholesterol - Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with O-18(2) techniques in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURES; BIOSYNTHESIS; LIVER; CELLS; HOMEOSTASIS; HUMANS; PLASMA	The brain is the most cholesterol-rich organ in the body, Brain cholesterol is characterized by a very Bow turnover with very little exchange with lipoproteins in the circulation, Very recently we showed that there is a continuous age-dependent flux of 24(S)-hydroxycholesterol from the human brain into the circulation (Liitjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Siden, A., Diczfalusy, U., and Bjorkhem, I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9799-9804), Here we measured the rate of synthesis of cholesterol as well as the conversion of cholesterol into 24(S)-hydroxycholesterol in rat brain in vivo with use of an O-18(2) inhalation technique and mass isotopomer distribution analysis, Cholesterol synthesis was found to correspond to 0.03 +/- 0.01% of the pool per h. Conversion of cholesterol into 24(S)-hydroxycholesterol was of a similar magnitude, about 0.02% of the pool per h. Brain microsomes converted endogenous cholestesol into 24(S)-hydroxycholesterol at a similar rate when incubated in the presence of NADPH. When incubated with whole homogenate and subcellular fractions of rat brain, there was no significant conversion of tritium-labeled 24-hydroxycholesterol into more polar products. Plasma from O-18(2)-exposed rats contained 24(S)-hydroxycholesterol with an enrichment of O-18 similar to that in 24(S)-hydroxycholesterol in the brain. The results suggest that the present 24(S)hydroxylase mediated mechanism is most important for elimination of cholesterol from the brain of rats, There is a slow conversion of brain cholesterol into 24(S)-hydroxycholesterol with a rapid turnover of the small pool of the latter oxysterol due to leakage to the circulation (half-life of brain 24(S)-hydroxycholesterol is about 0.5 days as compared with 2-4 months for brain cholesterol), It is evident that the 24(S)-hydroxylation greatly facilitates transfer of cholesterol over-the blood-brain barrier and that this hydroxylation may be critical for cholesterol homeostasis in the brain.	HUDDINGE HOSP,KAROLINSKA INST,DIV CLIN CHEM,SE-14186 HUDDINGE,SWEDEN; GOTHENBURG UNIV,SAHLGRENS UNIV HOSP,DIV CLIN PHYSIOL,GOTHENBURG,SWEDEN	Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg				Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON M, 1990, FEBS LETT, V269, P15, DOI 10.1016/0014-5793(90)81107-Y; ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; Benthin G, 1997, BIOCHEM J, V323, P853, DOI 10.1042/bj3230853; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1979, J BIOL CHEM, V254, P5252; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8591; BREUER O, 1995, J BIOL CHEM, V270, P20278, DOI 10.1074/jbc.270.35.20278; DEVRIES H, 1995, THESIS BADHOEVEDEDOR; DHAR AK, 1973, J NEUROCHEM, V21, P51, DOI 10.1111/j.1471-4159.1973.tb04224.x; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; GORDON EL, 1991, IN VITRO CELL DEV B, V27, P312; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; LANGE Y, 1995, J LIPID RES, V36, P1092; LIN YY, 1974, BIOCHIM BIOPHYS ACTA, V348, P189; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; PEDERSEN JI, 1989, BIOCHEM INT, V18, P615; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SEROUGNE.C, 1973, BIOCHIM BIOPHYS ACTA, V316, P244, DOI 10.1016/0005-2760(73)90014-3; SHEFER S, 1981, J LIPID RES, V22, P532; Snipes G J, 1997, Subcell Biochem, V28, P173; STAPLEGON G, 1996, J BIOL CHEM, V270, P29739; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; ZHANG J, 1995, CR ACAD SCI III-VIE, V318, P345; ZHANG J, 1996, THESIS KAROLINSKA I	30	236	240	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30178	30184		10.1074/jbc.272.48.30178	http://dx.doi.org/10.1074/jbc.272.48.30178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374499	hybrid			2022-12-27	WOS:A1997YH61300031
J	Ware, MF; Tice, DA; Parsons, SJ; Lauffenburger, DA				Ware, MF; Tice, DA; Parsons, SJ; Lauffenburger, DA			Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; EGF RECEPTOR; SH3 DOMAINS; A431 CELLS; MITOGENIC RESPONSIVENESS; SIGNAL-TRANSDUCTION; TYROSINE KINASES; ACTIVATION; DYNAMIN; PHOSPHORYLATION	Previous studies have demonstrated a requirement for the nonreceptor tyrosine kinase, cellular Src (c-Src), in epidermal growth factor (EGF)-induced mitogenesis and a synergistic interaction between c-Src and EGF receptor (EG;FR) in tumorigenesis, Although endocytic internalization of EGFR may be thought to attenuate EGF-stimulated signaling, recent evidence suggests that signaling through Ras can be amplified by repeated encounters of endosome-localized, receptor . Shc . Grb2 . Sos complexes with the plasma membrane, where Ras resides almost exclusively. Based on these reports, we examined EGFR trafficking behavior in a set of single and double c-Src/EGFR C3H10T1/2 overexpressors to determine if c-Src affects basal receptor half-life, ligand-induced internalization, and/or recycling. Our results show that overexpression of c-Src causes no change in EGFR half-life but does produce an increase in the internalization rate constant of EGF EGFR complexes when the endocytic apparatus is not stoichiometrically saturated; this effect of c-Src on EGFR endocytosis is negligible at high receptor occupancy in cells overexpressing the receptor, In neither case are EGFR recycling rate constants affected by c-Src, These data indicate a functional role for c-Src in receptor internalization, which in turn could alter some aspects of EGFR signaling related to mitogenesis and tumorigenesis.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,CTR BIOMED ENGN,CAMBRIDGE,MA 02139; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,CHARLOTTESVILLE,VA 22903	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Virginia; University of Virginia					NCI NIH HHS [CA69213, CA71449, CA39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449, R01CA039438, R01CA069213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHANG CP, 1993, J BIOL CHEM, V268, P19312; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUNTS J, 1985, JPN J CANCER RES, V76, P663; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNG HJ, 1994, BIOCH MOL ASPECTS SE, V2, P19; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SINGLETARY SE, 1987, CANCER RES, V47, P403; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	42	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30185	30190		10.1074/jbc.272.48.30185	http://dx.doi.org/10.1074/jbc.272.48.30185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374500	hybrid			2022-12-27	WOS:A1997YH61300032
J	Bova, MP; Ding, LL; Horwitz, J; Fung, BKK				Bova, MP; Ding, LL; Horwitz, J; Fung, BKK			Subunit exchange of alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CALF LENS NUCLEUS; B-CRYSTALLIN; CHAPERONE ACTIVITY; MOLECULAR CHAPERONES; QUATERNARY STRUCTURE; EXPRESSION; TISSUES; TEMPERATURE; DISEASE	alpha-Crystallin, the major protein in the mammalian lens, is a molecular chaperone that can bind denaturing proteins and prevent their aggregation, Like other structurally related small heat shock proteins, each alpha-crystallin molecule is composed of an average of 40 subunits that can undergo extensive reorganization. In this study we used fluorescence resonance energy transfer to monitor the rapid exchange of recombinant cu-crystallin subunits. We labeled alpha A-crystallin with stilbene iodoacetamide (4-acetamido-4'-((iodoacetyl)amino)stilbene-2,2'-disulfonic acid), which serves as an energy donor and with lucifer yellow iodoacetamide, which serves as an energy acceptor. Upon mixing the two populations of labeled alpha A-crystallin, we observed a reversible, time-dependent decrease in stilbene iodoacetamide emission intensity and a concomitant increase in lucifer yellow iodoacetamide fluorescence, This result is indicative of an exchange reaction that brings the fluorescent alpha A-crystallin subunits close to each other. We further showed that the exchange reaction is strongly dependent on temperature, with a rate constant of 0.075 min(-1) at 37 degrees C and an activation energy of 60 kcal/mol, The subunit exchange is independent of pH and calcium concentration but decreases at low and high ionic strength, suggesting the involvement of both ionic and hydrophobic interactions, It is also markedly reduced by the binding of large denatured proteins, The degree of inhibition is directly proportional to the molecular mass and the amount of bound polypeptide, suggesting an interaction of several alpha A-crystallin subunits with multiple binding sites of the denaturing protein. Our findings reveal a dynamic organization of alpha A-crystallin subunits, which may be a key factor in preventing protein aggregation during denaturation.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NEI NIH HHS [EY07026, EY05895, EY03897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY003897, R01EY003897, T32EY007026, R01EY005895] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bhat SP, 1996, PROTEIN ENG, V9, P713, DOI 10.1093/protein/9.8.713; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BOVA MP, 1996, INVESTIG OPHTHALMOL, V38, P251; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAUWAERT J, 1989, CURR EYE RES, V8, P397, DOI 10.3109/02713688908996387; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fairclough R H, 1978, Methods Enzymol, V48, P347; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FEIN M, 1979, INVEST OPHTH VIS SCI, V18, P761; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JEDZINIAK JA, 1972, INVEST OPHTH VISUAL, V11, P905; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NENE V, 1986, MOL BIOCHEM PARASIT, V21, P179, DOI 10.1016/0166-6851(86)90021-6; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PIETROWSKI D, 1994, GENE, V144, P171, DOI 10.1016/0378-1119(94)90375-1; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1979, EXP EYE RES, V28, P551, DOI 10.1016/0014-4835(79)90043-5; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P795; SPECTOR A, 1973, INVEST OPHTH VISUAL, V12, P225; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P982; SPECTOR A, 1971, INVEST OPHTH VISUAL, V10, P677; SPECTOR A, 1973, EXP EYE RES, V16, P115, DOI 10.1016/0014-4835(73)90306-0; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717	59	264	266	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29511	29517		10.1074/jbc.272.47.29511	http://dx.doi.org/10.1074/jbc.272.47.29511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368012	hybrid			2022-12-27	WOS:A1997YG64700022
J	Brady, MJ; Nairn, AC; Saltiel, AR				Brady, MJ; Nairn, AC; Saltiel, AR			The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes - Evidence for a potential role for DARPP-32 in insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADIPOSE-TISSUE; AFFINITY-CHROMATOGRAPHY; STIMULATION; KINASE; SUBUNIT; EXPRESSION; PHOSPHORYLATION; PHOSPHOPROTEIN; IDENTIFICATION	The stimulation of glycogen-targeted protein phosphatase 1 (PP1), glycogen synthase, and glycogen synthesis by insulin was examined during the differentiation of 3T3-L1 fibroblasts into adipocytes. Insulin treatment barely changed the low levels of glycogen synthesis measured in fibroblasts. Following differentiation into adipocytes, insulin increased glycogen synthesis up to 40-fold. After further culturing of the adipocytes for a week, insulin stimulated glycogen accumulation 700-fold, Differentiation of 3T3-L1 cells also resulted in the increased expression of glycogen synthase and in increases in both total glycogen synthase activity and -fold stimulation by insulin, While the levels of PP1 protein were unchanged by differentiation, PP1 specific activity decreased over 60%, although sensitivity to insulin treatment was augmented. Concurrently, levels of the PP1 inhibitor protein DARPP-32 were dramatically induced upon 3T3-L1 adipogenesis. DARPP-32 in both 3T3-L1 and primary rat adipocytes was exclusively localized to the particulate fractions, including the glycogen enriched pellet. PP1 activity from 3T3-L1 adipocytes exhibited a kinetic lag in vitro, which was not present in fibroblast extracts, Insulin pretreatment of the adipocyte cells overcame the in vitro lag in PP1 activity, resulting in up to 5-fold stimulation of PP1 activity being measured at early assay time points, These results suggest that in 3T3-L1 adipocytes, DARPP-32 may maintain glycogen-targeted PP1 activity in a low basal state, priming the phosphatase for stimulation by insulin.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105; ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Pfizer; Rockefeller University			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Nairn, Angus/0000-0002-7075-0195				Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MATOVCIK LM, 1995, FEBS LETT, V64, P67; MEISTER B, 1988, P NATL ACAD SCI USA, V85, P8713, DOI 10.1073/pnas.85.22.8713; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	31	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29698	29703		10.1074/jbc.272.47.29698	http://dx.doi.org/10.1074/jbc.272.47.29698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368038	hybrid			2022-12-27	WOS:A1997YG64700048
J	Kuras, R; de Vitry, C; Choquet, Y; Girard-Bascou, J; Culler, D; Buschlen, S; Merchant, S; Wollman, FA				Kuras, R; de Vitry, C; Choquet, Y; Girard-Bascou, J; Culler, D; Buschlen, S; Merchant, S; Wollman, FA			Molecular genetic identification of a pathway for heme binding to cytochrome b(6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; SITE-DIRECTED MUTAGENESIS; IRON-SULFUR PROTEIN; C-TYPE CYTOCHROMES; CHLAMYDOMONAS-REINHARDTII; CHLOROPLAST TRANSFORMATION; AXIAL LIGANDS; BC1 COMPLEX; PURIFICATION; BIOSYNTHESIS	Heme binding to cytochrome b(6) is resistant, in part, to denaturing conditions that typically destroy the noncovalent interactions between the b hemes and their apoproteins, suggesting that one of two b hemes of holocytochrome b(6) is tightly bound to the polypeptide, We exploited this property to define a pathway for the conversion of apo- to holocytochrome b(6), and to identify mutants that are blocked at one step of this pathway, Chlamydomonas reinhardtii strains carrying substitutions in either one of the four histidines that coordinate the b(h) or b(1) hemes to the apoprotein were created, These mutations resulted in the appearance of distinct immunoreactive species of cytochrome b(6), which allowed us to specifically identify cytochrome b(6) with altered b(h) or b(1) ligation, In gabaculine-treated (i.e. heme-depleted) wild type and site-directed mutant strains, we established that (i) the single immunoreactive band, observed in strains carrying the b(1) site-directed mutations, corresponds to apocytochrome b(6) and (ii) the additional band present in strains carrying b(h) site-directed mutations corresponds to a b(1)-heme-dependent intermediate in the formation of holocytochrome b(6). Five nuclear mutants (ccb strains) that are defective in holocytochrome b(6) formation display a phenotype that is indistinguishable from that of strains carrying site-directed b(h) ligand mutants, The defect is specific for cytochrome b(6) assembly, because the ccb strains can synthesize other b cytochromes and all c-type cytochromes. The ccb strains, which define four nuclear loci (CCB1, CCB2, CCB3, and CCB4), provide the first evidence that a b-type cytochrome requires trans-acting factors for its heme association.	CNRS, Inst Biol Physicochim, UPR 9072, F-75005 Paris, France; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Los Angeles	Wollman, FA (corresponding author), CNRS, Inst Biol Physicochim, UPR 9072, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.		Choquet, Yves/ABE-3084-2020; Choquet, Yves/M-5533-2019	Choquet, Yves/0000-0003-4760-3397	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048350, K04GM000594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM00594, GM 48350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ascoli F, 1981, Methods Enzymol, V76, P72; Bald D., 1992, RES PHOTOSYNTHESIS, VI, P629; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CRAMER WA, 1994, J BIOENERG BIOMEMBR, V26, P31, DOI 10.1007/BF00763218; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; CRIVELLONE MD, 1994, J BIOL CHEM, V269, P21284; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; deVitry C, 1996, J BIOL CHEM, V271, P10667, DOI 10.1074/jbc.271.18.10667; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; GIRARDBASCOU J, 1995, PHOTOSYNTHESIS LIGHT, V3, P683; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; Gumpel NJ, 1995, PLANT MOL BIOL, V29, P921, DOI 10.1007/BF00014966; HARRIS EH, 1989, CHLAMYDOMANAS SOURCE; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; HURT EC, 1984, FEBS LETT, V168, P149, DOI 10.1016/0014-5793(84)80225-2; HURT EC, 1983, FEBS LETT, V153, P413, DOI 10.1016/0014-5793(83)80655-3; Ketchner SL, 1996, BBA-BIOENERGETICS, V1273, P195, DOI 10.1016/0005-2728(95)00157-3; KINDLE KL, 1991, P NATL ACAD SCI USA, V88, P1721, DOI 10.1073/pnas.88.5.1721; KRANZ RG, 1995, ANOXYGENIC PHOTOSYNT, P709; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PALMER G, 1994, BIOCHEMISTRY-US, V33, P176, DOI 10.1021/bi00167a023; PHILLIPS AL, 1983, EUR J BIOCHEM, V137, P553, DOI 10.1111/j.1432-1033.1983.tb07861.x; Pierre Y, 1997, J BIOL CHEM, V272, P21901, DOI 10.1074/jbc.272.35.21901; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; SIMPKIN D, 1989, BIOCHEMISTRY-US, V33, P176; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WU M, 1989, J BIOL CHEM, V264, P11122; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; Zito F, 1997, PLANT MOL BIOL, V33, P79, DOI 10.1023/A:1005734809834	57	87	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32427	32435		10.1074/jbc.272.51.32427	http://dx.doi.org/10.1074/jbc.272.51.32427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405452	hybrid			2022-12-27	WOS:000071108000071
J	Winter, H; Hofmann, I; Langbein, L; Rogers, MA; Schweizer, J				Winter, H; Hofmann, I; Langbein, L; Rogers, MA; Schweizer, J			A splice site mutation in the gene of the human type I hair keratin hHa1 results in the expression of a tailless keratin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT ASSEMBLY INVITRO; INTERMEDIATE FILAMENTS; MESSENGER-RNA; DONOR SITE; SEQUENCE; PROTEINS; CYTOKERATINS; ORGANIZATION; FOLLICLE; VIMENTIN	In this study, we have elucidated the molecular mechanisms underlying the expression of an acidic 41-kDa protein inherited as an autosomal dominant trait of the hair keratin pattern of about 5% of the human population. We show that this protein is a size variant of the large type I hair cortex keratin hHa1 due to a genetic polymorphism in the hHa1 gene. We detected a G-A substitution in the 5' splice site of intron 6 of the hHa1 gene, which segregates with the 41-kDa protein phenotype in two pedigrees and is responsible for the formation of an abnormally spliced hHa1 mRNA species. The use of an alternative 5' splice site leads to the retention of 41 nucleotides of the initial intron 6 sequences in the mature transcript. The open reading frame of the aberrant mRNA creates a premature stop codon immediately downstream of the mutation site. The resulting hHa1 protein variant, hHa1-t, is about 6-kDa smaller than the 47-kDa hHa1 hair keratin and lacks the complete nonhelical tail domain. We show that the tailless hHa1-t is functional, since both recombinant hHa1 and hHa1-t form identical keratin intermediate filaments when assembled in vitro with a type II hair keratin partner. This finding confirms the view of a noninvolvement of the keratin tail domain in filament assembly and explains the lack of a pathological hair phenotype in hHa1-t positive individuals.	German Canc Res Ctr, Res Program 2, D-69120 Heidelberg, Germany; German Canc Res Ctr, Res Program 1, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Winter, H (corresponding author), German Canc Res Ctr, Res Program 2, 5th Floor,Room 522,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BADEN HP, 1977, AM J HUM GENET, V27, P472; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BERTOLINO AP, 1988, J INVEST DERMATOL, V91, P541, DOI 10.1111/1523-1747.ep12476901; BERTOLINO AP, 1990, J INVEST DERMATOL, V94, P293; Bowden P E, 1994, J Dermatol Sci, V7 Suppl, pS152, DOI 10.1016/0923-1811(94)90046-9; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P1125; COOPER DN, 1993, HUMAN GENE MUTATIONS; Costa EJ, 1996, BRAZ J MED BIOL RES, V29, P1427; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; FINK P, 1995, BBA-GENE STRUCT EXPR, V1264, P12, DOI 10.1016/0167-4781(95)00122-W; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; HATZFELD M, 1990, J CELL SCI, V97, P317; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HEID HW, 1986, DIFFERENTIATION, V37, P215; HOFMANN I, 1991, EUR J CELL BIOL, V56, P328; Hofmann I, 1997, EUR J CELL BIOL, V72, P122; HRDY DB, 1977, AM J HUM GENET, V29, P98; Hunter TC, 1996, SOMAT CELL MOLEC GEN, V22, P145, DOI 10.1007/BF02369904; KRAWCZAK M, 1992, HUM GENET, V90, P41; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MARSHALL RC, 1980, J INVEST DERMATOL, V75, P264, DOI 10.1111/1523-1747.ep12523296; MARUYAMA T, 1995, EUR J BIOCHEM, V232, P700, DOI 10.1111/j.1432-1033.1995.700zz.x; OHNO K, 1988, J BIOL CHEM, V263, P18563; POWELL B, 1992, DEVELOPMENT, V114, P417; Powell B C, 1997, EXS, V78, P59; Powell B.C., 1990, CELLULAR MOL BIOL IN, P267; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; RENNER W, 1981, J MOL BIOL, V149, P285, DOI 10.1016/0022-2836(81)90303-X; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 1996, J INVEST DERMATOL, V107, P633, DOI 10.1111/1523-1747.ep12584243; SCHIMKAT M, 1990, HUM GENET, V85, P311; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, BIOCHEM BIOPH RES CO, V197, P840, DOI 10.1006/bbrc.1993.2555; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; STEINERT PM, 1995, INTERMEDIATE FILAMEN, P145; STEINERT PM, 1995, INTERMEDIATE FILAMEN, P123; Westgate GE, 1996, INT CONGR SER, V1111, P167; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; WINTER H, 1994, EXP CELL RES, V212, P190, DOI 10.1006/excr.1994.1134; WINTER H, 1997, IN PRESS HUM GENET; YU JL, 1993, J INVEST DERMATOL, V101, pS56, DOI 10.1111/1523-1747.ep12362635	49	25	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	1997	272	51					32345	32352		10.1074/jbc.272.51.32345	http://dx.doi.org/10.1074/jbc.272.51.32345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YM852	9405442	hybrid			2022-12-27	WOS:000071108000061
J	Finkenzeller, D; Kromer, B; Thompson, J; Zimmermann, W				Finkenzeller, D; Kromer, B; Thompson, J; Zimmermann, W			cea5, a structurally divergent member of the murine carcinoembryonic antigen gene family, is exclusively expressed during early placental development in trophoblast giant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANCY-SPECIFIC GLYCOPROTEIN; MOLECULE C-CAM; MOUSE HEPATITIS-VIRUS; ADHESION MOLECULE; BILIARY GLYCOPROTEIN; COLORECTAL CARCINOMAS; ECTO-ATPASE; RAT-LIVER; RECEPTOR; IDENTIFICATION	The carcinoembryonic antigen (CEA) gene family encodes a large family of glycoproteins. Some are probably involved in the homeostasis/development of epithelial cells and granulocyte activation, while others e.g. the pregnancy-specific glycoproteins, are expressed in the placenta and are essential for a positive outcome of pregnancy, In this paper, we have characterized cea5, a member of the murine CEA gene family, RNase protection and in situ hybridization analyses revealed that Cea5 mRNA is exclusively synthesized in primary and secondary trophoblast giant cells of the placenta only during early stages of development, Bull-length Cea5 cDNA was obtained by a reverse transcription-polymerase chain reaction using day 10.5 post-coitum placental RNA, The 1.6-kilobase pair (kb) Cea5 mRNA encodes a secreted glycoprotein with a predicted size of 30 kDa, It is composed of a leader peptide (L), one immunoglobulin (Ig) variable or N, and one Ig constant-like or A domain, This domain organization is unique within the human and murine CEA families, Two overlapping cosmid clones covering 54 kb of the cea5 gene locus were mapped, cea5 consists of three exons (L, N, A/3'-untranslated region exon) located within a 4-kb region, rnCGM2, the rat cea5 counterpart, exhibits the same restricted expression pattern, This together with their exceptional conservation within the rat and murine CEA families and their absence from the human CEA family suggests that cea5 and rnCGM2 are of functional importance for rodent placental development.	UNIV FREIBURG,INST IMMUNOBIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Zimmermann, Wolfgang/L-9277-2013					ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRANDRIFF BF, 1992, GENOMICS, V12, P773, DOI 10.1016/0888-7543(92)90308-F; CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; Chen DS, 1995, P NATL ACAD SCI USA, V92, P12095, DOI 10.1073/pnas.92.26.12095; CHEN HW, 1994, BIOCHEMISTRY-US, V33, P9615, DOI 10.1021/bi00198a030; CHEN HW, 1992, DNA CELL BIOL, V11, P139, DOI 10.1089/dna.1992.11.139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Earley K, 1996, BIOCHEM J, V315, P799, DOI 10.1042/bj3150799; EDLUND M, 1993, EUR J BIOCHEM, V213, P1109, DOI 10.1111/j.1432-1033.1993.tb17860.x; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HSIEH JT, 1995, CANCER RES, V55, P190; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P469; KECK U, 1995, EUR J BIOCHEM, V229, P455, DOI 10.1111/j.1432-1033.1995.0455k.x; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KODELJA V, 1989, J BIOL CHEM, V264, P6906; Kromer B, 1996, EUR J BIOCHEM, V242, P280, DOI 10.1111/j.1432-1033.1996.0280r.x; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUIJPERS TW, 1993, J IMMUNOL, V151, P4934; KUROKI M, 1991, BIOCHEM BIOPH RES CO, V176, P578, DOI 10.1016/S0006-291X(05)80223-2; LI WH, 1985, MOL BIOL EVOL, V2, P150; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; REBSTOCK S, 1993, DEV DYNAM, V198, P171, DOI 10.1002/aja.1001980303; REBSTOCK S, 1990, J BIOL CHEM, V265, P7872; ROSENBERG M, 1993, CANCER RES, V53, P4938; RUDERT F, 1992, MAMM GENOME, V3, P262, DOI 10.1007/BF00292154; RUTHERFURD KJ, 1995, MOL ENDOCRINOL, V9, P1297, DOI 10.1210/me.9.10.1297; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; STOCKS SC, 1992, BIOCHEM J, V288, P23, DOI 10.1042/bj2880023; Stubbs L, 1996, GENOMICS, V35, P499, DOI 10.1006/geno.1996.0390; TEGLUND S, 1994, GENOMICS, V23, P669, DOI 10.1006/geno.1994.1556; Thompson J, 1997, CANCER RES, V57, P1776; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; THOMPSON JA, 1995, TUMOR BIOL, V16, P10, DOI 10.1159/000217923; Turbide C, 1997, CANCER RES, V57, P2781; TURBIDE C, 1991, J BIOL CHEM, V266, P309; ZIMMERMANN W, 1997, IN PRESS CELL ADHESI	54	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	1997	272	50					31369	31376		10.1074/jbc.272.50.31369	http://dx.doi.org/10.1074/jbc.272.50.31369			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YL419	9395467	hybrid			2022-12-27	WOS:A1997YL41900026
J	Fraizer, GC; Shimamura, R; Zhang, XH; Saunders, GF				Fraizer, GC; Shimamura, R; Zhang, XH; Saunders, GF			PAX 8 regulates human WT1 transcription through a novel DNA binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR GENE; PAIRED BOX GENE; SUPPRESSOR GENE; KIDNEY DEVELOPMENT; PROMOTER ACTIVITY; MESSENGER-RNA; EXPRESSION; SEQUENCE; GROWTH; REPRESSION	The Wilms' tumor gene (WT1) is an essential gene for kidney and gonadal development, although how WT1 expression is induced in these tissues is not known, One kidney transcription factor likely to play a role in this regulation is PAX 8, The co-expression of WT1 and PAX 8 during kidney development and in Wilms' tumors with an epithelium predominant histology suggested a possible interaction, and indeed, we identified potential core PAX-binding sites in the WT1 promoter, Endogenous PAX 8 plays an important role in the activation of the WT1 promoter, since promoter activity is much stronger in cells with PAX 8 than without, Using binding assays, we searched for evidence of PAX 8-DNA interactions throughout the 652-base pair human WT1 promoter and found only one functional PAX 8 site with DNA binding activity, located 250 base pairs 5' of the minimal promoter, The responsiveness of the PAX 8 site was con firmed by assessing its ability to function as an enhancer significantly activating the minimal promoter in a position-and orientation-independent manner. Using transfection assays, we demonstrated that either endogenous or exogenously added PAX 8 activated the WT1 promoter and that this promoter up-regulation depended upon the presence of an intact PAX 8-binding site, In contrast, the previously reported core PAX 8-binding sites identified by computer analysis of the WT1 promoter failed to specifically bind in vitro translated PAX 8 protein or activate the minimal promoter, Thus, we identified a novel functional binding site for the transcription factor PAX 8, suggesting that part of its role in kidney development may be as a modulator of WT1 expression in the kidney.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 1996, ONCOGENE, V13, P2197; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; HEWITT SM, 1995, CANCER RES, V55, P5386; HEWITT SM, 1997, IN PRESS ANTICANCER; HOFMANN W, 1993, ONCOGENE, V8, P3123; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; Jun S, 1996, DEVELOPMENT, V122, P2639; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PLACHOV D, 1990, DEVELOPMENT, V110, P643; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SEKIYA M, 1994, BLOOD, V83, P1876; SHIMAMURA R, 1997, IN PRESS CLIN CANC R; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Song DL, 1996, DEVELOPMENT, V122, P627; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TAGGE EP, 1994, J PEDIATR SURG, V29, P134, DOI 10.1016/0022-3468(94)90308-5; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	56	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30678	30687		10.1074/jbc.272.49.30678	http://dx.doi.org/10.1074/jbc.272.49.30678			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388203	hybrid			2022-12-27	WOS:000071640800016
J	Leveillard, T; Wasylyk, B				Leveillard, T; Wasylyk, B			The MDM2 C-terminal region binds to TAF(II)250 and is required for MDM2 regulation of the cyclin A promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RING FINGER DOMAIN; TATA-BOX-BINDING; WILD-TYPE P53; TUMOR-SUPPRESSOR P53; SOFT-TISSUE SARCOMAS; A GENE-TRANSCRIPTION; CELL-CYCLE; S-PHASE; P53-ASSOCIATED PROTEIN; TRANSACTIVATION DOMAIN	MDM2 proto-oncogene expression is aberrant in many human tumors. Its normal role is to modulate the functions of p53. The N terminus of MDM2 interacts with p53, whereas the properties of the rest of the molecule are poorly understood. We show that MDM2 binds to the general transcription factor TFIID in vivo. The C-terminal Ring finger interacts with TAF(II)250/CCG1, and the central acidic domain interacts with TBP. Expression of MDM2 activates the cyclin A gene promoter but not c-fos, showing that the effects of MDM2 are specific. Deletion of the C-terminal region of MDM2 abolishes activation, showing that the C-terminal domain of MDM2 is functionally important. We found that increasing MDM2 expression to higher levels inhibits the cyclin A promoter. Inhibition appears to result from titration of general transcription factors because MDM2 overexpression inhibits c-fos as well as other promoters in vivo and basal transcription in vitro. The mechanisms of repression of the cyclin A and fos promoters appear to be different. Cyclin A repression is lost by deleting the C terminus, whereas that of c-fos is lost by removal of the acidic domain, These results reinforce the conclusion that the C terminus of MDM2 mediates effects on the cyclin A promoter, MDM2 transformed cells contain elevated levels of cyclin A mRNA, showing that activation occurs under physiological conditions. There is a positive correlation between MDM2 binding to TAF(II)250 and MDM2 activation of the cyclin A promoter. The C-terminal region of MDM2, which contains the Ring finger, interacts with TAF(II)250 and is required for regulation of the cyclin A promoter by MDM2. Our results link the activity of MDM2, a transforming protein implicated in many human tumors, with cyclin A, a regulator of the cell cycle.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020; Léveillard, Thierry/AAR-1804-2020	Wasylyk, Bohdan/0000-0002-1718-1237; Léveillard, Thierry/0000-0001-5692-8770				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Fisher RP, 1997, CURR OPIN GENET DEV, V7, P32, DOI 10.1016/S0959-437X(97)80106-2; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GERARD M, 1991, J BIOL CHEM, V266, P20940; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIROD SC, 1995, ANTICANCER RES, V15, P1453; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Gorgoulis VG, 1996, J PATHOL, V180, P129; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAYASHIDA T, 1994, GENE, V141, P267; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Huet X, 1996, MOL CELL BIOL, V16, P3789; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JUVEN T, 1993, ONCOGENE, V8, P3411; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; Keleti J, 1996, AM J PATHOL, V149, P143; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEACH FS, 1993, CANCER RES, V53, P2231; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Leveillard Thierry, 1993, Gene Expression, V3, P135; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumura T, 1996, ONCOLOGY, V53, P308; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MIYASHITA T, 1995, CELL, V80, P293; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRICE BD, 1994, CANCER RES, V54, P896; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; THOME KZ, 1996, ONCOGENE, V13, P2323; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WALDMAN T, 1995, CANCER RES, V55, P5187; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	113	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30651	30661		10.1074/jbc.272.49.30651	http://dx.doi.org/10.1074/jbc.272.49.30651			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388200	hybrid			2022-12-27	WOS:000071640800013
J	Lin, FT; Krueger, KM; Kendall, HE; Daaka, Y; Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ				Lin, FT; Krueger, KM; Kendall, HE; Daaka, Y; Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ			Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-arrestin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PLASMA-MEMBRANE; COATED VESICLES; BETA(2)-ADRENERGIC RECEPTOR; ARRESTIN; BINDING; INTERNALIZATION; SPECIFICITY; ADAPTERS; DESENSITIZATION	beta-Arrestins serve a dual regulatory role in the life cycle of G protein-coupled receptors such as the ,beta(2)-adrenergic receptor, First, they mediate rapid desensitization by binding to G protein-coupled receptor kinase-phosphorylated receptors, Second, they target the receptors for internalization into endosomal vesicles, wherein receptor dephosphorylation and resensitization occur, Here we report that phosphorylation of a carboxyl terminal serine (Ser-412) in beta-arrestin1 regulates its endocytotic but not its desensitization function, Cytoplasmic beta-arrestin1 is constitutively phosphorylated and is recruited to the plasma membrane by agonist stimulation of the receptors. At the plasma membrane, beta-arrestin1 is rapidly dephosphorylated, a process that is required for its clathrin binding and receptor endocytosis but not for its receptor binding and desensitization. Once internalized, beta-arrestin1 is re-phosphorylated., Thus, as with the classical endocytic adaptor protein complex AP2, beta-arrestin1 functions as a clathrin adaptor in receptor endocytosis which is regulated by dephosphorylation at the plasma membrane.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BENETT N, 1988, BIOCHEMISTRY-US, V27, P1710; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GRAHAM JM, 1992, CELL BIOL LUBFAX; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HEUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; JONES DH, 1992, BIOTECHNIQUES, V12, P575; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEFTON BM, 1991, METHOD ENZYMOL, V291, P245; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; YU SS, 1993, J BIOL CHEM, V268, P337; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	43	200	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					31051	31057		10.1074/jbc.272.49.31051	http://dx.doi.org/10.1074/jbc.272.49.31051			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388255	hybrid			2022-12-27	WOS:000071640800068
J	Raman, N; Black, PN; DiRusso, CC				Raman, N; Black, PN; DiRusso, CC			Characterization of the fatty acid-responsive transcription factor FadR - Biochemical and genetic analyses of the native conformation and functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT NEGATIVE MUTATIONS; ESCHERICHIA-COLI; ACYL-COENZYME; DNA-BINDING; REPRESSOR; PROTEIN; EXPRESSION; REGULATOR; RECOGNITION; METABOLISM	In Escherichia coli, fatty acid synthesis and degradation are coordinately controlled at the level of transcription by FadR. FadR represses transcription of at least eight genes required for fatty acid transport and beta-oxidation and activates transcription of at least two genes required for unsaturated fatty acid biosynthesis and the gene encoding the transcriptional regulator of the ace-BAK operon encoding the glyoxylate shunt enzymes, IclR, FadR dependent DNA binding and transcriptional activation is prevented by long chain fatty acyl-CoA. In the present work, we provide physical and genetic evidence that FadR exists as a homodimer in solution and in vivo. Native polyacrylamide gel electrophoresis and glycerol gradient ultracentrifugation of the purified protein show that native FadR was a homodimer in solution with an apparent molecular mass of 53.5 and 57.8 kDa, respectively, Dominant negative mutations in fadR were generated by random and site-directed mutagenesis, Each mutation mapped to the amino terminus of the protein (residues 1-66) and resulted in a decrease in DNA binding in vitro. In an effort to separate domains of FadR required for DNA binding, dimerization, and ligand binding, chimeric protein fusions between the DNA binding domain of LexA and different regions of FadR were constructed. One fusion, LexA1-87-FadR102-239, was able to repress the LexA reporter sulA-lacZ, and beta-galactosidase activities were derepressed by fatty acids, suggesting that the fusion protein had determinants both for dimerization and ligand binding, These studies support the conclusion that native FadR exists as a stable homo-dimer in solution and that determinants for DNA binding and acyl-CoA binding are found within the amino terminus and carboxyl terminus, respectively.	Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Albany Medical College; University of Tennessee System; University of Tennessee Health Science Center	DiRusso, CC (corresponding author), Albany Med Coll, Dept Biochem & Mol Biol, A-10,47 New Scotland Ave, Albany, NY 12208 USA.	concetta_dirusso@ccgateway.amc.edu		Black, Paul/0000-0002-6272-6881				BADE H, 1984, J IMMUNOL METHODS, V72, P421, DOI 10.1016/0022-1759(84)90010-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DiRusso CC, 1996, GWUMC DEPT, P15; Farewell A, 1996, J BACTERIOL, V178, P6443, DOI 10.1128/jb.178.22.6443-6450.1996; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; JO YL, 1986, J BIOL CHEM, V261, P15253; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Miller J.H., 1972, EXPT MOL GENETICS; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Scopes RK., 1987, PROTEIN PURIFICATION, V2nd ed; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P567; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA KI, 1993, J MOL BIOL, V231, P167, DOI 10.1006/jmbi.1993.1270	36	50	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30645	30650		10.1074/jbc.272.49.30645	http://dx.doi.org/10.1074/jbc.272.49.30645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388199	hybrid			2022-12-27	WOS:000071640800012
J	Sacerdoti-Sierra, N; Jaffe, CL				Sacerdoti-Sierra, N; Jaffe, CL			Release of ecto-protein kinases by the protozoan parasite Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; SURFACE; CELL; GROWTH; INHIBITION; TARGET	Leishmania major promastigotes have externally oriented ecto-protein kinases (PK) that are capable of phosphorylating both endogenous membrane substrates and foreign proteins. Live parasites phosphorylate protamine sulfate, casein, and phosvitin but not bovine serum albumin. Addition of exogenous PK substrates, such as phosvitin or casein, induced the shedding of ecto-PK that are capable of phosphorylating protamine sulfate. No phosphorylation of protamine sulfate was seen when cell-free supernatants from promastigotes incubated with either buffer alone or bovine serum albumin were used. A second enzyme, a constitutively released PR that phosphorylates casein or phosvitin and not protamine sulfate or mixed histones, was identified and characterized. This PK is inhibited by 5 mu M staurosporine, 50 mu g/ml heparin, and 75 mu M CKI-7, concentrations typical of the IC50 found for other eukaryotic casein kinases (CK). The constitutively shed ecto PK specifically phosphorylated a peptide substrate for CK1 but not for CK2, suggesting that this shed PK is similar to CK1.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Jaffe, CL (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, POB 12272, IL-91120 Jerusalem, Israel.	cjaffe@cc.huji.ac.il	Jaffe, Charles/AAU-8686-2020	Jaffe, Charles/0000-0002-2042-9993				ASSEFA D, 1995, BBA-MOL BASIS DIS, V1270, P157, DOI 10.1016/0925-4439(94)00080-A; Becker S, 1997, PARASITOL RES, V83, P273, DOI 10.1007/s004360050246; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CORBIN JD, 1983, METHOD ENZYMOL, V99, P317; DEY CS, 1988, BIOCHEM INT, V17, P367; EKDAHL KN, 1995, J IMMUNOL, V154, P6502; FORSBERG PO, 1990, J BIOL CHEM, V265, P2941; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; Hermoso T., 1996, Molecular and immune mechanisms in the pathogenesis of cutaneous leishmaniasis., P71; HERMOSO T, 1991, EMBO J, V10, P4061, DOI 10.1002/j.1460-2075.1991.tb04982.x; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACKSON PR, 1985, SCIENCE, V227, P435, DOI 10.1126/science.2578226; Jaffe C. L., 1984, Genes and antigens of parasites. A laboratory manual. Proceedings of a course held 14 November-17 December 1983, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil., P47; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, EUR J CELL BIOL, V26, P306; LESTER DS, 1990, BIOCHIM BIOPHYS ACTA, V1052, P293, DOI 10.1016/0167-4889(90)90224-2; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P519; PAAS Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P780, DOI 10.1006/abbi.1995.1104; PETERS W, 1987, LEISHMANIASIS BIOL M, V1, P941; SimanTov MM, 1996, MOL BIOCHEM PARASIT, V77, P201, DOI 10.1016/0166-6851(96)02601-1; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	30	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30760	30765		10.1074/jbc.272.49.30760	http://dx.doi.org/10.1074/jbc.272.49.30760			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388215	hybrid			2022-12-27	WOS:000071640800028
J	Seidel, G; Adermann, K; Schindler, T; Ejchart, A; Jaenicke, R; Forssmann, WG; Rosch, P				Seidel, G; Adermann, K; Schindler, T; Ejchart, A; Jaenicke, R; Forssmann, WG; Rosch, P			Solution structure of porcine delta sleep-inducing peptide immunoreactive peptide a homolog of the shortsighted gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; HELICAL COILED-COILS; GCN4 LEUCINE-ZIPPER; STRUCTURE PREDICTION; ELECTROSTATIC INTERACTIONS; CRYSTAL-STRUCTURE; MODEL PROTEIN; CHAIN-LENGTH; STABILITY; DOMAIN	The 77-residue delta sleep inducing peptide immunoreactive peptide (DIP) is a close homolog of the Drosophila melanogaster shortsighted gene product. Porcine DIP (pDIP) and a peptide containing a leucine zipper-related partial sequence of pDIP, pDIP(9-46), was synthesized and studied by circular dichroism and nuclear magnetic resonance spectroscopy in combination with molecular dynamics calculations. Ultracentrifugation, size exclusion chromatography, and model calculations indicated that pDIP forms a dimer. This was confirmed by the observation of concentration-dependent thermal folding-unfolding transitions. From CD spectroscopy and thermal folding-unfolding transitions of pDIP(9-46), it was concluded that the dimerization of pDIP is a result of interaction between helical structures localized in the leucine zipper motif. The three-dimensional structure of the protein was determined with a modified simulated annealing protocol using experimental data derived from nuclear magnetic resonance spectra and a modeling approach based on an established strategy for coiled coil structures. The left handed super helical structure of the leucine zipper type sequence resulting from the modeling approach is in agreement with known leucine zipper structures. In addition to the hydrophobic interactions between the amino acids at the heptade positions a and d, the structure of pDTP is stabilized by the formation of interhelical i to i' + 5 salt bridges. This result was confirmed by the pH dependence of the thermal-folding transitions. In addition to the amphipatic helix of the leucine zipper, a second helix is formed in the NH2-terminal part of pDIP. This helix exhibits more 3(10)-helix character and is less stable than the leucine zipper helix. For the COOH-terminal region of pDIP no elements of regular secondary structure were observed.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany; Niedersachs Inst Peptid Forsch GmbH, D-30625 Hannover, Germany; Univ Bayreuth, Lehrstuhl Biochem, D-95447 Bayreuth, Germany; Univ Regensburg, Inst Biophys & Phys Biochem, D-93053 Regensburg, Germany	University of Bayreuth; University of Bayreuth; University of Regensburg	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.		Rösch, Paul/I-5445-2014	Rösch, Paul/0000-0003-3330-2446				Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRUNGER A, 1993, XPLOR VERSION 3 1; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; DELANO WL, 1994, PROTEINS, V20, P105, DOI 10.1002/prot.340200202; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FAIRMAN R, 1995, PROTEIN SCI, V4, P1457, DOI 10.1002/pro.5560040803; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HODGES R S, 1988, Peptide Research, V1, P19; HU JC, 1992, NUCLEIC ACIDS MOL BI, V6, P82; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jardetzky O., 1981, NMR MOL BIOL; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KOHN WD, 1995, PROTEIN SCI, V4, P237; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEHTA PK, 1995, PROTEIN SCI, V4, P2517, DOI 10.1002/pro.5560041208; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; MONNIER M, 1977, EXPERIENTIA, V33, P548, DOI 10.1007/BF01922266; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; NAUTIYAL S, 1995, BIOCHEMISTRY-US, V34, P11645, DOI 10.1021/bi00037a001; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRICE NC, 1995, MOL BIOL BIOTECHNOLO; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SAUDEK V, 1990, PROTEIN ENG, V4, P3, DOI 10.1093/protein/4.1.3; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SILLARD R, 1993, EUR J BIOCHEM, V216, P429, DOI 10.1111/j.1432-1033.1993.tb18160.x; STONE D, 1975, PROTEINS CONTRACTILE, P125; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Vogel P, 1996, BBA-GENE STRUCT EXPR, V1309, P200, DOI 10.1016/S0167-4781(96)00177-7; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YU H, 1996, J MOL BIOL, V255, P367; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383	70	11	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30918	30927		10.1074/jbc.272.49.30918	http://dx.doi.org/10.1074/jbc.272.49.30918			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388238	hybrid, Green Submitted			2022-12-27	WOS:000071640800051
J	Yan, ZF; Chen, MX; Perucho, M; Friedman, E				Yan, ZF; Chen, MX; Perucho, M; Friedman, E			Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin beta 1-chain maturation in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; KERATINOCYTE TERMINAL DIFFERENTIATION; ASN-LINKED OLIGOSACCHARIDES; CARCINOMA-CELLS; ADHESION RECEPTORS; COLORECTAL-CANCER; PLASMA-MEMBRANE; APICAL POLARITY; BLADDER-CANCER; ALPHA-SUBUNITS	Human colorectal tumors commonly contain mutations in Ki-ras but rarely, if ever, in Ha-ras. The selectivity for Ki-ras mutations in this tumor was explored using the HD6-4 colon epithelial cell line which contains no ras mutations, after adhesion to an extracellular matrix, HD6-4 cells polarize into columnar goblet cells with distinct apical and basal regions. Stable HD6-4 transfectants were made with mini-gene constructs of the oncogenic cellular Ki-ras4B(G12V) gene, the oncogenic Ha-ras(G12V) gene, or mini-gene constructs of wild-type Ki-ras4B as a control, Ki-ras mutations, but not Ha-ras mutations, disrupted colon epithelial cell apicobasal polarity and adhesion to collagen I and laminin. Three Ha-ras transfectants and three Ki-ras transfectants exhibited Ras proteins expressing the Val-12 mutation by Western blotting with pan-ras(G12V) antibody. Only wild-type Ki-ras transfectant cells and oncogenic Ha-ras transfectant cells synthesized the mature, fully glycosylated forms of beta 1 integrin. Instead of the mature integrin beta 1-chain, a faster migrating beta 1-chain intermediate was detected on the cell surface and in the cytoplasm of the oncogenic Ki-ras transfectants. Expression of the oncogenic Ki-ras gene caused the altered beta 1 integrin maturation because phosphorothiolated antisense oligonucleotides to Ki-ras reduced expression of both the mutant Hi-Ras protein and the aberrant integrin beta 1-chain and increased expression of the mature integrin beta 1-chain. Altered glycosylation generated the new beta 1-integrin form since integrin core beta 1-chain proteins of the same molecular weight were yielded in Ki-ras, Ha-ras, and control transfectants after removal of sugar residues with endoglycosidase F or following tunicamycin treatment to inhibit glycosylation. The selective effect of oncogenic Ki-ras on beta 1 integrin glycosylation was not due to selective activation of mitogen activated protein kinases because both mutated Ki- and Ha-ras genes activated this pathway and increased cell proliferation. Since blocking the glycosylation of integrin beta 1-chain inhibited the adherence, polarization, and subsequent differentiation of colon epithelial cells, the selective effects of the oncogenic cellular Ki-ras gene on integrin beta 1-chain glycosylation may account, at least in part, for the selection of Ki-ras mutations in human colon tumors.	SUNY Hlth Sci Ctr, Dept Pathol, Syracuse, NY 13210 USA; Burnham Inst, La Jolla, CA 92037 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Sanford Burnham Prebys Medical Discovery Institute	Friedman, E (corresponding author), SUNY Hlth Sci Ctr, Dept Pathol, 2305 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Perucho, Manuel/0000-0002-2169-2662	NATIONAL CANCER INSTITUTE [R01CA045783, R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45783, R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA S, 1995, CANCER LETT, V91, P145, DOI 10.1016/0304-3835(95)03735-F; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HEINO J, 1989, J BIOL CHEM, V264, P380; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HUANG F, 1994, ONCOGENE, V9, P3701; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAHN S, 1987, ANTICANCER RES, V7, P639; KOIVISTO L, 1994, BIOCHEM J, V300, P771, DOI 10.1042/bj3000771; KORETZ K, 1991, AM J PATHOL, V138, P741; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENTER M, 1994, J BIOL CHEM, V269, P12263; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; OJAKIAN GK, 1994, J CELL SCI, V107, P561; PIGATELLI M, 1990, BRIT J CANCER, V61, P636; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUCHY B, 1992, INT J CANCER, V52, P30, DOI 10.1002/ijc.2910520107; WANG AZ, 1990, J CELL SCI, V95, P153; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YAN ZF, 1992, ONCOGENE, V7, P801; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	49	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1997	272	49					30928	30936		10.1074/jbc.272.49.30928	http://dx.doi.org/10.1074/jbc.272.49.30928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT745	9388239	hybrid			2022-12-27	WOS:000071640800052
J	Berezutskaya, E; Bagchi, S				Berezutskaya, E; Bagchi, S			The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KERATINOCYTES; GENE-PRODUCT; ZINC-BINDING; CELL-CYCLE; KAPPA-B; TYPE-16; PROTEIN; UBIQUITIN; E6; TRANSFORMATION	Human papillomaviruses (HPV) have been etiologically linked to human cervical cancer. More than 90% of cervical cancer tissues express two HPV-encoded oncoproteins E6 and E7, Both E6 and E7 proteins possess transformation activity. and together they cooperate to transform primary human keratinocytes, fibroblasts, and epithelial cells, The transforming activity of E7 is associated with its ability to bind the retinoblastoma tumor suppressor protein (Rb), However, the carboxyl-terminal mutants of E7 are also defective for transformation, suggesting that other cellular targets for E7 might exist, We screened a human placenta cDNA library by yeast two hybrid assay using HPV 16 E7 as a bait and identified the subunit 4 (S4) ATPase of the 26 S proteasome as a novel E7-binding protein, E7 binds to S4 through the carboxyl-terminal zinc binding motif, and the binding is independent of E7 sequences involved in binding to Rb, The interaction between S4 and E7 can be easily detected by in vitro protein binding assays, Moreover, we found that E7 increases the ATPase activity of S4, A recent study has shown that, in epithelial cells, E7 degrades Rb through the 26 S proteasome pathway. We hypothesize that E7 might target Rb for degradation by 26 S proteasome through its interaction with the subunit 4 of the proteasome.	UNIV ILLINOIS,COLL DENT,CTR MOL BIOL ORAL DIS,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Boyer SN, 1996, CANCER RES, V56, P4620; CLEMENS K, 1996, VIROLOGY, V214, P289; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RANDERATH KJ, 1963, CHROMATOGRAPHY, V10, P235; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ullman CG, 1996, BIOCHEM J, V319, P229, DOI 10.1042/bj3190229; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	43	114	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30135	30140		10.1074/jbc.272.48.30135	http://dx.doi.org/10.1074/jbc.272.48.30135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374493	hybrid			2022-12-27	WOS:A1997YH61300025
J	Chen, XH; Tsien, RW				Chen, XH; Tsien, RW			Aspartate substitutions establish the concerted action of P-region glutamates in repeats I and III in forming the protonation site of L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CURRENT FLUCTUATIONS; CALCIUM CHANNELS; ION PERMEATION; ESCHERICHIA-COLI; SELECTIVITY; CELLS; DETERMINANTS; DEPENDENCE; MECHANISMS; ALTERS	Hydrogen ions reduced ion flux through voltage-gated Ca2+ channels by binding to a single protonation site with an unusually high pK(a). Recent evidence localizes the protonation site to the same locus that supports high affinity Ca2+ binding and selectivity, a set of four conserved glutamate residues near the external mouth of the pore. Remaining controversy concerns the question of whether the protonation site arises from a single glutamate, Glu-1086 (EIII), or a combination of Glu-1086 and Glu-334 (EI) working in concert. We tested these hypotheses with individual Glu --> Asp substitutions. The Glu --> Asp replacements in repeats I and III stood out in two ways. First, in both EID and EIIID, protonation was destabilized relative to wild type, whereas it was unchanged in EIID and stabilized in EIVD. The changes in affinity were entirely due to alterations in H+ off-rate. Second, the ratio of protonated conductance to deprotonated conductance was significantly closer to unity for EID and EIIID than for wild-type channels or other Asp mutants. both results support the idea that EI and EIII act together to stabilize a single titratable H+ ion and behave nearly symmetrically in influencing pore conductance. Neutralization of EIII by alanine replacement clearly failed to abolish susceptibility to protonation, indicting that no single glutamate was absolutely required. Taken together, all the evidence supports a model in which multiple carboxylates work in concert to form a single high affinity protonation site.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University								CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CHAIMVIMONVAT N, 1996, NEURON, V16, P1037; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; Colquhoun David, 1995, P397; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P10166, DOI 10.1021/bi960995r; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P665, DOI 10.1085/jgp.103.4.665; KRAFTE DS, 1988, J GEN PHYSIOL, V91, P641, DOI 10.1085/jgp.91.5.641; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PIETROBON D, 1988, NATURE, V333, P373, DOI 10.1038/333373a0; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	25	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30002	30008		10.1074/jbc.272.48.30002	http://dx.doi.org/10.1074/jbc.272.48.30002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374474	hybrid			2022-12-27	WOS:A1997YH61300006
J	Inaba, K; Wakasugi, K; Ishimori, K; Konno, T; Kataoka, M; Morishima, I				Inaba, K; Wakasugi, K; Ishimori, K; Konno, T; Kataoka, M; Morishima, I			Structural and functional roles of modules in hemoglobin - substitution of module M4 in hemoglobin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; SEQUENCE-SPECIFIC PROTEOLYSIS; ESCHERICHIA-COLI; MINI-MYOGLOBIN; INTRINSIC FLUORESCENCE; BINDING-PROPERTIES; MOLTEN GLOBULE; CENTRAL EXON; BETA-GLOBIN; PROTEIN	The alpha- and beta-subunits of human hemoglobin consist of the modules M1, M2 + M3, and M4, which correspond to the exons 1, 2, and 3, respectively (Go, M. (1981) Nature 291, 90-92). To gain further insight into functional and structural significance of the modules, we designed two kinds of chimeric hemoglobin subunits (chimeric alpha alpha beta- and beta beta alpha-subunits), in which the module M4 was replaced by the partner subunits. CD spectra in the far-UV region showed that the secondary structure of the chimeric alpha alpha beta-subunit drastically collapsed, while the chimeric beta beta alpha-subunit conserved the native globin structure (Wakasugi, K., Ishimori, It., Imai, IT., Wada, Y., and Morishima, I. (1994) J. Biol. Chem. 269, 18750-18756). SAXS data also suggested a partially disordered structure of the chimeric alpha alpha beta-subunit. Based on tryptophan-fluorescence spectra and computer modeling from x-ray structures of native globins, steric constraint between Trp(14) and Tyr(125) would be induced in the chimeric alpha alpha beta-subunit, which would perturb the packing of the A- and H-helices and destabilize the globule structure, On the other hand, such a steric constraint was not found for the counterpart chimeric subunit, the beta beta alpha-subunit The different stabilities of these module-substituted globins imply that nodules would not always be stable ''structural'' units, and interactions between modules are crucial to construct stable globin subunits.	KYOTO UNIV,GRAD SCH ENGN,DEPT MOL ENGN,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,FAC SCI,DEPT EARTH & SPACE,TOYONAKA,OSAKA 560,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Osaka University			Ishimori, Koichiro/AAQ-4434-2021; Kataoka, Mikio/H-4402-2011; Wakasugi, Keisuke/AAQ-1642-2020; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Inaba, Kenji/0000-0001-8229-0467; Wakasugi, Keisuke/0000-0002-8408-5616				BEYCHOK S, 1967, J BIOL CHEM, V242, P2460; BLAKE CCF, 1979, NATURE, V277, P598, DOI 10.1038/277598a0; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CRAIK CS, 1980, P NATL ACAD SCI-BIOL, V77, P1384, DOI 10.1073/pnas.77.3.1384; CRAIK CS, 1981, NATURE, V291, P87, DOI 10.1038/291087a0; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; DESANCTIS G, 1986, J MOL BIOL, V188, P73, DOI 10.1016/0022-2836(86)90481-X; DESANCTIS G, 1991, J MOL BIOL, V222, P637, DOI 10.1016/0022-2836(91)90501-V; DIIORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025, DOI 10.1073/pnas.90.5.2025; EATON WA, 1980, NATURE, V284, P183, DOI 10.1038/284183a0; Fasman GD, 1976, HDB BIOCH MOL BIOL, P183; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Glatter O., 1982, SMALL ANGLE XRAY SCA; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guinier A., 1955, SMALL ANGLE SCATTERI; HIRSCH RE, 1986, BIOCHIM BIOPHYS ACTA, V872, P147, DOI 10.1016/0167-4838(86)90158-5; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; HSU MC, 1971, J AM CHEM SOC, V93, P3515; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JONATHAN DH, 1994, J MOL BIOL, V243, P173; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P1188, DOI 10.1021/bi00219a004; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Kataoka M, 1997, PROTEIN SCI, V6, P422; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KONNO T, 1993, BIOCHIM BIOPHYS ACTA, V1162, P93, DOI 10.1016/0167-4838(93)90133-C; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OLAH GA, 1993, J BIOL CHEM, V268, P16241; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; TAINSKY M, 1973, J MOL BIOL, V75, P735, DOI 10.1016/0022-2836(73)90304-5; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; VALDES R, 1977, J BIOL CHEM, V252, P74; WADA Y, 1989, BIOMED ENVIRON MASS, V18, P563, DOI 10.1002/bms.1200180809; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WAKASUGI K, 1997, IN PRESS BIOPHYS CHE	42	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30054	30060		10.1074/jbc.272.48.30054	http://dx.doi.org/10.1074/jbc.272.48.30054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374481	hybrid			2022-12-27	WOS:A1997YH61300013
J	Sawada, K; Kuroda, N; Watanabe, H; MoritaniOtsuka, C; Kanazawa, H				Sawada, K; Kuroda, N; Watanabe, H; MoritaniOtsuka, C; Kanazawa, H			Interaction of the delta and b subunits contributes to F-1 and F-0 interaction in the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; H+-ATPASE; EPSILON-SUBUNIT; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; COUPLING FACTOR; GAMMA-SUBUNIT; BETA-SUBUNIT; UNC OPERON	Interactions of the F-1-F-0-ATPase subunits between the cytoplasmic domain of the b subunit (residues 26-156, b(cyt)) and other membrane peripheral subunits including alpha, beta, gamma, delta, epsilon, and putative cytoplasmic domains of the a subunit were analyzed with the yeast two-hybrid system and in vitro reconstitution of ATPase from the purified subunits as well, Only the combination of b(cyt) fused to the activation domain of the yeast GAL-4, and delta subunit fused to the DNA binding domain resulted in the strong expression of the beta-galactosidase reporter gene, suggesting a specific interaction of these subunits, Expression of b(cyt) fused to glutathione S-transferase (GST) together with the delta subunit in Escherichia coli resulted in the overproduction of these subunits in soluble form, whereas expression of the GST-b(cyt) fusion alone had no such effect, indicating that GST-b(cyt) was protected by the co-expressed delta subunit from proteolytic attack in the cell, These results indicated that the membrane peripheral domain of b subunit stably interacted with the delta subunit in the cell, The affinity purified GST-b(cyt) did not contain significant amounts of delta, suggesting that the interaction of these subunits was relatively weak, Binding of these subunits observed in a direct binding assay significantly supported the capability of binding of the subunits, The ATPase activity was reconstituted from the purified b(cyt) together with alpha, beta, gamma, delta, and epsilon, or with the same combination except epsilon, Specific elution of the ATPase activity from glutathione affinity column with the addition of glutathione after reconstitution demonstrated that the reconstituted ATPase formed a complex, The result indicated that interaction of b and delta was stabilized by F-1 subunits other than epsilon and also suggested that b-delta interaction was important for F-1-F-0 interaction.	OKAYAMA UNIV, FAC ENGN, DEPT BIOTECHNOL, OKAYAMA 700, JAPAN	Okayama University								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; EYA S, 1988, J BIOL CHEM, V263, P10056; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HAZARD AL, 1994, J BIOL CHEM, V269, P427; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; KANAZAWA H, 1982, ANN NY ACAD SCI, V402, P45, DOI 10.1111/j.1749-6632.1982.tb25731.x; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; KUKI M, 1988, J BIOL CHEM, V263, P17437; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; Maniatis T., 1982, MOL CLONING; MEDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; MONTICELLO RA, 1994, J BACTERIOL, V176, P1383, DOI 10.1128/jb.176.5.1383-1389.1994; MORITANI C, 1996, BIOCHIM BIOPHYS ACTA, V258, P14599; NIELSEN J, 1981, MOL GEN GENET, V184, P33, DOI 10.1007/BF00271191; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYME REGUL, V64, P173; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shin YC, 1996, BBA-BIOENERGETICS, V1273, P62, DOI 10.1016/0005-2728(95)00132-8; Shin YC, 1997, ARCH BIOCHEM BIOPHYS, V340, P36, DOI 10.1006/abbi.1997.9883; STACK AE, 1994, J BACTERIOL, V176, P540, DOI 10.1128/JB.176.2.540-542.1994; STERNWEIS PC, 1978, J BIOL CHEM, V253, P3123; VIK SB, 1988, J BIOL CHEM, V263, P6599; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WILKENS S, 1997, NAT STRUCT BIOL, V4, P196; XIONG H, 1995, J BIOL CHEM, V270, P23300, DOI 10.1074/jbc.270.40.23300; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	55	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30047	30053		10.1074/jbc.272.48.30047	http://dx.doi.org/10.1074/jbc.272.48.30047			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374480	hybrid			2022-12-27	WOS:A1997YH61300012
J	Graber, MN; Alfonso, A; Gill, DL				Graber, MN; Alfonso, A; Gill, DL			Recovery of Ca2+ pools and growth in Ca2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; CALCIUM POOLS; 5,6-EPOXYEICOSATRIENOIC ACID; PERFUSED KIDNEY; PROTEIN-KINASE; THAPSIGARGIN; LIPOXYGENASE; MECHANISM; RAT	Depletion of Ca2+ pools using the irreversible Ca2+ pump blocker, thapsigargin, induces DDT1MF-S smooth muscle cells to enter a stable nonproliferative state, Reversal of this state can be mediated by high (20%) serum treatment, which induces new Ca2+ pump protein, return of Ca2+ pools, and reentry of cells into the cell cycle; the effect of serum can be mimicked by the essential fatty acids (EFA), arachidonic, linoleic, and alpha-linolenic acids (Graber, M.N., Alfonso, A., and Gill, D.L., (1996) J. Biol. Chem, 271, 883-888), The possible requirement for EFA metabolism in inducing recovery of Ca2+ pool depleted growth-arrested cells was investigated, Neither cyclooxygenase or lipoxygenase inhibitors had any effect on arachidonic acid induced growth recovery of thapsigargin-treated cells. In contrast, the cytochrome P-450 epoxygenase inhibitors, SKF525A and metyrapone, substantially reduced arachidonic acid-induced recovery of growth while having minimal effects on control cell growth. Both epoxygenase inhibitors completely prevented the arachidonic acid-induced recovery of bradykinin-releasable Ca2+-pumping pools, whereas cyclooxygenase and lipoxygenase inhibitors had no effect, The effectiveness of the four cytochrome P-450 metabolites of arachidonic acid on recovery of Ca2+ pools were compared; 8,9- and 11,12-epoxyeicosatrienoic acid (EET) at 1.5 mu M were completely effective in recovering agonist-sensitive Ca2+ pools, whereas the 5,6- and 14,15-EETs were without effect. SKF525A did not block the action of 8,9- or 11,12-EET indicating further P-450 metabolism was not required, Hydration of the active EET molecules prevented Ca2+ pool recovery since the dihydroxy-derivatives of both 8,9- and 11,12-EET were ineffective. The specificity of effectiveness among EET molecules for subsequent resumption of growth of thapsigargin-treated cells was the same as for Ca2+ pool recovery, Significantly, the P-450 inhibitors, SKF525A metyrapone, both prevented the action of 20% serum in inducing recovery of thapsigargin treated cells, whereas cyclooxygenase and lipoxygenase inhibitors were ineffective, indicating that EFAs are the active component within serum that is responsible for recovery of Ca2+ pool depleted cells, The specific action of EETs in mediating recovery of Ca2+ pools and growth of thapsigargin-treated cells represents not only a novel action of epoxygenase products from EFAs, but also a potentially significant new signaling pathway that may effect translational control and regulate transition from a stationary to proliferative growth state.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM & MOL BIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Alfonso, Amparo/GLN-2591-2022	Alfonso Rancano, Maria Amparo/0000-0003-1572-9016	NHLBI NIH HHS [HL55426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL R, 1991, DRUG METAB DISPOS, V19, P620; BALAZY M, 1991, J BIOL CHEM, V266, P23561; BERRIDGE MJ, 1993, BIOCHEM J, V312, P1; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BYCZKOWSKI JZ, 1992, INT J BIOCHEM, V24, P1691, DOI 10.1016/0020-711X(92)90114-G; CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CASHMAN JR, 1992, EICOSANOIDS, V5, P153; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CUCUROU C, 1991, BIOCHEMISTRY-US, V30, P8964, DOI 10.1021/bi00101a008; CUNNINGHAM FM, 1994, LIPID MEDIATORS; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JOSEPH P, 1993, BIOCHEM J, V293, P83, DOI 10.1042/bj2930083; KAUSER K, 1991, CIRC RES, V68, P1154, DOI 10.1161/01.RES.68.4.1154; KIMURA Y, 1987, BIOCHIM BIOPHYS ACTA, V922, P278; KOHOUT TA, 1995, J BIOL CHEM, V270, P20432, DOI 10.1074/jbc.270.35.20432; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NIEUWENHUIZEN WF, 1995, BIOCHEMISTRY-US, V34, P10538, DOI 10.1021/bi00033a028; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OYEKAN AO, 1991, CIRC RES, V68, P958, DOI 10.1161/01.RES.68.4.958; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SARUBBI D, 1991, EUR J PHARMACOL, V197, P27, DOI 10.1016/0014-2999(91)90360-3; SHEN TY, 1977, ADV DRUG RES, V12, P89; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; STERN N, 1989, AM J PHYSIOL, V257, pH434, DOI 10.1152/ajpheart.1989.257.2.H434; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOBIAS LD, 1978, LIPIDS, V14, P181; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440	55	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29546	29553		10.1074/jbc.272.47.29546	http://dx.doi.org/10.1074/jbc.272.47.29546			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368016	hybrid			2022-12-27	WOS:A1997YG64700026
J	Soucek, T; Pusch, O; Wienecke, R; DeClue, JE; Hengstschlager, M				Soucek, T; Pusch, O; Wienecke, R; DeClue, JE; Hengstschlager, M			Role of the tuberous sclerosis gene-2 product in cell cycle control - Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANTLY INHERITED CANCER; TUBEROUS-SCLEROSIS-2 TSC2 GENE; EKER RAT MODEL; DEPENDENT KINASES; THYMIDINE KINASE; RENAL-CARCINOMA; MUTATION; HETEROZYGOSITY; TRANSFORMATION; REGION	Tuberous sclerosis is an autosomal dominant disorder characterized by the development of benign growths in many tissues and organs. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16. The TSC2 gene on chromosome 16 encodes a 1784-amino acid tumor suppressor protein, tuberin, that functions as a GTPase activating protein for Rap1, a member of the superfamily of Ras-related proteins, By immunoblot analyses, we found TSC2 expression to be high in G(0) as well as in early small G(1) cells. Analyses after different cell synchronization procedures revealed that TSC2 mRNA and protein expression do not fluctuate throughout the cell cycle, Using inducible expression systems we further demonstrated that TSC2 expression is not affected by overexpression of the mitogenic transcription factor E2F-1 or c-Myc. Nevertheless, antisense inhibition of tuberin expression in logarithmically growing cells markedly decreased the percentage of cells in G(1). Furthermore, we found that cells exposed to TSC2 antisense oligonucleotides did not undergo G(0) arrest after serum withdrawal, Antisense inhibition of TSC2 expression also induced quiescent G(0)-arrested fibroblasts to reenter the cell cycle. Our data show for the first time that the absence of tuberin can both induce cells to pass through the G(1)/S transition of the eukaryotic cell cycle and prevent them from entering a quiescent state. These results have clear implications for the tumor suppressor function of TSC2, We further found that reentry into the cell cycle upon loss of TSC2 is dependent on the activity of the G(1) cyclin-dependent kinases (CDKs), Cdk2 or Cdk4. Taken together with our finding that antisense inhibition of TSC2 causes up regulation of cyclin D1 expression, these results provide the first evidence for a connection between tuberin/Rap1 and the G(1) CDK-dependent regulation of the transition from G(0)/G(1) to S phase.	UNIV VIENNA, DEPT PRENATAL DIAGNOSIS & THERAPY, A-1090 VIENNA, AUSTRIA; NCI, CELLULAR ONCOL LAB, NIH, BETHESDA, MD 20892 USA	University of Vienna; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Pusch, Oliver/0000-0001-7166-2800				BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	42	164	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29301	29308		10.1074/jbc.272.46.29301	http://dx.doi.org/10.1074/jbc.272.46.29301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361010	hybrid			2022-12-27	WOS:A1997YF68400069
